
<html lang="en"     class="pb-page"  data-request-id="1918f7d4-72ec-425d-b65d-40685787bab3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-3;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.9b00726;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets" /></meta><meta name="dc.Creator" content="Žiga  Skok" /></meta><meta name="dc.Creator" content="Nace  Zidar" /></meta><meta name="dc.Creator" content="Danijel  Kikelj" /></meta><meta name="dc.Creator" content="Janez  Ilaš" /></meta><meta name="dc.Description" content="Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit thei..." /></meta><meta name="Description" content="Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit thei..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 8, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00726" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00726" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00726" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00726" /></link>
        
    
    

<title>Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00726" /></meta><meta property="og:title" content="Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0022.jpeg" /></meta><meta property="og:description" content="Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clinical efficacy. To maximize the therapeutic potential of anticancer drugs, combination therapies and multitarget drugs have been suggested in many studies, where the use of multitarget drugs is advantageous from a pharmacokinetic point of view. There are various different options for the preparation of dual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, and kinases) and functionally (e.g., histone deacetylases and proteasome) connected to many validated anticancer targets. In this Perspective, we discuss the scientific background behind targeting topoisomerase II together with a number of other targets important in cancer therapy, review the present status, and discuss further options in the field." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00726"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00726">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00726&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00726&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00726&amp;href=/doi/10.1021/acs.jmedchem.9b00726" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 884-904</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00036" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00835" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Žiga Skok</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Žiga Skok</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=%C5%BDiga++Skok">Žiga Skok</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nace Zidar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nace Zidar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nace++Zidar">Nace Zidar</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1905-0158" title="Orcid link">http://orcid.org/0000-0003-1905-0158</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Danijel Kikelj</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Danijel Kikelj</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Danijel++Kikelj">Danijel Kikelj</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Janez Ilaš</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Janez Ilaš</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia</div></div><span class="conrtib-corresp"><strong>*</strong>Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia. E-mail: <a href="/cdn-cgi/l/email-protection#761c1718130c581f1a1705361010175803181f5b1a1c58051f"><span class="__cf_email__" data-cfemail="e288838c8798cc8b8e8391a2848483cc978c8bcf8e88cc918b">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Janez++Ila%C5%A1">Janez Ilaš</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0124-0474" title="Orcid link">http://orcid.org/0000-0002-0124-0474</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00726&amp;href=/doi/10.1021%2Facs.jmedchem.9b00726" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 884–904</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 8, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 May 2019</li><li><span class="item_label"><b>Published</b> online</span>8 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 February 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00726" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00726</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00726"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6653</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00726" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Žiga&quot;,&quot;last_name&quot;:&quot;Skok&quot;},{&quot;first_name&quot;:&quot;Nace&quot;,&quot;last_name&quot;:&quot;Zidar&quot;},{&quot;first_name&quot;:&quot;Danijel&quot;,&quot;last_name&quot;:&quot;Kikelj&quot;},{&quot;first_name&quot;:&quot;Janez&quot;,&quot;last_name&quot;:&quot;Ilaš&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;884-904&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00726&quot;},&quot;abstract&quot;:&quot;Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clinical efficacy. To maximize the therapeutic potential of anticancer drugs, combination therapies and multitarget drugs have been suggested in many studies, where the use of multitarget drugs is advantageous from a pharmacokinetic point of view. There are various different options for the preparation of dual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, and kinases) and functionally (e.g., histone deacetylases and proteasome) connected to many validated anticancer targets. In this Perspective, we discuss the scientific background behind targeting topoisomerase II together with a number of other targets important in cancer therapy, review the present status, and discuss further options in the field.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00726&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00726" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00726&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00726" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00726&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00726" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00726&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00726&amp;href=/doi/10.1021/acs.jmedchem.9b00726" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00726" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00726" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00726%26sid%3Dliteratum%253Aachs%26pmid%3D31592646%26genre%3Darticle%26aulast%3DSkok%26date%3D2020%26atitle%3DDual%2BInhibitors%2Bof%2BHuman%2BDNA%2BTopoisomerase%2BII%2Band%2BOther%2BCancer-Related%2BTargets%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D3%26spage%3D884%26epage%3D904%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/jmcmar.2020.63.issue-3/20200213/jmcmar.2020.63.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clinical efficacy. To maximize the therapeutic potential of anticancer drugs, combination therapies and multitarget drugs have been suggested in many studies, where the use of multitarget drugs is advantageous from a pharmacokinetic point of view. There are various different options for the preparation of dual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, and kinases) and functionally (e.g., histone deacetylases and proteasome) connected to many validated anticancer targets. In this Perspective, we discuss the scientific background behind targeting topoisomerase II together with a number of other targets important in cancer therapy, review the present status, and discuss further options in the field.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36688" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36688" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1.1.  Multitarget Therapies</h3><div class="NLM_p">Multitarget therapies have for many years attracted the interest of medicinal chemists in the field of complex diseases, such as cancers, inflammation, psychiatric disorders, and thrombotic disorders.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> These diseases can be affected by many factors, and they are often resilient to single-target treatments due to activation of compensatory mechanisms and redundant cellular pathways.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Despite the many challenges of cancer therapies, current chemotherapeutics and targeted drugs can significantly prolong patient lives and in some cases also cure the disease.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> To maximize their efficacy, the use of drug combinations has become a well-established approach. Targeting two different pathways involved in the development of a disease often leads to additive or synergistic effects and can reduce the potential for the development of resistance.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8−11)</a> Furthermore, on the basis of the enhanced therapeutic effects of combination therapies, smaller therapeutic doses of the individual drugs are needed, which has the potential to decrease side effects compared to the individual drug treatments.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">Over the past decade, the use of combination therapies (i.e., drug cocktails) has moved toward the design of multitarget ligands, which has attracted significant scientific interest because of some clear advantages of this approach.<a onclick="showRef(event, 'ref1 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref3">(1,3)</a> The most important of these are the more predictable pharmacokinetics and the reduced risks of drug interactions, along with fewer complications with intellectual property rights and the regulatory approval processes, compared to the use of mixtures of drugs.<a onclick="showRef(event, 'ref1 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref1 ref12 ref13">(1,12,13)</a> It is important, however, that multitarget ligands have the required selectivity to hit the selected targets (“beneficial polypharmacology”) and to avoid off-target interactions that can lead to adverse effects (“harmful promiscuity”).<a onclick="showRef(event, 'ref9 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref14 ref15">(9,14,15)</a></div><div class="NLM_p">Multitarget drugs have been used from the beginning of modern pharmacology; however, their multitarget nature, which is often responsible for their clinical success, was mostly discovered in retrospect.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Some examples of such drugs are acetylsalicylic acid, statins, paracetamol, and metformin. While the multitarget profile of these drugs, which is responsible for their additive or synergistic effects, was obtained serendipitously, today we are trying to design multitarget ligands that would target prespecified rationally selected targets. The selection of targets is often based on clinical data obtained from combination therapy, phenotypic screening of drug combinations, or <i>in silico</i> approaches. One of the most successful examples of multitarget design is the discovery of atypical antipsychotics with balanced dopaminergic–serotoninergic modulation, e.g., aripiprazole.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p last">The prime examples of multitarget agents in cancer therapy are multikinase inhibitors, such as imatinib, sunitinib, and sorafenib. They show increased effectiveness due to synergistic effects, decreased severe adverse effects compared to other anticancer drugs, and decreased development of resistance.<a onclick="showRef(event, 'ref5 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref5 ref17 ref18 ref19">(5,17−19)</a> Multikinase inhibitors increase the survival time of patients with chronic myeloid leukemia and gastrointestinal stromal tumors for multiple years.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Historically, the main paradigm in the development of kinase inhibitors was the development of selective inhibitors of specific kinases. Originally, it was thought that some of the successful multikinase inhibitors were relatively selective toward one of the kinases.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Now it is known that a majority of cancers quickly develop resistance against any of the single-kinase inhibitors, so it appears that interacting with multiple kinases is a key feature of this successful class of anticancer drugs and is critical for their effectiveness.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">1.2.  Human DNA Topoisomerase II</h3><div class="NLM_p">DNA topoisomerases are nuclear enzymes that catalyze the introduction of topological changes to the DNA molecule. Replication and transcription of DNA require the unwinding of the DNA helix, which results in helical tension in the rest of the DNA molecule. Topoisomerases release this tension through the formation of transient single-stranded (i.e., type I topoisomerases) or double-stranded (i.e., type II topoisomerases) breaks in the DNA double helix, which makes topoisomerases essential for proliferating cells.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> Human topoisomerase II (topo II) is a type II topoisomerase that has been shown to be an effective target in the treatment of a wide spectrum of cancers. It is targeted by the anticancer drugs etoposide, doxorubicin, daunorubicin, and mitoxantrone (<b>1–4</b>, respectively, in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of clinically important topo II “poisons”.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There are two isoforms of topo II in human cells: topo IIα and topo IIβ. Topo IIα is overexpressed in proliferating cells and serves as a biomarker for cell proliferation, while expression of topo IIβ is evenly distributed across all cells. Therefore, topo IIα is considered to be responsible for the anticancer effects of topo II inhibitors. Topo IIα is a homodimeric protein, where each monomer is comprised of four distinct sections: the N gate (with an ATP-binding site of the GHKL ATPase family), the DNA gate, the C gate, and the C-terminal domain. The first three of these are involved in the topo II catalytic cycle, while the C-terminal domain is mainly responsible for nuclear localization and recognition of DNA geometry during the catalytic cycle.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27−30)</a></div><div class="NLM_p">Topo II activity follows a multistep catalytic cycle, where the main steps are (i) recognition of and binding to the first double-stranded DNA chain (the G-segment) on the DNA gate, (ii) trapping of the second double-stranded DNA chain (the T-segment) on the N-terminal domain through ATPase domain dimerization, (iii) cleavage of the G-segment, which results in the formation of a covalent complex between DNA and topo II, (iv) passing of the T-segment through the transient break in the G-segment, which is mediated through hydrolysis of ATP, (v) religation of the G-segment, and (vi) opening of the C-gate and N-gate, to release the G-segment and T-segment.<a onclick="showRef(event, 'ref28 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref28 ref31 ref32 ref33">(28,31−33)</a></div><div class="NLM_p">Drugs that target topo II can be divided into two groups on the basis of the nature of their actions. The first group comprises the “topo II poisons”, which include the clinically successful drugs mentioned above (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>1–4</b>). These compounds act through stabilization of the covalent complex between topo II and DNA, which results in an increased level of DNA damage in cells. The increased levels of the covalent topo II–DNA complex act as a cellular toxin, as by blocking DNA replication and transcription, this eventually promotes cell apoptosis. The second group of topo II-targeting drugs includes the topo II catalytic inhibitors. Here, the cytotoxic effects are mediated through inhibition of the catalytic function of topo II, without the generation of DNA damage.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> This diverse group of topo II catalytic inhibitors can act through different mechanisms, such as through competition for binding with ATP [e.g., novobiocin (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <b>5</b>)], prevention of DNA cleavage [e.g., merbarone (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <b>6</b>)], and prevention of hydrolysis of ATP [e.g., dexrazoxane (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <b>7</b>)].<a onclick="showRef(event, 'ref25 ref34'); return false;" href="javascript:void(0);" class="ref ref25 ref34">(25,34)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of some of the catalytic inhibitors of topo II.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite the clinical success of topo II poisons, there are some major limitations associated with their use in cancer therapy. The most important of these are the development of drug resistance and the frequent side effects, such as the development of secondary malignancies and cardiotoxicity.<a onclick="showRef(event, 'ref25 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref25 ref35 ref36">(25,35,36)</a> The manifestation of secondary malignancies is a direct consequence of the mechanism of action of topo II poisons. While the elevated concentration of broken DNA strands in cells results in apoptotic effects of topo II poisons, it also causes specific chromosome translocations that can trigger the development of secondary leukemias.<a onclick="showRef(event, 'ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40">(37−40)</a> Many studies have focused on the understanding of mechanisms of the resistance of cancer cells against topo II poisons, which would help to tackle this major issue.<a onclick="showRef(event, 'ref41 ref42 ref43 ref44 ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43 ref44 ref45 ref46 ref47">(41−47)</a> The main resistance mechanism associated with topo II poisons is overexpression of P-glycoprotein, which results in the efflux of the drugs from cancer cells.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, the other important mechanisms include altered expression or cytoplasmic accumulation of topo II, altered DNA repair mechanisms, or altered apoptotic signaling.<a onclick="showRef(event, 'ref42 ref46'); return false;" href="javascript:void(0);" class="ref ref42 ref46">(42,46)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic representation of the most common mechanisms of resistance against topo II-targeting drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Many efforts have been made to develop a successor to etoposide and doxorubicin that would have an improved pharmacological and toxicological profile; however, no new topo II inhibitors have been approved for clinical use for over two decades.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Nevertheless, research in the field of topo II remains very lively.<a onclick="showRef(event, 'ref48 ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51 ref52">(48−52)</a> Recently, Lee et al. reported a natural polyphenol resveratrol as a topo II inhibitor.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The extensive biological evaluation of resveratrol revealed that it acts on topo II through a previously unknown mode of action, as it prevents ATPase domain dimerization and therefore inhibits the catalytic action of topo II. Other natural polyphenols such as flavonoids were also shown to inhibit topo II and/or topo I and have been suggested to act as poisons but might also act through this novel mode of action.<a onclick="showRef(event, 'ref51 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref51 ref53 ref54">(51,53,54)</a> Another notable recent example of development of new topo II inhibitors is a study by Hao et al., who performed a structure–activity relationship (SAR) study on novel 2-phenylnaphthalene-based inhibitors.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The best compounds of the series showed submicromolar cytotoxic IC<sub>50</sub> values on breast, liver, and prostate cancer cell lines.</div><div class="NLM_p">A recent prominent approach for the design of new topo II inhibitors is the attachment of molecules with a defined target delivery to known inhibitors, to improve their tumor selectivity. One example is the attachment of polyamines to drugs to exploit the polyamine transport system of cells, which results in faster, more efficient, and more selective delivery of the drug to tumor cells. This approach is considered very promising in the development of new anticancer agents.<a onclick="showRef(event, 'ref21 ref55'); return false;" href="javascript:void(0);" class="ref ref21 ref55">(21,55)</a></div><div class="NLM_p last">One of the most common approaches to overcoming the limitations of topo II poisons in cancer therapy is the development of dual-target inhibitors.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> Topo II is structurally and functionally connected to many other proteins that are used as targets in anticancer therapies, such as human topoisomerase I (topo I), histone deacetylases (HDACs), proteasome, heat shock protein 90 (Hsp90), and various kinases. The structural similarities in the ATP-binding sites of topo II, Hsp90, and some kinases have been widely exploited in the design of dual-target inhibitors, while the functional connection of topo II and HDACs has been defined through numerous studies that have shown that these two enzymes modulate each other’s activities.<a onclick="showRef(event, 'ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60">(58−60)</a> These connections are explained in more detail in the individual sections of this review. We also discuss some targets that do not show any obvious connections to topo II activity but are valuable targets in anticancer therapy on their own (e.g., telomerase and microtubules). These are thus also useful co-targets in the development of dual-target topo II inhibitors, as shown by some effective treatments with combinations of single-target drugs used in the clinic. We present here an overview of the dual inhibitors of topo II and other cancer-related targets, with a focus on the rationale of target selection, the design of dual-target inhibitors, and the biological activities of dual-target inhibitors compared to single-target drugs.</div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">1.3.  Design of Dual Inhibitors of Topoisomerase II and Other Selected Target</h3><div class="NLM_p">Many drugs that are currently used in clinical practice act through modulation of multiple targets; however, such a dual-target or multitarget mechanism of action was often not a part of their design but was discovered only in retrospect. More recently, compounds designed specifically as dual-target ligands have attracted a great deal of interest. The increased complexity of dual-target ligands, compared to single-target ligands, creates several challenges for medicinal chemists, such as the need to combine balanced biological activities on the desired targets and to maintain favorable physicochemical properties.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> To tackle these challenges, medicinal chemists have developed different strategies. The easiest approach in the design of dual-target ligands is to introduce cleavable or noncleavable linkers between two single-target ligands, although this often results in conjugates that show unfavorable pharmacokinetic profiles and low ligand efficiencies. The construction of ligands with fused or overlapping pharmacophores is a more difficult design approach, although this has generally produced compounds with highly improved drug-like and biopharmaceutical properties.<a onclick="showRef(event, 'ref1 ref62'); return false;" href="javascript:void(0);" class="ref ref1 ref62">(1,62)</a></div><div class="NLM_p">Design of dual-target topo II ligands with overlapping pharmacophores is applicable mostly for targets that are structurally related to topo II, such as topo I, which belongs to the same family of enzymes, and Hsp90 and some of the kinases, which have similar ATPase domain structures. The overlapping pharmacophore approach has also been successful in the design of dual-target topo II/telomerase inhibitors, even though these targets are not structurally similar. However, both topo II and telomerase are often targeted by planar compounds, such as ruthenium complexes with planar ligands, which enables the development of dual inhibitors of both of these targets.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> For combinations of topo II inhibitors with inhibitors of targets that have fewer structural similarities, such as HDACs, hybrid inhibitors have mainly been developed.</div><div class="NLM_p">On the basis of our literature survey, a structure-based approach has rarely been used in the design of dual-target inhibitors of topo II. The crystal structure of the full topo II enzyme remains to be determined, which is an important limitation for the design of new inhibitors. For most dual-target (and single-target) inhibitors of topo II described in the literature, the exact modes of their interactions with the target are not known. There are, on the other hand, some crystal structures available for individual domains or fragments of topo II. In 2005, the crystal structure of the ATPase domain of topo IIα with AMP-PNP was published [Protein Data Bank (PDB) entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a><a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a>]. This crystal structure has been successfully used in the development of some new ATP-competitive inhibitors.<a onclick="showRef(event, 'ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref65 ref66 ref67">(65−67)</a> On the basis of the same crystal structure (and two crystal structures of Hsp90, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKR">3EKR</a><a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BYQ">1BYQ</a><a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a>), a molecular docking study was performed that resulted in the development of the pharmacophore model for dual inhibitors of topo II and Hsp90, which should be useful for the future design of dual-target inhibitors.</div><div class="NLM_p last">The crystal structure of topo II with an ATP-competitive small ligand would be even more significant, although this remains unavailable. There are some other topo II crystal structures that are now available: two structures of a human topo IIβ fragment in complex with DNA and etoposide (PDB entries <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3">3QX3</a><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZRF">5ZRF</a><a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a>), a structure of the DNA-bound human topo IIα fragment (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FM9">4FM9</a><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>), and a recent structure of the human topo IIα fragment in complex with DNA and etoposide (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GWK">5GWK</a><a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a>). Despite many efforts, the conformational changes to topo II upon binding of small ligands are still hard to predict, which is why the precise interactions of topo II inhibitors in the active site remain to be defined.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">2.  Dual Inhibitors of Topoisomerase II and Other Cancer-Related Targets</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78804" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78804" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.1.  Topoisomerase I/Topoisomerase II (topo I/II)</h3><div class="NLM_p">The role of topo I is to relax the positively and negatively supercoiled DNA through the formation of single-stranded breaks in the DNA molecule. Contrary to topo II, topo I does not require ATP for its function. Topo I is as well as Topo II a validated target for cancer therapy. Both of these targets share overlapping functions in DNA metabolism and have essential roles in the normal progression of the cell cycle, so targeting both topo I and topo II simultaneously might lead to synergistic anticancer effects.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> Additionally, studies have shown that drug resistance against topo I and topo II inhibitors is often a consequence of downregulation of the target enzyme and compensatory upregulation of the other topoisomerase enzyme. One of the possible mechanisms of resistance to topo II poisons is thus a decrease in topo II levels in cells that is accompanied by an increase in topo I levels, which makes these cells hypersensitive to topo I inhibitors. The reverse phenomenon has also been reported for the development of resistance against topo I. Therefore, targeting both topo I and topo II simultaneously should lower the potential for the development of resistance against such inhibitors.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div><div class="NLM_p">There are many experimental data available on co-application of topo I and topo II inhibitors, with various levels of success. Surprisingly, many of these studies have demonstrated reduced anticancer effects of these combinations compared to the individual topo I or topo II inhibitors,<a onclick="showRef(event, 'ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81">(74−81)</a> while other studies have reported additive or synergistic effects of their co-application.<a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82,83)</a> It has also been demonstrated that the effects are dependent on not only the two drugs that are used in any combination but also many other factors, such as their molar ratio and the application regime (i.e., simultaneous or sequential application).<a onclick="showRef(event, 'ref73 ref84'); return false;" href="javascript:void(0);" class="ref ref73 ref84">(73,84)</a> Indeed, it has been shown almost universally that simultaneous application of topo I and topo II inhibitors results in reduced effects, while their sequential administration results in additive or synergistic effects.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Although clinical trials have been performed for both simultaneous and sequential applications of topo I and topo II poisons, they have all failed due to toxicity issues, more specifically due to severe neutropenia and anemia.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a></div><div class="NLM_p">Dual inhibitors of topo I and topo II have been suggested as an alternative to the combinational approaches.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Many studies in tumor models have shown that compounds that inhibit both targets have an improved <i>in vitro</i> efficacy compared to those of single-target drugs and show potentially reduced toxicity compared to that of the combination therapy.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Thus far, many dual inhibitors of topo I/II have been identified and described. According to Denny et al., dual inhibitors of topo I/II that contain the structural motifs necessary to inhibit both of these targets can be divided into three main groups: intercalators, conjugates (hybrid inhibitors), and non-intercalative molecules.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> These three groups are described below.</div><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">2.1.1.  Intercalators</h4><div class="NLM_p">DNA intercalators are flat aromatic molecules that can bind between two base pairs of a DNA molecule, which results in structural changes to the DNA molecule, such as partial unwinding and extension of the DNA chain. Many DNA intercalators are used clinically for the treatment of cancer, where the mechanism of their action is based on inhibition of DNA and RNA synthesis or DNA damage through topo I or topo II inhibition.<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> Intercalators represent the largest group of known dual topo I/II inhibitors, so the preparation of structural analogues of these scaffolds is the first possible strategy in the design of improved topo I/II inhibitors. A well-studied structural modification of known intercalating scaffolds that often results in potent biological activity is the introduction of a side chain that carries a tertiary amino group. Several compounds that share this structural feature show dual topo I/II inhibition with extremely potent and broad-spectrum activities against different cancer cell lines and in <i>in vivo</i> tumor models (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>8–15</b>). While most of the compounds of this structural type act through poisoning of both topo I and topo II, some also inhibit the catalytic activity of these enzymes (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of the dual intercalating topo I/II inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Intercalating Dual Topo I/II Inhibitors and Their Mechanisms of Inhibition</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">inhibition mechanism</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">intercalating scaffold</th><th class="colsep0 rowsep0" align="center">topo I</th><th class="colsep0 rowsep0" align="center">topo II</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">acridine</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">benzopyridinoindole</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">benzophenazine</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">acridine</td><td class="colsep0 rowsep0" align="left">catalytic</td><td class="colsep0 rowsep0" align="left">catalytic</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">indenoquinoline</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">benzophenazine</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left">catalytic</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">tarcine</td><td class="colsep0 rowsep0" align="left">catalytic</td><td class="colsep0 rowsep0" align="left">catalytic</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">pyrroloquinolinone</td><td class="colsep0 rowsep0" align="left">catalytic</td><td class="colsep0 rowsep0" align="left">catalytic</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">isoindoloquinazoline</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">tetrahydrotetracene</td><td class="colsep0 rowsep0" align="left">poison</td><td class="colsep0 rowsep0" align="left">catalytic</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a>, <a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></td></tr></tbody></table></div></div><div class="NLM_p">In 1993, Riou et al. published the synthesis and evaluation of intoplicine (<b>9</b>) analogues, which demonstrated the importance of dual topo I/II inhibition for improved anticancer activities. Structural modifications of intoplicine led to mixed effects, as only three of 22 synthesized analogues retained dual topo I/II inhibitory activities, eight analogues retained only topo I activities, three retained only topo II activities, and eight lost their activities against both topo I and topo II. As exemplified in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the analogues that acted as dual-target inhibitors showed the best antitumor activities.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Series of Intoplicine (<b>9</b>) Analogues and Their Biological Activities<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0021.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">substituents</th><th class="rowsep1 colsep0" colspan="2" align="center">topoisomerase inhibition score<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">topo I</th><th class="colsep0 rowsep0" align="center">topo II</th><th class="colsep0 rowsep0" align="center" char=".">antitumor activity (%T/C)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">270</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.1</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="char" char=".">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.2</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="char" char=".">202</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.3</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="char" char=".">149</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.4</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">215</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.5</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="char" char=".">164</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.6</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="char" char=".">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.7</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">243</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.8</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="char" char=".">124</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.9</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="char" char=".">143</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9.10</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">232</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">A plus sign indicates the compound accelerated cleavage of pBR322 at least 2-fold compared to the control; a minus sign indicates the extent of stimulation of cleavage was lower.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Percent ratio of median survival time of treated (T) and control (C) mice with iv-implanted P388 leukemia cells.</p></div></div></div><div class="NLM_p">Many intercalating topo I/II inhibitors show <i>in vitro</i> activity against cancer cell lines that are otherwise resistant to topo I and topo II inhibitors, e.g., cell lines with lower levels of expression of topo I or topo II (where <b>8</b> and <b>9</b> show activity) and multidrug-resistant cell lines (where <b>8</b>, <b>10</b>, and <b>11</b> show activity). This confirms the potential of dual topo I/II inhibitors to overcome such mechanisms of resistance.<a onclick="showRef(event, 'ref72 ref86'); return false;" href="javascript:void(0);" class="ref ref72 ref86">(72,86)</a> Another dual intercalating topo I/II inhibitor that is structurally similar to <b>8–15</b> is batracylin (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>16</b>), although batracylin does not have a side chain with a tertiary amino group but does have a directly linked primary amino group. Encouraging preclinical data for <b>8–12</b> and <b>16</b> led to extensive clinical studies; however, none of these compounds reached the marketing stage, which was mostly due to a lack of clinical efficacy.<a onclick="showRef(event, 'ref72 ref86'); return false;" href="javascript:void(0);" class="ref ref72 ref86">(72,86)</a></div><div class="NLM_p">A second important strategy for the discovery of dual topo I/II inhibitors is the introduction of new substituents to the existing topo I or topo II inhibitors that would lead from selective to dual topo I/II inhibition. This strategy has proven to be useful for both intercalating and non-intercalating agents. Anthracycline intercalators isolated from <i>Streptomyces peucetius</i> are clinically well established as topo II poisons, with the most notable examples of doxorubicin and daunorubicin (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>2</b> and <b>3</b>, respectively). Addition of two sugar moieties to the anthracycline scaffold resulted in the discovery of aclarubicin (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>17</b>), which switched in its mechanism of action from stabilization of the topo II–DNA complex to prevention of the formation of this complex.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Additionally, it has been shown that aclarubicin acts as topo I poison, which makes it a dual topo I/II inhibitor.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Aclarubicin has been used in a number of clinical trials and has been approved by the U.S. Food and Drug Administration for treatment of acute myeloid leukemia. Clinical research on aclarubicin is still ongoing, which includes its potential use in different combinations for acute myeloid leukemia, and as a single agent for the treatment of retinal vasculopathy with cerebral leukodystrophy.<a onclick="showRef(event, 'ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref101 ref102">(101,102)</a></div><div class="NLM_p">Ruthenium complexes with polypyridyl ligands have also been identified as intercalating topo II poisons with potential anticancer activities.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> More recently, several similar complexes were synthesized by Wang et al. and He et al. and were demonstrated to have dual topo I/II inhibitory activities, through their poisoning of both topo I and topo II. These compounds have moderate cytotoxic activities against HeLa and HepG2 cancer cell lines, with IC<sub>50</sub> values in the low to mid micromolar range. The most potent, compound <b>18</b>, is shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.<a onclick="showRef(event, 'ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref104 ref105">(104,105)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structure of the ruthenium complex with dual topo I/II inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">2.1.2.  Conjugates</h4><div class="NLM_p">The preparation of conjugates of two single-target binders is one of the well-known approaches in the design of dual-target inhibitors, which appears to be especially useful when pharmacophores have little similarity. One of the main drawbacks of the preparation of conjugates is the loss of “drug-likeness”, as this usually leads to very large molecules.<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(106,107)</a> As demonstrated above, the design of dual-target inhibitors with integrated pharmacophores is feasible in the case of topo I/II, which is probably the reason why the design of topo I/II conjugates has not been the main focus of studies to date. One of the rare attempts was the preparation of camptothecin (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>19</b>)–podophyllotoxin (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>20</b>) hybrids (e.g., <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>21</b>), the development of which was terminated early due to their low potency.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of the topo I inhibitor camptothecin, the topo II inhibitor podophyllotoxin, and their conjugate (<b>21</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A combination of doxorubicin and camptothecin has been shown to have a very promising synergistic antiproliferative activity in some cancer cell lines, but only at certain molar ratios between these two drugs. As doxorubicin and camptothecin have large differences in their pharmacokinetics (i.e., half-lives in humans: 4 min for doxorubicin and 71–90 min for camptothecin<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a>), it is difficult to achieve optimal concentrations for synergistic activity <i>in vivo</i>. This is why polymeric conjugates with hyaluronic acid that carry the optimal ratio between doxorubicin and camptothecin have been designed recently. Conjugates of this type retain the synergistic activities of doxorubicin and camptothecin, and they have been shown to deliver both of these drugs to the cancer cells in a favorable ratio <i>in vivo</i>, with an additionally increased level of accumulation in tumors, which indicates their potential for further development.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.1.3.  Non-Intercalative Dual Topoisomerase I/II Inhibitors</h4><div class="NLM_p">As already mentioned for aclarubicin (<b>17</b>), selective topo I and topo II inhibitors can be structurally optimized to obtain dual topo I/II inhibitory activities, with the prime examples of tafluposide and elomotecan (BN80927) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>22</b> and <b>23</b>, respectively). Tafluposide is an etoposide derivative that shows dual catalytic inhibition of topo I/II and, compared to the parent molecule, shows additional activity on topo I. The excellent cytotoxic activity of tafluposide has been attributed to its induction of mitochondrion-mediated apoptosis. Tafluposide shows potent <i>in vivo</i> activity in different tumor models. Elomotecan was developed from the topo I poison camptothecin and retains the activity of the parent molecule on topo I, while it has an additional catalytic inhibitory activity on topo II. The potent actions of elomotecan against various cell lines, and its improved plasma stability compared to that of camptothecin, have made it a clinical candidate.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Tafluposide (from Pierre Fabre Laboratories) and elomotecan (from the Ipsen Group) both entered phase I clinical trials for the treatment of advanced malignant solid tumors, where they provided acceptable pharmacokinetic and toxicological profiles.<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a> Tafluposide had an especially promising toxicological profile, and in contrast to the combinational topoI/II therapy, it resulted in only slight and infrequent hematological adverse effects. The main toxicity issues associated with exposure to tafluposide were short-term and reversible hepatotoxicity.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Despite the promising initial data, judging by the lack of reports, the clinical development of both of these drugs was later terminated.<a onclick="showRef(event, 'ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref111 ref112">(111,112)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of non-intercalating topo I/II inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Triarylpyridines represent an established structural type of dual topo I/II inhibitors that show significant antiproliferative activities in cancer cell lines.<a onclick="showRef(event, 'ref113 ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref113 ref114 ref115">(113−115)</a> Extensive studies of these compounds have involved systematic substitutions of their three aryl moieties with hydroxyl and chlorine, which has provided information about their structure–activity relationships. Three-dimensional quantitative structure–activity relationship models for these triarylpyridines have also been developed using comparative molecular field analysis, so their further optimization is still expected. The mechanism of action of triarylpyridines has been shown to be non-intercalative catalytic inhibition of topo I and topo II. Example compound <b>24</b> is shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>.<a onclick="showRef(event, 'ref113 ref116'); return false;" href="javascript:void(0);" class="ref ref113 ref116">(113,116)</a> Park et al. designed and synthesized diphenyl benzofuro[3,2-<i>b</i>]pyridines as new dual-target human topoisomerase inhibitors that structurally resemble triarylpyridines. Structure–activity relationship studies were performed to determine the optimal substitution patterns of both phenyl moieties attached to the central scaffold, which identified the phenol substituent at position 4 of the pyridine ring as being essential for dual topo I/II inhibition, as well as for the activity in cancer cell lines. Antiproliferative activities of these compounds were determined using the HCT16, HeLa, and T47D cell lines, where many of these compounds showed significant potency, with IC<sub>50</sub> values ranging from 0.01 to 10 μM. The mechanism of action of compound <b>25</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) was also studied, which turned out to be a non-intercalative catalytic inhibitor of both topo I and topo II.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><div class="NLM_p last">The natural product evodiamine (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>26</b>) was isolated from <i>Camptotheca acuminata</i> (the same plant that is used for camptothecin<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a>) and has been shown to be a dual catalytic topo I/II inhibitor, with moderate activity on both targets.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Evodiamine was later used as a starting point in the design of a novel series of dual topo I/II inhibitors. The best compounds of this series were the hydroxylated derivatives, which showed cytotoxic activities in the nanomolar range and had potent anticancer activities in tumor models, as well as improved physicochemical properties. One of the most promising compounds of this series was 3-amino-10-hydroxyevodiamine (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>27</b>).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.2.  Topoisomerase II/Histone Deacetylases</h3><div class="NLM_p">The important role of epigenetics in cancer has been widely recognized.<a onclick="showRef(event, 'ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref121 ref122">(121,122)</a> Compounds that can modulate the activities of epigenetic enzymes represent potential anticancer drugs. The histone deacetylases (HDACs) are among the most studied epigenetic targets. Changes in HDAC activities have been associated with tumor development, as the HDACs affect the expression of proteins that are important in cell-cycle regulation. Many HDAC inhibitors that have good anticancer activities have been developed, and several are currently used in clinical practice, e.g., vorinostat [also known as suberoylanilide hydroxamic acid (SAHA) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, <b>28</b>)].<a onclick="showRef(event, 'ref123 ref124 ref125 ref126 ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref123 ref124 ref125 ref126 ref127 ref128">(123−128)</a> Targeting HDACs indirectly modulates the expression of some important targets in cancer therapies, such as Hsp90, tubulin, p53, and topo II, which poses the question of their potential synergistic effects in cancer therapies.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Histone deacetylase (HDAC) inhibitor vorinostat (<b>28</b>) and a representation of the general pharmacophore combination concept of dual topo II/HDAC inhibitors, based on compound <b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Vorinostat was the first HDAC inhibitor to enter the clinical practice, when it was approved for the treatment of cutaneous T-cell lymphoma in 2006.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Today, many HDAC inhibitors are in clinical trials for the treatment of different cancers, mostly to be used in combinations with other drugs. They show a promising clinical efficiency for the treatment of acute myeloid leukemia, which is the leading cause of leukemia-related mortality in the United States.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> The current standard therapy for the treatment of acute myeloid leukemia consists of topo II inhibitors, such as mitoxantrone, etoposide, and daunorubicin, in different combinations, most commonly with alkylating agents.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a> Introduction of epigenetic modulators into the established therapy through the use of drug cocktails or through the development of new multitarget inhibitors could prove to be a promising approach to make acute myeloid leukemia a more successfully treatable disease.</div><div class="NLM_p">HDACs and topo II interact directly <i>in vivo</i> as they form functional complexes, whereby each protein modulates the activity of the other.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> Pretreatment of cancer cells with HDAC inhibitors at doses small enough not to affect cell viability on their own increases the sensitivity of cancer cells to topo II poisons <i>in vitro</i> and <i>in vivo</i>, as has been shown by numerous studies.<a onclick="showRef(event, 'ref133 ref134 ref135 ref136 ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref133 ref134 ref135 ref136 ref137 ref138">(133−138)</a> This suggests that the interaction of topo II with HDACs might be of great significance for topo II as a drug target.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Increased anticancer effects of topo II poisons after pretreatment of cancer cells with HDAC inhibitors were also observed in some otherwise resistant cell lines, with downregulated and/or mutated topo II. This effect can be explained with histone hyperacetylation after treatment with HDAC inhibitors and the consequential change in expression of heterochromatin-modulating genes.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> This essentially leads to chromatin decondensation and easier accessibility of the DNA molecule, which is associated with an increased level of binding of topo II poisons and potentiation of their cytotoxic activities. These effects strongly depend on the exposure time of cancer cells to HDAC inhibitors and on their concentration and can under certain conditions also be reversed. The reversed effect was shown by Johnson et al., who observed the decreased cytotoxic activity of etoposide on leukemia cells after pretreatment with the HDAC inhibitor trichostatin A at smaller doses and for shorter exposure times.<a onclick="showRef(event, 'ref133 ref134 ref139'); return false;" href="javascript:void(0);" class="ref ref133 ref134 ref139">(133,134,139)</a></div><div class="NLM_p">Due to the physical and functional interactions between topo II and HDACs <i>in vivo</i>, inhibition of both of these targets simultaneously represents an interesting approach for cancer therapy. The variability of the effects due to different exposure times and doses represents the main limitation of this concept. Due to the different pharmacokinetics of these drugs, co-application might not be the best approach. This problem can potentially be solved by the preparation of dual topo II/HDAC inhibitors, which has recently been attempted.<a onclick="showRef(event, 'ref129 ref140 ref141 ref142 ref143'); return false;" href="javascript:void(0);" class="ref ref129 ref140 ref141 ref142 ref143">(129,140−143)</a></div><div class="NLM_p">Currently known dual topo II/HDAC inhibitors are limited to hybrid molecules of known topo II and HDAC inhibitors. The pioneers of this field, Guerrant et al.,<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> reported on the first dual topo II/HDAC inhibitors in 2012. Their design was based on a general HDAC pharmacophore that contained a cap group with a topo II inhibitor, an aliphatic linker, and a terminal zinc-binding group (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, <b>29</b>). This design approach was also used in later studies. Zhang et al.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> prepared a series of podophyllotoxin (<b>20</b>) derivatives, where they systematically varied the cap group and the linker, and identified compound <b>30</b> as the best in the series (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), which also showed activity in cancer cell lines. He et al.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> used this approach to prepare triple topo I/II/HDAC inhibitors, with the dual topo I/II inhibitor 3-amino-10-hydroxyevodiamine (<b>27</b>) as the cap group. Compound <b>31</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) had triple inhibitory activity and potent cytotoxic effects. More recently, Yamashita et al.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> and Chen et al.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> designed and synthesized novel classes of topo II and HDAC inhibitors. The starting point of the design of the hybrid series of Yamashita et al. was a nucleoside-type topo II inhibitor <b>32</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) that had shown antiproliferative effects on cancer cell lines. Compound <b>33</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), the best of this series, showed inhibition of HDAC1 and HDAC6 in the nanomolar range, with moderate 20-fold selectivity toward HDAC6 compared to HDAC1 and antiproliferative activity against cancer cell lines in the low micromolar range. Topoisomerase II inhibitory activity was determined in a cell-free DNA decatenation assay, where compound <b>33</b> showed activities comparable to those of etoposide, which was used as a control.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Chen et al. used the structure of acridine-like topo II poisons [e.g., amsacrine (m-AMSA) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, <b>34</b>)] as a template, to which they added a linker with the hydroxamic acid group. Compound <b>35</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) inhibited HDACs ∼10-fold more potently than SAHA (<b>28</b>) and additionally showed topo II inhibition and moderate antiproliferative activity in cancer cell lines.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Examples of dual topo II/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Many of the designed dual topo II/HDAC inhibitors have retained their activity against both topo II and HDACs, thus demonstrating that this could be a successful design approach. Dual topo II/HDAC inhibitors usually show good cytotoxic activities; however, synergistic activities have not been observed, as their anticancer activities are at best only comparable to those of the topo II inhibitor included in the conjugate. One of the most potent dual topo II/HDAC inhibitors prepared so far is compound <b>29</b>, a hybrid molecule that is comprised of daunorubicin and SAHA. While <b>29</b> showed better cytotoxic activities in the tested cell lines (e.g., DU-145, SK-MES-1, and MCF-7 cells) compared to SAHA, it was similarly (i.e., DU-145 and MCF-7 cells) or slightly less (i.e., SK-MES-1 cells) active (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) than daunorubicin.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Despite this, dual-target topo II/HDAC inhibitors still show potential as anticancer drugs. The best in class compounds show cytotoxic activities that are comparable to the marketed anticancer drugs and have the advantage of potentially reduced probability for the development of resistance. Nevertheless, some synergistic side effects have been observed, which should be extensively evaluated before further development.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Activities of the Representative Topo II Inhibitor Daunorubicin (<b>3</b>), the Representative Histone Deacetylase (HDAC) Inhibitor SAHA (<b>28</b>), and the Dual Topo II/HDAC Inhibitors, Along with Their Cytotoxic Activities on Selected Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">HDAC inhibition</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">cytotoxic activity</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">topo II inhibition<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">HDAC1</th><th class="colsep0 rowsep0" align="center" char=".">HDAC6</th><th class="colsep0 rowsep0" align="center" char=".">DU-145</th><th class="colsep0 rowsep0" align="center" char=".">HCT-116</th><th class="colsep0 rowsep0" align="center" char=".">MCF-7</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="char" char=".">0.95</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a>, <a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">0.047</td><td class="colsep0 rowsep0" align="char" char=".">0.020</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="char" char=".">0.99</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.0056</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">0.024</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">0.73</td><td class="colsep0 rowsep0" align="char" char=".">0.051</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">+</td><td class="colsep0 rowsep0" align="char" char=".">0.0039</td><td class="colsep0 rowsep0" align="char" char=".">0.0029</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">NT</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Activity in topo II relaxation or decatenation assay: +, active; NT, not tested.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.3.  Topoisomerase II/Hsp90</h3><div class="NLM_p">Topo II poisons act through DNA damage, which leads to apoptosis. However, cells possess complex mechanisms of DNA repair that can, if successful, prevent cell death.<a onclick="showRef(event, 'ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref145 ref146">(145,146)</a> Indeed, overexpression of proteins that are a part of the DNA repair system positively correlates with resistance of cancer cells to topo II poisons. Hsp90 has an important role in the process of DNA repair, as some important proteins in the DNA repair machinery depend heavily on its chaperone activity. Hsp90 is itself an attractive target in anticancer therapy, as it has protein partners that are involved in cancer development, and it is overexpressed in proliferating cancer cells. Co-administration of topo II and Hsp90 inhibitors therefore has the potential to improve the anticancer activity of the individual components and to decrease the rate of resistance development. Synergistic effects of etoposide and 17-allylamino-17-demethoxygeldanamycin [tanespimycin (17-AAG) (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <b>36</b>)], a specific Hsp90 inhibitor, have been shown <i>in vitro</i> in a leukemia cell line.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structure of the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin [tanespimycin (17-AAG), <b>36</b>] and topo II/Hsp90 inhibitor heteronemin (<b>37</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Topo II and Hsp90 both include an ATP-binding site. Indeed, they belong to the same “gyrase, Hsp90, histidine kinase, and MutL” (GHKL) ATPase superfamily. Even though the degree of homology between these two ATP-binding domains is low (16%), their three-dimensional structures can be superimposed <i>in silico</i>, which shows their structural similarity. Recently, Jun et al. published a molecular modeling study in which they compared the topo II and Hsp90 ATPase domains and generated a pharmacophore model for dual topo II/Hsp90 inhibitors. This model might be useful for the discovery of dual inhibitors of these two targets.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p last">Heteronemin (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <b>37</b>) is a secondary metabolite that was isolated from <i>Hyrtios</i> sp. marine sponges and was first described in 1994 as a potent cytotoxic agent in different cancer cell lines at submicromolar concentrations.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> More recently, a study of the mechanism of action of this natural product demonstrated that heteronemin interacts with human topoisomerases and Hsp90.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The induction of apoptosis in a prostate cancer cell line by heteronemin was shown to be immensely multimechanistic, with inhibition of the catalytic activities of both topo I and topo II, and inhibition of the N-terminal domain of Hsp90 in an ATP-competitive fashion, combined with oxidative and endoplasmic reticulum stress.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">2.4.  Topoisomerase II/Proteasome</h3><div class="NLM_p">As discussed in the previous section, the mechanisms of DNA repair can limit the cytotoxic activities of topo II poisons. It has been shown that topo II-induced DNA breaks cannot be processed by the DNA repair mechanisms unless topo II is first proteolytically degraded by the ubiquitin/26 S proteasome. As topo II is degraded, DNA breaks are presented to the DNA repair mechanisms, which enables these repair mechanisms to function properly.<a onclick="showRef(event, 'ref150 ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref150 ref151 ref152">(150−152)</a> It has been shown that inhibition of proteasome with its known inhibitor MG132 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, <b>38</b>) increases the half-lives of the topo IIα–DNA complex in the presence of etoposide and mitoxantrone, from 0.5 and 10 h to >2 and >24 h, respectively, which results in the delay and/or prevention of DNA repair.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> According to Ogiso et al.,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> proteasome inhibition can also restore topo II levels in resistant cells and can therefore reverse the development of resistance. Proteasome inhibitors have therefore been suggested as co-therapies with topo II poisons. Additionally, proteasome inhibition is known to reduce resistance against other anticancer drugs via numerous different mechanisms.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of proteasome inhibitor MG132 (<b>38</b>) and dual topo II/proteasome inhibitor <b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, it appears that the regulatory effects of proteasome on topo II are more complicated than they were initially believed to be, with different studies reaching different conclusions about the effects of proteasome inhibitors on topo II poison-mediated cytotoxicity. Desai et al.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> and Zhang et al.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> reported antagonistic activities of proteasome inhibition on growth-inhibitory effects of topo II poisons, while Lee et al.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> and von Metzler et al.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> showed potentiating effects of proteasome inhibitor MG132 on cytotoxic activities of all six tested topo II poisons, in the K562 leukemia cell line. These studies suggested that the effects were strongly dependent on the model cell lines and the experimental conditions used.</div><div class="NLM_p">Besides the mediating role of proteasome on treatment with topo II poisons, proteasome itself represents a validated anticancer target. Bortezomib was the first proteasome inhibitor that entered the clinical practice as it was approved for the treatment of multiple myeloma.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> It also entered clinical trials for the treatment of acute leukemia. While it failed as a single agent, it showed a good response in phase II studies in combinations with different cytotoxic agents, including doxorubicin.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><div class="NLM_p last">Dual inhibitors of topo II and proteasome might have some advantages compared to current anticancer drugs, specifically decreased resistance development. Few data are available in the literature on dual topo II/proteasome inhibitors, with the only example being the tetra-acridine derivatives reported in 2007, some of which have been shown to inhibit topo II and proteasome <i>in vitro</i> and in cellular models (e.g., <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, <b>39</b>).<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> These compounds also show activities toward the HL-60/MX2 leukemia cell line, which shows resistance to the acridine-type topo II poison <b>34</b>. This supports the assumption that this type of inhibitors can avoid the mechanisms of resistance. However, to confirm this hypothesis, more expanded studies are needed, including confirmation from <i>in vivo</i> data.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.5.  Topoisomerase II/Kinases</h3><div class="NLM_p">Kinase signaling pathways have major roles in normal cell function, and abnormal kinase activities have often been linked to diseases, including cancer. Kinase inhibitors are among the most successful anticancer drugs currently on the market.<a onclick="showRef(event, 'ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref160 ref161">(160,161)</a></div><div class="NLM_p">Kinases can regulate many different proteins in the human body via phosphorylation, including topo II.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Phosphorylation of topo II increases the rate of the religation step of the catalytic cycle by approximately 2-fold, which decreases the levels of etoposide-induced and m-AMSA-induced DNA cleavage by up to 50%. This makes topo II less sensitive to topo II poisons. These findings were supported <i>in vitro</i> by Boichuk et al., who demonstrated that the fibroblast growth factor receptor (FGFR) inhibitor infigratinib (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>40</b>) greatly sensitizes imatinib-resistant gastrointestinal stromal tumor cells to low concentrations of the topo II poisons doxorubicin and etoposide.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Translation of these results to an <i>in vivo</i> syste would mean that kinase inhibition is an interesting approach to potentiating the activity of topo II poisons.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of the tyrosine kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Imatinib (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>41</b>), the prototype kinase inhibitor, has been successfully used in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a><i>In vitro</i> imatinib shows synergistic effects with topo II inhibitors mitoxantrone and etoposide on chronic myeloid leukemia models.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The combination of etoposide and imatinib additionally shows potential to eradicate leukemic stem cells, which is thought to prevent long-term remissions in patients with chronic myeloid leukemia.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> As a relatively new drug class, kinase inhibitors are still undergoing extensive clinical trials. For example, alvocidib (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>42</b>) is showing promising results in phase II clinical trials for the treatment of acute myeloid leukemia in combination with topo II inhibitor mitoxantrone.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><div class="NLM_p">Fluoroquinolones act as bacterial topoisomerase inhibitors, and they represent some of the most important antibacterial agents. At the same time, they were shown to have antiproliferative properties that appear to be mediated through their actions on eukaryotic topoisomerase II, as they produce DNA damage in the same way as topo II poisons.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Other mechanisms might also be associated with the antiproliferative activity of these compounds, such as the regulation of tumor growth factors.<a onclick="showRef(event, 'ref168 ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref168 ref169 ref170">(168−170)</a> On the basis of the structures of the tyrosine kinase inhibitor sunitinib (<b>43</b>) and the bacterial topoisomerase inhibitor ciprofloxacin (<b>44</b>) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), <b>20</b> hybrid molecules that included structural elements of both of these drugs were designed and synthesized. HMNE3 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, <b>45</b>) is structurally a ciprofloxacin dimer that contains sunitinib’s chalcone-like structural motif. This molecule was the most promising compound of this series and showed inhibitory activity against tyrosine kinases and topo II and cytotoxic activity in six selected cell lines (i.e., Panc-1, T24, BGC-823, PU145, HCG-27, and Capan-1 cells), with low micromolar IC<sub>50</sub> values.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of sunitinib (<b>43</b>), ciprofloxacin (<b>44</b>), and a dual inhibitor of topo II and kinases (<b>45</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Topo II and epidermal growth factor receptor (EGFR) tyrosine kinase have been shown to modify each other’s expression <i>in vivo</i> in various cancer types, and furthermore, high levels of EGFR have been shown to be linked to the development of resistance of cancer cells to topo II inhibitors.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> EGFR is overexpressed in a variety of cancers and has a regulatory role in their growth. Simultaneous inhibition of topo II and EGFR might thus be an effective strategy for anticancer treatments. Recently, Chauhan et al. reported on the first dual inhibitors of topo II and EGFR.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Their design strategy was based on the quinazoline-type EGFR inhibitors [e.g., gefitinib (<b>46</b>) and erlotinib (<b>47</b>) (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>)], which also act on topoisomerases. On the basis of these EGFR inhibitors, a series of quinoline derivatives were designed, synthesized, and tested for their inhibition of both topo II and EGFR and for their cytotoxic activities in cancer cell lines <i>in vitro</i>. These compounds (e.g., <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>48</b>) were confirmed to be dual topo II/EGFR inhibitors that showed catalytic inhibition of topo II and possessed antiproliferative activities against selected cell lines (i.e., A549, H460, HCT-116 p53, and PC-3 cells), with micromolar IC<sub>50</sub> values. Further optimization of these compounds was indicated, but to date, there have been no further reports of these in the literature.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of the quinazoline-type EGFR inhibitors gefitinib (<b>46</b>), erlotinib (<b>47</b>), and the dual topo II/EGFR inhibitor (<b>48</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dovitinib (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>49</b>) is a multikinase inhibitor that has recently been used in extensive clinical studies. It was designed as an ATP-competitive kinase inhibitor and was demonstrated to be a potent inhibitor of an array of human kinases, including the FGFR1, FGFR3, vascular endothelial growth factor receptor (VEGFR), FLT3, c-KIT, and colony-stimulating factor 1 receptor kinases.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Due to its nonselective affinity for ATP-binding sites, catalytic inhibition of topo II was also considered. Additionally, as dovitinib is closely structurally similar to the intercalating dye Hoechst 33258 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>50</b>), studies have also shown its intercalating properties.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> As intercalators commonly show cytotoxic activities through inhibition of the topoisomerase enzymes, dovitinib was screened against topo I and topo II and demonstrated to be a dual topo I/II poison as well as a catalytic ATP-competitive inhibitor of topo II. Kinase inhibition is still considered to be the main mechanism of action of dovitinib, although dual topo I/II inhibition might also have a role in its cytotoxicity.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structure of dovitinib (<b>49</b>), the Hoechst 33258 dye (<b>50</b>), and NK314 (<b>51</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">NK314 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>51</b>) is a topo II poison that has shown potent <i>in vitro</i> and <i>in vivo</i> anticancer activities, especially in different adult T-cell leukemia cell lines (IC<sub>50</sub> values, 23–70 nM). Subsequent in-depth investigations of the mechanism of action of NK314 revealed that in addition to its inhibition of topo II, the anticancer effects were also a consequence of inhibition of DNA-dependent protein kinase (DNA-PK) and ataxia telangiectasia mutated (ATM) protein kinase. DNA-PKs are abundant in adult T-cell leukemia cells, which appears to be the main reason for the greater activity of NK314 against adult T-cell leukemia cell lines. NK314 showed antitumor activity in xenograft models that are resistant to etoposide and doxorubicin and is thus an example of the potential of dual-target inhibitors to combat resistance.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Toxicity studies have also been performed, where NK314 showed acceptable toxicity, with mild toxicity on bone marrow cells. Due to its remarkable anticancer activity and acceptable toxicological profile, NK314 is a drug candidate for the treatment of adult T-cell leukemia and has already been taken into clinical trials in Japan.<a onclick="showRef(event, 'ref175 ref176'); return false;" href="javascript:void(0);" class="ref ref175 ref176">(175,176)</a></div><div class="NLM_p">The tyrosine kinase receptors, i.e., EGFR, VEGFR, PDGFR, and FGFR, have also been shown to play major roles in angiogenesis, which promotes tumor growth. Indeed, simultaneous therapies with cytotoxic and anti-angiogenic agents have been suggested as a promising strategy for cancer therapy.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Wang et al. designed and synthesized a series of naphthalimide derivatives as dual topo II/tyrosine kinase receptor inhibitors. Most compounds showed topo II inhibition and cytotoxic activities in HL60, MDA-MB-231, and A549 cancer cell lines, with IC<sub>50</sub> values in the micromolar range, although only two of these compounds also weakly inhibited tyrosine kinase receptors. One of them has also been confirmed to have anti-angiogenic activity (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, <b>52</b>).<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structure of compound <b>52</b> and its inhibitory activities against selected tyrosine kinases and cancer cell lines (as indicated).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">2.6.  Topoisomerase II/Telomerase</h3><div class="NLM_p">During each cell cycle, approximately 50 terminal nucleotides are lost, as the DNA polymerases cannot copy the genetic material at the end of the chromosomes. Telomere sequences prevent the loss of genetic material during replication, and when they get too short, they can trigger cell death.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> This limits the life span of human somatic cells to 50–70 cell divisions. Telomerases are enzymes that maintain the lengths of the telomeres, which means that cells with telomerase activity have unlimited replication potential, and as such, they are often termed immortal. Telomerases are found in gametes, tumor cells, and stem cells.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> As telomerases define the immortality of cancer cells, they represent exciting targets for anticancer therapy and might be useful in combination with established anticancer drugs.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">The quinobenzoxazine derivative A-62176 (<b>53</b>) has a structure that resembles that of the fluoroquinolone levofloxacin (<b>54</b>), and it has been reported to be a dual topo II/telomerase inhibitor (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Because of its planar structure, A-62176 acts as a topo II poison, although it has also been shown that it inhibits the catalytic activity of topo II and that it interacts with the planar G-quadruplex structures that are known secondary structures of guanine-rich nucleic acid sequences. Interactions with the G-quadruplex represent a known mechanism of inhibition of telomerase activity. On the basis of this discovery, Kim et al.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> identified several new classes of dual topo II/telomerase inhibitors with additional cyclic structures attached to the parent molecule that improved the π–π stacking with the G-quadruplex. This led to the discovery of pyridobenzophenoxazines, fluoroquinophenoxazines, and fluoroquinoanthroxazines.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Compound <b>55</b> and its stereoisomer (<b>56</b>) are fluoroquinoanthroxazines, and they were determined to have the most balanced dual topo II/telomerase inhibitor activities (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, <b>56</b> shows similar cytotoxicity in cell lines that are either sensitive or resistant to topo II inhibitors, which demonstrates the potential of this approach to overcome resistance issues.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> More recently, Liao et al. reported on ruthenium(II) polypyridyl complexes that act through induction and stabilization of the G-quadruplex to inhibit telomerase, while they also have dual topo I/II poisoning activities.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Structurally, these complexes are very similar to topo I/II inhibiting complex <b>18</b>. The most promising of the three ruthenium complexes (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>57</b>) showed moderate cytotoxic activities, with IC<sub>50</sub> values against the HepG2, HeLa, and A549 cancer cell lines of 20–25 μM.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of levofloxacin (<b>54</b>) and the dual topo II/telomerase inhibitors <b>53</b>, <b>55</b>, and <b>56</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure of a topo II/telomerase inhibiting ruthenium complex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> Cytotoxic Activities of Doxorubicin (<b>2</b>) and Compounds <b>55</b> and <b>56</b> on Selected Cancer Cell Lines<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">MCF-7</th><th class="colsep0 rowsep0" align="center" char=".">8226/S<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">8226/DOX1V<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">DOX1V/S ratio<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">0.037</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">0.69</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Multiple myeloma cancer cell line.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Doxorubicin-resistant 8226/S cancer cell line.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Ratio of IC<sub>50</sub> values against 8226/DOX1V and 8226/S cell lines.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">2.7.  Topoisomerase II/Microtubule-Interfering Agents</h3><div class="NLM_p">Microtubules are polymers that are composed of α-tubulin and β-tubulin subunits, which constitute the major part of the cytoskeleton in eukaryotic cells. They are essential for the maintenance of cell shape and are involved in intracellular transport, cell motility, growth, and division, and cell interactions with the environment. Microtubules control these biological processes through their polymerization dynamics, which enables them to actively and rapidly grow or shrink in response to cellular needs. Drugs that influence the dynamics of microtubules can block mitosis and therefore act as anticancer agents.<a onclick="showRef(event, 'ref182 ref183'); return false;" href="javascript:void(0);" class="ref ref182 ref183">(182,183)</a></div><div class="NLM_p">Microtubule-interfering agents can be divided into two major groups: destabilizers [e.g., <i>Vinca</i> alkaloids (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>58</b>) and colchicine (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>59</b>)] and stabilizers [e.g., taxanes (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>60</b> and <b>61</b>)]. Both of these groups are widely used in the treatment of cancer, especially in combination with other established anticancer drugs.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a><i>Vinca</i> alkaloids and topo II inhibitors have been successfully used in drug cocktails for the treatment of different cancers. For example, a combination of vinblastine, doxorubicin, belomycin, and dacarbazine is currently very efficiently used in the first-line treatment of Hodgkin lymphoma, while the combination of vincristine, doxorubicin, cyclophosphamide, and dexamethasone has been successfully used for acute lymphoblastic leukemia.<a onclick="showRef(event, 'ref158 ref185'); return false;" href="javascript:void(0);" class="ref ref158 ref185">(158,185)</a> Other clinically important combinations are combinations of the microtubule stabilizers docetaxel (<b>58</b>) or paclitaxel (<b>59</b>) with the topo II poison doxorubicin (<b>2</b>).<a onclick="showRef(event, 'ref186 ref187'); return false;" href="javascript:void(0);" class="ref ref186 ref187">(186,187)</a> The combination of docetaxel and doxorubicin was clinically investigated for the treatment of breast cancer, showing very high efficacy but also high toxicity due to pharmacokinetic interactions between both drugs.<a onclick="showRef(event, 'ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref188 ref189">(188,189)</a> Most other combinations show no additive or synergistic effects. For example, the combination of colchicine (<b>57</b>) with etoposide resulted in the elimination of the effects of each by the other.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Another challenge is the development of resistance to these combinations, as both of the drugs used are sensitive to overexpression of efflux transporters.<a onclick="showRef(event, 'ref191 ref192'); return false;" href="javascript:void(0);" class="ref ref191 ref192">(191,192)</a> To overcome the limitations of these combination therapies, multitarget drugs have been suggested. The field of dual topo II/microtubule inhibitors is still underdeveloped, although some examples can be found in the literature.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of known microtubule-interfering agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">YCH337 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>, <b>62</b>) is an α-carboline derivative that was shown to target microtubules through its binding to the colchicine-binding site, which leads to the blocking of mitosis and subsequent cell apoptosis. Additionally, YCH337 (<b>62</b>) was shown to induce DNA double-stranded breaks through targeting topo II. The <i>in vitro</i> cytotoxicity of <b>62</b> was investigated in 19 cancer cell lines, where it showed a very promising activity with submicromolar IC<sub>50</sub> values in all of the cell lines used. Compound <b>62</b> therefore has broad-spectrum anticancer potential. It has also shown significant anticancer activity in <i>in vivo</i> assays in mouse xenograft models. On the basis of these promising data, <b>62</b> represents a lead compound for the development of new multitarget ligands that are aimed at topo II and microtubules.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of dual topo II/microtubule-interfering agents and their activities on selected cancer cell lines (as indicated).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">DTA0100 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>, <b>63</b>) is another recently described compound that interferes with topo II and microtubules. Like <b>62</b>, DTA0100 binds to the colchicine-binding site on microtubules and promotes cell apoptosis, although it has a different topo II inhibition mechanism, as it acts as a catalytic inhibitor.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Another promising feature of DTA0100 is its P-glycoprotein inhibition; this can potentially reduce the extent of P-glycoprotein-mediated drug efflux, which is an important issue of topo II and microtubule-targeting drugs.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Even more recently, Hao et al. prepared novel conjugates of podophyllotoxin and coumarin and evaluated their cytotoxic activities on A549, HepG2, HeLa, and LoVo cancer cell lines. The best compound of the series (<b>64</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) displayed superior cytotoxic activities compared to those of etoposide on the selected cell lines and was shown to inhibit topo IIβ and disrupt the microtubule organization in LoVo cells.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">3.  Conclusions and Outlook</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13572" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13572" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The design and development of dual inhibitors that target topo II and other cancer targets represent attractive approaches for new anticancer drugs. Extensive studies have been devoted to the discovery of dual topo I/II inhibitors, which have resulted in many clinical candidates; however, only one, aclarubicin, has reached the market to date. Nevertheless, the dual-target inhibition properties of this drug are also controversial, as topo II appears to be the major target of aclarubicin in cells, which poses the question of whether inhibition of topo I is relevant <i>in vivo</i>. There have also been efforts to develop dual inhibitors of topo II and HDACs, proteasome, tyrosine kinases, telomerase, and microtubule-interfering agents; however, more studies are needed to fully evaluate the potential of these dual-target inhibitors. There are currently no data in the literature on the development of new dual topo II/Hsp90 inhibitors, with the exception of the natural compound heteronemin, which was recently shown to inhibit both topo II and Hsp90.</div><div class="NLM_p last">In this Perspective, we have described the rationale behind the target selection for the development of dual topo II inhibitors. In our opinion, dual inhibitors of topo II and either topo I, Hsp90 or kinases currently show the greatest potential. As all of these targets are structurally similar to topo II, the pharmacophore overlap is high, which enables the development of integrated dual-target inhibitors that generally show better physicochemical properties compared to those of conjugates. Dual inhibitors of topo II and kinases represent an especially attractive approach because of the enormous success of the marketed kinase inhibitors over the past two decades. Additionally, the design of dual topo II/Hsp90 inhibitors represents an interesting opportunity because of the structural similarities of the ATP-binding sites of both enzymes and because Hsp90 has an important role in the DNA repair machinery, which is one of the major causes of resistance against topoisomerase-targeted drugs. Overall, the discovery of dual inhibitors of topo II and other cancer-related targets shows great potential but is currently greatly underdeveloped. However, we are convinced that such inhibitors will have an important role in the future discovery of new anticancer drugs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00726" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36106" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36106" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janez Ilaš</span> - <span class="hlFld-Affiliation affiliation">Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0124-0474" title="Orcid link">http://orcid.org/0000-0002-0124-0474</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f19b909f948bdf989d9082b1979790df849f98dc9d9bdf8298"><span class="__cf_email__" data-cfemail="096368676c73276065687a496f6f68277c6760246563277a60">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Žiga Skok</span> - <span class="hlFld-Affiliation affiliation">Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nace Zidar</span> - <span class="hlFld-Affiliation affiliation">Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1905-0158" title="Orcid link">http://orcid.org/0000-0003-1905-0158</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danijel Kikelj</span> - <span class="hlFld-Affiliation affiliation">Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77587" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77587" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Žiga Skok</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=BIO-d7e2362-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Žiga Skok</b> obtained his Master’s degree in pharmacy (2016) at the Faculty of Pharmacy of the University of Ljubljana (Ljubljana, Slovenia). The main focus of his Master’s thesis was the synthesis of new ATP-competitive inhibitors of Hsp90 and bacterial DNA gyrase. He subsequently started with his postgraduate studies (in biomedicine) and accepted a position as a Young Researcher at The Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana. His current research work is under the supervision of Associate Professor Janez Ilaš, Ph.D., and includes the design, synthesis, and evaluation of new DNA topoisomerase II inhibitors as potential anticancer drugs.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Nace Zidar</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=BIO-d7e2367-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Nace Zidar</b> is an assistant professor of medicinal chemistry at the Faculty of Pharmacy, University of Ljubljana. In 2015, he completed a two-year postdoctoral project on the discovery of voltage-gated sodium channel modulators. In 2017, he completed his postdoctoral training at the University of Milan (Milan, Italy). Recently, he collaborated in the EU H2020 MSCA-ITN INTEGRATE, where he was involved in the discovery of compounds with activity against Gram-negative bacteria. His research interests involve rational drug design, synthesis, and evaluation of new bioactive compounds with activities against topoisomerases and voltage-gated ion channels. He is a co-author of more than 30 SCI original scientific papers, a recipient of the 2010 Faculty of Pharmacy Award for high-impact publication, and the winner of the 2011 Krka Prize.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Danijel Kikelj</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=BIO-d7e2372-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Danijel Kikelj</b> obtained his Ph.D. in pharmaceutical chemistry at the University of Heidelberg (Heidelberg, Germany) in 1988. Since 2000, he has been working at the Faculty of Pharmacy, University of Ljubljana, as a full professor of medicinal chemistry. Since 1999, he has been the head of a research group and the head of the medicinal chemistry research program financed by the Slovenian Research Agency. He has participated in two EU projects from the seventh Framework Programme and from Horizon 2020 and in ongoing Marie Sklodowska Curie ETN INTEGRATE. The main areas of his research are medicinal chemistry, peptidomimetics, structure-based design of dual antithrombotic compounds, pharmaceutical leads based on marine bioactive compounds, and most recently discovery of inhibitors of bacterial topoisomerases with activity against Gram-negative bacteria.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Janez Ilaš</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=BIO-d7e2377-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Janez Ilaš</b> studied pharmacy at the Faculty of Pharmacy, University of Ljubljana, where he obtained a Ph.D. in 2008. He has been an associate professor of pharmaceutical chemistry at the Faculty of Pharmacy, University of Ljubljana, since 2013. His research interests are the design, synthesis, and evaluation of small-molecule enzyme inhibitors for different therapeutic areas, including infectious diseases and cancer. He has authored more than 50 papers and has been involved in academic and EU-funded drug discovery programs (Marie Sklodowska Curie ETN INTEGRATE).</p></figure></div><div class="ack" id="ACK-d7e2382-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Support was provided by the ARRS-Slovenian Research Agency (Project P1-0208). The authors thank Christopher Berrie for proofreading the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">17-AAG</td><td class="NLM_def"><p class="first last">17-<i>N</i>-allylamino-17-demethoxygeldanamycin</p></td></tr><tr><td class="NLM_term">AMP-PNP</td><td class="NLM_def"><p class="first last">adenylyl-imidodiphosphate</p></td></tr><tr><td class="NLM_term">ATM</td><td class="NLM_def"><p class="first last">ataxia telangiectasia mutated</p></td></tr><tr><td class="NLM_term">DNA-PK</td><td class="NLM_def"><p class="first last">DNA-dependent protein kinase</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">GHKL</td><td class="NLM_def"><p class="first last">ATP-binding superfamily (gyrase, Hsp90, histidine kinase, MutL)</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">Hsp90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">m-AMSA</td><td class="NLM_def"><p class="first last"><i>N</i>-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">SAHA</td><td class="NLM_def"><p class="first last">suberanilohydroxamic acid</p></td></tr><tr><td class="NLM_term">topo I</td><td class="NLM_def"><p class="first last">human DNA topoisomerase I</p></td></tr><tr><td class="NLM_term">topo II</td><td class="NLM_def"><p class="first last">human DNA topoisomerase II</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 196 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talevi, A.</span></span> <span> </span><span class="NLM_article-title">Multi-target pharmacology: possibilities and limitations of the ″skeleton key approach″ from a medicinal chemist perspective</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3389%2Ffphar.2015.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26441661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=205&author=A.+Talevi&title=Multi-target+pharmacology%3A+possibilities+and+limitations+of+the+%E2%80%B3skeleton+key+approach%E2%80%B3+from+a+medicinal+chemist+perspective&doi=10.3389%2Ffphar.2015.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective</span></div><div class="casAuthors">Talevi, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205/1-205/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues.  Prospective drug repositioning to treat comorbid conditions is an addnl., overlooked application of multi-target ligands.  While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacol. recognizes that the mid- and long-term effects of a given drug on a biol. system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature.  The design of multi-target agents usually imposes challenging restrictions on the topol. or flexibility of the candidate drugs, which are briefly discussed in the present article.  Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSdZokyMjNSLVg90H21EOLACvtfcHk0liWAprDwWkOnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM&md5=169718a4644d962da33806772a9a33e3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00205%26sid%3Dliteratum%253Aachs%26aulast%3DTalevi%26aufirst%3DA.%26atitle%3DMulti-target%2520pharmacology%253A%2520possibilities%2520and%2520limitations%2520of%2520the%2520%25E2%2580%25B3skeleton%2520key%2520approach%25E2%2580%25B3%2520from%2520a%2520medicinal%2520chemist%2520perspective%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D205%26doi%3D10.3389%2Ffphar.2015.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span> <span> </span><span class="NLM_article-title">Why is cancer drug discovery so difficult?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1038/nrd2155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrd2155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17159925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=115-120&issue=2&author=A.+Kambauthor=S.+Weeauthor=C.+Lengauer&title=Why+is+cancer+drug+discovery+so+difficult%3F&doi=10.1038%2Fnrd2155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Why is cancer drug discovery so difficult?</span></div><div class="casAuthors">Kamb, Alexander; Wee, Susan; Lengauer, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-120</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thirty-five years after the 'war on cancer' was declared, the discovery of anticancer drugs remains a highly challenging endeavor.  Here, we consider the factors responsible, such as tumor heterogeneity, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYsRgFvOR6O7Vg90H21EOLACvtfcHk0ljj9AGMjsXPig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGlsrw%253D&md5=0ee9e19541b8f3f0ed495b3de44b3ad3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd2155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2155%26sid%3Dliteratum%253Aachs%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWee%26aufirst%3DS.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DWhy%2520is%2520cancer%2520drug%2520discovery%2520so%2520difficult%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D2%26spage%3D115%26epage%3D120%26doi%3D10.1038%2Fnrd2155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: the rise of multitarget drugs over combination therapies</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.4155%2Ffmc.14.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24649950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=485-487&issue=5&author=M.+Rosini&title=Polypharmacology%3A+the+rise+of+multitarget+drugs+over+combination+therapies&doi=10.4155%2Ffmc.14.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: the rise of multitarget drugs over combination therapies</span></div><div class="casAuthors">Rosini, Michela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-487</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNBzYCAfAa7Vg90H21EOLACvtfcHk0ljj9AGMjsXPig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D&md5=0c32e1a1ae5a13cd25483ba18833fd54</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.25%26sid%3Dliteratum%253Aachs%26aulast%3DRosini%26aufirst%3DM.%26atitle%3DPolypharmacology%253A%2520the%2520rise%2520of%2520multitarget%2520drugs%2520over%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26issue%3D5%26spage%3D485%26epage%3D487%26doi%3D10.4155%2Ffmc.14.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikelj, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilas, J.</span></span> <span> </span><span class="NLM_article-title">Multitarget antithrombotic drugs</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2834</span>– <span class="NLM_lpage">2848</span>, <span class="refDoi"> DOI: 10.2174/156802611798184364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F156802611798184364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=22039882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2834-2848&issue=22&author=M.+Ilicauthor=D.+Kikeljauthor=J.+Ilas&title=Multitarget+antithrombotic+drugs&doi=10.2174%2F156802611798184364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget antithrombotic drugs</span></div><div class="casAuthors">Ilic, Milos; Kikelj, Danijel; Ilas, Janez</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2834-2848</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Thromboembolic disorders are still the leading causes of morbidity and mortality in developed societies.  Therefore, prophylaxis and treatment of arterial and venous thrombosis are among the main therapeutic challenges nowadays.  Simultaneous action on several targets involved in pathol. of thrombosis offers potential advantages compared to existing drugs which were developed as selective modulators of single targets.  The review focuses on dual inhibitors of coagulation enzymes, dual antiaggregatory compds. exerting their action on different combinations of platelet targets, as well as on anticoagulant/antiaggregatory compds. which interfere with at least one target involved in blood coagulation and at least one target engaged in the process leading to platelet aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqya91G6eGic7Vg90H21EOLACvtfcHk0ljj9AGMjsXPig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehtbk%253D&md5=244f7f10fae7d06573b5e8284e08f602</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F156802611798184364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798184364%26sid%3Dliteratum%253Aachs%26aulast%3DIlic%26aufirst%3DM.%26aulast%3DKikelj%26aufirst%3DD.%26aulast%3DIlas%26aufirst%3DJ.%26atitle%3DMultitarget%2520antithrombotic%2520drugs%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26issue%3D22%26spage%3D2834%26epage%3D2848%26doi%3D10.2174%2F156802611798184364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span> <span> </span><span class="NLM_article-title">Multi-kinase inhibitors</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.2174/0929867321666141216125528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F0929867321666141216125528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25511779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=695-712&issue=6&author=L.+Garutiauthor=M.+Robertiauthor=G.+Bottegoni&title=Multi-kinase+inhibitors&doi=10.2174%2F0929867321666141216125528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Kinase Inhibitors</span></div><div class="casAuthors">Garuti, Laura; Roberti, Marinella; Bottegoni, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-712</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The limitations of many mono-kinase inhibitors can be overcome by agents with multi-target action.  An important advantage of targeting more than one kinase, is an increase in potency, due to the synergistic effect.  Moreover, this approach can reduce the possibility of developing drug resistance.  Several multitarget agents have been designed as single kinase inhibitors and found to be multi-target inhibitors because of the structural homol. among the ATP-binding site of kinases.  In other cases, these inhibitors have been obtained by optimization of potent individual inhibitors or by combination of selective ligands.  Also some irreversible inhibitors act on different kinases and covalently modify the cysteine residues located near the ATP-binding pocket.  In this review the most recent examples of multi-kinase inhibitors are reported, focusing on chem. structures, structure-activity relationship (SAR) and biol. activity.  These inhibitors, suitably substituted, could be used in designing other multitarget agents.  Virtual mol. docking would suggest potential targets of mols., moreover combining pharmacophore combination and screening methods could probably help in the discovery of more potent multikinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJtiGNXK9ZFrVg90H21EOLACvtfcHk0liB4yx5pZAPqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKht70%253D&md5=2dea8ef8b5f7b5674f86969283e295c8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F0929867321666141216125528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666141216125528%26sid%3Dliteratum%253Aachs%26aulast%3DGaruti%26aufirst%3DL.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DMulti-kinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26issue%3D6%26spage%3D695%26epage%3D712%26doi%3D10.2174%2F0929867321666141216125528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C. J.</span></span> <span> </span><span class="NLM_article-title">The structural basis for cancer treatment decisions</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7285</span>– <span class="NLM_lpage">7302</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.18632%2Foncotarget.2439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25277176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC2M7ntVagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=7285-7302&issue=17&author=R.+Nussinovauthor=H.+Jangauthor=C.+J.+Tsai&title=The+structural+basis+for+cancer+treatment+decisions&doi=10.18632%2Foncotarget.2439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for cancer treatment decisions</span></div><div class="casAuthors">Nussinov Ruth; Jang Hyunbum; Tsai Chung-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7285-302</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer treatment decisions rely on genetics, large data screens and clinical pharmacology.  Here we point out that genetic analysis and treatment decisions may overlook critical elements in cancer development, progression and drug resistance.  Two critical structural elements are missing in genetics-based decision-making: the mechanisms of oncogenic mutations and the cellular network which is rewired in cancer.  These lay the foundation for the structural basis for cancer treatment decisions, which is rooted in the physical principles of the molecular conformational behavior of single molecules and their interactions.  Improved tumor mutational analysis platforms and knowledge of the redundant pathways which can take over in cancer, may not only supplement known actionable findings, but forecast possible cancer progression and resistance.  Such forward-looking can be powerful, endowing the oncologist with mechanistic insight and cancer prognosis, and consequently more informed treatment options.  Examples include redundant pathways taking over after inhibition of EGFR constitutive activation, mutations in PIK3CA p110α and p85, and the non-hotspot AKT1 mutants conferring constitutive membrane localization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbVVQKsYBUc4YPsCkJIw00fW6udTcc2ebhj-DgmFFl4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7ntVagtg%253D%253D&md5=9440f52e4e32b7e9a20309f7a909d7ad</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2439%26sid%3Dliteratum%253Aachs%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DTsai%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520structural%2520basis%2520for%2520cancer%2520treatment%2520decisions%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26issue%3D17%26spage%3D7285%26epage%3D7302%26doi%3D10.18632%2Foncotarget.2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Djulbegovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hozo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bepler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. L.</span></span> <span> </span><span class="NLM_article-title">Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006</span>. <i>Arch. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">632</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1001/archinte.168.6.632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1001%2Farchinte.168.6.632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18362256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BD1c3gtl2ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2008&pages=632-642&issue=6&author=B.+Djulbegovicauthor=A.+Kumarauthor=H.+P.+Soaresauthor=I.+Hozoauthor=G.+Beplerauthor=M.+Clarkeauthor=C.+L.+Bennett&title=Treatment+success+in+cancer%3A+new+cancer+treatment+successes+identified+in+phase+3+randomized+controlled+trials+conducted+by+the+National+Cancer+Institute-sponsored+cooperative+oncology+groups%2C+1955+to+2006&doi=10.1001%2Farchinte.168.6.632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006</span></div><div class="casAuthors">Djulbegovic Benjamin; Kumar Ambuj; Soares Heloisa P; Hozo Iztok; Bepler Gerold; Clarke Mike; Bennett Charles L</div><div class="citationInfo"><span class="NLM_cas:title">Archives of internal medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">632-42</span>
        ISSN:<span class="NLM_cas:issn">0003-9926</span>.
    </div><div class="casAbstract">BACKGROUND:  The evaluation of research output, such as estimation of the proportion of treatment successes, is of ethical, scientific, and public importance but has rarely been evaluated systematically.  We assessed how often experimental cancer treatments that undergo testing in randomized clinical trials (RCTs) result in discovery of successful new interventions.  METHODS:  We extracted data from all completed (published and unpublished) phase 3 RCTs conducted by the National Cancer Institute cooperative groups since their inception in 1955.  Therapeutic successes were determined by (1) assessing the proportion of statistically significant trials favoring new or standard treatments, (2) determining the proportion of the trials in which new treatments were considered superior to standard treatments according to the original researchers, and (3) quantitatively synthesizing data for main clinical outcomes (overall and event-free survival).  RESULTS:  Data from 624 trials (781 randomized comparisons) involving 216 451 patients were analyzed.  In all, 30% of trials had statistically significant results, of which new interventions were superior to established treatments in 80% of trials.  The original researchers judged that the risk-benefit profile favored new treatments in 41% of comparisons (316 of 766).  Hazard ratios for overall and event-free survival, available for 614 comparisons, were 0.95 (99% confidence interval [CI], 0.93-0.98) and 0.90 (99% CI, 0.87- 0.93), respectively, slightly favoring new treatments.  Breakthrough interventions were discovered in 15% of trials.  CONCLUSIONS:  Approximately 25% to 50% of new cancer treatments that reach the stage of assessment in RCTs will prove successful.  The pattern of successes has become more stable over time.  The results are consistent with the hypothesis that the ethical principle of equipoise defines limits of discoverability in clinical research and ultimately drives therapeutic advances in clinical medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlmFRnjv5cEgvupmecNw_lfW6udTcc2eY4vdF5cwkfzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3gtl2ltA%253D%253D&md5=db64df9c5c3dbc9ab767507f80349826</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1001%2Farchinte.168.6.632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchinte.168.6.632%26sid%3Dliteratum%253Aachs%26aulast%3DDjulbegovic%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSoares%26aufirst%3DH.%2BP.%26aulast%3DHozo%26aufirst%3DI.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DC.%2BL.%26atitle%3DTreatment%2520success%2520in%2520cancer%253A%2520new%2520cancer%2520treatment%2520successes%2520identified%2520in%2520phase%25203%2520randomized%2520controlled%2520trials%2520conducted%2520by%2520the%2520National%2520Cancer%2520Institute-sponsored%2520cooperative%2520oncology%2520groups%252C%25201955%2520to%25202006%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D2008%26volume%3D168%26issue%3D6%26spage%3D632%26epage%3D642%26doi%3D10.1001%2Farchinte.168.6.632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayat
Mokhtari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homayouni, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgatskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeger, H.</span></span> <span> </span><span class="NLM_article-title">Combination therapy in combating cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">38022</span>– <span class="NLM_lpage">38043</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.16723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.18632%2Foncotarget.16723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28410237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnvV2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=38022-38043&issue=23&author=R.+Bayat%0AMokhtariauthor=T.+S.+Homayouniauthor=N.+Baluchauthor=E.+Morgatskayaauthor=S.+Kumarauthor=B.+Dasauthor=H.+Yeger&title=Combination+therapy+in+combating+cancer&doi=10.18632%2Foncotarget.16723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy in combating cancer</span></div><div class="casAuthors">Bayat Mokhtari Reza; Homayouni Tina S; Morgatskaya Evgeniya; Kumar Sushil; Yeger Herman; Bayat Mokhtari Reza; Yeger Herman; Bayat Mokhtari Reza; Das Bikul; Baluch Narges</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">38022-38043</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Combination therapy, a treatment modality that combines two or more therapeutic agents, is a cornerstone of cancer therapy.  The amalgamation of anti-cancer drugs enhances efficacy compared to the mono-therapy approach because it targets key pathways in a characteristically synergistic or an additive manner.  This approach potentially reduces drug resistance, while simultaneously providing therapeutic anti-cancer benefits, such as reducing tumour growth and metastatic potential, arresting mitotically active cells, reducing cancer stem cell populations, and inducing apoptosis.  The 5-year survival rates for most metastatic cancers are still quite low, and the process of developing a new anti-cancer drug is costly and extremely time-consuming.  Therefore, new strategies that target the survival pathways that provide efficient and effective results at an affordable cost are being considered.  One such approach incorporates repurposing therapeutic agents initially used for the treatment of different diseases other than cancer.  This approach is effective primarily when the FDA-approved agent targets similar pathways found in cancer.  Because one of the drugs used in combination therapy is already FDA-approved, overall costs of combination therapy research are reduced.  This increases cost efficiency of therapy, thereby benefiting the "medically underserved".  In addition, an approach that combines repurposed pharmaceutical agents with other therapeutics has shown promising results in mitigating tumour burden.  In this systematic review, we discuss important pathways commonly targeted in cancer therapy.  Furthermore, we also review important repurposed or primary anti-cancer agents that have gained popularity in clinical trials and research since 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgglXQFVA86nO4gDb7JggCfW6udTcc2eY4vdF5cwkfzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnvV2ksw%253D%253D&md5=42ce7556d77313edc2ac9cd1ae29ad78</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.16723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.16723%26sid%3Dliteratum%253Aachs%26aulast%3DBayat%2BMokhtari%26aufirst%3DR.%26aulast%3DHomayouni%26aufirst%3DT.%2BS.%26aulast%3DBaluch%26aufirst%3DN.%26aulast%3DMorgatskaya%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DYeger%26aufirst%3DH.%26atitle%3DCombination%2520therapy%2520in%2520combating%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D23%26spage%3D38022%26epage%3D38043%26doi%3D10.18632%2Foncotarget.16723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&issue=19&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhfhK6TfFvckg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D19%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blagosklonny, M. V.</span></span> <span> </span><span class="NLM_article-title">Overcoming limitations of natural anticancer drugs by combining with artificial agents</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2004.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.tips.2004.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15681024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXoslagsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=77-81&issue=2&author=M.+V.+Blagosklonny&title=Overcoming+limitations+of+natural+anticancer+drugs+by+combining+with+artificial+agents&doi=10.1016%2Fj.tips.2004.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming limitations of natural anticancer drugs by combining with artificial agents</span></div><div class="casAuthors">Blagosklonny, Mikhail V.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-81</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  During a billion years of evolution, living creatures have perfected cytotoxic agents to kill other organisms without killing themselves, thus providing us with antibiotics to kill bacteria without killing eukaryotic (e.g. human) cells.  Some natural agents inhibit specifically most vital cellular structures and functions in cancer cells.  However, nature was not creating antibiotics for cancer, and natural agents kill cancer cells precisely because they share targets with normal cells.  To discriminate between particular cancer cells and normal cells, one can design or select artificial agents that are not necessarily lethal but are aimed either at cancer-specific targets or at dispensable and even unavailable (in cancer cells) targets.  Using rational drug combinations, such selective agents can assist natural agents to eradicate cancer cells selectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHEqPHb7M1qbVg90H21EOLACvtfcHk0lhfhK6TfFvckg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXoslagsg%253D%253D&md5=6160179fcd3935adebbab83716b470c5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DBlagosklonny%26aufirst%3DM.%2BV.%26atitle%3DOvercoming%2520limitations%2520of%2520natural%2520anticancer%2520drugs%2520by%2520combining%2520with%2520artificial%2520agents%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26issue%3D2%26spage%3D77%26epage%3D81%26doi%3D10.1016%2Fj.tips.2004.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albain, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nag, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderillo-Ruiz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordaan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melemed, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes-Vidal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhon, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span> <span> </span><span class="NLM_article-title">Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3950</span>– <span class="NLM_lpage">3957</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.11.9362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1200%2FJCO.2007.11.9362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18711184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BD1cris1Kmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3950-3957&issue=24&author=K.+S.+Albainauthor=S.+M.+Nagauthor=G.+Calderillo-Ruizauthor=J.+P.+Jordaanauthor=A.+C.+Llombartauthor=A.+Pluzanskaauthor=J.+Rolskiauthor=A.+S.+Melemedauthor=J.+M.+Reyes-Vidalauthor=J.+S.+Sekhonauthor=L.+Simmsauthor=J.+O%E2%80%99Shaughnessy&title=Gemcitabine+plus+Paclitaxel+versus+Paclitaxel+monotherapy+in+patients+with+metastatic+breast+cancer+and+prior+anthracycline+treatment&doi=10.1200%2FJCO.2007.11.9362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment</span></div><div class="casAuthors">Albain Kathy S; Nag Shona M; Calderillo-Ruiz German; Jordaan Johann P; Llombart Antonio C; Pluzanska Anna; Rolski Janusz; Melemed Allen S; Reyes-Vidal Jose M; Sekhon Jagdev S; Simms Lorinda; O'Shaughnessy Joyce</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3950-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The objective of this phase III global study was to compare the efficacy of gemcitabine plus paclitaxel (GT) versus paclitaxel in patients with advanced breast cancer.  It was designed as a pivotal study for the approval of G for a breast cancer treatment indication.  PATIENTS AND METHODS:  Patients who relapsed after adjuvant anthracyclines were randomly assigned to gemcitabine,1,250 mg/m(2) days 1 and 8 plus paclitaxel, 175 mg/m(2) on day 1; or, to paclitaxel at same dose on day 1 (both arms administered every 21 days, unblinded).  The primary end point was overall survival (OS) and secondary end points were time to progression (TTP), response rate (RR), progression-free survival, response duration, and toxicity.  This final OS analysis was planned at 380 deaths.  RESULTS:  A total of 266 patients were randomly assigned to GT and 263 to paclitaxel.  Median survival on GT was 18.6 months versus 15.8 months on paclitaxel (log-rank P = . 0489), with an adjusted Cox hazard ratio of 0.78 (95% CI, 0.64 to 0.96; P = .0187).  The TTP was longer (6.14 v 3.98 months; log-rank P = .0002) and the RR was better (41.4% v 26.2%; P = .0002) on GT.  There was more grade 3 to 4 neutropenia on GT and grade 2 to 4 fatigue and neuropathy were slightly more prevalent on GT.  CONCLUSION:  This phase III study documents a role for gemcitabine in advanced breast cancer after anthracycline-based adjuvant therapy.  The results establish GT as a reasonable choice for women who require cytoreduction with manageable toxicities and validate ongoing testing of GT in the adjuvant setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6uZmrDXhBdpotVjB3IRIyfW6udTcc2eZjaJxuwT4ifLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cris1Kmsw%253D%253D&md5=dcc70c8ba548199b4934cd8fee730c0c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.11.9362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.11.9362%26sid%3Dliteratum%253Aachs%26aulast%3DAlbain%26aufirst%3DK.%2BS.%26aulast%3DNag%26aufirst%3DS.%2BM.%26aulast%3DCalderillo-Ruiz%26aufirst%3DG.%26aulast%3DJordaan%26aufirst%3DJ.%2BP.%26aulast%3DLlombart%26aufirst%3DA.%2BC.%26aulast%3DPluzanska%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DMelemed%26aufirst%3DA.%2BS.%26aulast%3DReyes-Vidal%26aufirst%3DJ.%2BM.%26aulast%3DSekhon%26aufirst%3DJ.%2BS.%26aulast%3DSimms%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26atitle%3DGemcitabine%2520plus%2520Paclitaxel%2520versus%2520Paclitaxel%2520monotherapy%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%2520and%2520prior%2520anthracycline%2520treatment%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3D24%26spage%3D3950%26epage%3D3957%26doi%3D10.1200%2FJCO.2007.11.9362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&issue=1%E2%80%932&author=G.+R.+Zimmermannauthor=J.+Leharauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eZjaJxuwT4ifLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D1%25E2%2580%25932%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&issue=15&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lgVFsHDgQUjJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D15%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span> <span> </span><span class="NLM_article-title">Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.4155%2Ffmc.12.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKgsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=5-7&issue=1&author=L.+Costantinoauthor=D.+Barlocco&title=Challenges+in+the+design+of+multitarget+drugs+against+multifactorial+pathologies%3A+a+new+life+for+medicinal+chemistry%3F&doi=10.4155%2Ffmc.12.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?</span></div><div class="casAuthors">Costantino, Luca; Barlocco, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-7</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Medicinal chem. research addressed the design of multitarget agents for some disease areas.  These agents are detd. grounded on in vivo assays or the design of assembled pharmacophores of the target ligands under consideration, with or without the aid of computational techniques.  Sunitinib and sorafenib are examples of these agents.  E-therapeutics and Pharnext are among companies that are based on network pharmacol. in order to discover novel drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPWU0-tklUJbVg90H21EOLACvtfcHk0lji8fw1ub7wYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKgsLbE&md5=498fc24d3fed3c3657765f3df6e5235a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.193%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DL.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DChallenges%2520in%2520the%2520design%2520of%2520multitarget%2520drugs%2520against%2520multifactorial%2520pathologies%253A%2520a%2520new%2520life%2520for%2520medicinal%2520chemistry%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26issue%3D1%26spage%3D5%26epage%3D7%26doi%3D10.4155%2Ffmc.12.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sestito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runfola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapposelli, S.</span></span> <span> </span><span class="NLM_article-title">New multitarget approaches in the war against glioblastoma: a mini-perspective</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">874</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3389%2Ffphar.2018.00874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30123135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVartb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=874&author=S.+Sestitoauthor=M.+Runfolaauthor=M.+Tonelliauthor=G.+Chielliniauthor=S.+Rapposelli&title=New+multitarget+approaches+in+the+war+against+glioblastoma%3A+a+mini-perspective&doi=10.3389%2Ffphar.2018.00874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">New multitarget approaches in the war against glioblastoma: a mini-perspective</span></div><div class="casAuthors">Sestito, Simona; Runfola, Massimiliano; Tonelli, Marco; Chiellini, Grazia; Rapposelli, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">874/1-874/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common tumor of the CNS, and the deadliest form of brain cancer.  The rapid progression, the anat. location in the brain and a deficient knowledge of the pathophysiol., often limit the effectiveness of therapeutic interventions.  Current pillars of GBM therapies include surgical resection, radiotherapy and chemotherapy, but the low survival rate and the short life expectation following these treatments strongly underline the urgency to identify innovative and more effective therapeutic tools.  Frequently, patients subjected to a mono-target therapy, such as Temozolomide (TMZ), develop drug resistance and undergo relapse, indicating that targeting a single cellular node is not sufficient for eradication of this disease.  In this context, a multi-targeted therapeutic approach aimed at using compds., alone or in combination, capable of inhibiting more than one specific mol. target, offers a promising alternative.  Such strategies have already been well integrated into drug discovery campaigns, including in the field of anticancer drugs.  In this miniperspective, we will discuss the recent progress in the treatment of GBM focusing on innovative and effective preclin. strategies, which are based on a multi-targeted approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqElOSaMG0AwrVg90H21EOLACvtfcHk0lji8fw1ub7wYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVartb8%253D&md5=f935948cb45cb51df50beddb9d0486be</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00874%26sid%3Dliteratum%253Aachs%26aulast%3DSestito%26aufirst%3DS.%26aulast%3DRunfola%26aufirst%3DM.%26aulast%3DTonelli%26aufirst%3DM.%26aulast%3DChiellini%26aufirst%3DG.%26aulast%3DRapposelli%26aufirst%3DS.%26atitle%3DNew%2520multitarget%2520approaches%2520in%2520the%2520war%2520against%2520glioblastoma%253A%2520a%2520mini-perspective%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D874%26doi%3D10.3389%2Ffphar.2018.00874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&issue=2&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+a+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lg8VgjmmmnDTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520a%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cicenas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicenas, E.</span></span> <span> </span><span class="NLM_article-title">Multi-kinase inhibitors, AURKs and cancer</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1007/s12032-016-0758-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs12032-016-0758-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=27038473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC28fmsFagsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=43&issue=5&author=J.+Cicenasauthor=E.+Cicenas&title=Multi-kinase+inhibitors%2C+AURKs+and+cancer&doi=10.1007%2Fs12032-016-0758-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-kinase inhibitors, AURKs and cancer</span></div><div class="casAuthors">Cicenas Jonas; Cicenas Jonas; Cicenas Jonas; Cicenas Jonas; Cicenas Erikas</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inhibitors that impact function of kinases are valuable both for the biological research as well as therapy of kinase-associated diseases, such as different cancers.  There are quite a number of inhibitors, which are quite specific for certain kinases and several of them are either already approved for the cancer therapy or are in clinical studies of various phases.  However, that does not mean that each single kinase inhibitor is suitable for targeted therapy.  Some of them are not effective others might be toxic or fail some other criteria for the use in vivo.  On the other hand, even in case of successful therapy, many responders eventually develop resistance to the inhibitors.  The limitations of various single kinase inhibitors can be fought using compounds which target multiple kinases.  This tactics can increase effectiveness of the inhibitors by the synergistic effect or help to diminish the likelihood of drug resistance.  To date, several families of kinases are quite popular targets of the inhibition in cancers, such as tyrosine kinases, cycle-dependent kinases, mitogen-activated protein kinases, phosphoinositide 3-kinases as well as their pathway "players" and aurora kinases.  Aurora kinases play an important role in the control of the mitosis and are often altered in diverse human cancers.  Here, we will describe the most interesting multi-kinase inhibitors which inhibit aurora kinases among other targets and their use in preclinical and clinical cancer studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_XwZzssGi-C86Js-BCLiifW6udTcc2eaqJ7UTnQ4WJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fmsFagsA%253D%253D&md5=856bce3f15cc677f28676afc9a34f18b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs12032-016-0758-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-016-0758-4%26sid%3Dliteratum%253Aachs%26aulast%3DCicenas%26aufirst%3DJ.%26aulast%3DCicenas%26aufirst%3DE.%26atitle%3DMulti-kinase%2520inhibitors%252C%2520AURKs%2520and%2520cancer%26jtitle%3DMed.%2520Oncol.%26date%3D2016%26volume%3D33%26issue%3D5%26spage%3D43%26doi%3D10.1007%2Fs12032-016-0758-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sercus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahn, M.</span></span> <span> </span><span class="NLM_article-title">Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature</span>. <i>Curr. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.2174/157488609788173026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F157488609788173026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19442108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzks1arug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=143-154&issue=2&author=S.+Creanauthor=D.+M.+Boydauthor=B.+Sercusauthor=M.+Lahn&title=Safety+of+multi-targeted+kinase+inhibitors+as+monotherapy+treatment+of+cancer%3A+a+systematic+review+of+the+literature&doi=10.2174%2F157488609788173026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature</span></div><div class="casAuthors">Crean Sheila; Boyd Dylan M; Sercus Brian; Lahn Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current drug safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-54</span>
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    </div><div class="casAbstract">PURPOSE:  To identify potential safety profiles for small molecule multi-targeted kinase inhibitors for the treatment of advanced cancer.  METHODS:  A systematic review was performed on published papers and meeting abstracts reporting safety outcomes in cancer patients for selected multi-kinase inhibiting small molecules with mainly anti-angiogenic activity.  Specifically, we focused on single agent safety or early phase clinical development studies.  RESULTS:  Of 1,923 studies identified in a MEDLINE search, 26 primary studies met eligibility criteria.  Meeting materials included 7 papers, 6 posters, and 27 abstracts.  When grade I-IV safety results of all 23 kinases were summed together, diarrhea, fatigue, nausea, rash, anorexia, vomiting, hand/foot syndrome, and hypertension were common, occurring in greater than 10% of patients.  When only grade III and IV events are pooled together, fatigue and hypertension remain relatively common (> 5%).  When total adverse events were stratified by kinase or by kinase family, differences in safety profiles emerged.  CONCLUSIONS:  The results of this systematic review suggest that adverse events are common and varied for patients treated with a multi-kinase inhibitor.  However, unlike some systemic cytotoxic therapies, serious and severe adverse events for multikinase inhibitors are less frequent.  Sub-analyses by target kinase or kinase family demonstrate that certain groups of multi-kinase inhibitors can be associated with different safety profiles with unique adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx4DGQrD-4GbxanA7vODO6fW6udTcc2eaqJ7UTnQ4WJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzks1arug%253D%253D&md5=56140fff20032170d3d5a1500126d662</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F157488609788173026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488609788173026%26sid%3Dliteratum%253Aachs%26aulast%3DCrean%26aufirst%3DS.%26aulast%3DBoyd%26aufirst%3DD.%2BM.%26aulast%3DSercus%26aufirst%3DB.%26aulast%3DLahn%26aufirst%3DM.%26atitle%3DSafety%2520of%2520multi-targeted%2520kinase%2520inhibitors%2520as%2520monotherapy%2520treatment%2520of%2520cancer%253A%2520a%2520systematic%2520review%2520of%2520the%2520literature%26jtitle%3DCurr.%2520Drug%2520Saf.%26date%3D2009%26volume%3D4%26issue%3D2%26spage%3D143%26epage%3D154%26doi%3D10.2174%2F157488609788173026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S.</span></span> <span> </span><span class="NLM_article-title">From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.2174/092986708783503212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F092986708783503212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18288997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=422-432&issue=5&author=A.+Petrelliauthor=S.+Giordano&title=From+single-+to+multi-target+drugs+in+cancer+therapy%3A+when+aspecificity+becomes+an+advantage&doi=10.2174%2F092986708783503212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">From single- to multi-target drugs in cancer therapy: when a specificity becomes an advantage</span></div><div class="casAuthors">Petrelli, A.; Giordano, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">422-432</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted therapies by means of compds. that inhibit a specific target mol. represent a new perspective in the treatment of cancer.  In contrast to conventional chemotherapy which acts on all dividing cells generating toxic effects and damage of normal tissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells directly involved in tumor progression.  Mols. controlling cell proliferation and death, such as Tyrosine Kinase Receptors (RTKs) for growth factors, are among the best targets for this type of therapeutic approach.  Two classes of compds. targeting RTKs are currently used in clin. practice: monoclonal antibodies and tyrosine kinase inhibitors.  The era of targeted therapy began with the approval of Trastuzumab, a monoclonal antibody against HER2, for treatment of metastatic breast cancer, and Imatinib, a small tyrosine kinase inhibitor targeting BCR-Abl, in Chronic Myeloid Leukemia.  Despite the initial enthusiasm for the efficacy of these treatments, clinicians had to face soon the problem of relapse, as almost invariably cancer patients developed drug resistance, often due to the activation of alternative RTKs pathways.  In this view, the rationale at the basis of targeting drugs is radically shifting.  In the past, the main effort was aimed at developing highly specific inhibitors acting on single RTKs.  Now, there is a general agreement that mols. interfering simultaneously with multiple RTKs might be more effective than single target agents.  With the recent approval by FDA of Sorafenib and Sunitinib - targeting VEGFR, PDGFR, FLT-3 and c-Kit - a different scenario has been emerging, where a new generation of anti-cancer drugs, able to inhibit more than one pathway, would probably play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8AXb2ROTStLVg90H21EOLACvtfcHk0liuy__9VVbMTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D&md5=d90df6a670921b6fad58caa46db01fa5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F092986708783503212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708783503212%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DFrom%2520single-%2520to%2520multi-target%2520drugs%2520in%2520cancer%2520therapy%253A%2520when%2520aspecificity%2520becomes%2520an%2520advantage%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26issue%3D5%26spage%3D422%26epage%3D432%26doi%3D10.2174%2F092986708783503212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&issue=2&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0liuy__9VVbMTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailly, C.</span></span> <span> </span><span class="NLM_article-title">Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3611</span>– <span class="NLM_lpage">3640</span>, <span class="refDoi"> DOI: 10.1021/cr200325f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200325f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2012&pages=3611-3640&issue=7&author=C.+Bailly&title=Contemporary+challenges+in+the+design+of+topoisomerase+II+inhibitors+for+cancer+chemotherapy&doi=10.1021%2Fcr200325f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy</span></div><div class="casAuthors">Bailly, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3611-3640</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review reports the use of topoisomerase II modulators as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozIpYLsh9eCLVg90H21EOLACvtfcHk0libg-6n0jD3yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChtbY%253D&md5=f5ba565e42cd9ff9a38e47ad7c1e77c0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fcr200325f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200325f%26sid%3Dliteratum%253Aachs%26aulast%3DBailly%26aufirst%3DC.%26atitle%3DContemporary%2520challenges%2520in%2520the%2520design%2520of%2520topoisomerase%2520II%2520inhibitors%2520for%2520cancer%2520chemotherapy%26jtitle%3DChem.%2520Rev.%26date%3D2012%26volume%3D112%26issue%3D7%26spage%3D3611%26epage%3D3640%26doi%3D10.1021%2Fcr200325f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valabrega, G.</span></span> <span> </span><span class="NLM_article-title">Multitarget drugs: the present and the future of cancer therapy</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1517/14656560902781907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1517%2F14656560902781907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19284362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=589-600&issue=4&author=A.+Petrelliauthor=G.+Valabrega&title=Multitarget+drugs%3A+the+present+and+the+future+of+cancer+therapy&doi=10.1517%2F14656560902781907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget drugs: the present and the future of cancer therapy</span></div><div class="casAuthors">Petrelli, Annalisa; Valabrega, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-600</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Target therapies for the treatment of human cancers have revolutionized the concept of oncol. medicine.  This type of therapeutic approach is directed to the inhibition of mol. targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compds. able to block their activity.  In the beginning, the aim of target therapies was specifically to hit a single mol. expressed in neoplastic cells.  Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease.  Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different mols.  This review summarizes the mol. basis of multitarget therapies and the most relevant results obtained in different cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSM1xsRJGBX7Vg90H21EOLACvtfcHk0libg-6n0jD3yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D&md5=c84e048407e6d9354a1f4a595fb4a468</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14656560902781907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560902781907%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DValabrega%26aufirst%3DG.%26atitle%3DMultitarget%2520drugs%253A%2520the%2520present%2520and%2520the%2520future%2520of%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26issue%3D4%26spage%3D589%26epage%3D600%26doi%3D10.1517%2F14656560902781907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase II and its growing repertoire of biological functions</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrc2608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc2608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19377505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12ktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=327-337&issue=5&author=J.+L.+Nitiss&title=DNA+topoisomerase+II+and+its+growing+repertoire+of+biological+functions&doi=10.1038%2Fnrc2608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerase II and its growing repertoire of biological functions</span></div><div class="casAuthors">Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are enzymes that disentangle the topol. problems that arise in double-stranded DNA.  Many of these can be solved by the generation of either DNA single- or double-strand breaks.  However, where there is a clear requirement to alter DNA topol. by introducing transient double-strand breaks, only DNA topoisomerase II (I) can carry out this reaction.  Extensive biochem. and structural studies have provided detailed models of how I alters DNA structure, and recent mol. studies have greatly expanded knowledge of the biol. contexts in which I functions, such as DNA replication, transcription, and chromosome segregation, processes that are essential for preventing tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAj0wiBApAc7Vg90H21EOLACvtfcHk0ljtRoNvVeHd2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12ktLo%253D&md5=4be33ccf2701425ef3933b894b31e7fd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrc2608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2608%26sid%3Dliteratum%253Aachs%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DDNA%2520topoisomerase%2520II%2520and%2520its%2520growing%2520repertoire%2520of%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D5%26spage%3D327%26epage%3D337%26doi%3D10.1038%2Fnrc2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Cellular roles of DNA topoisomerases: a molecular perspective</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/nrm831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrm831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12042765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=430-440&issue=6&author=J.+C.+Wang&title=Cellular+roles+of+DNA+topoisomerases%3A+a+molecular+perspective&doi=10.1038%2Fnrm831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular roles of DNA topoisomerases: a molecular perspective</span></div><div class="casAuthors">Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are the magicians of the DNA world , by allowing DNA strands or double helixes to pass through each other, they can solve all of the topol. problems of DNA in replication, transcription and other cellular transactions.  Extensive biochem. and structural studies over the past three decades have provided mol. models of how the various subfamilies of DNA topoisomerase manipulate DNA.  In this review, the cellular roles of these enzymes are examd. from a mol. point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ptPGi1NWFLVg90H21EOLACvtfcHk0ljtRoNvVeHd2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D&md5=5b9641a6d78a019ebad9307c854a7f7e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrm831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm831%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DCellular%2520roles%2520of%2520DNA%2520topoisomerases%253A%2520a%2520molecular%2520perspective%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26issue%3D6%26spage%3D430%26epage%3D440%26doi%3D10.1038%2Fnrm831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA topoisomerase II in cancer chemotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1038/nrc2607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc2607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19377506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12kur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=338-350&issue=5&author=J.+L.+Nitiss&title=Targeting+DNA+topoisomerase+II+in+cancer+chemotherapy&doi=10.1038%2Fnrc2607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA topoisomerase II in cancer chemotherapy</span></div><div class="casAuthors">Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">338-350</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent mol. studies have expanded the biol. contexts in which topoisomerase II (TOP2) has crucial functions, including DNA replication, transcription and chromosome segregation.  Although the biol. functions of TOP2 are important for ensuring genomic integrity, the ability to interfere with TOP2 and generate enzyme-mediated DNA damage is an effective strategy for cancer chemotherapy.  The mol. tools that have allowed an understanding of the biol. functions of TOP2 are also being applied to understanding the details of drug action.  These studies promise refined targeting of TOP2 as an effective anticancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_7Nq6nIe1RbVg90H21EOLACvtfcHk0ljtRoNvVeHd2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12kur0%253D&md5=a787de602687580188cda6a2af7b6a07</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc2607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2607%26sid%3Dliteratum%253Aachs%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DTargeting%2520DNA%2520topoisomerase%2520II%2520in%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D5%26spage%3D338%26epage%3D350%26doi%3D10.1038%2Fnrc2607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase II as a target for cancer chemotherapy</span>. <i>Cancer Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">570</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1081/CNV-120002156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1081%2FCNV-120002156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12094551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1eitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=570-589&issue=4&author=J.+V.+Walkerauthor=J.+L.+Nitiss&title=DNA+topoisomerase+II+as+a+target+for+cancer+chemotherapy&doi=10.1081%2FCNV-120002156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerase II as a target for cancer chemotherapy</span></div><div class="casAuthors">Walker, Jerrylaine V.; Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">570-589</span>CODEN:
                <span class="NLM_cas:coden">CINVD7</span>;
        ISSN:<span class="NLM_cas:issn">0735-7907</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review on the biochem. and pharmacol. properties of topoisomerase II inhibitors.  Biochem. mechanisms that lead from trapping topoisomerase II on DNA to a potentially lethal DNA lesion, and the resistance mechanisms to topoisomerase II poisons are discussed.  The potential of topoisomerase II-targeting agents for cancer chemotherapy is emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrla9YLz1gCB7Vg90H21EOLACvtfcHk0lioyakkubAODQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1eitL4%253D&md5=f0203b590bc9439c2f69264760536d25</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1081%2FCNV-120002156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FCNV-120002156%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DJ.%2BV.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DDNA%2520topoisomerase%2520II%2520as%2520a%2520target%2520for%2520cancer%2520chemotherapy%26jtitle%3DCancer%2520Invest.%26date%3D2002%26volume%3D20%26issue%3D4%26spage%3D570%26epage%3D589%26doi%3D10.1081%2FCNV-120002156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendorff, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">The structure of DNA-bound human topoisomerase IIα: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>424</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2012.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.jmb.2012.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=22841979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1emtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=424&publication_year=2012&pages=109-124&issue=3%E2%80%934&author=T.+J.+Wendorffauthor=B.+H.+Schmidtauthor=P.+Heslopauthor=C.+A.+Austinauthor=J.+M.+Berger&title=The+structure+of+DNA-bound+human+topoisomerase+II%CE%B1%3A+conformational+mechanisms+for+coordinating+inter-subunit+interactions+with+DNA+cleavage&doi=10.1016%2Fj.jmb.2012.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA Cleavage</span></div><div class="casAuthors">Wendorff, Timothy J.; Schmidt, Bryan H.; Heslop, Pauline; Austin, Caroline A.; Berger, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">424</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">109-124</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Type II topoisomerases are required for the management of DNA superhelicity and chromosome segregation, and serve as frontline targets for a variety of small-mol. therapeutics.  To better understand how these enzymes act in both contexts, we detd. the 2.9-Å-resoln. structure of the DNA cleavage core of human topoisomerase IIα (TOP2A) bound to a doubly nicked, 30-bp duplex oligonucleotide.  In accord with prior biochem. and structural studies, TOP2A significantly bends its DNA substrate using a bipartite, nucleolytic center formed at an N-terminal dimerization interface of the cleavage core.  However, the protein also adopts a global conformation in which the second of its two inter-protomer contact points, one at the C-terminus, has sepd.  This finding, together with comparative structural analyses, reveals that the principal site of DNA engagement undergoes highly quantized conformational transitions between distinct binding, cleavage, and drug-inhibited states that correlate with the control of subunit-subunit interactions.  Addnl. consideration of our TOP2A model in light of an etoposide-inhibited complex of human topoisomerase IIβ (TOP2B) suggests possible modification points for developing paralog-specific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfXTBKuw0XXLVg90H21EOLACvtfcHk0lioyakkubAODQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1emtb%252FN&md5=e62b148c35816a31f2b8f5457ffa29f6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2012.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2012.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DWendorff%26aufirst%3DT.%2BJ.%26aulast%3DSchmidt%26aufirst%3DB.%2BH.%26aulast%3DHeslop%26aufirst%3DP.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520structure%2520of%2520DNA-bound%2520human%2520topoisomerase%2520II%25CE%25B1%253A%2520conformational%2520mechanisms%2520for%2520coordinating%2520inter-subunit%2520interactions%2520with%2520DNA%2520cleavage%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D424%26issue%3D3%25E2%2580%25934%26spage%3D109%26epage%3D124%26doi%3D10.1016%2Fj.jmb.2012.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8947</span>– <span class="NLM_lpage">8980</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01202</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01202" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8947-8980&issue=20&author=W.+Huauthor=X.+S.+Huangauthor=J.+F.+Wuauthor=L.+Yangauthor=Y.+T.+Zhengauthor=Y.+M.+Shenauthor=Z.+Y.+Liauthor=X.+Li&title=Discovery+of+novel+topoisomerase+II+inhibitors+by+medicinal+chemistry+approaches&doi=10.1021%2Facs.jmedchem.7b01202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches</span></div><div class="casAuthors">Hu, Wei; Huang, Xu-Sheng; Wu, Ji-Feng; Yang, Liang; Zheng, Yong-Tang; Shen, Yue-Mao; Li, Zhi-Yu; Li, Xun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8947-8980</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA topoisomerase II (topo II) is an important enzyme involved in DNA replication, recombination, and repair.  Despite the popular applications of topo II inhibitors in cancer therapy, there is still an urgent need to upgrade topo II inhibitors to cope with drug resistance and severe adverse effects.  Accordingly, novel topo II catalytic or multitarget topo II inhibitors are gaining more attention and make it possible to ease the toxic limitations of topo II poisons.  In this review, medicinal chem. approaches are mainly discussed toward the development of potent topo II inhibitors with low toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWv9JERcv7XbVg90H21EOLACvtfcHk0liAjf2II34zdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsL3P&md5=51468c5ca4b8fd437760567e78e1d393</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01202%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BF.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DY.%2BT.%26aulast%3DShen%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DZ.%2BY.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520topoisomerase%2520II%2520inhibitors%2520by%2520medicinal%2520chemistry%2520approaches%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D20%26spage%3D8947%26epage%3D8980%26doi%3D10.1021%2Facs.jmedchem.7b01202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>333</i></span> (<span class="NLM_issue">6041</span>),  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1126/science.1204117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1126%2Fscience.1204117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21778401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovF2mur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2011&pages=459-462&issue=6041&author=C.+C.+Wuauthor=T.+K.+Liauthor=L.+Farhauthor=L.+Y.+Linauthor=T.+S.+Linauthor=Y.+J.+Yuauthor=T.+J.+Yenauthor=C.+W.+Chiangauthor=N.+L.+Chan&title=Structural+basis+of+type+II+topoisomerase+inhibition+by+the+anticancer+drug+etoposide&doi=10.1126%2Fscience.1204117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide</span></div><div class="casAuthors">Wu, Chyuan-Chuan; Li, Tsai-Kun; Farh, Lynn; Lin, Li-Ying; Lin, Te-Sheng; Yu, Yu-Jen; Yen, Tien-Jui; Chiang, Chia-Wang; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">6041</span>),
    <span class="NLM_cas:pages">459-462</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Type II topoisomerases (TOP2s) resolve the topol. problems of DNA by transiently cleaving both strands of a DNA duplex to form a cleavage complex through which another DNA segment can be transported.  Several widely prescribed anticancer drugs increase the population of TOP2 cleavage complex, which leads to TOP2-mediated chromosome DNA breakage and death of cancer cells.  We present the crystal structure of a large fragment of human TOP2β complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex.  The interplay between the protein, the DNA, and the drug explains the structure-activity relations of etoposide derivs. and the mol. basis of drug-resistant mutations.  The anal. of protein-drug interactions provides information applicable for developing an isoform-specific TOP2-targeting strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBC6vqPeyB-bVg90H21EOLACvtfcHk0liAjf2II34zdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovF2mur0%253D&md5=c2eab1b2e9b8a75322b88e76c62c4b74</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1126%2Fscience.1204117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1204117%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DFarh%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DL.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DT.%2BJ.%26aulast%3DChiang%26aufirst%3DC.%2BW.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DStructural%2520basis%2520of%2520type%2520II%2520topoisomerase%2520inhibition%2520by%2520the%2520anticancer%2520drug%2520etoposide%26jtitle%3DScience%26date%3D2011%26volume%3D333%26issue%3D6041%26spage%3D459%26epage%3D462%26doi%3D10.1126%2Fscience.1204117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deweese, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">41</span>),  <span class="NLM_fpage">6595</span>– <span class="NLM_lpage">6602</span>, <span class="refDoi"> DOI: 10.1021/bi5010816</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi5010816" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OitLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=6595-6602&issue=41&author=R.+H.+Lindseyauthor=M.+Pendletonauthor=R.+E.+Ashleyauthor=S.+L.+Mercerauthor=J.+E.+Deweeseauthor=N.+Osheroff&title=Catalytic+core+of+human+topoisomerase+II%CE%B1%3A+insights+into+enzyme-DNA+interactions+and+drug+mechanism&doi=10.1021%2Fbi5010816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Core of Human Topoisomerase IIα: Insights into Enzyme-DNA Interactions and Drug Mechanism</span></div><div class="casAuthors">Lindsey, R. Hunter; Pendleton, MaryJean; Ashley, Rachel E.; Mercer, Susan L.; Deweese, Joseph E.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">6595-6602</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Coordination between the N-terminal gate and the catalytic core of topoisomerase II allows the proper capture, cleavage, and transport of DNA during the catalytic cycle.  Because the activities of these domains are tightly linked, it has been difficult to discern their individual contributions to enzyme-DNA interactions and drug mechanism.  To further address the roles of these domains, we analyzed the activity of the catalytic core of human topoisomerase IIα.  The catalytic core and the wild-type enzyme both maintained higher levels of cleavage with neg. (as compared to pos.) supercoiled plasmid, indicating that the ability to distinguish supercoil handedness is embedded within the catalytic core.  However, the catalytic core alone displayed little ability to cleave DNA substrates that did not intrinsically provide the enzyme with a transport segment (i.e., substrates that did not contain crossovers).  Finally, in contrast to interfacial topoisomerase II poisons, covalent poisons did not enhance DNA cleavage mediated by the catalytic core.  This distinction allowed us to further characterize the mechanism of etoposide quinone, a drug metabolite that functions primarily as a covalent poison.  Etoposide quinone retained some ability to enhance DNA cleavage mediated by the catalytic core, indicating that it still can function as an interfacial poison.  These results further define the distinct contributions of the N-terminal gate and the catalytic core to topoisomerase II function.  The catalytic core senses the handedness of DNA supercoils during cleavage, while the N-terminal gate is crit. for capturing the transport segment and for the activity of covalent poisons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru665se8ASNLVg90H21EOLACvtfcHk0li_ey7ggdd_Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OitLfJ&md5=8e75ebeb675d0899dacbb30a63bcc006</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fbi5010816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi5010816%26sid%3Dliteratum%253Aachs%26aulast%3DLindsey%26aufirst%3DR.%2BH.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DAshley%26aufirst%3DR.%2BE.%26aulast%3DMercer%26aufirst%3DS.%2BL.%26aulast%3DDeweese%26aufirst%3DJ.%2BE.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DCatalytic%2520core%2520of%2520human%2520topoisomerase%2520II%25CE%25B1%253A%2520insights%2520into%2520enzyme-DNA%2520interactions%2520and%2520drug%2520mechanism%26jtitle%3DBiochemistry%26date%3D2014%26volume%3D53%26issue%3D41%26spage%3D6595%26epage%3D6602%26doi%3D10.1021%2Fbi5010816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Recent developments in DNA topoisomerase II structure and mechanism</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/S0959-440X(96)80099-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0959-440X%2896%2980099-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8696977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK28Xhtlamt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=84-90&issue=1&author=J.+M.+Bergerauthor=J.+C.+Wang&title=Recent+developments+in+DNA+topoisomerase+II+structure+and+mechanism&doi=10.1016%2FS0959-440X%2896%2980099-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in DNA topoisomerase II structure and mechanism</span></div><div class="casAuthors">Berger, James M.; Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">A review with 67 refs.  Type II DNA topoisomerases are enzymes that are capable of transporting one duplex DNA through another.  Recent exptl. results, including the structure of a fragment of yeast DNA topoisomerase II, have provided new insights into the mechanism of the strand passage reaction.  Other results have begun to define the role of ATP in the catalytic cycle and illuminate how DNA breaks mediated by DNA topoisomerase II can occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyV4XwSXlNM7Vg90H21EOLACvtfcHk0li_ey7ggdd_Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xhtlamt7Y%253D&md5=c9555bfd45bacd24e2ef779923b856e4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0959-440X%2896%2980099-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-440X%252896%252980099-6%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DRecent%2520developments%2520in%2520DNA%2520topoisomerase%2520II%2520structure%2520and%2520mechanism%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D1996%26volume%3D6%26issue%3D1%26spage%3D84%26epage%3D90%26doi%3D10.1016%2FS0959-440X%2896%2980099-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3085</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-05406-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fs41467-018-05406-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30082834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ls1aktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3085&issue=1&author=S.+F.+Chenauthor=N.+L.+Huangauthor=J.+H.+Linauthor=C.+C.+Wuauthor=Y.+R.+Wangauthor=Y.+J.+Yuauthor=M.+K.+Gilsonauthor=N.+L.+Chan&title=Structural+insights+into+the+gating+of+DNA+passage+by+the+topoisomerase+II+DNA-gate&doi=10.1038%2Fs41467-018-05406-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate</span></div><div class="casAuthors">Chen Shin-Fu; Wu Chyuan-Chuan; Wang Ying-Ren; Yu Yu-Jen; Chan Nei-Li; Huang Nan-Lan; Lin Jung-Hsin; Huang Nan-Lan; Gilson Michael K; Wu Chyuan-Chuan; Chan Nei-Li; Chan Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3085</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type IIA topoisomerases (Top2s) manipulate the handedness of DNA crossovers by introducing a transient and protein-linked double-strand break in one DNA duplex, termed the DNA-gate, whose opening allows another DNA segment to be transported through to change the DNA topology.  Despite the central importance of this gate-opening event to Top2 function, the DNA-gate in all reported structures of Top2-DNA complexes is in the closed state.  Here we present the crystal structure of a human Top2 DNA-gate in an open conformation, which not only reveals structural characteristics of its DNA-conducting path, but also uncovers unexpected yet functionally significant conformational changes associated with gate-opening.  This structure further implicates Top2's preference for a left-handed DNA braid and allows the construction of a model representing the initial entry of another DNA duplex into the DNA-gate.  Steered molecular dynamics calculations suggests the Top2-catalyzed DNA passage may be achieved by a rocker-switch-type movement of the DNA-gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM5cMY9cr24-dfST00W0BcfW6udTcc2eZ1Si16UqsTBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ls1aktg%253D%253D&md5=04dc82195836cb9e26bb2967da6f0630</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05406-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05406-y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DHuang%26aufirst%3DN.%2BL.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DYu%26aufirst%3DY.%2BJ.%26aulast%3DGilson%26aufirst%3DM.%2BK.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DStructural%2520insights%2520into%2520the%2520gating%2520of%2520DNA%2520passage%2520by%2520the%2520topoisomerase%2520II%2520DNA-gate%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D3085%26doi%3D10.1038%2Fs41467-018-05406-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burden, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme</span>. <i>Biochim. Biophys. Acta, Gene Struct. Expression</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>1400</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1016/S0167-4781(98)00132-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0167-4781%2898%2900132-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9748545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFWisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1400&publication_year=1998&pages=139-154&issue=1%E2%80%933&author=D.+A.+Burdenauthor=N.+Osheroff&title=Mechanism+of+action+of+eukaryotic+topoisomerase+II+and+drugs+targeted+to+the+enzyme&doi=10.1016%2FS0167-4781%2898%2900132-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme</span></div><div class="casAuthors">Burden, D. Andrew; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Structure and Expression</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">1400</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">139-154</span>CODEN:
                <span class="NLM_cas:coden">BBGSD5</span>;
        ISSN:<span class="NLM_cas:issn">0167-4781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 166 refs.  Topoisomerase II is a ubiquitous enzyme that is essential for the survival of all eukaryotic organisms and plays crit. roles in virtually every aspect of DNA metab.  The enzyme unknots and untangles DNA by passing an intact helix through a transient double-stranded break that it generates in a sep. helix.  Beyond its physiol. functions, topoisomerase II is the target for some of the most active and widely prescribed anticancer drugs currently utilized for the treatment of human cancers.  These drugs act in an insidious fashion and kill cells by increasing levels of covalent topoisomerase II-cleaved DNA complexes that are normally fleeting intermediates in the catalytic cycle of the enzyme.  Over the past several years, we have made considerable strides in our understanding of the catalytic mechanism of topoisomerase II and the mechanism of action of drugs targeted to this enzyme.  These advances have provided novel insights into the physiol. functions of topoisomerase II and have led to the development of more efficacious chemotherapeutic regimens and novel anticancer drugs.  Considering the importance of topoisomerase II to the eukaryotic cell and to cancer chemotherapy, it is essential to understand its enzymic function and pharmacol. properties.  Therefore, this review will discuss the mechanism of action of eukaryotic topoisomerase II and topoisomerase II-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhrmz2NE2EhLVg90H21EOLACvtfcHk0ljxuxCd3ZgtBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFWisrg%253D&md5=9e84fbeb6f394a48368e6ce51c47d6a7</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0167-4781%2898%2900132-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-4781%252898%252900132-8%26sid%3Dliteratum%253Aachs%26aulast%3DBurden%26aufirst%3DD.%2BA.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DMechanism%2520of%2520action%2520of%2520eukaryotic%2520topoisomerase%2520II%2520and%2520drugs%2520targeted%2520to%2520the%2520enzyme%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Struct.%2520Expression%26date%3D1998%26volume%3D1400%26issue%3D1%25E2%2580%25933%26spage%3D139%26epage%3D154%26doi%3D10.1016%2FS0167-4781%2898%2900132-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escargueil, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skladanowski, A.</span></span> <span> </span><span class="NLM_article-title">Catalytic topoisomerase II inhibitors in cancer therapy</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>99</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(03)00058-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0163-7258%2803%2900058-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12888111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=167-181&issue=2&author=A.+K.+Larsenauthor=A.+E.+Escargueilauthor=A.+Skladanowski&title=Catalytic+topoisomerase+II+inhibitors+in+cancer+therapy&doi=10.1016%2FS0163-7258%2803%2900058-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic topoisomerase II inhibitors in cancer therapy</span></div><div class="casAuthors">Larsen, Annette K.; Escargueil, Alexandre E.; Skladanowski, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The nuclear enzyme DNA topoisomerase II is a major target for antineoplastic agents.  All topoisomerase II-directed agents are able to interfere with at least one step of the catalytic cycle.  Agents able to stabilize the covalent DNA topoisomerase II complex (also known as the cleavable complex) are traditionally called topoisomerase II poisons, while agents acting on any of the other steps in the catalytic cycle are called catalytic inhibitors.  Thus, catalytic topoisomerase II inhibitors are a heterogeneous group of compds. that might interfere with the binding between DNA and topoisomerase II (aclarubicin and suramin), stabilize noncovalent DNA topoisomerase II complexes (merbarone, ICRF-187, and structurally related bisdioxopiperazine derivs.), or inhibit ATP binding (novobiocin).  Some, such as fostriecin, may also have alternative biol. targets.  Whereas topoisomerase II poisons are used solely for their antitumor activities, catalytic inhibitors are utilized for a variety of reasons, including their activity as antineoplastic agents (aclarubicin and MST-16), cardioprotectors (ICRF-187), or modulators in order to increase the efficacy of other agents (suramin and novobiocin).  In this review, the mechanism and biol. activity of different catalytic inhibitors is described, with emphasis on therapeutically used compds.  We will then discuss future development and applications of this interesting class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGote2bOTWP17bVg90H21EOLACvtfcHk0ljxuxCd3ZgtBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D&md5=4207fb899e2b98345f97e91983514913</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900058-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900058-5%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DEscargueil%26aufirst%3DA.%2BE.%26aulast%3DSkladanowski%26aufirst%3DA.%26atitle%3DCatalytic%2520topoisomerase%2520II%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D99%26issue%3D2%26spage%3D167%26epage%3D181%26doi%3D10.1016%2FS0163-7258%2803%2900058-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohajeri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahebkar, A.</span></span> <span> </span><span class="NLM_article-title">Protective effects of curcumin against doxorubicin-induced toxicity and resistance: a review</span>. <i>Crit Rev. Oncol Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2017.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.critrevonc.2017.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29458788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1MrjtFGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2018&pages=30-51&author=M.+Mohajeriauthor=A.+Sahebkar&title=Protective+effects+of+curcumin+against+doxorubicin-induced+toxicity+and+resistance%3A+a+review&doi=10.1016%2Fj.critrevonc.2017.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review</span></div><div class="casAuthors">Mohajeri Mohammad; Sahebkar Amirhossein</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Doxorubicin (DOX)-induced toxicity and resistance are major obstacles in chemotherapeutic approaches.  Despite effective in the treatment of numerous malignancies, some clinicians have voiced concern that DOX has the potential to cause debilitating consequences in organ tissues, especially the heart.  The mechanisms of toxicity and resistance are respectively related to induction of reactive oxygen species (ROS) and up-regulation of ATP-binding cassette (ABC) transporter.  Curcumin (CUR) with several biological and pharmacological properties is expected to restore DOX-mediated impairments to tissues.  This review is intended to address the current knowledge on DOX adverse effects and CUR protective actions in the heart, kidneys, liver, brain, and reproductive organs.  Coadministration of CUR and DOX is capable of ameliorating DOX toxicity pertained to antioxidant, apoptosis, autophagy, and mitochondrial permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkdQYA6PIKujUE-swuRqsHfW6udTcc2eb--Y2zDF3c_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrjtFGhtg%253D%253D&md5=026d1c99a8539d42415e48a02f832b4c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2017.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2017.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DMohajeri%26aufirst%3DM.%26aulast%3DSahebkar%26aufirst%3DA.%26atitle%3DProtective%2520effects%2520of%2520curcumin%2520against%2520doxorubicin-induced%2520toxicity%2520and%2520resistance%253A%2520a%2520review%26jtitle%3DCrit%2520Rev.%2520Oncol%2520Hematol.%26date%3D2018%26volume%3D122%26spage%3D30%26epage%3D51%26doi%3D10.1016%2Fj.critrevonc.2017.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kros, J. M.</span></span> <span> </span><span class="NLM_article-title">Breakthroughs in modern cancer therapy and elusive cardiotoxicity: critical research-practice gaps, challenges, and insights</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1002/med.21463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fmed.21463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28862319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKitb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=325-376&issue=1&author=P.+P.+Zhengauthor=J.+Liauthor=J.+M.+Kros&title=Breakthroughs+in+modern+cancer+therapy+and+elusive+cardiotoxicity%3A+critical+research-practice+gaps%2C+challenges%2C+and+insights&doi=10.1002%2Fmed.21463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights</span></div><div class="casAuthors">Zheng, Ping-Pin; Li, Jin; Kros, Johan M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">325-376</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  To date, five cancer treatment modalities have been defined.  The three traditional modalities of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two modern modalities include molecularly targeted therapy (the fourth modality) and immunotherapy (the fifth modality).  The cardiotoxicity assocd. with conventional chemotherapy and radiotherapy is well known.  Similar adverse cardiac events are resurging with the fourth modality.  Aside from the conventional and newer targeted agents, even the most newly developed, immune-based therapeutic modalities of anticancer treatment (the fifth modality), e.g., immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, have unfortunately led to potentially lethal cardiotoxicity in patients.  Cardiac complications represent unresolved and potentially life-threatening conditions in cancer survivors, while effective clin. management remains quite challenging.  As a consequence, morbidity and mortality related to cardiac complications now threaten to offset some favorable benefits of modern cancer treatments in cancer-related survival, regardless of the oncol. prognosis.  This review focuses on identifying crit. research-practice gaps, addressing real-world challenges and pinpointing real-time insights in general terms under the context of clin. cardiotoxicity induced by the fourth and fifth modalities of cancer treatment.  The information ranges from basic science to clin. management in the field of cardio-oncol. and crosses the interface between oncol. and onco-pharmacolgy.  The complexity of the ongoing clin. problem is addressed at different levels.  A better understanding of these research-practice gaps may advance research initiatives on the development of mechanism-based diagnoses and treatments for the effective clin. management of cardiotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-toVIgflHZbVg90H21EOLACvtfcHk0lgtA0STfjhWoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKitb3F&md5=0e8b5cbeaa3f8621e92b525c9be7a956</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fmed.21463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21463%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DP.%2BP.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKros%26aufirst%3DJ.%2BM.%26atitle%3DBreakthroughs%2520in%2520modern%2520cancer%2520therapy%2520and%2520elusive%2520cardiotoxicity%253A%2520critical%2520research-practice%2520gaps%252C%2520challenges%252C%2520and%2520insights%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26issue%3D1%26spage%3D325%26epage%3D376%26doi%3D10.1002%2Fmed.21463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Froelich-Ammon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase poisons: harnessing the dark side of enzyme mechanism</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">21429</span>– <span class="NLM_lpage">21432</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.37.21429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.270.37.21429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=7665550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2MXotFajtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=21429-21432&issue=37&author=S.+J.+Froelich-Ammonauthor=N.+Osheroff&title=Topoisomerase+poisons%3A+harnessing+the+dark+side+of+enzyme+mechanism&doi=10.1074%2Fjbc.270.37.21429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase poisons: harnessing the dark side of enzyme mechanism</span></div><div class="casAuthors">Froelich-Ammon, Stacie J.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">21429-32</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review, with 78 refs.  The authors report here mechanism by which drugs alter the catalytic functions of topoisomerases and convert these essential enzymes into lethal cellular weapons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQRnYWeK6g0rVg90H21EOLACvtfcHk0lgtA0STfjhWoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotFajtLs%253D&md5=4330a75545091d245162164465f6bbe7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.37.21429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.37.21429%26sid%3Dliteratum%253Aachs%26aulast%3DFroelich-Ammon%26aufirst%3DS.%2BJ.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DTopoisomerase%2520poisons%253A%2520harnessing%2520the%2520dark%2520side%2520of%2520enzyme%2520mechanism%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26issue%3D37%26spage%3D21429%26epage%3D21432%26doi%3D10.1074%2Fjbc.270.37.21429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwade, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase II and leukemia</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1310</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1111/nyas.12358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1111%2Fnyas.12358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24495080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslyltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1310&publication_year=2014&pages=98-110&issue=1&author=M.+Pendletonauthor=R.+H.+Lindseyauthor=C.+A.+Felixauthor=D.+Grimwadeauthor=N.+Osheroff&title=Topoisomerase+II+and+leukemia&doi=10.1111%2Fnyas.12358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase II and leukemia</span></div><div class="casAuthors">Pendleton, MaryJean; Lindsey, R. Hunter Jr.; Felix, Carolyn A.; Grimwade, David; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1310</span>
        (<span class="NLM_cas:issue">y</span>),
    <span class="NLM_cas:pages">98-110</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Type II topoisomerases are essential enzymes that modulate DNA under- and overwinding, knotting, and tangling.  Beyond their crit. physiol. functions, these enzymes are the targets for some of the most widely prescribed anticancer drugs (topoisomerase II poisons) in clin. use.  Topoisomerase II poisons kill cells by increasing levels of covalent enzyme-cleaved DNA complexes that are normal reaction intermediates.  Drugs such as etoposide, doxorubicin, and mitoxantrone are frontline therapies for a variety of solid tumors and hematol. malignancies.  Unfortunately, their use also is assocd. with the development of specific leukemias.  Regimens that include etoposide or doxorubicin are linked to the occurrence of acute myeloid leukemias that feature rearrangements at chromosomal band 11q23.  Similar rearrangements are seen in infant leukemias and are assocd. with gestational diets that are high in naturally occurring topoisomerase II-active compds.  Finally, regimens that include mitoxantrone and epirubicin are linked to acute promyelocytic leukemias that feature t(15;17) rearrangements.  The first part of this article will focus on type II topoisomerases and describe the mechanism of enzyme and drug action.  The second part will discuss how topoisomerase II poisons trigger chromosomal breaks that lead to leukemia and potential approaches for dissocg. the actions of drugs from their leukemogenic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiALYgvTJB7LVg90H21EOLACvtfcHk0ljjzMc_uA619g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslyltr8%253D&md5=9bb86013f9a010450587baa0c924bfec</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12358%26sid%3Dliteratum%253Aachs%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DLindsey%26aufirst%3DR.%2BH.%26aulast%3DFelix%26aufirst%3DC.%2BA.%26aulast%3DGrimwade%26aufirst%3DD.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DTopoisomerase%2520II%2520and%2520leukemia%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D1310%26issue%3D1%26spage%3D98%26epage%3D110%26doi%3D10.1111%2Fnyas.12358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClendon, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase II, genotoxicity, and cancer</span>. <i>Mutat. Res., Fundam. Mol. Mech. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>623</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.mrfmmm.2007.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.mrfmmm.2007.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17681352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWmsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=623&publication_year=2007&pages=83-97&issue=1%E2%80%932&author=A.+K.+McClendonauthor=N.+Osheroff&title=DNA+topoisomerase+II%2C+genotoxicity%2C+and+cancer&doi=10.1016%2Fj.mrfmmm.2007.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerase II, genotoxicity, and cancer</span></div><div class="casAuthors">McClendon, A. Kathleen; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">623</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">83-97</span>CODEN:
                <span class="NLM_cas:coden">MUREAV</span>;
        ISSN:<span class="NLM_cas:issn">0027-5107</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Type II topoisomerases are ubiquitous enzymes that play essential roles in a no. of fundamental DNA processes.  They regulate DNA under- and overwinding, and resolve knots and tangles in the genetic material by passing an intact double helix through a transient double-stranded break that they generate in a sep. segment of DNA.  Because type II topoisomerases generate DNA strand breaks as a requisite intermediate in their catalytic cycle, they have the potential to fragment the genome every time they function.  Thus, while these enzymes are essential to the survival of proliferating cells, they also have significant genotoxic effects.  This latter aspect of type II topoisomerase has been exploited for the development of several classes of anticancer drugs that are widely employed for the clin. treatment of human malignancies.  However, considerable evidence indicates that these enzymes also trigger specific leukemic chromosomal translocations.  In light of the impact, both pos. and neg., of type II topoisomerases on human cells, it is important to understand how these enzymes function and how their actions can destabilize the genome.  This article discusses both aspects of human type II topoisomerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Pg1M5Ibtq7Vg90H21EOLACvtfcHk0ljjzMc_uA619g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWmsbzF&md5=5377bb3255ce5136b684261d05a3b071</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.mrfmmm.2007.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mrfmmm.2007.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcClendon%26aufirst%3DA.%2BK.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DDNA%2520topoisomerase%2520II%252C%2520genotoxicity%252C%2520and%2520cancer%26jtitle%3DMutat.%2520Res.%252C%2520Fundam.%2520Mol.%2520Mech.%2520Mutagen.%26date%3D2007%26volume%3D623%26issue%3D1%25E2%2580%25932%26spage%3D83%26epage%3D97%26doi%3D10.1016%2Fj.mrfmmm.2007.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deweese, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">The DNA cleavage reaction of topoisomerase II: wolf in sheep’s clothing</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1093/nar/gkn937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1093%2Fnar%2Fgkn937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19042970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFekur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=738-748&author=J.+E.+Deweeseauthor=N.+Osheroff&title=The+DNA+cleavage+reaction+of+topoisomerase+II%3A+wolf+in+sheep%E2%80%99s+clothing&doi=10.1093%2Fnar%2Fgkn937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing</span></div><div class="casAuthors">Deweese, Joseph E.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">738-748</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Topoisomerase II is an essential enzyme that is required for virtually every process that requires movement of DNA within the nucleus or the opening of the double helix.  This enzyme helps to regulate DNA under- and over-winding and removes knots and tangles from the genetic material.  In order to carry out its crit. physiol. functions, topoisomerase II generates transient double-stranded breaks in DNA.  Consequently, while necessary for cell survival, the enzyme also has the capacity to fragment the genome.  The DNA cleavage/ligation reaction of topoisomerase II is the target for some of the most successful anticancer drugs currently in clin. use.  However, this same reaction also is believed to trigger chromosomal translocations that are assocd. with specific types of leukemia.  This article will familiarize the reader with the DNA cleavage/ligation reaction of topoisomerase II and other aspects of its catalytic cycle.  In addn., it will discuss the interaction of the enzyme with anticancer drugs and the mechanisms by which these agents increase levels of topoisomerase II-generated DNA strand breaks.  Finally, it will describe dietary and environmental agents that enhance DNA cleavage mediated by the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEHw6iKFH3x7Vg90H21EOLACvtfcHk0ljjzMc_uA619g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFekur0%253D&md5=825d9227c9017b9a90a8b3993499a234</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkn937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkn937%26sid%3Dliteratum%253Aachs%26aulast%3DDeweese%26aufirst%3DJ.%2BE.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DThe%2520DNA%2520cleavage%2520reaction%2520of%2520topoisomerase%2520II%253A%2520wolf%2520in%2520sheep%25E2%2580%2599s%2520clothing%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2009%26volume%3D37%26spage%3D738%26epage%3D748%26doi%3D10.1093%2Fnar%2Fgkn937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCombie, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannon, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase levels determine chemotherapy response <i>in vitro</i> and <i>in vivo</i></span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">9053</span>– <span class="NLM_lpage">9058</span>, <span class="refDoi"> DOI: 10.1073/pnas.0803513105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1073%2Fpnas.0803513105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18574145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=9053-9058&issue=26&author=D.+J.+Burgessauthor=J.+Dolesauthor=L.+Zenderauthor=W.+Xueauthor=B.+Maauthor=W.+R.+McCombieauthor=G.+J.+Hannonauthor=S.+W.+Loweauthor=M.+T.+Hemann&title=Topoisomerase+levels+determine+chemotherapy+response+in+vitro+and+in+vivo&doi=10.1073%2Fpnas.0803513105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase levels determine chemotherapy response in vitro and in vivo</span></div><div class="casAuthors">Burgess, Darren J.; Doles, Jason; Zender, Lars; Xue, Wen; Ma, Beicong; McCombie, W. Richard; Hannon, Gregory J.; Lowe, Scott W.; Hemann, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9053-9058</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Topoisomerase poisons are chemotherapeutic agents that are used extensively for treating human malignancies.  These drugs can be highly effective, yet tumors are frequently refractory to treatment or become resistant upon tumor relapse.  Using a pool-based RNAi screening approach and a well characterized mouse model of lymphoma, we explored the genetic basis for heterogeneous responses to topoisomerase poisons in vitro and in vivo.  These expts. identified Top2A expression levels as major determinants of response to the topoisomerase 2 poison doxorubicin and showed that suppression of Top2A produces resistance to doxorubicin in vitro and in vivo.  Analogously, using a targeted RNAi approach, we demonstrated that suppression of Top1 produces resistance to the topoisomerase 1 poison camptothecin yet hypersensitizes cancer cells to doxorubicin.  Importantly, lymphomas relapsing after treatment display spontaneous changes in topoisomerase levels as predicted by in vitro gene knockdown studies.  These results highlight the utility of pooled shRNA screens for identifying genetic determinants of chemotherapy response and suggest strategies for improving the effectiveness of topoisomerase poisons in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTnklAO5hzqrVg90H21EOLACvtfcHk0lhuVWIcK2uoPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCiur8%253D&md5=62e61e8ba30635bac005d239ee561e2e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803513105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803513105%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DD.%2BJ.%26aulast%3DDoles%26aufirst%3DJ.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DMcCombie%26aufirst%3DW.%2BR.%26aulast%3DHannon%26aufirst%3DG.%2BJ.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26atitle%3DTopoisomerase%2520levels%2520determine%2520chemotherapy%2520response%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D26%26spage%3D9053%26epage%3D9058%26doi%3D10.1073%2Fpnas.0803513105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowbay, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacogenetics of target genes across doxorubicin disposition pathway: a review</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.2174/138920010791110890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F138920010791110890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=20302569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFymtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=115-128&issue=1&author=S.+Lalauthor=A.+Mahajanauthor=W.+N.+Chenauthor=B.+Chowbay&title=Pharmacogenetics+of+target+genes+across+doxorubicin+disposition+pathway%3A+a+review&doi=10.2174%2F138920010791110890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenetics of target genes across doxorubicin disposition pathway: a review</span></div><div class="casAuthors">Lal, Suman; Mahajan, Anupama; Chen, Wei Ning; Chowbay, Balram</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-128</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Increased understanding of the mol. mechanisms of tumor heterogeneity combined with rapid advances in the field of pharmacogenetics and pharmacogenomics have fuelled studies on individualizing anticancer therapy.  Doxorubicin (Adriamycin), is an anthracycline glycoside antibiotic originally produced by Streptomyces peucetius var. caesius, and is widely used either as a single agent or in combination with other chemotherapeutic regimens for curative, adjuvant, and palliative treatment in cancer patients.  The pharmacogenetics of doxorubicin has not been well characterized.  The polygenic influence of functional candidate gene variants across doxorubicin biochem. pathway is hypothesized to contribute to its heterogeneity in disposition, influencing the efficacy of treatment and occurrence of adverse effects like cardiomyopathy in patients undergoing doxorubicin based adjuvant and neo-adjuvant chemotherapy.  The pharmacogenetics of Asian population differs from that of other ethnic groups, particularly from Caucasian and African populations, and indicates an important role of ethnicity in detg. predictive end points during chemotherapy and in individualizing treatment.  This review comprehensively examines the pharmacogenetics of the regulatory nuclear receptor Pregnane-X Receptor (PXR), influx (SLC22A16) and efflux drug transporters (ABCB1, ABCG2, ABCC5, ABCB5 and RLIP76) and drug metabolizing enzymes (CBR1, CBR3) across the biochem. pathway of doxorubicin in Asian breast cancer patients receiving doxorubicin based adjuvant chemotherapy.  The influence of functional genetic variants on the inter-individual variability in pharmacokinetics of doxorubicin and its major metabolite are also discussed.  The incorporation of non-genetic factors and subsequent validation of these findings in different patient and population groups will be valuable in tailoring doxorubicin dosage regimens to an individual to maximize therapeutic efficacy and minimize adverse reactions, leading to improved clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQo1fI7cxbI7Vg90H21EOLACvtfcHk0lhuVWIcK2uoPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFymtb4%253D&md5=04bcf7537f760926299f85e09b5c2c4e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F138920010791110890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920010791110890%26sid%3Dliteratum%253Aachs%26aulast%3DLal%26aufirst%3DS.%26aulast%3DMahajan%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DW.%2BN.%26aulast%3DChowbay%26aufirst%3DB.%26atitle%3DPharmacogenetics%2520of%2520target%2520genes%2520across%2520doxorubicin%2520disposition%2520pathway%253A%2520a%2520review%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2010%26volume%3D11%26issue%3D1%26spage%3D115%26epage%3D128%26doi%3D10.2174%2F138920010791110890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1862</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2018.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bbagen.2018.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29425806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivVSjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2018&pages=1126-1133&issue=5&author=K.+H.+Jeonauthor=H.+V.+Yuauthor=Y.+Kwon&title=Hyperactivated+m-calpain+affects+acquisition+of+doxorubicin+resistance+in+breast+cancer+cells&doi=10.1016%2Fj.bbagen.2018.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells</span></div><div class="casAuthors">Jeon, Kyung-Hwa; Yu, Han Vit; Kwon, Youngjoo</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1126-1133</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Doxorubicin is commonly using chemotherapeutic agents for breast cancer.  However, doxorubicin has limitations in clin. use because of dose-dependent cardiotoxicity and drug resistance.  Despite of previously reported studies about mechanisms of doxorubicin resistance including overexpression of P-gp and abnormal expression and mutation of topoisomerase IIα, resistance to this agent still abundantly occur and is regarded as a major obstacle to successful treatment.  The authors have established doxorubicin resistant T47D cells.  Intracellular calcium and ROS levels and calpain activity were measured using fluorometric expts.  Cell viability assay, cell cycle anal., immunofluorescence and western blot anal. were performed to evaluate m-calpain specific truncation of topoisomerase IIα and mol. mechanism in doxorubicin resistant cells.  The authors obsd. that doxorubicin treatment increased intracellular calcium and ROS (Reactive Oxygen Species) in parental and doxorubicin resistant T47D cells.  The increases in intracellular calcium and ROS were much greater in doxorubicin resistant T47D cells, which led to higher activity of calpains.  Hyperactivated m-calpain, but not μ-calpain, specifically induced cleavage of topoisomerase IIα and accumulation of truncated topoisomerase IIα in the cytoplasm.  The increase in cytoplasmic truncated topoisomerase IIα reduced the efficacy of doxorubicin.  Doxorubicin resistant T47D cells, with hyperactivated m-calpain and truncated cytosolic topoisomerase IIα, obtained cross-resistance to other topoisomerase II-targeting drugs.  Hyperactivated m-calpain induced cytoplasmic accumulation of truncated topoisomerase IIα in doxorubicin resistant T47D cells.  These data provide a new mechanism of doxorubicin resistance and suggest a novel strategy for overcoming drug resistance in topoisomerase IIα-targeting therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPQqi8RMrjrVg90H21EOLACvtfcHk0lhuVWIcK2uoPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivVSjtbs%253D&md5=1b70cc8ce292eeea3a83c3b5ec1533b8</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2018.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2018.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DJeon%26aufirst%3DK.%2BH.%26aulast%3DYu%26aufirst%3DH.%2BV.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DHyperactivated%2520m-calpain%2520affects%2520acquisition%2520of%2520doxorubicin%2520resistance%2520in%2520breast%2520cancer%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2018%26volume%3D1862%26issue%3D5%26spage%3D1126%26epage%3D1133%26doi%3D10.1016%2Fj.bbagen.2018.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brattain, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casazza, A. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5275</span>– <span class="NLM_lpage">5283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1717144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3MXmslSisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=5275-5283&issue=19&author=B.+H.+Longauthor=L.+Wangauthor=A.+Loricoauthor=R.+C.+Wangauthor=M.+G.+Brattainauthor=A.+M.+Casazza&title=Mechanisms+of+resistance+to+etoposide+and+teniposide+in+acquired+resistant+human+colon+and+lung+carcinoma+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines</span></div><div class="casAuthors">Long, Byron H.; Wang, Lotte; Lorico, Aurelio; Wang, Richard C. C.; Brattain, Michael G.; Casazza, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5275-83</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Stable, acquired resistance to etoposide (VP-16) on teniposide (VM-26) in HCT116 human colon carcinoma cells and A549 human lung adenocarcinoma cells was previously obtained by weekly 1-h exposures to either drug.  The purpose of this study was to identify possible mechanisms of resistance present in these cells by using human mdr1 and topoisomerase II DNA probes, antibodies to these gene products, and P4 phage unknotting assay for topoisomerase II activities.  HCT116(VP)35 cells were 9-, 7-, and 6-fold resistant to VP-16, VM-26, and Adriamycin, resp., and showed no cross-resistance to colchicine and actinomycin D.  These cells had no differences in mdr1 gene, mrd1 mRNA, or P-glycoprotein levels but displayed decreased levels of topoisomerase II mRNA and enzyme activity without any alteration of drug sensitivity displayed by the enzyme.  HCT116(VM)34 cells were 5-, 7-, and 21-fold resistant to VP-16, VM-26, and Adriamycin; were cross-resistant to colchicine (7-fold) and actinomycin D (18-fold); and possessed a 9-fold increase in mdr1 mRNA and increased P-glycoprotein without evidence of mdr1 gene amplification.  No alterations in topoisomerase II gene or mRNA levels, enzyme activity, or drug sensitivity were obsd.  A549(VP)28 and A549(VM)28 cells were 8-fold resistant to VP-16 and VM-26 and 3-fold resistant to Adramycin.  Both lines were not cross-resistant to colchicine or actinomycin D but were hypersensitive to cis-platinum.  No alterations in mdr1 gene, mdr1 mRNA, or P-glycoprotein levels, but lower topoisomerase II mRNA levels and decreased enzyme activities, were obsd.  Of the four acquired resistant cell lines, resistance is likely related to elevated mdr1 expression in one line and to decreased topoisomerase II expression in the other three lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBeeAgQj89FbVg90H21EOLACvtfcHk0ljgUoPewe4jQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmslSisb8%253D&md5=948b4b3ccaabf89d4b1d9adf47ff3174</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DB.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLorico%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DR.%2BC.%26aulast%3DBrattain%26aufirst%3DM.%2BG.%26aulast%3DCasazza%26aufirst%3DA.%2BM.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520etoposide%2520and%2520teniposide%2520in%2520acquired%2520resistant%2520human%2520colon%2520and%2520lung%2520carcinoma%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26issue%3D19%26spage%3D5275%26epage%3D5283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Runger, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diem, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellfritsch, D.</span></span> <span> </span><span class="NLM_article-title">Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1046/j.1523-1747.2000.00844.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1046%2Fj.1523-1747.2000.00844.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10620112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFKltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2000&pages=34-39&issue=1&author=T.+M.+Rungerauthor=S.+Emmertauthor=D.+Schadendorfauthor=C.+Diemauthor=B.+Epeauthor=D.+Hellfritsch&title=Alterations+of+DNA+repair+in+melanoma+cell+lines+resistant+to+cisplatin%2C+fotemustine%2C+or+etoposide&doi=10.1046%2Fj.1523-1747.2000.00844.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide</span></div><div class="casAuthors">Runger, Thomas M.; Emmert, Steffen; Schadendorf, Dirk; Diem, Caroline; Epe, Bernd; Hellfritsch, Doris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-39</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">Resistance to chemotherapy is a common phenomenon in malignant melanoma.  In order to assess the role of altered DNA repair in chemoresistant melanoma, we investigated different DNA repair pathways in one parental human melanoma line (MeWo) and in sublines of MeWo selected in vitro for drug resistance against four commonly used drugs (cisplatin, fotemustine, etoposide, and vindesine).  Host cell reactivation assays with the plasmid pRSV cat were used to assess processing of different DNA lesions.  With UV-irradiated plasmids, no significant differences were found, indicating a normal (nucleotide excision) repair of DNA photoproducts.  With singlet oxygen-treated plasmid, the fotemustine- and cisplatin-resistant lines exhibited a significantly increased (base excision) repair of oxidative DNA damage.  With fotemustine-treated plasmid, the fotemustine-resistant subline did not exhibit an increased repair of directly fotemustine-induced DNA damage.  Similar results were obtained with cisplatin-induced DNA crosslinks in the cisplatin-resistant line.  The fotemustine- and etoposide-resistant sublines have been shown to exhibit a reduced expression of genes involved in DNA mismatch repair.  We used a "host cell microsatellite stability assay" with the plasmid pZCA29 and found a 2.0-fold to 2.5-fold increase of microsatellite frameshift mutations (p ≤ 0.002) in the two resistant sublines.  This indicates microsatellite instability, the hallmark of an impaired DNA mismatch repair.  The increased repair of oxidative DNA damage might mediate an increased chemoresistance through an improved repair of drug-induced DNA damage.  In contrast, a reduced DNA mismatch repair might confer resistance by preventing futile degrdn. of newly synthesized DNA opposite alkylation damage, or by an inability to detect such damage and subsequent inability to undergo DNA-damage-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ-dqopHnNiLVg90H21EOLACvtfcHk0ljgUoPewe4jQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFKltrc%253D&md5=45a00fd918ee0216eb14386c5615cee4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1747.2000.00844.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1747.2000.00844.x%26sid%3Dliteratum%253Aachs%26aulast%3DRunger%26aufirst%3DT.%2BM.%26aulast%3DEmmert%26aufirst%3DS.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DDiem%26aufirst%3DC.%26aulast%3DEpe%26aufirst%3DB.%26aulast%3DHellfritsch%26aufirst%3DD.%26atitle%3DAlterations%2520of%2520DNA%2520repair%2520in%2520melanoma%2520cell%2520lines%2520resistant%2520to%2520cisplatin%252C%2520fotemustine%252C%2520or%2520etoposide%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2000%26volume%3D114%26issue%3D1%26spage%3D34%26epage%3D39%26doi%3D10.1046%2Fj.1523-1747.2000.00844.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, U. G.</span></span> <span> </span><span class="NLM_article-title">Tumor cell resistance to DNA topoisomerase II inhibitors: new developments</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1054/drup.1999.0110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1054%2Fdrup.1999.0110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11498354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFWmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1999&pages=382-389&issue=6&author=W.+T.+Beckauthor=S.+E.+Morganauthor=Y.+Y.+Moauthor=U.+G.+Bhat&title=Tumor+cell+resistance+to+DNA+topoisomerase+II+inhibitors%3A+new+developments&doi=10.1054%2Fdrup.1999.0110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor cell resistance to DNA topoisomerase II inhibitors: new developments</span></div><div class="casAuthors">Beck, William T.; Morgan, Susan E.; Mo, Yin-Yuan; Bhat, Uppoor G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">382-389</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">A review with 94 refs.  DNA topoisomerases are crit. enzymes involved in replication, transcription, chromatin assembly and other aspects of DNA metab.  They are also the targets of important anticancer drugs.  The type II topoisomerases are specific targets of drug classes that comprise complex-stabilizing (epipodophyllotoxins, anthracyclines) and catalytic (merbarone, bisdioxopiperazines) inhibitors.  In this review, we update our current knowledge of resistance to the antitumor inhibitors of the type II DNA topoisomerases, with special emphasis on the catalytic inhibitors, since novel catalytic inhibitor resistance cell lines have only recently been described.  Resistance to topoisomerase II inhibitors can manifest as decreased or increased expression of or mutation in the topoisomerase II genes.  However, the tumor cell's response to exposure to these inhibitors involves more than the target enzyme, and these other responses are a major focus of this review.  Such cellular changes are assocd. with and may contribute to the drug resistance phenotype.  They involve decreased drug accumulation due to expression of membrane "pump" proteins, altered cytotoxic signaling through stress-activated protein kinases, and alterations in apoptosis and cell cycle proteins (e.g. Bcl-2, Bax, p53, Rb).  While it is evident that mutation in or altered expression of the topoisomerase II genes are sufficient to confer resistance to topoisomerase inhibitors, it is not clear whether the other changes are a consequence of the selection or a response to the cytotoxic insult, nor is it clear how these other cellular changes contribute to the drug resistance phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTuKIVCK9wNbVg90H21EOLACvtfcHk0ljgUoPewe4jQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFWmsro%253D&md5=8d6d163670828eb8ba91f729287a5794</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1054%2Fdrup.1999.0110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fdrup.1999.0110%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DW.%2BT.%26aulast%3DMorgan%26aufirst%3DS.%2BE.%26aulast%3DMo%26aufirst%3DY.%2BY.%26aulast%3DBhat%26aufirst%3DU.%2BG.%26atitle%3DTumor%2520cell%2520resistance%2520to%2520DNA%2520topoisomerase%2520II%2520inhibitors%253A%2520new%2520developments%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D1999%26volume%3D2%26issue%3D6%26spage%3D382%26epage%3D389%26doi%3D10.1054%2Fdrup.1999.0110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marbeuf-Gueye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxterman, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubru, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priebe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier-Suillerot, A.</span></span> <span> </span><span class="NLM_article-title">Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1124/mol.53.1.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1124%2Fmol.53.1.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9443942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXot1ahsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=141-147&issue=1&author=C.+Marbeuf-Gueyeauthor=H.+J.+Broxtermanauthor=F.+Dubruauthor=W.+Priebeauthor=A.+Garnier-Suillerot&title=Kinetics+of+anthracycline+efflux+from+multidrug+resistance+protein-expressing+cancer+cells+compared+with+P-glycoprotein-expressing+cancer+cells&doi=10.1124%2Fmol.53.1.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells</span></div><div class="casAuthors">Marbeuf-Gueye, C.; Broxterman, H. J.; Dubru, F.; Priebe, W.; Garnier-Suillerot, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-147</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide.  Thus, this protein does confer a multidrug resistant phenotype to cancer cells, similar to P-glycoprotein (Pgp).  The substrate specificity of both transporter proteins is partly over-lapping but is otherwise very distinct; because MRP is a multiple org. anion transporter, it transports certain glutathione conjugates and may be partly dependent on intracellular glutathione levels for the transport of anthracyclines.  We have studied the transport kinetics of a series of anthracyclines in MRP and Pgp that overexpress tumor cell lines to obtain information on the substrate specificity of these proteins.  The anthracyclines have modifications in the sugar moiety.  The mean active efflux coeff. ka, used to characterize the efficiency of the active efflux, was very similar for DNR and one of its 4'-deoxy- derivs. (eso-DNR) for MRP and Pgp [10-20 × 10-/s/(cells/mL)].  The permanently neutral derivs. 3'-deamino-3'-hydroxy-doxorubicin (OH-DOX) and 3'-deamino-3'-hydroxy-daunorubicin (OH-DNR) were effluxed by both proteins but had a lower ka [2 × 10-10/s/(cells/mL) (OH-DOX) and 2 × 10-10 and 5 × 10-10/s/(cells/mL) (OH-DNR)] for MRP and Pgp.  Two anthracyclines, the doxorubicin deriv. pirarubicin and 2'-bromo-4'-epi-DNR seemed to have a slightly higher ka value for Pgp than for MRP.  The apparent Michaelis-Menten consts. (Km) and maximal efflux rates (VM) for the active transport were within a narrow range for both transporters, except for OH-DOX and OH-DNR, which had a lower VM in the case of MRP-mediated transport, suggesting a role of the amino group in the interaction with glutathione.  Detn. of the Hill coeff. (nH) of the MRP-mediated efflux gave most values close to 2, which suggests cooperativity of the transport of anthracyclines as reported before for Pgp.  In conclusion, the transport kinetics of anthracyclines by MRP and Pgp are very similar.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIQ9bO-zQ2PbVg90H21EOLACvtfcHk0ljgUoPewe4jQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXot1ahsA%253D%253D&md5=03cb5fa3d6cea541228cbdefc5d942fa</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fmol.53.1.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.53.1.141%26sid%3Dliteratum%253Aachs%26aulast%3DMarbeuf-Gueye%26aufirst%3DC.%26aulast%3DBroxterman%26aufirst%3DH.%2BJ.%26aulast%3DDubru%26aufirst%3DF.%26aulast%3DPriebe%26aufirst%3DW.%26aulast%3DGarnier-Suillerot%26aufirst%3DA.%26atitle%3DKinetics%2520of%2520anthracycline%2520efflux%2520from%2520multidrug%2520resistance%2520protein-expressing%2520cancer%2520cells%2520compared%2520with%2520P-glycoprotein-expressing%2520cancer%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D53%26issue%3D1%26spage%3D141%26epage%3D147%26doi%3D10.1124%2Fmol.53.1.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8947</span>– <span class="NLM_lpage">8980</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01202</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01202" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8947-8980&issue=20&author=W.+Huauthor=X.+S.+Huangauthor=J.+F.+Wuauthor=L.+Yangauthor=Y.+T.+Zhengauthor=Y.+M.+Shenauthor=Z.+Y.+Liauthor=X.+Li&title=Discovery+of+novel+topoisomerase+II+inhibitors+by+medicinal+chemistry+approaches&doi=10.1021%2Facs.jmedchem.7b01202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches</span></div><div class="casAuthors">Hu, Wei; Huang, Xu-Sheng; Wu, Ji-Feng; Yang, Liang; Zheng, Yong-Tang; Shen, Yue-Mao; Li, Zhi-Yu; Li, Xun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8947-8980</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA topoisomerase II (topo II) is an important enzyme involved in DNA replication, recombination, and repair.  Despite the popular applications of topo II inhibitors in cancer therapy, there is still an urgent need to upgrade topo II inhibitors to cope with drug resistance and severe adverse effects.  Accordingly, novel topo II catalytic or multitarget topo II inhibitors are gaining more attention and make it possible to ease the toxic limitations of topo II poisons.  In this review, medicinal chem. approaches are mainly discussed toward the development of potent topo II inhibitors with low toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWv9JERcv7XbVg90H21EOLACvtfcHk0lgMdFEOi5uNcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsL3P&md5=51468c5ca4b8fd437760567e78e1d393</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01202%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BF.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DY.%2BT.%26aulast%3DShen%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DZ.%2BY.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520topoisomerase%2520II%2520inhibitors%2520by%2520medicinal%2520chemistry%2520approaches%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D20%26spage%3D8947%26epage%3D8980%26doi%3D10.1021%2Facs.jmedchem.7b01202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hevener, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutat, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggsbee, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, J. W.</span></span> <span> </span><span class="NLM_article-title">Recent developments in topoisomerase-targeted cancer chemotherapy</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">844</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2018.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.apsb.2018.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30505655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslSmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=844-861&issue=6&author=K.+Hevenerauthor=T.+A.+Verstakauthor=K.+E.+Lutatauthor=D.+L.+Riggsbeeauthor=J.+W.+Mooney&title=Recent+developments+in+topoisomerase-targeted+cancer+chemotherapy&doi=10.1016%2Fj.apsb.2018.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in topoisomerase-targeted cancer chemotherapy</span></div><div class="casAuthors">Hevener KirkE; Verstak Tatsiana A; Lutat Katie E; Riggsbee Daniel L; Mooney Jeremiah W</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">844-861</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The DNA topoisomerase enzymes are essential to cell function and are found ubiquitously in all domains of life.  The various topoisomerase enzymes perform a wide range of functions related to the maintenance of DNA topology during DNA replication, and transcription are the targets of a wide range of antimicrobial and cancer chemotherapeutic agents.  Natural product-derived agents, such as the camptothecin, anthracycline, and podophyllotoxin drugs, have seen broad use in the treatment of many types of cancer.  Selective targeting of the topoisomerase enzymes for cancer treatment continues to be a highly active area of basic and clinical research.  The focus of this review will be to summarize the current state of the art with respect to clinically used topoisomerase inhibitors for targeted cancer treatment and to discuss the pharmacology and chemistry of promising new topoisomerase inhibitors in clinical and pre-clinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ912zKLJkkBxwLZxei1HN8fW6udTcc2eZJteovCtfUIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslSmsw%253D%253D&md5=419d4b19bd7d1343db55e1bef20ec11b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2018.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2018.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DHevener%26aufirst%3DK.%26aulast%3DVerstak%26aufirst%3DT.%2BA.%26aulast%3DLutat%26aufirst%3DK.%2BE.%26aulast%3DRiggsbee%26aufirst%3DD.%2BL.%26aulast%3DMooney%26aufirst%3DJ.%2BW.%26atitle%3DRecent%2520developments%2520in%2520topoisomerase-targeted%2520cancer%2520chemotherapy%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2018%26volume%3D8%26issue%3D6%26spage%3D844%26epage%3D861%26doi%3D10.1016%2Fj.apsb.2018.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelcnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.2174/092986713804999402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F092986713804999402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23210851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Sqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=694-709&issue=5&author=B.+Pogorelcnikauthor=A.+Perdihauthor=T.+Solmajer&title=Recent+advances+in+the+development+of+catalytic+inhibitors+of+human+DNA+topoisomerase+II%CE%B1+as+novel+anticancer+agents&doi=10.2174%2F092986713804999402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents</span></div><div class="casAuthors">Pogorelcnik, B.; Perdih, A.; Solmajer, T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">694-709</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases comprise an important family of enzymes that catalyze the induction of topol. changes (e.g. relaxation/supercoiling, catenation/decatenation and knotting/unknotting) in the DNA mol.  These enzymes perform their functions by creating transient either single-stranded or double-stranded breaks in the DNA mol.  Due to their ability to modulate the topol. of the DNA mol., DNA topoisomerases play vital roles in replication, transcription, chromosome sepn. and segregation, and thus represent an important collection of design targets for novel anticancer drugs.  The aim of this review is to provide an overview of the development of catalytic inhibitors of the human topoisomerase IIα enzyme - an important member of the DNA topoisomerase family - as potential novel anticancer agents.  The group of catalytic topoII inhibitors is classified into four types according to their mol. mechanism of action: inhibitors that bind to the ATP binding site, inhibitors that prevent the ATP hydrolysis step and trap the enzyme in a closed clamp, inhibitors that block the DNA cleavage and inhibitors that prevent the enzyme binding to the DNA.  One of the important considerations highlighted throughout this review is the structure-based perspective of inhibitor design, giving the reader a medicinal chemist's perspective on this vibrant and active field of drug design research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAlJEjtNBzFLVg90H21EOLACvtfcHk0lgMdFEOi5uNcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Sqtbg%253D&md5=b9ddc44bde368e46089477089ef67dc6</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F092986713804999402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986713804999402%26sid%3Dliteratum%253Aachs%26aulast%3DPogorelcnik%26aufirst%3DB.%26aulast%3DPerdih%26aufirst%3DA.%26aulast%3DSolmajer%26aufirst%3DT.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520catalytic%2520inhibitors%2520of%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520as%2520novel%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D5%26spage%3D694%26epage%3D709%26doi%3D10.2174%2F092986713804999402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendorff, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">Resveratrol: A novel type of topoisomerase II inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span> (<span class="NLM_issue">51</span>),  <span class="NLM_fpage">21011</span>– <span class="NLM_lpage">21022</span>, <span class="refDoi"> DOI: 10.1074/jbc.M117.810580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.M117.810580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29074616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVejsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=21011-21022&issue=51&author=J.+H.+Leeauthor=T.+J.+Wendorffauthor=J.+M.+Berger&title=Resveratrol%3A+A+novel+type+of+topoisomerase+II+inhibitor&doi=10.1074%2Fjbc.M117.810580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol: A novel type of topoisomerase II inhibitor</span></div><div class="casAuthors">Lee, Joyce H.; Wendorff, Timothy J.; Berger, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">21011-21022</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Resveratrol, a polyphenol found in various plant sources, has gained attention as a possible agent responsible for the purported health benefits of certain foods, such as red wine.  Despite annual multi-million dollar market sales as a nutriceutical, there is little consensus about the physiol. roles of resveratrol.  One suggested mol. target of resveratrol is eukaryotic topoisomerase II (topo II), an enzyme essential for chromosome segregation and DNA supercoiling homeostasis.  Interestingly, resveratrol is chem. similar to ICRF-187, a clin. approved chemotherapeutic that stabilizes an ATP-dependent dimerization interface in topo II to block enzyme activity.  Based on this similarity, we hypothesized that resveratrol may antagonize topo II by a similar mechanism.  Using a variety of biochem. assays, we find that resveratrol indeed acts through the ICRF-187 binding locus, but that it inhibits topo II by preventing ATPase domain dimerization rather than stabilizing it.  This work presents the first comprehensive anal. of the biochem. effects of both ICRF-187 and resveratrol on the human isoforms of topo II, and reveals a new mode for the allosteric regulation of topo II through modulation of ATPase status.  Natural polyphenols related to resveratrol that have been shown to impact topo II function may operate in a similar manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnhiw4uOND1bVg90H21EOLACvtfcHk0ljJmGvt0NWB4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVejsbjK&md5=a33eb2b6b11da6eea8de109455b7e851</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.810580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.810580%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DWendorff%26aufirst%3DT.%2BJ.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DResveratrol%253A%2520A%2520novel%2520type%2520of%2520topoisomerase%2520II%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26issue%3D51%26spage%3D21011%26epage%3D21022%26doi%3D10.1074%2Fjbc.M117.810580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 2-phenylnaphthalenoids and 2-phenylbenzofuranoids as DNA topoisomerase inhibitors and antitumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.07.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2015.07.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26291037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=277-287&author=H.+Haoauthor=W.+Chenauthor=J.+Zhuauthor=C.+Luauthor=Y.+Shen&title=Design+and+synthesis+of+2-phenylnaphthalenoids+and+2-phenylbenzofuranoids+as+DNA+topoisomerase+inhibitors+and+antitumor+agents&doi=10.1016%2Fj.ejmech.2015.07.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of 2-phenylnaphthalenoids and 2-phenylbenzofuranoids as DNA topoisomerase inhibitors and antitumor agents</span></div><div class="casAuthors">Hao, Huilin; Chen, Wang; Zhu, Jing; Lu, Chunhua; Shen, Yuemao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277-287</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eight 2-phenylnaphthalenoids (2PNs) and twenty four 2-phenylbenzofuranoids (2PBFs) were successfully designed, synthesized and their antiproliferative and in vitro DNA topoisomerase inhibitory activities were evaluated.  Nine compds. (four 2PNs and five 2PBFs) showed either TopoI or TopoIIα inhibitory activities.  Six compds. (four 2PNs and two 2PBFs) exhibited potent cytotoxicity with IC50 values for 72 h exposure ranging from 0.3 to above 20 μM against MDA-MB-231, MDA-MB-435, HepG2 and PC3 cell lines.  The two 2PBFs displayed comparable and even better antiproliferative as well as TopoIIα inhibitory activities than 2PNs.  Interestingly, the active 2PBFs displayed different mechanisms of TopoIIα inhibition from that of 2PNs, suggesting that the chromophore scaffold replacement may result in a change of the binding site of inhibitors to TopoIIα.  Furthermore, the mechanisms of antiproliferation on MDA-MB-231 cells indicate that compds. I and II are promising for further development of anticancer agents.  The results of this study reveal that the evolutionary strategy of medicinal chem. through scaffold hopping is a promising strategy for structure optimization of TopoIIα inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptY9xrEHooKbVg90H21EOLACvtfcHk0ljJmGvt0NWB4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegtb%252FO&md5=1ab3a31789c3ac2b7d632d379bb48992</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.07.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.07.048%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DDesign%2520and%2520synthesis%2520of%25202-phenylnaphthalenoids%2520and%25202-phenylbenzofuranoids%2520as%2520DNA%2520topoisomerase%2520inhibitors%2520and%2520antitumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D102%26spage%3D277%26epage%3D287%26doi%3D10.1016%2Fj.ejmech.2015.07.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandele, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Bioflavonoids as poisons of human topoisomerase Iiα and IIβ</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6097</span>– <span class="NLM_lpage">6108</span>, <span class="refDoi"> DOI: 10.1021/bi7000664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi7000664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXks1Sis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=6097-6108&issue=20&author=O.+J.+Bandeleauthor=N.+Osheroff&title=Bioflavonoids+as+poisons+of+human+topoisomerase+Ii%CE%B1+and+II%CE%B2&doi=10.1021%2Fbi7000664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bioflavonoids as Poisons of Human Topoisomerase IIα and IIβ</span></div><div class="casAuthors">Bandele, Omari J.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6097-6108</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bioflavonoids are human dietary components that have been linked to the prevention of cancer in adults and the generation of specific types of leukemia in infants.  While these compds. have a broad range of cellular activities, many of their genotoxic effects have been attributed to their actions as topoisomerase II poisons.  However, the activities of bioflavonoids against the individual isoforms of human topoisomerase II have not been analyzed.  Therefore, we characterized the activity and mechanism of action of three major classes of bioflavonoids, flavones, flavonols, and isoflavones, against human topoisomerase IIα and IIβ.  Genistein was the most active bioflavonoid tested and stimulated enzyme-mediated DNA cleavage ∼10-fold.  Generally, compds. were more active against topoisomerase IIβ.  DNA cleavage with both enzyme isoforms required a 5-OH and a 4'-OH and was enhanced by the presence of addnl. hydroxyl groups on the pendant ring.  Competition DNA cleavage and topoisomerase II binding studies indicate that the 5-OH group plays an important role in mediating genistein binding, while the 4'-OH moiety contributes primarily to bioflavonoid function.  Bioflavonoids do not require redox cycling for activity and function primarily by inhibiting enzyme-mediated DNA ligation.  Mutagenesis studies suggest that the TOPRIM region of topoisomerase II plays a role in genistein binding.  Finally, flavones, flavonols, and isoflavones with activity against purified topoisomerase IIα and IIβ enhanced DNA cleavage by both isoforms in human CEM leukemia cells.  These data support the hypothesis that bioflavonoids function as topoisomerase II poisons in humans and provide a framework for further anal. of these important dietary components.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqBsFnYVVe7rVg90H21EOLACvtfcHk0ljJmGvt0NWB4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXks1Sis7g%253D&md5=698b3f68a5a8e4ed0010227ee2a5d097</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fbi7000664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi7000664%26sid%3Dliteratum%253Aachs%26aulast%3DBandele%26aufirst%3DO.%2BJ.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DBioflavonoids%2520as%2520poisons%2520of%2520human%2520topoisomerase%2520Ii%25CE%25B1%2520and%2520II%25CE%25B2%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26issue%3D20%26spage%3D6097%26epage%3D6108%26doi%3D10.1021%2Fbi7000664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2019.03.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30917303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVClsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2019&pages=129-168&author=X.+Liangauthor=Q.+Wuauthor=S.+Luanauthor=Z.+Yinauthor=C.+Heauthor=L.+Yinauthor=Y.+Zouauthor=Z.+Yuanauthor=L.+Liauthor=X.+Songauthor=M.+Heauthor=C.+Lvauthor=W.+Zhang&title=A+comprehensive+review+of+topoisomerase+inhibitors+as+anticancer+agents+in+the+past+decade&doi=10.1016%2Fj.ejmech.2019.03.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade</span></div><div class="casAuthors">Liang, Xiaoxia; Wu, Qiang; Luan, Shangxian; Yin, Zhongqiong; He, Changliang; Yin, Lizi; Zou, Yuanfeng; Yuan, Zhixiang; Li, Lixia; Song, Xu; He, Min; Lv, Cheng; Zhang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-168</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The topoisomerase enzymes play an important role in DNA metab., and searching for enzyme inhibitors is an important target in the search for new anticancer drugs.  Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research.  Therefore, biologists, org. chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive mols. targeting topoisomerase.  This review summarizes types of topoisomerase inhibitors in the past decade, and divides them into nine classes by structural characteristics, including N-heterocycles compds., quinone derivs., flavonoids derivs., coumarin derivs., lignan derivs., polyphenol derivs., diterpenes derivs., fatty acids derivs., and metal complexes.  Then we discussed the application prospect and development of these anticancer compds., as well as concluded parts of their structural-activity relationships.  We believe this review would be invaluable in helping to further search potential topoisomerase inhibition as antitumor agent in clin. usage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYAU-SIaKdi7Vg90H21EOLACvtfcHk0lhIXlhQJsc46w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVClsr8%253D&md5=797d805869cfd92fce346c4bd076ea92</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DLuan%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLv%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DA%2520comprehensive%2520review%2520of%2520topoisomerase%2520inhibitors%2520as%2520anticancer%2520agents%2520in%2520the%2520past%2520decade%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D171%26spage%3D129%26epage%3D168%26doi%3D10.1016%2Fj.ejmech.2019.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meignan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couderc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narducci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruczynski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilbaud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annereau, J. P.</span></span> <span> </span><span class="NLM_article-title">F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2015.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.canlet.2015.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26404751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGhtrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2016&pages=10-18&issue=1&author=B.+Thibaultauthor=E.+Clementauthor=G.+Zorzaauthor=S.+Meignanauthor=J.+P.+Delordauthor=B.+Coudercauthor=C.+Baillyauthor=F.+Narducciauthor=I.+Vandenbergheauthor=A.+Kruczynskiauthor=N.+Guilbaudauthor=P.+Ferreauthor=J.+P.+Annereau&title=F14512%2C+a+polyamine-vectorized+inhibitor+of+topoisomerase+II%2C+exhibits+a+marked+anti-tumor+activity+in+ovarian+cancer&doi=10.1016%2Fj.canlet.2015.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer</span></div><div class="casAuthors">Thibault, Benoit; Clement, Emily; Zorza, Gregoire; Meignan, Samuel; Delord, Jean-Pierre; Couderc, Bettina; Bailly, Christian; Narducci, Fabrice; Vandenberghe, Isabelle; Kruczynski, Anna; Guilbaud, Nicolas; Ferre, Pierre; Annereau, Jean-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Epithelial ovarian cancer is the fourth cause of death among cancer-bearing women and frequently assocd. with carboplatin resistance, underlining the need for more efficient and targeted therapies.  F14512 is an epipodophyllotoxin-core linked to a spermine chain which enters cells via the polyamine transport system (PTS).  Here, we investigate this novel concept of vectorization in ovarian cancer.  We compared the effects of etoposide and F14512 on a panel of five carboplatin-sensitive or resistant ovarian cancer models.  We assessed the incorporation of F17073, a spermine-linked fluorescent probe, in these cells and in 18 clin. samples.  We then showed that F14512 exhibits a high anti-proliferative and pro-apoptotic activity, particularly in cells with high levels of F17073 incorporation.  Consistently, F14512 significantly inhibited tumor growth compared to etoposide, in a cisplatin-resistant A2780R s.c. model, at a dose of 1.25 mg/kg.  In addn., ex vivo anal. indicated that 15 out of 18 patients presented a higher F17073 incorporation into tumor cells compared to normal cells.  Overall, our data suggest that F14512, a targeted drug with a potent antitumor efficacy, constitutes a potential new therapy for highly PTS-pos. and platinum-resistant ovarian cancer-bearing patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGThk1B2FIprVg90H21EOLACvtfcHk0lhIXlhQJsc46w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGhtrjK&md5=e7f45567d11507656d904a45396d1eae</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2015.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2015.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DThibault%26aufirst%3DB.%26aulast%3DClement%26aufirst%3DE.%26aulast%3DZorza%26aufirst%3DG.%26aulast%3DMeignan%26aufirst%3DS.%26aulast%3DDelord%26aufirst%3DJ.%2BP.%26aulast%3DCouderc%26aufirst%3DB.%26aulast%3DBailly%26aufirst%3DC.%26aulast%3DNarducci%26aufirst%3DF.%26aulast%3DVandenberghe%26aufirst%3DI.%26aulast%3DKruczynski%26aufirst%3DA.%26aulast%3DGuilbaud%26aufirst%3DN.%26aulast%3DFerre%26aufirst%3DP.%26aulast%3DAnnereau%26aufirst%3DJ.%2BP.%26atitle%3DF14512%252C%2520a%2520polyamine-vectorized%2520inhibitor%2520of%2520topoisomerase%2520II%252C%2520exhibits%2520a%2520marked%2520anti-tumor%2520activity%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D370%26issue%3D1%26spage%3D10%26epage%3D18%26doi%3D10.1016%2Fj.canlet.2015.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antolin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in Precision Oncology: Current Applications and Future Prospects</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">6935</span>– <span class="NLM_lpage">6945</span>, <span class="refDoi"> DOI: 10.2174/1381612822666160923115828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1381612822666160923115828" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=6935-6945&issue=46&author=A.+A.+Antolinauthor=P.+Workmanauthor=J.+Mestresauthor=B.+Al-Lazikani&title=Polypharmacology+in+Precision+Oncology%3A+Current+Applications+and+Future+Prospects&doi=10.2174%2F1381612822666160923115828"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F1381612822666160923115828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612822666160923115828%26sid%3Dliteratum%253Aachs%26aulast%3DAntolin%26aufirst%3DA.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26atitle%3DPolypharmacology%2520in%2520Precision%2520Oncology%253A%2520Current%2520Applications%2520and%2520Future%2520Prospects%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2017%26volume%3D22%26issue%3D46%26spage%3D6935%26epage%3D6945%26doi%3D10.2174%2F1381612822666160923115828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: drug discovery for the future</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1586/ecp.12.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-7&issue=1&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+drug+discovery+for+the+future&doi=10.1586%2Fecp.12.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lhIXlhQJsc46w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520drug%2520discovery%2520for%2520the%2520future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26issue%3D1%26spage%3D41%26epage%3D7%26doi%3D10.1586%2Fecp.12.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Proposal of dual inhibitor targeting ATPase domains of topoisomerase II and heat shock protein 90</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2016.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.4062%2Fbiomolther.2016.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFSq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=453-468&issue=5&author=K.+Y.+Junauthor=Y.+Kwon&title=Proposal+of+dual+inhibitor+targeting+ATPase+domains+of+topoisomerase+II+and+heat+shock+protein+90&doi=10.4062%2Fbiomolther.2016.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Proposal of dual inhibitor targeting ATPase domains of topoisomerase II and heat shock protein 90</span></div><div class="casAuthors">Jun, Kyu-Yeon; Kwon, Youngjoo</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">453-468</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">There is a conserved ATPase domain in topoisomerase II (topo II) and heat shock protein 90 (Hsp90) which belong to the GHKL (gyrase, Hsp90, histidine kinase, and MutL) family.  The inhibitors that target each of topo II and Hsp90 are intensively studied as anti-cancer drugs since they play very important roles in cell proliferation and survival.  Therefore the development of dual targeting anti-cancer drugs for topo II and Hsp90 is suggested to be a promising area.  The topo II and Hsp90 inhibitors, known to bind to their ATP binding site, were searched.  All the inhibitors investigated were docked to both topo II and Hsp90.  Four candidate compds. as possible dual inhibitors were selected by analyzing the mol. docking study.  The pharmacophore model of dual inhibitors for topo II and Hsp90 were generated and the design of novel dual inhibitor was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtymxVS4DsqrVg90H21EOLACvtfcHk0ljhgZ1SrBx-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFSq&md5=2fa259235646cfa6ad8738fb5d48bafc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2016.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2016.168%26sid%3Dliteratum%253Aachs%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DProposal%2520of%2520dual%2520inhibitor%2520targeting%2520ATPase%2520domains%2520of%2520topoisomerase%2520II%2520and%2520heat%2520shock%2520protein%252090%26jtitle%3DBiomol.%2520Ther.%26date%3D2016%26volume%3D24%26issue%3D5%26spage%3D453%26epage%3D468%26doi%3D10.4062%2Fbiomolther.2016.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valkov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gump, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase interacts directly with DNA topoisomerase II</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1038/81671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2F81671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11062478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotVWhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2000&pages=349-353&issue=3&author=S.+C.+Tsaiauthor=N.+Valkovauthor=W.+M.+Yangauthor=J.+Gumpauthor=D.+Sullivanauthor=E.+Seto&title=Histone+deacetylase+interacts+directly+with+DNA+topoisomerase+II&doi=10.1038%2F81671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase interacts directly with DNA topoisomerase II</span></div><div class="casAuthors">Tsai, Shih-Chang; Valkov, Nikola; Yang, Wen-Ming; Gump, Jana; Sullivan, Daniel; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-353</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) modify nucleosomal histones, have a key role in the regulation of gene transcription, and may be involved in cell-cycle regulation, differentiation and human cancer.  Purified recombinant human HDAC1 protein was used to screen a cDNA expression library, and one of the clones identified encoded DNA topoisomerase II (Topo II), an enzyme known to have a role in transcriptional regulation and chromatin organization.  Coimmunopptn. expts. indicate that HDAC1 and HDAC2 are assocd. with Topo II in vivo under normal physiol. conditions.  Complexes contg. Topo II possess HDAC activities, and complexes contg. HDAC1 or HDAC2 possess Topo II activities.  HDAC and Topo II modify each other's activity in vitro and in vivo.  Our results indicate the existence of a functionally coupled complex between these two enzymes and offer insights into the potential mechanisms of action of both enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEYt2puIf_1rVg90H21EOLACvtfcHk0ljhgZ1SrBx-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotVWhsbY%253D&md5=9adf7bd4fc5527b248b48833e5772d72</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2F81671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F81671%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DS.%2BC.%26aulast%3DValkov%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DW.%2BM.%26aulast%3DGump%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHistone%2520deacetylase%2520interacts%2520directly%2520with%2520DNA%2520topoisomerase%2520II%26jtitle%3DNat.%2520Genet.%26date%3D2000%26volume%3D26%26issue%3D3%26spage%3D349%26epage%3D353%26doi%3D10.1038%2F81671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title"><i>In-vivo</i> synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">2000</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-05-0194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=16373714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCnsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1993-2000&issue=12&author=D.+C.+Marchionauthor=E.+Bicakuauthor=A.+I.+Daudauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=In-vivo+synergy+between+topoisomerase+II+and+histone+deacetylase+inhibitors%3A+predictive+correlates&doi=10.1158%2F1535-7163.MCT-05-0194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Daud, Adil I.; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1993-2000</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) are a promising class of anticancer agents, yet the specific biol. effects resulting in cell death are still poorly understood and clin. relevant markers of response are not adequately defined.  The anticonvulsant valproic acid has recently emerged as an HDACi, and in vitro studies suggested that valproic acid may potentiate cytotoxic agents.  We evaluated the pharmacol. and biol. effects of valproic acid on histone acetylation, chromatin structure, and DNA damage induced by topoisomerase II inhibitors in mice bearing breast cancer tumors and developed an ex vivo methodol. for response prediction using comet assays.  The exposure of mice to valproic acid before exposure to epirubicin led to tumor regression when valproic acid was given for 48 h at concns. sufficient for histone hyperacetylation, down-regulation of heterochromatin maintenance proteins, and chromatin decondensation.  Tumor response was accurately predicted by ex vivo comet moments.  Valproic acid did not exacerbate epirubicin-related toxicity.  Antitumor effects were not obsd. with valproic acid alone despite biol. active valproic acid concns.  These findings suggest that exposure of tumor-bearing mice to valproic acid potentiated the antitumor effects of topoisomerase II inhibitors without enhancing toxicity.  The HDACi-induced histone acetylation and modulation of heterochromatin correlated with potentiation of epirubicin-mediated DNA damage.  However, these effects did not result in antitumor activity when using a HDACi alone and hence should not be considered a surrogate marker.  Ex vivo comet assays may be useful as a predictive tool when tumor cells are limited and serial biopsies are difficult to obtain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr22AJiKgejK7Vg90H21EOLACvtfcHk0ljhgZ1SrBx-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCnsrjP&md5=0598f67f024ed153636a4244fbf38b3e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0194%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DIn-vivo%2520synergy%2520between%2520topoisomerase%2520II%2520and%2520histone%2520deacetylase%2520inhibitors%253A%2520predictive%2520correlates%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26issue%3D12%26spage%3D1993%26epage%3D2000%26doi%3D10.1158%2F1535-7163.MCT-05-0194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Fragments, network biology and designing multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.drudis.2006.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17275736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&issue=3%E2%80%934&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+network+biology+and+designing+multiple+ligands&doi=10.1016%2Fj.drudis.2006.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Fragments, network biology and designing multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3&4</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Modulating multiple protein targets simultaneously can be beneficial for treating complex diseases.  The redundancy that exists within biol. networks means that modulating single proteins might not be sufficient to produce the desired efficacy while, at the same time, minimizing adverse effects.  Designing multi-target drugs can be challenging for medicinal chemists, with current lead-discovery strategies often producing large, complex mols. with low ligand efficiency and poor oral bioavailability.  Paradoxically, analyses of the relationship between the selectivity of biol. active compds. and their mol. size suggest that promiscuous compds. should typically be smaller than target-selective compds.  A fragment-based approach to multi-target drug discovery could lead to a new generation of compds. with improved physicochem. and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRYwI33BCNLVg90H21EOLACvtfcHk0ljhgZ1SrBx-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D&md5=64a3c7e8c3280db166dda799a77d689a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520network%2520biology%2520and%2520designing%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D3%25E2%2580%25934%26spage%3D156%26epage%3D160%26doi%3D10.1016%2Fj.drudis.2006.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&issue=21&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljFF7Y3UvHFHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D21%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleason-Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, L. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1021/jm0203377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0203377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtlCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=571-583&issue=4&author=M.+Y.+Kimauthor=W.+Duanauthor=M.+Gleason-Guzmanauthor=L.+H.+Hurley&title=Design%2C+synthesis%2C+and+biological+evaluation+of+a+series+of+fluoroquinoanthroxazines+with+contrasting+dual+mechanisms+of+action+against+topoisomerase+II+and+G-quadruplexes&doi=10.1021%2Fjm0203377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of a Series of Fluoroquinoanthroxazines with Contrasting Dual Mechanisms of Action against Topoisomerase II and G-Quadruplexes</span></div><div class="casAuthors">Kim, Mu-Yong; Duan, Wenhu; Gleason-Guzman, Mary; Hurley, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Topoisomerase inhibitors are important and clin. effective drugs, while G-quadruplex-interactive compds. that disrupt telomere maintenance mechanisms have yet to be proven useful in the clinic.  If G-quadruplex-interactive compds. are to be clin. useful, it will most likely be in combination with more established cytotoxic agents.  A family of topoisomerase II inhibitors that also interact with G-quadruplexes was previously reported.  On the basis of previously established structure-activity relationships (SARs) for compds. that are able to inhibit topoisomerase II or interact with G-quadruplex to varying degrees, four new fluoroquinoanthroxazines (FQAs)with different profiles of mixed topoisomerase II poisoning effects and G-quadruplex interactions were designed and synthesized.  The biol. profiles of the four new compds. were detd. with respect to G-quadruplex interaction (polymerase stop and photocleavage assays) and topoisomerase II interaction (DNA cleavage and kDNA decatenation assays), alongside cytotoxicity tests with matched pairs of topoisomerase II-resistant and topoisomerase II-sensitive cells and with telomerase (+) and ALT (+) cell lines (ALT = alternative lengthening of telomeres).  From this study, two FQAs with sharply contrasting profiles of potent G-quadruplex interaction with a weak topoisomerase II poisoning effect, and vice versa, were identified for further evaluation to det. the optimum combination of these activities in subsequent in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZIPiN4rdFWrVg90H21EOLACvtfcHk0ljFF7Y3UvHFHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtlCmuw%253D%253D&md5=47eb857b7c1fe9981e1743f4a0d59474</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm0203377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0203377%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BY.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DGleason-Guzman%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DL.%2BH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520fluoroquinoanthroxazines%2520with%2520contrasting%2520dual%2520mechanisms%2520of%2520action%2520against%2520topoisomerase%2520II%2520and%2520G-quadruplexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D4%26spage%3D571%26epage%3D583%26doi%3D10.1021%2Fjm0203377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruthenburg, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechis, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdine, G. L.</span></span> <span> </span><span class="NLM_article-title">Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">37041</span>– <span class="NLM_lpage">37047</span>, <span class="refDoi"> DOI: 10.1074/jbc.M506520200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.M506520200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=16100112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKhtLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=37041-37047&issue=44&author=H.+Weiauthor=A.+J.+Ruthenburgauthor=S.+K.+Bechisauthor=G.+L.+Verdine&title=Nucleotide-dependent+domain+movement+in+the+ATPase+domain+of+a+human+type+IIA+DNA+topoisomerase&doi=10.1074%2Fjbc.M506520200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleotide-dependent Domain Movement in the ATPase Domain of a Human Type IIA DNA Topoisomerase</span></div><div class="casAuthors">Wei, Hua; Ruthenburg, Alexander J.; Bechis, Seth K.; Verdine, Gregory L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37041-37047</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Type IIA DNA topoisomerases play multiple essential roles in the management of higher-order DNA structure, including modulation of topol. state, chromosome segregation, and chromatin condensation.  These diverse physiol. functions are all accomplished through a common mol. mechanism, wherein the protein catalyzes transient cleavage of a DNA duplex (the G-segment) to yield a double-stranded gap through which another duplex (the T-segment) is passed.  The overall process is orchestrated by the opening and closing of mol. "gates" in the topoisomerase structure, which is regulated by ATP binding, hydrolysis, and release of ADP and inorg. phosphate.  Here, we present two crystal structures of the ATPase domain of human DNA topoisomerase IIα in different nucleotide-bound states.  Comparison of these structures revealed rigid-body movement of the structural modules within the ATPase domain, suggestive of the motions of a mol. gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp657jcFw3OM7Vg90H21EOLACvtfcHk0ljFF7Y3UvHFHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKhtLrO&md5=e2672f1ac3605c57f10031edcd5c4584</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M506520200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M506520200%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DH.%26aulast%3DRuthenburg%26aufirst%3DA.%2BJ.%26aulast%3DBechis%26aufirst%3DS.%2BK.%26aulast%3DVerdine%26aufirst%3DG.%2BL.%26atitle%3DNucleotide-dependent%2520domain%2520movement%2520in%2520the%2520ATPase%2520domain%2520of%2520a%2520human%2520type%2520IIA%2520DNA%2520topoisomerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26issue%3D44%26spage%3D37041%26epage%3D37047%26doi%3D10.1074%2Fjbc.M506520200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kesharwani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, K.</span></span> <span> </span><span class="NLM_article-title">Computational study of curcumin analogues by targeting DNA topoisomerase II: a structure-based drug designing approach</span>. <i>Network Modeling and Analysis in Health Informatics and Bioinformatics Journal</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15</span>, <span class="refDoi"> DOI: 10.1007/s13721-018-0179-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs13721-018-0179-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=15&author=R.+Kesharwaniauthor=D.+B.+Singhauthor=D.+V.+Singhauthor=K.+Misra&title=Computational+study+of+curcumin+analogues+by+targeting+DNA+topoisomerase+II%3A+a+structure-based+drug+designing+approach&doi=10.1007%2Fs13721-018-0179-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs13721-018-0179-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13721-018-0179-8%26sid%3Dliteratum%253Aachs%26aulast%3DKesharwani%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DD.%2BB.%26aulast%3DSingh%26aufirst%3DD.%2BV.%26aulast%3DMisra%26aufirst%3DK.%26atitle%3DComputational%2520study%2520of%2520curcumin%2520analogues%2520by%2520targeting%2520DNA%2520topoisomerase%2520II%253A%2520a%2520structure-based%2520drug%2520designing%2520approach%26jtitle%3DNetwork%2520Modeling%2520and%2520Analysis%2520in%2520Health%2520Informatics%2520and%2520Bioinformatics%2520Journal%26date%3D2018%26volume%3D7%26spage%3D15%26doi%3D10.1007%2Fs13721-018-0179-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janezic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelcnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brvar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span> <span> </span><span class="NLM_article-title">3-substituted-1<i>H</i>-indazoles as catalytic inhibitors of the human DNA topoisomerase IIα</span>. <i>ChemistrySelect.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1002/slct.201601554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fslct.201601554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=480-488&issue=1&author=M.+Janezicauthor=B.+Pogorelcnikauthor=M.+Brvarauthor=T.+Solmajerauthor=A.+Perdih&title=3-substituted-1H-indazoles+as+catalytic+inhibitors+of+the+human+DNA+topoisomerase+II%CE%B1&doi=10.1002%2Fslct.201601554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">3-substituted-1H-indazoles as Catalytic Inhibitors of the Human DNA Topoisomerase IIα</span></div><div class="casAuthors">Janezic, Matej; Pogorelcnik, Barbara; Brvar, Matjaz; Solmajer, Tom; Perdih, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">480-488</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Catalytic inhibitors represent an attractive possibility of revisiting the established anticancer target human DNA topoisomerase IIα, taking advantage of the many different inhibition steps in its catalytic cycle.  In this study we present our efforts to expand the chem. space of inhibitors of the human DNA topoisomerase IIα with a combination of in silico and in vitro methods.  Using our previously reported compds. as a base, we constructed a ligand-based pharmacophore and conducted a virtual screening campaign.  This led to the discovery of 1H-indazole inhibitors for which the SAR data was subsequently expanded.  Addnl., several in vitro methods; cleavage assay, competitive cleavage assay, ATPase assay and microscale thermophoresis (MST) binding studies were employed to study the inhibitory mechanism, and it was confirmed that our compds. are catalytic inhibitors that bind to the ATPase domain.  IC50 values were in the lower micromolar range with multiple compds. showing stronger inhibitory activity than the established topoisomerase poison etoposide.  Using in silico methods we proposed a binding mode and evaluated it using mol. dynamics simulation. 1H-indazoles represent a new versatile scaffold that could be utilized for further development of catalytic inhibitors of the human DNA topoisomerase IIα targetting the ATPase domain where ATP binding site is located.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRrDGdQEJKqbVg90H21EOLACvtfcHk0ljPLDF952iAJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wkurs%253D&md5=e891fafff30d2c7a80e12e1422cf171c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fslct.201601554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201601554%26sid%3Dliteratum%253Aachs%26aulast%3DJanezic%26aufirst%3DM.%26aulast%3DPogorelcnik%26aufirst%3DB.%26aulast%3DBrvar%26aufirst%3DM.%26aulast%3DSolmajer%26aufirst%3DT.%26aulast%3DPerdih%26aufirst%3DA.%26atitle%3D3-substituted-1H-indazoles%2520as%2520catalytic%2520inhibitors%2520of%2520the%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DChemistrySelect.%26date%3D2017%26volume%3D2%26issue%3D1%26spage%3D480%26epage%3D488%26doi%3D10.1002%2Fslct.201601554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahisuddin</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, cytotoxicity, huTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2016.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bioorg.2016.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=27744115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=77-90&author=R.+Alamauthor=D.+Wahiauthor=R.+Singhauthor=D.+Sinhaauthor=V.+Tandonauthor=A.+Groverauthor=+Rahisuddin&title=Design%2C+synthesis%2C+cytotoxicity%2C+huTopoII%CE%B1+inhibitory+activity+and+molecular+docking+studies+of+pyrazole+derivatives+as+potential+anticancer+agents&doi=10.1016%2Fj.bioorg.2016.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents</span></div><div class="casAuthors">Alam, Raquib; Wahi, Divya; Singh, Raja; Sinha, Devapriya; Tandon, Vibha; Grover, Abhinav; Rahisuddin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-90</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an attempt to find potential anticancer agents, a series of novel Et 4-(3-(aryl)-1-phenyl-1H-pyrazol-4-yl)-2-oxo-6-(pyridin-3-yl)cyclohex-3-enecarboxylates 5a-i and 5-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-3-(pyridin-3-yl)-4,5-dihydropyrazole-1-carbothioamides 6a-i were designed, synthesized and evaluated for their topoisomerase IIα inhibitory activity and in vitro cytotoxicity against a panel of cancerous cell lines (MCF-7, NCI-H460, HeLa) and a normal cell line (HEK-293T).  Mol. docking studies of all the synthesized compds. into the binding site of topoisomerase IIα protein (PDB ID: 1ZXM) were performed to gain a comprehensive understanding into plausible binding modes.  These compds. were also screened for in silico drug-likeliness properties on the basis of the absorption, distribution, metab. and excretion (ADME) prediction.  Among all the synthesized compds., analog 5d showed superior cytotoxicity with an IC50 value of 7.01 ± 0.60 μM for HeLa, 8.55 ± 0.35 μM for NCI-H460 and 14.31 ± 0.90 for MCF-7 cancer cell lines.  Further, compd. 5d showed 70.82% inhibition of topoisomerase IIα at a concn. of 100 μM with max. docking score of -8.24.  Results of ADME prediction revealed that most of these compds. showed in silico drug-likeliness properties within the ideal range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLxtbyj0NKn7Vg90H21EOLACvtfcHk0ljPLDF952iAJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs7rP&md5=051350f7a9e61669e2421f8477010e3a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2016.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2016.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DWahi%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSinha%26aufirst%3DD.%26aulast%3DTandon%26aufirst%3DV.%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DRahisuddin%26atitle%3DDesign%252C%2520synthesis%252C%2520cytotoxicity%252C%2520huTopoII%25CE%25B1%2520inhibitory%2520activity%2520and%2520molecular%2520docking%2520studies%2520of%2520pyrazole%2520derivatives%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DBioorg.%2520Chem.%26date%3D2016%26volume%3D69%26spage%3D77%26epage%3D90%26doi%3D10.1016%2Fj.bioorg.2016.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. F.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, M. R.</span></span> <span> </span><span class="NLM_article-title">Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6278</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmcl.2008.09.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18929486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6273-6278&issue=23&author=P.+P.+Kungauthor=L.+Funkauthor=J.+Mengauthor=M.+Collinsauthor=J.+Z.+Zhouauthor=M.+C.+Johnsonauthor=A.+Ekkerauthor=J.+Wangauthor=P.+Mehtaauthor=M.+J.+Yinauthor=C.+Rodgersauthor=J.+F.+Daviesauthor=E.+Baymanauthor=T.+Smealauthor=K.+A.+Maegleyauthor=M.+R.+Gehring&title=Dihydroxylphenyl+amides+as+inhibitors+of+the+Hsp90+molecular+chaperone&doi=10.1016%2Fj.bmcl.2008.09.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone</span></div><div class="casAuthors">Kung, Pei-Pei; Funk, Lee; Meng, Jerry; Collins, Michael; Zhou, Joe Zhongxiang; Catherine Johnson, M.; Ekker, Anne; Wang, Jeff; Mehta, Pramod; Yin, Min-Jean; Rodgers, Caroline; Davies, Jay F., II; Bayman, Eileen; Smeal, Tod; Maegley, Karen A.; Gehring, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6273-6278</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Information from X-ray crystal structures were used to optimize the potency of a HTS hit in a Hsp90 competitive binding assay.  A class of novel and potent small mol. Hsp90 inhibitors were thereby identified.  Enantio-pure compds. I [n = 1, 2] were potent in PGA-based competitive binding assay and inhibited proliferation of various human cancer cell lines in vitro, with IC50 values averaging 20 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraBHD3PPbhDbVg90H21EOLACvtfcHk0ljPLDF952iAJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtrzE&md5=36eb69d7ffb65443bc5328f74806fa0b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.081%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%2BZ.%26aulast%3DJohnson%26aufirst%3DM.%2BC.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DM.%2BJ.%26aulast%3DRodgers%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DBayman%26aufirst%3DE.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DGehring%26aufirst%3DM.%2BR.%26atitle%3DDihydroxylphenyl%2520amides%2520as%2520inhibitors%2520of%2520the%2520Hsp90%2520molecular%2520chaperone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D23%26spage%3D6273%26epage%3D6278%26doi%3D10.1016%2Fj.bmcl.2008.09.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obermann, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, F. U.</span></span> <span> </span><span class="NLM_article-title"><i>In-vivo</i> function of Hsp90 is dependent on ATP binding and ATP hydrolysis</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>143</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">910</span>, <span class="refDoi"> DOI: 10.1083/jcb.143.4.901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1083%2Fjcb.143.4.901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9817749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVKhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=1998&pages=901-910&issue=4&author=W.+M.+Obermannauthor=H.+Sondermannauthor=A.+A.+Russoauthor=N.+P.+Pavletichauthor=F.+U.+Hartl&title=In-vivo+function+of+Hsp90+is+dependent+on+ATP+binding+and+ATP+hydrolysis&doi=10.1083%2Fjcb.143.4.901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis</span></div><div class="casAuthors">Obermann, Wolfgang M. J.; Sondermann, Holger; Russo, Alicia A.; Pavletich, Nikola P.; Hartl, F. Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">901-910</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90), an abundant mol. chaperone in the eukaryotic cytosol, is involved in the folding of a set of cell regulatory proteins and in the re-folding of stress-denatured polypeptides.  The basic mechanism of action of Hsp90 is not yet understood.  In particular, it has been debated whether Hsp90 function is ATP dependent.  A recent crystal structure of the NH2-terminal domain of yeast Hsp90 established the presence of a conserved nucleotide binding site that is identical with the binding site of geldanamycin, a specific inhibitor of Hsp90.  The functional significance of nucleotide binding by Hsp90 has remained unclear.  Here, the authors present evidence for a slow but clearly detectable ATPase activity in purified Hsp90.  Based on a new crystal structure of the NH2-terminal domain of human Hsp90 with bound ADP-Mg and on the structural homol. of this domain with the ATPase domain of Escherichia coli DNA gyrase, the residues of Hsp90 crit. in ATP binding (D93) and ATP hydrolysis (E47) were identified.  The corresponding mutations were made in the yeast Hsp90 homolog, Hsp82, and tested for their ability to functionally replace wild-type Hsp82.  The results show that both ATP binding and hydrolysis are required for Hsp82 function in vivo.  The mutant Hsp90 proteins tested are defective in the binding and ATP hydrolysis-dependent cycling of the co-chaperone p23, which is thought to regulate the binding and release of substrate polypeptide from Hsp90.  Remarkably, the complete Hsp90 protein is required for ATPase activity and for the interaction with p23, suggesting an intricate allosteric communication between the domains of the Hsp90 dimer.  These results establish Hsp90 as an ATP-dependent chaperone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotcz1fjTlrN7Vg90H21EOLACvtfcHk0lhNPqxr193FNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVKhtbY%253D&md5=6286ed975202b5a2fdc38ff5453f3b68</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1083%2Fjcb.143.4.901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.143.4.901%26sid%3Dliteratum%253Aachs%26aulast%3DObermann%26aufirst%3DW.%2BM.%26aulast%3DSondermann%26aufirst%3DH.%26aulast%3DRusso%26aufirst%3DA.%2BA.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DHartl%26aufirst%3DF.%2BU.%26atitle%3DIn-vivo%2520function%2520of%2520Hsp90%2520is%2520dependent%2520on%2520ATP%2520binding%2520and%2520ATP%2520hydrolysis%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1998%26volume%3D143%26issue%3D4%26spage%3D901%26epage%3D910%26doi%3D10.1083%2Fjcb.143.4.901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3085</span>– <span class="NLM_lpage">3085</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-05406-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fs41467-018-05406-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30082834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ls1aktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3085-3085&author=S.+F.+Chenauthor=N.+L.+Huangauthor=J.+H.+Linauthor=C.+C.+Wuauthor=Y.+R.+Wangauthor=Y.+J.+Yuauthor=M.+K.+Gilsonauthor=N.+L.+Chan&title=Structural+insights+into+the+gating+of+DNA+passage+by+the+topoisomerase+II+DNA-gate&doi=10.1038%2Fs41467-018-05406-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate</span></div><div class="casAuthors">Chen Shin-Fu; Wu Chyuan-Chuan; Wang Ying-Ren; Yu Yu-Jen; Chan Nei-Li; Huang Nan-Lan; Lin Jung-Hsin; Huang Nan-Lan; Gilson Michael K; Wu Chyuan-Chuan; Chan Nei-Li; Chan Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3085</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type IIA topoisomerases (Top2s) manipulate the handedness of DNA crossovers by introducing a transient and protein-linked double-strand break in one DNA duplex, termed the DNA-gate, whose opening allows another DNA segment to be transported through to change the DNA topology.  Despite the central importance of this gate-opening event to Top2 function, the DNA-gate in all reported structures of Top2-DNA complexes is in the closed state.  Here we present the crystal structure of a human Top2 DNA-gate in an open conformation, which not only reveals structural characteristics of its DNA-conducting path, but also uncovers unexpected yet functionally significant conformational changes associated with gate-opening.  This structure further implicates Top2's preference for a left-handed DNA braid and allows the construction of a model representing the initial entry of another DNA duplex into the DNA-gate.  Steered molecular dynamics calculations suggests the Top2-catalyzed DNA passage may be achieved by a rocker-switch-type movement of the DNA-gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM5cMY9cr24-dfST00W0BcfW6udTcc2eZG6aGUCLUG7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ls1aktg%253D%253D&md5=04dc82195836cb9e26bb2967da6f0630</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05406-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05406-y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DHuang%26aufirst%3DN.%2BL.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DYu%26aufirst%3DY.%2BJ.%26aulast%3DGilson%26aufirst%3DM.%2BK.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DStructural%2520insights%2520into%2520the%2520gating%2520of%2520DNA%2520passage%2520by%2520the%2520topoisomerase%2520II%2520DNA-gate%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D3085%26epage%3D3085%26doi%3D10.1038%2Fs41467-018-05406-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">10861</span>– <span class="NLM_lpage">10871</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1093%2Fnar%2Fgkx742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28977631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Kit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=10861-10871&issue=18&author=Y.+R.+Wangauthor=S.+F.+Chenauthor=C.+C.+Wuauthor=Y.+W.+Liaoauthor=T.+S.+Linauthor=K.+T.+Liuauthor=Y.+S.+Chenauthor=T.+K.+Liauthor=T.+C.+Chienauthor=N.+L.+Chan&title=Producing+irreversible+topoisomerase+II-mediated+DNA+breaks+by+site-specific+Pt%28II%29-methionine+coordination+chemistry&doi=10.1093%2Fnar%2Fgkx742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry</span></div><div class="casAuthors">Wang, Ying-Ren; Chen, Shin-Fu; Wu, Chyuan-Chuan; Liao, Yi-Wen; Lin, Te-Sheng; Liu, Ko-Ting; Chen, Yi-Song; Li, Tsai-Kun; Chien, Tun-Cheng; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10861-10871</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Human type II topoisomerase (Top2) isoforms, hTop2α and hTop2β, are targeted by some of the most successful anticancer drugs.  These drugs induce Top2-mediated DNA cleavage to trigger cell-death pathways.  The potency of these drugs correlates pos. with their efficacy in stabilizing the enzyme-mediated DNA breaks.  Structural anal. of hTop2α and hTop2β revealed the presence of methionine residues in the drug binding pocket, we therefore tested whether a tighter Top2-drug assocn. may be accomplished by introducing a methionine-reactive Pt2+ into a drug to further stabilize the DNA break.  Herein, we synthesized an organoplatinum compd., etoplatin-N2β, by replacing the methioninejuxtaposing group of the drug etoposide with a cis-dichlorodiammineplatinum(II) moiety.  Compared to etoposide, etoplatin-N2β more potently inhibits both human Top2s.  While the DNA breaks arrested by etoposide can be rejoined, those captured by etoplatin-N2 are practically irreversible.  Crystallog. analyses of hTop2β complexed with DNA and etoplatin-N2β demonstrate coordinate bond formation between Pt2+ and a flanking methionine.  Notably, this stable coordinate tether can be loosened by disrupting the structural integrity of drug-binding pocket, suggesting that Pt2+ coordination chem. may allow for the development of potent inhibitors with protein conformation-dependent reversibility.  This approach may be exploited to achieve isoformspecific targeting of human Top2s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ_1lsBFMml7Vg90H21EOLACvtfcHk0lhNPqxr193FNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Kit7k%253D&md5=ddc7d7d51f099dc62d40a04819287178</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx742%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DY.%2BW.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DLiu%26aufirst%3DK.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DChien%26aufirst%3DT.%2BC.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DProducing%2520irreversible%2520topoisomerase%2520II-mediated%2520DNA%2520breaks%2520by%2520site-specific%2520Pt%2528II%2529-methionine%2520coordination%2520chemistry%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2017%26volume%3D45%26issue%3D18%26spage%3D10861%26epage%3D10871%26doi%3D10.1093%2Fnar%2Fgkx742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Settimo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taliani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simorini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Motta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornaciari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, A. M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">4270</span>– <span class="NLM_lpage">4290</span>, <span class="refDoi"> DOI: 10.2174/092986710793361252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F092986710793361252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=20939813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1artr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=4270-4290&issue=35&author=S.+Salernoauthor=F.+Da+Settimoauthor=S.+Talianiauthor=F.+Simoriniauthor=C.+La+Mottaauthor=G.+Fornaciariauthor=A.+M.+Marini&title=Recent+advances+in+the+development+of+dual+topoisomerase+I+and+II+inhibitors+as+anticancer+drugs&doi=10.2174%2F092986710793361252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs</span></div><div class="casAuthors">Salerno, S.; De Settimo, F.; Taliani, S.; Simorini, F.; La Motta, C.; Fornaciari, G.; Marini, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4270-4290</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases (topos) are essential enzymes that regulate the topol. state of DNA during cellular processes such as replication, transcription, recombination, and chromatin remodeling.  Topoisomerase I (Topo I) is a ubiquitous nuclear enzyme which catalyzes the relaxation of superhelical DNA generating a transient single strand nick in the duplex, through cycles of cleavage and religation.  Topoisomerase II (Topo II) mediates the ATP-dependent induction of coordinated nicks in both strands of the DNA duplex, followed by crossing of another double strand DNA through the transiently broken duplex.  Although the biol. functions of Topoisomerases are important for ensuing genomic integrity, the ability to interfere with enzymes or generate enzyme-mediated damage is an effective strategy for cancer therapy and, in this connection, DNA topos (I and II) proved to be the excellent targets of clin. significant classes of anti-cancer drugs.  Actually, specific Topo I and Topo II inhibitors reversibly trap the enzyme-DNA complexes, thus converting topos into physiol. poisons, able to produce permanent DNA damage, which triggers cell death.  Given that both enzymes are good targets, it would be desirable to jointly inhibit them, but use-limiting toxicity of sequential or simultaneous combinations of Topo I and II poisons include severe to life-threatening neutropenia and anemia.  Furthermore, the emergence of resistance phenomena to Topo I inhibitors is often accompanied by a concomitant rise in the level of Topo II expression and viceversa, leading to the failure of clin. therapies.  In this regard, a single compd. able to inhibit both Topo I and II may present the advantage of improving anti-topoisomerase activity, with reduced toxic side effects, with respect to the combination of two inhibitors.  Due to the high interest in such compds., this review represents an update of previous works dealing with the development of dual Topo I and II inhibitors as novel anti-cancer agents.  The newly collected derivs. have been described focusing attention on their chem. structures and their biol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFTv42gLvD4rVg90H21EOLACvtfcHk0lg1xZnINFrnXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1artr%252FI&md5=39e95fc132e22d69ff3c983504095b4e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2174%2F092986710793361252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710793361252%26sid%3Dliteratum%253Aachs%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DTaliani%26aufirst%3DS.%26aulast%3DSimorini%26aufirst%3DF.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DFornaciari%26aufirst%3DG.%26aulast%3DMarini%26aufirst%3DA.%2BM.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520dual%2520topoisomerase%2520I%2520and%2520II%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26issue%3D35%26spage%3D4270%26epage%3D4290%26doi%3D10.2174%2F092986710793361252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Gijn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lendfers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bult, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J.</span></span> <span> </span><span class="NLM_article-title">Dual topoisomerase I/II inhibitors</span>. <i>J. Oncol. Pharm. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">92</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1191/107815500701563317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1191%2F107815500701563317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVSgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=92-108&issue=3&author=R.+van%0AGijnauthor=R.+Lendfersauthor=J.+Schellensauthor=A.+Bultauthor=J.+Beijnen&title=Dual+topoisomerase+I%2FII+inhibitors&doi=10.1191%2F107815500701563317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Dual topoisomerase I/II inhibitors</span></div><div class="casAuthors">Van Gijn, R.; Lendfers, R. R. H.; Schellens, J. H. M.; Bult, A.; Beijnen, J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Oncology Pharmacy Practice</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">92-108</span>CODEN:
                <span class="NLM_cas:coden">JOPPFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-1552</span>.
    
            (<span class="NLM_cas:orgname">Arnold, Hodder Headline</span>)
        </div><div class="casAbstract">A review is given.  Topoisomerase (topo) I and II are nuclear enzymes, which play a major role in the topol. rearrangement of DNA during replication and transcription processes.  In the course of years, many different agents were found which can inhibit the topos and thereby exploit cytotoxicity, also against tumor cells.  Selective inhibition of the topo I enzyme can, however, induce a reactive increase in topo II levels, and vice versa.  This mechanism is assocd. with the development of drug resistance.  Dual inhibition of both topo I and II may, theor., overcome this resistance problem.  In this review, the most important and promising dual topo I/II inhibitors designed as anticancer agents will be discussed.  Thus far, only the indolyl quinoline deriv. TAS-103, the 7H-benzo[e]pyrido[4,3-b] indole deriv. intoplicine, and the acridine deriv. PZA were shown to be dual topo inhibitors with high cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx0-IuZ8mYR7Vg90H21EOLACvtfcHk0lg1xZnINFrnXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVSgsrc%253D&md5=e6f08f13165cdbde050e5ee2033f04bc</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1191%2F107815500701563317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1191%252F107815500701563317%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGijn%26aufirst%3DR.%26aulast%3DLendfers%26aufirst%3DR.%26aulast%3DSchellens%26aufirst%3DJ.%26aulast%3DBult%26aufirst%3DA.%26aulast%3DBeijnen%26aufirst%3DJ.%26atitle%3DDual%2520topoisomerase%2520I%252FII%2520inhibitors%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2000%26volume%3D6%26issue%3D3%26spage%3D92%26epage%3D108%26doi%3D10.1191%2F107815500701563317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Arpa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beardmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6919</span>– <span class="NLM_lpage">6924</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1698546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3MXivFQ%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1990&pages=6919-6924&issue=21&author=P.+D%E2%80%99Arpaauthor=C.+Beardmoreauthor=L.+F.+Liu&title=Involvement+of+nucleic+acid+synthesis+in+cell+killing+mechanisms+of+topoisomerase+poisons"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons</span></div><div class="casAuthors">D'Arpa, Peter; Beardmore, Christopher; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6919-24</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The primary cytotoxic mechanism of camptothecin has been proposed to involve an interaction between the replication machinery and the camptothecin-mediated topoisomerase I-DNA cleavable complex.  The present study show that killing of V79 cells by the topoisomerase II poisons 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide may involve ongoing RNA synthesis in addn. to ongoing DNA synthesis.  V79 cells synchronized by mitotic shake-off were treated with topoisomerase poisons in the presence of inhibitors of nucleic acid synthesis.  S-Phase V79 cells were more sensitive to the topoisomerase I poison camptothecin and the topoisomerase II poison m-AMSA than G1-phase cells.  The greater sensitivity of S-phase cells to killing by m-AMSA and camptothecin was abolished during cotreatment, but not posttreatment, with aphidicolin, suggesting that ongoing DNA synthesis is involved in cell killing by both topoisomerase I and II poisons.  Cotreatment with transcription inhibitors, such as 5,6-dichloro-1-β-D-ribofuranosyl benzimidazole or cordycepin, partially protected cells from the cytotoxic effects of m-AMSA but had no effect on camptothecin-mediated cytotoxicity.  These results suggest that ongoing RNA transcription may be involved in cell killing by topoisomerase II poisons but not topoisomerase I poisons.  Cotreatment with camptothecin reduced m-AMSA-mediated cytotoxicity in G1-phase V79 cells, suggesting a possible antagonism between topoisomerase I and II poisons.  This antagonistic effect between topoisomerase I and II poisons could be explained by the strong inhibitory effect of camptothecin on RNA transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKbW8PDr36bVg90H21EOLACvtfcHk0lhQkdAO8_drHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXivFQ%253D&md5=cdf75c946eb70fb695a5e6278178aaeb</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Arpa%26aufirst%3DP.%26aulast%3DBeardmore%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DInvolvement%2520of%2520nucleic%2520acid%2520synthesis%2520in%2520cell%2520killing%2520mechanisms%2520of%2520topoisomerase%2520poisons%26jtitle%3DCancer%2520Res.%26date%3D1990%26volume%3D50%26issue%3D21%26spage%3D6919%26epage%3D6924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1705167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3MXhslOqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=1129-1136&issue=4&author=S.+H.+Kaufmann&title=Antagonism+between+camptothecin+and+topoisomerase+II-directed+chemotherapeutic+agents+in+a+human+leukemia+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line</span></div><div class="casAuthors">Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1129-36</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">To search for possible synergy between topoisomerase (topo) II-directed chemotherapeutic agents and topo I-directed agents, HL-60 human progranulocytic leukemia cells were incubated with etoposide in the absence or presence of camptothecin (CPT).  Treatment of HL-60 cells for 1 h with 15-20 μM etoposide resulted in the death of 99-99.9% of the cells as assessed by colony formation in soft agar.  Unexpectedly, simultaneous incubation with 1 μM CPT increased the survival of etoposide-treated cells as much as 30-fold.  Inhibition of etoposide cytotoxicity was obsd. at CPT concns. as low as 0.01 μM and was one-half maximal at 0.1 μM.  CPT also antagonized the cytotoxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide and daunorubicin, two structurally unrelated topo II-directed agents.  Topotecan, a CPT analog currently undergoing Phase I clin. trials, had a similar effect.  Studies using an alk. unwinding assay (to measure DNA strand breaks) and Western blotting (to assess formation of covalent adducts involving topo II) revealed that CPT did not alter the ability of etoposide to stabilize topo II-DNA adducts.  CPT is a potent inhibitor of both DNA and RNA synthesis.  To further assess the mechanism by which CPT diminished the cytotoxicity of topo II-directed agents, inhibitors of DNA synthesis or RNA synthesis were substituted for CPT.  Aphidicolin, an inhibitor of replicative DNA polymerases, enhanced the survival of etoposide-treated HL-60 cells <3-fold.  In contrast, inhibitors of RNA synthesis (cordycepin or 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) enhanced the survival of etoposide-treated HL-60 cells as much as 20-fold.  The potential biol. and therapeutic implications of these results are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOza2BIZerprVg90H21EOLACvtfcHk0lhQkdAO8_drHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhslOqurs%253D&md5=cac810ef53df744939858154d0b45755</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DAntagonism%2520between%2520camptothecin%2520and%2520topoisomerase%2520II-directed%2520chemotherapeutic%2520agents%2520in%2520a%2520human%2520leukemia%2520cell%2520line%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26issue%3D4%26spage%3D1129%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirabayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinushi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span> <span> </span><span class="NLM_article-title">Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1002/ijc.2910500516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fijc.2910500516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1312063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK38XisVOqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1992&pages=760-766&issue=5&author=R.+Kimauthor=N.+Hirabayashiauthor=M.+Nishiyamaauthor=K.+Jinushiauthor=T.+Togeauthor=K.+Okada&title=Experimental+studies+on+biochemical+modulation+targeting+topoisomerase+I+and+II+in+human+tumor+xenografts+in+nude+mice&doi=10.1002%2Fijc.2910500516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice</span></div><div class="casAuthors">Kim, Ryungsa; Hirabayashi, Naoki; Nishiyama, Masahiko; Jinushi, Kazuto; Toge, Tetsuya; Okada, Kosuke</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">760-6</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">Topoisomerase (topo) I and II are nuclear enzymes which are novel targets of cancer chemotherapy.  A new camptothecin (CPT) analog, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl-oxy-CPT (CPT-11), is a topo-I inhibitor with a higher activity and less toxicity than CPT.  To investigate topo-I and -II-targeting chemotherapy in an in vivo model, the authors studied the effect of sequential or co-treatment using CPT-11 and adriamycin (ADR), a topo-II inhibitor, in 6 human tumor xenografts (2 esophageal, 2 gastric and 2 colon tumor lines).  In sequential treatment, adriamycin was administered i.v. 24 h after CPT-11 treatment, and no antagonistic effect of this treatment schedule was obsd.  ADR cytotoxicity was potentiated by CPT-11 pretreatment in the case of 2 esophageal and 2 gastric tumor lines and 1 colon tumor line.  On the other hand, co-treatment abolished the sensitivity to CPT-11 and ADR in all 6 tumor lines.  Moreover, CPT-11 did not enhance the cytotoxicity of other agents tested, including mitomycin C (MMC) and cisplatin (CDDP).  Flow cytometry and dot-blot analyses showed that CPT-11 pretreatment induced an increase in the S-phase cell population with an increase of topo-II mRNA expression after 24 and 48 h, resp., in the esophageal and colon tumor lines.  These results suggest that CPT-11 can modulate topo-II levels to enhance the effect of topo-II inhibitors in some human tumors, and this suggests a new clin. method of topo-I and -II targeting chemotherapy for human solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5cfYtwzBXG7Vg90H21EOLACvtfcHk0lhQkdAO8_drHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisVOqu78%253D&md5=2cc34b4b4c2d78729a8aa8d7b40a0ad1</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910500516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910500516%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%26aulast%3DHirabayashi%26aufirst%3DN.%26aulast%3DNishiyama%26aufirst%3DM.%26aulast%3DJinushi%26aufirst%3DK.%26aulast%3DToge%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DK.%26atitle%3DExperimental%2520studies%2520on%2520biochemical%2520modulation%2520targeting%2520topoisomerase%2520I%2520and%2520II%2520in%2520human%2520tumor%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1992%26volume%3D50%26issue%3D5%26spage%3D760%26epage%3D766%26doi%3D10.1002%2Fijc.2910500516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerrigan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>28a</i></span> (<span class="NLM_issue">4–5</span>),  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1016/0959-8049(92)90107-D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0959-8049%2892%2990107-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1326304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK38XmtVClurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28a&publication_year=1992&pages=743-748&issue=4%E2%80%935&author=R.+Bertrandauthor=P.+M.+O%E2%80%99Connorauthor=D.+Kerriganauthor=Y.+Pommier&title=Sequential+administration+of+camptothecin+and+etoposide+circumvents+the+antagonistic+cytotoxicity+of+simultaneous+drug+administration+in+slowly+growing+human+colon+carcinoma+HT-29+cells&doi=10.1016%2F0959-8049%2892%2990107-D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells</span></div><div class="casAuthors">Bertrand, Richard; O'Connor, Patrick M.; Kerrigan, Donna; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title"></span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">28A</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">743-8</span>CODEN:
                <span class="NLM_cas:coden">EJCTEA</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The authors compared the cytotoxicity of simultaneous and sequential combination chemotherapy with camptothecin and etoposide, in slowly growing human colon carcinoma, HT-29 cells.  Simultaneous treatments of HT-29 cells with etoposide and camptothecin produced no marked enhancement of cytotoxicity over single agent administration.  This finding demonstrates antagonism of one drug's cytotoxicity over the other.  When these studies were repeated in sequential treatment protocols, the authors obsd. that antagonism could be circumvented if the period between individual drug administration was sepd. by 6-8 h.  The cytotoxicity that was obsd. with this approach was never more than additive and the order of camptothecin or etoposide administration did not significantly affect the extent of combined cytotoxicity obsd.  The protective effect of simultaneous camptothecin and etoposide exposure was not due to reduced formation or alterations in the rate of cleavable complex reversal, and protection persisted for a considerably longer period of time than DNA strand breaks.  Protection correlated with the kinetics of DNA and RNA synthesis inhibition produced by either drug.  Remarkably, full cytotoxic protection could be afforded by one drug over the other, in the presence of only partial inhibition of DNA or RNA synthesis (50-60%).  These findings suggest that sequential rather than simultaneous administration of topoisomerase I and II inhibitors in future cancer chemotherapy schedules will enhance cytotoxicity over single-agent administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwFeqpb3AHZbVg90H21EOLACvtfcHk0lgqNpMlhVqO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmtVClurc%253D&md5=5a407cba17cc7b458cdd91574f11cbba</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0959-8049%2892%2990107-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0959-8049%252892%252990107-D%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%2BM.%26aulast%3DKerrigan%26aufirst%3DD.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DSequential%2520administration%2520of%2520camptothecin%2520and%2520etoposide%2520circumvents%2520the%2520antagonistic%2520cytotoxicity%2520of%2520simultaneous%2520drug%2520administration%2520in%2520slowly%2520growing%2520human%2520colon%2520carcinoma%2520HT-29%2520cells%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1992%26volume%3D28a%26issue%3D4%25E2%2580%25935%26spage%3D743%26epage%3D748%26doi%3D10.1016%2F0959-8049%2892%2990107-D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span> <span> </span><span class="NLM_article-title">Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1007/s002800050825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs002800050825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9744779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXls1WltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=327-335&issue=4&author=J.+P.+Ederauthor=V.+Chanauthor=J.+Wongauthor=Y.+W.+Wongauthor=G.+Araauthor=D.+Northeyauthor=N.+Rizviauthor=B.+A.+Teicher&title=Sequence+effect+of+irinotecan+%28CPT-11%29+and+topoisomerase+II+inhibitors+in+vivo&doi=10.1007%2Fs002800050825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo</span></div><div class="casAuthors">Eder, Joseph Paul; Chan, Victor; Wong, Julia; Wong, Yee W.; Ara, Gulshan; Northey, David; Rizvi, Naiyer; Teicher, Beverly A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">327-335</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">To develop empiric treatment regimens of combinations and sequences of the topoisomerase I inhibitor irinotecan (CPT-11) and the topoisomerase II inhibitors etoposide and doxorubicin, in vivo studies were performed in mice bearing the EMT-6 mammary tumor to assess efficacy, host tolerance, and the resultant biochem. changes in topoisomerase mRNA and protein.  At 24 h after therapy, depletion of the target topoisomerase mRNA and protein with reciprocal increases in the alternate topoisomerase mRNA and, to a lesser extent, protein were noted.  No therapeutic antagonism was found with any combination or sequence of agents, and therapeutic antagonism was noted with concurrent irinotecan/etoposide and sequential doxorubicin/irinotecan.  Depletion of target isomerases by combined therapy beyond a threshold necessary for therapeutic efficacy produced no addnl. benefit.  Antineoplastic therapy with combinations of topoisomerase I and II agents was feasible and was supposed to produce therapeutic synergy.  The appropriate sequence was supposed to depend on the particular agents used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryp1iUYS74ALVg90H21EOLACvtfcHk0lgqNpMlhVqO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1WltLg%253D&md5=b2b1c904e7f26569bad8810d7aed74f3</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs002800050825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050825%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DY.%2BW.%26aulast%3DAra%26aufirst%3DG.%26aulast%3DNorthey%26aufirst%3DD.%26aulast%3DRizvi%26aufirst%3DN.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26atitle%3DSequence%2520effect%2520of%2520irinotecan%2520%2528CPT-11%2529%2520and%2520topoisomerase%2520II%2520inhibitors%2520in%2520vivo%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1998%26volume%3D42%26issue%3D4%26spage%3D327%26epage%3D335%26doi%3D10.1007%2Fs002800050825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshire, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallman, J. D.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9816097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK28Xht1agsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=107-118&issue=1&author=J.+A.+Houghtonauthor=P.+J.+Cheshireauthor=J.+D.+Hallmanauthor=L.+Lutzauthor=X.+Luoauthor=Y.+Liauthor=P.+J.+Houghton&title=Evaluation+of+irinotecan+in+combination+with+5-fluorouracil+or+etoposide+in+xenograft+models+of+colon+adenocarcinoma+and+rhabdomyosarcoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma</span></div><div class="casAuthors">Houghton, Janet A.; Cheshire, Pamela J.; Hallman, James D. II; Lutz, Lois; Luo, Xialolong; Li, Yulan; Houghton, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-18</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Irinotecan [7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin] administered i.v. in two courses, each course consisting of administration every day for 5 days [(d×5)2] on days 1-5 and 8-12, has demonstrated significant activity against advanced human tumor xenografts derived from colon adenocarcinomas and several childhood cancers.  To build on this therapy, the authors have evaluated the combination of irinotecan given on this schedule with 5-fluorouracil given on days 1, 7, and 14 with or without leucovorin [(d×5)3 i.v.] against colon tumors, or combined with etoposide administered (d×5)2 i.v. either 2 h before or 2 h after irinotecan for treatment of colon tumors and rhabdomyosarcomas.  A combination of 5-fluorouracil at 75% and irinotecan at 50% of their resp. max. tolerated doses when administered as single agents on this schedule gave acceptable toxicity.  Against colon adenocarcinoma xenografts, 5-fluorouracil did not enhance the response rate compared with that obtained with the optimum dose of irinotecan given as a single agent.  Against GC3/TK- xenografts, which lack thymidine kinase and cannot salvage thymidine to circumvent the inhibition of thymidylate synthase, the addn. of leucovorin to the combination increased the complete response rate from 10 to >90%, whereas the response rates for the optimal doses of irinotecan or 5-fluorouracil, as single agents, were 30 and <10%, resp.  Etoposide d×5 i.v. for two or three courses or (d×5)3 p.o. did not cause objective regression of any colon tumors.  In contrast, three of five rhabdomyosarcoma lines demonstrated a high frequency of partial regressions or complete regressions when treated (d×5)1 i.v.  Repetitive courses [e.g., (d×5)2 or (d×5)3] i.v. or p.o. or by 4-h infusion d×3 i.v. were either equally effective or less effective.  Irinotecan and etoposide were combined using the (d×5)2 i.v. schedule for both drugs, in which irinotecan was given 2 h before or 2 h after the administration of etoposide.  Each drug could be combined at only 38% of its resp. max. tolerated dose when administered as a single agent, indicating greater than additive toxicity.  Toxicity was similar irresp. of the sequence of administration and was manifested by loss of wt. (73% of the initial wt., nadir day 7), myelosuppression, and prolonged thrombocytopenia.  The responses of colon carcinomas to the combination given in either sequence were similar to that achieved with irinotecan given alone at the same dose as used in the combination.  Similarly, when etoposide was given before irinotecan, the responses of rhabdomyosarcomas were similar to those for irinotecan.  However, in expts. in which etoposide was administered 2 h after each dose of irinotecan, there was significant antagonism of the antitumor activity of irinotecan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSruAY1CS-jrVg90H21EOLACvtfcHk0lgqNpMlhVqO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xht1agsL4%253D&md5=5777043c817593ae111d0af25f5a0280</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoughton%26aufirst%3DJ.%2BA.%26aulast%3DCheshire%26aufirst%3DP.%2BJ.%26aulast%3DHallman%26aufirst%3DJ.%2BD.%26aulast%3DLutz%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DEvaluation%2520of%2520irinotecan%2520in%2520combination%2520with%25205-fluorouracil%2520or%2520etoposide%2520in%2520xenograft%2520models%2520of%2520colon%2520adenocarcinoma%2520and%2520rhabdomyosarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1996%26volume%3D2%26issue%3D1%26spage%3D107%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2401308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fsj.leu.2401308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10086724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1MXitFamtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=343-347&issue=3&author=M.+Crumpauthor=J.+Liptonauthor=D.+Hedleyauthor=D.+Suttonauthor=F.+Shepherdauthor=M.+Mindenauthor=K.+Stewartauthor=S.+Beareauthor=E.+Eisenhauer&title=Phase+I+trial+of+sequential+topotecan+followed+by+etoposide+in+adults+with+myeloid+leukemia%3A+a+National+Cancer+Institute+of+Canada+Clinical+Trials+Group+Study&doi=10.1038%2Fsj.leu.2401308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study</span></div><div class="casAuthors">Crump, M.; Lipton, J.; Hedley, D.; Sutton, D.; Shepherd, F.; Minden, M.; Stewart, K.; Beare, S.; Eisenhauer, E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-347</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Prolonged exposure to a topoisomerase I inhibitor may increase expression of topoisomerase II, making cells more susceptible inhibitors of that enzyme.  This study was undertaken to establish the max. tolerated dose (MTD) of a topotecan/topoisomerase II inhibitor sequential combination that may be active in acute leukemia, and to evaluate the effects of in vivo exposure to topotecan on topoisomerase II levels in leukemic blast cells as measured by image cytometry.  Patients who were eligible for this phase I study had relapsed or refractory acute myeloid leukemia (≤2 prior regimens) or CML blast crisis (0 or 1 prior regimen).  Topotecan was given as a 5 day continuous i.v. infusion and was to be escalated through three levels (1.5, 1.75 and 2.0 mg/m2 day), followed by etoposide at two dose levels (100 and 150 mg/m2) i.v. bolus days 6, 7 and 8.  Topoisomerase IIα levels in leukemic blasts from bone marrow were measured by image cytometry prior to starting treatment, on day 5 of topotecan infusion and on day 28; and daily during topotecan in peripheral blood blasts.  Dose-limiting toxicity was seen in two of six patients at the first dose level (topotecan 1.5 mg/m2/day, etoposide 100 mg/m2/day; ≥grade 3 mucositis in both cases).  This cohort was expanded to 10 patients; no further non-hematol. dose-limiting toxicity was obsd., but given the extent of toxicity seen, further dose escalation was judged not to be feasible.  Topo IIα levels increased in peripheral blood blasts during the first 72 h of topotecan infusion and returned to near baseline by day 5, whereas levels appeared to decrease in bone marrow blasts by day 5 compared to pretreatment.  One complete hematol. and cytogenetic remission in a patient with CML blast crisis was obsd. in the 10 patients evaluable for response.  The sequential administration of topotecan 1.5 mg/m2/day continuous infusion for 5 days followed by etoposide 100 mg/m2/day × 3 is the recommended phase II dose for this schedule.  Topotecan increases topo IIα expression in vivo in leukemia cells, but levels of the enzyme are cell cycle dependent.  Pharmacodynamic evaluation of the sequential or combination administration of novel antileukemic agents may help improve treatment strategies in acute leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIIsIJN1Tyn7Vg90H21EOLACvtfcHk0liLzEBnAyNsfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFamtr8%253D&md5=1764faacd74ed39f469e6d9fe6455fc6</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2401308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2401308%26sid%3Dliteratum%253Aachs%26aulast%3DCrump%26aufirst%3DM.%26aulast%3DLipton%26aufirst%3DJ.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DShepherd%26aufirst%3DF.%26aulast%3DMinden%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DBeare%26aufirst%3DS.%26aulast%3DEisenhauer%26aufirst%3DE.%26atitle%3DPhase%2520I%2520trial%2520of%2520sequential%2520topotecan%2520followed%2520by%2520etoposide%2520in%2520adults%2520with%2520myeloid%2520leukemia%253A%2520a%2520National%2520Cancer%2520Institute%2520of%2520Canada%2520Clinical%2520Trials%2520Group%2520Study%26jtitle%3DLeukemia%26date%3D1999%26volume%3D13%26issue%3D3%26spage%3D343%26epage%3D347%26doi%3D10.1038%2Fsj.leu.2401308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estey, E.</span></span> <span> </span><span class="NLM_article-title">Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1023/A:1006271618635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1023%2FA%3A1006271618635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10555127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1MXntFOnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=89-95&issue=1&author=N.+Veyauthor=H.+Kantarjianauthor=M.+Beranauthor=S.+O%E2%80%99Brienauthor=J.+Cortesauthor=C.+Kollerauthor=E.+Estey&title=Combination+of+topotecan+with+cytarabine+or+etoposide+in+patients+with+refractory+or+relapsed+acute+myeloid+leukemia%3A+results+of+a+randomized+phase+I%2FII+study&doi=10.1023%2FA%3A1006271618635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study</span></div><div class="casAuthors">Vey, Norbert; Kantarjian, Hagop; Beran, Miloslav; O'Brien, Susan; Cortes, Jorge; Koller, Charles; Estey, Elihu</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-95</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">This study assessed whether topotecan with cytosine arabinoside (ara-C) or with etoposide (VP-16) should be studied in phase II trials in patients with refractory or relapsed acute myeloid leukemia (AML).  Patients with refractory or relapsed AML were assigned to one of 3 strata defined by expected complete response (CR) rates of 7%, 20% and 40%, and then randomly assigned to receive topotecan (days 1-5) and ara-C (1 g/m2 over 2 h; days 1-5), topotecan (days 1-5) followed by VP-16 (250 mg/m2 twice daily, days 6-7), or VP-16 (250 mg/m2 twice daily days 1-2) followed by topotecan (days 3-d7).  A dose-finding phase was conducted in the poorest stratum of each arm (topotecan starting dose: 1.0 mg/m2/day × 5).  A Bayesian prephase II selection design was used to assess whether the CR rate with a given arm was sufficient to merit investigation in phase II.  Thirty-seven patients, median age 58 yr, were treated.  Their median 1st CR duration was after 28 wk, and 24% were primary refractory.  Grade 3-4 mucositis occurred in the initial patients in the topotecan → VP-16 arm, but not in the topotecan plus ara-C or VP-16 → topotecan arms.  Consequently, in subsequent patients, the topotecan dose was lower in the topotecan → VP-16 arm than in the other 2 arms (1.0 vs. 1.25 mg/m2 daily × 5) and the VP-16 dose was lower in the topotecan → VP-16 arm (200 vs. 250 mg/m2 twice daily × 2).  One CR occurred (topotecan → VP-16 arm), and the treatment arms were terminated after 10, 15, and 12 patients had been treated on the topotecan plus ara-C, topotecan → VP-16, and VP-16 → topotecan arms, resp.  The principal cause of failure was insufficient antileukemia effect rather than death during the study, and toxicity was minimal at the final doses used.  It is concluded that none of the combinations studied here warrants phase II evaluation in very-poor-prognosis AML salvage patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVtzdpzFGtbLVg90H21EOLACvtfcHk0liLzEBnAyNsfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFOnu7c%253D&md5=4e6d6fb695156bba039dc5f2668ba8a5</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006271618635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006271618635%26sid%3Dliteratum%253Aachs%26aulast%3DVey%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DEstey%26aufirst%3DE.%26atitle%3DCombination%2520of%2520topotecan%2520with%2520cytarabine%2520or%2520etoposide%2520in%2520patients%2520with%2520refractory%2520or%2520relapsed%2520acute%2520myeloid%2520leukemia%253A%2520results%2520of%2520a%2520randomized%2520phase%2520I%252FII%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D1999%26volume%3D17%26issue%3D1%26spage%3D89%26epage%3D95%26doi%3D10.1023%2FA%3A1006271618635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taudou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portemer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaxel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duguet, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(93)90068-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0006-2952%2893%2990068-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8382059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXhtl2ns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1993&pages=331-337&issue=2&author=G.+Taudouauthor=C.+Portemerauthor=C.+Jaxelauthor=M.+Duguet&title=Inhibition+of+DNA+synthesis+and+DNA+fragmentation+in+stimulated+splenocytes+by+the+concerted+action+of+topoisomerase+I+and+II+poisons&doi=10.1016%2F0006-2952%2893%2990068-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons</span></div><div class="casAuthors">Taudou, Georges; Portemer, Christiane; Jaxel, Christine; Duguet, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-7</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Stimulated splenocytes were used as a model system to investigate the effects of topoisomerase inhibitors on normal, non-transformed, non-tumoral proliferating cells.  The concerted action of camptothecin (a poison of topoisomerase I) and etoposide (a poison of topoisomerase II) lead to nearly complete inhibition of DNA synthesis in Con A-stimulated splenocytes.  Anal. of replicated cellular DNA after a short treatment with both drugs revealed a DNA cleavage to medium size fragments.  This effect was additive, suggesting that cleavable complexes were formed independently by both topoisomerases on their resp. DNA sites.  In contrast, prolonged contact with both drugs was followed by degrdn. of the bulk cellular DNA to nucleosome size fragments, indicating that apoptosis took place in these cells.  Combination of camptothecin and etoposide enhanced this phenomenon, consistent with the fact that degrdn. was the result of secondary events which may amplify the signal.  Thus, aphidicolin, an inhibitor of eukaryotic replicases which blocks replication, also triggered DNA degrdn. in proliferating splenocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMv748H-7UKbVg90H21EOLACvtfcHk0liLzEBnAyNsfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtl2ns70%253D&md5=5a66cd3e06cf28363aef9f5cd0b7f677</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2893%2990068-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252893%252990068-8%26sid%3Dliteratum%253Aachs%26aulast%3DTaudou%26aufirst%3DG.%26aulast%3DPortemer%26aufirst%3DC.%26aulast%3DJaxel%26aufirst%3DC.%26aulast%3DDuguet%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520DNA%2520synthesis%2520and%2520DNA%2520fragmentation%2520in%2520stimulated%2520splenocytes%2520by%2520the%2520concerted%2520action%2520of%2520topoisomerase%2520I%2520and%2520II%2520poisons%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1993%26volume%3D45%26issue%3D2%26spage%3D331%26epage%3D337%26doi%3D10.1016%2F0006-2952%2893%2990068-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinero, J.</span></span> <span> </span><span class="NLM_article-title">Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1007/BF00685566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2FBF00685566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8070008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2MXit1WmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1994&pages=411-415&issue=5&author=F.+Cortesauthor=J.+Pinero&title=Synergistic+effect+of+inhibitors+of+topoisomerase+I+and+II+on+chromosome+damage+and+cell+killing+in+cultured+Chinese+hamster+ovary+cells&doi=10.1007%2FBF00685566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells</span></div><div class="casAuthors">Cortes, Felipe; Pinero, Joaquin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-15</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">Simultaneous treatment of cultured Chinese hamster ovary cells with the topoisomerase I inhibitor camptothecin and the topoisomerase II inhibitor 4'-(9-acridinylamino)-methanesulfon-m-anisidide results in a clear synergistic effect on both chromosome damage detected at metaphase and loss of colony-forming ability.  In contrast, the effect of combined treatment with these topoisomerase inhibitors on sister chromatid exchanges was not significantly different from that expected if the effects were additive.  Taken as a whole, these results seem to support the hypothesis that topoisomerase inhibitors can lead to cell death, presumably when DNA replication forks collide with drug-stabilized cleavable complexes.  Nevertheless, no evidence of apoptosis was obtained from DNA fragmentation anal.  The possible clin. implications of our findings are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-GMX8e9A1GbVg90H21EOLACvtfcHk0ljrOo_eQafYzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1WmsLg%253D&md5=ef7a7bac26aec0cdfb51a491366d1352</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1007%2FBF00685566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00685566%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DF.%26aulast%3DPinero%26aufirst%3DJ.%26atitle%3DSynergistic%2520effect%2520of%2520inhibitors%2520of%2520topoisomerase%2520I%2520and%2520II%2520on%2520chromosome%2520damage%2520and%2520cell%2520killing%2520in%2520cultured%2520Chinese%2520hamster%2520ovary%2520cells%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1994%26volume%3D34%26issue%3D5%26spage%3D411%26epage%3D415%26doi%3D10.1007%2FBF00685566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menegatti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogus, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselmo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitragotri, S.</span></span> <span> </span><span class="NLM_article-title">Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2015.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.jconrel.2015.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25921087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFChurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2015&pages=198-207&author=K.+M.+Camachoauthor=S.+Kumarauthor=S.+Menegattiauthor=D.+R.+Vogusauthor=A.+C.+Anselmoauthor=S.+Mitragotri&title=Synergistic+antitumor+activity+of+camptothecin-doxorubicin+combinations+and+their+conjugates+with+hyaluronic+acid&doi=10.1016%2Fj.jconrel.2015.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid</span></div><div class="casAuthors">Camacho, Kathryn M.; Kumar, Sunny; Menegatti, Stefano; Vogus, Douglas R.; Anselmo, Aaron C.; Mitragotri, Samir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">198-207</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Combinations of topoisomerase inhibitors I and II have been found to synergistically inhibit cancer cell growth in vitro, yet clin. studies of these types of combinations have not progressed beyond phase II trials.  The results of clin. combinations of topoisomerase (top) I and II inhibitors typically fall within one of two categories: little to no improvement in therapeutic efficacy, or augmented toxicity compared to the single drug counterparts.  Hence, despite the promising activity of top I and II inhibitor combinations in vitro, their clin. applicability has not been realized.  Here, we report the use of polymer-drug conjugates as a means to co-deliver synergistic doses of top I and II inhibitors camptothecin (CPT) and doxorubicin (DOX) to tumors in vivo in a 4T1 breast cancer model.  At specific molar ratios, DOX and CPT were found to be among the most synergistic combinations reported to date, with combination indexes between 0.01 and 0.1.  The identified optimal ratios were controllably conjugated to hyaluronic acid, and elicited significant tumor redn. of murine 4T1 breast cancer model when administered i.v.  This study elucidates a method to identify synergistic drug combinations and translate them to in vivo by preserving the synergistic ratio via conjugation to a carrier polymer, thus opening a promising approach to translate drug combinations to clin. viable treatment regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn5-cVyTUSCbVg90H21EOLACvtfcHk0ljrOo_eQafYzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFChurY%253D&md5=2c98677df8fb4f99ebd972eb1a15215f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2015.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2015.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%26aufirst%3DK.%2BM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DMenegatti%26aufirst%3DS.%26aulast%3DVogus%26aufirst%3DD.%2BR.%26aulast%3DAnselmo%26aufirst%3DA.%2BC.%26aulast%3DMitragotri%26aufirst%3DS.%26atitle%3DSynergistic%2520antitumor%2520activity%2520of%2520camptothecin-doxorubicin%2520combinations%2520and%2520their%2520conjugates%2520with%2520hyaluronic%2520acid%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2015%26volume%3D210%26spage%3D198%26epage%3D207%26doi%3D10.1016%2Fj.jconrel.2015.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasey, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span> <span> </span><span class="NLM_article-title">Combined inhibition of topoisomerases I and II - is this a worthwhile/ feasible strategy?</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1397</span>, <span class="refDoi"> DOI: 10.1038/bjc.1997.568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fbjc.1997.568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9400932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADyaK1c%252Fmt1Wjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1997&pages=1395-1397&issue=11&author=P.+A.+Vaseyauthor=S.+B.+Kaye&title=Combined+inhibition+of+topoisomerases+I+and+II+-+is+this+a+worthwhile%2F+feasible+strategy%3F&doi=10.1038%2Fbjc.1997.568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?</span></div><div class="casAuthors">Vasey P A; Kaye S B</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1395-7</span>
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7KUv6d8-GJf3jf77P2BG3fW6udTcc2eZz-UKYHB5P9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252Fmt1Wjtg%253D%253D&md5=7f0bd7dc42bbd7c856b61b778df971ae</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1997.568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1997.568%26sid%3Dliteratum%253Aachs%26aulast%3DVasey%26aufirst%3DP.%2BA.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DCombined%2520inhibition%2520of%2520topoisomerases%2520I%2520and%2520II%2520-%2520is%2520this%2520a%2520worthwhile%252F%2520feasible%2520strategy%253F%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1997%26volume%3D76%26issue%3D11%26spage%3D1395%26epage%3D1397%26doi%3D10.1038%2Fbjc.1997.568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span> <span> </span><span class="NLM_article-title">Dual topoisomerase I/II inhibitors in cancer therapy</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.2174/1568026033452555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1568026033452555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12570767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1CksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=339-353&issue=3&author=W.+A.+Dennyauthor=B.+C.+Baguley&title=Dual+topoisomerase+I%2FII+inhibitors+in+cancer+therapy&doi=10.2174%2F1568026033452555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Dual topoisomerase I/II inhibitors in cancer therapy</span></div><div class="casAuthors">Denny, William A.; Baguley, Bruce C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-353</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  While the majority of topoisomerase (topo) inhibitors show selectivity against either topo I or topo II, a small class of compds. can act against both enzymes.  These can be divided into three classes.  The first and largest class comprise drugs that bind to DNA by intercalation and include the clin.-evaluated acridine DACA, the benzopyridoindole intoplicine, the indenoquinolinone TAS-103, the benzophenazine XR11576, and the pyrazoloacridine NSC 366140.  The second category comprises hybrid mols., prepd. by phys. linking sep. inhibitors of topo I and topo II, or by linking pure topo inhibitors to other DNA-interactive carriers.  While several derivs. (e.g., camptothecin-epipodophyllotoxin and ellipticine-distamycin hybrids) have been prepd., there have been no detailed studies.  The third category are less well defined as a structural class, but apparently recognize structural motifs that are present in both topo I and II enzymes.  These include a series of benzoisoquinolinium quaternary salts such as NK 109, and more interestingly modified versions of classical topo I or topo II inhibitors; e.g., the modified camptothecin BN 80927 and the modified epipodophyllotoxin tafluposide (F-11782).  There is as yet no detailed understanding of the factors that result in selective or dual inhibition, but structure-activity studies in several classes show that structural changes can influence topo I/II selectivity.  DNA intercalation mode also appears to play a part.  The basis for the high antitumor activity of some topo inhibitors is not yet understood but may depend on the complex pattern of activities that include both inhibition and poisoning of the two enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSlke14mUdcLVg90H21EOLACvtfcHk0ljrOo_eQafYzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1CksA%253D%253D&md5=110f2d5abc8d8bbaf733a1034387c75b</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.2174%2F1568026033452555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026033452555%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26atitle%3DDual%2520topoisomerase%2520I%252FII%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2003%26volume%3D3%26issue%3D3%26spage%3D339%26epage%3D353%26doi%3D10.2174%2F1568026033452555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miskovic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baus Loncar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glavas-Obrovac, L.</span></span> <span> </span><span class="NLM_article-title">Antineoplastic DNA-binding compounds: intercalating and minor groove binding drugs</span>. <i>Arh. Hig. Rada Toksikol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.2478/10004-1254-64-2013-2371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2478%2F10004-1254-64-2013-2371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24384766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFKkt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=593-602&issue=4&author=K.+Miskovicauthor=M.+Bujakauthor=M.+Baus+Loncarauthor=L.+Glavas-Obrovac&title=Antineoplastic+DNA-binding+compounds%3A+intercalating+and+minor+groove+binding+drugs&doi=10.2478%2F10004-1254-64-2013-2371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Antineoplastic DNA-binding compounds: intercalating and minor groove binding drugs</span></div><div class="casAuthors">Miskovic, Katarina; Bujak, Maro; Baus Loncar, Mirela; Glavas-Obrovac, Ljubica</div><div class="citationInfo"><span class="NLM_cas:title">Arhiv za Higijenu Rada i Toksikologiju</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">593-602</span>CODEN:
                <span class="NLM_cas:coden">AHRTAN</span>;
        ISSN:<span class="NLM_cas:issn">0004-1254</span>.
    
            (<span class="NLM_cas:orgname">Institute for Medical Research and Occupational Health</span>)
        </div><div class="casAbstract">A review.  DNA intercalating and minor groove binding compds. are new weapons in the battle against malignant diseases.  These antineoplastic agents target the DNA mol. and interfere with the cell cycle leading to rapidly proliferating cell death.  They are mainly derivates of a naturally occurring org. compd. derived from a microorganism or plant.  Intercalators usually act as topoisomerase I and/or II poisons, while the mechanisms of DNA minor groove binders are a combination of several steps including topoisomerase poisoning.  This paper gives an overview of some of the developed DNA intercalating and minor groove binding compds., as well as an explanation of their chem. structures, origins, and application in chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK1zyx1Qk7JrVg90H21EOLACvtfcHk0lgPMmKh6nQtaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFKkt70%253D&md5=4aeabbfb2dc587a978167b80efbdfa9f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2478%2F10004-1254-64-2013-2371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2478%252F10004-1254-64-2013-2371%26sid%3Dliteratum%253Aachs%26aulast%3DMiskovic%26aufirst%3DK.%26aulast%3DBujak%26aufirst%3DM.%26aulast%3DBaus%2BLoncar%26aufirst%3DM.%26aulast%3DGlavas-Obrovac%26aufirst%3DL.%26atitle%3DAntineoplastic%2520DNA-binding%2520compounds%253A%2520intercalating%2520and%2520minor%2520groove%2520binding%2520drugs%26jtitle%3DArh.%2520Hig.%2520Rada%2520Toksikol.%26date%3D2013%26volume%3D64%26issue%3D4%26spage%3D593%26epage%3D602%26doi%3D10.2478%2F10004-1254-64-2013-2371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, L. H.</span></span> <span> </span><span class="NLM_article-title">DNA and its associated processes as targets for cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1038/nrc749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11990855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1KktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=188-200&issue=3&author=L.+H.+Hurley&title=DNA+and+its+associated+processes+as+targets+for+cancer+therapy&doi=10.1038%2Fnrc749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">DNA and its associated processes as targets for cancer therapy</span></div><div class="casAuthors">Hurley, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">188-200</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA is the mol. target for many of the drugs that are used in cancer therapeutics, and is viewed as a non-specific target of cytotoxic agents.  Although this is true for traditional chemotherapeutics, other agents that were discovered more recently have shown enhanced efficacy.  Furthermore, a new generation of agents that target DNA-assocd. processes are anticipated to be far more specific and effective.  How have these agents evolved, and what are their mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXfymv1PT0YLVg90H21EOLACvtfcHk0lgPMmKh6nQtaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1KktL0%253D&md5=e9ca715b3e7374aeb919f340c46cc59d</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnrc749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc749%26sid%3Dliteratum%253Aachs%26aulast%3DHurley%26aufirst%3DL.%2BH.%26atitle%3DDNA%2520and%2520its%2520associated%2520processes%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26issue%3D3%26spage%3D188%26epage%3D200%26doi%3D10.1038%2Fnrc749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span> <span> </span><span class="NLM_article-title">From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>32a</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1016/0959-8049(95)00604-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0959-8049%2895%2900604-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8695277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK28XjsFSqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32a&publication_year=1996&pages=708-714&issue=4&author=G.+J.+Finlayauthor=J.+F.+Riouauthor=B.+C.+Baguley&title=From+amsacrine+to+DACA+%28N-%5B2-%28dimethylamino%29ethyl%5Dacridine-4-carboxamide%29%3A+selectivity+for+topoisomerases+I+and+II+among+acridine+derivatives&doi=10.1016%2F0959-8049%2895%2900604-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">From Amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): Selectivity for Topoisomerases I and II among acridine derivatives</span></div><div class="casAuthors">Finlay, G. J.; Riou, J. -F.; Baguley, B. C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer, Part A</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">32A</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">708-714</span>CODEN:
                <span class="NLM_cas:coden">EJCTEA</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A no. of acridine derivs., including the clin. antileukemia agent amsacrine and the exptl. agent DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide), target the enzyme topoisomerase II.  We demonstrate here that DACA induces DNA cleavage in the presence of topoisomerase I as well as of topoisomerase II.  We also investigate a series of acridine derivs. which link amsacrine to DACA in terms of DNA binding, topoisomerase poisoning and biol. activity.  The presence of an acridine 4-linked N-2-(dimethylamino)ethyl group provides both a pronounced G-C preference for DNA binding and activity towards topoisomerase I.  The removal of the anilino side chain of amsacrine, in combination with the presence of the N-2-(dimethylamino)ethyl group, provides in vitro biol. activity against "atypical" multidrug resistant leukemia lines with low topoisomerase II activity.  Among these compds., suppression of the ionization of the acridine nitrogen to produce the compd. DACA is assocd. with exptl. activity against solid tumors.  The addn. of an acridine 2-chloro substituent to DACA suppresses the stimulation of topoisomerase II-dependent DNA cleavage but increases stimulation of topoisomerase I cleavage.  2-Substitution also increases activity against the "atypical" multidrug resistant cell lines.  Overall, the results suggest that augmentation of topoisomerase I-dependent activity in this series by appropriate chem. substitution in this series leads to circumvention of topoisomerase II-mediated multidrug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRcA2mITlodbVg90H21EOLACvtfcHk0lgPMmKh6nQtaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsFSqs7k%253D&md5=34e7389becadf899f0e047427f455b96</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2F0959-8049%2895%2900604-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0959-8049%252895%252900604-4%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DG.%2BJ.%26aulast%3DRiou%26aufirst%3DJ.%2BF.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26atitle%3DFrom%2520amsacrine%2520to%2520DACA%2520%2528N-%255B2-%2528dimethylamino%2529ethyl%255Dacridine-4-carboxamide%2529%253A%2520selectivity%2520for%2520topoisomerases%2520I%2520and%2520II%2520among%2520acridine%2520derivatives%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1996%26volume%3D32a%26issue%3D4%26spage%3D708%26epage%3D714%26doi%3D10.1016%2F0959-8049%2895%2900604-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poddevin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavelle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8232227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2cXitlWlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1993&pages=767-774&issue=4&author=B.+Poddevinauthor=J.+F.+Riouauthor=F.+Lavelleauthor=Y.+Pommier&title=Dual+topoisomerase+I+and+II+inhibition+by+intoplicine+%28RP-60475%29%2C+a+new+antitumor+agent+in+early+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials</span></div><div class="casAuthors">Poddevin, Bruno; Riou, Jean Francois; Lavelle, Francois; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">767-74</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The mechanisms of action of intoplicine (RP-60475), a 7H-benzo[e]pyrido[4,3-b]indole deriv. that is presently in early clin. trials, were studied.  Intoplicine induced both topoisomerase I- and II-mediated DNA strand breaks, using purified topoisomerases.  The topoisomerase cleavage site patterns induced by intoplicine were unique, relative to those of camptothecin, 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA), and other known topoisomerase inhibitors.  Both topoisomerase I- and II-induced DNA breaks decreased at drug concns. > 1 μM, which is consistent with the DNA-intercalating activity of intoplicine.  DNA damage was studied in KB cells in culture by using alk. elution.  Intoplicine induced single-strand breaks (SSB) in a bell-shaped manner with respect to drug concn. (max. frequency at 1 μM ≈ 220 rad-equiv.).  SSB formation was fast, whereas reversal after drug removal was slow.  Similar bell-shaped curves were obtained for DNA double-strand breaks (DSB) and DNA-protein cross-links.  SSB and DNA-protein cross-link frequencies were approx. equal, and no protein-free breaks were detectable, indicating the protein concealment of the breaks, as expected for topoisomerase inhibition.  Comparison of SSB and DSB frequencies indicated that intoplicine produced a amt. of SSB not related to DSB, which is consistent with concomitant inhibition of both DNA topoisomerases I and II in cells.  Data derived from resistant cell lines indicated that multidrug-resistant cells were cross-resistant to intoplicine but that m-AMSA- and camptothecin-resistant cells were sensitive to intoplicine.  Hence, intoplicine might circumvent topoisomerase I-mediated and topoisomerase II-mediated resistance by poisoning both enzymes simultaneously.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVYTHAtG4ODbVg90H21EOLACvtfcHk0lguXFTeACh6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlWlsw%253D%253D&md5=f7a79d21f80e1a98b368370954e715df</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPoddevin%26aufirst%3DB.%26aulast%3DRiou%26aufirst%3DJ.%2BF.%26aulast%3DLavelle%26aufirst%3DF.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DDual%2520topoisomerase%2520I%2520and%2520II%2520inhibition%2520by%2520intoplicine%2520%2528RP-60475%2529%252C%2520a%2520new%2520antitumor%2520agent%2520in%2520early%2520clinical%2520trials%26jtitle%3DMol.%2520Pharmacol.%26date%3D1993%26volume%3D44%26issue%3D4%26spage%3D767%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svingen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebolt-Leopold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ames, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9533538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXit1aqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=683-691&issue=3&author=A.+A.+Adjeiauthor=M.+Charronauthor=E.+K.+Rowinskyauthor=P.+A.+Svingenauthor=J.+Millerauthor=J.+M.+Reidauthor=J.+Sebolt-Leopoldauthor=M.+M.+Amesauthor=S.+H.+Kaufmann&title=Effect+of+pyrazoloacridine+%28NSC+366140%29+on+DNA+topoisomerases+I+and+II"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II</span></div><div class="casAuthors">Adjei, Alex A.; Charron, Martin; Rowinsky, Eric K.; Svingen, Phyllis A.; Miller, Jennifer; Reid, Joel M.; Sebolt-Leopold, Judith; Ames, Matthew M.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">683-691</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pyrazoloacridine (PA), an acridine congener with an unknown mechanism of action, has shown selective activity against solid tumor cells, cytotoxicity in noncycling and hypoxic cells, and promising antitumor activity in Phase I clin. trials.  In the present study, the effect of PA on topoisomerase (topo) activity was evaluated using yeast strains lacking functional topo I or II, mammalian cell nuclear exts., purified samples of mammalian topo I and topo II, and intact mammalian tissue culture cells.  Clonogenic assays revealed that PA cytotoxicity in yeast strains was unaffected by selective loss of topo I or topo II activity.  On the other hand, enzyme assays revealed that 2-4 μM PA abolished the catalytic activity of both topo I and topo II in vitro.  In contrast to topotecan and etoposide, PA did not stabilize covalent topo-DNA complexes.  Instead, PA inhibited topotecan-induced stabilization of covalent topo I-DNA complexes and etoposide-induced stabilization of topo II-DNA complexes in vitro and in intact cells.  Consistent with these results, colony-forming assays indicated that short-term PA exposure inhibited the cytotoxicity of topotecan and etoposide, whereas prolonged PA exposure was itself toxic to these cells.  Accumulation studies revealed that PA was concd. as much as 250-fold in drug-treated cells, resulting in intranuclear concns. that far exceeded those required to inhibit topo I and topo II.  Collectively, these results not only suggest that PA can target both topo I and topo II at clin. achievable concns. but also indicate that its mechanism is distinct from topo I and topo II poisons presently licensed for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlQoZ13UrTJ7Vg90H21EOLACvtfcHk0lguXFTeACh6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXit1aqu78%253D&md5=2324fba34e332e8ee8fd7d19cea12354</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DCharron%26aufirst%3DM.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DSvingen%26aufirst%3DP.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DEffect%2520of%2520pyrazoloacridine%2520%2528NSC%2520366140%2529%2520on%2520DNA%2520topoisomerases%2520I%2520and%2520II%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1998%26volume%3D4%26issue%3D3%26spage%3D683%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Utsugi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierzba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II</span>. <i>Jpn. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">992</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.1997.tb00320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1111%2Fj.1349-7006.1997.tb00320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9414662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Gjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1997&pages=992-1002&issue=10&author=T.+Utsugiauthor=K.+Aoyagiauthor=T.+Asaoauthor=S.+Okazakiauthor=Y.+Aoyagiauthor=M.+Sanoauthor=K.+Wierzbaauthor=Y.+Yamada&title=Antitumor+activity+of+a+novel+quinoline+derivative%2C+TAS-103%2C+with+inhibitory+effects+on+topoisomerases+I+and+II&doi=10.1111%2Fj.1349-7006.1997.tb00320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II</span></div><div class="casAuthors">Utsugi, Teruhiro; Aoyagi, Kumio; Asao, Tetsuji; Okazaki, Shinji; Aoyagi, Yoshimi; Sano, Masaki; Wierzba, Konstanty; Yamada, Yuji</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">992-1002</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">A novel quinoline deriv., TAS-103 (6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride), was developed as an anticancer agent targeting topoisomerases (topo) I and II, with marked efficacy in solid tumors.  TAS-103 inhibited topo I and II (IC50: 2 μM, 6.5 μM) at a concn. similar to or lower than those of previous agents, and had a strong cytotoxic effect on P388 and KB cells (IC50: 0.0011 μM, 0.0096 μM).  TAS-103 stabilized top I and II-DNA complex to that induced by etoposide (VP-16) but a smaller amt. of topo I-DNA complex than that produced by camptothecin (CPT).  In the in vivo study, intermittent i.v. administration was markedly effective against s.c.-implanted murine tumors.  Furthermore, TAS-103 had marked efficacy against various lung metastatic tumors, and a broad antitumor spectrum in human tumor xenografts (derived from lung, colon, stomach, breast, and pancreatic cancer).  The efficacy of TAS-103 was generally greater than that of irinotecan (CP-11), VP-16, or cis-diamminedichloroplatinum (CDDP).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVovc2P_1CG7Vg90H21EOLACvtfcHk0lguXFTeACh6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Gjt7k%253D&md5=078432e189697cb13b8779176e89339d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.1997.tb00320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.1997.tb00320.x%26sid%3Dliteratum%253Aachs%26aulast%3DUtsugi%26aufirst%3DT.%26aulast%3DAoyagi%26aufirst%3DK.%26aulast%3DAsao%26aufirst%3DT.%26aulast%3DOkazaki%26aufirst%3DS.%26aulast%3DAoyagi%26aufirst%3DY.%26aulast%3DSano%26aufirst%3DM.%26aulast%3DWierzba%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26atitle%3DAntitumor%2520activity%2520of%2520a%2520novel%2520quinoline%2520derivative%252C%2520TAS-103%252C%2520with%2520inhibitory%2520effects%2520on%2520topoisomerases%2520I%2520and%2520II%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D1997%26volume%3D88%26issue%3D10%26spage%3D992%26epage%3D1002%26doi%3D10.1111%2Fj.1349-7006.1997.tb00320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[<i>a</i>]phenazin derivatives as dual topoisomerase I/II inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2015.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25599951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFeqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=540-553&author=B.+L.+Yaoauthor=Y.+W.+Maiauthor=S.+B.+Chenauthor=H.+T.+Xieauthor=P.+F.+Yaoauthor=T.+M.+Ouauthor=J.+H.+Tanauthor=H.+G.+Wangauthor=D.+Liauthor=S.+L.+Huangauthor=L.+Q.+Guauthor=Z.+S.+Huang&title=Design%2C+synthesis+and+biological+evaluation+of+novel+7-alkylamino+substituted+benzo%5Ba%5Dphenazin+derivatives+as+dual+topoisomerase+I%2FII+inhibitors&doi=10.1016%2Fj.ejmech.2015.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors</span></div><div class="casAuthors">Yao, Bing-Lei; Mai, Yan-Wen; Chen, Shuo-Bin; Xie, Hua-Ting; Yao, Pei-Fen; Ou, Tian-Miao; Tan, Jia-Heng; Wang, Hong-Gen; Li, Ding; Huang, Shi-Liang; Gu, Lian-Quan; Huang, Zhi-Shu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">540-553</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of benzo[a]phenazine derivs. (e.g. I) bearing alkylamino side chains were designed, synthesized and evaluated for their topoisomerase inhibitory activity as well as cytotoxicity against four human cancer cell lines (HL-60, K-562, HeLa, and A549).  These compds. were found to be dual inhibitors of topoisomerase (Topo) I and Topo II, and exhibited excellent antiproliferative activity, in particular against HL-60 cells with submicromolar IC50 values.  Further mechanistic studies showed that this class of compds. acted as Topo I poisons by stabilizing the Topo I-DNA cleavage complexes and Topo II catalytic inhibitors by inhibiting the ATPase activity of hTopo II.  Mol. docking studies revealed the binding modes of these compds. for Topo I and Topo II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxjnEG72_zALVg90H21EOLACvtfcHk0lj0ujtRkAC5ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFeqsQ%253D%253D&md5=01e94691b81dc1185eb5109930b0d41d</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%2BL.%26aulast%3DMai%26aufirst%3DY.%2BW.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DXie%26aufirst%3DH.%2BT.%26aulast%3DYao%26aufirst%3DP.%2BF.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%25207-alkylamino%2520substituted%2520benzo%255Ba%255Dphenazin%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%252FII%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D540%26epage%3D553%26doi%3D10.1016%2Fj.ejmech.2015.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janockova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plsikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jendzelovsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparkova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamulakova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorocko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozurkova, M.</span></span> <span> </span><span class="NLM_article-title">Tacrine derivatives as dual topoisomerase I and II catalytic inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2015.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bioorg.2015.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25827869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFWmtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=168-176&author=J.+Janockovaauthor=J.+Plsikovaauthor=J.+Kovalauthor=R.+Jendzelovskyauthor=J.+Mikesauthor=J.+Kasparkovaauthor=V.+Brabecauthor=S.+Hamulakovaauthor=P.+Fedorockoauthor=M.+Kozurkova&title=Tacrine+derivatives+as+dual+topoisomerase+I+and+II+catalytic+inhibitors&doi=10.1016%2Fj.bioorg.2015.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine derivatives as dual topoisomerase I and II catalytic inhibitors</span></div><div class="casAuthors">Janockova, Jana; Plsikova, Jana; Koval, Jan; Jendzelovsky, Rastislav; Mikes, Jaromir; Kasparkova, Jana; Brabec, Viktor; Hamulakova, Slavka; Fedorocko, Peter; Kozurkova, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">168-176</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study examines the binding properties of a series of newly synthesized tacrine derivs. 1-4 and their anticancer effects.  Spectroscopic techniques (UV-Vis, fluorescence spectroscopy, thermal denaturation, and linear spectropolarimetry) and viscometry were used to study DNA binding properties and to det. the types of DNA interaction with the studied derivs.  The binding consts. for the complexes with DNA were obtained using UV-Vis spectroscopic titrns. (K = 1.6 × 104-4.0 × 105 M-1) and electrophoretic methods were used to det. the effect of the derivs. on topoisomerase I and II activity.  Monotacrine deriv. 1 showed evidence of topoisomerase I relaxation activity at a concn. of 30 × 10-6 M, while bistacrine derivs. 2-4 produced a complete inhibition of topoisomerase I at a concn. of 5 × 10-6 M.  The biol. activities of the derivs. were studied using MTT-assay and flow cytometric methods (detection of mitochondrial membrane potential and measurement of cell viability) following incubation of 24 and 48 h with human leukemic cancer cell line HL60.  The ability of the derivs. to impair cell proliferation was also tested through the anal. of cell cycle distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUjQmb4QejbVg90H21EOLACvtfcHk0lj0ujtRkAC5ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFWmtb4%253D&md5=7bfc53c704e4a38a019345be87e3c471</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2015.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2015.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DJanockova%26aufirst%3DJ.%26aulast%3DPlsikova%26aufirst%3DJ.%26aulast%3DKoval%26aufirst%3DJ.%26aulast%3DJendzelovsky%26aufirst%3DR.%26aulast%3DMikes%26aufirst%3DJ.%26aulast%3DKasparkova%26aufirst%3DJ.%26aulast%3DBrabec%26aufirst%3DV.%26aulast%3DHamulakova%26aufirst%3DS.%26aulast%3DFedorocko%26aufirst%3DP.%26aulast%3DKozurkova%26aufirst%3DM.%26atitle%3DTacrine%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%2520and%2520II%2520catalytic%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2015%26volume%3D59%26spage%3D168%26epage%3D176%26doi%3D10.1016%2Fj.bioorg.2015.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalla
Via, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrarese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gia, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilin, A.</span></span> <span> </span><span class="NLM_article-title">Pyrroloquinolinone-based dual topoisomerase I/II inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.02.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2014.02.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24631729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=103-109&author=L.+Dalla%0AViaauthor=G.+Marzaroauthor=A.+Ferrareseauthor=O.+Giaauthor=A.+Chilin&title=Pyrroloquinolinone-based+dual+topoisomerase+I%2FII+inhibitor&doi=10.1016%2Fj.ejmech.2014.02.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrroloquinolinone-based dual topoisomerase I/II inhibitor</span></div><div class="casAuthors">Dalla Via, Lisa; Marzaro, Giovanni; Ferrarese, Alessandro; Gia, Ornella; Chilin, Adriana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-109</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new series of pyrroloquinolinones I [X = (CH2)2; (CH2)3; (CH2)4; R = Me2N, Me2NCH2CH2] bearing different alkylamino side chains were synthesized and evaluated as cytotoxic compds. against three different human tumor cell lines (HeLa, HL-60 and A431).  Some compds. showed interesting antiproliferative activity, in particular against A431 cells.  The compds. were tested for their ability to counteract topoisomerase II relaxation activity and the most interesting one I [X = (CH2)4; R = Me2NCH2CH2] was tested also against topoisomerase I, resulting a dual inhibitor.  The mol. interactions between this compd. and the intracellular targets were finally investigated through mol. modeling simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0hZVMaV2pFLVg90H21EOLACvtfcHk0lj0ujtRkAC5ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSht7g%253D&md5=d687922a8b6503655fc1363cf85676ab</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.02.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.02.064%26sid%3Dliteratum%253Aachs%26aulast%3DDalla%2BVia%26aufirst%3DL.%26aulast%3DMarzaro%26aufirst%3DG.%26aulast%3DFerrarese%26aufirst%3DA.%26aulast%3DGia%26aufirst%3DO.%26aulast%3DChilin%26aufirst%3DA.%26atitle%3DPyrroloquinolinone-based%2520dual%2520topoisomerase%2520I%252FII%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D77%26spage%3D103%26epage%3D109%26doi%3D10.1016%2Fj.ejmech.2014.02.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbeck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone γ-H2AX as a biomarker of DNA damage</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9971</span>– <span class="NLM_lpage">9979</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-0804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F0008-5472.CAN-07-0804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17942930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9971-9979&issue=20&author=V.+A.+Raoauthor=K.+Agamaauthor=S.+Holbeckauthor=Y.+Pommier&title=Batracylin+%28NSC+320846%29%2C+a+dual+inhibitor+of+DNA+topoisomerases+I+and+II+induces+histone+%CE%B3-H2AX+as+a+biomarker+of+DNA+damage&doi=10.1158%2F0008-5472.CAN-07-0804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Batracylin (NSC 320846), a Dual Inhibitor of DNA Topoisomerases I and II Induces Histone γ-H2AX as a Biomarker of DNA Damage</span></div><div class="casAuthors">Rao, V. Ashutosh; Agama, Keli; Holbeck, Susan; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9971-9979</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Batracylin (8-aminoisoindolo [1,2-b]quinazolin-10(12H)-one; NSC320846) is an investigational clin. anticancer agent.  Previous animal studies showed activity against solid tumors and Adriamycin-resistant leukemia.  We initially sought to test the proposed Top2-mediated DNA cleavage activity of batracylin and identify potential biomarkers for activity.  COMPARE anal. in the NCI-60 cell lines showed batracylin activity to be most closely related to the class of Top2 inhibitors.  The 50% growth inhibition (GI50) value for batracylin in HT29 colon carcinoma cells was 10 μmol/L.  DNA-protein cross-links, consistent with Top2 targeting, were measured by alk. elution.  DNA single-strand breaks were also detected and found to be protein assocd.  However, only a weak induction of DNA double-strand breaks was obsd.  Because batracylin induced almost exclusively DNA single-strand breaks, we tested batracylin as a Top1 inhibitor.  Batracylin exhibited both Top1- and Top2α/β-mediated DNA cleavage in vitro and in cells.  The phosphorylation of histone (γ-H2AX) was tested to measure the extent of DNA damage.  Kinetics of γ-H2AX "foci" showed early activation with low μmol/L concns., thus presenting a useful early biomarker of DNA damage.  The half-life of γ-H2AX signal reversal after drug removal was consistent with reversal of DNA-protein cross-links.  The persistence of the DNA-protein complexes induced by batracylin was markedly longer than by etoposide or camptothecin.  The phosphorylated DNA damage-responsive kinase, ataxia telangiectasia mutated, was also found activated at sites of γ-H2AX.  The cell cycle checkpoint kinase, Chk2, was only weakly phosphorylated.  Thus, batracylin is a dual Top1 and Top2 inhibitor and γ-H2AX could be considered a biomarker in the ongoing clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIPYuZCTcod7Vg90H21EOLACvtfcHk0lj0ujtRkAC5ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbbP&md5=0bce626fda4536088a5245f164faa5bf</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-0804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-0804%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DV.%2BA.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DHolbeck%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DBatracylin%2520%2528NSC%2520320846%2529%252C%2520a%2520dual%2520inhibitor%2520of%2520DNA%2520topoisomerases%2520I%2520and%2520II%2520induces%2520histone%2520%25CE%25B3-H2AX%2520as%2520a%2520biomarker%2520of%2520DNA%2520damage%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D20%26spage%3D9971%26epage%3D9979%26doi%3D10.1158%2F0008-5472.CAN-07-0804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westergaard, O.</span></span> <span> </span><span class="NLM_article-title">Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>228</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1016/0022-2836(92)90863-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0022-2836%2892%2990863-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1335085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXlt1Shuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=1992&pages=778-786&issue=3&author=B.+S.+Sorensenauthor=J.+Sindingauthor=A.+H.+Andersenauthor=J.+Alsnerauthor=P.+B.+Jensenauthor=O.+Westergaard&title=Mode+of+action+of+topoisomerase+II-targeting+agents+at+a+specific+DNA+sequence.+Uncoupling+the+DNA+binding%2C+cleavage+and+religation+events&doi=10.1016%2F0022-2836%2892%2990863-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Mode of action of topoisomerase II-targeting agents at a specific DNA sequence.  Uncoupling the DNA binding, cleavage and religation events</span></div><div class="casAuthors">Sorensen, Boe S.; Sinding, Jens; Andersen, Anni H.; Alsner, Jan; Jensen, Peter B.; Westergaard, Ole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">778-86</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">Methods for uncoupling the DNA binding, cleavage and religation reactions of topoisomerase II were employed to investigate the influence of topoisomerase II-directed drugs on the individual steps in the enzyme's catalytic cycle.  A special DNA substrate contg. a major topoisomerase II interaction site, which can be cleaved by the enzyme in the absence of any concomitant religation, was used to examine the effect of topoisomerase II-directed agents upon the DNA cleavage reaction.  The expt. demonstrated that the topoisomerase II targeting agent Ro 15-0216 stimulates the DNA cleavage reaction extensively, whereas the traditional topoisomerase II inhibitor, mAMSA, has only a minor effect on this reaction.  Topoisomerase II trapped in the cleavage complexes can religate to the 3' hydroxyl end of another DNA strand.  Using this religation assay, it was demonstrated that the major effect of mAMSA is an inhibition of the enzyme's religation reaction, whereas Ro 15-0216 has no effect on this reaction.  Recently, considerable attention has been given to drugs preventing topoisomerase II from introducing DNA cleavages.  In the present paper the initial non-covalent DNA binding reaction of topoisomerase II was investigated under conditions excluding enzyme-mediated DNA cleavage.  This demonstrated that the anthracycline, aclarubicin, prevents topoisomerase II from performing its initial non-covalent DNA binding reaction and thereby abolishes the DNA cleavage reaction of the enzyme.  The results presented here demonstrate that profound differences exist in the mode of action of different agents targeting topoisomerase II, and that the enzyme can be affected by such agents at both its DNA binding, cleavage and religation subreactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_qa0T1FlNF7Vg90H21EOLACvtfcHk0lgXOe0hKVFy7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlt1Shuw%253D%253D&md5=ee63232df869c9e2b5886e9a0af928d1</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2F0022-2836%2892%2990863-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-2836%252892%252990863-F%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DB.%2BS.%26aulast%3DSinding%26aufirst%3DJ.%26aulast%3DAndersen%26aufirst%3DA.%2BH.%26aulast%3DAlsner%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DP.%2BB.%26aulast%3DWestergaard%26aufirst%3DO.%26atitle%3DMode%2520of%2520action%2520of%2520topoisomerase%2520II-targeting%2520agents%2520at%2520a%2520specific%2520DNA%2520sequence.%2520Uncoupling%2520the%2520DNA%2520binding%252C%2520cleavage%2520and%2520religation%2520events%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1992%26volume%3D228%26issue%3D3%26spage%3D778%26epage%3D786%26doi%3D10.1016%2F0022-2836%2892%2990863-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourquier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binaschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Animati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capranico, G.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase poisoning activity of novel disaccharide anthracyclines</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1124/mol.56.1.77</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1124%2Fmol.56.1.77" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10385686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1MXksFOmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=77-84&issue=1&author=F.+Guanoauthor=P.+Pourquierauthor=S.+Tinelliauthor=M.+Binaschiauthor=M.+Bigioniauthor=F.+Animatiauthor=S.+Manziniauthor=F.+Zuninoauthor=G.+Kohlhagenauthor=Y.+Pommierauthor=G.+Capranico&title=Topoisomerase+poisoning+activity+of+novel+disaccharide+anthracyclines&doi=10.1124%2Fmol.56.1.77"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase poisoning activity of novel disaccharide anthracyclines</span></div><div class="casAuthors">Guano, Fulvio; Pourquier, Philippe; Tinelli, Stella; Binaschi, Monica; Bigioni, Mario; Animati, Fabio; Manzini, Stefano; Zunino, Franco; Kohlhagen, Glenda; Pommier, Yves; Capranico, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-84</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Doxorubicin and idarubicin are very effective anticancer drugs in the treatment of human hematol. malignancies and solid tumors.  These agents are well known topoisomerase II poisons; however, some anthracycline analogs recently have been shown to poison topoisomerase I.  In the present work, we assayed novel disaccharide analogs and the parent drug, idarubicin, for their poisoning effects of human topoisomerase I and topoisomerases IIα and IIβ.  Drugs were evaluated with a DNA cleavage assay in vitro and with a yeast system to test whether the agents were able to poison the enzymes in vivo.  We have found that the test agents are potent poisons of both topoisomerases IIα and IIβ.  The axial orientation of the second sugar relative to the first one of the novel disaccharide analogs was shown to be required for poisoning activity and cytotoxicity.  Interestingly, idarubicin and the new analogs stimulated topoisomerase I-mediated DNA cleavage at low levels in vitro.  As expected, the cytotoxic level of the drug was highly affected by the content of topoisomerase II; nevertheless, the test agents had a yeast cell-killing activity that also was weakly dependent on cellular topoisomerase I content.  The results are relevant for the full understanding of the mol. mechanism of topoisomerase poisoning by anticancer drugs, and they define structural determinants of anthracyclines that may help in the rational design of new compds. directed against topoisomerase I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYw-4euo7PZ7Vg90H21EOLACvtfcHk0lgXOe0hKVFy7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksFOmtrc%253D&md5=3cecaa5ccb46a4ced61d0656c8145b3a</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1124%2Fmol.56.1.77&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.56.1.77%26sid%3Dliteratum%253Aachs%26aulast%3DGuano%26aufirst%3DF.%26aulast%3DPourquier%26aufirst%3DP.%26aulast%3DTinelli%26aufirst%3DS.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DBigioni%26aufirst%3DM.%26aulast%3DAnimati%26aufirst%3DF.%26aulast%3DManzini%26aufirst%3DS.%26aulast%3DZunino%26aufirst%3DF.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCapranico%26aufirst%3DG.%26atitle%3DTopoisomerase%2520poisoning%2520activity%2520of%2520novel%2520disaccharide%2520anthracyclines%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26issue%3D1%26spage%3D77%26epage%3D84%26doi%3D10.1124%2Fmol.56.1.77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissery, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saucier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisagni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavelle, F.</span></span> <span> </span><span class="NLM_article-title">Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5987</span>– <span class="NLM_lpage">5993</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8261412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2cXht1Cisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=5987-5993&issue=24&author=J.+F.+Riouauthor=P.+Fosseauthor=C.+H.+Nguyenauthor=A.+K.+Larsenauthor=M.+C.+Bisseryauthor=L.+Grondardauthor=J.+M.+Saucierauthor=E.+Bisagniauthor=F.+Lavelle&title=Intoplicine+%28RP+60475%29+and+its+derivatives%2C+a+new+class+of+antitumor+agents+inhibiting+both+topoisomerase+I+and+II+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities</span></div><div class="casAuthors">Riou, Jean Francois; Fosse, Philippe; Chi Hung Nguyen; Larsen, Annette Kragh; Bissery, Marie Christine; Grondard, Lucile; Saucier, Jean Marie; Bisagni, Emile; Lavelle, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5987-93</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Intoplicine (RP 60475, NSC 645008) (I) is an antitumor compd. of the 7H-benzo[e]pyrido[4,3-b]indole series which is now being tested in clin. trials.  Intoplicine and 22 analogs were evaluated for their effects on topoisomerase I- and II-mediated DNA cleavage reactions by using enzyme purified from calf thymus.  Site-specific DNA cleavage mediated by topoisomerase occurred with 7H-benzo[e]pyrido[4,3-b]indole derivs. but not with 11H-benzo[g]pyrido[4,3-b]indole derivs.  Site-specific DNA cleavage mediated by topoisomerase II occurred with derivs. having OH groups at the 3-position on the 7H-benzo[e]pyrido[4,3-b]indole ring or at the 4-position on the 11H-benzo[g]pyrido[4,3-b]indole ring.  Study of the relationships between the in vivo antitumor activity on P388 leukemia and the topoisomerase I- and/or II-mediated DNA cleavage activity revealed that the most highly active antitumor compds. possessed both topoisomerase I- and II-inhibitory properties.  Compds. selectively inhibiting either topoisomerase I or II were less active.  These results suggest that dual topoisomerase I and II inhibition is crit. for the antitumor activity of this new series of antitumor compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNYqdvrEdRfLVg90H21EOLACvtfcHk0lgXOe0hKVFy7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXht1Cisbw%253D&md5=2cbf243e21dbd1b76e971a848da8d1f4</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiou%26aufirst%3DJ.%2BF.%26aulast%3DFosse%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DC.%2BH.%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DBissery%26aufirst%3DM.%2BC.%26aulast%3DGrondard%26aufirst%3DL.%26aulast%3DSaucier%26aufirst%3DJ.%2BM.%26aulast%3DBisagni%26aufirst%3DE.%26aulast%3DLavelle%26aufirst%3DF.%26atitle%3DIntoplicine%2520%2528RP%252060475%2529%2520and%2520its%2520derivatives%252C%2520a%2520new%2520class%2520of%2520antitumor%2520agents%2520inhibiting%2520both%2520topoisomerase%2520I%2520and%2520II%2520activities%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26issue%3D24%26spage%3D5987%26epage%3D5993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelcnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span> <span> </span><span class="NLM_article-title">Recent developments of DNA poisons - human DNA topoisomerase IIα inhibitors - as anticancer agents</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2474</span>– <span class="NLM_lpage">2488</span>, <span class="refDoi"> DOI: 10.2174/1381612811319130016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1381612811319130016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23363399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2474-2488&issue=13&author=B.+Pogorelcnikauthor=A.+Perdihauthor=T.+Solmajer&title=Recent+developments+of+DNA+poisons+-+human+DNA+topoisomerase+II%CE%B1+inhibitors+-+as+anticancer+agents&doi=10.2174%2F1381612811319130016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments of DNA poisons - human DNA topoisomerase IIα inhibitors - as anticancer agents</span></div><div class="casAuthors">Pogorelcnik, Barbara; Perdih, Andrej; Solmajer, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2474-2488</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are an important family of enzymes that catalyze the induction of topol. changes in the DNA mol.  Their ability to modulate the topol. of the DNA makes DNA topoisomerases a key player in several vital cell processes such as replication, transcription, chromosome sepn. and segregation.  Consequently, they already represent an important collection of macromol. targets for some of the established anticancer drugs on the market as well as serve as templates in the development of novel anticancer drugs esp. supported by recent structural advances in the field.  The aim of this review is to provide an overview of the recent developments in the field of DNA poisons - a major class of human topoisomerase IIα inhibitors - of which several are already in clin. use.  Due to frequently experienced occurrence of serious side effects of these mols. during therapy, esp. cardiotoxicity issues, further drug design efforts were initiated already yielding novel promising compds. that have overcome this issue and already entered into clin. studies.  Some of the presented and discussed chem. classes include intercalators, non-intercalators and redox-dependent poisons of human topoisomerase IIα.  In particular, this review focuses on the currently available structure-based standpoint of mol. design and on the medicinal chemist's perspective of this field of anticancer drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC9ShTXwqB17Vg90H21EOLACvtfcHk0lgajyfgQFZvzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrw%253D&md5=77e1705a6cf13bda0216d3c73f8ddac9</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.2174%2F1381612811319130016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319130016%26sid%3Dliteratum%253Aachs%26aulast%3DPogorelcnik%26aufirst%3DB.%26aulast%3DPerdih%26aufirst%3DA.%26aulast%3DSolmajer%26aufirst%3DT.%26atitle%3DRecent%2520developments%2520of%2520DNA%2520poisons%2520-%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520inhibitors%2520-%2520as%2520anticancer%2520agents%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26issue%3D13%26spage%3D2474%26epage%3D2488%26doi%3D10.2174%2F1381612811319130016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span>WHO
drug information. Volume  <span class="NLM_volume">1</span>, Number 4, <span class="NLM_year">1987</span>, Recommended INN list 27. <a href="http://apps.who.int/medicinedocs/index/assoc/h5775e/h5775e.pdf" class="extLink">http://apps.who.int/medicinedocs/index/assoc/h5775e/h5775e.pdf</a> (accessed April 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=WHO%0Adrug+information.+Volume+1%2C+Number+4%2C+1987%2C+Recommended+INN+list+27.+http%3A%2F%2Fapps.who.int%2Fmedicinedocs%2Findex%2Fassoc%2Fh5775e%2Fh5775e.pdf+%28accessed+April+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26volume%3D1%26date%3D1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span class="NLM_publisher-name">U.S. National Library of Medicine</span>. Search result
for aclarubicin. <a href="https://clinicaltrials.gov/ct2/results?term=aclarubicin&amp;rank=1#rowId0" class="extLink">https://clinicaltrials.gov/ct2/results?term=aclarubicin&rank=1#rowId0</a> (accessed April 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+U.S.+National+Library+of+Medicine.+Search+result%0Afor+aclarubicin.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3Daclarubicin%26rank%3D1%23rowId0+%28accessed+April+20%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26pub%3DU.S.%2520National%2520Library%2520of%2520Medicine" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis, GC selective DNA binding and topoisomerase II inhibition activities of ruthenium(II) polypyridyl complex containing 11-aminopteridino[6,7-f][1,10]phenanthrolin-13(12<i>H</i>)-one</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1059</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2007.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.jinorgbio.2007.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18295337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVyjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=1050-1059&issue=5%E2%80%936&author=F.+Gaoauthor=H.+Chaoauthor=F.+Zhouauthor=X.+Chenauthor=Y.+F.+Weiauthor=L.+N.+Ji&title=Synthesis%2C+GC+selective+DNA+binding+and+topoisomerase+II+inhibition+activities+of+ruthenium%28II%29+polypyridyl+complex+containing+11-aminopteridino%5B6%2C7-f%5D%5B1%2C10%5Dphenanthrolin-13%2812H%29-one&doi=10.1016%2Fj.jinorgbio.2007.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, GC selective DNA binding and topoisomerase II inhibition activities of ruthenium(II) polypyridyl complex containing 11-aminopteridino[6,7-f][1,10]phenanthrolin-13(12H)-one</span></div><div class="casAuthors">Gao, Feng; Chao, Hui; Zhou, Feng; Chen, Xin; Wei, Yuan-Fang; Ji, Liang-Nian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">1050-1059</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A DNA-intercalating Ru(II) polypyridyl complex [Ru(bpy)2(appo)]2+ (bpy = 2,2'-bipyridine; appo = 11-aminopteridino[6,7-f][1,10]phenanthrolin-13(12H)-one) has been synthesized and characterized by elemental anal., electrospray mass spectra, 1H NMR, UV/Vis spectrum, fluorescent spectrum and electrochem.  The DNA-binding, photocleavage, and topoisomerase inhibition of the complex was studied.  Interestingly, the complex binds to DNA via an intercalative mode with preference for GC sequences and cleaves the pBR322 DNA upon irradn.  In addn., the complex shows high inhibition activity against topoisomerase II by interfere the DNA religation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdmzHnUcpiJrVg90H21EOLACvtfcHk0lgajyfgQFZvzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVyjs7c%253D&md5=ca8943da37c82a045904daa8a79e2eb3</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2007.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2007.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DF.%26aulast%3DChao%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DY.%2BF.%26aulast%3DJi%26aufirst%3DL.%2BN.%26atitle%3DSynthesis%252C%2520GC%2520selective%2520DNA%2520binding%2520and%2520topoisomerase%2520II%2520inhibition%2520activities%2520of%2520ruthenium%2528II%2529%2520polypyridyl%2520complex%2520containing%252011-aminopteridino%255B6%252C7-f%255D%255B1%252C10%255Dphenanthrolin-13%252812H%2529-one%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2008%26volume%3D102%26issue%3D5%25E2%2580%25936%26spage%3D1050%26epage%3D1059%26doi%3D10.1016%2Fj.jinorgbio.2007.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span> <span> </span><span class="NLM_article-title">DNA-binding, topoisomerases I and II inhibition and <i>in-vitro</i> cytotoxicity of ruthenium(II) polypyridyl complexes: [Ru(dppz)2L](2+) (L = dppz-11-CO2Me and dppz)</span>. <i>Spectrochim. Acta, Part A</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.saa.2014.06.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.saa.2014.06.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25062055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KlsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=101-109&author=X.+Heauthor=L.+Jinauthor=L.+Tan&title=DNA-binding%2C+topoisomerases+I+and+II+inhibition+and+in-vitro+cytotoxicity+of+ruthenium%28II%29+polypyridyl+complexes%3A+%5BRu%28dppz%292L%5D%282%2B%29+%28L+%3D+dppz-11-CO2Me+and+dppz%29&doi=10.1016%2Fj.saa.2014.06.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-binding, topoisomerases I and II inhibition and in vitro cytotoxicity of ruthenium(II) polypyridyl complexes: [Ru(dppz)2L]2+ (L = dppz-11-CO2Me and dppz)</span></div><div class="casAuthors">He, Xiaojun; Jin, Lianhe; Tan, Lifeng</div><div class="citationInfo"><span class="NLM_cas:title">Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101-109</span>CODEN:
                <span class="NLM_cas:coden">SAMCAS</span>;
        ISSN:<span class="NLM_cas:issn">1386-1425</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two ruthenium(II) polypyridyl complexes, [Ru(dppz)2dppz-11-CO2Me](ClO4)2 (Ru1) and [Ru(dppz)3](ClO4)2 (Ru2), have been synthesized and characterized (dppz = dipyrido[3,2-a:2',3'-c]phenazine; dppz-11-CO2Me = Me dipyrido[3,2-a:2',3'-c]phenazine-11-carboxylate).  The spectral characteristics of Ru1 and Ru2 were investigated by fluorescence spectroscopy and revealed that both complexes were sensitive to solvent polarity.  The binding properties of the two complexes towards calf-thymus DNA (CT-DNA) have been investigated by different spectrophotometric methods and viscosity measurements, indicating that both complexes bind to CT-DNA by intercalation, but with different binding affinities.  Topoisomerase inhibition and DNA strand passage assay demonstrates that the two complexes are dual inhibitors of topoisomerases I and IIa.  However, the cytotoxicity of both complexes has been evaluated by MTT assays and Giemsa staining expts.  The main results reveal that the ester functional group has a significant effect on the DNA-binding affinities and topoisomerases inhibition effects of Ru1 and Ru2, and further advance the authors' knowledge on the DNA-binding and topoisomerase inhibition by Ru(II) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppit6q12DgL7Vg90H21EOLACvtfcHk0lgajyfgQFZvzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KlsrbL&md5=8e0cc6e987cdf93432132daa43790600</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.saa.2014.06.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.saa.2014.06.147%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DL.%26atitle%3DDNA-binding%252C%2520topoisomerases%2520I%2520and%2520II%2520inhibition%2520and%2520in-vitro%2520cytotoxicity%2520of%2520ruthenium%2528II%2529%2520polypyridyl%2520complexes%253A%2520%255BRu%2528dppz%25292L%255D%25282%252B%2529%2520%2528L%2520%253D%2520dppz-11-CO2Me%2520and%2520dppz%2529%26jtitle%3DSpectrochim.%2520Acta%252C%2520Part%2520A%26date%3D2015%26volume%3D135%26spage%3D101%26epage%3D109%26doi%3D10.1016%2Fj.saa.2014.06.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span> <span> </span><span class="NLM_article-title">Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f][1,10]phenanthroline derivatives</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2013.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.jinorgbio.2013.09.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24145066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWju7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2014&pages=15-27&author=Y.+C.+Wangauthor=C.+Qianauthor=Z.+L.+Pengauthor=X.+J.+Houauthor=L.+L.+Wangauthor=H.+Chaoauthor=L.+N.+Ji&title=Dual+topoisomerase+I+and+II+poisoning+by+chiral+Ru%28II%29+complexes+containing+2-thiophenylimidazo%5B4%2C5-f%5D%5B1%2C10%5Dphenanthroline+derivatives&doi=10.1016%2Fj.jinorgbio.2013.09.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f|[1,10|phenanthroline derivatives</span></div><div class="casAuthors">Wang, Yu-Chuan; Qian, Chen; Peng, Zai-Li; Hou, Xiao-Juan; Wang, Li-Li; Chao, Hui; Ji, Liang-Nian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of chiral RuII complexes bearing thiophene ligands were synthesized and characterized.  Both RuII complexes Δ/Λ-Rubpy2pscl|2+ Δ/Λ-1 and Δ/Λ-Rubpy2psbr|2+ Δ/Λ-2 bpy = 2,2'-bipyridine, pscl = 2-5-chlorothiophen-2-ylimidazo4,5-f|1,10|phenanthroline, psbr = 2-5-bromothiophen-2-ylimidazo4,5-f|1,10|phenanthroline showed antitumor activities against A549, HepG2 and BEL-7402 tumor cell lines, esp. HeLa tumor cell line.  Moreover, Δ enantiomers were more active than Λ enantiomers, accounting for the different cellular uptake.  In addn., with the extension of time, these enantiomers could finally accumulate in the nucleus, suggesting that nucleic acids were the cellular target of these enantiomers.  The DNA-binding behaviors of complexes were studied using spectroscopic and viscosity measurements.  Results suggested that four complexes could bind to DNA in an intercalative mode but no obvious DNA-binding selectivity between the enantiomers was obsd.  Topoisomerase inhibition and DNA religation assay confirmed that four complexes acted as efficient dual topoisomerase I and II poisons, DNA strand breaks had also been obsd. from alk. single cell gel electrophoresis comet assay. Δ-1 and Δ-2 inhibited the growth of HeLa cells through the induction of apoptotic cell death, as evidenced by the Alexa Fluor 488 annexin V staining assays and flow cytometry anal.  The results demonstrated that Δ/Λ-1 and Δ/Λ-2 acted as dual topoisomerase I and II poisons and caused DNA damage that could lead to cell cycle arrest by apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5JeacrSJiWrVg90H21EOLACvtfcHk0liNRo0thGDfKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWju7vN&md5=6401d758e09548ffdb3ed7aebb6889e8</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2013.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2013.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DZ.%2BL.%26aulast%3DHou%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DChao%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DL.%2BN.%26atitle%3DDual%2520topoisomerase%2520I%2520and%2520II%2520poisoning%2520by%2520chiral%2520Ru%2528II%2529%2520complexes%2520containing%25202-thiophenylimidazo%255B4%252C5-f%255D%255B1%252C10%255Dphenanthroline%2520derivatives%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2014%26volume%3D130%26spage%3D15%26epage%3D27%26doi%3D10.1016%2Fj.jinorgbio.2013.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A perspective on multi-target drug discovery and design for complex diseases</span>. <i>Clinical and Translational Medicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29340951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=3&issue=1&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+perspective+on+multi-target+drug+discovery+and+design+for+complex+diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on multi-target drug discovery and design for complex diseases</span></div><div class="casAuthors">Ramsay Rona R; Popovic-Nikolic Marija R; Nikolic Katarina; Uliassi Elisa; Bolognesi Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract">Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors.  Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds.  Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done.  These approaches depend on the prior identification of clinically and biologically validated targets.  This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJhSGsWpifCZcXNb62YGmbfW6udTcc2eYazj9-O5OR17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D&md5=5b05a73a3bbc955c77b9b2df93deb946</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520perspective%2520on%2520multi-target%2520drug%2520discovery%2520and%2520design%2520for%2520complex%2520diseases%26jtitle%3DClinical%2520and%2520Translational%2520Medicine%26date%3D2018%26volume%3D7%26issue%3D1%26spage%3D3%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korcsmaros, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szalay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csermely, P.</span></span> <span> </span><span class="NLM_article-title">How to design multi-target drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1517/17460441.2.6.799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1517%2F17460441.2.6.799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23488998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptFGru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=799-808&issue=6&author=T.+Korcsmarosauthor=M.+S.+Szalayauthor=C.+Bodeauthor=I.+A.+Kovacsauthor=P.+Csermely&title=How+to+design+multi-target+drugs&doi=10.1517%2F17460441.2.6.799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">How to design multi-target drugs: target search options in cellular networks</span></div><div class="casAuthors">Korcsmaros, Tamas; Szalay, Mate S.; Bode, Csaba; Kovacs, Istvan A.; Csermely, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">799-808</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Despite improved rational drug design and a remarkable progress in genomic, proteomic and high-throughput screening methods, the no. of novel, single-target drugs has fallen far behind expectations during the past decade.  Multi-target drugs multiply the no. of pharmacol. relevant target mols. by introducing a set of indirect, network-dependent effects.  Parallel with this, the low-affinity binding of multi-target drugs eases the constraints of druggability and significantly increases the size of the druggable proteome.  These effects tremendously expand the no. of potential drug targets and introduce novel classes of multi-target drugs with smaller side effects and toxicity.  Here, the authors review the recent progress in this field, compare possible network attack strategies and propose several methods to find target-sets for multi-target drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGAOF7QblLM7Vg90H21EOLACvtfcHk0lgT-ejgnIJAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptFGru7s%253D&md5=7d132e26ec4f481ee64392f457a2dd6c</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.6.799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.6.799%26sid%3Dliteratum%253Aachs%26aulast%3DKorcsmaros%26aufirst%3DT.%26aulast%3DSzalay%26aufirst%3DM.%2BS.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DKovacs%26aufirst%3DI.%2BA.%26aulast%3DCsermely%26aufirst%3DP.%26atitle%3DHow%2520to%2520design%2520multi-target%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D799%26epage%3D808%26doi%3D10.1517%2F17460441.2.6.799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span> <span> </span><span class="NLM_article-title">Antitumor agents - CLXXIII. Synthesis and evaluation of camptothecin-4 beta-amino-4′-<i>O</i>-demethyl epipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases and as cytotoxic agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1488</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(97)00102-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0968-0896%2897%2900102-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9313854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVGku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1997&pages=1481-1488&issue=8&author=K.+F.+Bastowauthor=H.+K.+Wangauthor=Y.+C.+Chengauthor=K.+H.+Lee&title=Antitumor+agents+-+CLXXIII.+Synthesis+and+evaluation+of+camptothecin-4+beta-amino-4%E2%80%B2-O-demethyl+epipodophyllotoxin+conjugates+as+inhibitors+of+mammalian+DNA+topoisomerases+and+as+cytotoxic+agents&doi=10.1016%2FS0968-0896%2897%2900102-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor agents-CLXXIII. Synthesis and evaluation of camptothecin-4β-amino-4'-O-demethyl epipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases I and as cytotoxic agents</span></div><div class="casAuthors">Bastow, Kenneth F.; Wang, Hui-Kang; Cheng, Yung-Chi; Lee, Kuo-Hsiung</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1481-1488</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Two conjugates composed of a camptothecin and a 4'-O-demethyl epipodophyllotoxin deriv. joined by an imine linkage were prepd. and evaluated as inhibitors of mammalian DNA topoisomerases I and II.  Target compds. stimulated cleavable complex formation with both types of enzyme in vitro although activities were reduced at least 2-fold relative to the activity of unconjugated constituents.  The behavior of the most active conjugate as an inhibitor of cell growth closely resembled both topoisomerase I- and II- inhibitory components in that the compd. displayed a combined spectrum of activity against various drug-resistant KB sublines.  Cytotoxic activity and selectivity were largely retained through conjugation, the exception being a lower than expected activity against a pleiotrophic multidrug-resistant subline.  The induced levels and the properties of cellular protein-assocd. DNA complexes were consistent with topoisomerase involvement and with the in vitro cleavage assay results.  Based on the present findings, conjugation afforded cleavable complex-forming topoisomerase inhibitors which display dual target specificity and a broad spectrum of cytotoxic activity against drug-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdGOBboPvKS7Vg90H21EOLACvtfcHk0lgT-ejgnIJAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVGku7s%253D&md5=6715e0cf9ffe34007edce360407afbce</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2897%2900102-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252897%252900102-8%26sid%3Dliteratum%253Aachs%26aulast%3DBastow%26aufirst%3DK.%2BF.%26aulast%3DWang%26aufirst%3DH.%2BK.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26aulast%3DLee%26aufirst%3DK.%2BH.%26atitle%3DAntitumor%2520agents%2520-%2520CLXXIII.%2520Synthesis%2520and%2520evaluation%2520of%2520camptothecin-4%2520beta-amino-4%25E2%2580%25B2-O-demethyl%2520epipodophyllotoxin%2520conjugates%2520as%2520inhibitors%2520of%2520mammalian%2520DNA%2520topoisomerases%2520and%2520as%2520cytotoxic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1997%26volume%3D5%26issue%3D8%26spage%3D1481%26epage%3D1488%26doi%3D10.1016%2FS0968-0896%2897%2900102-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Troconiz, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendros, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prunonosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Mayoral, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peraire, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Principe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delavault, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvitkovic, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesimple, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetic/ pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a phase I dose finding study in patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1007/s00280-012-1906-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs00280-012-1906-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=22699813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2012&pages=239-250&issue=2&author=I.+F.+Troconizauthor=J.+M.+Cendrosauthor=E.+Sotoauthor=J.+Prunonosaauthor=A.+Perez-Mayoralauthor=C.+Peraireauthor=P.+Principeauthor=P.+Delavaultauthor=F.+Cvitkovicauthor=T.+Lesimpleauthor=R.+Obach&title=Population+pharmacokinetic%2F+pharmacodynamic+modeling+of+drug-induced+adverse+effects+of+a+novel+homocamptothecin+analog%2C+elomotecan+%28BN80927%29%2C+in+a+phase+I+dose+finding+study+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-012-1906-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors</span></div><div class="casAuthors">Troconiz, Inaki F.; Cendros, Josep-Maria; Soto, Elena; Prunonosa, Joan; Perez-Mayoral, Ana; Peraire, Concepcion; Principe, Paola; Delavault, Patrick; Cvitkovic, Frederique; Lesimple, Thierry; Obach, Rosendo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-250</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">To characterize the pharmacokinetic profile of elomotecan, a novel homocamptothecin analog, evaluate the dose-limiting toxicities, and establish the relationship between exposure and toxicity in the first Phase I study in patients with advanced malignant solid tumors.  Preliminary antitumor efficacy results are also provided.  Elomotecan was administered as a 30-min i.v. infusion at doses ranging from 1.5 to 75 mg once every 3 wk to 56 patients with advanced solid tumors.  Plasma concn. data and adverse effects were modeled using the population approach.  Elomotecan showed linear pharmacokinetics, and clearance was decreased with age.  The model predicts a 47 and 61 % redn. in CL for patients aged 60 and 80 years, resp., when compared with younger patients (30 years).  Neutropenia represented the dose-limiting toxicity.  The max. tolerated dose and the recommended dose (RD) were 75 and 60 mg, resp.  Elomotecan elicited a 20, 5, 2, and 2 % severe (grade 4) neutropenia, asthenia, nausea, and vomiting at the RD, resp.  Of the subjects in the RD cohort, 41.7 % had a stable disease mean duration of 123.6 ± 43.4 days.  The pharmacokinetic parameters and the toxicity pattern of elomotecan suggest that this novel homocamptothecin analog should be further explored in the clin. setting using a dose of 60 mg administered as a 30-min i.v. infusion, once every 3 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLbTogIgYLaLVg90H21EOLACvtfcHk0lgT-ejgnIJAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhsb3M&md5=f21ecb02aedc90e42f2fdc93ff14f680</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1906-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1906-y%26sid%3Dliteratum%253Aachs%26aulast%3DTroconiz%26aufirst%3DI.%2BF.%26aulast%3DCendros%26aufirst%3DJ.%2BM.%26aulast%3DSoto%26aufirst%3DE.%26aulast%3DPrunonosa%26aufirst%3DJ.%26aulast%3DPerez-Mayoral%26aufirst%3DA.%26aulast%3DPeraire%26aufirst%3DC.%26aulast%3DPrincipe%26aufirst%3DP.%26aulast%3DDelavault%26aufirst%3DP.%26aulast%3DCvitkovic%26aufirst%3DF.%26aulast%3DLesimple%26aufirst%3DT.%26aulast%3DObach%26aufirst%3DR.%26atitle%3DPopulation%2520pharmacokinetic%252F%2520pharmacodynamic%2520modeling%2520of%2520drug-induced%2520adverse%2520effects%2520of%2520a%2520novel%2520homocamptothecin%2520analog%252C%2520elomotecan%2520%2528BN80927%2529%252C%2520in%2520a%2520phase%2520I%2520dose%2520finding%2520study%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D70%26issue%3D2%26spage%3D239%26epage%3D250%26doi%3D10.1007%2Fs00280-012-1906-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennouna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefresne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douillard, J. Y.</span></span> <span> </span><span class="NLM_article-title">First-in-man study of tafluposide, a novel inhibitor of topoisomerase I and II</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">A138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17237274" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=A138&issue=11&author=J.+P.+Delordauthor=J.+Bennounaauthor=V.+Di%C3%A9rasauthor=M.+Camponeauthor=F.+Lefresneauthor=V.+Aslanisauthor=J.+Y.+Douillard&title=First-in-man+study+of+tafluposide%2C+a+novel+inhibitor+of+topoisomerase+I+and+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelord%26aufirst%3DJ.%2BP.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DLefresne%26aufirst%3DF.%26aulast%3DAslanis%26aufirst%3DV.%26aulast%3DDouillard%26aufirst%3DJ.%2BY.%26atitle%3DFirst-in-man%2520study%2520of%2520tafluposide%252C%2520a%2520novel%2520inhibitor%2520of%2520topoisomerase%2520I%2520and%2520II%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D11%26spage%3DA138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span>AdisInsight. <span class="NLM_publisher-name">Springer Science</span>. <a href="https://adisinsight.springer.com/drugs/800012192" class="extLink">https://adisinsight.springer.com/drugs/800012192</a> (accessed April 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AdisInsight.+Springer+Science.+https%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800012192+%28accessed+April+20%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26pub%3DSpringer%2520Science" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span class="NLM_publisher-name">U.S. National Library of Medicine</span>. Search result
for elomotecan. <a href="https://clinicaltrials.gov/ct2/show/record/NCT01435096?term=Elomotecan&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/record/NCT01435096?term=Elomotecan&rank=1</a> (accessed April 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+U.S.+National+Library+of+Medicine.+Search+result%0Afor+elomotecan.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT01435096%3Fterm%3DElomotecan%26rank%3D1+%28accessed+April+20%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26pub%3DU.S.%2520National%2520Library%2520of%2520Medicine" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: synthesis, biological evaluation and 3D-QSAR study</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2016.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26945111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1egu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=228-245&author=R.+Karkiauthor=K.+Y.+Junauthor=T.+M.+Kadayatauthor=S.+Shinauthor=T.+B.+Thapa+Magarauthor=G.+Bistauthor=A.+Shresthaauthor=Y.+Naauthor=Y.+Kwonauthor=E.+S.+Lee&title=A+new+series+of+2-phenol-4-aryl-6-chlorophenyl+pyridine+derivatives+as+dual+topoisomerase+I%2FII+inhibitors%3A+synthesis%2C+biological+evaluation+and+3D-QSAR+study&doi=10.1016%2Fj.ejmech.2016.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study</span></div><div class="casAuthors">Karki, Radha; Jun, Kyu-Yeon; Kadayat, Tara Man; Shin, Somin; Thapa Magar, Til Bahadur; Bist, Ganesh; Shrestha, Aarajana; Na, Younghwa; Kwon, Youngjoo; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-245</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As a continuous effort to develop novel antitumor agents, a new series of forty-five 2-phenol-4-aryl-6-chlorophenyl pyridine compds. I (R1 = 2-HOC6H4, 3-HOC6H4, 4-HOC6H4; R2 = Ph, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl; R3 = 2-ClC6H4, 3-ClC6H4, 4-ClC6H4) were synthesized and evaluated for cytotoxicity against four different human cancer cell lines (DU145, HCT15, T47D, and HeLa), and topoisomerase I and II inhibitory activity.  Several compds. I (R1 = 3-HOC6H4, 4-HOC6H4; R2 = Ph, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl; R3 = 2-ClC6H4, 3-ClC6H4, 4-ClC6H4) displayed strong to moderate dual topoisomerase I and II inhibitory activity at 100 μM.  It was obsd. that hydroxyl and chlorine moiety at meta or para position of Ph ring is favorable for dual topoisomerase inhibitory activity and cytotoxicity.  Most of the compds. I displayed stronger cytotoxicities than those of all pos. controls against the HCT15 and T47D cell lines.  For investigation of the structure-activity relationships, a 3D-QSAR anal. using the method of comparative mol. field anal. (CoMFA) was performed.  The generated 3D contour maps can be used for further rational design of novel terpyridine derivs. I as highly selective and potent cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeg-6-GpSiTrVg90H21EOLACvtfcHk0liqAVK4xGmReQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1egu70%253D&md5=1d85da38e23e3c8d9e35188d189c64d8</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DA%2520new%2520series%2520of%25202-phenol-4-aryl-6-chlorophenyl%2520pyridine%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%252FII%2520inhibitors%253A%2520synthesis%252C%2520biological%2520evaluation%2520and%25203D-QSAR%2520study%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D113%26spage%3D228%26epage%3D245%26doi%3D10.1016%2Fj.ejmech.2016.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, topoisomerase I inhibition and structure-activity relationship study of 2,4,6-trisubstituted pyridine derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.11.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmcl.2003.11.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=14980693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFelsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1333-1337&issue=5&author=L.+X.+Zhaoauthor=Y.+S.+Moonauthor=A.+Basnetauthor=E.+K.+Kimauthor=Y.+Jahngauthor=J.+G.+Parkauthor=T.+C.+Jeongauthor=W.+J.+Choauthor=S.+U.+Choiauthor=C.+O.+Leeauthor=S.+Y.+Leeauthor=C.+S.+Leeauthor=E.+S.+Lee&title=Synthesis%2C+topoisomerase+I+inhibition+and+structure-activity+relationship+study+of+2%2C4%2C6-trisubstituted+pyridine+derivatives&doi=10.1016%2Fj.bmcl.2003.11.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, topoisomerase I inhibition and structure-activity relationship study of 2,4,6-trisubstituted pyridine derivatives</span></div><div class="casAuthors">Zhao, Long-Xuan; Moon, Yoon-Soo; Basnet, Arjun; Kim, Eun-kyung; Jahng, Yurngdong; Park, Jae Gyu; Jeong, Tae Cheon; Cho, Won-Jea; Choi, Sang-Un; Lee, Chong Ock; Lee, Sun-Young; Lee, Chong-Soon; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">For the development of new anticancer agents, 2,4,6-trisubstituted pyridines carrying Ph, 2-pyridyl, 2-furyl, 2-thienyl, 2-furylvinyl and 2-thienylvinyl substituents were prepd. and evaluated for their topoisomerase I inhibitory activity.  Among the thirteen prepd. compds., four compds. exhibited strong topoisomerase I inhibitory activity.  A structure-activity relationship study indicated that the 2-thienyl-4-furylpyridine skeleton was important for topoisomerase I inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_JMnIZ_8ES7Vg90H21EOLACvtfcHk0liqAVK4xGmReQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFelsrc%253D&md5=c32796b3ef09a22f7d697fe903599af1</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.11.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.11.084%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%2BX.%26aulast%3DMoon%26aufirst%3DY.%2BS.%26aulast%3DBasnet%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DE.%2BK.%26aulast%3DJahng%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DJ.%2BG.%26aulast%3DJeong%26aufirst%3DT.%2BC.%26aulast%3DCho%26aufirst%3DW.%2BJ.%26aulast%3DChoi%26aufirst%3DS.%2BU.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DSynthesis%252C%2520topoisomerase%2520I%2520inhibition%2520and%2520structure-activity%2520relationship%2520study%2520of%25202%252C4%252C6-trisubstituted%2520pyridine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D5%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2003.11.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.10.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmc.2009.10.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19939682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFykurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=377-386&issue=1&author=P.+Thapaauthor=R.+Karkiauthor=U.+Thapaauthor=Y.+Jahngauthor=M.+J.+Jungauthor=J.+M.+Namauthor=Y.+Naauthor=Y.+Kwonauthor=E.+S.+Lee&title=2-Thienyl-4-furyl-6-aryl+pyridine+derivatives%3A+synthesis%2C+topoisomerase+I+and+II+inhibitory+activity%2C+cytotoxicity%2C+and+structure-activity+relationship+study&doi=10.1016%2Fj.bmc.2009.10.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">2-Thienyl-4-furyl-6-aryl pyridine derivatives: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study</span></div><div class="casAuthors">Thapa, Pritam; Karki, Radha; Thapa, Uttam; Jahng, Yurngdong; Jung, Mi-Ja; Nam, Jung Min; Na, Younghwa; Kwon, Youngjoo; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">377-386</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Designed and synthesized 60 2-thienyl-4-furyl-6-aryl pyridine derivs. were evaluated for their topoisomerase I and II inhibitory activities at 20 μM and 100 μM and cytotoxicity against several human cancer cell lines.  Compds. 8 (I), 9, 11-29 showed significant topoisomerase II inhibitory activity and compds. 10 and 11 showed significant topoisomerase I inhibitory activity.  Most of the compds. (7-21) possessing 2-(5-chlorothiophen-2-yl)-4-(furan-3-yl) moiety showed higher or similar cytotoxicity against HCT15 cell line as compared to stds.  Most of the selected compds. displayed moderate cytotoxicity against MCF-7, HeLa, DU145, and K562 cell lines.  Structure-activity relationship study revealed that 2-(5-chlorothiophen-2-yl)-4-(furan-3-yl) moiety has an important role in displaying biol. activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps7zeBj2eZmbVg90H21EOLACvtfcHk0lgtNYuJxQAUIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFykurjL&md5=076ed7207901c120269a5bc2095b45d9</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.10.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.10.049%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DThapa%26aufirst%3DU.%26aulast%3DJahng%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DM.%2BJ.%26aulast%3DNam%26aufirst%3DJ.%2BM.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3D2-Thienyl-4-furyl-6-aryl%2520pyridine%2520derivatives%253A%2520synthesis%252C%2520topoisomerase%2520I%2520and%2520II%2520inhibitory%2520activity%252C%2520cytotoxicity%252C%2520and%2520structure-activity%2520relationship%2520study%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26issue%3D1%26spage%3D377%26epage%3D386%26doi%3D10.1016%2Fj.bmc.2009.10.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.03.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2017.03.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28384547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslejtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2017&pages=69-84&author=G.+Bistauthor=S.+Parkauthor=C.+Songauthor=T.+B.+Thapa+Magarauthor=A.+Shresthaauthor=Y.+Kwonauthor=E.+S.+Lee&title=Dihydroxylated+2%2C6-diphenyl-4-chlorophenylpyridines%3A+topoisomerase+I+and+II%CE%B1+dual+inhibitors+with+DNA+non-intercalative+catalytic+activity&doi=10.1016%2Fj.ejmech.2017.03.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity</span></div><div class="casAuthors">Bist, Ganesh; Park, Seojeong; Song, Chanju; Thapa Magar, Til Bahadur; Shrestha, Aarajana; Kwon, Youngjoo; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-84</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new series of eighteen dihydroxylated 2,6-diphenyl-phenylpyridines I were systematically designed, prepd., and investigated for their topoisomerase (topo) I and IIα inhibitory properties and antiproliferative effect in three different human cancer cell lines (HCT15, T47D, and HeLa).  Compds. I [R1 = R3 = 3-OH, 4-OH; R2 = 2-Cl, 3-Cl, 4-Cl] which possess a meta- or para-phenol on 2-, or 6-position of central pyridine ring showed significant dual topo I and topo IIα inhibitory activities with strong antiproliferative activities against all the tested human cancer cell lines.  However, compds. I [R1 = 2-OH; R3 = 2-OH, 3-OH, 4-OH; R2 = 2-Cl, 3-Cl, 4-Cl] which possess an ortho-phenol on 2-, or 6-position of central pyridine ring did not show significant topo I and topo IIα inhibitory activities but displayed moderate antiproliferative activities against all the tested human cancer cell lines.  Compd. I [R1 = R3 = 3-OH; R2 = 3-Cl] exhibited the highest antiproliferative potency as much as 348.5 and 105 times compared to etoposide and camptothecin, resp., in T47D cancer cell line.  The structure-activity relationship study revealed that the para position of a hydroxyl group at 2-and 6-Ph ring and chlorine atom at the para position of 4-Ph ring of the central pyridine exhibited the most significant topo I and topo IIα inhibition, which might indicate introduction of the chlorine atom at the Ph ring of 4-pyridine had an important role as dual inhibitors of topo I and topo IIα.  Compd. I [R1 = R3 = 4-OH, R2 = 4-Cl] which showed the most potent dual topo I and topo IIα inhibition with strong antiproliferative activity in T47D cell line was selected to perform further study on the mechanism of action, which revealed that compd. I [R1 = R3 = 4-OH, R2 = 4-Cl] functions as a potent DNA non-intercalative catalytic topo I and IIα dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZBmm2O2IZrrVg90H21EOLACvtfcHk0lgtNYuJxQAUIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslejtL8%253D&md5=81d5d8cee74161de7ddf670bdb26c648</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DBist%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DDihydroxylated%25202%252C6-diphenyl-4-chlorophenylpyridines%253A%2520topoisomerase%2520I%2520and%2520II%25CE%25B1%2520dual%2520inhibitors%2520with%2520DNA%2520non-intercalative%2520catalytic%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D133%26spage%3D69%26epage%3D84%26doi%3D10.1016%2Fj.ejmech.2017.03.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Rational design, synthesis, and evaluation of novel 2,4-chloro- and hydroxy-substituted diphenyl benzofuro[3,2-b]pyridines: non-intercalative catalytic topoisomerase I and II dual inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2017.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28068603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=318-333&author=S.+Parkauthor=T.+B.+Thapa+Magarauthor=T.+M.+Kadayatauthor=H.+J.+Leeauthor=G.+Bistauthor=A.+Shresthaauthor=E.+S.+Leeauthor=Y.+Kwon&title=Rational+design%2C+synthesis%2C+and+evaluation+of+novel+2%2C4-chloro-+and+hydroxy-substituted+diphenyl+benzofuro%5B3%2C2-b%5Dpyridines%3A+non-intercalative+catalytic+topoisomerase+I+and+II+dual+inhibitor&doi=10.1016%2Fj.ejmech.2017.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor</span></div><div class="casAuthors">Park, Seojeong; Thapa Magar, Til Bahadur; Kadayat, Tara Man; Lee, Hwa Jong; Bist, Ganesh; Shrestha, Aarajana; Lee, Eung-Seok; Kwon, Youngjoo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">318-333</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel series of conformationally constrained 2,4-chloro- and hydroxy-substituted di-Ph benzofuro[3,2-b]pyridines were rationally designed and synthesized.  Their biol. activities were evaluated for topoisomerase I and II inhibitory activity, and antiproliferative activity against several human cancer cell lines for the development of novel anticancer agents.  Most of the compds. with phenol moiety at 4-position of central pyridine exhibited significant dual topoisomerase I and II inhibitory activities, and strong antiproliferative activity in low micromolar range.  Structure activity relationship study suggested that phenol moiety at 4-position of the central pyridine regardless of chlorophenyl moiety at 2-position of the central pyridine has an important role in dual topoisomerase inhibitory activity as well as antiproliferative activity.  For investigation of mode of action for compd. I which displayed the most strong dual topoisomerase I and II inhibitory activity and antiproliferative activity against HCT15 cell, cleavable complex assay, band depletion assay, comet assay, and competitive EtBr displacement assays were performed.  This compd. functioned as non-intercalative catalytic topo I and II dual inhibitor.  In addn., compd. I induced apoptosis in HCT15 cells through increase of Bax, decrease of Bcl-2 and increase of PARP cleavage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-jJXfkEZ-RLVg90H21EOLACvtfcHk0lgtNYuJxQAUIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlChtw%253D%253D&md5=1967ec3a3aa95b573bb8f48886586ce6</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DRational%2520design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520novel%25202%252C4-chloro-%2520and%2520hydroxy-substituted%2520diphenyl%2520benzofuro%255B3%252C2-b%255Dpyridines%253A%2520non-intercalative%2520catalytic%2520topoisomerase%2520I%2520and%2520II%2520dual%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D318%26epage%3D333%26doi%3D10.1016%2Fj.ejmech.2017.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris-Natschke, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span> <span> </span><span class="NLM_article-title">Biologically active quinoline and quinazoline alkaloids, part I</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1002/med.21466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fmed.21466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28902434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=775-828&issue=3&author=X.+F.+Shangauthor=S.+L.+Morris-Natschkeauthor=Y.+Q.+Liuauthor=X.+Guoauthor=X.+S.+Xuauthor=M.+Gotoauthor=J.+C.+Liauthor=G.+Z.+Yangauthor=K.+H.+Lee&title=Biologically+active+quinoline+and+quinazoline+alkaloids%2C+part+I&doi=10.1002%2Fmed.21466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Biologically active quinoline and quinazoline alkaloids part I</span></div><div class="casAuthors">Shang, Xiao-Fei; Morris-Natschke, Susan L.; Liu, Ying-Qian; Guo, Xiao; Xu, Xiao-Shan; Goto, Masuo; Li, Jun-Cai; Yang, Guan-Zhou; Lee, Kuo-Hsiung</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">775-828</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Quinoline and quinazoline alkaloids, two important classes of N-based heterocyclic compds., have attracted tremendous attention from researchers worldwide since the 19th century.  Over the past 200 years, many compds. from these two classes were isolated from natural sources, and most of them and their modified analogs possess significant bioactivities.  Quinine and camptothecin are two of the most famous and important quinoline alkaloids, and their discoveries opened new areas in antimalarial and anticancer drug development, resp.  In this review, we survey the literature on bioactive alkaloids from these two classes and highlight research achievements prior to the year 2008 (Part I).  Over 200 mols. with a broad range of bioactivities, including antitumor, antimalarial, antibacterial and antifungal, antiparasitic and insecticidal, antiviral, antiplatelet, anti-inflammatory, herbicidal, antioxidant and other activities, were reviewed.  This survey should provide new clues or possibilities for the discovery of new and better drugs from the original naturally occurring quinoline and quinazoline alkaloids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS24I0edWKTbVg90H21EOLACvtfcHk0lj0nTZ4pJWqTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGmtL0%253D&md5=2abf4a48e13222579026e74a217ba6c4</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1002%2Fmed.21466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21466%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DX.%2BF.%26aulast%3DMorris-Natschke%26aufirst%3DS.%2BL.%26aulast%3DLiu%26aufirst%3DY.%2BQ.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%2BS.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DG.%2BZ.%26aulast%3DLee%26aufirst%3DK.%2BH.%26atitle%3DBiologically%2520active%2520quinoline%2520and%2520quinazoline%2520alkaloids%252C%2520part%2520I%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26issue%3D3%26spage%3D775%26epage%3D828%26doi%3D10.1002%2Fmed.21466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bligh, S. W.</span></span> <span> </span><span class="NLM_article-title">Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells</span>. <i>Phytomedicine</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1016/j.phymed.2012.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.phymed.2012.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=22402246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=618-624&issue=7&author=X.+Panauthor=J.+M.+Hartleyauthor=J.+A.+Hartleyauthor=K.+N.+Whiteauthor=Z.+Wangauthor=S.+W.+Bligh&title=Evodiamine%2C+a+dual+catalytic+inhibitor+of+type+I+and+II+topoisomerases%2C+exhibits+enhanced+inhibition+against+camptothecin+resistant+cells&doi=10.1016%2Fj.phymed.2012.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells</span></div><div class="casAuthors">Pan, Xiaobei; Hartley, Janet M.; Hartley, John A.; White, Kenneth N.; Wang, Zhengtao; Bligh, S. W. Annie</div><div class="citationInfo"><span class="NLM_cas:title">Phytomedicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">618-624</span>CODEN:
                <span class="NLM_cas:coden">PYTOEY</span>;
        ISSN:<span class="NLM_cas:issn">0944-7113</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">DNA topoisomerases are nuclear enzymes that are the targets for several anticancer drugs.  In this study we investigated the antiproliferative activity against human leukemia cell lines and the effects on topoisomerase I and II of evodiamine, which is a quinazolinocarboline alkaloid isolated from the fruit of a traditional Chinese medicinal plant, Evodia rutaecarpa.  We report here the anti-proliferative activity against human leukemia cells K562, THP-1, CCRF-CEM and CCRF-CEM/C1 and the inhibitory mechanism on human topoisomerases I and II, important anti-cancer drugs targets, of evodiamine.  Evodiamine failed to trap [Topo-DNA] complexes and induce any detectable DNA damage in cells, was unable to bind or intercalate DNA, and arrested cells in the G2/M phase.  The results suggest evodiamine is a dual catalytic inhibitor of topoisomerases I and II, with IC50 of 60.74 and 78.81 μM, resp.  The improved toxicity towards camptothecin resistant cells further supports its inhibitory mechanism which is different from camptothecin, and its therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4xTfr9qM8KbVg90H21EOLACvtfcHk0lj0nTZ4pJWqTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ans7w%253D&md5=1c20f3244e3434eeef44222e9f0bac40</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.phymed.2012.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phymed.2012.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DX.%26aulast%3DHartley%26aufirst%3DJ.%2BM.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BN.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBligh%26aufirst%3DS.%2BW.%26atitle%3DEvodiamine%252C%2520a%2520dual%2520catalytic%2520inhibitor%2520of%2520type%2520I%2520and%2520II%2520topoisomerases%252C%2520exhibits%2520enhanced%2520inhibition%2520against%2520camptothecin%2520resistant%2520cells%26jtitle%3DPhytomedicine%26date%3D2012%26volume%3D19%26issue%3D7%26spage%3D618%26epage%3D624%26doi%3D10.1016%2Fj.phymed.2012.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7593</span>– <span class="NLM_lpage">7613</span>, <span class="refDoi"> DOI: 10.1021/jm300605m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300605m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7593-7613&issue=17&author=G.+Dongauthor=S.+Wangauthor=Z.+Miaoauthor=J.+Yaoauthor=Y.+Zhangauthor=Z.+Guoauthor=W.+Zhangauthor=C.+Sheng&title=New+tricks+for+an+old+natural+product%3A+discovery+of+highly+potent+evodiamine+derivatives+as+novel+antitumor+agents+by+systemic+structure-activity+relationship+analysis+and+biological+evaluations&doi=10.1021%2Fjm300605m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives as Novel Antitumor Agents by Systemic Structure-Activity Relationship Analysis and Biological Evaluations</span></div><div class="casAuthors">Dong, Guoqiang; Wang, Shengzheng; Miao, Zhenyuan; Yao, Jianzhong; Zhang, Yongqiang; Guo, Zizhao; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7593-7613</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Evodiamine is a quinazolinocarboline alkaloid isolated from the fruits of traditional Chinese herb Evodiae fructus.  Herein, a library of novel evodiamine derivs. bearing various substitutions or modified scaffold were synthesized.  Among them, a no. of evodiamine derivs. showed substantial increase of the antitumor activity, with GI50 values lower than 3 nM.  Moreover, these highly potent compds. can effectively induce the apoptosis of A549 cells.  Interestingly, further computational target prediction calcns. in combination with biol. assays confirmed that the evodiamine derivs. acted by dual inhibition of topoisomerases I and II.  Moreover, several hydroxyl derivs., such as 10-hydroxyevodiamine and 3-amino-10-hydroxyevodiamine, also showed good in vivo antitumor efficacy and low toxicity at the dose of 1 mg/kg or 2 mg/kg.  They represent promising candidates for the development of novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocJjv8REdBnrVg90H21EOLACvtfcHk0lj0nTZ4pJWqTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurfP&md5=6e7d03671ac1be56b8bd68dc0fc03062</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fjm300605m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300605m%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DNew%2520tricks%2520for%2520an%2520old%2520natural%2520product%253A%2520discovery%2520of%2520highly%2520potent%2520evodiamine%2520derivatives%2520as%2520novel%2520antitumor%2520agents%2520by%2520systemic%2520structure-activity%2520relationship%2520analysis%2520and%2520biological%2520evaluations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7593%26epage%3D7613%26doi%3D10.1021%2Fjm300605m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span> <span> </span><span class="NLM_article-title">Epigenetics in cancer</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgp220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1093%2Fcarcin%2Fbgp220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19752007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlCntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=27-36&issue=1&author=S.+Sharmaauthor=T.+K.+Kellyauthor=P.+A.+Jones&title=Epigenetics+in+cancer&doi=10.1093%2Fcarcin%2Fbgp220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics in cancer</span></div><div class="casAuthors">Sharma, Shikhar; Kelly, Theresa K.; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Epigenetic mechanisms are essential for normal development and maintenance of tissue-specific gene expression patterns in mammals.  Disruption of epigenetic processes can lead to altered gene function and malignant cellular transformation.  Global changes in the epigenetic landscape are a hallmark of cancer.  The initiation and progression of cancer, traditionally seen as a genetic disease, is now realized to involve epigenetic abnormalities along with genetic alterations.  Recent advancements in the rapidly evolving field of cancer epigenetics have shown extensive reprogramming of every component of the epigenetic machinery in cancer including DNA methylation, histone modifications, nucleosome positioning and non-coding RNAs, specifically microRNA expression.  The reversible nature of epigenetic aberrations has led to the emergence of the promising field of epigenetic therapy, which is already making progress with the recent FDA approval of three epigenetic drugs for cancer treatment.  In this review, we discuss the current understanding of alterations in the epigenetic landscape that occur in cancer compared with normal cells, the roles of these changes in cancer initiation and progression, including the cancer stem cell model, and the potential use of this knowledge in designing more effective treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqicaNrvhDly7Vg90H21EOLACvtfcHk0lirgP6zN3mBRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlCntw%253D%253D&md5=e44f5fb2c52d06a941eaa03e2a27766d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgp220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgp220%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKelly%26aufirst%3DT.%2BK.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DEpigenetics%2520in%2520cancer%26jtitle%3DCarcinogenesis%26date%3D2010%26volume%3D31%26issue%3D1%26spage%3D27%26epage%3D36%26doi%3D10.1093%2Fcarcin%2Fbgp220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span> <span> </span><span class="NLM_article-title">Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1038/s41591-019-0376-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fs41591-019-0376-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30842676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsV2itLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=403-418&issue=3&author=H.+P.+Mohammadauthor=O.+Barbashauthor=C.+L.+Creasy&title=Targeting+epigenetic+modifications+in+cancer+therapy%3A+erasing+the+roadmap+to+cancer&doi=10.1038%2Fs41591-019-0376-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer</span></div><div class="casAuthors">Mohammad, Helai P.; Barbash, Olena; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-418</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Epigenetic dysregulation is a common feature of most cancers, often occurring directly through alteration of epigenetic machinery.  Over the last several years, a new generation of drugs directed at epigenetic modulators have entered clin. development, and results from these trials are now being disclosed.  Unlike first-generation epigenetic therapies, these new agents are selective, and many are targeted to proteins which are mutated or translocated in cancer.  This review will provide a summary of the epigenetic modulatory agents currently in clin. development and discuss the opportunities and challenges in their development.  As these drugs advance in the clinic, drug discovery has continued with a focus on both novel and existing epigenetic targets.  This article provides an overview of these efforts and the strategies being employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSkOyprsvHNrVg90H21EOLACvtfcHk0lirgP6zN3mBRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsV2itLs%253D&md5=0b306f94147fd7cb89f5eca82496bba7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fs41591-019-0376-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-019-0376-8%26sid%3Dliteratum%253Aachs%26aulast%3DMohammad%26aufirst%3DH.%2BP.%26aulast%3DBarbash%26aufirst%3DO.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DTargeting%2520epigenetic%2520modifications%2520in%2520cancer%2520therapy%253A%2520erasing%2520the%2520roadmap%2520to%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2019%26volume%3D25%26issue%3D3%26spage%3D403%26epage%3D418%26doi%3D10.1038%2Fs41591-019-0376-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piekarz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1586/era.10.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1586%2Fera.10.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=20645688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=997-1008&issue=7&author=C.+Grantauthor=F.+Rahmanauthor=R.+Piekarzauthor=C.+Peerauthor=R.+Fryeauthor=R.+W.+Robeyauthor=E.+R.+Gardnerauthor=W.+D.+Figgauthor=S.+E.+Bates&title=Romidepsin%3A+a+new+therapy+for+cutaneous+T-cell+lymphoma+and+a+potential+therapy+for+solid+tumors&doi=10.1586%2Fera.10.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span></div><div class="casAuthors">Grant, Cliona; Rahman, Fahd; Piekarz, Richard; Peer, Cody; Frye, Robin; Robey, Robert W.; Gardner, Erin R.; Figg, William D.; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">997-1008</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL).  Although various mechanisms have been proposed for the activity of HDIs, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and direct induction of apoptosis, the mechanism underlying activity of romidepsin and other HDIs in CTCL is not known.  Romidepsin induces long-lasting responses.  The side-effect profile is similar to that of other HDIs, causing fatigue, nausea and thrombocytopenia.  Management of the CTCL population requires vigilence to prevent infection with skin contaminants, and monitoring of potassium and magnesium, electrolytes found to be low in a large proportion of patients.  Electrocardiog. (ECG) changes are common but are not assocd. with myocardial damage.  When mol. end points were evaluated in 61 patients enrolled on a Phase II trial with romidepsin, response was assocd. with persistence of acetylated histone H3, suggesting that drug exposure is important in effective therapy with romidepsin.  Future studies will endeavor to identify combination strategies to increase the efficacy both in resistant CTCL and in solid tumors and to identify biomarkers of response that will allow selection of patients most likely to benefit from the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGXcIbdqpk7Vg90H21EOLACvtfcHk0lirgP6zN3mBRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D&md5=b28fd17c77991e4662f7c0e08d6d7297</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1586%2Fera.10.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.10.88%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DC.%26aulast%3DRahman%26aufirst%3DF.%26aulast%3DPiekarz%26aufirst%3DR.%26aulast%3DPeer%26aufirst%3DC.%26aulast%3DFrye%26aufirst%3DR.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DRomidepsin%253A%2520a%2520new%2520therapy%2520for%2520cutaneous%2520T-cell%2520lymphoma%2520and%2520a%2520potential%2520therapy%2520for%2520solid%2520tumors%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2010%26volume%3D10%26issue%3D7%26spage%3D997%26epage%3D1008%26doi%3D10.1586%2Fera.10.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&issue=10&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0lirgP6zN3mBRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26issue%3D10%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnock-Jones, K. P.</span></span> <span> </span><span class="NLM_article-title">Panobinostat: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0388-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs40265-015-0388-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25837990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntlCks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=695-704&issue=6&author=K.+P.+Garnock-Jones&title=Panobinostat%3A+first+global+approval&doi=10.1007%2Fs40265-015-0388-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat: First Global Approval</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-704</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Novartis has developed oral and i.v. formulations of panobinostat (Farydak), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer.  HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumor suppressor genes, and thus represent valid targets in the search for cancer therapeutics.  Oral panobinostat is approved in the US, as combination therapy with bortezomib and dexamethasone in patients with recurrent multiple myeloma who have received at least two prior treatment regimens, including bortezomib and an immunomodulatory agent.  Regulatory submissions have been made for the use of combination therapy with panobinostat in patients with recurrent multiple myeloma in the EU and Japan.  Panobinostat is in various stages of clin. development worldwide for a range of haematol. and solid tumors.  This article summarizes the milestones in the development of panobinostat leading to this first approval for multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7ozQIb-0DLVg90H21EOLACvtfcHk0limIOFupqyGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntlCks7c%253D&md5=87426a90e7cab1334d2a79055af962f1</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0388-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0388-8%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DPanobinostat%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26issue%3D6%26spage%3D695%26epage%3D704%26doi%3D10.1007%2Fs40265-015-0388-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwitkowski, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Valle, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomquist, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrotra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2666</span>– <span class="NLM_lpage">2670</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1078-0432.CCR-14-3119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25802282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2666-2670&issue=12&author=H.+Z.+Leeauthor=V.+E.+Kwitkowskiauthor=P.+L.+Del+Valleauthor=M.+S.+Ricciauthor=H.+Saberauthor=B.+A.+Habtemariamauthor=J.+Bullockauthor=E.+Bloomquistauthor=Y.+Li+Shenauthor=X.+H.+Chenauthor=J.+Brownauthor=N.+Mehrotraauthor=S.+Dorffauthor=R.+Charlabauthor=R.+C.+Kaneauthor=E.+Kaminskasauthor=R.+Justiceauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+approval%3A+belinostat+for+the+treatment+of+patients+with+relapsed+or+refractory+peripheral+T-cell+lymphoma&doi=10.1158%2F1078-0432.CCR-14-3119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma</span></div><div class="casAuthors">Lee, Hyon-Zu; Kwitkowski, Virginia E.; Del Valle, Pedro L.; Ricci, M. Stacey; Saber, Haleh; Habtemariam, Bahru A.; Bullock, Julie; Bloomquist, Erik; Shen, Yuan Li; Chen, Xiao-Hong; Brown, Janice; Mehrotra, Nitin; Dorff, Sarah; Charlab, Rosane; Kane, Robert C.; Kaminskas, Edvardas; Justice, Robert; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2666-2670</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On July 3, 2014, the FDA granted accelerated approval for belinostat (Beleodaq; Spectrum Pharmaceuticals, Inc.), a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).  A single-arm, open-label, multicenter, international trial in the indicated patient population was submitted in support of the application.  Belinostat was administered i.v. at a dose of 1000 mg/m2 over 30 min once daily on days 1 to 5 of a 21-day cycle.  The primary efficacy endpoint was overall response rate (ORR) based on central radiol. readings by an independent review committee.  The ORR was 25.8% [95% confidence interval (CI), 18.3-34.6] in 120 patients that had confirmed diagnoses of PTCL by the Central Pathol. Review Group.  The complete and partial response rates were 10.8% (95% CI, 5.9-17.8) and 15.0% (95% CI, 9.1-22.7), resp.  The median duration of response, the key secondary efficacy endpoint, was 8.4 mo (95% CI, 4.5-29.4).  The most common adverse reactions (>25%) were nausea, fatigue, pyrexia, anemia, and vomiting.  Grade 3/4 toxicities (≥5.0%) included anemia, thrombocytopenia, dyspnea, neutropenia, fatigue, and pneumonia.  Belinostat is the third drug to receive accelerated approval for the treatment of relapsed or refractory PTCL.  Clin Cancer Res; 21(12); 2666-70. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1RbkvuHSk6rVg90H21EOLACvtfcHk0limIOFupqyGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfM&md5=c1e64c9d01d18272d25ad03001e7041a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3119%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BZ.%26aulast%3DKwitkowski%26aufirst%3DV.%2BE.%26aulast%3DDel%2BValle%26aufirst%3DP.%2BL.%26aulast%3DRicci%26aufirst%3DM.%2BS.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DHabtemariam%26aufirst%3DB.%2BA.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBloomquist%26aufirst%3DE.%26aulast%3DLi%2BShen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DMehrotra%26aufirst%3DN.%26aulast%3DDorff%26aufirst%3DS.%26aulast%3DCharlab%26aufirst%3DR.%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%253A%2520belinostat%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsed%2520or%2520refractory%2520peripheral%2520T-cell%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D12%26spage%3D2666%26epage%3D2670%26doi%3D10.1158%2F1078-0432.CCR-14-3119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">The role of histone deacetylases (HDACs) in human cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.molonc.2007.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19383284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=19-25&issue=1&author=S.+Roperoauthor=M.+Esteller&title=The+role+of+histone+deacetylases+%28HDACs%29+in+human+cancer&doi=10.1016%2Fj.molonc.2007.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histone deacetylases (HDACs) in human cancer</span></div><div class="casAuthors">Ropero, Santiago; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The balance of histone acetylation and deacetylation is an epigenetic layer with a crit. role in the regulation of gene expression.  Histone acetylation induced by histone acetyl transferases (HATs) is assocd. with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is assocd. with gene silencing.  Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis.  Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbJD8bqroSLVg90H21EOLACvtfcHk0limIOFupqyGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI&md5=d925bcde258dce7d53cbb98563e1f2ae</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520histone%2520deacetylases%2520%2528HDACs%2529%2520in%2520human%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26issue%3D1%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.molonc.2007.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1373</span>– <span class="NLM_lpage">1428</span>, <span class="refDoi"> DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&issue=6&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+search+for+potent%2C+small-molecule+HDACIs+in+cancer+treatment%3A+a+decade+after+vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2ebj_gyUrcBwYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520search%2520for%2520potent%252C%2520small-molecule%2520HDACIs%2520in%2520cancer%2520treatment%253A%2520a%2520decade%2520after%2520vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26issue%3D6%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canzoneri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1477</span>, <span class="refDoi"> DOI: 10.1021/jm200799p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200799p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1465-1477&issue=4&author=W.+Guerrantauthor=V.+Patilauthor=J.+C.+Canzoneriauthor=A.+K.+Oyelere&title=Dual+targeting+of+histone+deacetylase+and+topoisomerase+II+with+novel+bifunctional+inhibitors&doi=10.1021%2Fjm200799p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors</span></div><div class="casAuthors">Guerrant, William; Patil, Vishal; Canzoneri, Joshua C.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1465-1477</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Strategies to ameliorate the flaws of current chemotherapeutic agents, while maintaining potent anticancer activity, are of particular interest.  Agents which can modulate multiple targets may have superior utility and fewer side effects than current single-target drugs.  To explore the prospect in cancer therapy of a bivalent agent that combines two complementary chemo-active groups within a single mol. architecture, we have synthesized dual-acting histone deacetylase and topoisomerase II inhibitors.  These dual-acting agents are derived from suberoylanilide hydroxamic acid (SAHA) and anthracycline daunorubicin, prototypical histone deacetylase (HDAC) and topoisomerase II (Topo II) inhibitors, resp.  For example, 4-aminobenzyl alc. reacted with suberic anhydride to give 4-HOCH2C6H4NHCO(CH2)6CO2H, which was oxidized to the corresponding benzaldehyde.  This benzaldehyde reacted with H2NOCPh3 to give the terminal O-tritylated amide, which, after addn. to daunorubicin HCl and removal of the trityl group, produced conjugate I.  We report herein that these agents present the signatures of inhibition of HDAC and Topo II in both cell-free and whole-cell assays.  Moreover, these agents potently inhibit the proliferation of representative cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Yf6AQQjHxLVg90H21EOLACvtfcHk0lgfVBUX2g2EYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVyhuw%253D%253D&md5=f0d6a8b98bb524de8e9fbbf1680610a1</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm200799p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200799p%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DCanzoneri%26aufirst%3DJ.%2BC.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DDual%2520targeting%2520of%2520histone%2520deacetylase%2520and%2520topoisomerase%2520II%2520with%2520novel%2520bifunctional%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D4%26spage%3D1465%26epage%3D1477%26doi%3D10.1021%2Fjm200799p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&issue=10&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0lgfVBUX2g2EYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26issue%3D10%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the understanding and treatment of acute myeloid leukemia</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1196</span>, <span class="refDoi"> DOI: 10.12688/f1000research.14116.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.12688%2Ff1000research.14116.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWqsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=1196&author=J.+Wattsauthor=S.+Nimer&title=Recent+advances+in+the+understanding+and+treatment+of+acute+myeloid+leukemia&doi=10.12688%2Ff1000research.14116.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the understanding and treatment of acute myeloid leukemia [version 1; referees: 3 approved]</span></div><div class="casAuthors">Watts, Justin; Nimer, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1196/1-1196/14</span>CODEN:
                <span class="NLM_cas:coden">FRESJL</span>;
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    
            (<span class="NLM_cas:orgname">F1000 Research Ltd.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a clin. and genetically heterogeneous</div> disease that has a poor prognosis.  Recent advances in genomics and</div> mol. biol. have led to a greatly improved understanding of the disease.</div> Until 2017, there had been no new drugs approved for AML in decades.  Here,</div> we review novel drug targets in AML with a focus on epigenetic-targeted</div> therapies in pre-clin. and clin. development as well as the recent new</div> drug approvals.</div>.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_5ZTwW9jqjLVg90H21EOLACvtfcHk0lgfVBUX2g2EYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWqsb7O&md5=262aea9a1152835b47144f52f804b84f</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.14116.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.14116.1%26sid%3Dliteratum%253Aachs%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DNimer%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520the%2520understanding%2520and%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DF1000Research%26date%3D2018%26volume%3D7%26spage%3D1196%26doi%3D10.12688%2Ff1000research.14116.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perissinotti, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benitez, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scappaticci, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, B. L.</span></span> <span> </span><span class="NLM_article-title">The leukemia strikes back: a review of pathogenesis and treatment of secondary AML</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1007/s00277-019-03606-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs00277-019-03606-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30666431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BB3cjjslenug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2019&pages=541-559&issue=3&author=E.+Cheungauthor=A.+J.+Perissinottiauthor=D.+L.+Bixbyauthor=P.+W.+Burkeauthor=K.+M.+Pettitauthor=L.+L.+Benitezauthor=J.+Brownauthor=G.+B.+Scappaticciauthor=B.+L.+Marini&title=The+leukemia+strikes+back%3A+a+review+of+pathogenesis+and+treatment+of+secondary+AML&doi=10.1007%2Fs00277-019-03606-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The leukemia strikes back: a review of pathogenesis and treatment of secondary AML</span></div><div class="casAuthors">Cheung Edna; Perissinotti Anthony J; Benitez Lydia L; Brown Julia; Scappaticci Gianni B; Marini Bernard L; Bixby Dale L; Burke Patrick W; Pettit Kristen M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of hematology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">541-559</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Secondary AML is associated with a disproportionately poor prognosis, consistently shown to exhibit inferior response rates, event-free survival, and overall survival in comparison with de novo AML.  Secondary AML may arise from the evolution of an antecedent hematologic disorder, or it may arise as a complication of prior cytotoxic chemotherapy or radiation therapy in the case of therapy-related AML.  Because of the high frequency of poor-risk cytogenetics and high-risk molecular features, such as alterations in TP53, leukemic clones are often inherently chemoresistant.  Standard of care induction had long remained conventional 7 + 3 until its reformulation as CPX-351, recently FDA approved specifically for secondary AML.  However, recent data also suggests relatively favorable outcomes with regimens based on high-dose cytarabine or hypomethylating agents.  With several investigational agents being studied, the therapeutic landscape becomes even more complex, and the treatment approach involves patient-specific, disease-specific, and therapy-specific considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKCQUOKEG4Qub6AVA-44PTfW6udTcc2eZpqYiMENMOSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjjslenug%253D%253D&md5=799c29baebc802faae7e06fb409ea9af</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1007%2Fs00277-019-03606-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-019-03606-0%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DE.%26aulast%3DPerissinotti%26aufirst%3DA.%2BJ.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DBurke%26aufirst%3DP.%2BW.%26aulast%3DPettit%26aufirst%3DK.%2BM.%26aulast%3DBenitez%26aufirst%3DL.%2BL.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DScappaticci%26aufirst%3DG.%2BB.%26aulast%3DMarini%26aufirst%3DB.%2BL.%26atitle%3DThe%2520leukemia%2520strikes%2520back%253A%2520a%2520review%2520of%2520pathogenesis%2520and%2520treatment%2520of%2520secondary%2520AML%26jtitle%3DAnn.%2520Hematol.%26date%3D2019%26volume%3D98%26issue%3D3%26spage%3D541%26epage%3D559%26doi%3D10.1007%2Fs00277-019-03606-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">8467</span>– <span class="NLM_lpage">8475</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1078-0432.CCR-05-1073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=16322310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KjsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=8467-8475&issue=23&author=D.+C.+Marchionauthor=E.+Bicakuauthor=J.+G.+Turnerauthor=A.+I.+Daudauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=Synergistic+interaction+between+histone+deacetylase+and+topoisomerase+II+inhibitors+is+mediated+through+topoisomerase+II%CE%B2&doi=10.1158%2F1078-0432.CCR-05-1073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Turner, Joel G.; Daud, Adil I.; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8467-8475</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BACKGROUND: DNA topoisomerase II inhibitors and poisons are among the most efficacious drugs for the treatment of cancer.  Sensitivity of cancer cells to the cytotoxic effects of topoisomerase II targeting agents is thought to depend on the expression of the topoisomerase IIα isoform, and drug resistance is often assocd. with loss or mutation of topoisomerase IIα.  Histone deacetylase inhibitors (HDACi) are a novel class of compds. that potentiate the antitumor effects of topoisomerase II-targeting agents.  METHODS: The interaction between HDACi and topoisomerase II-targeting agents in cancer cells was evaluated as a function of topoisomerase IIα and topoisomerase IIβ expression.  Topoisomerase II isoforms were selectively depleted using small interfering RNA and antisense.  Drug-induced formation of cleavable complexes involving topoisomerase IIα and topoisomerase IIβ was evaluated by trapped-in-agarose DNA immunostaining and band depletion assays in the presence and absence of HDACi.  RESULTS: Preexposure to HDACi increased the cytotoxicity of topoisomerase II poisons.  This was assocd. with a down-regulation of topoisomerase IIα expression but had no effects on topoisomerase IIβ.  In the setting of HDACi-induced chromatin decondensation and topoisomerase IIα depletion, topoisomerase II poison cytotoxicity was mediated through topoisomerase IIβ cleavable complex formation.  The HDACi-induced sensitization was also obsd. in cells with target-specific resistance to topoisomerase II poisons.  CONCLUSIONS: The recruitment of topoisomerase IIβ as a target may overcome primary or emergent drug resistance to topoisomerase II-targeting agents and hence may broaden the applicability of this important class of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozxAiIAX42b7Vg90H21EOLACvtfcHk0li8bR-iW-AbnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KjsrbF&md5=453b23ac674f68548ed46246b43fabbf</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1073%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DTurner%26aufirst%3DJ.%2BG.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DSynergistic%2520interaction%2520between%2520histone%2520deacetylase%2520and%2520topoisomerase%2520II%2520inhibitors%2520is%2520mediated%2520through%2520topoisomerase%2520II%25CE%25B2%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26issue%3D23%26spage%3D8467%26epage%3D8475%26doi%3D10.1158%2F1078-0432.CCR-05-1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1002/jcb.20045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fjcb.20045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15108350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVaqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2004&pages=223-237&issue=2&author=D.+C.+Marchionauthor=E.+Bicakuauthor=A.+I.+Daudauthor=V.+Richonauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=Sequence-specific+potentiation+of+topoisomerase+II+inhibitors+by+the+histone+deacetylase+inhibitor+suberoylanilide+hydroxamic+acid&doi=10.1002%2Fjcb.20045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Daud, Adil I.; Richon, Victoria; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-237</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Acetylation of histones leads to conformational changes of DNA.  We have previously shown that the histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA), induced cell cycle arrest, differentiation, and apoptosis.  In addn. to their antitumor effects as single agents, HDAC inhibitors may cause conformational changes in the chromatin, rendering the DNA more vulnerable to DNA damaging agents.  We examd. the effects of SAHA on cell death induced by topo II inhibitors in breast cancer cell lines.  Topo II inhibitors stabilize the topo II-DNA complex, resulting in DNA damage.  Treatment of cells with SAHA promoted chromatin decondensation assocd. with increased nuclear concn. and DNA binding of the topo II inhibitor and subsequent potentiation of DNA damage.  While SAHA-induced histone hyperacetylation occurred as early as 4 h, chromatin decondensation was most profound at 48 h.  SAHA-induced potentiation of topo II inhibitors was sequence-specific.  Pre-exposure of cells to SAHA for 48 h was synergistic, whereas shorter pre-exposure periods abrogated synergy and exposure of cells to SAHA after the topo II inhibitor resulted in antagonistic effects.  Synergy was not obsd. in cells with depleted topo II levels.  These effects were not limited to specific types of topo II inhibitors.  We propose that SAHA significantly potentiates the DNA damage induced by topo II inhibitors; however, synergy is dependent on the sequence of drug administration and the expression of the target.  These findings may impact the clin. development of combining HDAC inhibitors with DNA damaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd_EzmdHJvU7Vg90H21EOLACvtfcHk0li8bR-iW-AbnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVaqs7c%253D&md5=71f10a1a96c0e666a5f410c9b32a3893</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fjcb.20045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.20045%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DSequence-specific%2520potentiation%2520of%2520topoisomerase%2520II%2520inhibitors%2520by%2520the%2520histone%2520deacetylase%2520inhibitor%2520suberoylanilide%2520hydroxamic%2520acid%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2004%26volume%3D92%26issue%3D2%26spage%3D223%26epage%3D237%26doi%3D10.1002%2Fjcb.20045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">7291</span>– <span class="NLM_lpage">7300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=14612526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGlt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7291-7300&issue=21&author=M.+S.+Kimauthor=M.+Blakeauthor=J.+H.+Baekauthor=G.+Kohlhagenauthor=Y.+Pommierauthor=F.+Carrier&title=Inhibition+of+histone+deacetylase+increases+cytotoxicity+to+anticancer+drugs+targeting+DNA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA</span></div><div class="casAuthors">Kim, Myoung Sook; Blake, Mellissa; Baek, Jin Hyen; Kohlhagen, Glenda; Pommier, Yves; Carrier, France</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7291-7300</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Several anticancer drugs target DNA or enzymes acting on the DNA.  Because chromatin DNA is tightly compacted, accessibility to the drug target may reduce the efficiency of these anticancer drugs.  We thus treated four human cancer cell lines and two normal epithelial cell lines with either trichostatin A (TSA) or SAHA, two histone deacetylase inhibitors, before exposing the cells to VP-16, ellipticine, camptothecin, doxorubicin, cisplatin, 5-fluorouracil, or cyclophosphamide.  Pretreatment with TSA or SAHA increased the killing efficiency of VP-16, ellipticine, doxorubicin, and cisplatin.  The magnitude of sensitization is cell type specific and is >10-fold for VP-16 in D54, a brain tumor cell line intrinsically resistant to topoisomerase II inhibitors.  Topoisomerase II levels and activity were not affected by this treatment, but p53, p21, and Gadd45 protein levels were markedly induced.  Moreover, pretreatment with TSA also increased VP-16-induced apoptosis in a p53-dependent and -independent manner.  Treating the cells in the reverse order (anticancer drug first, followed by TSA or SAHA) had no more cytotoxic effect than the drug alone.  These data suggest that loosening-up the chromatin structure by histone acetylation can increase the efficiency of several anticancer drugs targeting DNA.  This may be advantageous for treating tumors intrinsically resistant to these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq24HjggpPirLVg90H21EOLACvtfcHk0liyk8DYR8TrWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGlt70%253D&md5=6fe3bc8b32550917fc8f80ac648e680b</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DBlake%26aufirst%3DM.%26aulast%3DBaek%26aufirst%3DJ.%2BH.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCarrier%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520histone%2520deacetylase%2520increases%2520cytotoxicity%2520to%2520anticancer%2520drugs%2520targeting%2520DNA%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26issue%3D21%26spage%3D7291%26epage%3D7300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Valproic acid alters chromatin structure by regulation of chromatin modulation proteins</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3815</span>– <span class="NLM_lpage">3822</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-2478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F0008-5472.CAN-04-2478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15867379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3815-3822&issue=9&author=D.+C.+Marchionauthor=E.+Bicakuauthor=A.+I.+Daudauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=Valproic+acid+alters+chromatin+structure+by+regulation+of+chromatin+modulation+proteins&doi=10.1158%2F0008-5472.CAN-04-2478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Valproic acid alters chromatin structure by regulation of chromatin modulation proteins</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Daud, Adil I.; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3815-3822</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are crucial in the regulation of gene expression.  Dynamic changes in gene expression may affect chromatin structure and, consequently, the interaction of chromatin with regulatory factors.  In this study, the effects of the antiseizure drug valproic acid (VPA) on the expression of genes that regulate the structure of chromatin and the access of macromols. to the DNA were investigated.  Exposure of breast cancer cells to VPA resulted in rapid dose-dependent hyperacetylation of the histones H3 and H4.  VPA further induced a depletion of several members of the structural maintenance of chromatin (SMC) proteins, SMC-assocd. proteins, DNA methyltransferase, and heterochromatin proteins.  Down-regulation of these proteins was assocd. with chromatin decondensation.  The obsd. alterations of chromatin structure correlated with enhanced sensitivity of DNA to nucleases and increased interaction of DNA with intercalating agents.  VPA-induced chromatin decondensation led to a sequence-specific potentiation of DNA-damaging agents in cell culture and xenograft models.  Modulation of heterochromatin maintenance proteins was not a direct, but a downstream, effect of histone acetylation.  The effects on the chromatin structure were reversible upon drug withdrawal, but obligatory for the potentiation of DNA-damaging agents.  In addn. to their antitumor activity as single agents, the chromatin decondensation induced by histone deacetylase inhibitors may enhance the efficacy of cytotoxic agents that act by targeting DNA.  The proposed mechanism of action suggests an effect of drug sequencing on the antitumor activity of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoahFbSWhN10bVg90H21EOLACvtfcHk0liyk8DYR8TrWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGks78%253D&md5=50f433688151bbc4795dcd1a3fe33108</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-2478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-2478%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DValproic%2520acid%2520alters%2520chromatin%2520structure%2520by%2520regulation%2520of%2520chromatin%2520modulation%2520proteins%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D9%26spage%3D3815%26epage%3D3822%26doi%3D10.1158%2F0008-5472.CAN-04-2478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niitsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasukabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe-Kado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto-Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, Y.</span></span> <span> </span><span class="NLM_article-title">Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1124/mol.58.1.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1124%2Fmol.58.1.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10860924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Krurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2000&pages=27-36&issue=1&author=N.+Niitsuauthor=T.+Kasukabeauthor=A.+Yokoyamaauthor=J.+Okabe-Kadoauthor=Y.+Yamamoto-Yamaguchiauthor=M.+Umedaauthor=Y.+Honma&title=Anticancer+derivative+of+butyric+acid+%28pivalyloxymethyl+butyrate%29+specifically+potentiates+the+cytotoxicity+of+doxorubicin+and+daunorubicin+through+the+suppression+of+microsomal+glycosidic+activity&doi=10.1124%2Fmol.58.1.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity</span></div><div class="casAuthors">Niitsu, Nozomi; Kasukabe, Takashi; Yokoyama, Akihiro; Okabe-Kado, Junko; Yamamoto-Yamaguchi, Yuri; Umeda, Masanori; Honma, Yoshio</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pivalyloxymethyl butyrate (AN9) is an anticancer deriv. of butyric acid.  In this study, doxorubicin (DXR) and AN9 synergistically inhibited the growth of lymphoma and lung carcinoma cells, whereas there was no synergy between AN9 and antimetabolites.  AN9 did not affect the intracellular uptake of DXR.  Among anthracyclines and their derivs., the synergistic effect was prominent in compds. with a daunosamine moiety, suggesting that AN9 may affect the catabolism of these compds.  The degrdn. of DXR in the ext. from AN9-treated cells was much less than that in ext. from untreated cells.  AN9 did not directly inhibit the enzyme activity but rather suppressed expression of the enzyme.  With respect to the expression of drug resistance-related genes, there was no significant difference between untreated and AN9-treated cells.  However, AN9 significantly down-regulated the levels NADPH-cytochrome P 450 reductase and DT-diaphorase mRNA in the presence of DXR but not the level of xanthine oxidase mRNA.  The enhancement of the sensitivity to anthracyclines was closely assocd. with the suppression of the mRNA expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIATqdykNpG7Vg90H21EOLACvtfcHk0liyk8DYR8TrWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Krurs%253D&md5=3b7fc125787b69583a4857205952159c</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1124%2Fmol.58.1.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.58.1.27%26sid%3Dliteratum%253Aachs%26aulast%3DNiitsu%26aufirst%3DN.%26aulast%3DKasukabe%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DA.%26aulast%3DOkabe-Kado%26aufirst%3DJ.%26aulast%3DYamamoto-Yamaguchi%26aufirst%3DY.%26aulast%3DUmeda%26aufirst%3DM.%26aulast%3DHonma%26aufirst%3DY.%26atitle%3DAnticancer%2520derivative%2520of%2520butyric%2520acid%2520%2528pivalyloxymethyl%2520butyrate%2529%2520specifically%2520potentiates%2520the%2520cytotoxicity%2520of%2520doxorubicin%2520and%2520daunorubicin%2520through%2520the%2520suppression%2520of%2520microsomal%2520glycosidic%2520activity%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D58%26issue%3D1%26spage%3D27%26epage%3D36%26doi%3D10.1124%2Fmol.58.1.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, E. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leader, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampey, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalowich, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, D. J.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase IIα expression and confers hypersensitivity to etoposide in human leukemic cell lines</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12467229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=121-131&issue=2&author=E.+U.+Kurzauthor=S.+E.+Wilsonauthor=K.+B.+Leaderauthor=B.+P.+Sampeyauthor=W.+P.+Allanauthor=J.+C.+Yalowichauthor=D.+J.+Kroll&title=The+histone+deacetylase+inhibitor+sodium+butyrate+induces+DNA+topoisomerase+II%CE%B1+expression+and+confers+hypersensitivity+to+etoposide+in+human+leukemic+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase IIα expression and confers hypersensitivity to etoposide in human leukemic cell lines</span></div><div class="casAuthors">Kurz, Ebba U.; Wilson, Sara E.; Leader, Kelly B.; Sampey, Brante P.; Allan, William P.; Yalowich, Jack C.; Kroll, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-131</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The differentiating agent and histone deacetylase inhibitor, sodium butyrate (NaB), was shown previously to cause a transient, 3-17-fold induction of human DNA topoisomerase IIα (topo IIα) gene promoter activity and a 2-fold increase in topo IIα protein early in monocytic differentiation of HL-60 cells.  This observation has now been extended to other short chain fatty acids and arom. butyrate analogs, and evidence is presented that human topo IIα promoter induction correlates closely with histone H4 acetylation status.  Because increased topo IIα expression is assocd. with enhanced efficacy of topo II-poisoning antitumor drugs such as etoposide, the hypothesis tested in this report was whether NaB pretreatment could sensitize HL-60 myeloid leukemia and K562 erythroleukemia cells to etoposide-triggered DNA damage and cell death.  A 24-72 h NaB treatment (0.4-0.5 mM) induced topo IIα 2-2.5-fold in both HL-60 and K562 cells and caused a dose-dependent enhancement of etoposide-stimulated, protein-linked DNA complexes in both cell lines.  At concns. with minimal effects on cell cycle kinetics (0.4 mM in HL-60; 0.5 mM in K562), NaB pretreatment also modestly enhanced etoposide-triggered apoptosis in HL-60 cells, as detd. morphol. after acridine orange/ethidium bromide staining, and substantially increased K562 growth inhibition and poly(ADP-ribose)polymerase cleavage after etoposide exposure.  Therefore, a temporal window may exist whereby a differentiating agent may sensitize exptl. leukemias to a cytotoxic antitumor agent.  These results indicate that histone deacetylase inhibitors should be investigated for etoposide sensitization of other butyrate-responsive hematopoietic and nonhematopoietic tumor lines in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6QUXll4sIpLVg90H21EOLACvtfcHk0liogKrKRxewdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbY%253D&md5=62d25117a11f3e994bd81167c7bdac58</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKurz%26aufirst%3DE.%2BU.%26aulast%3DWilson%26aufirst%3DS.%2BE.%26aulast%3DLeader%26aufirst%3DK.%2BB.%26aulast%3DSampey%26aufirst%3DB.%2BP.%26aulast%3DAllan%26aufirst%3DW.%2BP.%26aulast%3DYalowich%26aufirst%3DJ.%2BC.%26aulast%3DKroll%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520sodium%2520butyrate%2520induces%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520expression%2520and%2520confers%2520hypersensitivity%2520to%2520etoposide%2520in%2520human%2520leukemic%2520cell%2520lines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2001%26volume%3D1%26issue%3D2%26spage%3D121%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padget, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span> <span> </span><span class="NLM_article-title">Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4542</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000824200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.C000824200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11136718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlOqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=4539-4542&issue=7&author=C.+A.+Johnsonauthor=K.+Padgetauthor=C.+A.+Austinauthor=B.+M.+Turner&title=Deacetylase+activity+associates+with+topoisomerase+II+and+is+necessary+for+etoposide-induced+apoptosis&doi=10.1074%2Fjbc.C000824200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis</span></div><div class="casAuthors">Johnson, Colin A.; Padget, Kay; Austin, Caroline A.; Turner, Bryan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4539-4542</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">DNA topoisomerase II (topo II) is a ubiquitous nuclear enzyme that is involved in DNA replication, transcription, chromosome segregation, and apoptosis.  Here we show by immunopptn., pull down with glutathione S-transferase fusion proteins, and yeast two-hybrid anal. that both topo IIα and -β phys. interact with the histone deacetylase HDAC1.  The in vitro DNA decatenation activity of recombinant topo IIα and -β is inhibited by assocn. with catalytically inactive, recombinant HDAC1.  We provide evidence for the in vivo significance of the topo II-HDAC1 assocn., showing that inhibition of HDAC activity with trichostatin A suppresses apoptosis induced by the topo II poison etoposide, but not by the topoisomerase I inhibitor camptothecin.  We suggest that chromatin remodeling by an HDAC-contg. complex facilitates both topo II-catalyzed DNA rearrangement and etoposide-induced DNA damage in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG-EArV25rfLVg90H21EOLACvtfcHk0liogKrKRxewdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlOqsLg%253D&md5=8cfacaa935b0351d3cf55aad2405b138</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000824200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000824200%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BA.%26aulast%3DPadget%26aufirst%3DK.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26atitle%3DDeacetylase%2520activity%2520associates%2520with%2520topoisomerase%2520II%2520and%2520is%2520necessary%2520for%2520etoposide-induced%2520apoptosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26issue%3D7%26spage%3D4539%26epage%3D4542%26doi%3D10.1074%2Fjbc.C000824200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6981</span>– <span class="NLM_lpage">6995</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmc.2013.09.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24095018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOlurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=6981-6995&issue=22&author=X.+Zhangauthor=B.+Baoauthor=X.+Yuauthor=L.+Tongauthor=Y.+Luoauthor=Q.+Huangauthor=M.+Suauthor=L.+Shengauthor=J.+Liauthor=H.+Zhuauthor=B.+Yangauthor=X.+Zhangauthor=Y.+Chenauthor=W.+Lu&title=The+discovery+and+optimization+of+novel+dual+inhibitors+of+topoisomerase+II+and+histone+deacetylase&doi=10.1016%2Fj.bmc.2013.09.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase</span></div><div class="casAuthors">Zhang, Xuan; Bao, Bin; Yu, Xiuhua; Tong, Linjiang; Luo, Yu; Huang, Qingqing; Su, Mingbo; Sheng, Li; Li, Jia; Zhu, Hong; Yang, Bo; Zhang, Xiongwen; Chen, Yi; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6981-6995</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of podophyllotoxin derivs. have been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors.  Their inhibitory activities towards histone deacetylases and Topo II and their cytotoxicities in cancer cell lines were evaluated.  The arom. capping group connection, linker length and zinc-binding group were systematically varied and preliminary conclusions regarding structure-activity relationships are discussed.  Among all of the synthesized hybrid compds., compd. I showed the most potent HDAC inhibitory activity at a low nanomolar level and exhibited powerful antiproliferative activity towards HCT116 colon carcinoma cells at a low micromolar level.  Further exploration of this series led to the discovery of potent dual inhibitor II, which exhibited the strongest in vitro cytotoxic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2q6l9WK2gW7Vg90H21EOLACvtfcHk0liogKrKRxewdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOlurnE&md5=e983212ec3320d5606018e94063f98ad</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520novel%2520dual%2520inhibitors%2520of%2520topoisomerase%2520II%2520and%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26issue%3D22%26spage%3D6981%26epage%3D6995%26doi%3D10.1016%2Fj.bmc.2013.09.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-targeted inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1920</span>– <span class="NLM_lpage">1928</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmc.2018.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29519604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVGhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1920-1928&issue=8&author=M.+Yamashitaauthor=T.+Taharaauthor=S.+Hayakawaauthor=H.+Matsumotoauthor=S.+I.+Wadaauthor=K.+Tomiokaauthor=A.+Iida&title=Synthesis+and+biological+evaluation+of+histone+deacetylase+and+DNA+topoisomerase+II-targeted+inhibitors&doi=10.1016%2Fj.bmc.2018.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors</span></div><div class="casAuthors">Yamashita, Mitsuaki; Tahara, Teruyuki; Hayakawa, Shinya; Matsumoto, Hironobu; Wada, Shun-ichi; Tomioka, Kiyoshi; Iida, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1920-1928</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HDAC inhibitors enable histones to maintain a high degree of acetylation.  The resulting looser state of chromatin DNA may increase the accessibility of DNA drug targets and consequently improve the efficiency of anticancer drugs targeting DNA, such as Topo II inhibitors.  A novel class of nucleoside-SAHA derivs. has been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors.  Their inhibitory activities toward histone deacetylases and Topo II, and their cytotoxicities in cancer cell lines, were evaluated.  Among the synthesized hybrid compds., compd. 16b showed the potent HDAC inhibitory activity at a low nanomolar level and exhibited antiproliferative activity toward cancer cell lines including MCF-7 (breast), HCT-116 (colon), and DU-145 (prostate) cancer cells at a low micromolar level.  Moreover, compd. 16a showed HDAC6-selectivity 20-fold over HDAC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-RP6VIX6qLVg90H21EOLACvtfcHk0liogKrKRxewdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVGhsro%253D&md5=99154f34a66242dc1a2501474a0bf091</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DWada%26aufirst%3DS.%2BI.%26aulast%3DTomioka%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520histone%2520deacetylase%2520and%2520DNA%2520topoisomerase%2520II-targeted%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1920%26epage%3D1928%26doi%3D10.1016%2Fj.bmc.2018.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3958</span>– <span class="NLM_lpage">3966</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmc.2018.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29954683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3958-3966&issue=14&author=J.+Chenauthor=D.+Liauthor=W.+Liauthor=J.+Yinauthor=Y.+Zhangauthor=Z.+Yuanauthor=C.+Gaoauthor=F.+Liuauthor=Y.+Jiang&title=Design%2C+synthesis+and+anticancer+evaluation+of+acridine+hydroxamic+acid+derivatives+as+dual+Topo+and+HDAC+inhibitors&doi=10.1016%2Fj.bmc.2018.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors</span></div><div class="casAuthors">Chen, Jiwei; Li, Dan; Li, Wenlu; Yin, Jingxian; Zhang, Yueying; Yuan, Zigao; Gao, Chunmei; Liu, Feng; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3958-3966</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multitarget inhibitors design has generated great interest in cancer treatment.  Based on the synergistic effects of topoisomerase and histone deacetylase inhibitors, we designed and synthesized a new series of acridine hydroxamic acid derivs. as potential novel dual Topo and HDAC inhibitors.  MTT assays indicated that all the hybrid compds. displayed good antiproliferative activities with IC50 values in low micromolar range, among which compd. 8c displayed potent activity against U937 (IC50=0.90μM).  In addn., compd. 8c also displayed the best HDAC inhibitory activity, which was several times more potent than HDAC inhibitor SAHA.  Subsequent studies indicated that all the compds. displayed Topo II inhibition activity at 50μM.  Moreover, compd. 8c could interact with DNA and induce U937 apoptosis.  This study provides a suite of compds. for further exploration of dual Topo and HDAC inhibitors, and compd. 8c can be a new dual Topo and HDAC inhibitory anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCVb9uGhgIqrVg90H21EOLACvtfcHk0ljL6WEwRjRm3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SjsLrM&md5=bb2ad2ab72c4a871c1ecabda608d31b9</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520anticancer%2520evaluation%2520of%2520acridine%2520hydroxamic%2520acid%2520derivatives%2520as%2520dual%2520Topo%2520and%2520HDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D14%26spage%3D3958%26epage%3D3966%26doi%3D10.1016%2Fj.bmc.2018.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1021/ml500327q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500327q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=239-243&issue=3&author=S.+Heauthor=G.+Dongauthor=Z.+Wangauthor=W.+Chenauthor=Y.+Huangauthor=Z.+Liauthor=Y.+Jiangauthor=N.+Liuauthor=J.+Yaoauthor=Z.+Miaoauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+novel+multiacting+topoisomerase+I%2FII+and+histone+deacetylase+inhibitors&doi=10.1021%2Fml500327q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wang, Zhibin; Chen, Wei; Huang, Yahui; Li, Zhengang; Jiang, Yan; Liu, Na; Yao, Jianzhong; Miao, Zhenyuan; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs remains a significant challenge in current antitumor drug discovery.  Because of the synergistic effect between topoisomerase and HDAC inhibitors, the present study reported the first-in-class triple inhibitors of topoisomerase I/II and HDAC.  On the basis of 3-amino-10-hydroxylevodiamine and SAHA, a series of hybrid mols. was successfully designed and synthesized.  In particular, compd. 8c was proven to be a potent inhibitor of topoisomerase I/II and HDAC with good antiproliferative and apoptotic activities.  This proof-of-concept study also validated the effectiveness of discovering triple topoisomerase I/II and HDAC inhibitors as novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFr6sR4u6kbVg90H21EOLACvtfcHk0ljL6WEwRjRm3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D&md5=9630a82acaa4df7023a07aa7ed395e86</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fml500327q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500327q%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520multiacting%2520topoisomerase%2520I%252FII%2520and%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D3%26spage%3D239%26epage%3D243%26doi%3D10.1021%2Fml500327q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seo, Y. H.</span></span> <span> </span><span class="NLM_article-title">Dual inhibitors against topoisomerases and histone deacetylases</span>. <i>J. Cancer Prev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.15430/JCP.2015.20.2.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.15430%2FJCP.2015.20.2.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26151040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FgvVOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=85-91&issue=2&author=Y.+H.+Seo&title=Dual+inhibitors+against+topoisomerases+and+histone+deacetylases&doi=10.15430%2FJCP.2015.20.2.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitors Against Topoisomerases and Histone Deacetylases</span></div><div class="casAuthors">Seo Young Ho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cancer prevention</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-91</span>
        ISSN:<span class="NLM_cas:issn">2288-3649</span>.
    </div><div class="casAbstract">Topoisomerases and histone deacetylases (HDACs) are considered as important therapeutic targets for a wide range of cancers, due to their association with the initiation, proliferation and survival of cancer cells.  Topoisomerases are involved in the cleavage and religation processes of DNA, while HDACs regulate a dynamic epigenetic modification of the lysine amino acid on various proteins.  Extensive studies have been undertaken to discover small molecule inhibitor of each protein and thereby, several drugs have been transpired from this effort and successfully approved for clinical use.  However, the inherent heterogeneity and multiple genetic abnormalities of cancers challenge the clinical application of these single targeted drugs.  In order to overcome the limitations of a single target approach, a novel approach, simultaneously targeting topoisomerases and HDACs with a single molecule has been recently employed and attracted much attention of medicinal chemists in drug discovery.  This review highlights the current studies on the discovery of dual inhibitors against topoisomerases and HDACs, provides their pharmacological aspects and advantages, and discusses the challenges and promise of the dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM8k2AwC3rWlvAgqb2vdc5fW6udTcc2eYXL6hbPhJns7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FgvVOgtg%253D%253D&md5=3d3e5d2640e5860e04620d67cca16107</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.15430%2FJCP.2015.20.2.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15430%252FJCP.2015.20.2.85%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DY.%2BH.%26atitle%3DDual%2520inhibitors%2520against%2520topoisomerases%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Cancer%2520Prev.%26date%3D2015%26volume%3D20%26issue%3D2%26spage%3D85%26epage%3D91%26doi%3D10.15430%2FJCP.2015.20.2.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maede, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogame, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, J.</span></span> <span> </span><span class="NLM_article-title">Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-13-0551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24130054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFSmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=214-220&issue=1&author=Y.+Maedeauthor=H.+Shimizuauthor=T.+Fukushimaauthor=T.+Kogameauthor=T.+Nakamuraauthor=T.+Mikiauthor=S.+Takedaauthor=Y.+Pommierauthor=J.+Murai&title=Differential+and+common+DNA+repair+pathways+for+topoisomerase+I-+and+II-targeted+drugs+in+a+genetic+DT40+repair+cell+screen+panel&doi=10.1158%2F1535-7163.MCT-13-0551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel</span></div><div class="casAuthors">Maede, Yuko; Shimizu, Hiroyasu; Fukushima, Toru; Kogame, Toshiaki; Nakamura, Terukazu; Miki, Tsuneharu; Takeda, Shunichi; Pommier, Yves; Murai, Junko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. topoisomerase I (Top1) and II (Top2) inhibitors trap topoisomerases on DNA, thereby inducing protein-linked DNA breaks.  Cancer cells resist the drugs by removing topoisomerase-DNA complexes, and repairing the drug-induced DNA double-strand breaks (DSB) by homologous recombination and nonhomologous end joining (NHEJ).  Because numerous enzymes and cofactors are involved in the removal of the topoisomerase-DNA complexes and DSB repair, it has been challenging to comprehensively analyze the relative contribution of multiple genetic pathways in vertebrate cells.  Comprehending the relative contribution of individual repair factors would give insights into the lesions induced by the inhibitors and genetic determinants of response.  Ultimately, this information would be useful to target specific pathways to augment the therapeutic activity of topoisomerase inhibitors.  To this end, we put together 48 isogenic DT40 mutant cells deficient in DNA repair and generated one cell line deficient in autophagy (ATG5).  Sensitivity profiles were established for three clin. relevant Top1 inhibitors (camptothecin and the indenoisoquinolines LMP400 and LMP776) and three Top2 inhibitors (etoposide, doxorubicin, and ICRF-193).  Highly significant correlations were found among Top1 inhibitors as well as Top2 inhibitors, whereas the profiles of Top1 inhibitors were different from those of Top2 inhibitors.  Most distinct repair pathways between Top1 and Top2 inhibitors include NHEJ, TDP1, TDP2, PARP1, and Fanconi Anemia genes, whereas homologous recombination seems relevant esp. for Top1 and, to a lesser extent, for Top2 inhibitors.  We also found and discuss differential pathways among Top1 inhibitors and Top2 inhibitors.  Mol Cancer Ther; 13(1); 214-20. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrLkuEffSz27Vg90H21EOLACvtfcHk0li84QcJPWCpsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFSmsg%253D%253D&md5=346456ce64a6e142fb9df968cdc9f05e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0551%26sid%3Dliteratum%253Aachs%26aulast%3DMaede%26aufirst%3DY.%26aulast%3DShimizu%26aufirst%3DH.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DKogame%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DT.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DMurai%26aufirst%3DJ.%26atitle%3DDifferential%2520and%2520common%2520DNA%2520repair%2520pathways%2520for%2520topoisomerase%2520I-%2520and%2520II-targeted%2520drugs%2520in%2520a%2520genetic%2520DT40%2520repair%2520cell%2520screen%2520panel%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D1%26spage%3D214%26epage%3D220%26doi%3D10.1158%2F1535-7163.MCT-13-0551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">DNA repair functions that control sensitivity to topoisomerase-targeting drugs</span>. <i>Eukaryotic Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1128/EC.3.1.82-90.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1128%2FEC.3.1.82-90.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=14871939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1WhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=82-90&issue=1&author=M.+Malikauthor=J.+L.+Nitiss&title=DNA+repair+functions+that+control+sensitivity+to+topoisomerase-targeting+drugs&doi=10.1128%2FEC.3.1.82-90.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair functions that control sensitivity to topoisomerase-targeting drugs</span></div><div class="casAuthors">Malik, Mobeen; Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Eukaryotic Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-90</span>CODEN:
                <span class="NLM_cas:coden">ECUEA2</span>;
        ISSN:<span class="NLM_cas:issn">1535-9778</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">DNA topoisomerases play crit. roles in a wide range of cellular processes by altering DNA topol. to facilitate replication, transcription, and chromosome segregation.  Topoisomerases alter DNA topol. by introducing transient DNA strand breaks that involve a covalent protein DNA intermediate.  Many agents have been found to prevent the religation of DNA strand breaks induced by the enzymes, thereby converting the enzymes into DNA-damaging agents.  Repair of the DNA damage induced by topoisomerases is significant in understanding drug resistance arising following treatment with topoisomerase-targeting drugs.  We have used the fission yeast Schizosaccharomyces pombe to identify DNA repair pathways that are important for cell survival following drug treatment.  S. pombe strains carrying mutations in genes required for homologous recombination such as rad22A or rad32 (homologs of RAD52 and MRE11) are hypersensitive to drugs targeting either topoisomerase I or topoisomerase II.  In contrast to results obsd. with Saccharomyces cerevisiae, S. pombe strains defective in nucleotide excision repair are also hypersensitive to topoisomerase-targeting agents.  The loss of DNA replication or DNA damage checkpoints also sensitizes cells to both topoisomerase I and topoisomerase II inhibitors.  Finally, repair genes (such as the S. pombe rad8+ gene) with no obvious homologs in other systems also play important roles in causing sensitivity to topoisomerase drugs.  Since the pattern of sensitivity is distinct from that seen with other systems (such as the S. cerevisiae system), our results highlight the usefulness of S. pombe in understanding how cells deal with the unique DNA damage induced by topoisomerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD6wsBkilopLVg90H21EOLACvtfcHk0li84QcJPWCpsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1WhsLw%253D&md5=ebdda5e1f9faa6a6a904b7ff392e4e2a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1128%2FEC.3.1.82-90.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FEC.3.1.82-90.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DM.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DDNA%2520repair%2520functions%2520that%2520control%2520sensitivity%2520to%2520topoisomerase-targeting%2520drugs%26jtitle%3DEukaryotic%2520Cell%26date%3D2004%26volume%3D3%26issue%3D1%26spage%3D82%26epage%3D90%26doi%3D10.1128%2FEC.3.1.82-90.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kersey, J.</span></span> <span> </span><span class="NLM_article-title">Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-1750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1078-0432.CCR-06-1750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17332306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1591-1600&issue=5&author=Q.+Yaoauthor=B.+Weigelauthor=J.+Kersey&title=Synergism+between+etoposide+and+17-AAG+in+leukemia+cells%3A+critical+roles+for+Hsp90%2C+FLT3%2C+topoisomerase+II%2C+Chk1%2C+and+Rad51&doi=10.1158%2F1078-0432.CCR-06-1750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51</span></div><div class="casAuthors">Yao, Qing; Weigel, Brenda; Kersey, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1591-1600</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">DNA-damaging agents, such as etoposide, while clin. useful in leukemia therapy, are limited by DNA repair pathways that are not well understood.  17-(Allylamino)-17-demethoxygeldanamycin (17-AAG), an inhibitor of the mol. chaperone heat shock protein 90 (Hsp90), inhibits growth and induces apoptosis in FLT3+ leukemia cells.  In this study, we evaluated the effects of etoposide and 17-AAG in leukemia cells and the roles of Hsp90, FMS-like tyrosine kinase 3 (FLT3), checkpoint kinase 1 (Chk1), Rad51, and topoisomerase II in this inhibition.  The single and combined effects of 17-AAG and etoposide and the mechanism of these effects were evaluated.  FLT3 and the DNA repair-related proteins, Chk1 and Rad51, were studied in small interfering RNA (siRNA)-induced cell growth inhibition expts. in human leukemia cells with wild-type or mutated FLT3.  We found that etoposide and the Hsp90/FLT3 inhibitor 17-AAG, had synergistic inhibitory effects on FLT3+ MLL-fusion gene leukemia cells.  Cells with an internal tandem duplication (ITD) FLT3 (Molm13 and MV4;11) were more sensitive to etoposide/17-AAG than leukemias with wild-type FLT3 (HPB-Null and RS4;11).  A crit. role for FLT3 was shown in expts. with FLT3 ligand and siRNA targeted to FLT3.  An important role for topoisomerase II and the DNA repair-related proteins, Chk1 and Rad51, in the synergistic effects was suggested from the results.  The repair of potentially lethal DNA damage by etoposide in leukemia cells is dependent on intact and functioning FLT3 esp. leukemias with ITD-FLT3.  These data suggest a rational therapeutic strategy for FLT3+ leukemias that combines etoposide or other DNA-damaging agents with Hsp90/FLT3 inhibitors such as 17-AAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYkcf05rkfnbVg90H21EOLACvtfcHk0lg4TIFx7RpvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLY%253D&md5=1baa24d5f1f46ce7eb7ee2eda7075da1</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1750%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DWeigel%26aufirst%3DB.%26aulast%3DKersey%26aufirst%3DJ.%26atitle%3DSynergism%2520between%2520etoposide%2520and%252017-AAG%2520in%2520leukemia%2520cells%253A%2520critical%2520roles%2520for%2520Hsp90%252C%2520FLT3%252C%2520topoisomerase%2520II%252C%2520Chk1%252C%2520and%2520Rad51%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D5%26spage%3D1591%26epage%3D1600%26doi%3D10.1158%2F1078-0432.CCR-06-1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitagawa, I.</span></span> <span> </span><span class="NLM_article-title">Marine natural products. XXXII. Absolute configurations of C-4 of the manoalide family, biologically active sesterterpenes from the marine sponge <i>Hyrtios erecta</i></span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1248/cpb.42.265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1248%2Fcpb.42.265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8149454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2cXltlShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1994&pages=265-270&issue=2&author=M.+Kobayashiauthor=T.+Okamotoauthor=K.+Hayashiauthor=N.+Yokoyamaauthor=T.+Sasakiauthor=I.+Kitagawa&title=Marine+natural+products.+XXXII.+Absolute+configurations+of+C-4+of+the+manoalide+family%2C+biologically+active+sesterterpenes+from+the+marine+sponge+Hyrtios+erecta&doi=10.1248%2Fcpb.42.265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Marine natural products. XXXII. Absolute configurations of C-4 of the manoalide family, biologically active sesterterpenes from the marine sponge Hyrtios erecta</span></div><div class="casAuthors">Kobayashi, Motomasa; Okamoto, Takumi; Hayashi, Kozo; Yokoyama, Norio; Sasaki, Takuma; Kitagawa, Isao</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-70</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">Cytotoxic sesterterpenes, manoalide 25-acetals (I), seco-manoalide (II), (E)-neomanoalide (III), (Z)-neomanoalide (IV), and heteronemin (V), were isolated from the marine sponge Hyrtios erecta (collected at Amami Island, Kagoshima Prefecture, Japan) by bioassay-guided sepn. and the abs. configurations of these manoalide family members have been detd.  Manoalide 25-acetals (I) were shown to exhibit in vivo antitumor activity and to inhibit the DNA-relaxing activity of mouse DNA topoisomerase I and the DNA-unknotting activity of calf thymus DNA topoisomerase II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr39_b7pYTT5rVg90H21EOLACvtfcHk0lg4TIFx7RpvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXltlShtbs%253D&md5=1c6f8704a87f032da5d9ff162c2ec7f9</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1248%2Fcpb.42.265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.42.265%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DYokoyama%26aufirst%3DN.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKitagawa%26aufirst%3DI.%26atitle%3DMarine%2520natural%2520products.%2520XXXII.%2520Absolute%2520configurations%2520of%2520C-4%2520of%2520the%2520manoalide%2520family%252C%2520biologically%2520active%2520sesterterpenes%2520from%2520the%2520marine%2520sponge%2520Hyrtios%2520erecta%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1994%26volume%3D42%26issue%3D2%26spage%3D265%26epage%3D270%26doi%3D10.1248%2Fcpb.42.265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Shazly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. C.</span></span> <span> </span><span class="NLM_article-title">Heteronemin, a marine sesterterpenoid-type metabolite, induces apoptosis in prostate LNcap cells via oxidative and ER stress combined with the inhibition of topoisomerase II and Hsp90</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">204</span>, <span class="refDoi"> DOI: 10.3390/md16060204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3390%2Fmd16060204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVersb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=204&issue=6&author=M.+G.+Leeauthor=Y.+C.+Liuauthor=Y.+L.+Leeauthor=M.+El-Shazlyauthor=K.+H.+Laiauthor=S.+P.+Shihauthor=S.+C.+Keauthor=M.+C.+Hongauthor=Y.+C.+Duauthor=J.+C.+Yangauthor=P.+J.+Sungauthor=Z.+H.+Wenauthor=M.+C.+Lu&title=Heteronemin%2C+a+marine+sesterterpenoid-type+metabolite%2C+induces+apoptosis+in+prostate+LNcap+cells+via+oxidative+and+ER+stress+combined+with+the+inhibition+of+topoisomerase+II+and+Hsp90&doi=10.3390%2Fmd16060204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Heteronemin, a marine sesterterpenoid-type metabolite, induces apoptosis in prostate LNcap cells via oxidative and ER stress combined with the inhibition of topoisomerase II and Hsp90</span></div><div class="casAuthors">Lee, Man-Gang; Liu, Yi-Chang; Lee, Yi-Lun; El-Shazly, Mohamed; Lai, Kuei-Hung; Shih, Shou-Ping; Ke, Seng-Chung; Hong, Ming-Chang; Du, Ying-Chi; Yang, Juan-Cheng; Sung, Ping-Jyun; Wen, Zhi-Hong; Lu, Mei-Chin</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">204/1-204/24</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Heteronemin, a marine sesterterpenoid-type natural product, possesses diverse bioactivities, esp. antitumor effect.  Accumulating evidence shows that heteronemin may act as a potent anticancer agent in clin. therapy.  To fully understand the antitumor mechanism of heteronemin, we further explored the precise mol. targets in prostate cancer cells.  Initially, heteronemin exhibited potent cytotoxic effect against LNcap and PC3 prostate cancer cells with IC50 1.4 and 2.7 μM after 24 h, resp.  In the xenograft animal model, the tumor size was significantly suppressed to about 51.9% in the heteronemin-treated group in comparison with the control group with no significant difference in the mice body wts.  In addn., the results of a cell-free system assay indicated that heteronemin could act as topoisomerase II (topo II) catalytic inhibitor through the elimination of essential enzymic activity of topoisomerase IIα expression.  We found that the use of heteronemin-triggered apoptosis by 20.1-68.3%, caused disruption of mitochondrial membrane potential (MMP) by 66.9-99.1% and promoted calcium release by 1.8-, 2.0-, and 2.1-fold compared with the control group in a dose-dependent manner, as demonstrated by annexin-V/PI, rhodamine 123 and Fluo-3 staining assays, resp.  Moreover, our findings indicated that the pretreatment of LNcap cells with an inhibitor of protein tyrosine phosphatase (PTPi) diminished growth inhibition, oxidative and Endoplasmic Reticulum (ER) stress, as well as activation of Chop/Hsp70 induced by heteronemin, suggesting PTP activation plays a crucial rule in the cytotoxic activity of heteronemin.  Using mol. docking anal., heteronemin exhibited more binding affinity to the N-terminal ATP-binding pocket of Hsp90 protein than 17-AAG, a std. Hsp90 inhibitor.  Finally, heteronemin promoted autophagy and apoptosis through the inhibition of Hsp 90 and topo II as well as PTP activation in prostate cancer cells.  Taken together, these multiple targets present heteronemin as an interesting candidate for its future development as an antiprostatic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsfEBw43CTXrVg90H21EOLACvtfcHk0lg4TIFx7RpvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVersb3M&md5=bfea332fc6c2244f39dcd83eb61e9247</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.3390%2Fmd16060204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd16060204%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BG.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DLee%26aufirst%3DY.%2BL.%26aulast%3DEl-Shazly%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DK.%2BH.%26aulast%3DShih%26aufirst%3DS.%2BP.%26aulast%3DKe%26aufirst%3DS.%2BC.%26aulast%3DHong%26aufirst%3DM.%2BC.%26aulast%3DDu%26aufirst%3DY.%2BC.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DSung%26aufirst%3DP.%2BJ.%26aulast%3DWen%26aufirst%3DZ.%2BH.%26aulast%3DLu%26aufirst%3DM.%2BC.%26atitle%3DHeteronemin%252C%2520a%2520marine%2520sesterterpenoid-type%2520metabolite%252C%2520induces%2520apoptosis%2520in%2520prostate%2520LNcap%2520cells%2520via%2520oxidative%2520and%2520ER%2520stress%2520combined%2520with%2520the%2520inhibition%2520of%2520topoisomerase%2520II%2520and%2520Hsp90%26jtitle%3DMar.%2520Drugs%26date%3D2018%26volume%3D16%26issue%3D6%26spage%3D204%26doi%3D10.3390%2Fmd16060204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Bauman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5926</span>– <span class="NLM_lpage">5932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11479235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVCgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=5926-5932&issue=15&author=S.+D.+Desaiauthor=T.+K.+Liauthor=A.+Rodriguez-Baumanauthor=E.+H.+Rubinauthor=L.+F.+Liu&title=Ubiquitin%2F26S+proteasome-mediated+degradation+of+topoisomerase+I+as+a+resistance+mechanism+to+camptothecin+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells</span></div><div class="casAuthors">Desai, Shyamal D.; Li, Tsai-Kun; Rodriguez-Bauman, Alexandra; Rubin, Eric H.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5926-5932</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Camptothecin (CPT) induces down-regulation of topoisomerase I (TOP1) via an ubiquitin/26S proteasome pathway.  Studies using a panel of breast and colorectal cancer cell lines as well as primary nontransformed and oncogene-transformed cells have demonstrated that CPT-induced down-regulation exhibits a high degree of heterogeneity.  In general, non-transformed cells are much more proficient in CPT-induced TOP1 down-regulation than their transformed counterparts.  Among the breast and colorectal cancer cell lines, there was a general correlation between the extent of CPT-induced TOP1 down-regulation and CPT resistance.  The breast cancer cell line ZR-75-1, the most sensitive to CPT, was completely defective in CPT-induced TOP1 down-regulation, whereas the breast cancer cell line BT474, the least sensitive to CPT, exhibited effective CPT-induced TOP1 down-regulation.  The 26S proteasome inhibitor MG132 was shown to inhibit CPT-induced down-regulation of TOP1 in BT474 cells and selectively sensitized BT474 but not ZR-75-1 cells to CPT-induced cytotoxicity and apoptosis.  In the aggregate, these results suggest that CPT-induced down-regulation of TOP1 could be an important parameter for detg. CPT sensitivity/resistance in tumor cells.  Anal. of the levels of TOP1 cleavable complexes, SUMO-1-TOP1 conjugates, and ubiquitin-TOP1 conjugates in ZR-75-1 and BT474 cells has suggested that the heterogeneity of CPT-induced down-regulation of TOP1 in tumor cells is at least in part attributable to altered regulation of a process(es) downstream from the TOP1 cleavable complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQv9Lv4_pMRrVg90H21EOLACvtfcHk0liQf2WPfyJuhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVCgu7s%253D&md5=f2cc6a3b43b2cf892aa0109c487743f1</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DS.%2BD.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DRodriguez-Bauman%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DUbiquitin%252F26S%2520proteasome-mediated%2520degradation%2520of%2520topoisomerase%2520I%2520as%2520a%2520resistance%2520mechanism%2520to%2520camptothecin%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26issue%3D15%26spage%3D5926%26epage%3D5932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellenberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2.DNA and Top2.RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">17960</span>– <span class="NLM_lpage">17969</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.565374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.M114.565374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24808172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=17960-17969&issue=26&author=R.+Gaoauthor=M.+J.+Schellenbergauthor=S.+Y.+Huangauthor=M.+Abdelmalakauthor=C.+Marchandauthor=K.+C.+Nitissauthor=J.+L.+Nitissauthor=R.+S.+Williamsauthor=Y.+Pommier&title=Proteolytic+degradation+of+topoisomerase+II+%28Top2%29+enables+the+processing+of+Top2.DNA+and+Top2.RNA+covalent+complexes+by+tyrosyl-DNA-phosphodiesterase+2+%28TDP2%29&doi=10.1074%2Fjbc.M114.565374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2·DNA and Top2·RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)</span></div><div class="casAuthors">Gao, Rui; Schellenberg, Matthew J.; Huang, Shar-yin N.; Abdelmalak, Monica; Marchand, Christophe; Nitiss, Karin C.; Nitiss, John L.; Williams, R. Scott; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">17960-17969</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Eukaryotic type II topoisomerases (Top2α and Top2β) are homodimeric enzymes; they are essential for altering DNA topol. by the formation of normally transient double strand DNA cleavage.  Anticancer drugs (etoposide, doxorubicin, and mitoxantrone) and also Top2 oxidn. and DNA helical alterations cause potentially irreversible Top2·DNA cleavage complexes (Top2cc), leading to Top2-linked DNA breaks.  Top2cc are the therapeutic mechanism for killing cancer cells.  Yet Top2cc can also generate recombination, translocations, and apoptosis in normal cells.  The Top2 protein-DNA covalent complexes are excised (in part) by tyrosyl-DNA-phosphodiesterase 2 (TDP2/TTRAP/EAP2/VPg unlinkase).  In this study, we show that irreversible Top2cc induced in suicidal substrates are not processed by TDP2 unless they first undergo proteolytic processing or denaturation.  We also demonstrate that TDP2 is most efficient when the DNA attached to the tyrosyl is in a single-stranded configuration and that TDP2 can efficiently remove a tyrosine linked to a single misincorporated ribonucleotide or to polyribonucleotides, which expands the TDP2 catalytic profile with RNA substrates.  The 1.6-Å resoln. crystal structure of TDP2 bound to a substrate bearing a 5'-ribonucleotide defines a mechanism through which RNA can be accommodated in the TDP2 active site, albeit in a strained conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlhM_DAQWZurVg90H21EOLACvtfcHk0liQf2WPfyJuhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FN&md5=653acb97787ce2f52c0ed47101cfa0d5</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.565374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.565374%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DR.%26aulast%3DSchellenberg%26aufirst%3DM.%2BJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DAbdelmalak%26aufirst%3DM.%26aulast%3DMarchand%26aufirst%3DC.%26aulast%3DNitiss%26aufirst%3DK.%2BC.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26aulast%3DWilliams%26aufirst%3DR.%2BS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DProteolytic%2520degradation%2520of%2520topoisomerase%2520II%2520%2528Top2%2529%2520enables%2520the%2520processing%2520of%2520Top2.DNA%2520and%2520Top2.RNA%2520covalent%2520complexes%2520by%2520tyrosyl-DNA-phosphodiesterase%25202%2520%2528TDP2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D26%26spage%3D17960%26epage%3D17969%26doi%3D10.1074%2Fjbc.M114.565374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prajapati, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span> <span> </span><span class="NLM_article-title">Proteasome-mediated proteostasis: novel medicinal and pharmacological strategies for diseases</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1916</span>– <span class="NLM_lpage">1973</span>, <span class="refDoi"> DOI: 10.1002/med.21502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fmed.21502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29719055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1MjptVGlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=1916-1973&issue=6&author=R.+Mishraauthor=A.+Upadhyayauthor=V.+K.+Prajapatiauthor=A.+Mishra&title=Proteasome-mediated+proteostasis%3A+novel+medicinal+and+pharmacological+strategies+for+diseases&doi=10.1002%2Fmed.21502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome-mediated proteostasis: Novel medicinal and pharmacological strategies for diseases</span></div><div class="casAuthors">Mishra Ribhav; Upadhyay Arun; Mishra Amit; Prajapati Vijay Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1916-1973</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Proteins actively participate in a wide range of cellular physiological functions.  But aggregation of proteins results in cytotoxicity, and unwanted aggregation of misfolded proteins often causes many diseases.  During abnormal protein aggregation events, cells try to cope against such deleterious consequences because of the remarkable functional attempts of two distinct proteolytic mechanisms.  These tightly regulative and signaling mechanisms are autophagy pathway and ubiquitin proteasome system.  Proteasome complex system holds the elimination capacity of intracellular aberrant protein aggregation.  Despite the considerable progress that has been achieved, which elucidates wide function and diverse roles of proteasome system, still several crucial problems remain unanswered.  For example, how the complex proteasomes assembly and their interactive pathways determine the precise sense of several proteotoxic insults, which can severely affect the cell survival and homeostasis? The specific degradation of various aberrant proteins that can disturb cellular homeostasis is achieved by proper proteasome functionality, which is yet another unclear and critical challenge.  Therefore, a better understanding of the various cellular signaling mechanisms composing the proteasome machinery carries broad therapeutic implications linked with proteopathies.  This article signifies the urgent need, which is now crucial for us to improve our understanding of the proteasome architecture, structure, and functions that span multiple level strategies from the molecular level to the cellular level.  This systematic in-depth information of proteasome may be helpful in the near future to design a new molecular framework based on intrinsic and extrinsic cellular mechanisms that drive the assembly of proteasome to induce cellular survival against proteostasis imbalance and disease conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReA_VqWYLezCnGiHuhFGv8fW6udTcc2eZK1dYszGoiLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjptVGlsA%253D%253D&md5=1768ffef72eb04f44d273d8509fd5875</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fmed.21502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21502%26sid%3Dliteratum%253Aachs%26aulast%3DMishra%26aufirst%3DR.%26aulast%3DUpadhyay%26aufirst%3DA.%26aulast%3DPrajapati%26aufirst%3DV.%2BK.%26aulast%3DMishra%26aufirst%3DA.%26atitle%3DProteasome-mediated%2520proteostasis%253A%2520novel%2520medicinal%2520and%2520pharmacological%2520strategies%2520for%2520diseases%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26issue%3D6%26spage%3D1916%26epage%3D1973%26doi%3D10.1002%2Fmed.21502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogiso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruo, T.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2429</span>– <span class="NLM_lpage">2434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10811120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtV2qt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=2429-2434&issue=9&author=Y.+Ogisoauthor=A.+Tomidaauthor=S.+Leiauthor=S.+Omuraauthor=T.+Tsuruo&title=Proteasome+inhibition+circumvents+solid+tumor+resistance+to+topoisomerase+II-directed+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs</span></div><div class="casAuthors">Ogiso, Yasunari; Tomida, Akihiro; Lei, Shuhong; Omura, Satoshi; Tsuruo, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2429-2434</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Physiol. cell conditions, such as glucose deprivation and hypoxia, play a role in developing drug resistance in solid tumors.  These tumor-specific conditions cause decreased expression of DNA topoisomerase IIα (topo IIα), rendering cells resistant to topo II-targeted drugs, such as etoposide and doxorubicin.  We show here that inhibition of proteasome attenuated drug resistance by inhibiting topo IIα depletion induced by glucose starvation and hypoxia.  Topo IIα restoration was seen only at the protein levels, indicating that the topo IIα protein depletion occurred through a proteasome-mediated degrdn. mechanism.  The stress-induced etoposide resistance was effectively prevented in vitro by the proteasome inhibitor lactacystin in both intrinsically resistant and sensitive tumor cells (colon cancer HT-29 and ovarian cancer A2780 cells, resp.).  Furthermore, lactacystin effectively enhanced the antitumor activity of etoposide in the refractory HT-29 xenograft.  These results indicate that lactacystin could serve as a new therapeutic agent to circumvent resistance to topo II-targeted chemotherapy in solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIqgiEa74irVg90H21EOLACvtfcHk0liQf2WPfyJuhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtV2qt70%253D&md5=c5bec676e519125c1e25150cd3141dff</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOgiso%26aufirst%3DY.%26aulast%3DTomida%26aufirst%3DA.%26aulast%3DLei%26aufirst%3DS.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DTsuruo%26aufirst%3DT.%26atitle%3DProteasome%2520inhibition%2520circumvents%2520solid%2520tumor%2520resistance%2520to%2520topoisomerase%2520II-directed%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26issue%3D9%26spage%3D2429%26epage%3D2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">A protease pathway for the repair of topoisomerase II-DNA covalent complexes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">35997</span>– <span class="NLM_lpage">36003</span>, <span class="refDoi"> DOI: 10.1074/jbc.M604149200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.M604149200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=16973621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ajtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=35997-36003&issue=47&author=A.+Zhangauthor=Y.+L.+Lyuauthor=C.+P.+Linauthor=N.+Zhouauthor=A.+M.+Azarovaauthor=L.+M.+Woodauthor=L.+F.+Liu&title=A+protease+pathway+for+the+repair+of+topoisomerase+II-DNA+covalent+complexes&doi=10.1074%2Fjbc.M604149200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A Protease Pathway for the Repair of Topoisomerase II-DNA Covalent Complexes</span></div><div class="casAuthors">Zhang, Ailing; Lyu, Yi Lisa; Lin, Chao-Po; Zhou, Nai; Azarova, Anna M.; Wood, Laurence M.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">35997-36003</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Despite rapid advances in the field of DNA repair, little is known about the repair of protein-DNA adducts.  Previous studies have demonstrated that topoisomerase II (TopII)-DNA adducts (TopII-DNA covalent complexes) are rapidly degraded by the proteasome.  It has been hypothesized that proteasomal degrdn. of TopII-DNA covalent adducts exposes TopII-concealed DNA double-strand breaks (DSBs) for repair.  To test this hypothesis, the anticancer drug, VP-16 (etoposide), was employed to induce TopII-DNA covalent complexes in mammalian cells, and the involvement of proteasome in processing TopII-DNA covalent complexes into DSBs was investigated.  Consistent with the hypothesis, VP-16-induced DSBs as monitored by neutral comet assay, as well as DNA damage signals (e.g. γ-H2AX) were significantly reduced in the presence of the proteasome inhibitor, MG132.  Using both top2β knock-out mouse embryonic fibroblasts and Top2β small interfering RNA knockdown PC12 cells, as well as postmitotic neurons in which TopIIα was absent, we showed that VP-16-induced DNA damage signals were attenuated upon proteasome inhibition, suggesting the involvement of proteasome in the repair/processing of both TopIIα-DNA and TopIIβ-DNA adducts.  By contrast, hydrogen peroxide-induced γ-H2AX was unaffected upon proteasome inhibition, suggesting a specific requirement of the proteasome pathway in the processing of TopII-DNA covalent complexes into DNA damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj7nwjxWfE47Vg90H21EOLACvtfcHk0ljp8eEVvnPbqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ajtrbJ&md5=74210337471ef6053780a3ee8a8e24c4</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M604149200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M604149200%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DLyu%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BP.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DWood%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DA%2520protease%2520pathway%2520for%2520the%2520repair%2520of%2520topoisomerase%2520II-DNA%2520covalent%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26issue%3D47%26spage%3D35997%26epage%3D36003%26doi%3D10.1074%2Fjbc.M604149200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramley, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span> <span> </span><span class="NLM_article-title">Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bcp.2015.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26794000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=29-39&author=K.+C.+Leeauthor=R.+L.+Bramleyauthor=I.+G.+Cowellauthor=G.+H.+Jacksonauthor=C.+A.+Austin&title=Proteasomal+inhibition+potentiates+drugs+targeting+DNA+topoisomerase+II&doi=10.1016%2Fj.bcp.2015.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II</span></div><div class="casAuthors">Lee, Ka C.; Bramley, Rebecca L.; Cowell, Ian G.; Jackson, Graham H.; Austin, Caroline A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The reaction mechanism of DNA topoisomerase II (TOP2) involves a covalent double-strand break intermediate in which the enzyme is coupled to DNA via a 5'-phosphotyrosyl bond.  This normally transient enzyme-bridged break is stabilized by drugs such as mitoxantrone, mAMSA, etoposide, doxorubicin, epirubicin and idarubicin, which are referred to as TOP2 poisons.  Removal of topoisomerase II by the proteasome is involved in the repair of these lesions.  In K562 cells, inhibiting the proteasome with MG132 significantly potentiated the growth inhibition by these six drugs that target topoisomerase II, and the highest level of potentiation was obsd. with mitoxantrone.  Mitoxantrone also showed the greatest potentiation by MG132 in three Nalm 6 cell lines with differing levels of TOP2A or TOP2B.  Mitoxantrone was also potentiated by the clin. used proteasome inhibitor PS341 (Velcade).  We have also shown that proteasome inhibition with MG132 in K562 cells reduces the rate of removal of mitoxantrone or etoposide stabilized topoisomerase complexes from DNA, suggesting a possible mechanism for the potentiation of topoisomerase II drugs by proteasomal inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLiamWQ6CSF7Vg90H21EOLACvtfcHk0ljp8eEVvnPbqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVyhtg%253D%253D&md5=ac412751243ac54d9fca38227a13042e</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DBramley%26aufirst%3DR.%2BL.%26aulast%3DCowell%26aufirst%3DI.%2BG.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26atitle%3DProteasomal%2520inhibition%2520potentiates%2520drugs%2520targeting%2520DNA%2520topoisomerase%2520II%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D103%26spage%3D29%26epage%3D39%26doi%3D10.1016%2Fj.bcp.2015.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von Metzler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heider, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamottke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sezer, O.</span></span> <span> </span><span class="NLM_article-title">Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>315</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2471</span>– <span class="NLM_lpage">2478</span>, <span class="refDoi"> DOI: 10.1016/j.yexcr.2009.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.yexcr.2009.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19410573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnslyktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2009&pages=2471-2478&issue=14&author=I.+von+Metzlerauthor=U.+Heiderauthor=M.+Miethauthor=B.+Lamottkeauthor=M.+Kaiserauthor=C.+Jakobauthor=O.+Sezer&title=Synergistic+interaction+of+proteasome+and+topoisomerase+II+inhibition+in+multiple+myeloma&doi=10.1016%2Fj.yexcr.2009.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma</span></div><div class="casAuthors">von Metzler, Ivana; Heider, Ulrike; Mieth, Maren; Lamottke, Britta; Kaiser, Martin; Jakob, Christian; Sezer, Orhan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2471-2478</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multiple myeloma is a malignancy of terminally differentiated plasma cells and is incurable in the majority of the patients.  Thus, novel effective treatment regimens are urgently needed.  In this study, we examd. the effects of co-treatment with proteasome-inhibitor bortezomib and topoisomerase II inhibitor etoposide in multiple myeloma cells lines OPM-2, RPMI-S and NCI-H929.  Using the median effect method of Chou and Talalay, we evaluated the combination indexes (CI) for simultaneous and sequential treatment schedules.  In the sequential treatment schedule, we found strong synergistic effects in all three cell lines, even at low single-agent cytotoxicity levels.  When cells were treated simultaneously with both drugs, the synergy was present but less pronounced than in the sequential treatment schedule.  The synergistic effects obsd. in the co-treatment schedules were accompanied by an inhibition of anti-apoptotic effects that were induced by etoposide alone.  Namely, bortezomib abrogated both etoposide-induced NF-κB activation and etoposide-induced bcl-2 up-regulation.  Our data suggest that combining etoposide with bortezomib might be useful for cancer treatment, as bortezomib potentially inhibits counter-regulatory mechanisms of tumor cells, which are induced by topoisomerase II inhibition and which may contribute to acquired chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIc0Z3J4DBOrVg90H21EOLACvtfcHk0ljp8eEVvnPbqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnslyktLw%253D&md5=be75ddc33833dfed0508fec17d7f5481</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2009.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2009.04.019%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMetzler%26aufirst%3DI.%26aulast%3DHeider%26aufirst%3DU.%26aulast%3DMieth%26aufirst%3DM.%26aulast%3DLamottke%26aufirst%3DB.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DJakob%26aufirst%3DC.%26aulast%3DSezer%26aufirst%3DO.%26atitle%3DSynergistic%2520interaction%2520of%2520proteasome%2520and%2520topoisomerase%2520II%2520inhibition%2520in%2520multiple%2520myeloma%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2009%26volume%3D315%26issue%3D14%26spage%3D2471%26epage%3D2478%26doi%3D10.1016%2Fj.yexcr.2009.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q. P.</span></span> <span> </span><span class="NLM_article-title">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.2174/156800911794519752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F156800911794519752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21247388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=239-253&issue=3&author=D.+Chenauthor=M.+Frezzaauthor=S.+Schmittauthor=J.+Kanwarauthor=Q.+P.+Dou&title=Bortezomib+as+the+first+proteasome+inhibitor+anticancer+drug%3A+current+status+and+future+perspectives&doi=10.2174%2F156800911794519752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span></div><div class="casAuthors">Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-253</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer.  Based on pos. preclin. and clin. studies, bortezomib was subsequently approved for the clin. use as a front-line treatment for newly diagnosed multiple myeloma patients and for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this drug has become the staple of treatment.  The approval of bortezomib by the US Food and Drug Administration (FDA) represented a significant milestone as the first proteasome inhibitor to be implemented in the treatment of malignant disease.  Bortezomib has shown a pos. clin. benefit either alone or as a part of combination therapy to induce chemo-/radio-sensitization or overcome drug resistance.  One of the major mechanisms of bortezomib assocd. with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-XL and Bcl-2, and result in apoptotic cell death in malignant cells.  Another important mechanism of bortezomib is through suppression of the NF-κB signaling pathway resulting in the down-regulation of its anti-apoptotic target genes.  Although the majority of success achieved with bortezomib has been in hematol. malignancies, its effect toward solid tumors has been less than encouraging.  Addnl., the widespread clin. use of bortezomib continues to be hampered by the appearance of dose-limiting toxicities, drug-resistance and interference by some natural compds.  These findings could help guide physicians in refining the clin. use of bortezomib, and encourage basic scientists to generate next generation proteasome inhibitors that broaden the spectrum of efficacy and produce a more durable clin. response in cancer patients.  Other desirable applications for the use of proteasome inhibitors include the development of inhibitors against specific E3 ligases, which act at an early step in the ubiquitin-proteasome pathway, and the discovery of less toxic and novel proteasome inhibitors from natural products and traditional medicines, which may provide more viable drug candidates for cancer chemoprevention and the treatment of cancer patients in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4QCk3nP8BLVg90H21EOLACvtfcHk0lhi0VT1gD_U0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D&md5=15becbceb98ec3e244fc066315815dd2</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.2174%2F156800911794519752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911794519752%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFrezza%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DS.%26aulast%3DKanwar%26aufirst%3DJ.%26aulast%3DDou%26aufirst%3DQ.%2BP.%26atitle%3DBortezomib%2520as%2520the%2520first%2520proteasome%2520inhibitor%2520anticancer%2520drug%253A%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26issue%3D3%26spage%3D239%26epage%3D253%26doi%3D10.2174%2F156800911794519752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Hay, M.</span></span> <span> </span><span class="NLM_article-title">Acute lymphoblastic leukemia: a comprehensive review and 2017 update</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e577</span>, <span class="refDoi"> DOI: 10.1038/bcj.2017.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fbcj.2017.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28665419" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e577&issue=6&author=T.+Terwilligerauthor=M.+Abdul-Hay&title=Acute+lymphoblastic+leukemia%3A+a+comprehensive+review+and+2017+update&doi=10.1038%2Fbcj.2017.53"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2017.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2017.53%26sid%3Dliteratum%253Aachs%26aulast%3DTerwilliger%26aufirst%3DT.%26aulast%3DAbdul-Hay%26aufirst%3DM.%26atitle%3DAcute%2520lymphoblastic%2520leukemia%253A%2520a%2520comprehensive%2520review%2520and%25202017%2520update%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2017%26volume%3D7%26issue%3D6%26spage%3De577%26doi%3D10.1038%2Fbcj.2017.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vispe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annereau, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creancier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruczynski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barret, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailly, C.</span></span> <span> </span><span class="NLM_article-title">Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1863</span>– <span class="NLM_lpage">1872</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2007.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bcp.2007.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17391647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFOjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1863-1872&issue=12&author=S.+Vispeauthor=I.+Vandenbergheauthor=M.+Robinauthor=J.+P.+Annereauauthor=L.+Creancierauthor=V.+Piqueauthor=J.+P.+Galyauthor=A.+Kruczynskiauthor=J.+M.+Barretauthor=C.+Bailly&title=Novel+tetra-acridine+derivatives+as+dual+inhibitors+of+topoisomerase+II+and+the+human+proteasome&doi=10.1016%2Fj.bcp.2007.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome</span></div><div class="casAuthors">Vispe, S.; Vandenberghe, I.; Robin, M.; Annereau, J. P.; Creancier, L.; Pique, V.; Galy, J. P.; Kruczynski, A.; Barret, J. M.; Bailly, C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1863-1872</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acridine derivs., such as amsacrine, represent a well known class of multi-targeted anti-cancer agents that generally interfere with DNA synthesis and inhibit topoisomerase II.  But in addn., these tricyclic mols. often display secondary effects on other biochem. pathways including protein metab.  To identify novel anti-cancer drugs, we evaluated the mechanism of action of a novel series of bis- and tetra-acridines.  As expected, these mols. were found to interact with DNA and inhibit the topoisomerase II-mediated DNA decatenation.  Interestingly when tested on human tumor cells either sensitive (HL-60) or resistant (HL-60/MX2) to topoisomerase II inhibitors, these mols. proved equicytotoxic against the two cell lines, suggesting that they do not only rely on topoisomerase II inhibition to exert their cytotoxic effects.  To identify alternative targets, we tested the capacity of acridines 1-9 to inhibit the proteasome machinery.  Four tetra-acridines inhibited the proteasome in vitro, with IC50 values up to 40 times lower than that of the ref. proteasome inhibitor lactacystin.  Moreover, unlike peptide aldehydes used as ref. inhibitors for the proteasome, these new acridine compds. demonstrated a good selectivity towards the proteasome, when tested against four unrelated proteases.  A cellular assay based on the degrdn. of a proteasome protein substrate indicated that at least two of the tetra-acridines maintained this proteasome inhibition activity in a cellular context.  This is the first report of tetra-acridines that demonstrate dual topoisomerase II and proteasome inhibition properties.  This new dual activity could represent a novel anti-cancer approach to circumvent certain forms of tumor resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXYfECvL9ru7Vg90H21EOLACvtfcHk0lhi0VT1gD_U0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFOjtbo%253D&md5=91068f0219e5114ff5a7c2b19010e57f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2007.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2007.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DVispe%26aufirst%3DS.%26aulast%3DVandenberghe%26aufirst%3DI.%26aulast%3DRobin%26aufirst%3DM.%26aulast%3DAnnereau%26aufirst%3DJ.%2BP.%26aulast%3DCreancier%26aufirst%3DL.%26aulast%3DPique%26aufirst%3DV.%26aulast%3DGaly%26aufirst%3DJ.%2BP.%26aulast%3DKruczynski%26aufirst%3DA.%26aulast%3DBarret%26aufirst%3DJ.%2BM.%26aulast%3DBailly%26aufirst%3DC.%26atitle%3DNovel%2520tetra-acridine%2520derivatives%2520as%2520dual%2520inhibitors%2520of%2520topoisomerase%2520II%2520and%2520the%2520human%2520proteasome%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26issue%3D12%26spage%3D1863%26epage%3D1872%26doi%3D10.1016%2Fj.bcp.2007.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Protein kinases - the major drug targets of the twenty-first century?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nrd773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrd773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12120282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&issue=4&author=P.+Cohen&title=Protein+kinases+-+the+major+drug+targets+of+the+twenty-first+century%3F&doi=10.1038%2Fnrd773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Protein kinases - the major drug targets of the twenty-first century?</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease.  A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clin. use.  Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors.  Here, I give a personal view of some of the most important advances that have shaped this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRd_GqiGAWaLVg90H21EOLACvtfcHk0lhi0VT1gD_U0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D&md5=67d2fbc11a55b5980ee0692f7bc13cc9</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fnrd773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd773%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520kinases%2520-%2520the%2520major%2520drug%2520targets%2520of%2520the%2520twenty-first%2520century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D4%26spage%3D309%26epage%3D315%26doi%3D10.1038%2Fnrd773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhullar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagarón, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupasinghe, H. P. V.</span></span> <span> </span><span class="NLM_article-title">Kinase-targeted cancer therapies: progress, challenges and future directions</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">48</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0804-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1186%2Fs12943-018-0804-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29455673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=48&issue=1&author=K.+S.+Bhullarauthor=N.+O.+Lagar%C3%B3nauthor=E.+M.+McGowanauthor=I.+Parmarauthor=A.+Jhaauthor=B.+P.+Hubbardauthor=H.+P.+V.+Rupasinghe&title=Kinase-targeted+cancer+therapies%3A+progress%2C+challenges+and+future+directions&doi=10.1186%2Fs12943-018-0804-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-targeted cancer therapies: progress, challenges and future directions</span></div><div class="casAuthors">Bhullar, Khushwant S.; Lagaron, Naiara Orrego; McGowan, Eileen M.; Parmar, Indu; Jha, Amitabh; Hubbard, Basil P.; Rupasinghe, H. P. Vasantha</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48/1-48/20</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues.  Many of these kinases are assocd. with human cancer initiation and progression.  The recent development of small-mol. kinase inhibitors for the treatment of diverse types of cancer has proven successful in clin. therapy.  Significantly, protein kinases are the second most targeted group of drug targets, after the G-proteincoupled receptors.  Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer.  Furthermore, about 150 kinase-targeted drugs are in clin. phase trials, and many kinase-specific inhibitors are in the preclin. stage of drug development.  Nevertheless, many factors confound the clin. efficacy of these mols.  Specific tumor genetics, tumor microenvironment, drug resistance, and pharmacogenomics det. how useful a compd. will be in the treatment of a given cancer.  This review provides an overview of kinase-targeted drug discovery and development in relation to oncol. and highlights the challenges and future potential for kinase-targeted cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb-edOGHyJPbVg90H21EOLACvtfcHk0lhNmDJjBoMUBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7fP&md5=30811747f13749327d998c5dadd2161d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0804-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0804-2%26sid%3Dliteratum%253Aachs%26aulast%3DBhullar%26aufirst%3DK.%2BS.%26aulast%3DLagar%25C3%25B3n%26aufirst%3DN.%2BO.%26aulast%3DMcGowan%26aufirst%3DE.%2BM.%26aulast%3DParmar%26aufirst%3DI.%26aulast%3DJha%26aufirst%3DA.%26aulast%3DHubbard%26aufirst%3DB.%2BP.%26aulast%3DRupasinghe%26aufirst%3DH.%2BP.%2BV.%26atitle%3DKinase-targeted%2520cancer%2520therapies%253A%2520progress%252C%2520challenges%2520and%2520future%2520directions%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D48%26doi%3D10.1186%2Fs12943-018-0804-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardenas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, S. M.</span></span> <span> </span><span class="NLM_article-title">Regulation of topoisomerase II by phosphorylation: a role for casein kinase II</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8389373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXktVeiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1993&pages=219-225&author=M.+E.+Cardenasauthor=S.+M.+Gasser&title=Regulation+of+topoisomerase+II+by+phosphorylation%3A+a+role+for+casein+kinase+II"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of topoisomerase II by phosphorylation: a role for casein kinase II</span></div><div class="casAuthors">Cardenas, Maria E.; Gasser, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-25</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    </div><div class="casAbstract">A review with 74 refs.  Casein kinase II is the major kinase responsible for the phosphorylation of eukaryotic topoisomerase II in vivo.  The phosphorylation is regulated by the cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofq3RL78K34LVg90H21EOLACvtfcHk0lhNmDJjBoMUBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVeiu74%253D&md5=990ff716d1a33072554da8e8699a2e32</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCardenas%26aufirst%3DM.%2BE.%26aulast%3DGasser%26aufirst%3DS.%2BM.%26atitle%3DRegulation%2520of%2520topoisomerase%2520II%2520by%2520phosphorylation%253A%2520a%2520role%2520for%2520casein%2520kinase%2520II%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D1993%26volume%3D104%26spage%3D219%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boichuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunaev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galembikova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeeva, E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1097%2FCAD.0000000000000637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29697413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFOiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=549-559&issue=6&author=S.+Boichukauthor=P.+Dunaevauthor=A.+Galembikovaauthor=I.+Mustafinauthor=E.+Valeeva&title=Inhibition+of+fibroblast+growth+factor+receptor-signaling+sensitizes+imatinib-resistant+gastrointestinal+stromal+tumors+to+low+doses+of+topoisomerase+II+inhibitors&doi=10.1097%2FCAD.0000000000000637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors</span></div><div class="casAuthors">Boichuk, Sergei; Dunaev, Pavel; Galembikova, Aigul; Mustafin, Ilshat; Valeeva, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">549-559</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The acquired resistance of gastrointestinal stromal tumors (GISTs) to the targeted-based therapy remains the driving force to identify the novel approaches that are capable of increasing the sensitivity of GISTs to the current therapeutic regimens.  Our present data show that BGJ398, a selective fibroblast growth factor receptor (FGFR) inhibitor, sensitizes imatinib (IM)-resistant GIST cells with receptor tyrosine kinase (RTK) switch (loss of c-KIT/gain of pFGFR2a) to the low doses of topoisomerase II inhibitors - doxorubicin (Dox) and etoposide (Eto).  Mechanistically, pretreatment of IM-resistant GIST cells with BGJ398 for 12 h markedly enhanced proapoptotic and growth-suppressive effects of Dox (or Eto).  Indeed, a significant cleavage of PARP and caspase-3 was obsd. in GIST cells treated with a combination of FGFR and topoisomerase II inhibitor.  In contrast, no signs of apoptosis were detected in IM-resistant GIST cells treated with BGJ398, whereas the low doses of Dox (Eto) exerted the minor proapoptotic effects on GISTs.  The mechanism of BGJ398-induced sensitization of GIST to topoisomerase II inhibitors might be because of attenuation of DNA damage signaling and repair.  Indeed, we obsd. a marked decrease in Rad51 expression in GIST cells treated with BGJ398 together with Dox.  Similar results were obtained when an overexpressed pFGFR2a was knocked down by corresponding siRNA before Dox (Eto) exposure.  Moreover, FGFR inhibition/depletion caused a loss of Rad51 foci in Dox-treated GIST cells, suggesting that FGFR-signaling plays an important regulatory role in homol.-mediated DNA repair.  Our data show that combined therapy (RTKs inhibitors supplemented with low doses of topoisomerase II inhibitors) might be effective for unresectable and metastatic forms of GISTs.  In case of resistance to IM because of RTKs switch indicated above, FGFR inhibitors (e.g. BGJ398) might be potentially useful because of their ability to sensitize tumor cells to topoisomerase II inhibitors and induce tumor cell apoptosis by targeting DNA double-strand breaks repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8TTqQx7Pm8LVg90H21EOLACvtfcHk0lhNmDJjBoMUBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFOiurY%253D&md5=b3b470cf3c38766aecc4c67ee9fc3b04</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000637%26sid%3Dliteratum%253Aachs%26aulast%3DBoichuk%26aufirst%3DS.%26aulast%3DDunaev%26aufirst%3DP.%26aulast%3DGalembikova%26aufirst%3DA.%26aulast%3DMustafin%26aufirst%3DI.%26aulast%3DValeeva%26aufirst%3DE.%26atitle%3DInhibition%2520of%2520fibroblast%2520growth%2520factor%2520receptor-signaling%2520sensitizes%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%2520to%2520low%2520doses%2520of%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2018%26volume%3D29%26issue%3D6%26spage%3D549%26epage%3D559%26doi%3D10.1097%2FCAD.0000000000000637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVore, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methane-sulfon-m-anisidide</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2156</span>– <span class="NLM_lpage">2161</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1313738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXit1Gjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1992&pages=2156-2161&issue=8&author=R.+F.+DeVoreauthor=A.+H.+Corbettauthor=N.+Osheroff&title=Phosphorylation+of+topoisomerase+II+by+casein+kinase+II+and+protein+kinase+C%3A+effects+on+enzyme-mediated+DNA+cleavage%2Freligation+and+sensitivity+to+the+antineoplastic+drugs+etoposide+and+4%E2%80%B2-%289-acridinylamino%29methane-sulfon-m-anisidide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of topoisomerase II by casein kinase II and protein kinase C:  effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide</span></div><div class="casAuthors">DeVore, Russell F.; Corbett, Anita H.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2156-61</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The effects of serine phosphorylation on the DNA cleavage/religation equil. of topoisomerase II and the sensitivity of the enzyme to antineoplastic drugs were characterized.  Both casein kinase II and protein kinase C were used for these studies.  Each kinase incorporated a max. of ∼1.4 phosphate mols. per homodimer of topoisomerase II.  When the enzyme was incubated with both kinases simultaneously, phosphate incorporation increased to ∼2.6 mols./homodimer.  In the absence of antineoplastic drugs, phosphorylation had only a slight effect on the DNA cleavage/religation equil. of topoisomerase II.  However, in the presence of etoposide or 4'-(9-acridinylamino)methanesulfon-m-anisidide, phosphorylation attenuated the ability of drugs to stabilize enzyme-DNA cleavage complexes.  Levels of drug-induced DNA cleavage products decreased ∼33% following phosphorylation of topoisomerase II by casein kinase II, ∼17% following modification by protein kinase C, and ∼50% following simultaneous phosphorylation of the enzyme by both kinases.  This latter 50% redn. in DNA cleavage products correlated with an ∼2-fold increase in the apparent first order rate const. for DNA religation mediated by simultaneously modified topoisomerase II.  These results strongly suggest that the sensitivity of topoisomerase II toward antineoplastic drugs can be modulated by altering the phosphorylation state of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMG0WJJv8tI7Vg90H21EOLACvtfcHk0ljQkPS9jsQUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit1Gjsbg%253D&md5=bf8b1c47180ae2d60a8bc10b673a1348</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeVore%26aufirst%3DR.%2BF.%26aulast%3DCorbett%26aufirst%3DA.%2BH.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DPhosphorylation%2520of%2520topoisomerase%2520II%2520by%2520casein%2520kinase%2520II%2520and%2520protein%2520kinase%2520C%253A%2520effects%2520on%2520enzyme-mediated%2520DNA%2520cleavage%252Freligation%2520and%2520sensitivity%2520to%2520the%2520antineoplastic%2520drugs%2520etoposide%2520and%25204%25E2%2580%25B2-%25289-acridinylamino%2529methane-sulfon-m-anisidide%26jtitle%3DCancer%2520Res.%26date%3D1992%26volume%3D52%26issue%3D8%26spage%3D2156%26epage%3D2161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guilhot, F.</span></span> <span> </span><span class="NLM_article-title">Indications for imatinib mesylate therapy and clinical management</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.9-3-271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1634%2Ftheoncologist.9-3-271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15169982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFKqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=271-281&issue=3&author=F.+Guilhot&title=Indications+for+imatinib+mesylate+therapy+and+clinical+management&doi=10.1634%2Ftheoncologist.9-3-271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Indications for imatinib mesylate therapy and clinical management</span></div><div class="casAuthors">Guilhot, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-281</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Imatinib mesylate (Gleevec, Glivec, formerly STI571; Novartis Pharma AG; Basel, Switzerland) is a rationally-designed, molecularly-specific oral anticancer agent that selectively inhibits several protein tyrosine kinases central to the pathogenesis of human cancer.  It has demonstrated remarkable clin. efficacy in patients with chronic myeloid leukemia and malignant gastrointestinal stromal tumors.  Treatment with imatinib is generally well tolerated, and the risk for severe adverse effects is low.  Adverse effects most commonly include mild-to-moderate edema, nausea and vomiting, diarrhea, muscle cramps, and cutaneous reactions.  Hepatic transaminase level elevations and myelosuppression occur less frequently and resolve with interruption of imatinib therapy.  In general, the incidence and severity of adverse effects tend to correlate with imatinib dose and, in chronic myeloid leukemia patients, the phase of disease; but, patient age and other factors are also assocd. with some types of reactions.  With prompt and appropriate intervention, adverse effects in imatinib-treated patients have proven to be manageable across the spectrum of severity, and they seldom require permanent cessation of therapy.  Dose redn. is not usually necessary, and redn. to subtherapeutic levels is not recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0LSN0zReO-bVg90H21EOLACvtfcHk0ljQkPS9jsQUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFKqurc%253D&md5=32f0f9eec5155fff00b1088ff4d8efdb</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.9-3-271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.9-3-271%26sid%3Dliteratum%253Aachs%26aulast%3DGuilhot%26aufirst%3DF.%26atitle%3DIndications%2520for%2520imatinib%2520mesylate%2520therapy%2520and%2520clinical%2520management%26jtitle%3DOncologist%26date%3D2004%26volume%3D9%26issue%3D3%26spage%3D271%26epage%3D281%26doi%3D10.1634%2Ftheoncologist.9-3-271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. Y.</span></span> <span> </span><span class="NLM_article-title">Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate <i>in vitro</i></span>. <i>Cell Biol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1002/cbin.10686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fcbin.10686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=27677634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2ksL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2017&pages=16-23&issue=1&author=M.+Y.+Liuauthor=W.+Z.+Wangauthor=F.+F.+Liaoauthor=Q.+Q.+Wuauthor=X.+H.+Linauthor=Y.+H.+Chenauthor=L.+Chengauthor=X.+B.+Jinauthor=J.+Y.+Zhu&title=Selective+and+effective+targeting+of+chronic+myeloid+leukemia+stem+cells+by+topoisomerase+II+inhibitor+etoposide+in+combination+with+imatinib+mesylate+in+vitro&doi=10.1002%2Fcbin.10686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro</span></div><div class="casAuthors">Liu, Man-Yu; Wang, Wei-Zhang; Liao, Fen-Fang; Wu, Qing-Qing; Lin, Xiang-Hua; Chen, Yong-Hen; Cheng, Lin; Jin, Xiao-Bao; Zhu, Jia-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology International</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">CBIIEV</span>;
        ISSN:<span class="NLM_cas:issn">1095-8355</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (TKIs) have improved chronic myeloid leukemia (CML) patient survival markedly but fail to eradicate quiescent CML leukemia stem cells (LSCs).  Thus, strategies targeting LSCs are required to induce long-term remission and achieve cure.  Here, we investigated the ability of topoisomerase II (Top II) inhibitor etoposide (Eto) to target CML LSCs.  Treatment with Eto combined with IM markedly induced apoptosis in primitive CML CD34+CD38- stem cells resistant to eradication by IM alone, but not in normal hematopoietic stem cells, CML and normal mature CD34- cells, and other leukemia and lymphoma cell lines.  The interaction of IM and Eto significantly inhibited phosphorylation of PDK1, AKT, GSK3, S6, and ERK proteins; increased the expression of pro-apoptotic gene Bax; and decreased the expression of anti-apoptotic gene c-Myc in CML CD34+ cells.  Top II inhibitors treatment represents an attractive approach for targeting LSCs in CML patients undergoing TKIs monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSdID5GFe-KbVg90H21EOLACvtfcHk0ljQkPS9jsQUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2ksL3L&md5=3a07ec363ffacd97c59ba459dba7a3ff</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fcbin.10686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbin.10686%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%2BY.%26aulast%3DWang%26aufirst%3DW.%2BZ.%26aulast%3DLiao%26aufirst%3DF.%2BF.%26aulast%3DWu%26aufirst%3DQ.%2BQ.%26aulast%3DLin%26aufirst%3DX.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DX.%2BB.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26atitle%3DSelective%2520and%2520effective%2520targeting%2520of%2520chronic%2520myeloid%2520leukemia%2520stem%2520cells%2520by%2520topoisomerase%2520II%2520inhibitor%2520etoposide%2520in%2520combination%2520with%2520imatinib%2520mesylate%2520in%2520vitro%26jtitle%3DCell%2520Biol.%2520Int.%26date%3D2017%26volume%3D41%26issue%3D1%26spage%3D16%26epage%3D23%26doi%3D10.1002%2Fcbin.10686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span> <span> </span><span class="NLM_article-title">Ciprofloxacin: mammalian DNA topoisomerase type II poison <i>in vivo</i></span>. <i>Mutat. Res. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>301</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/0165-7992(93)90029-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0165-7992%2893%2990029-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=7678175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXhtFKhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=1993&pages=87-92&issue=2&author=A.+Mukherjeeauthor=S.+Senauthor=K.+Agarwal&title=Ciprofloxacin%3A+mammalian+DNA+topoisomerase+type+II+poison+in+vivo&doi=10.1016%2F0165-7992%2893%2990029-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Ciprofloxacin:  mammalian DNA topoisomerase type II poison in vivo</span></div><div class="casAuthors">Mukherjee, A.; Sen, S.; Agarwal, K.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research Letters</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">MRLEDH</span>;
        ISSN:<span class="NLM_cas:issn">0165-7992</span>.
    </div><div class="casAbstract">Ciprofloxacin (CF), a fluoroquinolone widely used as a potent antimicrobial drug, was evaluated in vivo in mouse bone marrow cells for its ability to induce clastogenicity and DNA damage in terms of increased sister-chromatid exchange (SCE) frequencies.  Doses of 0.6, 6 and 20 mg/kg body wt. of CF given i.p. induced a pos. dose-dependent significant clastogenicity (trend test α ≤ 0.05), though the effects were not specific for specific phases of the cell cycle.  The DNA-damaging effect obsd. as increased SCE frequencies using doses of 0.15, 0.30, 0.60, 1.2 and 6 mg/kg body wt. showed a significant dose-dependent increase (trend test α ≤ 0.05; lowest effective concn. 1.2 mg/kg of body wt.).  Compared to a potent eukaryotic DNA topoisomerase type II poison, etoposide (VP-16, 0.5, 1 and 5 mg/kg body wt., given i.p.), ciprofloxacin produced comparable dose-dependent SCE frequency increases.  Ciprofloxacin was postulated to be specific for the target DNA gyrase, the prokaryotic homolog of DNA topoisomerase type II enzyme.  The present paper along with the existing earlier data strongly suggest that topoisomerase type II and DNA gyrase are physiol. targets for the drug action.  In view of the present significant in vivo mammalian DNA topoisomerase type II-mediated genotoxicity and clastogenicity data, ciprofloxacin should be administered with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRP3mRFCSfabVg90H21EOLACvtfcHk0lgdrITULmzlUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtFKhtLY%253D&md5=2d3141f04b4f8a62f20bc251394db836</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2F0165-7992%2893%2990029-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-7992%252893%252990029-U%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DAgarwal%26aufirst%3DK.%26atitle%3DCiprofloxacin%253A%2520mammalian%2520DNA%2520topoisomerase%2520type%2520II%2520poison%2520in%2520vivo%26jtitle%3DMutat.%2520Res.%2520Lett.%26date%3D1993%26volume%3D301%26issue%3D2%26spage%3D87%26epage%3D92%26doi%3D10.1016%2F0165-7992%2893%2990029-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bredberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaszyk, M.</span></span> <span> </span><span class="NLM_article-title">Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1128/AAC.35.3.448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1128%2FAAC.35.3.448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1645508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFKlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1991&pages=448-450&issue=3&author=A.+Bredbergauthor=M.+Brantauthor=M.+Jaszyk&title=Ciprofloxacin-induced+inhibition+of+topoisomerase+II+in+human+lymphoblastoid+cells&doi=10.1128%2FAAC.35.3.448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells</span></div><div class="casAuthors">Bredberg, Anders; Brant, Marta; Jaszyk, Malgorzata</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">448-50</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The antibacterial activities of the fluorinated 4-quinolones (e.g., ciprofloxacin) have been ascribed to a marked inhibition of bacterial DNA gyrase.  In contrast, the influence on purified mammalian DNA enzymes, including topoisomerases, has been reported to be several orders of magnitude weaker, occurring at concns. higher than 100 μg of ciprofloxacin per mL.  In this study, using a nondenaturing filter elution method, a marked induction of double-strand DNA breaks in human lymphoblastoid cells exposed to 80 μg of ciprofloxacin per mL was seen.  The proportion of single-strand vs. double-strand DNA breaks was similar to that seen with the topoisomerase II inhibitory antitumor agent VP-16.  The cellular recovery was more rapid after treatment with ciprofloxacin than after treatment with VP-16, displaying a normal elution profile within 15 min at 37° (60 min for VP-16).  These data indicate that ciprofloxacin has an effect on intracellularly located topoisomerase II in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo57QXAcJQTKLVg90H21EOLACvtfcHk0lgdrITULmzlUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFKlt7Y%253D&md5=fc226cd357f2d97eec40f764a68648f9</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1128%2FAAC.35.3.448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.35.3.448%26sid%3Dliteratum%253Aachs%26aulast%3DBredberg%26aufirst%3DA.%26aulast%3DBrant%26aufirst%3DM.%26aulast%3DJaszyk%26aufirst%3DM.%26atitle%3DCiprofloxacin-induced%2520inhibition%2520of%2520topoisomerase%2520II%2520in%2520human%2520lymphoblastoid%2520cells%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1991%26volume%3D35%26issue%3D3%26spage%3D448%26epage%3D450%26doi%3D10.1128%2FAAC.35.3.448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beberok, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrzesniok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzepka, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Respondek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buszman, E.</span></span> <span> </span><span class="NLM_article-title">Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.3892/ijo.2018.4310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3892%2Fijo.2018.4310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29532860" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Beberokauthor=D.+Wrzesniokauthor=J.+Rokauthor=Z.+Rzepkaauthor=M.+Respondekauthor=E.+Buszman&title=Ciprofloxacin+triggers+the+apoptosis+of+human+triple-negative+breast+cancer+MDA-MB-231+cells+via+the+p53%2FBax%2FBcl-2+signaling+pathway&doi=10.3892%2Fijo.2018.4310"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.3892%2Fijo.2018.4310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2018.4310%26sid%3Dliteratum%253Aachs%26aulast%3DBeberok%26aufirst%3DA.%26aulast%3DWrzesniok%26aufirst%3DD.%26aulast%3DRok%26aufirst%3DJ.%26aulast%3DRzepka%26aufirst%3DZ.%26aulast%3DRespondek%26aufirst%3DM.%26aulast%3DBuszman%26aufirst%3DE.%26atitle%3DCiprofloxacin%2520triggers%2520the%2520apoptosis%2520of%2520human%2520triple-negative%2520breast%2520cancer%2520MDA-MB-231%2520cells%2520via%2520the%2520p53%252FBax%252FBcl-2%2520signaling%2520pathway%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2018%26doi%3D10.3892%2Fijo.2018.4310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Idowu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span> <span> </span><span class="NLM_article-title">Ubiquitous Nature of Fluoroquinolones: The oscillation between antibacterial and anticancer activities</span>. <i>Antibiotics (Basel, Switz.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.3390/antibiotics6040026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3390%2Fantibiotics6040026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVKmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=26&issue=4&author=T.+Idowuauthor=F.+Schweizer&title=Ubiquitous+Nature+of+Fluoroquinolones%3A+The+oscillation+between+antibacterial+and+anticancer+activities&doi=10.3390%2Fantibiotics6040026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitous nature of fluoroquinolones: the oscillation between antibacterial and anticancer activities</span></div><div class="casAuthors">Idowu, Temilolu; Schweizer, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Antibiotics (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">26/1-26/24</span>CODEN:
                <span class="NLM_cas:coden">ABSNC4</span>;
        ISSN:<span class="NLM_cas:issn">2079-6382</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Fluoroquinolones are synthetic antibacterial agents that stabilize the ternary complex of prokaryotic topoisomerase II enzymes (gyrase and Topo IV), leading to extensive DNA fragmentation and bacteria death.  Despite the similar structural folds within the crit. regions of prokaryotic and eukaryotic topoisomerases, clin. relevant fluoroquinolones display a remarkable selectivity for prokaryotic topoisomerase II, with excellent safety records in humans.  Typical agents that target human topoisomerases (such as etoposide, doxorubicin and mitoxantrone) are assocd. with significant toxicities and secondary malignancies, whereas clin. relevant fluoroquinolones are not known to exhibit such propensities.  Although many fluoroquinolones have been shown to display topoisomerase-independent antiproliferative effects against various human cancer cells, those that are significantly active against eukaryotic topoisomerase show the same DNA damaging properties as other topoisomerase poisons.  Empirical models also show that fluoroquinolones mediate some unique immunomodulatory activities of suppressing pro-inflammatory cytokines and super-inducing interleukin-2.  This article reviews the extended roles of fluoroquinolones and their prospects as lead for the unmet needs of "small and safe" multimodal-targeting drug scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBCOvxD53kLrVg90H21EOLACvtfcHk0lgdrITULmzlUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVKmu7w%253D&md5=a0c215221a571c09eb87ae11d11279df</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.3390%2Fantibiotics6040026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantibiotics6040026%26sid%3Dliteratum%253Aachs%26aulast%3DIdowu%26aufirst%3DT.%26aulast%3DSchweizer%26aufirst%3DF.%26atitle%3DUbiquitous%2520Nature%2520of%2520Fluoroquinolones%253A%2520The%2520oscillation%2520between%2520antibacterial%2520and%2520anticancer%2520activities%26jtitle%3DAntibiotics%2520%2528Basel%252C%2520Switz.%2529%26date%3D2017%26volume%3D6%26issue%3D4%26spage%3D26%26doi%3D10.3390%2Fantibiotics6040026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. J.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of topoisomerase II and tyrosine kinases by the novel bis-fluoroquinolone chalcone-like derivative HMNE3 in human pancreatic cancer cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">e0162821</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0162821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1371%2Fjournal.pone.0162821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=27760157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1ynsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0162821&issue=10&author=Y.+C.+Maauthor=Z.+X.+Wangauthor=S.+J.+Jinauthor=Y.+X.+Zhangauthor=G.+Q.+Huauthor=D.+T.+Cuiauthor=J.+S.+Wangauthor=M.+Wangauthor=F.+Q.+Wangauthor=Z.+J.+Zhao&title=Dual+inhibition+of+topoisomerase+II+and+tyrosine+kinases+by+the+novel+bis-fluoroquinolone+chalcone-like+derivative+HMNE3+in+human+pancreatic+cancer+cells&doi=10.1371%2Fjournal.pone.0162821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of topoisomerase II and tyrosine kinases by the novel bis-fluoroquinolone chalcone-like derivative HMNE3 in human pancreatic cancer cells</span></div><div class="casAuthors">Ma, Yong-Chao; Wang, Zhi-Xin; Jin, Shao-Ju; Zhang, Yan-Xin; Hu, Guo-Qiang; Cui, Dong-Tao; Wang, Jiang-Shuan; Wang, Min; Wang, Fu-Qing; Zhao, Zhi-Jun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0162821/1-e0162821/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Both tyrosine kinase and topoisomerase II (TopII) are important anticancer targets, and their resp. inhibitors are widely used in cancer therapy.  However, some combinations of anticancer drugs could exhibit mutually antagonistic actions and drug resistance, which further limit their therapeutic efficacy.  Here, we report that HMNE3, a novel bis-fluoroquinolone chalcone-like deriv. that targets both tyrosine kinase and TopII, induces tumor cell proliferation and growth inhibition.  The viabilities of 6 different cancer cell lines treated with a range of HMNE3 doses were detected using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  Cellular apoptosis was detd. using Hoechst 33258 fluorescence staining and the terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay.  The expression of activated Caspase-3 was examd. by immunocytochem.  The tyrosine kinase activity was measured with a human receptor tyrosine kinase (RTK) detection kit using a horseradish peroxidase (HRP)-conjugated phosphotyrosine (pY20) antibody as the substrate.  The topoisomerase II activity was measured using agarose gel electrophoresis with the DNA plasmid pBR322 as the substrate.  The expression levels of the P53, Bax, Bcl-2, Caspase-3, -8, -9, p-cSrc, c-Src and topoisomerase II proteins were detected by western blot anal.  The proliferation of five of the six cancer cell lines was significantly inhibited by HMNE3 at 0.312 to 10 μmol/L in a time- and dose-dependent manner.  Treatment of the Capan-1 and Panc-1 cells with 1.6 to 3.2 μM HMNE3 for 48 h significantly increased the percentage of apoptotic cells (P<0.05), and this effect was accompanied by a decrease in tyrosine kinase activity.  HMNE3 potentially inhibited tyrosine kinase activity in vitro with an IC50 value of 0.64 ± 0.34 μmol/L in Capan-1 cells and 3.1 ± 0.86 μmol/L in Panc-1 cells.  The activity of c-Src was significantly inhibited by HMNE3 in a dose- and time-dependent manner in different cellular contexts.  Compared with the control group, HMNE3 induced increased expression of cellular apoptosis-related proteins.  Consistent with cellular apoptosis data, a significant decrease in topoisomerase IIβ activity was noted following treatment with HMNE3 for 24 h.  Our data suggest that HMNE3 induced apoptosis in Capan-1 and Panc-1 cells by inhibiting the activity of both tyrosine kinases and topoisomerase II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroUVWjN_qq-bVg90H21EOLACvtfcHk0liiC8wP7Wb1Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1ynsbk%253D&md5=57d35af75c7761850331854ec402f964</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0162821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0162821%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%2BC.%26aulast%3DWang%26aufirst%3DZ.%2BX.%26aulast%3DJin%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DHu%26aufirst%3DG.%2BQ.%26aulast%3DCui%26aufirst%3DD.%2BT.%26aulast%3DWang%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%2BQ.%26aulast%3DZhao%26aufirst%3DZ.%2BJ.%26atitle%3DDual%2520inhibition%2520of%2520topoisomerase%2520II%2520and%2520tyrosine%2520kinases%2520by%2520the%2520novel%2520bis-fluoroquinolone%2520chalcone-like%2520derivative%2520HMNE3%2520in%2520human%2520pancreatic%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3De0162821%26doi%3D10.1371%2Fjournal.pone.0162821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) and its cross-talks with topoisomerases: challenges and opportunities for multi-target anticancer drugs</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3226</span>– <span class="NLM_lpage">3236</span>, <span class="refDoi"> DOI: 10.2174/1381612822666160224142200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1381612822666160224142200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26907945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVags74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=3226-3236&issue=21&author=M.+Chauhanauthor=G.+Sharmaauthor=G.+Joshiauthor=R.+Kumar&title=Epidermal+growth+factor+receptor+%28EGFR%29+and+its+cross-talks+with+topoisomerases%3A+challenges+and+opportunities+for+multi-target+anticancer+drugs&doi=10.2174%2F1381612822666160224142200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor (EGFR) and its Cross-Talks with Topoisomerases: Challenges and Opportunities for Multi-Target Anticancer Drugs</span></div><div class="casAuthors">Chauhan, Monika; Sharma, Gourav; Joshi, Gaurav; Kumar, Raj</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3226-3236</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The interactions of Epidermal Growth Factor Receptor (EGFR) and topoisomerases have been seen in various cancer including brain, breast, ovarian, colorectal, gastric, etc.  Methods: The studies in adenocarcinoma patients, chromogenic in situ hybridization, western blotting, receptor binding assay and electromobility shift assays, etc. threw light on the biophys. and biochem. features of EGFR and Topoisomerase cross-talks.  Results: It has been revealed that both the isomers of topoisomerase (Topo I and Topo II) interact via different mechanisms with EGFR.  Topo II and HER2 share the same location i.e. 17q12-21 regions which could be a possible cause of predominant interactions seen between them.  Topo I and EGFR interactions are mech. related to the nucleolar translocation of heparenase by EGF and c-Jun.  Conclusion: We compiled literature findings including the mechanistic interventions, signaling pathways, patents, in vitro and in vivo data of tested inhibitors and combinations in clin. trials, which provide convincing confirmations for the interactions of EGFR and topoisomerases.  These interactions may be used for deriving a consistent route of mechanism, design and development of std. drug combinations and dual or multi inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPuO9YphOWNLVg90H21EOLACvtfcHk0lhCHOGWXDcrVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVags74%253D&md5=b169a47d30513c5274cf1146545867b6</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.2174%2F1381612822666160224142200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612822666160224142200%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DJoshi%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520its%2520cross-talks%2520with%2520topoisomerases%253A%2520challenges%2520and%2520opportunities%2520for%2520multi-target%2520anticancer%2520drugs%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2016%26volume%3D22%26issue%3D21%26spage%3D3226%26epage%3D3236%26doi%3D10.2174%2F1381612822666160224142200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angevin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schran, H.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1177/0091270011433330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1177%2F0091270011433330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23400739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ylsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=14-20&issue=1&author=X.+Wangauthor=A.+Kayauthor=O.+Anakauthor=E.+Angevinauthor=B.+Escudierauthor=W.+Zhouauthor=Y.+Fengauthor=M.+Duganauthor=H.+Schran&title=Population+pharmacokinetic%2Fpharmacodynamic+modeling+to+assist+dosing+schedule+selection+for+dovitinib&doi=10.1177%2F0091270011433330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib</span></div><div class="casAuthors">Wang, Xiaofeng; Kay, Andrea; Anak, Oezlem; Angevin, Eric; Escudier, Bernard; Zhou, Wei; Feng, Yilin; Dugan, Margaret; Schran, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-20</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Dovitinib is an oral multitargeted kinase inhibitor with potent activity against receptors for vascular endothelial growth factor, platelet-derived growth factor, and basic fibroblast growth factor.  Initial phase 1 to 2 studies of dovitinib using a continuous daily dosing schedule has shown that dovitinib exhibits a prolonged and overproportional increase in dose and exposure relationship above 400 mg/d.  To address this, intermittent dosing schedules were explored using a model-based approach.  A semi-mechanistic population pharmcokinetic/pharmacodynamic (PD) model was developed from 4 dovitinib phase 1 studies with daily dosing schedules.  Autoinduction of cytochrome P 450 1A (CYP1A) responsible for dovitinib metab. was described using an indirect response model.  Simulation of dovitinib plasma concn. profiles following 4 intermittent dosing schedules suggested that intermittent dosing could prevent prolonged drug accumulation.  Based on the simulated plasma profiles, PD response, and patient compliance, a 5-days-on/2-days-off intermittent dosing schedule was selected for a phase 1 to 2 clin. study.  The obsd. dovitinib plasma concns. in this study confirmed the model predictions.  Furthermore, dovitinib was well tolerated, and antitumor activity was obsd. as well in this new study.  The 5-days-on/2-days-off dosing schedule is currently used in a dovitinib registration trial and other clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrulg5AQZUyZ7Vg90H21EOLACvtfcHk0ljFEaJJdOF7bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ylsLjN&md5=6f3967fd1d64d33cde4849ad9448e91e</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1177%2F0091270011433330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270011433330%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DAnak%26aufirst%3DO.%26aulast%3DAngevin%26aufirst%3DE.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DSchran%26aufirst%3DH.%26atitle%3DPopulation%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%2520to%2520assist%2520dosing%2520schedule%2520selection%2520for%2520dovitinib%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26issue%3D1%26spage%3D14%26epage%3D20%26doi%3D10.1177%2F0091270011433330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasinoff, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanagasabai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalowich, J. C.</span></span> <span> </span><span class="NLM_article-title">The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>84</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1617</span>– <span class="NLM_lpage">1626</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2012.09.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bcp.2012.09.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23041231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKgu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=1617-1626&issue=12&author=B.+B.+Hasinoffauthor=X.+Wuauthor=J.+L.+Nitissauthor=R.+Kanagasabaiauthor=J.+C.+Yalowich&title=The+anticancer+multi-kinase+inhibitor+dovitinib+also+targets+topoisomerase+I+and+topoisomerase+II&doi=10.1016%2Fj.bcp.2012.09.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II</span></div><div class="casAuthors">Hasinoff, Brian B.; Wu, Xing; Nitiss, John L.; Kanagasabai, Ragu; Yalowich, Jack C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1617-1626</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dovitinib (TKI258/CHIR258) is a multi-kinase inhibitor in phase III development for the treatment of several cancers.  Dovitinib is a benzimidazole-quinolinone compd. that structurally resembles the bisbenzimidazole minor groove binding dye Hoechst 33258.  Dovitinib bound to DNA as shown by its ability to increase the DNA melting temp. and by increases in its fluorescence spectrum that occurred upon the addn. of DNA.  Mol. modeling studies of the docking of dovitinib into an X-ray structure of a Hoechst 33258-DNA complex showed that dovitinib could reasonably be accommodated in the DNA minor groove.  Because DNA binders are often topoisomerase I (EC 5.99.1.2) and topoisomerase II (EC 5.99.1.3) inhibitors, the ability of dovitinib to inhibit these DNA processing enzymes was also investigated.  Dovitinib inhibited the catalytic decatenation activity of topoisomerase IIα.  It also inhibited the DNA-independent ATPase activity of yeast topoisomerase II which suggested that it interacted with the ATP binding site.  Using isolated human topoisomerase IIα, dovitinib stabilized the enzyme-cleavage complex and acted as a topoisomerase IIα poison.  Dovitinib was also found to be a cellular topoisomerase II poison in human leukemia K562 cells and induced double-strand DNA breaks in K562 cells as evidenced by increased phosphorylation of H2AX.  Finally, dovitinib inhibited the topoisomerase I-catalyzed relaxation of plasmid DNA and acted as a cellular topoisomerase I poison.  In conclusion, the cell growth inhibitory activity and the anticancer activity of dovitinib may result not only from its ability to inhibit multiple kinases, but also, in part, from its ability to target topoisomerase I and topoisomerase II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7o2T_-J6Gz7Vg90H21EOLACvtfcHk0ljFEaJJdOF7bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKgu7zP&md5=4522d9895299c2e897d2e00c12a5a0bf</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.09.023%26sid%3Dliteratum%253Aachs%26aulast%3DHasinoff%26aufirst%3DB.%2BB.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26aulast%3DKanagasabai%26aufirst%3DR.%26aulast%3DYalowich%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520anticancer%2520multi-kinase%2520inhibitor%2520dovitinib%2520also%2520targets%2520topoisomerase%2520I%2520and%2520topoisomerase%2520II%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26issue%3D12%26spage%3D1617%26epage%3D1626%26doi%3D10.1016%2Fj.bcp.2012.09.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hisatomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueoka-Aragane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomimasu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueoka, E.</span></span> <span> </span><span class="NLM_article-title">NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIα and DNA-dependent protein kinase</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3575</span>– <span class="NLM_lpage">3584</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-02-270439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1182%2Fblood-2010-02-270439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21245486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslagtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3575-3584&issue=13&author=T.+Hisatomiauthor=N.+Sueoka-Araganeauthor=A.+Satoauthor=R.+Tomimasuauthor=M.+Ideauthor=A.+Kurimasaauthor=K.+Okamotoauthor=S.+Kimuraauthor=E.+Sueoka&title=NK314+potentiates+antitumor+activity+with+adult+T-cell+leukemia-lymphoma+cells+by+inhibition+of+dual+targets+on+topoisomerase+II%CE%B1+and+DNA-dependent+protein+kinase&doi=10.1182%2Fblood-2010-02-270439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIα and DNA-dependent protein kinase</span></div><div class="casAuthors">Hisatomi, Takashi; Sueoka-Aragane, Naoko; Sato, Akemi; Tomimasu, Rika; Ide, Masaru; Kurimasa, Akihiro; Okamoto, Kazuya; Kimura, Shinya; Sueoka, Eisaburo</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3575-3584</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Adult T-cell leukemia-lymphoma (ATL) is an aggressive disease, incurable by std. chemotherapy.  NK314, a new anticancer agent possessing inhibitory activity specific for topoisomerase IIα (Top2α), inhibited the growth of various ATL cell lines (50% inhibitory concn.: 23-70nM) with more potent activity than that of etoposide.  In addn. to the induction of DNA double-strand breaks by inhibition of Top2α, NK314 induced degrdn. of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), resulting in impaired DNA double-strand break repair.  The contribution of DNA-PK to inhibition of cell growth was affirmed by the following results: NK314 inhibited cell growth of M059J (a DNA-PKcs-deficient cell line) and M059K (a cell line with DNA-PKcs present) with the same potency, whereas etoposide exhibited weak inhibition of cell growth with M059K cells.  A DNA-PK specific inhibitor, NU7026, enhanced inhibitory activity of etoposide on M059K as well as on ATL cells.  These results suggest that NK314 is a dual inhibitor of Top2α and DNA-PK.  Because ATL cells express a high amt. of DNA-PKcs, NK314 as a dual mol. targeting anticancer agent is a potential therapeutic tool for treatment of ATL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2J07vNnlfR7Vg90H21EOLACvtfcHk0ljFEaJJdOF7bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslagtbo%253D&md5=a1a0d0ae5e0d958cfeeead0c12393ba6</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-02-270439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-02-270439%26sid%3Dliteratum%253Aachs%26aulast%3DHisatomi%26aufirst%3DT.%26aulast%3DSueoka-Aragane%26aufirst%3DN.%26aulast%3DSato%26aufirst%3DA.%26aulast%3DTomimasu%26aufirst%3DR.%26aulast%3DIde%26aufirst%3DM.%26aulast%3DKurimasa%26aufirst%3DA.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DSueoka%26aufirst%3DE.%26atitle%3DNK314%2520potentiates%2520antitumor%2520activity%2520with%2520adult%2520T-cell%2520leukemia-lymphoma%2520cells%2520by%2520inhibition%2520of%2520dual%2520targets%2520on%2520topoisomerase%2520II%25CE%25B1%2520and%2520DNA-dependent%2520protein%2520kinase%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26issue%3D13%26spage%3D3575%26epage%3D3584%26doi%3D10.1182%2Fblood-2010-02-270439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span> <span> </span><span class="NLM_article-title">DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1124/mol.109.057125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1124%2Fmol.109.057125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21546556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1yqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=321-327&issue=2&author=L.+Guoauthor=X.+Liuauthor=Y.+Jiangauthor=K.+Nishikawaauthor=W.+Plunkett&title=DNA-dependent+protein+kinase+and+ataxia+telangiectasia+mutated+%28ATM%29+promote+cell+survival+in+response+to+NK314%2C+a+topoisomerase+II%CE%B1+inhibitor&doi=10.1124%2Fmol.109.057125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor</span></div><div class="casAuthors">Guo, Lei; Liu, Xiaojun; Jiang, Yingjun; Nishikawa, Kiyohiro; Plunkett, William</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">321-327</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">4-Hydroxy-5-methoxy-2,3-dihydro-1H-[1,3]benzodioxolo[5,6-c]pyrrolo[1,2-f]-phenanthridium chloride (NK314) is a benzo[c] phenanthridine alkaloid that inhibits topoisomerase IIα, leading to the generation of DNA double-strand breaks (DSBs) and activating the G2 checkpoint pathway.  The purpose of the present studies was to investigate the DNA intercalating properties of NK314, to evaluate the DNA repair mechanisms activated in cells that may lead to resistance to NK314, and to develop mechanism-based combination strategies to maximize the antitumor effect of the compd.  A DNA unwinding assay indicated that NK314 intercalates in DNA, a property that likely cooperates with its ability to trap topoisomerase IIα in its cleavage complex form.  The consequence of this is the formation of DNA DSBs, as demonstrated by pulsed-field gel electrophoresis and H2AX phosphorylation.  Clonogenic assays demonstrated a significant sensitization in NK314-treated cells deficient in DNA-dependent protein kinase (DNA-PK) catalytic subunit, Ku80, ataxia telangiectasia mutated (ATM), BRCA2, or XRCC3 compared with wild-type cells, indicating that both nonhomologous end-joining and homologous recombination DNA repair pathways contribute to cell survival.  Furthermore, both the DNA-PK inhibitor 8-(4-dibenzothienyl)-2-(4-morpholinyl)-4H-1-benzopyran-4-one (NU7441) and the ATM inhibitor 2-(4-morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one (KU55933) significantly sensitized cells to NK314.  We conclude that DNA-PK and ATM contribute to cell survival in response to NK314 and could be potential targets for abrogating resistance and maximizing the antitumor effect of NK314.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgVrCSKedkI7Vg90H21EOLACvtfcHk0lil6Xc5a9HSpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1yqsLc%253D&md5=3c0ef03f47e51b3faa638c44e7f63549</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.057125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.057125%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DNishikawa%26aufirst%3DK.%26aulast%3DPlunkett%26aufirst%3DW.%26atitle%3DDNA-dependent%2520protein%2520kinase%2520and%2520ataxia%2520telangiectasia%2520mutated%2520%2528ATM%2529%2520promote%2520cell%2520survival%2520in%2520response%2520to%2520NK314%252C%2520a%2520topoisomerase%2520II%25CE%25B1%2520inhibitor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26issue%3D2%26spage%3D321%26epage%3D327%26doi%3D10.1124%2Fmol.109.057125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, D. J.</span></span> <span> </span><span class="NLM_article-title">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3670</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-08-0715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19074844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3670-3684&issue=12&author=J.+Maauthor=D.+J.+Waxman&title=Combination+of+antiangiogenesis+with+chemotherapy+for+more+effective+cancer+treatment&doi=10.1158%2F1535-7163.MCT-08-0715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span></div><div class="casAuthors">Ma, Jie; Waxman, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3670-3684</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a hallmark of tumor development and metastasis and is now a validated target for cancer treatment.  However, the survival benefits of antiangiogenic drugs have thus far been rather modest, stimulating interest in developing more effective ways to combine antiangiogenic drugs with established chemotherapies.  This review discusses recent progress and emerging challenges in this field; interactions between antiangiogenic drugs and conventional chemotherapeutic agents are examd., and strategies for the optimization of combination therapies are discussed.  Antiangiogenic drugs such as the anti-vascular endothelial growth factor antibody bevacizumab can induce a functional normalization of the tumor vasculature that is transient and can potentiate the activity of coadministered chemoradiotherapies.  However, chronic angiogenesis inhibition typically reduces tumor uptake of coadministered chemotherapeutics, indicating a need to explore new approaches, including intermittent treatment schedules and provascular strategies to increase chemotherapeutic drug exposure.  In cases where antiangiogenesis-induced tumor cell starvation augments the intrinsic cytotoxic effects of a conventional chemotherapeutic drug, combination therapy may increase antitumor activity despite a decrease in cytotoxic drug exposure.  As new angiogenesis inhibitors enter the clinic, reliable surrogate markers are needed to monitor the progress of antiangiogenic therapies and to identify responsive patients.  New targets for antiangiogenesis continue to be discovered, increasing the opportunities to interdict tumor angiogenesis and circumvent resistance mechanisms that may emerge with chronic use of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFuKsU4WlEmLVg90H21EOLACvtfcHk0lil6Xc5a9HSpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN&md5=187b65f71cce4580756ae01973ca758f</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0715%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520of%2520antiangiogenesis%2520with%2520chemotherapy%2520for%2520more%2520effective%2520cancer%2520treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26issue%3D12%26spage%3D3670%26epage%3D3684%26doi%3D10.1158%2F1535-7163.MCT-08-0715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2013.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23770449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=477-486&author=X.+Wangauthor=Z.+Chenauthor=L.+Tongauthor=S.+Tanauthor=W.+Zhouauthor=T.+Pengauthor=K.+Hanauthor=J.+Dingauthor=H.+Xieauthor=Y.+Xu&title=Naphthalimides+exhibit+in+vitro+antiproliferative+and+antiangiogenic+activities+by+inhibiting+both+topoisomerase+II+%28topo+II%29+and+receptor+tyrosine+kinases+%28RTKs%29&doi=10.1016%2Fj.ejmech.2013.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs)</span></div><div class="casAuthors">Wang, Xin; Chen, Zhuo; Tong, Linjiang; Tan, Shaoying; Zhou, Wei; Peng, Ting; Han, Kun; Ding, Jian; Xie, Hua; Xu, Yufang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">477-486</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel naphthalimide derivs. I [R = Me, Et, n-Bu, etc.] were designed and synthesized to modulate both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).  Most target compds. exhibited effective and selective antiproliferative activities against three cancer cell lines by inhibiting topo II.  The IC50 values ranged from 1.5 to 19.1 μM.  Moreover, compds. 8 d and 12 d moderately inhibited various angiogenesis-related RTKs, including FGFR1, VEGFR2 and PDGFRα.  The representative compd. 8 d was then proved to possess antiangiogenic activity, which was evidenced by the inhibition of migration and tube formation activities of HMEC-1 cells.  To the knowledge, it is the first time naphthalimides were identified as tyrosine kinases inhibitors (TKIs) besides their conventional cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruL6A4uMIwIbVg90H21EOLACvtfcHk0liJ8Uob2w9wAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrrF&md5=703b14b696d6354cfaf8c530d459c735</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DK.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DNaphthalimides%2520exhibit%2520in%2520vitro%2520antiproliferative%2520and%2520antiangiogenic%2520activities%2520by%2520inhibiting%2520both%2520topoisomerase%2520II%2520%2528topo%2520II%2529%2520and%2520receptor%2520tyrosine%2520kinases%2520%2528RTKs%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D477%26epage%3D486%26doi%3D10.1016%2Fj.ejmech.2013.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Counter, C. M.</span></span> <span> </span><span class="NLM_article-title">The roles of telomeres and telomerase in cell life span</span>. <i>Mutat. Res., Rev. Genet. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/S0165-1110(96)90006-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0165-1110%2896%2990006-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8921986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK28XntVKhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=1996&pages=45-63&issue=1&author=C.+M.+Counter&title=The+roles+of+telomeres+and+telomerase+in+cell+life+span&doi=10.1016%2FS0165-1110%2896%2990006-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of telomeres and telomerase in cell life span</span></div><div class="casAuthors">Counter, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Reviews in Genetic Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-63</span>CODEN:
                <span class="NLM_cas:coden">MRRTEP</span>;
        ISSN:<span class="NLM_cas:issn">0165-1110</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 179 refs.  Telomers cap and protect the ends of chromosomes from degrdn. and illegitimate recombination.  The termini of a linear template cannot, however, be completely replicated by conventional DNA-dependent DNA polymerases, and thus in the absence of a mechanisms of counter this effect, telomers of eukaryotic cells shorten every round of DNA replication.  In humans and possibly other higher eukaryotes, telomere shortening may have been adopted to limit the life span of somatic cells.  Human somatic cells have a finite proliferative capacity and enter a viable growth arrested state called senescence.  Life span appears to be governed by cell division, not time.  The regular loss of telomeric DNA could therefore serve as a mitotic clock in the senescence program, counting cell divisions.  In most eukaryotic organisms, however, telomere shortening can be counted by the de novo addn. of telomeric repeats by the enzyme telomerase.  Cells which are 'immortal' such as the human germ line or tumor cell lines, established mouse cells, yeast and ciliates, all maintain a stable telomere length through the action of telomerase.  Abolition of telomerase activity in such cells nevertheless results in telomere shortening, a process that eventually destabilizes the ends of chromosomes, leading to genomic instability and cell growth arrest or death.  Therefore, loss of terminal DNA sequences may limit cell life span by two mechanisms: by acting a mitotic clock and by denuding chromosomes of protective telomeric DNA necessary for cell viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwuVktuW9lI7Vg90H21EOLACvtfcHk0liJ8Uob2w9wAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntVKhtrc%253D&md5=8774f7b0f01fdcc7acaf7011753e393e</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2FS0165-1110%2896%2990006-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-1110%252896%252990006-8%26sid%3Dliteratum%253Aachs%26aulast%3DCounter%26aufirst%3DC.%2BM.%26atitle%3DThe%2520roles%2520of%2520telomeres%2520and%2520telomerase%2520in%2520cell%2520life%2520span%26jtitle%3DMutat.%2520Res.%252C%2520Rev.%2520Genet.%2520Toxicol.%26date%3D1996%26volume%3D366%26issue%3D1%26spage%3D45%26epage%3D63%26doi%3D10.1016%2FS0165-1110%2896%2990006-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zvereva, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shcherbakova, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontsova, O. A.</span></span> <span> </span><span class="NLM_article-title">Telomerase: structure, functions, and activity regulation</span>. <i>Biochemistry (Moscow)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1563</span>– <span class="NLM_lpage">1583</span>, <span class="refDoi"> DOI: 10.1134/S0006297910130055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1134%2FS0006297910130055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21417995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFOrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=1563-1583&issue=13&author=M.+I.+Zverevaauthor=D.+M.+Shcherbakovaauthor=O.+A.+Dontsova&title=Telomerase%3A+structure%2C+functions%2C+and+activity+regulation&doi=10.1134%2FS0006297910130055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Telomerase: Structure, functions, and activity regulation</span></div><div class="casAuthors">Zvereva, M. I.; Shcherbakova, D. M.; Dontsova, O. A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1563-1583</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">MAIK Nauka/Interperiodica</span>)
        </div><div class="casAbstract">A review.  Telomerase is the enzyme responsible for maintenance of the length of telomeres by the addn. of guanine-rich repetitive sequences.  Telomerase activity is exhibited in gametes and stem and tumor cells.  In human somatic cells, proliferation potential is strictly limited and senescence follows ∼50-70 cell divisions.  In most tumor cells, on the contrary, replication potential is unlimited.  The key role in this process of the system of telomere length maintenance with involvement of telomerase is still poorly studied.  No doubt, DNA polymerase is not capable to completely copy DNA at the very ends of chromosomes; therefore, ∼50 nucleotides are lost during each cell cycle, which results in gradual telomere length shortening.  Critically short telomeres cause senescence, following crisis, and cell death.  However, in tumor cells the system of telomere length maintenance is activated.  In addn. to catalytic telomere elongation, independent telomerase functions can be also involved in cell cycle regulation.  Inhibition of telomerase catalytic function and the resulting cessation of telomere length maintenance will help in restriction of tumor cell replication potential.  On the other hand, the formation of temporarily active enzyme via its intracellular activation or due to stimulation of expression of telomerase components will result in telomerase activation and telomere elongation that can be used for correction of degenerative changes.  Data on telomerase structure and function are summarized by the authors, and they are compared for evolutionarily remote organisms.  Problems of telomerase activity measurement and modulation by enzyme inhibitors or activators are considered as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVZVLy00ezkbVg90H21EOLACvtfcHk0liJ8Uob2w9wAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFOrtg%253D%253D&md5=468169f6df072ca67437461c6fcaf5cd</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1134%2FS0006297910130055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS0006297910130055%26sid%3Dliteratum%253Aachs%26aulast%3DZvereva%26aufirst%3DM.%2BI.%26aulast%3DShcherbakova%26aufirst%3DD.%2BM.%26aulast%3DDontsova%26aufirst%3DO.%2BA.%26atitle%3DTelomerase%253A%2520structure%252C%2520functions%252C%2520and%2520activity%2520regulation%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26date%3D2010%26volume%3D75%26issue%3D13%26spage%3D1563%26epage%3D1583%26doi%3D10.1134%2FS0006297910130055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span> <span> </span><span class="NLM_article-title">Ruthenium(II) polypyridyl complexes as dual inhibitors of telomerase and topoisomerase</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">15145</span>– <span class="NLM_lpage">15156</span>, <span class="refDoi"> DOI: 10.1039/C4DT03585B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1039%2FC4DT03585B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25604798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=15145-15156&issue=34&author=G.+Liaoauthor=X.+Chenauthor=J.+Wuauthor=C.+Qianauthor=Y.+Wangauthor=L.+Jiauthor=H.+Chao&title=Ruthenium%28II%29+polypyridyl+complexes+as+dual+inhibitors+of+telomerase+and+topoisomerase&doi=10.1039%2FC4DT03585B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium(II) polypyridyl complexes as dual inhibitors of telomerase and topoisomerase</span></div><div class="casAuthors">Liao, Guoliang; Chen, Xiang; Wu, Jingheng; Qian, Chen; Wang, Yi; Ji, Liangnian; Chao, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">15145-15156</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">One novel ruthenium polypyridyl complex, [Ru(bpy)2(icip)]2+ (1), and two previously reported ruthenium polypyridyl complexes, [Ru(bpy)2(pdppz)]2+ (2) and [Ru(bpy)2(tactp)]2+ (3) (bpy = 2,2'-bipyridine, icip = 2-(indeno[2,1-b]chromen-6-yl)-1H-imidazo[4,5-f][1,10]phenanthroline, pdppz = phenanthro[4,5-abc]dipyrido[3,2-h:2',3'-j]phenazine, tactp = 4,5,9,18-tetraazachryseno[9,10-b]-triphenylene), have been synthesized.  As expected, these complexes show inhibition towards telomerase by inducing and stabilizing the G-quadruplex structure, and behave as topoisomerase I/II poisons at the same time.  Addnl., the acute and chronic cytotoxicities of the complexes are considered.  Furthermore, cell apoptosis expts. are used to briefly study the mechanism.  Because studies involving multi-target inhibition towards topoisomerase and telomerase of Ru(II) complexes have not been reported previously, the present research may help to develop innovative chem. strategies and therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQVeScR7gzCrVg90H21EOLACvtfcHk0lgvqtdM-IHLSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFCjtw%253D%253D&md5=5811c8fb4ea224370196e8c79d691e4b</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1039%2FC4DT03585B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4DT03585B%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DH.%26atitle%3DRuthenium%2528II%2529%2520polypyridyl%2520complexes%2520as%2520dual%2520inhibitors%2520of%2520telomerase%2520and%2520topoisomerase%26jtitle%3DDalton%2520Trans.%26date%3D2015%26volume%3D44%26issue%3D34%26spage%3D15145%26epage%3D15156%26doi%3D10.1039%2FC4DT03585B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhami, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, H.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&issue=2&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-13-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0lgvqtdM-IHLSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D2%26spage%3D275%26epage%3D284%26doi%3D10.1158%2F1535-7163.MCT-13-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, T. J.</span></span> <span> </span><span class="NLM_article-title">Microtubule polymerization dynamics</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.13.1.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1146%2Fannurev.cellbio.13.1.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9442869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1997&pages=83-117&author=A.+Desaiauthor=T.+J.+Mitchison&title=Microtubule+polymerization+dynamics&doi=10.1146%2Fannurev.cellbio.13.1.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule polymerization dynamics</span></div><div class="casAuthors">Desai, Arshad; Mitchison, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Cell and Developmental Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-117</span>CODEN:
                <span class="NLM_cas:coden">ARDBF8</span>;
        ISSN:<span class="NLM_cas:issn">1081-0706</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 187 refs.  The polymn. dynamics of microtubules are central to their biol. functions.  Polymn. dynamics allow microtubules to adopt spatial arrangements that can change rapidly in response to cellular needs and, in some cases, to perform mech. work.  Microtubules utilize the energy of GTP hydrolysis to fuel a unique polymn. mechanism termed dynamic instability.  In this review, the authors 1st describe progress toward understanding the mechanism of dynamic instability of pure tubulin and then discuss the function and regulation of microtubule dynamic instability in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2VFXflA9be7Vg90H21EOLACvtfcHk0lgvqtdM-IHLSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSksg%253D%253D&md5=92189bc321980f4162ce2defcddbb48e</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.13.1.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.13.1.83%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DA.%26aulast%3DMitchison%26aufirst%3DT.%2BJ.%26atitle%3DMicrotubule%2520polymerization%2520dynamics%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D1997%26volume%3D13%26spage%3D83%26epage%3D117%26doi%3D10.1146%2Fannurev.cellbio.13.1.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&issue=4&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lgllBi9DaWRcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26issue%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanbhag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambinder, R. F.</span></span> <span> </span><span class="NLM_article-title">Hodgkin lymphoma: A review and update on recent progress</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.3322/caac.21438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3322%2Fcaac.21438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29194581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1M3mvVyksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=116-132&issue=2&author=S.+Shanbhagauthor=R.+F.+Ambinder&title=Hodgkin+lymphoma%3A+A+review+and+update+on+recent+progress&doi=10.3322%2Fcaac.21438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Hodgkin lymphoma: A review and update on recent progress</span></div><div class="casAuthors">Shanbhag Satish; Ambinder Richard F</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-132</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed-Sternberg cells in an inflammatory background.  Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms.  Even in advanced-stage disease, HL is highly curable with combination chemotherapy, radiation, or combined-modality treatment.  Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk-adapted approaches have helped de-escalate therapy in low-risk patients while intensifying treatment for higher risk patients.  Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody-drug conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem cell transplantation.  The programmed death-1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL.  Alternate donor sources and reduced-intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients.  Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long-term treatment toxicities.  CA Cancer J Clin 2018;68:116-132. © 2017 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO_JmRpWRqUpWtyewyzkyLfW6udTcc2eYS-x_3EnYIqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3mvVyksg%253D%253D&md5=9ddf948ca58315d966b68e26b3c7f9e8</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21438%26sid%3Dliteratum%253Aachs%26aulast%3DShanbhag%26aufirst%3DS.%26aulast%3DAmbinder%26aufirst%3DR.%2BF.%26atitle%3DHodgkin%2520lymphoma%253A%2520A%2520review%2520and%2520update%2520on%2520recent%2520progress%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2018%26volume%3D68%26issue%3D2%26spage%3D116%26epage%3D132%26doi%3D10.3322%2Fcaac.21438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nabholtz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, A.</span></span> <span> </span><span class="NLM_article-title">Taxane/anthracycline combinations: setting a new standard in breast cancer?</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">Suppl. 3</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.6-suppl_3-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1634%2Ftheoncologist.6-suppl_3-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11346678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktValur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=5-12&issue=Suppl.+3&author=J.+M.+Nabholtzauthor=A.+Riva&title=Taxane%2Fanthracycline+combinations%3A+setting+a+new+standard+in+breast+cancer%3F&doi=10.1634%2Ftheoncologist.6-suppl_3-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Taxane/anthracycline combinations: Setting a new standard in breast cancer?</span></div><div class="casAuthors">Nabholtz, Jean-Marc; Riva, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">5-12</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review with 26 ref.  Among the novel chemotherapeutic drugs introduced in the 1990s, the taxanes have emerged as the most powerful compds. in breast cancer.  Both compds., paclitaxel and docetaxel, have been evaluated in metastatic settings before adjuvant trials proceeded.  Docetaxel was shown in several phase III trials to be superior, particularly in terms of survival, for salvaging poly-chemotherapies after failure of prior chemotherapy, including that with anthracyclines.  A benefit of docetaxel was also reported when compared with doxorubicin after failure of alkylating agents.  In phase III trials paclitaxel was reported to be as efficacious over 24 h as doxorubicin 60 mg/m2, while paclitaxel was significantly inferior to doxorubicin 75 mg/m2 over 3 h and was close to CMF in another trial.  The role of taxanes in combination with anthracyclines in first-line therapy of advanced breast cancer is emerging.  Following several phase II studies, a phase III trial showed the significant superiority of docetaxel/doxorubicin (AT) vs. doxorubicin/cyclophosphamide (AC) in terms of response and time to progression.  In several phase II studies with paclitaxel (3 h), anthracyclines in the metastatic setting showed high efficacy but produced cardiac toxicity related to a pharmacokinetic interaction between the two agents.  This finding led to the implementation of metastatic strategies (phase III trials) aimed at avoiding the pharmacokinetic interaction, while the adjuvant strategies with paclitaxel focused primarily on the sequential approach (AC followed by paclitaxel).  In contrast, adjuvant strategies with docetaxel/anthracycline-based programs were implemented following both sequential and combination approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfscJLTLeTD7Vg90H21EOLACvtfcHk0lgllBi9DaWRcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktValur4%253D&md5=c038013a18664df7b4420344e5f4e4d5</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.6-suppl_3-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.6-suppl_3-5%26sid%3Dliteratum%253Aachs%26aulast%3DNabholtz%26aufirst%3DJ.%2BM.%26aulast%3DRiva%26aufirst%3DA.%26atitle%3DTaxane%252Fanthracycline%2520combinations%253A%2520setting%2520a%2520new%2520standard%2520in%2520breast%2520cancer%253F%26jtitle%3DOncologist%26date%3D2001%26volume%3D6%26issue%3DSuppl.%25203%26spage%3D5%26epage%3D12%26doi%3D10.1634%2Ftheoncologist.6-suppl_3-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervinka, M.</span></span> <span> </span><span class="NLM_article-title">Topoisomerases and tubulin inhibitors: a promising combination for cancer treatment</span>. <i>Curr. Med. Chem.: Anti-Cancer Agents</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.2174/1568011033482242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1568011033482242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=14529450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFOns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=421-429&issue=6&author=E.+Rudolfauthor=M.+Cervinka&title=Topoisomerases+and+tubulin+inhibitors%3A+a+promising+combination+for+cancer+treatment&doi=10.2174%2F1568011033482242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerases and tubulin inhibitors: A promising combination for cancer treatment</span></div><div class="casAuthors">Rudolf, E.; Cervinka, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">421-429</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Modern approaches to treatment of cancer seek to activate the internal suicide program in the malignant cells, and thereby effectively eliminate them without engaging most of other bodily systems.  Many currently used cytostatics are known to induce apoptosis and efforts are being paid to develop new ones with better and more effective proapoptotic potential.  Nevertheless, despite recent developments in this field, there are still numerous malignancies showing a varying degree of resistance to cell death due to the corrupted signaling pathways and genetic alterations, often in conjunction with expansive proliferation rate.  It has been shown that topoisomerase inhibiting agents such as etoposide, camptothecin and others represent a powerful and dynamic group of cytostatic chems. used in exptl. and clin. conditions.  So, it is a group of microtubule targeting poisons comprising classical colchicines on the one hand and new taxanes on the other hand.  Since several members of both groups have been evidenced as apoptosis inducers operating via distinct mechanism, their combination should theor. enhance the final therapeutic outcome.  This minireview focuses on the possibilities of such a combinational approach with respect to possible benefits and hazards of this strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJiCqrOtqGHLVg90H21EOLACvtfcHk0li2a_J1gAC64A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFOns7s%253D&md5=2ecc33565f5b54921de17a2fac21e916</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.2174%2F1568011033482242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011033482242%26sid%3Dliteratum%253Aachs%26aulast%3DRudolf%26aufirst%3DE.%26aulast%3DCervinka%26aufirst%3DM.%26atitle%3DTopoisomerases%2520and%2520tubulin%2520inhibitors%253A%2520a%2520promising%2520combination%2520for%2520cancer%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2003%26volume%3D3%26issue%3D6%26spage%3D421%26epage%3D429%26doi%3D10.2174%2F1568011033482242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorr, R. T.</span></span> <span> </span><span class="NLM_article-title">Drug interactions with the taxanes: clinical implications</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1053/ctrv.2001.0228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1053%2Fctrv.2001.0228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11545542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt1SktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2001&pages=221-233&issue=4&author=A.+F.+Bakerauthor=R.+T.+Dorr&title=Drug+interactions+with+the+taxanes%3A+clinical+implications&doi=10.1053%2Fctrv.2001.0228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Drug interactions with the taxanes: Clinical implications</span></div><div class="casAuthors">Baker, A. F.; Dorr, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders</span>)
        </div><div class="casAbstract">A review.  The taxanes paclitaxel and docetaxel are among the most active antitumor agents.  Clin. important pharmacodynamic interactions have been reported to occur with these agents that are sequence or schedule dependent.  Because the taxanes undergo hepatic oxidn. via the cytochrome P 450 system, pharmacokinetic interactions due to enzyme induction or inhibition can also occur.  A comprehensive literature search was conducted using Medline to identify clin. important drug-interactions with the taxanes.  Clin. significant taxane interactions were identified for carboplatin, cisplatin, doxorubicin, docetaxel, epirubicin and anticonvulsants.  Doxorubicin and epirubicin should be administered 24h before paclitaxel, and the cumulative anthracycline dose limited to 360 mg/m2.  This will prevent the enhanced toxicities due to sequence and schedule dependent interactions between anthracyclines and paclitaxel.  Conversely, paclitaxel should be administered at least 24h before cisplatin to avoid a decrease in clearance and increase in myelosuppression.  With concurrent anticonvulsant therapy, cytochrome P 450 enzyme induction results in decreased paclitaxel plasma steady state concns., possibly requiring an increased dose of paclitaxel.  A no. of other drug interactions have been reported in preliminary studies for which clin. significance has yet to be established.  Clin. significant drug interactions have been reported to occur when paclitaxel is administered with doxorubicin, cisplatin, or anticonvulsants (phenytoin, carbamazepine, and phenobarbital).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFYUmRGtPwPbVg90H21EOLACvtfcHk0li2a_J1gAC64A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt1SktLo%253D&md5=b374723b96807c5c10862a7a20cb0eb7</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1053%2Fctrv.2001.0228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fctrv.2001.0228%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DA.%2BF.%26aulast%3DDorr%26aufirst%3DR.%2BT.%26atitle%3DDrug%2520interactions%2520with%2520the%2520taxanes%253A%2520clinical%2520implications%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2001%26volume%3D27%26issue%3D4%26spage%3D221%26epage%3D233%26doi%3D10.1053%2Fctrv.2001.0228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span> <span> </span><span class="NLM_article-title">Review of docetaxel/doxorubicin combination in metastatic breast cancer</span>. <i>Oncology (Williston Park)</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9364539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADyaK1c%252FjtFWhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=31-33&issue=8&author=V.+Di%C3%A9ras&title=Review+of+docetaxel%2Fdoxorubicin+combination+in+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Review of docetaxel/doxorubicin combination in metastatic breast cancer</span></div><div class="casAuthors">Dieras V</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8 Suppl 8</span>),
    <span class="NLM_cas:pages">31-3</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Docetaxel (Taxotere) and doxorubicin (Adriamycin) have each demonstrated significant activity in metastatic breast cancer.  Thus, the combination of docetaxel and doxorubicin has been evaluated in phase I trials to establish the dose-limiting toxicity, maximum tolerated dose, recommended dose for future phase II and III studies, and toxicity profile of the two agents used in combination.  Results from phase I trials in patients with metastatic breast cancer indicate that the docetaxel/doxorubicin combination is well tolerated.  The recommended dose for the combination regimen is either 50 mg/m2 of doxorubicin followed by 75 mg/m2 of docetaxel or 60 mg/m2 of both drugs, without granulocyte colony-stimulating factor (G-CSF) support.  Febrile neutropenia complicated by grade 3 infection was the dose-limiting effect at the maximum tolerated dose.  The response rate at this dose level was 90%.  Based on the preliminary results of phase I studies, further phase II and III studies of a docetaxel/doxorubicin combination regimen are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRugEZYQeiChWGmni0r9GoKfW6udTcc2eYf5XU5euT0Gbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252FjtFWhsA%253D%253D&md5=d352b42637b90485d1e996c70fc833e6</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26atitle%3DReview%2520of%2520docetaxel%252Fdoxorubicin%2520combination%2520in%2520metastatic%2520breast%2520cancer%26jtitle%3DOncology%2520%2528Williston%2520Park%2529%26date%3D1997%26volume%3D11%26issue%3D8%26spage%3D31%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cervinka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, E.</span></span> <span> </span><span class="NLM_article-title">Apoptosis in Hep2 cells treated with etoposide and colchicine</span>. <i>Cancer Detect. Prev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1016/j.cdp.2004.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.cdp.2004.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15225902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVyqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=214-226&issue=3&author=M.+Cervinkaauthor=J.+Cermanauthor=E.+Rudolf&title=Apoptosis+in+Hep2+cells+treated+with+etoposide+and+colchicine&doi=10.1016%2Fj.cdp.2004.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis in Hep2 cells treated with etoposide and colchicine</span></div><div class="casAuthors">Cervinka, Miroslav; Cerman, Jaroslav; Rudolf, Emil</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Detection and Prevention</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-226</span>CODEN:
                <span class="NLM_cas:coden">CDPRD4</span>;
        ISSN:<span class="NLM_cas:issn">0361-090X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">When malignant cells undergo apoptosis, they exhibit many distinct patterns of behavior, with blebbing being one of the most spectacular and mysterious features.  Despite huge advancements in our understanding of cell death, the mechanisms of apoptosis assocd. blebbing have not been elucidated.  In order to verify the putative involvement of actin and tubulin in this process.  Hep2 cells were treated with a combination of etoposide (10 μg/mL) and colchicine (0.2 μg/mL) for 24 h.  Blebbing was analyzed using immunofluorescence staining of actin and tubulin, and the course of apoptosis was followed by time-lapse videomicroscopy, immunofluorescence detection of caspase-3 and cytokeratin fragment 18.  The results indicate that microfilaments (actin) and not microtubules (tubulin) are involved in blebbing of Hep2 cells.  Furthermore, despite the different mechanisms by which both chems. act, their combined effects are not additive, but rather eliminate each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofo3s2OXdvA7Vg90H21EOLACvtfcHk0ljC6zLhwkxryw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVyqurs%253D&md5=70531e2f71a164900d5039292344d03a</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.cdp.2004.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cdp.2004.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DCervinka%26aufirst%3DM.%26aulast%3DCerman%26aufirst%3DJ.%26aulast%3DRudolf%26aufirst%3DE.%26atitle%3DApoptosis%2520in%2520Hep2%2520cells%2520treated%2520with%2520etoposide%2520and%2520colchicine%26jtitle%3DCancer%2520Detect.%2520Prev.%26date%3D2004%26volume%3D28%26issue%3D3%26spage%3D214%26epage%3D226%26doi%3D10.1016%2Fj.cdp.2004.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathi, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathi, M. K.</span></span> <span> </span><span class="NLM_article-title">Mechanisms regulating resistance to inhibitors of topoisomerase II</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.3389/fphar.2013.00089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3389%2Ffphar.2013.00089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23914174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC3sfmslWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=89&author=R.+N.+Ganapathiauthor=M.+K.+Ganapathi&title=Mechanisms+regulating+resistance+to+inhibitors+of+topoisomerase+II&doi=10.3389%2Ffphar.2013.00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms regulating resistance to inhibitors of topoisomerase II</span></div><div class="casAuthors">Ganapathi Ram N; Ganapathi Mahrukh K</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Inhibitors of topoisomerase II (topo II) are clinically effective in the management of hematological malignancies and solid tumors.  The efficacy of anti-tumor drugs targeting topo II is often limited by resistance and studies with in vitro cell culture models have provided several insights on potential mechanisms.  Multidrug transporters that are involved in the efflux and consequently reduced cytotoxicity of diverse anti-tumor agents suggest that they play an important role in resistance to clinically active drugs.  However, in clinical trials, modulating the multidrug-resistant phenotype with agents that inhibit the efflux pump has not had an impact.  Since reduced drug accumulation per se is insufficient to explain tumor cell resistance to topo II inhibitors several studies have focused on characterizing mechanisms that impact on DNA damage mediated by drugs that target the enzyme.  Mammalian topo IIα and topo IIβ isozymes exhibit similar catalytic, but different biologic, activities.  Whereas topo IIα is associated with cell division, topo IIβ is involved in differentiation.  In addition to site specific mutations that can affect drug-induced topo II-mediated DNA damage, post-translation modification of topo II primarily by phosphorylation can potentially affect enzyme-mediated DNA damage and the downstream cytotoxic response of drugs targeting topo II.  Signaling pathways that can affect phosphorylation and changes in intracellular calcium levels/calcium dependent signaling that can regulate site-specific phosphorylation of topoisomerase have an impact on downstream cytotoxic effects of topo II inhibitors.  Overall, tumor cell resistance to inhibitors of topo II is a complex process that is orchestrated not only by cellular pharmacokinetics but more importantly by enzymatic alterations that govern the intrinsic drug sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-P0PWb68VA8ScOqQTSkOffW6udTcc2eYf5XU5euT0Gbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfmslWqtQ%253D%253D&md5=7828c568fa64b072dd47e8dee2ce767c</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2013.00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2013.00089%26sid%3Dliteratum%253Aachs%26aulast%3DGanapathi%26aufirst%3DR.%2BN.%26aulast%3DGanapathi%26aufirst%3DM.%2BK.%26atitle%3DMechanisms%2520regulating%2520resistance%2520to%2520inhibitors%2520of%2520topoisomerase%2520II%26jtitle%3DFront.%2520Pharmacol.%26date%3D2013%26volume%3D4%26spage%3D89%26doi%3D10.3389%2Ffphar.2013.00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, E. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2095</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-09-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19671735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2086-2095&issue=8&author=E.+A.+Perez&title=Microtubule+inhibitors%3A+Differentiating+tubulin-inhibiting+agents+based+on+mechanisms+of+action%2C+clinical+activity%2C+and+resistance&doi=10.1158%2F1535-7163.MCT-09-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span></div><div class="casAuthors">Perez, Edith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2095</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis.  Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis.  In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clin. efficacy.  Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs.  This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents. [Mol Cancer Ther 2009;8(8):2086-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1HM8JP4QG8LVg90H21EOLACvtfcHk0lg0v7nGkxDonA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D&md5=1d8dec9ed6c0f061032cec57c96c833e</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0366%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26atitle%3DMicrotubule%2520inhibitors%253A%2520Differentiating%2520tubulin-inhibiting%2520agents%2520based%2520on%2520mechanisms%2520of%2520action%252C%2520clinical%2520activity%252C%2520and%2520resistance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D8%26spage%3D2086%26epage%3D2095%26doi%3D10.1158%2F1535-7163.MCT-09-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z. H.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of microtubule and topoisomerase II by alpha-carboline derivative YCH337 for tumor proliferation and growth inhibition</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">8960</span>– <span class="NLM_lpage">8973</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.18632%2Foncotarget.3264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25840421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjgs1Oltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8960-8973&issue=11&author=J.+M.+Yiauthor=X.+F.+Zhangauthor=X.+J.+Huanauthor=S.+S.+Songauthor=W.+Wangauthor=Q.+T.+Tianauthor=Y.+M.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Q.+Wangauthor=C.+H.+Yangauthor=Z.+H.+Miao&title=Dual+targeting+of+microtubule+and+topoisomerase+II+by+alpha-carboline+derivative+YCH337+for+tumor+proliferation+and+growth+inhibition&doi=10.18632%2Foncotarget.3264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition</span></div><div class="casAuthors">Yi Jun-Mei; Huan Xia-Juan; Song Shan-Shan; Wang Wei; Tian Qian-Ting; Sun Yi-Ming; Chen Yi; Ding Jian; Wang Ying-Qing; Miao Ze-Hong; Zhang Xiao-Fei; Yang Chun-Hao</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8960-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Both microtubule and topoisomerase II (Top2) are important anticancer targets and their respective inhibitors are widely used in combination for cancer therapy.  However, some combinations could be mutually antagonistic and drug resistance further limits their therapeutic efficacy.  Here we report YCH337, a novel α-carboline derivative that targets both microtubule and Top2, eliciting tumor proliferation and growth inhibition and overcoming drug resistance.  YCH337 inhibited microtubule polymerization by binding to the colchicine site and subsequently led to mitotic arrest.  It also suppressed Top2 and caused DNA double-strand breaks.  It disrupted microtubule more potently than Top2.  YCH337 induced reversible mitotic arrest at low concentrations but persistent DNA damage.  YCH337 caused intrinsic and extrinsic apoptosis and decreased MCL-1, cIAP1 and XIAP proteins.  In this aspect, YCH337 behaved differently from the combination of vincristine and etoposide.  YCH337 inhibited proliferation of tumor cells with an averaged IC50 of 0.3 μM.  It significantly suppressed the growth of HT-29 xenografts in nude mice too.  Importantly, YCH337 nearly equally killed different-mechanism-mediated resistant tumor cells and corresponding parent cells.  Together with the novelty of its chemical structure, YCH337 could serve as a promising lead for drug development and a prototype for a dual microtubule/Top2 targeting strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG7_gaQunNwoJKJbLTgsvCfW6udTcc2eYmI0T7WEzTfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjgs1Oltw%253D%253D&md5=bd05960113eda9a65fa6626a8277ca20</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3264%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DX.%2BF.%26aulast%3DHuan%26aufirst%3DX.%2BJ.%26aulast%3DSong%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DQ.%2BT.%26aulast%3DSun%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26atitle%3DDual%2520targeting%2520of%2520microtubule%2520and%2520topoisomerase%2520II%2520by%2520alpha-carboline%2520derivative%2520YCH337%2520for%2520tumor%2520proliferation%2520and%2520growth%2520inhibition%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D11%26spage%3D8960%26epage%3D8973%26doi%3D10.18632%2Foncotarget.3264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silveira-Dorta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios-Luci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, J. M.</span></span> <span> </span><span class="NLM_article-title">Molecular docking studies of the interaction between propargylic enol ethers and human DNA topoisomerase IIα</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5382</span>– <span class="NLM_lpage">5384</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.07.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmcl.2013.07.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23953196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5382-5384&issue=19&author=G.+Silveira-Dortaauthor=I.+J.+Sousaauthor=C.+Rios-Luciauthor=V.+S.+Martinauthor=M.+X.+Fernandesauthor=J.+M.+Padron&title=Molecular+docking+studies+of+the+interaction+between+propargylic+enol+ethers+and+human+DNA+topoisomerase+II%CE%B1&doi=10.1016%2Fj.bmcl.2013.07.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular docking studies of the interaction between propargylic enol ethers and human DNA topoisomerase IIα</span></div><div class="casAuthors">Silveira-Dorta, Gaston; Sousa, Ines J.; Rios-Luci, Carla; Martin, Victor S.; Fernandes, Miguel X.; Padron, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5382-5384</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Having identified a novel human DNA topoisomerase IIα (TOP2) catalytic inhibitor from a small and structure-focused library of propargylic enol ethers, we decided to analyze if the chirality of these compds. plays a determinant role in their antiproliferative activity.  In this study, we describe for the first time the synthesis of the corresponding enantiomers and the biol. evaluation against a panel of representative human solid tumor cell lines.  Exptl. results show that chirality does not influence the reported antiproliferative activity of these compds.  Docking studies of corresponding enantiomers against TOP2 reinforce the finding that the biol. effect is not chiral-dependent and that these family of compds. seem to act as TOP2 catalytic inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVjr69oup13rVg90H21EOLACvtfcHk0lg0v7nGkxDonA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrjK&md5=7598d2e52816ebb4291940cb7c78061c</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.07.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.07.055%26sid%3Dliteratum%253Aachs%26aulast%3DSilveira-Dorta%26aufirst%3DG.%26aulast%3DSousa%26aufirst%3DI.%2BJ.%26aulast%3DRios-Luci%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DV.%2BS.%26aulast%3DFernandes%26aufirst%3DM.%2BX.%26aulast%3DPadron%26aufirst%3DJ.%2BM.%26atitle%3DMolecular%2520docking%2520studies%2520of%2520the%2520interaction%2520between%2520propargylic%2520enol%2520ethers%2520and%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D19%26spage%3D5382%26epage%3D5384%26doi%3D10.1016%2Fj.bmcl.2013.07.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podolski-Renic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios-Luci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacevic-Grujicic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesic, M.</span></span> <span> </span><span class="NLM_article-title">DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejps.2017.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28502672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2017&pages=159-168&author=A.+Podolski-Renicauthor=J.+Bankovicauthor=J.+Dinicauthor=C.+Rios-Luciauthor=M.+X.+Fernandesauthor=N.+Ortegaauthor=N.+Kovacevic-Grujicicauthor=V.+S.+Martinauthor=J.+M.+Padronauthor=M.+Pesic&title=DTA0100%2C+dual+topoisomerase+II+and+microtubule+inhibitor%2C+evades+paclitaxel+resistance+in+P-glycoprotein+overexpressing+cancer+cells&doi=10.1016%2Fj.ejps.2017.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells</span></div><div class="casAuthors">Podolski-Renic, Ana; Bankovic, Jasna; Dinic, Jelena; Rios-Luci, Carla; Fernandes, Miguel X.; Ortega, Nuria; Kovacevic-Grujicic, Natasa; Martin, Victor S.; Padron, Jose M.; Pesic, Milica</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-168</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The efficacy of microtubule targeting agents in cancer treatment has been compromised by the development of drug resistance that may involve both, P-glycoprotein overexpression and the changes in β-tubulin isoforms' expression.  The anti-Topoisomerase II activity of Me 4-((E)-2-(methoxycarbonyl)vinyloxy)oct-2-ynoate (DTA0100) was recently reported.  Herein, we further evaluated this propargylic enol ether deriv. and found that it exerts inhibitory effect on tubulin polymn. by binding to colchicine binding site.  DTA0100 mitotic arrest properties were investigated in two multi-drug resistant cancer cell lines with P-glycoprotein overexpression (colorectal carcinoma and glioblastoma).  The sensitivity of multi-drug resistant cancer cell lines to DTA0100 was not significantly changed in contrast to microtubule targeting agents such as paclitaxel, vinblastine and colchicine.  DTA0100 clearly induced microtubule depolymn., leading to disturbance of cell cycle kinetics and subsequent apoptosis.  The fine-tuning in β-tubulin isoforms expression obsd. in multi-drug resistant cancer cells may influence the efficacy of DTA0100.  Importantly, DTA0100 blocked the P-glycoprotein function in both multi-drug resistant cancer cell lines without inducing the increase in P-glycoprotein expression.  Therefore, DTA0100 acting as dual inhibitor of Topoisomerase II and microtubule formation could be considered as multi-potent anticancer agent.  Besides, it is able to overcome the problem of drug resistance that emerges in the therapeutic approaches with either Topoisomerase II or microtubule targeting agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Yr0A5xxeibVg90H21EOLACvtfcHk0liXI-JJGSe6UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVCmtr4%253D&md5=415d67d933dd9d2933cb3b4f5dd37b45</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DPodolski-Renic%26aufirst%3DA.%26aulast%3DBankovic%26aufirst%3DJ.%26aulast%3DDinic%26aufirst%3DJ.%26aulast%3DRios-Luci%26aufirst%3DC.%26aulast%3DFernandes%26aufirst%3DM.%2BX.%26aulast%3DOrtega%26aufirst%3DN.%26aulast%3DKovacevic-Grujicic%26aufirst%3DN.%26aulast%3DMartin%26aufirst%3DV.%2BS.%26aulast%3DPadron%26aufirst%3DJ.%2BM.%26aulast%3DPesic%26aufirst%3DM.%26atitle%3DDTA0100%252C%2520dual%2520topoisomerase%2520II%2520and%2520microtubule%2520inhibitor%252C%2520evades%2520paclitaxel%2520resistance%2520in%2520P-glycoprotein%2520overexpressing%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D105%26spage%3D159%26epage%3D168%26doi%3D10.1016%2Fj.ejps.2017.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, L.</span></span> <span> </span><span class="NLM_article-title">Novel conjugates of podophyllotoxin and coumarin: Synthesis, cytotoxicities, cell cycle arrest, binding CT DNA and inhibition of Topo IIβ</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2135</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.06.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmcl.2019.06.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=31278032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlejs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2129-2135&issue=16&author=S.+Y.+Haoauthor=S.+L.+Fengauthor=X.+R.+Wangauthor=Z.+Wangauthor=S.+W.+Chenauthor=L.+Hui&title=Novel+conjugates+of+podophyllotoxin+and+coumarin%3A+Synthesis%2C+cytotoxicities%2C+cell+cycle+arrest%2C+binding+CT+DNA+and+inhibition+of+Topo+II%CE%B2&doi=10.1016%2Fj.bmcl.2019.06.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Novel conjugates of podophyllotoxin and coumarin: Synthesis, cytotoxicities, cell cycle arrest, binding CT DNA and inhibition of Topo IIβ</span></div><div class="casAuthors">Hao, Shu-Yi; Feng, Shi-Liang; Wang, Xing-Rong; Wang, Zhichao; Chen, Shi-Wu; Hui, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2129-2135</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of conjugates of podophyllotoxin and coumarin, I (X = O, NH, R1 = H, Me, Br, OMe, R2 = H, Br, OMe), were prepd. using the click reaction, and their cytotoxicities against A549, HepG2, HeLa, and LoVo cells were evaluated.  Among them, compd. I (X = NH, R1 = OMe, R2 = H) (II) exhibited the strongest cytotoxicities against these cancer cells with IC50 values of 4.9-17.5 μM.  Furthermore, II disrupted microtubules and induced cell cycle arrest at G1 phase by regulating P21 and Cyclin D1 in LoVo cells.  In addn., II bound CT DNA and selectively inhibited Topo IIβ over Topo IIα.  Mol. docking model showed that II appeared to form stable hydrogen bonds with several DNA bases and residue Gln778.  Taken together, these conjugates have the potential to be developed as anti-tumor drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-st5yLtlaqrVg90H21EOLACvtfcHk0liXI-JJGSe6UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlejs77N&md5=5e9deabb0c6d9ad91c5ec1e9eedde56c</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.06.063%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DS.%2BY.%26aulast%3DFeng%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BR.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%2BW.%26aulast%3DHui%26aufirst%3DL.%26atitle%3DNovel%2520conjugates%2520of%2520podophyllotoxin%2520and%2520coumarin%253A%2520Synthesis%252C%2520cytotoxicities%252C%2520cell%2520cycle%2520arrest%252C%2520binding%2520CT%2520DNA%2520and%2520inhibition%2520of%2520Topo%2520II%25CE%25B2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2129%26epage%3D2135%26doi%3D10.1016%2Fj.bmcl.2019.06.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tingting Liu, Yichao Wan, Yuliang Xiao, Chengcai Xia, <span class="NLM_string-name hlFld-ContribAuthor">Guiyun Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 8977-9002. <a href="https://doi.org/10.1021/acs.jmedchem.0c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-Target%252BInhibitors%252BBased%252Bon%252BHDACs%25253A%252BNovel%252BAntitumor%252BAgents%252Bfor%252BCancer%252BTherapy%26aulast%3DLiu%26aufirst%3DTingting%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23032020%26date%3D30042020%26date%3D22042020%26volume%3D63%26issue%3D17%26spage%3D8977%26epage%3D9002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashwini Khanderao  Jadhav</span>, <span class="hlFld-ContribAuthor ">Sankunny Mohan  Karuppayil</span>. </span><span class="cited-content_cbyCitation_article-title">Topoisomerase II as a target for repurposed antibiotics in Candida albicans: an in silico study. </span><span class="cited-content_cbyCitation_journal-name">In Silico Pharmacology</span><span> <strong>2021,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1007/s40203-021-00082-1" title="DOI URL">https://doi.org/10.1007/s40203-021-00082-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40203-021-00082-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40203-021-00082-1%26sid%3Dliteratum%253Aachs%26jtitle%3DIn%2520Silico%2520Pharmacology%26atitle%3DTopoisomerase%252BII%252Bas%252Ba%252Btarget%252Bfor%252Brepurposed%252Bantibiotics%252Bin%252BCandida%252Balbicans%25253A%252Ban%252Bin%252Bsilico%252Bstudy%26aulast%3DJadhav%26aufirst%3DAshwini%2BKhanderao%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Afaf  El-Malah</span>, <span class="hlFld-ContribAuthor ">Amira  Youssef</span>, <span class="hlFld-ContribAuthor ">Mohamed  Ismail</span>, <span class="hlFld-ContribAuthor ">Mona  Kamel</span>, <span class="hlFld-ContribAuthor ">Zeinab  Mahmoud</span>. </span><span class="cited-content_cbyCitation_article-title">New promising levofloxacin derivatives: Design, synthesis, cytotoxic activity screening, Topo2β polymerase inhibition assay, cell cycle apoptosis profile analysis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>113 </em>, 105029. <a href="https://doi.org/10.1016/j.bioorg.2021.105029" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNew%252Bpromising%252Blevofloxacin%252Bderivatives%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bcytotoxic%252Bactivity%252Bscreening%25252C%252BTopo2%2525CE%2525B2%252Bpolymerase%252Binhibition%252Bassay%25252C%252Bcell%252Bcycle%252Bapoptosis%252Bprofile%252Banalysis%26aulast%3DEl-Malah%26aufirst%3DAfaf%26date%3D2021%26volume%3D113%26spage%3D105029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caroline  Molinaro</span>, <span class="hlFld-ContribAuthor ">Alain  Martoriati</span>, <span class="hlFld-ContribAuthor ">Katia  Cailliau</span>. </span><span class="cited-content_cbyCitation_article-title">Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (15)
                                     , 3819. <a href="https://doi.org/10.3390/cancers13153819" title="DOI URL">https://doi.org/10.3390/cancers13153819</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13153819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13153819%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DProteins%252Bfrom%252Bthe%252BDNA%252BDamage%252BResponse%25253A%252BRegulation%25252C%252BDysfunction%25252C%252Band%252BAnticancer%252BStrategies%26aulast%3DMolinaro%26aufirst%3DCaroline%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D15%26spage%3D3819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed  Shaaban</span>, <span class="hlFld-ContribAuthor ">Mohammad  Magdy El-Metwally</span>, <span class="hlFld-ContribAuthor ">Amal A. I.  Mekawey</span>, <span class="hlFld-ContribAuthor ">Ahmed B.  Abdelwahab</span>, <span class="hlFld-ContribAuthor ">Maha M.  Soltan</span>. </span><span class="cited-content_cbyCitation_article-title">Monascin and monascinol, azaphilonoid pigments from
              Mortierella polycephala
              AM1:
              in silico
              and
              in vitro
              targeting of the angiogenic VEGFR2 kinase. </span><span class="cited-content_cbyCitation_journal-name">Zeitschrift für Naturforschung C</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/znc-2021-0095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fznc-2021-0095%26sid%3Dliteratum%253Aachs%26jtitle%3DZeitschrift%2520f%25C3%25BCr%2520Naturforschung%2520C%26atitle%3DMonascin%252Band%252Bmonascinol%25252C%252Bazaphilonoid%252Bpigments%252Bfrom%252BMortierella%252Bpolycephala%252BAM1%25253A%252Bin%252Bsilico%252Band%252Bin%252Bvitro%252Btargeting%252Bof%252Bthe%252Bangiogenic%252BVEGFR2%252Bkinase%26aulast%3DShaaban%26aufirst%3DMohamed%26date%3D2021%26date%3D2021%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asier  Selas</span>, <span class="hlFld-ContribAuthor ">Endika  Martin-Encinas</span>, <span class="hlFld-ContribAuthor ">Maria  Fuertes</span>, <span class="hlFld-ContribAuthor ">Carme  Masdeu</span>, <span class="hlFld-ContribAuthor ">Gloria  Rubiales</span>, <span class="hlFld-ContribAuthor ">Francisco  Palacios</span>, <span class="hlFld-ContribAuthor ">Concepción  Alonso</span>. </span><span class="cited-content_cbyCitation_article-title">A patent review of topoisomerase I inhibitors (2016–present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (6)
                                     , 473-508. <a href="https://doi.org/10.1080/13543776.2021.1879051" title="DOI URL">https://doi.org/10.1080/13543776.2021.1879051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1879051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1879051%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Breview%252Bof%252Btopoisomerase%252BI%252Binhibitors%252B%2525282016%2525E2%252580%252593present%252529%26aulast%3DSelas%26aufirst%3DAsier%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D6%26spage%3D473%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Jiao</span>, <span class="hlFld-ContribAuthor ">Mengli  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Feng</span>, <span class="hlFld-ContribAuthor ">Han  Bao</span>, <span class="hlFld-ContribAuthor ">Feiran  Zhang</span>, <span class="hlFld-ContribAuthor ">Hao  Wu</span>, <span class="hlFld-ContribAuthor ">Junling  Wang</span>, <span class="hlFld-ContribAuthor ">Beisha  Tang</span>, <span class="hlFld-ContribAuthor ">Peng  Jin</span>, <span class="hlFld-ContribAuthor ">Lu  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Downregulation of
              TOP2
              modulates neurodegeneration caused by GGGGCC expanded repeats. </span><span class="cited-content_cbyCitation_journal-name">Human Molecular Genetics</span><span> <strong>2021,</strong> <em>30 </em>
                                    (10)
                                     , 893-901. <a href="https://doi.org/10.1093/hmg/ddab079" title="DOI URL">https://doi.org/10.1093/hmg/ddab079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/hmg/ddab079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fhmg%2Fddab079%26sid%3Dliteratum%253Aachs%26jtitle%3DHuman%2520Molecular%2520Genetics%26atitle%3DDownregulation%252Bof%252BTOP2%252Bmodulates%252Bneurodegeneration%252Bcaused%252Bby%252BGGGGCC%252Bexpanded%252Brepeats%26aulast%3DJiao%26aufirst%3DBin%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D10%26spage%3D893%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulun  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Tan</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">The ups, downs and new trends of IDO1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104815. <a href="https://doi.org/10.1016/j.bioorg.2021.104815" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104815%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DThe%252Bups%25252C%252Bdowns%252Band%252Bnew%252Btrends%252Bof%252BIDO1%252Binhibitors%26aulast%3DChen%26aufirst%3DShulun%26date%3D2021%26volume%3D110%26spage%3D104815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ezzat  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridine Derivatives as Biologically Active Precursors; Organics and Selected Coordination Complexes. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (13)
                                     , 3041-3064. <a href="https://doi.org/10.1002/slct.202100332" title="DOI URL">https://doi.org/10.1002/slct.202100332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100332%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DPyridine%252BDerivatives%252Bas%252BBiologically%252BActive%252BPrecursors%25253B%252BOrganics%252Band%252BSelected%252BCoordination%252BComplexes%26aulast%3DKhan%26aufirst%3DEzzat%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D13%26spage%3D3041%26epage%3D3064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karolina  Chrabąszcz</span>, <span class="hlFld-ContribAuthor ">Andrzej  Błauż</span>, <span class="hlFld-ContribAuthor ">Martyna  Gruchała</span>, <span class="hlFld-ContribAuthor ">Marcin  Wachulec</span>, <span class="hlFld-ContribAuthor ">Błażej  Rychlik</span>, <span class="hlFld-ContribAuthor ">Damian  Plażuk</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Activity of Ferrocenyl and Ruthenocenyl Analogues of Etoposide: Discovery of a Novel Dual Inhibitor of Topoisomerase II Activity and Tubulin Polymerization. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2021,</strong> <em>27 </em>
                                    (20)
                                     , 6254-6262. <a href="https://doi.org/10.1002/chem.202005133" title="DOI URL">https://doi.org/10.1002/chem.202005133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202005133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202005133%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DSynthesis%252Band%252BBiological%252BActivity%252Bof%252BFerrocenyl%252Band%252BRuthenocenyl%252BAnalogues%252Bof%252BEtoposide%25253A%252BDiscovery%252Bof%252Ba%252BNovel%252BDual%252BInhibitor%252Bof%252BTopoisomerase%252BII%252BActivity%252Band%252BTubulin%252BPolymerization%26aulast%3DChrab%25C4%2585szcz%26aufirst%3DKarolina%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D20%26spage%3D6254%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martina  Durcik</span>, <span class="hlFld-ContribAuthor ">Ákos  Nyerges</span>, <span class="hlFld-ContribAuthor ">Žiga  Skok</span>, <span class="hlFld-ContribAuthor ">Darja Gramec  Skledar</span>, <span class="hlFld-ContribAuthor ">Jurij  Trontelj</span>, <span class="hlFld-ContribAuthor ">Nace  Zidar</span>, <span class="hlFld-ContribAuthor ">Janez  Ilaš</span>, <span class="hlFld-ContribAuthor ">Anamarija  Zega</span>, <span class="hlFld-ContribAuthor ">Cristina D.  Cruz</span>, <span class="hlFld-ContribAuthor ">Päivi  Tammela</span>, <span class="hlFld-ContribAuthor ">Martin  Welin</span>, <span class="hlFld-ContribAuthor ">Yengo R.  Kimbung</span>, <span class="hlFld-ContribAuthor ">Dorota  Focht</span>, <span class="hlFld-ContribAuthor ">Ondřej  Benek</span>, <span class="hlFld-ContribAuthor ">Tamás  Révész</span>, <span class="hlFld-ContribAuthor ">Gábor  Draskovits</span>, <span class="hlFld-ContribAuthor ">Petra Éva  Szili</span>, <span class="hlFld-ContribAuthor ">Lejla  Daruka</span>, <span class="hlFld-ContribAuthor ">Csaba  Pál</span>, <span class="hlFld-ContribAuthor ">Danijel  Kikelj</span>, <span class="hlFld-ContribAuthor ">Lucija Peterlin  Mašič</span>, <span class="hlFld-ContribAuthor ">Tihomir  Tomašič</span>. </span><span class="cited-content_cbyCitation_article-title">New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113200. <a href="https://doi.org/10.1016/j.ejmech.2021.113200" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113200%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdual%252BATP-competitive%252Binhibitors%252Bof%252Bbacterial%252BDNA%252Bgyrase%252Band%252Btopoisomerase%252BIV%252Bactive%252Bagainst%252BESKAPE%252Bpathogens%26aulast%3DDurcik%26aufirst%3DMartina%26date%3D2021%26volume%3D213%26spage%3D113200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Lenci</span>, <span class="hlFld-ContribAuthor ">Andrea  Angeli</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Calugi</span>, <span class="hlFld-ContribAuthor ">Riccardo  Innocenti</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Carta</span>, <span class="hlFld-ContribAuthor ">Claudiu T.  Supuran</span>, <span class="hlFld-ContribAuthor ">Andrea  Trabocchi</span>. </span><span class="cited-content_cbyCitation_article-title">Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113260. <a href="https://doi.org/10.1016/j.ejmech.2021.113260" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113260%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMultitargeting%252Bapplication%252Bof%252Bproline-derived%252Bpeptidomimetics%252Baddressing%252Bcancer-related%252Bhuman%252Bmatrix%252Bmetalloproteinase%252B9%252Band%252Bcarbonic%252Banhydrase%252BII%26aulast%3DLenci%26aufirst%3DElena%26date%3D2021%26volume%3D214%26spage%3D113260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleksandr  Ianevski</span>, <span class="hlFld-ContribAuthor ">Jenni  Lahtela</span>, <span class="hlFld-ContribAuthor ">Komal K.  Javarappa</span>, <span class="hlFld-ContribAuthor ">Philipp  Sergeev</span>, <span class="hlFld-ContribAuthor ">Bishwa R.  Ghimire</span>, <span class="hlFld-ContribAuthor ">Prson  Gautam</span>, <span class="hlFld-ContribAuthor ">Markus  Vähä-Koskela</span>, <span class="hlFld-ContribAuthor ">Laura  Turunen</span>, <span class="hlFld-ContribAuthor ">Nora  Linnavirta</span>, <span class="hlFld-ContribAuthor ">Heikki  Kuusanmäki</span>, <span class="hlFld-ContribAuthor ">Mika  Kontro</span>, <span class="hlFld-ContribAuthor ">Kimmo  Porkka</span>, <span class="hlFld-ContribAuthor ">Caroline A.  Heckman</span>, <span class="hlFld-ContribAuthor ">Pirkko  Mattila</span>, <span class="hlFld-ContribAuthor ">Krister  Wennerberg</span>, <span class="hlFld-ContribAuthor ">Anil K.  Giri</span>, <span class="hlFld-ContribAuthor ">Tero  Aittokallio</span>. </span><span class="cited-content_cbyCitation_article-title">Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2021,</strong> <em>7 </em>
                                    (8)
                                     , eabe4038. <a href="https://doi.org/10.1126/sciadv.abe4038" title="DOI URL">https://doi.org/10.1126/sciadv.abe4038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.abe4038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.abe4038%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DPatient-tailored%252Bdesign%252Bfor%252Bselective%252Bco-inhibition%252Bof%252Bleukemic%252Bcell%252Bsubpopulations%26aulast%3DIanevski%26aufirst%3DAleksandr%26date%3D2021%26date%3D2021%26volume%3D7%26issue%3D8%26spage%3Deabe4038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiawei  Ma</span>, <span class="hlFld-ContribAuthor ">Qianqian  Li</span>, <span class="hlFld-ContribAuthor ">Dandan  Ji</span>, <span class="hlFld-ContribAuthor ">Liang  Luo</span>, <span class="hlFld-ContribAuthor ">Lei  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Predicting candidate therapeutic drugs for sepsis-induced acute respiratory distress syndrome based on transcriptome profiling. </span><span class="cited-content_cbyCitation_journal-name">Bioengineered</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 1369-1380. <a href="https://doi.org/10.1080/21655979.2021.1917981" title="DOI URL">https://doi.org/10.1080/21655979.2021.1917981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/21655979.2021.1917981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F21655979.2021.1917981%26sid%3Dliteratum%253Aachs%26jtitle%3DBioengineered%26atitle%3DPredicting%252Bcandidate%252Btherapeutic%252Bdrugs%252Bfor%252Bsepsis-induced%252Bacute%252Brespiratory%252Bdistress%252Bsyndrome%252Bbased%252Bon%252Btranscriptome%252Bprofiling%26aulast%3DMa%26aufirst%3DJiawei%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1%26spage%3D1369%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caroline  Molinaro</span>, <span class="hlFld-ContribAuthor ">Alain  Martoriati</span>, <span class="hlFld-ContribAuthor ">Lydie  Pelinski</span>, <span class="hlFld-ContribAuthor ">Katia  Cailliau</span>. </span><span class="cited-content_cbyCitation_article-title">Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 2863. <a href="https://doi.org/10.3390/cancers12102863" title="DOI URL">https://doi.org/10.3390/cancers12102863</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12102863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12102863%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCopper%252BComplexes%252Bas%252BAnticancer%252BAgents%252BTargeting%252BTopoisomerases%252BI%252Band%252BII%26aulast%3DMolinaro%26aufirst%3DCaroline%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D2863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta Erminia  Alberto</span>, <span class="hlFld-ContribAuthor ">Gloria  Mazzone</span>, <span class="hlFld-ContribAuthor ">Claudia  Regina</span>, <span class="hlFld-ContribAuthor ">Nino  Russo</span>, <span class="hlFld-ContribAuthor ">Emilia  Sicilia</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical exploration of the photophysical properties of two-component Ru
              II
              –porphyrin dyes as promising assemblies for a combined antitumor effect. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (36)
                                     , 12653-12661. <a href="https://doi.org/10.1039/D0DT02197K" title="DOI URL">https://doi.org/10.1039/D0DT02197K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0DT02197K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0DT02197K%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DTheoretical%252Bexploration%252Bof%252Bthe%252Bphotophysical%252Bproperties%252Bof%252Btwo-component%252BRu%252BII%252B%2525E2%252580%252593porphyrin%252Bdyes%252Bas%252Bpromising%252Bassemblies%252Bfor%252Ba%252Bcombined%252Bantitumor%252Beffect%26aulast%3DAlberto%26aufirst%3DMarta%2BErminia%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D36%26spage%3D12653%26epage%3D12661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kelly A.  Hyndman</span>, <span class="hlFld-ContribAuthor ">Joshua S.  Speed</span>, <span class="hlFld-ContribAuthor ">Luciano D.  Mendoza</span>, <span class="hlFld-ContribAuthor ">John M.  Allan</span>, <span class="hlFld-ContribAuthor ">Jackson  Colson</span>, <span class="hlFld-ContribAuthor ">Randee  Sedaka</span>, <span class="hlFld-ContribAuthor ">Chunhua  Jin</span>, <span class="hlFld-ContribAuthor ">Hyun Jun  Jung</span>, <span class="hlFld-ContribAuthor ">Samir  El-Dahr</span>, <span class="hlFld-ContribAuthor ">David M.  Pollock</span>, <span class="hlFld-ContribAuthor ">Jennifer S.  Pollock</span>. </span><span class="cited-content_cbyCitation_article-title">Fluid-electrolyte homeostasis requires histone deacetylase function. </span><span class="cited-content_cbyCitation_journal-name">JCI Insight</span><span> <strong>2020,</strong> <em>5 </em>
                                    (16)
                                     <a href="https://doi.org/10.1172/jci.insight.137792" title="DOI URL">https://doi.org/10.1172/jci.insight.137792</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1172/jci.insight.137792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1172%2Fjci.insight.137792%26sid%3Dliteratum%253Aachs%26jtitle%3DJCI%2520Insight%26atitle%3DFluid-electrolyte%252Bhomeostasis%252Brequires%252Bhistone%252Bdeacetylase%252Bfunction%26aulast%3DHyndman%26aufirst%3DKelly%2BA.%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oğuzhan  FIRAT</span>, <span class="hlFld-ContribAuthor ">İlkay  YILDIZ</span>. </span><span class="cited-content_cbyCitation_article-title">TOPOISOMERASE II ENZYME INHIBITORS. </span><span class="cited-content_cbyCitation_journal-name">Ankara Universitesi Eczacilik Fakultesi Dergisi</span><span> <strong>2020,</strong> <em> </em>, 356-372. <a href="https://doi.org/10.33483/jfpau.696349" title="DOI URL">https://doi.org/10.33483/jfpau.696349</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.33483/jfpau.696349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.33483%2Fjfpau.696349%26sid%3Dliteratum%253Aachs%26jtitle%3DAnkara%2520Universitesi%2520Eczacilik%2520Fakultesi%2520Dergisi%26atitle%3DTOPOISOMERASE%252BII%252BENZYME%252BINHIBITORS%26aulast%3DFIRAT%26aufirst%3DO%25C4%259Fuzhan%26date%3D2020%26date%3D2020%26spage%3D356%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaja Bergant  Loboda</span>, <span class="hlFld-ContribAuthor ">Katja  Valjavec</span>, <span class="hlFld-ContribAuthor ">Martina  Štampar</span>, <span class="hlFld-ContribAuthor ">Gerhard  Wolber</span>, <span class="hlFld-ContribAuthor ">Bojana  Žegura</span>, <span class="hlFld-ContribAuthor ">Metka  Filipič</span>, <span class="hlFld-ContribAuthor ">Marija Sollner  Dolenc</span>, <span class="hlFld-ContribAuthor ">Andrej  Perdih</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase IIα. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103828. <a href="https://doi.org/10.1016/j.bioorg.2020.103828" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103828</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103828%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B3%25252C5-substituted%252B1%25252C2%25252C4-oxadiazoles%252Bas%252Bcatalytic%252Binhibitors%252Bof%252Bhuman%252BDNA%252Btopoisomerase%252BII%2525CE%2525B1%26aulast%3DLoboda%26aufirst%3DKaja%2BBergant%26date%3D2020%26volume%3D99%26spage%3D103828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shabir Ahmad  Ganai</span>. </span><span class="cited-content_cbyCitation_article-title">Futuristic Approaches Towards Designing of Isozyme-Selective Histone Deacetylase Inhibitors Against Zinc-Dependent Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 241-258. <a href="https://doi.org/10.1007/978-981-15-8179-3_11" title="DOI URL">https://doi.org/10.1007/978-981-15-8179-3_11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-15-8179-3_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-15-8179-3_11%26sid%3Dliteratum%253Aachs%26atitle%3DFuturistic%252BApproaches%252BTowards%252BDesigning%252Bof%252BIsozyme-Selective%252BHistone%252BDeacetylase%252BInhibitors%252BAgainst%252BZinc-Dependent%252BHistone%252BDeacetylases%26aulast%3DGanai%26aufirst%3DShabir%2BAhmad%26date%3D2020%26date%3D2020%26spage%3D241%26epage%3D258%26pub%3DSpringer%2520Singapore%26atitle%3DHistone%252BDeacetylase%252BInhibitors%252Bin%252BCombinatorial%252BAnticancer%252BTherapy%26aulast%3DGanai%26aufirst%3DShabir%2BAhmad%26date%3D2020%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of clinically important topo II “poisons”.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of some of the catalytic inhibitors of topo II.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic representation of the most common mechanisms of resistance against topo II-targeting drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of the dual intercalating topo I/II inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structure of the ruthenium complex with dual topo I/II inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of the topo I inhibitor camptothecin, the topo II inhibitor podophyllotoxin, and their conjugate (<b>21</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of non-intercalating topo I/II inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Histone deacetylase (HDAC) inhibitor vorinostat (<b>28</b>) and a representation of the general pharmacophore combination concept of dual topo II/HDAC inhibitors, based on compound <b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Examples of dual topo II/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structure of the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin [tanespimycin (17-AAG), <b>36</b>] and topo II/Hsp90 inhibitor heteronemin (<b>37</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of proteasome inhibitor MG132 (<b>38</b>) and dual topo II/proteasome inhibitor <b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of the tyrosine kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of sunitinib (<b>43</b>), ciprofloxacin (<b>44</b>), and a dual inhibitor of topo II and kinases (<b>45</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of the quinazoline-type EGFR inhibitors gefitinib (<b>46</b>), erlotinib (<b>47</b>), and the dual topo II/EGFR inhibitor (<b>48</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structure of dovitinib (<b>49</b>), the Hoechst 33258 dye (<b>50</b>), and NK314 (<b>51</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structure of compound <b>52</b> and its inhibitory activities against selected tyrosine kinases and cancer cell lines (as indicated).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of levofloxacin (<b>54</b>) and the dual topo II/telomerase inhibitors <b>53</b>, <b>55</b>, and <b>56</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure of a topo II/telomerase inhibiting ruthenium complex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of known microtubule-interfering agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/medium/jm9b00726_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of dual topo II/microtubule-interfering agents and their activities on selected cancer cell lines (as indicated).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b00726/20200207/images/large/jm9b00726_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00726&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46557" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46557" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 196 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talevi, A.</span></span> <span> </span><span class="NLM_article-title">Multi-target pharmacology: possibilities and limitations of the ″skeleton key approach″ from a medicinal chemist perspective</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3389%2Ffphar.2015.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26441661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=205&author=A.+Talevi&title=Multi-target+pharmacology%3A+possibilities+and+limitations+of+the+%E2%80%B3skeleton+key+approach%E2%80%B3+from+a+medicinal+chemist+perspective&doi=10.3389%2Ffphar.2015.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective</span></div><div class="casAuthors">Talevi, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205/1-205/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues.  Prospective drug repositioning to treat comorbid conditions is an addnl., overlooked application of multi-target ligands.  While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacol. recognizes that the mid- and long-term effects of a given drug on a biol. system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature.  The design of multi-target agents usually imposes challenging restrictions on the topol. or flexibility of the candidate drugs, which are briefly discussed in the present article.  Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSdZokyMjNSLVg90H21EOLACvtfcHk0lhp7T-VyhKMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM&md5=169718a4644d962da33806772a9a33e3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00205%26sid%3Dliteratum%253Aachs%26aulast%3DTalevi%26aufirst%3DA.%26atitle%3DMulti-target%2520pharmacology%253A%2520possibilities%2520and%2520limitations%2520of%2520the%2520%25E2%2580%25B3skeleton%2520key%2520approach%25E2%2580%25B3%2520from%2520a%2520medicinal%2520chemist%2520perspective%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D205%26doi%3D10.3389%2Ffphar.2015.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span> <span> </span><span class="NLM_article-title">Why is cancer drug discovery so difficult?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1038/nrd2155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrd2155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17159925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=115-120&issue=2&author=A.+Kambauthor=S.+Weeauthor=C.+Lengauer&title=Why+is+cancer+drug+discovery+so+difficult%3F&doi=10.1038%2Fnrd2155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Why is cancer drug discovery so difficult?</span></div><div class="casAuthors">Kamb, Alexander; Wee, Susan; Lengauer, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-120</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thirty-five years after the 'war on cancer' was declared, the discovery of anticancer drugs remains a highly challenging endeavor.  Here, we consider the factors responsible, such as tumor heterogeneity, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYsRgFvOR6O7Vg90H21EOLACvtfcHk0lhp7T-VyhKMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGlsrw%253D&md5=0ee9e19541b8f3f0ed495b3de44b3ad3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd2155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2155%26sid%3Dliteratum%253Aachs%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWee%26aufirst%3DS.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DWhy%2520is%2520cancer%2520drug%2520discovery%2520so%2520difficult%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D2%26spage%3D115%26epage%3D120%26doi%3D10.1038%2Fnrd2155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: the rise of multitarget drugs over combination therapies</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.4155%2Ffmc.14.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24649950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=485-487&issue=5&author=M.+Rosini&title=Polypharmacology%3A+the+rise+of+multitarget+drugs+over+combination+therapies&doi=10.4155%2Ffmc.14.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: the rise of multitarget drugs over combination therapies</span></div><div class="casAuthors">Rosini, Michela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-487</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNBzYCAfAa7Vg90H21EOLACvtfcHk0lhp7T-VyhKMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D&md5=0c32e1a1ae5a13cd25483ba18833fd54</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.25%26sid%3Dliteratum%253Aachs%26aulast%3DRosini%26aufirst%3DM.%26atitle%3DPolypharmacology%253A%2520the%2520rise%2520of%2520multitarget%2520drugs%2520over%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26issue%3D5%26spage%3D485%26epage%3D487%26doi%3D10.4155%2Ffmc.14.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikelj, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilas, J.</span></span> <span> </span><span class="NLM_article-title">Multitarget antithrombotic drugs</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2834</span>– <span class="NLM_lpage">2848</span>, <span class="refDoi"> DOI: 10.2174/156802611798184364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F156802611798184364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=22039882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2834-2848&issue=22&author=M.+Ilicauthor=D.+Kikeljauthor=J.+Ilas&title=Multitarget+antithrombotic+drugs&doi=10.2174%2F156802611798184364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget antithrombotic drugs</span></div><div class="casAuthors">Ilic, Milos; Kikelj, Danijel; Ilas, Janez</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2834-2848</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Thromboembolic disorders are still the leading causes of morbidity and mortality in developed societies.  Therefore, prophylaxis and treatment of arterial and venous thrombosis are among the main therapeutic challenges nowadays.  Simultaneous action on several targets involved in pathol. of thrombosis offers potential advantages compared to existing drugs which were developed as selective modulators of single targets.  The review focuses on dual inhibitors of coagulation enzymes, dual antiaggregatory compds. exerting their action on different combinations of platelet targets, as well as on anticoagulant/antiaggregatory compds. which interfere with at least one target involved in blood coagulation and at least one target engaged in the process leading to platelet aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqya91G6eGic7Vg90H21EOLACvtfcHk0ljiXcABpKDg9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehtbk%253D&md5=244f7f10fae7d06573b5e8284e08f602</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F156802611798184364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798184364%26sid%3Dliteratum%253Aachs%26aulast%3DIlic%26aufirst%3DM.%26aulast%3DKikelj%26aufirst%3DD.%26aulast%3DIlas%26aufirst%3DJ.%26atitle%3DMultitarget%2520antithrombotic%2520drugs%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26issue%3D22%26spage%3D2834%26epage%3D2848%26doi%3D10.2174%2F156802611798184364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span> <span> </span><span class="NLM_article-title">Multi-kinase inhibitors</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.2174/0929867321666141216125528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F0929867321666141216125528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25511779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=695-712&issue=6&author=L.+Garutiauthor=M.+Robertiauthor=G.+Bottegoni&title=Multi-kinase+inhibitors&doi=10.2174%2F0929867321666141216125528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Kinase Inhibitors</span></div><div class="casAuthors">Garuti, Laura; Roberti, Marinella; Bottegoni, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-712</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The limitations of many mono-kinase inhibitors can be overcome by agents with multi-target action.  An important advantage of targeting more than one kinase, is an increase in potency, due to the synergistic effect.  Moreover, this approach can reduce the possibility of developing drug resistance.  Several multitarget agents have been designed as single kinase inhibitors and found to be multi-target inhibitors because of the structural homol. among the ATP-binding site of kinases.  In other cases, these inhibitors have been obtained by optimization of potent individual inhibitors or by combination of selective ligands.  Also some irreversible inhibitors act on different kinases and covalently modify the cysteine residues located near the ATP-binding pocket.  In this review the most recent examples of multi-kinase inhibitors are reported, focusing on chem. structures, structure-activity relationship (SAR) and biol. activity.  These inhibitors, suitably substituted, could be used in designing other multitarget agents.  Virtual mol. docking would suggest potential targets of mols., moreover combining pharmacophore combination and screening methods could probably help in the discovery of more potent multikinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJtiGNXK9ZFrVg90H21EOLACvtfcHk0ljiXcABpKDg9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKht70%253D&md5=2dea8ef8b5f7b5674f86969283e295c8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F0929867321666141216125528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666141216125528%26sid%3Dliteratum%253Aachs%26aulast%3DGaruti%26aufirst%3DL.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DMulti-kinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26issue%3D6%26spage%3D695%26epage%3D712%26doi%3D10.2174%2F0929867321666141216125528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C. J.</span></span> <span> </span><span class="NLM_article-title">The structural basis for cancer treatment decisions</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7285</span>– <span class="NLM_lpage">7302</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.18632%2Foncotarget.2439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25277176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC2M7ntVagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=7285-7302&issue=17&author=R.+Nussinovauthor=H.+Jangauthor=C.+J.+Tsai&title=The+structural+basis+for+cancer+treatment+decisions&doi=10.18632%2Foncotarget.2439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for cancer treatment decisions</span></div><div class="casAuthors">Nussinov Ruth; Jang Hyunbum; Tsai Chung-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7285-302</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer treatment decisions rely on genetics, large data screens and clinical pharmacology.  Here we point out that genetic analysis and treatment decisions may overlook critical elements in cancer development, progression and drug resistance.  Two critical structural elements are missing in genetics-based decision-making: the mechanisms of oncogenic mutations and the cellular network which is rewired in cancer.  These lay the foundation for the structural basis for cancer treatment decisions, which is rooted in the physical principles of the molecular conformational behavior of single molecules and their interactions.  Improved tumor mutational analysis platforms and knowledge of the redundant pathways which can take over in cancer, may not only supplement known actionable findings, but forecast possible cancer progression and resistance.  Such forward-looking can be powerful, endowing the oncologist with mechanistic insight and cancer prognosis, and consequently more informed treatment options.  Examples include redundant pathways taking over after inhibition of EGFR constitutive activation, mutations in PIK3CA p110α and p85, and the non-hotspot AKT1 mutants conferring constitutive membrane localization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbVVQKsYBUc4YPsCkJIw00fW6udTcc2eaSpgRPXjsn87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7ntVagtg%253D%253D&md5=9440f52e4e32b7e9a20309f7a909d7ad</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2439%26sid%3Dliteratum%253Aachs%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DTsai%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520structural%2520basis%2520for%2520cancer%2520treatment%2520decisions%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26issue%3D17%26spage%3D7285%26epage%3D7302%26doi%3D10.18632%2Foncotarget.2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Djulbegovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hozo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bepler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. L.</span></span> <span> </span><span class="NLM_article-title">Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006</span>. <i>Arch. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">632</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1001/archinte.168.6.632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1001%2Farchinte.168.6.632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18362256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BD1c3gtl2ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2008&pages=632-642&issue=6&author=B.+Djulbegovicauthor=A.+Kumarauthor=H.+P.+Soaresauthor=I.+Hozoauthor=G.+Beplerauthor=M.+Clarkeauthor=C.+L.+Bennett&title=Treatment+success+in+cancer%3A+new+cancer+treatment+successes+identified+in+phase+3+randomized+controlled+trials+conducted+by+the+National+Cancer+Institute-sponsored+cooperative+oncology+groups%2C+1955+to+2006&doi=10.1001%2Farchinte.168.6.632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006</span></div><div class="casAuthors">Djulbegovic Benjamin; Kumar Ambuj; Soares Heloisa P; Hozo Iztok; Bepler Gerold; Clarke Mike; Bennett Charles L</div><div class="citationInfo"><span class="NLM_cas:title">Archives of internal medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">632-42</span>
        ISSN:<span class="NLM_cas:issn">0003-9926</span>.
    </div><div class="casAbstract">BACKGROUND:  The evaluation of research output, such as estimation of the proportion of treatment successes, is of ethical, scientific, and public importance but has rarely been evaluated systematically.  We assessed how often experimental cancer treatments that undergo testing in randomized clinical trials (RCTs) result in discovery of successful new interventions.  METHODS:  We extracted data from all completed (published and unpublished) phase 3 RCTs conducted by the National Cancer Institute cooperative groups since their inception in 1955.  Therapeutic successes were determined by (1) assessing the proportion of statistically significant trials favoring new or standard treatments, (2) determining the proportion of the trials in which new treatments were considered superior to standard treatments according to the original researchers, and (3) quantitatively synthesizing data for main clinical outcomes (overall and event-free survival).  RESULTS:  Data from 624 trials (781 randomized comparisons) involving 216 451 patients were analyzed.  In all, 30% of trials had statistically significant results, of which new interventions were superior to established treatments in 80% of trials.  The original researchers judged that the risk-benefit profile favored new treatments in 41% of comparisons (316 of 766).  Hazard ratios for overall and event-free survival, available for 614 comparisons, were 0.95 (99% confidence interval [CI], 0.93-0.98) and 0.90 (99% CI, 0.87- 0.93), respectively, slightly favoring new treatments.  Breakthrough interventions were discovered in 15% of trials.  CONCLUSIONS:  Approximately 25% to 50% of new cancer treatments that reach the stage of assessment in RCTs will prove successful.  The pattern of successes has become more stable over time.  The results are consistent with the hypothesis that the ethical principle of equipoise defines limits of discoverability in clinical research and ultimately drives therapeutic advances in clinical medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlmFRnjv5cEgvupmecNw_lfW6udTcc2eY1WF0-QkU8E7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3gtl2ltA%253D%253D&md5=db64df9c5c3dbc9ab767507f80349826</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1001%2Farchinte.168.6.632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchinte.168.6.632%26sid%3Dliteratum%253Aachs%26aulast%3DDjulbegovic%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSoares%26aufirst%3DH.%2BP.%26aulast%3DHozo%26aufirst%3DI.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DC.%2BL.%26atitle%3DTreatment%2520success%2520in%2520cancer%253A%2520new%2520cancer%2520treatment%2520successes%2520identified%2520in%2520phase%25203%2520randomized%2520controlled%2520trials%2520conducted%2520by%2520the%2520National%2520Cancer%2520Institute-sponsored%2520cooperative%2520oncology%2520groups%252C%25201955%2520to%25202006%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D2008%26volume%3D168%26issue%3D6%26spage%3D632%26epage%3D642%26doi%3D10.1001%2Farchinte.168.6.632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayat
Mokhtari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homayouni, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgatskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeger, H.</span></span> <span> </span><span class="NLM_article-title">Combination therapy in combating cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">38022</span>– <span class="NLM_lpage">38043</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.16723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.18632%2Foncotarget.16723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28410237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnvV2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=38022-38043&issue=23&author=R.+Bayat%0AMokhtariauthor=T.+S.+Homayouniauthor=N.+Baluchauthor=E.+Morgatskayaauthor=S.+Kumarauthor=B.+Dasauthor=H.+Yeger&title=Combination+therapy+in+combating+cancer&doi=10.18632%2Foncotarget.16723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy in combating cancer</span></div><div class="casAuthors">Bayat Mokhtari Reza; Homayouni Tina S; Morgatskaya Evgeniya; Kumar Sushil; Yeger Herman; Bayat Mokhtari Reza; Yeger Herman; Bayat Mokhtari Reza; Das Bikul; Baluch Narges</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">38022-38043</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Combination therapy, a treatment modality that combines two or more therapeutic agents, is a cornerstone of cancer therapy.  The amalgamation of anti-cancer drugs enhances efficacy compared to the mono-therapy approach because it targets key pathways in a characteristically synergistic or an additive manner.  This approach potentially reduces drug resistance, while simultaneously providing therapeutic anti-cancer benefits, such as reducing tumour growth and metastatic potential, arresting mitotically active cells, reducing cancer stem cell populations, and inducing apoptosis.  The 5-year survival rates for most metastatic cancers are still quite low, and the process of developing a new anti-cancer drug is costly and extremely time-consuming.  Therefore, new strategies that target the survival pathways that provide efficient and effective results at an affordable cost are being considered.  One such approach incorporates repurposing therapeutic agents initially used for the treatment of different diseases other than cancer.  This approach is effective primarily when the FDA-approved agent targets similar pathways found in cancer.  Because one of the drugs used in combination therapy is already FDA-approved, overall costs of combination therapy research are reduced.  This increases cost efficiency of therapy, thereby benefiting the "medically underserved".  In addition, an approach that combines repurposed pharmaceutical agents with other therapeutics has shown promising results in mitigating tumour burden.  In this systematic review, we discuss important pathways commonly targeted in cancer therapy.  Furthermore, we also review important repurposed or primary anti-cancer agents that have gained popularity in clinical trials and research since 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgglXQFVA86nO4gDb7JggCfW6udTcc2eY1WF0-QkU8E7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnvV2ksw%253D%253D&md5=42ce7556d77313edc2ac9cd1ae29ad78</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.16723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.16723%26sid%3Dliteratum%253Aachs%26aulast%3DBayat%2BMokhtari%26aufirst%3DR.%26aulast%3DHomayouni%26aufirst%3DT.%2BS.%26aulast%3DBaluch%26aufirst%3DN.%26aulast%3DMorgatskaya%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DYeger%26aufirst%3DH.%26atitle%3DCombination%2520therapy%2520in%2520combating%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D23%26spage%3D38022%26epage%3D38043%26doi%3D10.18632%2Foncotarget.16723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&issue=19&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0ljLYoiDq9tarQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D19%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blagosklonny, M. V.</span></span> <span> </span><span class="NLM_article-title">Overcoming limitations of natural anticancer drugs by combining with artificial agents</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2004.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.tips.2004.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15681024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXoslagsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=77-81&issue=2&author=M.+V.+Blagosklonny&title=Overcoming+limitations+of+natural+anticancer+drugs+by+combining+with+artificial+agents&doi=10.1016%2Fj.tips.2004.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming limitations of natural anticancer drugs by combining with artificial agents</span></div><div class="casAuthors">Blagosklonny, Mikhail V.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-81</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  During a billion years of evolution, living creatures have perfected cytotoxic agents to kill other organisms without killing themselves, thus providing us with antibiotics to kill bacteria without killing eukaryotic (e.g. human) cells.  Some natural agents inhibit specifically most vital cellular structures and functions in cancer cells.  However, nature was not creating antibiotics for cancer, and natural agents kill cancer cells precisely because they share targets with normal cells.  To discriminate between particular cancer cells and normal cells, one can design or select artificial agents that are not necessarily lethal but are aimed either at cancer-specific targets or at dispensable and even unavailable (in cancer cells) targets.  Using rational drug combinations, such selective agents can assist natural agents to eradicate cancer cells selectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHEqPHb7M1qbVg90H21EOLACvtfcHk0ljhqXSwl8Vtmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXoslagsg%253D%253D&md5=6160179fcd3935adebbab83716b470c5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DBlagosklonny%26aufirst%3DM.%2BV.%26atitle%3DOvercoming%2520limitations%2520of%2520natural%2520anticancer%2520drugs%2520by%2520combining%2520with%2520artificial%2520agents%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26issue%3D2%26spage%3D77%26epage%3D81%26doi%3D10.1016%2Fj.tips.2004.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albain, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nag, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderillo-Ruiz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordaan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melemed, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes-Vidal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhon, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span> <span> </span><span class="NLM_article-title">Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3950</span>– <span class="NLM_lpage">3957</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.11.9362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1200%2FJCO.2007.11.9362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18711184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BD1cris1Kmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3950-3957&issue=24&author=K.+S.+Albainauthor=S.+M.+Nagauthor=G.+Calderillo-Ruizauthor=J.+P.+Jordaanauthor=A.+C.+Llombartauthor=A.+Pluzanskaauthor=J.+Rolskiauthor=A.+S.+Melemedauthor=J.+M.+Reyes-Vidalauthor=J.+S.+Sekhonauthor=L.+Simmsauthor=J.+O%E2%80%99Shaughnessy&title=Gemcitabine+plus+Paclitaxel+versus+Paclitaxel+monotherapy+in+patients+with+metastatic+breast+cancer+and+prior+anthracycline+treatment&doi=10.1200%2FJCO.2007.11.9362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment</span></div><div class="casAuthors">Albain Kathy S; Nag Shona M; Calderillo-Ruiz German; Jordaan Johann P; Llombart Antonio C; Pluzanska Anna; Rolski Janusz; Melemed Allen S; Reyes-Vidal Jose M; Sekhon Jagdev S; Simms Lorinda; O'Shaughnessy Joyce</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3950-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The objective of this phase III global study was to compare the efficacy of gemcitabine plus paclitaxel (GT) versus paclitaxel in patients with advanced breast cancer.  It was designed as a pivotal study for the approval of G for a breast cancer treatment indication.  PATIENTS AND METHODS:  Patients who relapsed after adjuvant anthracyclines were randomly assigned to gemcitabine,1,250 mg/m(2) days 1 and 8 plus paclitaxel, 175 mg/m(2) on day 1; or, to paclitaxel at same dose on day 1 (both arms administered every 21 days, unblinded).  The primary end point was overall survival (OS) and secondary end points were time to progression (TTP), response rate (RR), progression-free survival, response duration, and toxicity.  This final OS analysis was planned at 380 deaths.  RESULTS:  A total of 266 patients were randomly assigned to GT and 263 to paclitaxel.  Median survival on GT was 18.6 months versus 15.8 months on paclitaxel (log-rank P = . 0489), with an adjusted Cox hazard ratio of 0.78 (95% CI, 0.64 to 0.96; P = .0187).  The TTP was longer (6.14 v 3.98 months; log-rank P = .0002) and the RR was better (41.4% v 26.2%; P = .0002) on GT.  There was more grade 3 to 4 neutropenia on GT and grade 2 to 4 fatigue and neuropathy were slightly more prevalent on GT.  CONCLUSION:  This phase III study documents a role for gemcitabine in advanced breast cancer after anthracycline-based adjuvant therapy.  The results establish GT as a reasonable choice for women who require cytoreduction with manageable toxicities and validate ongoing testing of GT in the adjuvant setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6uZmrDXhBdpotVjB3IRIyfW6udTcc2ebZnH8qCBOBLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cris1Kmsw%253D%253D&md5=dcc70c8ba548199b4934cd8fee730c0c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.11.9362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.11.9362%26sid%3Dliteratum%253Aachs%26aulast%3DAlbain%26aufirst%3DK.%2BS.%26aulast%3DNag%26aufirst%3DS.%2BM.%26aulast%3DCalderillo-Ruiz%26aufirst%3DG.%26aulast%3DJordaan%26aufirst%3DJ.%2BP.%26aulast%3DLlombart%26aufirst%3DA.%2BC.%26aulast%3DPluzanska%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DMelemed%26aufirst%3DA.%2BS.%26aulast%3DReyes-Vidal%26aufirst%3DJ.%2BM.%26aulast%3DSekhon%26aufirst%3DJ.%2BS.%26aulast%3DSimms%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26atitle%3DGemcitabine%2520plus%2520Paclitaxel%2520versus%2520Paclitaxel%2520monotherapy%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%2520and%2520prior%2520anthracycline%2520treatment%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3D24%26spage%3D3950%26epage%3D3957%26doi%3D10.1200%2FJCO.2007.11.9362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&issue=1%E2%80%932&author=G.+R.+Zimmermannauthor=J.+Leharauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eaG4vvod0DMlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D1%25E2%2580%25932%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&issue=15&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0liz2fA5be9JHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D15%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span> <span> </span><span class="NLM_article-title">Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.4155%2Ffmc.12.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKgsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=5-7&issue=1&author=L.+Costantinoauthor=D.+Barlocco&title=Challenges+in+the+design+of+multitarget+drugs+against+multifactorial+pathologies%3A+a+new+life+for+medicinal+chemistry%3F&doi=10.4155%2Ffmc.12.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?</span></div><div class="casAuthors">Costantino, Luca; Barlocco, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-7</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Medicinal chem. research addressed the design of multitarget agents for some disease areas.  These agents are detd. grounded on in vivo assays or the design of assembled pharmacophores of the target ligands under consideration, with or without the aid of computational techniques.  Sunitinib and sorafenib are examples of these agents.  E-therapeutics and Pharnext are among companies that are based on network pharmacol. in order to discover novel drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPWU0-tklUJbVg90H21EOLACvtfcHk0liz2fA5be9JHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKgsLbE&md5=498fc24d3fed3c3657765f3df6e5235a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.193%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DL.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DChallenges%2520in%2520the%2520design%2520of%2520multitarget%2520drugs%2520against%2520multifactorial%2520pathologies%253A%2520a%2520new%2520life%2520for%2520medicinal%2520chemistry%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26issue%3D1%26spage%3D5%26epage%3D7%26doi%3D10.4155%2Ffmc.12.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sestito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runfola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapposelli, S.</span></span> <span> </span><span class="NLM_article-title">New multitarget approaches in the war against glioblastoma: a mini-perspective</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">874</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3389%2Ffphar.2018.00874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30123135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVartb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=874&author=S.+Sestitoauthor=M.+Runfolaauthor=M.+Tonelliauthor=G.+Chielliniauthor=S.+Rapposelli&title=New+multitarget+approaches+in+the+war+against+glioblastoma%3A+a+mini-perspective&doi=10.3389%2Ffphar.2018.00874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">New multitarget approaches in the war against glioblastoma: a mini-perspective</span></div><div class="casAuthors">Sestito, Simona; Runfola, Massimiliano; Tonelli, Marco; Chiellini, Grazia; Rapposelli, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">874/1-874/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common tumor of the CNS, and the deadliest form of brain cancer.  The rapid progression, the anat. location in the brain and a deficient knowledge of the pathophysiol., often limit the effectiveness of therapeutic interventions.  Current pillars of GBM therapies include surgical resection, radiotherapy and chemotherapy, but the low survival rate and the short life expectation following these treatments strongly underline the urgency to identify innovative and more effective therapeutic tools.  Frequently, patients subjected to a mono-target therapy, such as Temozolomide (TMZ), develop drug resistance and undergo relapse, indicating that targeting a single cellular node is not sufficient for eradication of this disease.  In this context, a multi-targeted therapeutic approach aimed at using compds., alone or in combination, capable of inhibiting more than one specific mol. target, offers a promising alternative.  Such strategies have already been well integrated into drug discovery campaigns, including in the field of anticancer drugs.  In this miniperspective, we will discuss the recent progress in the treatment of GBM focusing on innovative and effective preclin. strategies, which are based on a multi-targeted approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqElOSaMG0AwrVg90H21EOLACvtfcHk0ljD88LC3rNIVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVartb8%253D&md5=f935948cb45cb51df50beddb9d0486be</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00874%26sid%3Dliteratum%253Aachs%26aulast%3DSestito%26aufirst%3DS.%26aulast%3DRunfola%26aufirst%3DM.%26aulast%3DTonelli%26aufirst%3DM.%26aulast%3DChiellini%26aufirst%3DG.%26aulast%3DRapposelli%26aufirst%3DS.%26atitle%3DNew%2520multitarget%2520approaches%2520in%2520the%2520war%2520against%2520glioblastoma%253A%2520a%2520mini-perspective%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D874%26doi%3D10.3389%2Ffphar.2018.00874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&issue=2&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+a+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0ljD88LC3rNIVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520a%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cicenas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicenas, E.</span></span> <span> </span><span class="NLM_article-title">Multi-kinase inhibitors, AURKs and cancer</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1007/s12032-016-0758-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs12032-016-0758-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=27038473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC28fmsFagsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=43&issue=5&author=J.+Cicenasauthor=E.+Cicenas&title=Multi-kinase+inhibitors%2C+AURKs+and+cancer&doi=10.1007%2Fs12032-016-0758-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-kinase inhibitors, AURKs and cancer</span></div><div class="casAuthors">Cicenas Jonas; Cicenas Jonas; Cicenas Jonas; Cicenas Jonas; Cicenas Erikas</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inhibitors that impact function of kinases are valuable both for the biological research as well as therapy of kinase-associated diseases, such as different cancers.  There are quite a number of inhibitors, which are quite specific for certain kinases and several of them are either already approved for the cancer therapy or are in clinical studies of various phases.  However, that does not mean that each single kinase inhibitor is suitable for targeted therapy.  Some of them are not effective others might be toxic or fail some other criteria for the use in vivo.  On the other hand, even in case of successful therapy, many responders eventually develop resistance to the inhibitors.  The limitations of various single kinase inhibitors can be fought using compounds which target multiple kinases.  This tactics can increase effectiveness of the inhibitors by the synergistic effect or help to diminish the likelihood of drug resistance.  To date, several families of kinases are quite popular targets of the inhibition in cancers, such as tyrosine kinases, cycle-dependent kinases, mitogen-activated protein kinases, phosphoinositide 3-kinases as well as their pathway "players" and aurora kinases.  Aurora kinases play an important role in the control of the mitosis and are often altered in diverse human cancers.  Here, we will describe the most interesting multi-kinase inhibitors which inhibit aurora kinases among other targets and their use in preclinical and clinical cancer studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_XwZzssGi-C86Js-BCLiifW6udTcc2ebPPuedrc5mwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fmsFagsA%253D%253D&md5=856bce3f15cc677f28676afc9a34f18b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs12032-016-0758-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-016-0758-4%26sid%3Dliteratum%253Aachs%26aulast%3DCicenas%26aufirst%3DJ.%26aulast%3DCicenas%26aufirst%3DE.%26atitle%3DMulti-kinase%2520inhibitors%252C%2520AURKs%2520and%2520cancer%26jtitle%3DMed.%2520Oncol.%26date%3D2016%26volume%3D33%26issue%3D5%26spage%3D43%26doi%3D10.1007%2Fs12032-016-0758-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sercus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahn, M.</span></span> <span> </span><span class="NLM_article-title">Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature</span>. <i>Curr. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.2174/157488609788173026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F157488609788173026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19442108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzks1arug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=143-154&issue=2&author=S.+Creanauthor=D.+M.+Boydauthor=B.+Sercusauthor=M.+Lahn&title=Safety+of+multi-targeted+kinase+inhibitors+as+monotherapy+treatment+of+cancer%3A+a+systematic+review+of+the+literature&doi=10.2174%2F157488609788173026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature</span></div><div class="casAuthors">Crean Sheila; Boyd Dylan M; Sercus Brian; Lahn Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current drug safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-54</span>
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    </div><div class="casAbstract">PURPOSE:  To identify potential safety profiles for small molecule multi-targeted kinase inhibitors for the treatment of advanced cancer.  METHODS:  A systematic review was performed on published papers and meeting abstracts reporting safety outcomes in cancer patients for selected multi-kinase inhibiting small molecules with mainly anti-angiogenic activity.  Specifically, we focused on single agent safety or early phase clinical development studies.  RESULTS:  Of 1,923 studies identified in a MEDLINE search, 26 primary studies met eligibility criteria.  Meeting materials included 7 papers, 6 posters, and 27 abstracts.  When grade I-IV safety results of all 23 kinases were summed together, diarrhea, fatigue, nausea, rash, anorexia, vomiting, hand/foot syndrome, and hypertension were common, occurring in greater than 10% of patients.  When only grade III and IV events are pooled together, fatigue and hypertension remain relatively common (> 5%).  When total adverse events were stratified by kinase or by kinase family, differences in safety profiles emerged.  CONCLUSIONS:  The results of this systematic review suggest that adverse events are common and varied for patients treated with a multi-kinase inhibitor.  However, unlike some systemic cytotoxic therapies, serious and severe adverse events for multikinase inhibitors are less frequent.  Sub-analyses by target kinase or kinase family demonstrate that certain groups of multi-kinase inhibitors can be associated with different safety profiles with unique adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx4DGQrD-4GbxanA7vODO6fW6udTcc2ebPPuedrc5mwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzks1arug%253D%253D&md5=56140fff20032170d3d5a1500126d662</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F157488609788173026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488609788173026%26sid%3Dliteratum%253Aachs%26aulast%3DCrean%26aufirst%3DS.%26aulast%3DBoyd%26aufirst%3DD.%2BM.%26aulast%3DSercus%26aufirst%3DB.%26aulast%3DLahn%26aufirst%3DM.%26atitle%3DSafety%2520of%2520multi-targeted%2520kinase%2520inhibitors%2520as%2520monotherapy%2520treatment%2520of%2520cancer%253A%2520a%2520systematic%2520review%2520of%2520the%2520literature%26jtitle%3DCurr.%2520Drug%2520Saf.%26date%3D2009%26volume%3D4%26issue%3D2%26spage%3D143%26epage%3D154%26doi%3D10.2174%2F157488609788173026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S.</span></span> <span> </span><span class="NLM_article-title">From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.2174/092986708783503212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F092986708783503212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18288997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=422-432&issue=5&author=A.+Petrelliauthor=S.+Giordano&title=From+single-+to+multi-target+drugs+in+cancer+therapy%3A+when+aspecificity+becomes+an+advantage&doi=10.2174%2F092986708783503212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">From single- to multi-target drugs in cancer therapy: when a specificity becomes an advantage</span></div><div class="casAuthors">Petrelli, A.; Giordano, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">422-432</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted therapies by means of compds. that inhibit a specific target mol. represent a new perspective in the treatment of cancer.  In contrast to conventional chemotherapy which acts on all dividing cells generating toxic effects and damage of normal tissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells directly involved in tumor progression.  Mols. controlling cell proliferation and death, such as Tyrosine Kinase Receptors (RTKs) for growth factors, are among the best targets for this type of therapeutic approach.  Two classes of compds. targeting RTKs are currently used in clin. practice: monoclonal antibodies and tyrosine kinase inhibitors.  The era of targeted therapy began with the approval of Trastuzumab, a monoclonal antibody against HER2, for treatment of metastatic breast cancer, and Imatinib, a small tyrosine kinase inhibitor targeting BCR-Abl, in Chronic Myeloid Leukemia.  Despite the initial enthusiasm for the efficacy of these treatments, clinicians had to face soon the problem of relapse, as almost invariably cancer patients developed drug resistance, often due to the activation of alternative RTKs pathways.  In this view, the rationale at the basis of targeting drugs is radically shifting.  In the past, the main effort was aimed at developing highly specific inhibitors acting on single RTKs.  Now, there is a general agreement that mols. interfering simultaneously with multiple RTKs might be more effective than single target agents.  With the recent approval by FDA of Sorafenib and Sunitinib - targeting VEGFR, PDGFR, FLT-3 and c-Kit - a different scenario has been emerging, where a new generation of anti-cancer drugs, able to inhibit more than one pathway, would probably play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8AXb2ROTStLVg90H21EOLACvtfcHk0ljygDOWwXS9_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D&md5=d90df6a670921b6fad58caa46db01fa5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F092986708783503212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708783503212%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DFrom%2520single-%2520to%2520multi-target%2520drugs%2520in%2520cancer%2520therapy%253A%2520when%2520aspecificity%2520becomes%2520an%2520advantage%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26issue%3D5%26spage%3D422%26epage%3D432%26doi%3D10.2174%2F092986708783503212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&issue=2&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0ljygDOWwXS9_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailly, C.</span></span> <span> </span><span class="NLM_article-title">Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3611</span>– <span class="NLM_lpage">3640</span>, <span class="refDoi"> DOI: 10.1021/cr200325f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200325f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2012&pages=3611-3640&issue=7&author=C.+Bailly&title=Contemporary+challenges+in+the+design+of+topoisomerase+II+inhibitors+for+cancer+chemotherapy&doi=10.1021%2Fcr200325f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy</span></div><div class="casAuthors">Bailly, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3611-3640</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review reports the use of topoisomerase II modulators as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozIpYLsh9eCLVg90H21EOLACvtfcHk0ljygDOWwXS9_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChtbY%253D&md5=f5ba565e42cd9ff9a38e47ad7c1e77c0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fcr200325f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200325f%26sid%3Dliteratum%253Aachs%26aulast%3DBailly%26aufirst%3DC.%26atitle%3DContemporary%2520challenges%2520in%2520the%2520design%2520of%2520topoisomerase%2520II%2520inhibitors%2520for%2520cancer%2520chemotherapy%26jtitle%3DChem.%2520Rev.%26date%3D2012%26volume%3D112%26issue%3D7%26spage%3D3611%26epage%3D3640%26doi%3D10.1021%2Fcr200325f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valabrega, G.</span></span> <span> </span><span class="NLM_article-title">Multitarget drugs: the present and the future of cancer therapy</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1517/14656560902781907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1517%2F14656560902781907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19284362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=589-600&issue=4&author=A.+Petrelliauthor=G.+Valabrega&title=Multitarget+drugs%3A+the+present+and+the+future+of+cancer+therapy&doi=10.1517%2F14656560902781907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget drugs: the present and the future of cancer therapy</span></div><div class="casAuthors">Petrelli, Annalisa; Valabrega, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-600</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Target therapies for the treatment of human cancers have revolutionized the concept of oncol. medicine.  This type of therapeutic approach is directed to the inhibition of mol. targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compds. able to block their activity.  In the beginning, the aim of target therapies was specifically to hit a single mol. expressed in neoplastic cells.  Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease.  Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different mols.  This review summarizes the mol. basis of multitarget therapies and the most relevant results obtained in different cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSM1xsRJGBX7Vg90H21EOLACvtfcHk0liRhv8CT0404w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D&md5=c84e048407e6d9354a1f4a595fb4a468</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14656560902781907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560902781907%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DValabrega%26aufirst%3DG.%26atitle%3DMultitarget%2520drugs%253A%2520the%2520present%2520and%2520the%2520future%2520of%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26issue%3D4%26spage%3D589%26epage%3D600%26doi%3D10.1517%2F14656560902781907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase II and its growing repertoire of biological functions</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrc2608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc2608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19377505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12ktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=327-337&issue=5&author=J.+L.+Nitiss&title=DNA+topoisomerase+II+and+its+growing+repertoire+of+biological+functions&doi=10.1038%2Fnrc2608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerase II and its growing repertoire of biological functions</span></div><div class="casAuthors">Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are enzymes that disentangle the topol. problems that arise in double-stranded DNA.  Many of these can be solved by the generation of either DNA single- or double-strand breaks.  However, where there is a clear requirement to alter DNA topol. by introducing transient double-strand breaks, only DNA topoisomerase II (I) can carry out this reaction.  Extensive biochem. and structural studies have provided detailed models of how I alters DNA structure, and recent mol. studies have greatly expanded knowledge of the biol. contexts in which I functions, such as DNA replication, transcription, and chromosome segregation, processes that are essential for preventing tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAj0wiBApAc7Vg90H21EOLACvtfcHk0liRhv8CT0404w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12ktLo%253D&md5=4be33ccf2701425ef3933b894b31e7fd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrc2608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2608%26sid%3Dliteratum%253Aachs%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DDNA%2520topoisomerase%2520II%2520and%2520its%2520growing%2520repertoire%2520of%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D5%26spage%3D327%26epage%3D337%26doi%3D10.1038%2Fnrc2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Cellular roles of DNA topoisomerases: a molecular perspective</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/nrm831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrm831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12042765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=430-440&issue=6&author=J.+C.+Wang&title=Cellular+roles+of+DNA+topoisomerases%3A+a+molecular+perspective&doi=10.1038%2Fnrm831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular roles of DNA topoisomerases: a molecular perspective</span></div><div class="casAuthors">Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are the magicians of the DNA world , by allowing DNA strands or double helixes to pass through each other, they can solve all of the topol. problems of DNA in replication, transcription and other cellular transactions.  Extensive biochem. and structural studies over the past three decades have provided mol. models of how the various subfamilies of DNA topoisomerase manipulate DNA.  In this review, the cellular roles of these enzymes are examd. from a mol. point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ptPGi1NWFLVg90H21EOLACvtfcHk0lgRks921uKm8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D&md5=5b9641a6d78a019ebad9307c854a7f7e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrm831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm831%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DCellular%2520roles%2520of%2520DNA%2520topoisomerases%253A%2520a%2520molecular%2520perspective%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26issue%3D6%26spage%3D430%26epage%3D440%26doi%3D10.1038%2Fnrm831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA topoisomerase II in cancer chemotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1038/nrc2607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc2607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19377506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12kur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=338-350&issue=5&author=J.+L.+Nitiss&title=Targeting+DNA+topoisomerase+II+in+cancer+chemotherapy&doi=10.1038%2Fnrc2607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA topoisomerase II in cancer chemotherapy</span></div><div class="casAuthors">Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">338-350</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent mol. studies have expanded the biol. contexts in which topoisomerase II (TOP2) has crucial functions, including DNA replication, transcription and chromosome segregation.  Although the biol. functions of TOP2 are important for ensuring genomic integrity, the ability to interfere with TOP2 and generate enzyme-mediated DNA damage is an effective strategy for cancer chemotherapy.  The mol. tools that have allowed an understanding of the biol. functions of TOP2 are also being applied to understanding the details of drug action.  These studies promise refined targeting of TOP2 as an effective anticancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_7Nq6nIe1RbVg90H21EOLACvtfcHk0lgRks921uKm8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12kur0%253D&md5=a787de602687580188cda6a2af7b6a07</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc2607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2607%26sid%3Dliteratum%253Aachs%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DTargeting%2520DNA%2520topoisomerase%2520II%2520in%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D5%26spage%3D338%26epage%3D350%26doi%3D10.1038%2Fnrc2607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase II as a target for cancer chemotherapy</span>. <i>Cancer Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">570</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1081/CNV-120002156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1081%2FCNV-120002156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12094551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1eitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=570-589&issue=4&author=J.+V.+Walkerauthor=J.+L.+Nitiss&title=DNA+topoisomerase+II+as+a+target+for+cancer+chemotherapy&doi=10.1081%2FCNV-120002156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerase II as a target for cancer chemotherapy</span></div><div class="casAuthors">Walker, Jerrylaine V.; Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">570-589</span>CODEN:
                <span class="NLM_cas:coden">CINVD7</span>;
        ISSN:<span class="NLM_cas:issn">0735-7907</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review on the biochem. and pharmacol. properties of topoisomerase II inhibitors.  Biochem. mechanisms that lead from trapping topoisomerase II on DNA to a potentially lethal DNA lesion, and the resistance mechanisms to topoisomerase II poisons are discussed.  The potential of topoisomerase II-targeting agents for cancer chemotherapy is emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrla9YLz1gCB7Vg90H21EOLACvtfcHk0lgRks921uKm8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1eitL4%253D&md5=f0203b590bc9439c2f69264760536d25</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1081%2FCNV-120002156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FCNV-120002156%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DJ.%2BV.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DDNA%2520topoisomerase%2520II%2520as%2520a%2520target%2520for%2520cancer%2520chemotherapy%26jtitle%3DCancer%2520Invest.%26date%3D2002%26volume%3D20%26issue%3D4%26spage%3D570%26epage%3D589%26doi%3D10.1081%2FCNV-120002156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendorff, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">The structure of DNA-bound human topoisomerase IIα: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>424</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2012.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.jmb.2012.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=22841979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1emtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=424&publication_year=2012&pages=109-124&issue=3%E2%80%934&author=T.+J.+Wendorffauthor=B.+H.+Schmidtauthor=P.+Heslopauthor=C.+A.+Austinauthor=J.+M.+Berger&title=The+structure+of+DNA-bound+human+topoisomerase+II%CE%B1%3A+conformational+mechanisms+for+coordinating+inter-subunit+interactions+with+DNA+cleavage&doi=10.1016%2Fj.jmb.2012.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA Cleavage</span></div><div class="casAuthors">Wendorff, Timothy J.; Schmidt, Bryan H.; Heslop, Pauline; Austin, Caroline A.; Berger, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">424</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">109-124</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Type II topoisomerases are required for the management of DNA superhelicity and chromosome segregation, and serve as frontline targets for a variety of small-mol. therapeutics.  To better understand how these enzymes act in both contexts, we detd. the 2.9-Å-resoln. structure of the DNA cleavage core of human topoisomerase IIα (TOP2A) bound to a doubly nicked, 30-bp duplex oligonucleotide.  In accord with prior biochem. and structural studies, TOP2A significantly bends its DNA substrate using a bipartite, nucleolytic center formed at an N-terminal dimerization interface of the cleavage core.  However, the protein also adopts a global conformation in which the second of its two inter-protomer contact points, one at the C-terminus, has sepd.  This finding, together with comparative structural analyses, reveals that the principal site of DNA engagement undergoes highly quantized conformational transitions between distinct binding, cleavage, and drug-inhibited states that correlate with the control of subunit-subunit interactions.  Addnl. consideration of our TOP2A model in light of an etoposide-inhibited complex of human topoisomerase IIβ (TOP2B) suggests possible modification points for developing paralog-specific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfXTBKuw0XXLVg90H21EOLACvtfcHk0ljBOWVU2rY2yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1emtb%252FN&md5=e62b148c35816a31f2b8f5457ffa29f6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2012.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2012.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DWendorff%26aufirst%3DT.%2BJ.%26aulast%3DSchmidt%26aufirst%3DB.%2BH.%26aulast%3DHeslop%26aufirst%3DP.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520structure%2520of%2520DNA-bound%2520human%2520topoisomerase%2520II%25CE%25B1%253A%2520conformational%2520mechanisms%2520for%2520coordinating%2520inter-subunit%2520interactions%2520with%2520DNA%2520cleavage%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D424%26issue%3D3%25E2%2580%25934%26spage%3D109%26epage%3D124%26doi%3D10.1016%2Fj.jmb.2012.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8947</span>– <span class="NLM_lpage">8980</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01202</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01202" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8947-8980&issue=20&author=W.+Huauthor=X.+S.+Huangauthor=J.+F.+Wuauthor=L.+Yangauthor=Y.+T.+Zhengauthor=Y.+M.+Shenauthor=Z.+Y.+Liauthor=X.+Li&title=Discovery+of+novel+topoisomerase+II+inhibitors+by+medicinal+chemistry+approaches&doi=10.1021%2Facs.jmedchem.7b01202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches</span></div><div class="casAuthors">Hu, Wei; Huang, Xu-Sheng; Wu, Ji-Feng; Yang, Liang; Zheng, Yong-Tang; Shen, Yue-Mao; Li, Zhi-Yu; Li, Xun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8947-8980</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA topoisomerase II (topo II) is an important enzyme involved in DNA replication, recombination, and repair.  Despite the popular applications of topo II inhibitors in cancer therapy, there is still an urgent need to upgrade topo II inhibitors to cope with drug resistance and severe adverse effects.  Accordingly, novel topo II catalytic or multitarget topo II inhibitors are gaining more attention and make it possible to ease the toxic limitations of topo II poisons.  In this review, medicinal chem. approaches are mainly discussed toward the development of potent topo II inhibitors with low toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWv9JERcv7XbVg90H21EOLACvtfcHk0ljBOWVU2rY2yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsL3P&md5=51468c5ca4b8fd437760567e78e1d393</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01202%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BF.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DY.%2BT.%26aulast%3DShen%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DZ.%2BY.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520topoisomerase%2520II%2520inhibitors%2520by%2520medicinal%2520chemistry%2520approaches%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D20%26spage%3D8947%26epage%3D8980%26doi%3D10.1021%2Facs.jmedchem.7b01202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>333</i></span> (<span class="NLM_issue">6041</span>),  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1126/science.1204117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1126%2Fscience.1204117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21778401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovF2mur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2011&pages=459-462&issue=6041&author=C.+C.+Wuauthor=T.+K.+Liauthor=L.+Farhauthor=L.+Y.+Linauthor=T.+S.+Linauthor=Y.+J.+Yuauthor=T.+J.+Yenauthor=C.+W.+Chiangauthor=N.+L.+Chan&title=Structural+basis+of+type+II+topoisomerase+inhibition+by+the+anticancer+drug+etoposide&doi=10.1126%2Fscience.1204117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide</span></div><div class="casAuthors">Wu, Chyuan-Chuan; Li, Tsai-Kun; Farh, Lynn; Lin, Li-Ying; Lin, Te-Sheng; Yu, Yu-Jen; Yen, Tien-Jui; Chiang, Chia-Wang; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">6041</span>),
    <span class="NLM_cas:pages">459-462</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Type II topoisomerases (TOP2s) resolve the topol. problems of DNA by transiently cleaving both strands of a DNA duplex to form a cleavage complex through which another DNA segment can be transported.  Several widely prescribed anticancer drugs increase the population of TOP2 cleavage complex, which leads to TOP2-mediated chromosome DNA breakage and death of cancer cells.  We present the crystal structure of a large fragment of human TOP2β complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex.  The interplay between the protein, the DNA, and the drug explains the structure-activity relations of etoposide derivs. and the mol. basis of drug-resistant mutations.  The anal. of protein-drug interactions provides information applicable for developing an isoform-specific TOP2-targeting strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBC6vqPeyB-bVg90H21EOLACvtfcHk0li4McKCU_5GEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovF2mur0%253D&md5=c2eab1b2e9b8a75322b88e76c62c4b74</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1126%2Fscience.1204117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1204117%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DFarh%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DL.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DT.%2BJ.%26aulast%3DChiang%26aufirst%3DC.%2BW.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DStructural%2520basis%2520of%2520type%2520II%2520topoisomerase%2520inhibition%2520by%2520the%2520anticancer%2520drug%2520etoposide%26jtitle%3DScience%26date%3D2011%26volume%3D333%26issue%3D6041%26spage%3D459%26epage%3D462%26doi%3D10.1126%2Fscience.1204117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deweese, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">41</span>),  <span class="NLM_fpage">6595</span>– <span class="NLM_lpage">6602</span>, <span class="refDoi"> DOI: 10.1021/bi5010816</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi5010816" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OitLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=6595-6602&issue=41&author=R.+H.+Lindseyauthor=M.+Pendletonauthor=R.+E.+Ashleyauthor=S.+L.+Mercerauthor=J.+E.+Deweeseauthor=N.+Osheroff&title=Catalytic+core+of+human+topoisomerase+II%CE%B1%3A+insights+into+enzyme-DNA+interactions+and+drug+mechanism&doi=10.1021%2Fbi5010816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Core of Human Topoisomerase IIα: Insights into Enzyme-DNA Interactions and Drug Mechanism</span></div><div class="casAuthors">Lindsey, R. Hunter; Pendleton, MaryJean; Ashley, Rachel E.; Mercer, Susan L.; Deweese, Joseph E.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">6595-6602</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Coordination between the N-terminal gate and the catalytic core of topoisomerase II allows the proper capture, cleavage, and transport of DNA during the catalytic cycle.  Because the activities of these domains are tightly linked, it has been difficult to discern their individual contributions to enzyme-DNA interactions and drug mechanism.  To further address the roles of these domains, we analyzed the activity of the catalytic core of human topoisomerase IIα.  The catalytic core and the wild-type enzyme both maintained higher levels of cleavage with neg. (as compared to pos.) supercoiled plasmid, indicating that the ability to distinguish supercoil handedness is embedded within the catalytic core.  However, the catalytic core alone displayed little ability to cleave DNA substrates that did not intrinsically provide the enzyme with a transport segment (i.e., substrates that did not contain crossovers).  Finally, in contrast to interfacial topoisomerase II poisons, covalent poisons did not enhance DNA cleavage mediated by the catalytic core.  This distinction allowed us to further characterize the mechanism of etoposide quinone, a drug metabolite that functions primarily as a covalent poison.  Etoposide quinone retained some ability to enhance DNA cleavage mediated by the catalytic core, indicating that it still can function as an interfacial poison.  These results further define the distinct contributions of the N-terminal gate and the catalytic core to topoisomerase II function.  The catalytic core senses the handedness of DNA supercoils during cleavage, while the N-terminal gate is crit. for capturing the transport segment and for the activity of covalent poisons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru665se8ASNLVg90H21EOLACvtfcHk0li4McKCU_5GEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OitLfJ&md5=8e75ebeb675d0899dacbb30a63bcc006</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fbi5010816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi5010816%26sid%3Dliteratum%253Aachs%26aulast%3DLindsey%26aufirst%3DR.%2BH.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DAshley%26aufirst%3DR.%2BE.%26aulast%3DMercer%26aufirst%3DS.%2BL.%26aulast%3DDeweese%26aufirst%3DJ.%2BE.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DCatalytic%2520core%2520of%2520human%2520topoisomerase%2520II%25CE%25B1%253A%2520insights%2520into%2520enzyme-DNA%2520interactions%2520and%2520drug%2520mechanism%26jtitle%3DBiochemistry%26date%3D2014%26volume%3D53%26issue%3D41%26spage%3D6595%26epage%3D6602%26doi%3D10.1021%2Fbi5010816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Recent developments in DNA topoisomerase II structure and mechanism</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/S0959-440X(96)80099-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0959-440X%2896%2980099-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8696977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK28Xhtlamt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=84-90&issue=1&author=J.+M.+Bergerauthor=J.+C.+Wang&title=Recent+developments+in+DNA+topoisomerase+II+structure+and+mechanism&doi=10.1016%2FS0959-440X%2896%2980099-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in DNA topoisomerase II structure and mechanism</span></div><div class="casAuthors">Berger, James M.; Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">A review with 67 refs.  Type II DNA topoisomerases are enzymes that are capable of transporting one duplex DNA through another.  Recent exptl. results, including the structure of a fragment of yeast DNA topoisomerase II, have provided new insights into the mechanism of the strand passage reaction.  Other results have begun to define the role of ATP in the catalytic cycle and illuminate how DNA breaks mediated by DNA topoisomerase II can occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyV4XwSXlNM7Vg90H21EOLACvtfcHk0lg3IZ7GNVW3Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xhtlamt7Y%253D&md5=c9555bfd45bacd24e2ef779923b856e4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0959-440X%2896%2980099-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-440X%252896%252980099-6%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DRecent%2520developments%2520in%2520DNA%2520topoisomerase%2520II%2520structure%2520and%2520mechanism%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D1996%26volume%3D6%26issue%3D1%26spage%3D84%26epage%3D90%26doi%3D10.1016%2FS0959-440X%2896%2980099-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3085</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-05406-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fs41467-018-05406-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30082834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ls1aktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3085&issue=1&author=S.+F.+Chenauthor=N.+L.+Huangauthor=J.+H.+Linauthor=C.+C.+Wuauthor=Y.+R.+Wangauthor=Y.+J.+Yuauthor=M.+K.+Gilsonauthor=N.+L.+Chan&title=Structural+insights+into+the+gating+of+DNA+passage+by+the+topoisomerase+II+DNA-gate&doi=10.1038%2Fs41467-018-05406-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate</span></div><div class="casAuthors">Chen Shin-Fu; Wu Chyuan-Chuan; Wang Ying-Ren; Yu Yu-Jen; Chan Nei-Li; Huang Nan-Lan; Lin Jung-Hsin; Huang Nan-Lan; Gilson Michael K; Wu Chyuan-Chuan; Chan Nei-Li; Chan Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3085</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type IIA topoisomerases (Top2s) manipulate the handedness of DNA crossovers by introducing a transient and protein-linked double-strand break in one DNA duplex, termed the DNA-gate, whose opening allows another DNA segment to be transported through to change the DNA topology.  Despite the central importance of this gate-opening event to Top2 function, the DNA-gate in all reported structures of Top2-DNA complexes is in the closed state.  Here we present the crystal structure of a human Top2 DNA-gate in an open conformation, which not only reveals structural characteristics of its DNA-conducting path, but also uncovers unexpected yet functionally significant conformational changes associated with gate-opening.  This structure further implicates Top2's preference for a left-handed DNA braid and allows the construction of a model representing the initial entry of another DNA duplex into the DNA-gate.  Steered molecular dynamics calculations suggests the Top2-catalyzed DNA passage may be achieved by a rocker-switch-type movement of the DNA-gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM5cMY9cr24-dfST00W0BcfW6udTcc2eabU3rWEaR8Xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ls1aktg%253D%253D&md5=04dc82195836cb9e26bb2967da6f0630</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05406-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05406-y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DHuang%26aufirst%3DN.%2BL.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DYu%26aufirst%3DY.%2BJ.%26aulast%3DGilson%26aufirst%3DM.%2BK.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DStructural%2520insights%2520into%2520the%2520gating%2520of%2520DNA%2520passage%2520by%2520the%2520topoisomerase%2520II%2520DNA-gate%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D3085%26doi%3D10.1038%2Fs41467-018-05406-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burden, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme</span>. <i>Biochim. Biophys. Acta, Gene Struct. Expression</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>1400</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1016/S0167-4781(98)00132-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0167-4781%2898%2900132-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9748545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFWisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1400&publication_year=1998&pages=139-154&issue=1%E2%80%933&author=D.+A.+Burdenauthor=N.+Osheroff&title=Mechanism+of+action+of+eukaryotic+topoisomerase+II+and+drugs+targeted+to+the+enzyme&doi=10.1016%2FS0167-4781%2898%2900132-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme</span></div><div class="casAuthors">Burden, D. Andrew; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Structure and Expression</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">1400</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">139-154</span>CODEN:
                <span class="NLM_cas:coden">BBGSD5</span>;
        ISSN:<span class="NLM_cas:issn">0167-4781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 166 refs.  Topoisomerase II is a ubiquitous enzyme that is essential for the survival of all eukaryotic organisms and plays crit. roles in virtually every aspect of DNA metab.  The enzyme unknots and untangles DNA by passing an intact helix through a transient double-stranded break that it generates in a sep. helix.  Beyond its physiol. functions, topoisomerase II is the target for some of the most active and widely prescribed anticancer drugs currently utilized for the treatment of human cancers.  These drugs act in an insidious fashion and kill cells by increasing levels of covalent topoisomerase II-cleaved DNA complexes that are normally fleeting intermediates in the catalytic cycle of the enzyme.  Over the past several years, we have made considerable strides in our understanding of the catalytic mechanism of topoisomerase II and the mechanism of action of drugs targeted to this enzyme.  These advances have provided novel insights into the physiol. functions of topoisomerase II and have led to the development of more efficacious chemotherapeutic regimens and novel anticancer drugs.  Considering the importance of topoisomerase II to the eukaryotic cell and to cancer chemotherapy, it is essential to understand its enzymic function and pharmacol. properties.  Therefore, this review will discuss the mechanism of action of eukaryotic topoisomerase II and topoisomerase II-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhrmz2NE2EhLVg90H21EOLACvtfcHk0lgPyKd4HASrZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFWisrg%253D&md5=9e84fbeb6f394a48368e6ce51c47d6a7</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0167-4781%2898%2900132-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-4781%252898%252900132-8%26sid%3Dliteratum%253Aachs%26aulast%3DBurden%26aufirst%3DD.%2BA.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DMechanism%2520of%2520action%2520of%2520eukaryotic%2520topoisomerase%2520II%2520and%2520drugs%2520targeted%2520to%2520the%2520enzyme%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Struct.%2520Expression%26date%3D1998%26volume%3D1400%26issue%3D1%25E2%2580%25933%26spage%3D139%26epage%3D154%26doi%3D10.1016%2FS0167-4781%2898%2900132-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escargueil, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skladanowski, A.</span></span> <span> </span><span class="NLM_article-title">Catalytic topoisomerase II inhibitors in cancer therapy</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>99</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(03)00058-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0163-7258%2803%2900058-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12888111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=167-181&issue=2&author=A.+K.+Larsenauthor=A.+E.+Escargueilauthor=A.+Skladanowski&title=Catalytic+topoisomerase+II+inhibitors+in+cancer+therapy&doi=10.1016%2FS0163-7258%2803%2900058-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic topoisomerase II inhibitors in cancer therapy</span></div><div class="casAuthors">Larsen, Annette K.; Escargueil, Alexandre E.; Skladanowski, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The nuclear enzyme DNA topoisomerase II is a major target for antineoplastic agents.  All topoisomerase II-directed agents are able to interfere with at least one step of the catalytic cycle.  Agents able to stabilize the covalent DNA topoisomerase II complex (also known as the cleavable complex) are traditionally called topoisomerase II poisons, while agents acting on any of the other steps in the catalytic cycle are called catalytic inhibitors.  Thus, catalytic topoisomerase II inhibitors are a heterogeneous group of compds. that might interfere with the binding between DNA and topoisomerase II (aclarubicin and suramin), stabilize noncovalent DNA topoisomerase II complexes (merbarone, ICRF-187, and structurally related bisdioxopiperazine derivs.), or inhibit ATP binding (novobiocin).  Some, such as fostriecin, may also have alternative biol. targets.  Whereas topoisomerase II poisons are used solely for their antitumor activities, catalytic inhibitors are utilized for a variety of reasons, including their activity as antineoplastic agents (aclarubicin and MST-16), cardioprotectors (ICRF-187), or modulators in order to increase the efficacy of other agents (suramin and novobiocin).  In this review, the mechanism and biol. activity of different catalytic inhibitors is described, with emphasis on therapeutically used compds.  We will then discuss future development and applications of this interesting class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGote2bOTWP17bVg90H21EOLACvtfcHk0lgPyKd4HASrZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D&md5=4207fb899e2b98345f97e91983514913</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900058-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900058-5%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DEscargueil%26aufirst%3DA.%2BE.%26aulast%3DSkladanowski%26aufirst%3DA.%26atitle%3DCatalytic%2520topoisomerase%2520II%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D99%26issue%3D2%26spage%3D167%26epage%3D181%26doi%3D10.1016%2FS0163-7258%2803%2900058-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohajeri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahebkar, A.</span></span> <span> </span><span class="NLM_article-title">Protective effects of curcumin against doxorubicin-induced toxicity and resistance: a review</span>. <i>Crit Rev. Oncol Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2017.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.critrevonc.2017.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29458788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1MrjtFGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2018&pages=30-51&author=M.+Mohajeriauthor=A.+Sahebkar&title=Protective+effects+of+curcumin+against+doxorubicin-induced+toxicity+and+resistance%3A+a+review&doi=10.1016%2Fj.critrevonc.2017.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review</span></div><div class="casAuthors">Mohajeri Mohammad; Sahebkar Amirhossein</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Doxorubicin (DOX)-induced toxicity and resistance are major obstacles in chemotherapeutic approaches.  Despite effective in the treatment of numerous malignancies, some clinicians have voiced concern that DOX has the potential to cause debilitating consequences in organ tissues, especially the heart.  The mechanisms of toxicity and resistance are respectively related to induction of reactive oxygen species (ROS) and up-regulation of ATP-binding cassette (ABC) transporter.  Curcumin (CUR) with several biological and pharmacological properties is expected to restore DOX-mediated impairments to tissues.  This review is intended to address the current knowledge on DOX adverse effects and CUR protective actions in the heart, kidneys, liver, brain, and reproductive organs.  Coadministration of CUR and DOX is capable of ameliorating DOX toxicity pertained to antioxidant, apoptosis, autophagy, and mitochondrial permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkdQYA6PIKujUE-swuRqsHfW6udTcc2eZpPRUJ0HVcgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrjtFGhtg%253D%253D&md5=026d1c99a8539d42415e48a02f832b4c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2017.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2017.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DMohajeri%26aufirst%3DM.%26aulast%3DSahebkar%26aufirst%3DA.%26atitle%3DProtective%2520effects%2520of%2520curcumin%2520against%2520doxorubicin-induced%2520toxicity%2520and%2520resistance%253A%2520a%2520review%26jtitle%3DCrit%2520Rev.%2520Oncol%2520Hematol.%26date%3D2018%26volume%3D122%26spage%3D30%26epage%3D51%26doi%3D10.1016%2Fj.critrevonc.2017.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kros, J. M.</span></span> <span> </span><span class="NLM_article-title">Breakthroughs in modern cancer therapy and elusive cardiotoxicity: critical research-practice gaps, challenges, and insights</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1002/med.21463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fmed.21463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28862319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKitb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=325-376&issue=1&author=P.+P.+Zhengauthor=J.+Liauthor=J.+M.+Kros&title=Breakthroughs+in+modern+cancer+therapy+and+elusive+cardiotoxicity%3A+critical+research-practice+gaps%2C+challenges%2C+and+insights&doi=10.1002%2Fmed.21463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights</span></div><div class="casAuthors">Zheng, Ping-Pin; Li, Jin; Kros, Johan M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">325-376</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  To date, five cancer treatment modalities have been defined.  The three traditional modalities of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two modern modalities include molecularly targeted therapy (the fourth modality) and immunotherapy (the fifth modality).  The cardiotoxicity assocd. with conventional chemotherapy and radiotherapy is well known.  Similar adverse cardiac events are resurging with the fourth modality.  Aside from the conventional and newer targeted agents, even the most newly developed, immune-based therapeutic modalities of anticancer treatment (the fifth modality), e.g., immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, have unfortunately led to potentially lethal cardiotoxicity in patients.  Cardiac complications represent unresolved and potentially life-threatening conditions in cancer survivors, while effective clin. management remains quite challenging.  As a consequence, morbidity and mortality related to cardiac complications now threaten to offset some favorable benefits of modern cancer treatments in cancer-related survival, regardless of the oncol. prognosis.  This review focuses on identifying crit. research-practice gaps, addressing real-world challenges and pinpointing real-time insights in general terms under the context of clin. cardiotoxicity induced by the fourth and fifth modalities of cancer treatment.  The information ranges from basic science to clin. management in the field of cardio-oncol. and crosses the interface between oncol. and onco-pharmacolgy.  The complexity of the ongoing clin. problem is addressed at different levels.  A better understanding of these research-practice gaps may advance research initiatives on the development of mechanism-based diagnoses and treatments for the effective clin. management of cardiotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-toVIgflHZbVg90H21EOLACvtfcHk0li5E9q3OBzyBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKitb3F&md5=0e8b5cbeaa3f8621e92b525c9be7a956</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fmed.21463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21463%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DP.%2BP.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKros%26aufirst%3DJ.%2BM.%26atitle%3DBreakthroughs%2520in%2520modern%2520cancer%2520therapy%2520and%2520elusive%2520cardiotoxicity%253A%2520critical%2520research-practice%2520gaps%252C%2520challenges%252C%2520and%2520insights%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26issue%3D1%26spage%3D325%26epage%3D376%26doi%3D10.1002%2Fmed.21463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Froelich-Ammon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase poisons: harnessing the dark side of enzyme mechanism</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">21429</span>– <span class="NLM_lpage">21432</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.37.21429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.270.37.21429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=7665550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2MXotFajtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=21429-21432&issue=37&author=S.+J.+Froelich-Ammonauthor=N.+Osheroff&title=Topoisomerase+poisons%3A+harnessing+the+dark+side+of+enzyme+mechanism&doi=10.1074%2Fjbc.270.37.21429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase poisons: harnessing the dark side of enzyme mechanism</span></div><div class="casAuthors">Froelich-Ammon, Stacie J.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">21429-32</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review, with 78 refs.  The authors report here mechanism by which drugs alter the catalytic functions of topoisomerases and convert these essential enzymes into lethal cellular weapons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQRnYWeK6g0rVg90H21EOLACvtfcHk0li5E9q3OBzyBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotFajtLs%253D&md5=4330a75545091d245162164465f6bbe7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.37.21429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.37.21429%26sid%3Dliteratum%253Aachs%26aulast%3DFroelich-Ammon%26aufirst%3DS.%2BJ.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DTopoisomerase%2520poisons%253A%2520harnessing%2520the%2520dark%2520side%2520of%2520enzyme%2520mechanism%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26issue%3D37%26spage%3D21429%26epage%3D21432%26doi%3D10.1074%2Fjbc.270.37.21429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwade, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase II and leukemia</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1310</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1111/nyas.12358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1111%2Fnyas.12358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24495080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslyltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1310&publication_year=2014&pages=98-110&issue=1&author=M.+Pendletonauthor=R.+H.+Lindseyauthor=C.+A.+Felixauthor=D.+Grimwadeauthor=N.+Osheroff&title=Topoisomerase+II+and+leukemia&doi=10.1111%2Fnyas.12358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase II and leukemia</span></div><div class="casAuthors">Pendleton, MaryJean; Lindsey, R. Hunter Jr.; Felix, Carolyn A.; Grimwade, David; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1310</span>
        (<span class="NLM_cas:issue">y</span>),
    <span class="NLM_cas:pages">98-110</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Type II topoisomerases are essential enzymes that modulate DNA under- and overwinding, knotting, and tangling.  Beyond their crit. physiol. functions, these enzymes are the targets for some of the most widely prescribed anticancer drugs (topoisomerase II poisons) in clin. use.  Topoisomerase II poisons kill cells by increasing levels of covalent enzyme-cleaved DNA complexes that are normal reaction intermediates.  Drugs such as etoposide, doxorubicin, and mitoxantrone are frontline therapies for a variety of solid tumors and hematol. malignancies.  Unfortunately, their use also is assocd. with the development of specific leukemias.  Regimens that include etoposide or doxorubicin are linked to the occurrence of acute myeloid leukemias that feature rearrangements at chromosomal band 11q23.  Similar rearrangements are seen in infant leukemias and are assocd. with gestational diets that are high in naturally occurring topoisomerase II-active compds.  Finally, regimens that include mitoxantrone and epirubicin are linked to acute promyelocytic leukemias that feature t(15;17) rearrangements.  The first part of this article will focus on type II topoisomerases and describe the mechanism of enzyme and drug action.  The second part will discuss how topoisomerase II poisons trigger chromosomal breaks that lead to leukemia and potential approaches for dissocg. the actions of drugs from their leukemogenic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiALYgvTJB7LVg90H21EOLACvtfcHk0li6WWVHUWTS4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslyltr8%253D&md5=9bb86013f9a010450587baa0c924bfec</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12358%26sid%3Dliteratum%253Aachs%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DLindsey%26aufirst%3DR.%2BH.%26aulast%3DFelix%26aufirst%3DC.%2BA.%26aulast%3DGrimwade%26aufirst%3DD.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DTopoisomerase%2520II%2520and%2520leukemia%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D1310%26issue%3D1%26spage%3D98%26epage%3D110%26doi%3D10.1111%2Fnyas.12358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClendon, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase II, genotoxicity, and cancer</span>. <i>Mutat. Res., Fundam. Mol. Mech. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>623</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.mrfmmm.2007.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.mrfmmm.2007.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17681352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWmsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=623&publication_year=2007&pages=83-97&issue=1%E2%80%932&author=A.+K.+McClendonauthor=N.+Osheroff&title=DNA+topoisomerase+II%2C+genotoxicity%2C+and+cancer&doi=10.1016%2Fj.mrfmmm.2007.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerase II, genotoxicity, and cancer</span></div><div class="casAuthors">McClendon, A. Kathleen; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">623</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">83-97</span>CODEN:
                <span class="NLM_cas:coden">MUREAV</span>;
        ISSN:<span class="NLM_cas:issn">0027-5107</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Type II topoisomerases are ubiquitous enzymes that play essential roles in a no. of fundamental DNA processes.  They regulate DNA under- and overwinding, and resolve knots and tangles in the genetic material by passing an intact double helix through a transient double-stranded break that they generate in a sep. segment of DNA.  Because type II topoisomerases generate DNA strand breaks as a requisite intermediate in their catalytic cycle, they have the potential to fragment the genome every time they function.  Thus, while these enzymes are essential to the survival of proliferating cells, they also have significant genotoxic effects.  This latter aspect of type II topoisomerase has been exploited for the development of several classes of anticancer drugs that are widely employed for the clin. treatment of human malignancies.  However, considerable evidence indicates that these enzymes also trigger specific leukemic chromosomal translocations.  In light of the impact, both pos. and neg., of type II topoisomerases on human cells, it is important to understand how these enzymes function and how their actions can destabilize the genome.  This article discusses both aspects of human type II topoisomerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Pg1M5Ibtq7Vg90H21EOLACvtfcHk0li6WWVHUWTS4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWmsbzF&md5=5377bb3255ce5136b684261d05a3b071</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.mrfmmm.2007.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mrfmmm.2007.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcClendon%26aufirst%3DA.%2BK.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DDNA%2520topoisomerase%2520II%252C%2520genotoxicity%252C%2520and%2520cancer%26jtitle%3DMutat.%2520Res.%252C%2520Fundam.%2520Mol.%2520Mech.%2520Mutagen.%26date%3D2007%26volume%3D623%26issue%3D1%25E2%2580%25932%26spage%3D83%26epage%3D97%26doi%3D10.1016%2Fj.mrfmmm.2007.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deweese, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">The DNA cleavage reaction of topoisomerase II: wolf in sheep’s clothing</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1093/nar/gkn937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1093%2Fnar%2Fgkn937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19042970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFekur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=738-748&author=J.+E.+Deweeseauthor=N.+Osheroff&title=The+DNA+cleavage+reaction+of+topoisomerase+II%3A+wolf+in+sheep%E2%80%99s+clothing&doi=10.1093%2Fnar%2Fgkn937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing</span></div><div class="casAuthors">Deweese, Joseph E.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">738-748</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Topoisomerase II is an essential enzyme that is required for virtually every process that requires movement of DNA within the nucleus or the opening of the double helix.  This enzyme helps to regulate DNA under- and over-winding and removes knots and tangles from the genetic material.  In order to carry out its crit. physiol. functions, topoisomerase II generates transient double-stranded breaks in DNA.  Consequently, while necessary for cell survival, the enzyme also has the capacity to fragment the genome.  The DNA cleavage/ligation reaction of topoisomerase II is the target for some of the most successful anticancer drugs currently in clin. use.  However, this same reaction also is believed to trigger chromosomal translocations that are assocd. with specific types of leukemia.  This article will familiarize the reader with the DNA cleavage/ligation reaction of topoisomerase II and other aspects of its catalytic cycle.  In addn., it will discuss the interaction of the enzyme with anticancer drugs and the mechanisms by which these agents increase levels of topoisomerase II-generated DNA strand breaks.  Finally, it will describe dietary and environmental agents that enhance DNA cleavage mediated by the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEHw6iKFH3x7Vg90H21EOLACvtfcHk0likHOUL-RT-0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFekur0%253D&md5=825d9227c9017b9a90a8b3993499a234</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkn937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkn937%26sid%3Dliteratum%253Aachs%26aulast%3DDeweese%26aufirst%3DJ.%2BE.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DThe%2520DNA%2520cleavage%2520reaction%2520of%2520topoisomerase%2520II%253A%2520wolf%2520in%2520sheep%25E2%2580%2599s%2520clothing%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2009%26volume%3D37%26spage%3D738%26epage%3D748%26doi%3D10.1093%2Fnar%2Fgkn937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCombie, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannon, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase levels determine chemotherapy response <i>in vitro</i> and <i>in vivo</i></span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">9053</span>– <span class="NLM_lpage">9058</span>, <span class="refDoi"> DOI: 10.1073/pnas.0803513105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1073%2Fpnas.0803513105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18574145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=9053-9058&issue=26&author=D.+J.+Burgessauthor=J.+Dolesauthor=L.+Zenderauthor=W.+Xueauthor=B.+Maauthor=W.+R.+McCombieauthor=G.+J.+Hannonauthor=S.+W.+Loweauthor=M.+T.+Hemann&title=Topoisomerase+levels+determine+chemotherapy+response+in+vitro+and+in+vivo&doi=10.1073%2Fpnas.0803513105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase levels determine chemotherapy response in vitro and in vivo</span></div><div class="casAuthors">Burgess, Darren J.; Doles, Jason; Zender, Lars; Xue, Wen; Ma, Beicong; McCombie, W. Richard; Hannon, Gregory J.; Lowe, Scott W.; Hemann, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9053-9058</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Topoisomerase poisons are chemotherapeutic agents that are used extensively for treating human malignancies.  These drugs can be highly effective, yet tumors are frequently refractory to treatment or become resistant upon tumor relapse.  Using a pool-based RNAi screening approach and a well characterized mouse model of lymphoma, we explored the genetic basis for heterogeneous responses to topoisomerase poisons in vitro and in vivo.  These expts. identified Top2A expression levels as major determinants of response to the topoisomerase 2 poison doxorubicin and showed that suppression of Top2A produces resistance to doxorubicin in vitro and in vivo.  Analogously, using a targeted RNAi approach, we demonstrated that suppression of Top1 produces resistance to the topoisomerase 1 poison camptothecin yet hypersensitizes cancer cells to doxorubicin.  Importantly, lymphomas relapsing after treatment display spontaneous changes in topoisomerase levels as predicted by in vitro gene knockdown studies.  These results highlight the utility of pooled shRNA screens for identifying genetic determinants of chemotherapy response and suggest strategies for improving the effectiveness of topoisomerase poisons in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTnklAO5hzqrVg90H21EOLACvtfcHk0likHOUL-RT-0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCiur8%253D&md5=62e61e8ba30635bac005d239ee561e2e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803513105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803513105%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DD.%2BJ.%26aulast%3DDoles%26aufirst%3DJ.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DMcCombie%26aufirst%3DW.%2BR.%26aulast%3DHannon%26aufirst%3DG.%2BJ.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26atitle%3DTopoisomerase%2520levels%2520determine%2520chemotherapy%2520response%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D26%26spage%3D9053%26epage%3D9058%26doi%3D10.1073%2Fpnas.0803513105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowbay, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacogenetics of target genes across doxorubicin disposition pathway: a review</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.2174/138920010791110890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F138920010791110890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=20302569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFymtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=115-128&issue=1&author=S.+Lalauthor=A.+Mahajanauthor=W.+N.+Chenauthor=B.+Chowbay&title=Pharmacogenetics+of+target+genes+across+doxorubicin+disposition+pathway%3A+a+review&doi=10.2174%2F138920010791110890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenetics of target genes across doxorubicin disposition pathway: a review</span></div><div class="casAuthors">Lal, Suman; Mahajan, Anupama; Chen, Wei Ning; Chowbay, Balram</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-128</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Increased understanding of the mol. mechanisms of tumor heterogeneity combined with rapid advances in the field of pharmacogenetics and pharmacogenomics have fuelled studies on individualizing anticancer therapy.  Doxorubicin (Adriamycin), is an anthracycline glycoside antibiotic originally produced by Streptomyces peucetius var. caesius, and is widely used either as a single agent or in combination with other chemotherapeutic regimens for curative, adjuvant, and palliative treatment in cancer patients.  The pharmacogenetics of doxorubicin has not been well characterized.  The polygenic influence of functional candidate gene variants across doxorubicin biochem. pathway is hypothesized to contribute to its heterogeneity in disposition, influencing the efficacy of treatment and occurrence of adverse effects like cardiomyopathy in patients undergoing doxorubicin based adjuvant and neo-adjuvant chemotherapy.  The pharmacogenetics of Asian population differs from that of other ethnic groups, particularly from Caucasian and African populations, and indicates an important role of ethnicity in detg. predictive end points during chemotherapy and in individualizing treatment.  This review comprehensively examines the pharmacogenetics of the regulatory nuclear receptor Pregnane-X Receptor (PXR), influx (SLC22A16) and efflux drug transporters (ABCB1, ABCG2, ABCC5, ABCB5 and RLIP76) and drug metabolizing enzymes (CBR1, CBR3) across the biochem. pathway of doxorubicin in Asian breast cancer patients receiving doxorubicin based adjuvant chemotherapy.  The influence of functional genetic variants on the inter-individual variability in pharmacokinetics of doxorubicin and its major metabolite are also discussed.  The incorporation of non-genetic factors and subsequent validation of these findings in different patient and population groups will be valuable in tailoring doxorubicin dosage regimens to an individual to maximize therapeutic efficacy and minimize adverse reactions, leading to improved clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQo1fI7cxbI7Vg90H21EOLACvtfcHk0ljcoLLpdKnPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFymtb4%253D&md5=04bcf7537f760926299f85e09b5c2c4e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F138920010791110890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920010791110890%26sid%3Dliteratum%253Aachs%26aulast%3DLal%26aufirst%3DS.%26aulast%3DMahajan%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DW.%2BN.%26aulast%3DChowbay%26aufirst%3DB.%26atitle%3DPharmacogenetics%2520of%2520target%2520genes%2520across%2520doxorubicin%2520disposition%2520pathway%253A%2520a%2520review%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2010%26volume%3D11%26issue%3D1%26spage%3D115%26epage%3D128%26doi%3D10.2174%2F138920010791110890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1862</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2018.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bbagen.2018.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29425806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivVSjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2018&pages=1126-1133&issue=5&author=K.+H.+Jeonauthor=H.+V.+Yuauthor=Y.+Kwon&title=Hyperactivated+m-calpain+affects+acquisition+of+doxorubicin+resistance+in+breast+cancer+cells&doi=10.1016%2Fj.bbagen.2018.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells</span></div><div class="casAuthors">Jeon, Kyung-Hwa; Yu, Han Vit; Kwon, Youngjoo</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1126-1133</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Doxorubicin is commonly using chemotherapeutic agents for breast cancer.  However, doxorubicin has limitations in clin. use because of dose-dependent cardiotoxicity and drug resistance.  Despite of previously reported studies about mechanisms of doxorubicin resistance including overexpression of P-gp and abnormal expression and mutation of topoisomerase IIα, resistance to this agent still abundantly occur and is regarded as a major obstacle to successful treatment.  The authors have established doxorubicin resistant T47D cells.  Intracellular calcium and ROS levels and calpain activity were measured using fluorometric expts.  Cell viability assay, cell cycle anal., immunofluorescence and western blot anal. were performed to evaluate m-calpain specific truncation of topoisomerase IIα and mol. mechanism in doxorubicin resistant cells.  The authors obsd. that doxorubicin treatment increased intracellular calcium and ROS (Reactive Oxygen Species) in parental and doxorubicin resistant T47D cells.  The increases in intracellular calcium and ROS were much greater in doxorubicin resistant T47D cells, which led to higher activity of calpains.  Hyperactivated m-calpain, but not μ-calpain, specifically induced cleavage of topoisomerase IIα and accumulation of truncated topoisomerase IIα in the cytoplasm.  The increase in cytoplasmic truncated topoisomerase IIα reduced the efficacy of doxorubicin.  Doxorubicin resistant T47D cells, with hyperactivated m-calpain and truncated cytosolic topoisomerase IIα, obtained cross-resistance to other topoisomerase II-targeting drugs.  Hyperactivated m-calpain induced cytoplasmic accumulation of truncated topoisomerase IIα in doxorubicin resistant T47D cells.  These data provide a new mechanism of doxorubicin resistance and suggest a novel strategy for overcoming drug resistance in topoisomerase IIα-targeting therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPQqi8RMrjrVg90H21EOLACvtfcHk0ljcoLLpdKnPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivVSjtbs%253D&md5=1b70cc8ce292eeea3a83c3b5ec1533b8</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2018.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2018.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DJeon%26aufirst%3DK.%2BH.%26aulast%3DYu%26aufirst%3DH.%2BV.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DHyperactivated%2520m-calpain%2520affects%2520acquisition%2520of%2520doxorubicin%2520resistance%2520in%2520breast%2520cancer%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2018%26volume%3D1862%26issue%3D5%26spage%3D1126%26epage%3D1133%26doi%3D10.1016%2Fj.bbagen.2018.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brattain, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casazza, A. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5275</span>– <span class="NLM_lpage">5283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1717144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3MXmslSisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=5275-5283&issue=19&author=B.+H.+Longauthor=L.+Wangauthor=A.+Loricoauthor=R.+C.+Wangauthor=M.+G.+Brattainauthor=A.+M.+Casazza&title=Mechanisms+of+resistance+to+etoposide+and+teniposide+in+acquired+resistant+human+colon+and+lung+carcinoma+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines</span></div><div class="casAuthors">Long, Byron H.; Wang, Lotte; Lorico, Aurelio; Wang, Richard C. C.; Brattain, Michael G.; Casazza, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5275-83</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Stable, acquired resistance to etoposide (VP-16) on teniposide (VM-26) in HCT116 human colon carcinoma cells and A549 human lung adenocarcinoma cells was previously obtained by weekly 1-h exposures to either drug.  The purpose of this study was to identify possible mechanisms of resistance present in these cells by using human mdr1 and topoisomerase II DNA probes, antibodies to these gene products, and P4 phage unknotting assay for topoisomerase II activities.  HCT116(VP)35 cells were 9-, 7-, and 6-fold resistant to VP-16, VM-26, and Adriamycin, resp., and showed no cross-resistance to colchicine and actinomycin D.  These cells had no differences in mdr1 gene, mrd1 mRNA, or P-glycoprotein levels but displayed decreased levels of topoisomerase II mRNA and enzyme activity without any alteration of drug sensitivity displayed by the enzyme.  HCT116(VM)34 cells were 5-, 7-, and 21-fold resistant to VP-16, VM-26, and Adriamycin; were cross-resistant to colchicine (7-fold) and actinomycin D (18-fold); and possessed a 9-fold increase in mdr1 mRNA and increased P-glycoprotein without evidence of mdr1 gene amplification.  No alterations in topoisomerase II gene or mRNA levels, enzyme activity, or drug sensitivity were obsd.  A549(VP)28 and A549(VM)28 cells were 8-fold resistant to VP-16 and VM-26 and 3-fold resistant to Adramycin.  Both lines were not cross-resistant to colchicine or actinomycin D but were hypersensitive to cis-platinum.  No alterations in mdr1 gene, mdr1 mRNA, or P-glycoprotein levels, but lower topoisomerase II mRNA levels and decreased enzyme activities, were obsd.  Of the four acquired resistant cell lines, resistance is likely related to elevated mdr1 expression in one line and to decreased topoisomerase II expression in the other three lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBeeAgQj89FbVg90H21EOLACvtfcHk0ljcoLLpdKnPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmslSisb8%253D&md5=948b4b3ccaabf89d4b1d9adf47ff3174</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DB.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLorico%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DR.%2BC.%26aulast%3DBrattain%26aufirst%3DM.%2BG.%26aulast%3DCasazza%26aufirst%3DA.%2BM.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520etoposide%2520and%2520teniposide%2520in%2520acquired%2520resistant%2520human%2520colon%2520and%2520lung%2520carcinoma%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26issue%3D19%26spage%3D5275%26epage%3D5283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Runger, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diem, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellfritsch, D.</span></span> <span> </span><span class="NLM_article-title">Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1046/j.1523-1747.2000.00844.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1046%2Fj.1523-1747.2000.00844.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10620112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFKltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2000&pages=34-39&issue=1&author=T.+M.+Rungerauthor=S.+Emmertauthor=D.+Schadendorfauthor=C.+Diemauthor=B.+Epeauthor=D.+Hellfritsch&title=Alterations+of+DNA+repair+in+melanoma+cell+lines+resistant+to+cisplatin%2C+fotemustine%2C+or+etoposide&doi=10.1046%2Fj.1523-1747.2000.00844.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide</span></div><div class="casAuthors">Runger, Thomas M.; Emmert, Steffen; Schadendorf, Dirk; Diem, Caroline; Epe, Bernd; Hellfritsch, Doris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-39</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">Resistance to chemotherapy is a common phenomenon in malignant melanoma.  In order to assess the role of altered DNA repair in chemoresistant melanoma, we investigated different DNA repair pathways in one parental human melanoma line (MeWo) and in sublines of MeWo selected in vitro for drug resistance against four commonly used drugs (cisplatin, fotemustine, etoposide, and vindesine).  Host cell reactivation assays with the plasmid pRSV cat were used to assess processing of different DNA lesions.  With UV-irradiated plasmids, no significant differences were found, indicating a normal (nucleotide excision) repair of DNA photoproducts.  With singlet oxygen-treated plasmid, the fotemustine- and cisplatin-resistant lines exhibited a significantly increased (base excision) repair of oxidative DNA damage.  With fotemustine-treated plasmid, the fotemustine-resistant subline did not exhibit an increased repair of directly fotemustine-induced DNA damage.  Similar results were obtained with cisplatin-induced DNA crosslinks in the cisplatin-resistant line.  The fotemustine- and etoposide-resistant sublines have been shown to exhibit a reduced expression of genes involved in DNA mismatch repair.  We used a "host cell microsatellite stability assay" with the plasmid pZCA29 and found a 2.0-fold to 2.5-fold increase of microsatellite frameshift mutations (p ≤ 0.002) in the two resistant sublines.  This indicates microsatellite instability, the hallmark of an impaired DNA mismatch repair.  The increased repair of oxidative DNA damage might mediate an increased chemoresistance through an improved repair of drug-induced DNA damage.  In contrast, a reduced DNA mismatch repair might confer resistance by preventing futile degrdn. of newly synthesized DNA opposite alkylation damage, or by an inability to detect such damage and subsequent inability to undergo DNA-damage-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ-dqopHnNiLVg90H21EOLACvtfcHk0liCQ1AFZWba8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFKltrc%253D&md5=45a00fd918ee0216eb14386c5615cee4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1747.2000.00844.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1747.2000.00844.x%26sid%3Dliteratum%253Aachs%26aulast%3DRunger%26aufirst%3DT.%2BM.%26aulast%3DEmmert%26aufirst%3DS.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DDiem%26aufirst%3DC.%26aulast%3DEpe%26aufirst%3DB.%26aulast%3DHellfritsch%26aufirst%3DD.%26atitle%3DAlterations%2520of%2520DNA%2520repair%2520in%2520melanoma%2520cell%2520lines%2520resistant%2520to%2520cisplatin%252C%2520fotemustine%252C%2520or%2520etoposide%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2000%26volume%3D114%26issue%3D1%26spage%3D34%26epage%3D39%26doi%3D10.1046%2Fj.1523-1747.2000.00844.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, U. G.</span></span> <span> </span><span class="NLM_article-title">Tumor cell resistance to DNA topoisomerase II inhibitors: new developments</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1054/drup.1999.0110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1054%2Fdrup.1999.0110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11498354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFWmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1999&pages=382-389&issue=6&author=W.+T.+Beckauthor=S.+E.+Morganauthor=Y.+Y.+Moauthor=U.+G.+Bhat&title=Tumor+cell+resistance+to+DNA+topoisomerase+II+inhibitors%3A+new+developments&doi=10.1054%2Fdrup.1999.0110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor cell resistance to DNA topoisomerase II inhibitors: new developments</span></div><div class="casAuthors">Beck, William T.; Morgan, Susan E.; Mo, Yin-Yuan; Bhat, Uppoor G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">382-389</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">A review with 94 refs.  DNA topoisomerases are crit. enzymes involved in replication, transcription, chromatin assembly and other aspects of DNA metab.  They are also the targets of important anticancer drugs.  The type II topoisomerases are specific targets of drug classes that comprise complex-stabilizing (epipodophyllotoxins, anthracyclines) and catalytic (merbarone, bisdioxopiperazines) inhibitors.  In this review, we update our current knowledge of resistance to the antitumor inhibitors of the type II DNA topoisomerases, with special emphasis on the catalytic inhibitors, since novel catalytic inhibitor resistance cell lines have only recently been described.  Resistance to topoisomerase II inhibitors can manifest as decreased or increased expression of or mutation in the topoisomerase II genes.  However, the tumor cell's response to exposure to these inhibitors involves more than the target enzyme, and these other responses are a major focus of this review.  Such cellular changes are assocd. with and may contribute to the drug resistance phenotype.  They involve decreased drug accumulation due to expression of membrane "pump" proteins, altered cytotoxic signaling through stress-activated protein kinases, and alterations in apoptosis and cell cycle proteins (e.g. Bcl-2, Bax, p53, Rb).  While it is evident that mutation in or altered expression of the topoisomerase II genes are sufficient to confer resistance to topoisomerase inhibitors, it is not clear whether the other changes are a consequence of the selection or a response to the cytotoxic insult, nor is it clear how these other cellular changes contribute to the drug resistance phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTuKIVCK9wNbVg90H21EOLACvtfcHk0liCQ1AFZWba8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFWmsro%253D&md5=8d6d163670828eb8ba91f729287a5794</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1054%2Fdrup.1999.0110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fdrup.1999.0110%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DW.%2BT.%26aulast%3DMorgan%26aufirst%3DS.%2BE.%26aulast%3DMo%26aufirst%3DY.%2BY.%26aulast%3DBhat%26aufirst%3DU.%2BG.%26atitle%3DTumor%2520cell%2520resistance%2520to%2520DNA%2520topoisomerase%2520II%2520inhibitors%253A%2520new%2520developments%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D1999%26volume%3D2%26issue%3D6%26spage%3D382%26epage%3D389%26doi%3D10.1054%2Fdrup.1999.0110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marbeuf-Gueye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxterman, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubru, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priebe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier-Suillerot, A.</span></span> <span> </span><span class="NLM_article-title">Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1124/mol.53.1.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1124%2Fmol.53.1.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9443942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXot1ahsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=141-147&issue=1&author=C.+Marbeuf-Gueyeauthor=H.+J.+Broxtermanauthor=F.+Dubruauthor=W.+Priebeauthor=A.+Garnier-Suillerot&title=Kinetics+of+anthracycline+efflux+from+multidrug+resistance+protein-expressing+cancer+cells+compared+with+P-glycoprotein-expressing+cancer+cells&doi=10.1124%2Fmol.53.1.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells</span></div><div class="casAuthors">Marbeuf-Gueye, C.; Broxterman, H. J.; Dubru, F.; Priebe, W.; Garnier-Suillerot, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-147</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide.  Thus, this protein does confer a multidrug resistant phenotype to cancer cells, similar to P-glycoprotein (Pgp).  The substrate specificity of both transporter proteins is partly over-lapping but is otherwise very distinct; because MRP is a multiple org. anion transporter, it transports certain glutathione conjugates and may be partly dependent on intracellular glutathione levels for the transport of anthracyclines.  We have studied the transport kinetics of a series of anthracyclines in MRP and Pgp that overexpress tumor cell lines to obtain information on the substrate specificity of these proteins.  The anthracyclines have modifications in the sugar moiety.  The mean active efflux coeff. ka, used to characterize the efficiency of the active efflux, was very similar for DNR and one of its 4'-deoxy- derivs. (eso-DNR) for MRP and Pgp [10-20 × 10-/s/(cells/mL)].  The permanently neutral derivs. 3'-deamino-3'-hydroxy-doxorubicin (OH-DOX) and 3'-deamino-3'-hydroxy-daunorubicin (OH-DNR) were effluxed by both proteins but had a lower ka [2 × 10-10/s/(cells/mL) (OH-DOX) and 2 × 10-10 and 5 × 10-10/s/(cells/mL) (OH-DNR)] for MRP and Pgp.  Two anthracyclines, the doxorubicin deriv. pirarubicin and 2'-bromo-4'-epi-DNR seemed to have a slightly higher ka value for Pgp than for MRP.  The apparent Michaelis-Menten consts. (Km) and maximal efflux rates (VM) for the active transport were within a narrow range for both transporters, except for OH-DOX and OH-DNR, which had a lower VM in the case of MRP-mediated transport, suggesting a role of the amino group in the interaction with glutathione.  Detn. of the Hill coeff. (nH) of the MRP-mediated efflux gave most values close to 2, which suggests cooperativity of the transport of anthracyclines as reported before for Pgp.  In conclusion, the transport kinetics of anthracyclines by MRP and Pgp are very similar.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIQ9bO-zQ2PbVg90H21EOLACvtfcHk0lh4uDsgrBTWSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXot1ahsA%253D%253D&md5=03cb5fa3d6cea541228cbdefc5d942fa</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fmol.53.1.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.53.1.141%26sid%3Dliteratum%253Aachs%26aulast%3DMarbeuf-Gueye%26aufirst%3DC.%26aulast%3DBroxterman%26aufirst%3DH.%2BJ.%26aulast%3DDubru%26aufirst%3DF.%26aulast%3DPriebe%26aufirst%3DW.%26aulast%3DGarnier-Suillerot%26aufirst%3DA.%26atitle%3DKinetics%2520of%2520anthracycline%2520efflux%2520from%2520multidrug%2520resistance%2520protein-expressing%2520cancer%2520cells%2520compared%2520with%2520P-glycoprotein-expressing%2520cancer%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D53%26issue%3D1%26spage%3D141%26epage%3D147%26doi%3D10.1124%2Fmol.53.1.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8947</span>– <span class="NLM_lpage">8980</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01202</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01202" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8947-8980&issue=20&author=W.+Huauthor=X.+S.+Huangauthor=J.+F.+Wuauthor=L.+Yangauthor=Y.+T.+Zhengauthor=Y.+M.+Shenauthor=Z.+Y.+Liauthor=X.+Li&title=Discovery+of+novel+topoisomerase+II+inhibitors+by+medicinal+chemistry+approaches&doi=10.1021%2Facs.jmedchem.7b01202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches</span></div><div class="casAuthors">Hu, Wei; Huang, Xu-Sheng; Wu, Ji-Feng; Yang, Liang; Zheng, Yong-Tang; Shen, Yue-Mao; Li, Zhi-Yu; Li, Xun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8947-8980</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA topoisomerase II (topo II) is an important enzyme involved in DNA replication, recombination, and repair.  Despite the popular applications of topo II inhibitors in cancer therapy, there is still an urgent need to upgrade topo II inhibitors to cope with drug resistance and severe adverse effects.  Accordingly, novel topo II catalytic or multitarget topo II inhibitors are gaining more attention and make it possible to ease the toxic limitations of topo II poisons.  In this review, medicinal chem. approaches are mainly discussed toward the development of potent topo II inhibitors with low toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWv9JERcv7XbVg90H21EOLACvtfcHk0lh4uDsgrBTWSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsL3P&md5=51468c5ca4b8fd437760567e78e1d393</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01202%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BF.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DY.%2BT.%26aulast%3DShen%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DZ.%2BY.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520topoisomerase%2520II%2520inhibitors%2520by%2520medicinal%2520chemistry%2520approaches%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D20%26spage%3D8947%26epage%3D8980%26doi%3D10.1021%2Facs.jmedchem.7b01202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hevener, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutat, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggsbee, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, J. W.</span></span> <span> </span><span class="NLM_article-title">Recent developments in topoisomerase-targeted cancer chemotherapy</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">844</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2018.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.apsb.2018.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30505655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslSmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=844-861&issue=6&author=K.+Hevenerauthor=T.+A.+Verstakauthor=K.+E.+Lutatauthor=D.+L.+Riggsbeeauthor=J.+W.+Mooney&title=Recent+developments+in+topoisomerase-targeted+cancer+chemotherapy&doi=10.1016%2Fj.apsb.2018.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in topoisomerase-targeted cancer chemotherapy</span></div><div class="casAuthors">Hevener KirkE; Verstak Tatsiana A; Lutat Katie E; Riggsbee Daniel L; Mooney Jeremiah W</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">844-861</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The DNA topoisomerase enzymes are essential to cell function and are found ubiquitously in all domains of life.  The various topoisomerase enzymes perform a wide range of functions related to the maintenance of DNA topology during DNA replication, and transcription are the targets of a wide range of antimicrobial and cancer chemotherapeutic agents.  Natural product-derived agents, such as the camptothecin, anthracycline, and podophyllotoxin drugs, have seen broad use in the treatment of many types of cancer.  Selective targeting of the topoisomerase enzymes for cancer treatment continues to be a highly active area of basic and clinical research.  The focus of this review will be to summarize the current state of the art with respect to clinically used topoisomerase inhibitors for targeted cancer treatment and to discuss the pharmacology and chemistry of promising new topoisomerase inhibitors in clinical and pre-clinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ912zKLJkkBxwLZxei1HN8fW6udTcc2eZD5FmflktQlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslSmsw%253D%253D&md5=419d4b19bd7d1343db55e1bef20ec11b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2018.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2018.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DHevener%26aufirst%3DK.%26aulast%3DVerstak%26aufirst%3DT.%2BA.%26aulast%3DLutat%26aufirst%3DK.%2BE.%26aulast%3DRiggsbee%26aufirst%3DD.%2BL.%26aulast%3DMooney%26aufirst%3DJ.%2BW.%26atitle%3DRecent%2520developments%2520in%2520topoisomerase-targeted%2520cancer%2520chemotherapy%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2018%26volume%3D8%26issue%3D6%26spage%3D844%26epage%3D861%26doi%3D10.1016%2Fj.apsb.2018.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelcnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.2174/092986713804999402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F092986713804999402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23210851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Sqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=694-709&issue=5&author=B.+Pogorelcnikauthor=A.+Perdihauthor=T.+Solmajer&title=Recent+advances+in+the+development+of+catalytic+inhibitors+of+human+DNA+topoisomerase+II%CE%B1+as+novel+anticancer+agents&doi=10.2174%2F092986713804999402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents</span></div><div class="casAuthors">Pogorelcnik, B.; Perdih, A.; Solmajer, T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">694-709</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases comprise an important family of enzymes that catalyze the induction of topol. changes (e.g. relaxation/supercoiling, catenation/decatenation and knotting/unknotting) in the DNA mol.  These enzymes perform their functions by creating transient either single-stranded or double-stranded breaks in the DNA mol.  Due to their ability to modulate the topol. of the DNA mol., DNA topoisomerases play vital roles in replication, transcription, chromosome sepn. and segregation, and thus represent an important collection of design targets for novel anticancer drugs.  The aim of this review is to provide an overview of the development of catalytic inhibitors of the human topoisomerase IIα enzyme - an important member of the DNA topoisomerase family - as potential novel anticancer agents.  The group of catalytic topoII inhibitors is classified into four types according to their mol. mechanism of action: inhibitors that bind to the ATP binding site, inhibitors that prevent the ATP hydrolysis step and trap the enzyme in a closed clamp, inhibitors that block the DNA cleavage and inhibitors that prevent the enzyme binding to the DNA.  One of the important considerations highlighted throughout this review is the structure-based perspective of inhibitor design, giving the reader a medicinal chemist's perspective on this vibrant and active field of drug design research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAlJEjtNBzFLVg90H21EOLACvtfcHk0liCG1L9TocQCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Sqtbg%253D&md5=b9ddc44bde368e46089477089ef67dc6</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F092986713804999402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986713804999402%26sid%3Dliteratum%253Aachs%26aulast%3DPogorelcnik%26aufirst%3DB.%26aulast%3DPerdih%26aufirst%3DA.%26aulast%3DSolmajer%26aufirst%3DT.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520catalytic%2520inhibitors%2520of%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520as%2520novel%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D5%26spage%3D694%26epage%3D709%26doi%3D10.2174%2F092986713804999402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendorff, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">Resveratrol: A novel type of topoisomerase II inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span> (<span class="NLM_issue">51</span>),  <span class="NLM_fpage">21011</span>– <span class="NLM_lpage">21022</span>, <span class="refDoi"> DOI: 10.1074/jbc.M117.810580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.M117.810580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29074616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVejsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=21011-21022&issue=51&author=J.+H.+Leeauthor=T.+J.+Wendorffauthor=J.+M.+Berger&title=Resveratrol%3A+A+novel+type+of+topoisomerase+II+inhibitor&doi=10.1074%2Fjbc.M117.810580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol: A novel type of topoisomerase II inhibitor</span></div><div class="casAuthors">Lee, Joyce H.; Wendorff, Timothy J.; Berger, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">21011-21022</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Resveratrol, a polyphenol found in various plant sources, has gained attention as a possible agent responsible for the purported health benefits of certain foods, such as red wine.  Despite annual multi-million dollar market sales as a nutriceutical, there is little consensus about the physiol. roles of resveratrol.  One suggested mol. target of resveratrol is eukaryotic topoisomerase II (topo II), an enzyme essential for chromosome segregation and DNA supercoiling homeostasis.  Interestingly, resveratrol is chem. similar to ICRF-187, a clin. approved chemotherapeutic that stabilizes an ATP-dependent dimerization interface in topo II to block enzyme activity.  Based on this similarity, we hypothesized that resveratrol may antagonize topo II by a similar mechanism.  Using a variety of biochem. assays, we find that resveratrol indeed acts through the ICRF-187 binding locus, but that it inhibits topo II by preventing ATPase domain dimerization rather than stabilizing it.  This work presents the first comprehensive anal. of the biochem. effects of both ICRF-187 and resveratrol on the human isoforms of topo II, and reveals a new mode for the allosteric regulation of topo II through modulation of ATPase status.  Natural polyphenols related to resveratrol that have been shown to impact topo II function may operate in a similar manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnhiw4uOND1bVg90H21EOLACvtfcHk0liCG1L9TocQCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVejsbjK&md5=a33eb2b6b11da6eea8de109455b7e851</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.810580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.810580%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DWendorff%26aufirst%3DT.%2BJ.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DResveratrol%253A%2520A%2520novel%2520type%2520of%2520topoisomerase%2520II%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26issue%3D51%26spage%3D21011%26epage%3D21022%26doi%3D10.1074%2Fjbc.M117.810580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 2-phenylnaphthalenoids and 2-phenylbenzofuranoids as DNA topoisomerase inhibitors and antitumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.07.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2015.07.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26291037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=277-287&author=H.+Haoauthor=W.+Chenauthor=J.+Zhuauthor=C.+Luauthor=Y.+Shen&title=Design+and+synthesis+of+2-phenylnaphthalenoids+and+2-phenylbenzofuranoids+as+DNA+topoisomerase+inhibitors+and+antitumor+agents&doi=10.1016%2Fj.ejmech.2015.07.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of 2-phenylnaphthalenoids and 2-phenylbenzofuranoids as DNA topoisomerase inhibitors and antitumor agents</span></div><div class="casAuthors">Hao, Huilin; Chen, Wang; Zhu, Jing; Lu, Chunhua; Shen, Yuemao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277-287</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eight 2-phenylnaphthalenoids (2PNs) and twenty four 2-phenylbenzofuranoids (2PBFs) were successfully designed, synthesized and their antiproliferative and in vitro DNA topoisomerase inhibitory activities were evaluated.  Nine compds. (four 2PNs and five 2PBFs) showed either TopoI or TopoIIα inhibitory activities.  Six compds. (four 2PNs and two 2PBFs) exhibited potent cytotoxicity with IC50 values for 72 h exposure ranging from 0.3 to above 20 μM against MDA-MB-231, MDA-MB-435, HepG2 and PC3 cell lines.  The two 2PBFs displayed comparable and even better antiproliferative as well as TopoIIα inhibitory activities than 2PNs.  Interestingly, the active 2PBFs displayed different mechanisms of TopoIIα inhibition from that of 2PNs, suggesting that the chromophore scaffold replacement may result in a change of the binding site of inhibitors to TopoIIα.  Furthermore, the mechanisms of antiproliferation on MDA-MB-231 cells indicate that compds. I and II are promising for further development of anticancer agents.  The results of this study reveal that the evolutionary strategy of medicinal chem. through scaffold hopping is a promising strategy for structure optimization of TopoIIα inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptY9xrEHooKbVg90H21EOLACvtfcHk0liY_AvK6n4GNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegtb%252FO&md5=1ab3a31789c3ac2b7d632d379bb48992</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.07.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.07.048%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DDesign%2520and%2520synthesis%2520of%25202-phenylnaphthalenoids%2520and%25202-phenylbenzofuranoids%2520as%2520DNA%2520topoisomerase%2520inhibitors%2520and%2520antitumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D102%26spage%3D277%26epage%3D287%26doi%3D10.1016%2Fj.ejmech.2015.07.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandele, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Bioflavonoids as poisons of human topoisomerase Iiα and IIβ</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6097</span>– <span class="NLM_lpage">6108</span>, <span class="refDoi"> DOI: 10.1021/bi7000664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi7000664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXks1Sis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=6097-6108&issue=20&author=O.+J.+Bandeleauthor=N.+Osheroff&title=Bioflavonoids+as+poisons+of+human+topoisomerase+Ii%CE%B1+and+II%CE%B2&doi=10.1021%2Fbi7000664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bioflavonoids as Poisons of Human Topoisomerase IIα and IIβ</span></div><div class="casAuthors">Bandele, Omari J.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6097-6108</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bioflavonoids are human dietary components that have been linked to the prevention of cancer in adults and the generation of specific types of leukemia in infants.  While these compds. have a broad range of cellular activities, many of their genotoxic effects have been attributed to their actions as topoisomerase II poisons.  However, the activities of bioflavonoids against the individual isoforms of human topoisomerase II have not been analyzed.  Therefore, we characterized the activity and mechanism of action of three major classes of bioflavonoids, flavones, flavonols, and isoflavones, against human topoisomerase IIα and IIβ.  Genistein was the most active bioflavonoid tested and stimulated enzyme-mediated DNA cleavage ∼10-fold.  Generally, compds. were more active against topoisomerase IIβ.  DNA cleavage with both enzyme isoforms required a 5-OH and a 4'-OH and was enhanced by the presence of addnl. hydroxyl groups on the pendant ring.  Competition DNA cleavage and topoisomerase II binding studies indicate that the 5-OH group plays an important role in mediating genistein binding, while the 4'-OH moiety contributes primarily to bioflavonoid function.  Bioflavonoids do not require redox cycling for activity and function primarily by inhibiting enzyme-mediated DNA ligation.  Mutagenesis studies suggest that the TOPRIM region of topoisomerase II plays a role in genistein binding.  Finally, flavones, flavonols, and isoflavones with activity against purified topoisomerase IIα and IIβ enhanced DNA cleavage by both isoforms in human CEM leukemia cells.  These data support the hypothesis that bioflavonoids function as topoisomerase II poisons in humans and provide a framework for further anal. of these important dietary components.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqBsFnYVVe7rVg90H21EOLACvtfcHk0liY_AvK6n4GNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXks1Sis7g%253D&md5=698b3f68a5a8e4ed0010227ee2a5d097</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fbi7000664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi7000664%26sid%3Dliteratum%253Aachs%26aulast%3DBandele%26aufirst%3DO.%2BJ.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DBioflavonoids%2520as%2520poisons%2520of%2520human%2520topoisomerase%2520Ii%25CE%25B1%2520and%2520II%25CE%25B2%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26issue%3D20%26spage%3D6097%26epage%3D6108%26doi%3D10.1021%2Fbi7000664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2019.03.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30917303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVClsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2019&pages=129-168&author=X.+Liangauthor=Q.+Wuauthor=S.+Luanauthor=Z.+Yinauthor=C.+Heauthor=L.+Yinauthor=Y.+Zouauthor=Z.+Yuanauthor=L.+Liauthor=X.+Songauthor=M.+Heauthor=C.+Lvauthor=W.+Zhang&title=A+comprehensive+review+of+topoisomerase+inhibitors+as+anticancer+agents+in+the+past+decade&doi=10.1016%2Fj.ejmech.2019.03.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade</span></div><div class="casAuthors">Liang, Xiaoxia; Wu, Qiang; Luan, Shangxian; Yin, Zhongqiong; He, Changliang; Yin, Lizi; Zou, Yuanfeng; Yuan, Zhixiang; Li, Lixia; Song, Xu; He, Min; Lv, Cheng; Zhang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-168</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The topoisomerase enzymes play an important role in DNA metab., and searching for enzyme inhibitors is an important target in the search for new anticancer drugs.  Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research.  Therefore, biologists, org. chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive mols. targeting topoisomerase.  This review summarizes types of topoisomerase inhibitors in the past decade, and divides them into nine classes by structural characteristics, including N-heterocycles compds., quinone derivs., flavonoids derivs., coumarin derivs., lignan derivs., polyphenol derivs., diterpenes derivs., fatty acids derivs., and metal complexes.  Then we discussed the application prospect and development of these anticancer compds., as well as concluded parts of their structural-activity relationships.  We believe this review would be invaluable in helping to further search potential topoisomerase inhibition as antitumor agent in clin. usage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYAU-SIaKdi7Vg90H21EOLACvtfcHk0liY_AvK6n4GNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVClsr8%253D&md5=797d805869cfd92fce346c4bd076ea92</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DLuan%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLv%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DA%2520comprehensive%2520review%2520of%2520topoisomerase%2520inhibitors%2520as%2520anticancer%2520agents%2520in%2520the%2520past%2520decade%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D171%26spage%3D129%26epage%3D168%26doi%3D10.1016%2Fj.ejmech.2019.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meignan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couderc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narducci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruczynski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilbaud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annereau, J. P.</span></span> <span> </span><span class="NLM_article-title">F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2015.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.canlet.2015.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26404751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGhtrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2016&pages=10-18&issue=1&author=B.+Thibaultauthor=E.+Clementauthor=G.+Zorzaauthor=S.+Meignanauthor=J.+P.+Delordauthor=B.+Coudercauthor=C.+Baillyauthor=F.+Narducciauthor=I.+Vandenbergheauthor=A.+Kruczynskiauthor=N.+Guilbaudauthor=P.+Ferreauthor=J.+P.+Annereau&title=F14512%2C+a+polyamine-vectorized+inhibitor+of+topoisomerase+II%2C+exhibits+a+marked+anti-tumor+activity+in+ovarian+cancer&doi=10.1016%2Fj.canlet.2015.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer</span></div><div class="casAuthors">Thibault, Benoit; Clement, Emily; Zorza, Gregoire; Meignan, Samuel; Delord, Jean-Pierre; Couderc, Bettina; Bailly, Christian; Narducci, Fabrice; Vandenberghe, Isabelle; Kruczynski, Anna; Guilbaud, Nicolas; Ferre, Pierre; Annereau, Jean-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Epithelial ovarian cancer is the fourth cause of death among cancer-bearing women and frequently assocd. with carboplatin resistance, underlining the need for more efficient and targeted therapies.  F14512 is an epipodophyllotoxin-core linked to a spermine chain which enters cells via the polyamine transport system (PTS).  Here, we investigate this novel concept of vectorization in ovarian cancer.  We compared the effects of etoposide and F14512 on a panel of five carboplatin-sensitive or resistant ovarian cancer models.  We assessed the incorporation of F17073, a spermine-linked fluorescent probe, in these cells and in 18 clin. samples.  We then showed that F14512 exhibits a high anti-proliferative and pro-apoptotic activity, particularly in cells with high levels of F17073 incorporation.  Consistently, F14512 significantly inhibited tumor growth compared to etoposide, in a cisplatin-resistant A2780R s.c. model, at a dose of 1.25 mg/kg.  In addn., ex vivo anal. indicated that 15 out of 18 patients presented a higher F17073 incorporation into tumor cells compared to normal cells.  Overall, our data suggest that F14512, a targeted drug with a potent antitumor efficacy, constitutes a potential new therapy for highly PTS-pos. and platinum-resistant ovarian cancer-bearing patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGThk1B2FIprVg90H21EOLACvtfcHk0liY_AvK6n4GNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGhtrjK&md5=e7f45567d11507656d904a45396d1eae</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2015.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2015.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DThibault%26aufirst%3DB.%26aulast%3DClement%26aufirst%3DE.%26aulast%3DZorza%26aufirst%3DG.%26aulast%3DMeignan%26aufirst%3DS.%26aulast%3DDelord%26aufirst%3DJ.%2BP.%26aulast%3DCouderc%26aufirst%3DB.%26aulast%3DBailly%26aufirst%3DC.%26aulast%3DNarducci%26aufirst%3DF.%26aulast%3DVandenberghe%26aufirst%3DI.%26aulast%3DKruczynski%26aufirst%3DA.%26aulast%3DGuilbaud%26aufirst%3DN.%26aulast%3DFerre%26aufirst%3DP.%26aulast%3DAnnereau%26aufirst%3DJ.%2BP.%26atitle%3DF14512%252C%2520a%2520polyamine-vectorized%2520inhibitor%2520of%2520topoisomerase%2520II%252C%2520exhibits%2520a%2520marked%2520anti-tumor%2520activity%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D370%26issue%3D1%26spage%3D10%26epage%3D18%26doi%3D10.1016%2Fj.canlet.2015.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antolin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in Precision Oncology: Current Applications and Future Prospects</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">6935</span>– <span class="NLM_lpage">6945</span>, <span class="refDoi"> DOI: 10.2174/1381612822666160923115828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1381612822666160923115828" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=6935-6945&issue=46&author=A.+A.+Antolinauthor=P.+Workmanauthor=J.+Mestresauthor=B.+Al-Lazikani&title=Polypharmacology+in+Precision+Oncology%3A+Current+Applications+and+Future+Prospects&doi=10.2174%2F1381612822666160923115828"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F1381612822666160923115828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612822666160923115828%26sid%3Dliteratum%253Aachs%26aulast%3DAntolin%26aufirst%3DA.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26atitle%3DPolypharmacology%2520in%2520Precision%2520Oncology%253A%2520Current%2520Applications%2520and%2520Future%2520Prospects%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2017%26volume%3D22%26issue%3D46%26spage%3D6935%26epage%3D6945%26doi%3D10.2174%2F1381612822666160923115828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: drug discovery for the future</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1586/ecp.12.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-7&issue=1&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+drug+discovery+for+the+future&doi=10.1586%2Fecp.12.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lhtdAe5way_2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520drug%2520discovery%2520for%2520the%2520future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26issue%3D1%26spage%3D41%26epage%3D7%26doi%3D10.1586%2Fecp.12.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Proposal of dual inhibitor targeting ATPase domains of topoisomerase II and heat shock protein 90</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2016.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.4062%2Fbiomolther.2016.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFSq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=453-468&issue=5&author=K.+Y.+Junauthor=Y.+Kwon&title=Proposal+of+dual+inhibitor+targeting+ATPase+domains+of+topoisomerase+II+and+heat+shock+protein+90&doi=10.4062%2Fbiomolther.2016.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Proposal of dual inhibitor targeting ATPase domains of topoisomerase II and heat shock protein 90</span></div><div class="casAuthors">Jun, Kyu-Yeon; Kwon, Youngjoo</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">453-468</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">There is a conserved ATPase domain in topoisomerase II (topo II) and heat shock protein 90 (Hsp90) which belong to the GHKL (gyrase, Hsp90, histidine kinase, and MutL) family.  The inhibitors that target each of topo II and Hsp90 are intensively studied as anti-cancer drugs since they play very important roles in cell proliferation and survival.  Therefore the development of dual targeting anti-cancer drugs for topo II and Hsp90 is suggested to be a promising area.  The topo II and Hsp90 inhibitors, known to bind to their ATP binding site, were searched.  All the inhibitors investigated were docked to both topo II and Hsp90.  Four candidate compds. as possible dual inhibitors were selected by analyzing the mol. docking study.  The pharmacophore model of dual inhibitors for topo II and Hsp90 were generated and the design of novel dual inhibitor was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtymxVS4DsqrVg90H21EOLACvtfcHk0lhtdAe5way_2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFSq&md5=2fa259235646cfa6ad8738fb5d48bafc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2016.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2016.168%26sid%3Dliteratum%253Aachs%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DProposal%2520of%2520dual%2520inhibitor%2520targeting%2520ATPase%2520domains%2520of%2520topoisomerase%2520II%2520and%2520heat%2520shock%2520protein%252090%26jtitle%3DBiomol.%2520Ther.%26date%3D2016%26volume%3D24%26issue%3D5%26spage%3D453%26epage%3D468%26doi%3D10.4062%2Fbiomolther.2016.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valkov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gump, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase interacts directly with DNA topoisomerase II</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1038/81671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2F81671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11062478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotVWhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2000&pages=349-353&issue=3&author=S.+C.+Tsaiauthor=N.+Valkovauthor=W.+M.+Yangauthor=J.+Gumpauthor=D.+Sullivanauthor=E.+Seto&title=Histone+deacetylase+interacts+directly+with+DNA+topoisomerase+II&doi=10.1038%2F81671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase interacts directly with DNA topoisomerase II</span></div><div class="casAuthors">Tsai, Shih-Chang; Valkov, Nikola; Yang, Wen-Ming; Gump, Jana; Sullivan, Daniel; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-353</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) modify nucleosomal histones, have a key role in the regulation of gene transcription, and may be involved in cell-cycle regulation, differentiation and human cancer.  Purified recombinant human HDAC1 protein was used to screen a cDNA expression library, and one of the clones identified encoded DNA topoisomerase II (Topo II), an enzyme known to have a role in transcriptional regulation and chromatin organization.  Coimmunopptn. expts. indicate that HDAC1 and HDAC2 are assocd. with Topo II in vivo under normal physiol. conditions.  Complexes contg. Topo II possess HDAC activities, and complexes contg. HDAC1 or HDAC2 possess Topo II activities.  HDAC and Topo II modify each other's activity in vitro and in vivo.  Our results indicate the existence of a functionally coupled complex between these two enzymes and offer insights into the potential mechanisms of action of both enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEYt2puIf_1rVg90H21EOLACvtfcHk0lhtdAe5way_2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotVWhsbY%253D&md5=9adf7bd4fc5527b248b48833e5772d72</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2F81671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F81671%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DS.%2BC.%26aulast%3DValkov%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DW.%2BM.%26aulast%3DGump%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHistone%2520deacetylase%2520interacts%2520directly%2520with%2520DNA%2520topoisomerase%2520II%26jtitle%3DNat.%2520Genet.%26date%3D2000%26volume%3D26%26issue%3D3%26spage%3D349%26epage%3D353%26doi%3D10.1038%2F81671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title"><i>In-vivo</i> synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">2000</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-05-0194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=16373714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCnsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1993-2000&issue=12&author=D.+C.+Marchionauthor=E.+Bicakuauthor=A.+I.+Daudauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=In-vivo+synergy+between+topoisomerase+II+and+histone+deacetylase+inhibitors%3A+predictive+correlates&doi=10.1158%2F1535-7163.MCT-05-0194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Daud, Adil I.; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1993-2000</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) are a promising class of anticancer agents, yet the specific biol. effects resulting in cell death are still poorly understood and clin. relevant markers of response are not adequately defined.  The anticonvulsant valproic acid has recently emerged as an HDACi, and in vitro studies suggested that valproic acid may potentiate cytotoxic agents.  We evaluated the pharmacol. and biol. effects of valproic acid on histone acetylation, chromatin structure, and DNA damage induced by topoisomerase II inhibitors in mice bearing breast cancer tumors and developed an ex vivo methodol. for response prediction using comet assays.  The exposure of mice to valproic acid before exposure to epirubicin led to tumor regression when valproic acid was given for 48 h at concns. sufficient for histone hyperacetylation, down-regulation of heterochromatin maintenance proteins, and chromatin decondensation.  Tumor response was accurately predicted by ex vivo comet moments.  Valproic acid did not exacerbate epirubicin-related toxicity.  Antitumor effects were not obsd. with valproic acid alone despite biol. active valproic acid concns.  These findings suggest that exposure of tumor-bearing mice to valproic acid potentiated the antitumor effects of topoisomerase II inhibitors without enhancing toxicity.  The HDACi-induced histone acetylation and modulation of heterochromatin correlated with potentiation of epirubicin-mediated DNA damage.  However, these effects did not result in antitumor activity when using a HDACi alone and hence should not be considered a surrogate marker.  Ex vivo comet assays may be useful as a predictive tool when tumor cells are limited and serial biopsies are difficult to obtain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr22AJiKgejK7Vg90H21EOLACvtfcHk0lirfER5LiNQcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCnsrjP&md5=0598f67f024ed153636a4244fbf38b3e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0194%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DIn-vivo%2520synergy%2520between%2520topoisomerase%2520II%2520and%2520histone%2520deacetylase%2520inhibitors%253A%2520predictive%2520correlates%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26issue%3D12%26spage%3D1993%26epage%3D2000%26doi%3D10.1158%2F1535-7163.MCT-05-0194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Fragments, network biology and designing multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.drudis.2006.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17275736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&issue=3%E2%80%934&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+network+biology+and+designing+multiple+ligands&doi=10.1016%2Fj.drudis.2006.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Fragments, network biology and designing multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3&4</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Modulating multiple protein targets simultaneously can be beneficial for treating complex diseases.  The redundancy that exists within biol. networks means that modulating single proteins might not be sufficient to produce the desired efficacy while, at the same time, minimizing adverse effects.  Designing multi-target drugs can be challenging for medicinal chemists, with current lead-discovery strategies often producing large, complex mols. with low ligand efficiency and poor oral bioavailability.  Paradoxically, analyses of the relationship between the selectivity of biol. active compds. and their mol. size suggest that promiscuous compds. should typically be smaller than target-selective compds.  A fragment-based approach to multi-target drug discovery could lead to a new generation of compds. with improved physicochem. and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRYwI33BCNLVg90H21EOLACvtfcHk0lirfER5LiNQcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D&md5=64a3c7e8c3280db166dda799a77d689a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520network%2520biology%2520and%2520designing%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D3%25E2%2580%25934%26spage%3D156%26epage%3D160%26doi%3D10.1016%2Fj.drudis.2006.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&issue=21&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lirfER5LiNQcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D21%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleason-Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, L. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1021/jm0203377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0203377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtlCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=571-583&issue=4&author=M.+Y.+Kimauthor=W.+Duanauthor=M.+Gleason-Guzmanauthor=L.+H.+Hurley&title=Design%2C+synthesis%2C+and+biological+evaluation+of+a+series+of+fluoroquinoanthroxazines+with+contrasting+dual+mechanisms+of+action+against+topoisomerase+II+and+G-quadruplexes&doi=10.1021%2Fjm0203377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of a Series of Fluoroquinoanthroxazines with Contrasting Dual Mechanisms of Action against Topoisomerase II and G-Quadruplexes</span></div><div class="casAuthors">Kim, Mu-Yong; Duan, Wenhu; Gleason-Guzman, Mary; Hurley, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Topoisomerase inhibitors are important and clin. effective drugs, while G-quadruplex-interactive compds. that disrupt telomere maintenance mechanisms have yet to be proven useful in the clinic.  If G-quadruplex-interactive compds. are to be clin. useful, it will most likely be in combination with more established cytotoxic agents.  A family of topoisomerase II inhibitors that also interact with G-quadruplexes was previously reported.  On the basis of previously established structure-activity relationships (SARs) for compds. that are able to inhibit topoisomerase II or interact with G-quadruplex to varying degrees, four new fluoroquinoanthroxazines (FQAs)with different profiles of mixed topoisomerase II poisoning effects and G-quadruplex interactions were designed and synthesized.  The biol. profiles of the four new compds. were detd. with respect to G-quadruplex interaction (polymerase stop and photocleavage assays) and topoisomerase II interaction (DNA cleavage and kDNA decatenation assays), alongside cytotoxicity tests with matched pairs of topoisomerase II-resistant and topoisomerase II-sensitive cells and with telomerase (+) and ALT (+) cell lines (ALT = alternative lengthening of telomeres).  From this study, two FQAs with sharply contrasting profiles of potent G-quadruplex interaction with a weak topoisomerase II poisoning effect, and vice versa, were identified for further evaluation to det. the optimum combination of these activities in subsequent in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZIPiN4rdFWrVg90H21EOLACvtfcHk0lhXuDGfRmgzCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtlCmuw%253D%253D&md5=47eb857b7c1fe9981e1743f4a0d59474</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm0203377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0203377%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BY.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DGleason-Guzman%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DL.%2BH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520fluoroquinoanthroxazines%2520with%2520contrasting%2520dual%2520mechanisms%2520of%2520action%2520against%2520topoisomerase%2520II%2520and%2520G-quadruplexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D4%26spage%3D571%26epage%3D583%26doi%3D10.1021%2Fjm0203377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruthenburg, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechis, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdine, G. L.</span></span> <span> </span><span class="NLM_article-title">Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">37041</span>– <span class="NLM_lpage">37047</span>, <span class="refDoi"> DOI: 10.1074/jbc.M506520200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.M506520200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=16100112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKhtLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=37041-37047&issue=44&author=H.+Weiauthor=A.+J.+Ruthenburgauthor=S.+K.+Bechisauthor=G.+L.+Verdine&title=Nucleotide-dependent+domain+movement+in+the+ATPase+domain+of+a+human+type+IIA+DNA+topoisomerase&doi=10.1074%2Fjbc.M506520200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleotide-dependent Domain Movement in the ATPase Domain of a Human Type IIA DNA Topoisomerase</span></div><div class="casAuthors">Wei, Hua; Ruthenburg, Alexander J.; Bechis, Seth K.; Verdine, Gregory L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37041-37047</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Type IIA DNA topoisomerases play multiple essential roles in the management of higher-order DNA structure, including modulation of topol. state, chromosome segregation, and chromatin condensation.  These diverse physiol. functions are all accomplished through a common mol. mechanism, wherein the protein catalyzes transient cleavage of a DNA duplex (the G-segment) to yield a double-stranded gap through which another duplex (the T-segment) is passed.  The overall process is orchestrated by the opening and closing of mol. "gates" in the topoisomerase structure, which is regulated by ATP binding, hydrolysis, and release of ADP and inorg. phosphate.  Here, we present two crystal structures of the ATPase domain of human DNA topoisomerase IIα in different nucleotide-bound states.  Comparison of these structures revealed rigid-body movement of the structural modules within the ATPase domain, suggestive of the motions of a mol. gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp657jcFw3OM7Vg90H21EOLACvtfcHk0lhXuDGfRmgzCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKhtLrO&md5=e2672f1ac3605c57f10031edcd5c4584</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M506520200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M506520200%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DH.%26aulast%3DRuthenburg%26aufirst%3DA.%2BJ.%26aulast%3DBechis%26aufirst%3DS.%2BK.%26aulast%3DVerdine%26aufirst%3DG.%2BL.%26atitle%3DNucleotide-dependent%2520domain%2520movement%2520in%2520the%2520ATPase%2520domain%2520of%2520a%2520human%2520type%2520IIA%2520DNA%2520topoisomerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26issue%3D44%26spage%3D37041%26epage%3D37047%26doi%3D10.1074%2Fjbc.M506520200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kesharwani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, K.</span></span> <span> </span><span class="NLM_article-title">Computational study of curcumin analogues by targeting DNA topoisomerase II: a structure-based drug designing approach</span>. <i>Network Modeling and Analysis in Health Informatics and Bioinformatics Journal</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15</span>, <span class="refDoi"> DOI: 10.1007/s13721-018-0179-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs13721-018-0179-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=15&author=R.+Kesharwaniauthor=D.+B.+Singhauthor=D.+V.+Singhauthor=K.+Misra&title=Computational+study+of+curcumin+analogues+by+targeting+DNA+topoisomerase+II%3A+a+structure-based+drug+designing+approach&doi=10.1007%2Fs13721-018-0179-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs13721-018-0179-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13721-018-0179-8%26sid%3Dliteratum%253Aachs%26aulast%3DKesharwani%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DD.%2BB.%26aulast%3DSingh%26aufirst%3DD.%2BV.%26aulast%3DMisra%26aufirst%3DK.%26atitle%3DComputational%2520study%2520of%2520curcumin%2520analogues%2520by%2520targeting%2520DNA%2520topoisomerase%2520II%253A%2520a%2520structure-based%2520drug%2520designing%2520approach%26jtitle%3DNetwork%2520Modeling%2520and%2520Analysis%2520in%2520Health%2520Informatics%2520and%2520Bioinformatics%2520Journal%26date%3D2018%26volume%3D7%26spage%3D15%26doi%3D10.1007%2Fs13721-018-0179-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janezic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelcnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brvar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span> <span> </span><span class="NLM_article-title">3-substituted-1<i>H</i>-indazoles as catalytic inhibitors of the human DNA topoisomerase IIα</span>. <i>ChemistrySelect.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1002/slct.201601554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fslct.201601554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=480-488&issue=1&author=M.+Janezicauthor=B.+Pogorelcnikauthor=M.+Brvarauthor=T.+Solmajerauthor=A.+Perdih&title=3-substituted-1H-indazoles+as+catalytic+inhibitors+of+the+human+DNA+topoisomerase+II%CE%B1&doi=10.1002%2Fslct.201601554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">3-substituted-1H-indazoles as Catalytic Inhibitors of the Human DNA Topoisomerase IIα</span></div><div class="casAuthors">Janezic, Matej; Pogorelcnik, Barbara; Brvar, Matjaz; Solmajer, Tom; Perdih, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">480-488</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Catalytic inhibitors represent an attractive possibility of revisiting the established anticancer target human DNA topoisomerase IIα, taking advantage of the many different inhibition steps in its catalytic cycle.  In this study we present our efforts to expand the chem. space of inhibitors of the human DNA topoisomerase IIα with a combination of in silico and in vitro methods.  Using our previously reported compds. as a base, we constructed a ligand-based pharmacophore and conducted a virtual screening campaign.  This led to the discovery of 1H-indazole inhibitors for which the SAR data was subsequently expanded.  Addnl., several in vitro methods; cleavage assay, competitive cleavage assay, ATPase assay and microscale thermophoresis (MST) binding studies were employed to study the inhibitory mechanism, and it was confirmed that our compds. are catalytic inhibitors that bind to the ATPase domain.  IC50 values were in the lower micromolar range with multiple compds. showing stronger inhibitory activity than the established topoisomerase poison etoposide.  Using in silico methods we proposed a binding mode and evaluated it using mol. dynamics simulation. 1H-indazoles represent a new versatile scaffold that could be utilized for further development of catalytic inhibitors of the human DNA topoisomerase IIα targetting the ATPase domain where ATP binding site is located.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRrDGdQEJKqbVg90H21EOLACvtfcHk0lheOkif38ghKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wkurs%253D&md5=e891fafff30d2c7a80e12e1422cf171c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fslct.201601554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201601554%26sid%3Dliteratum%253Aachs%26aulast%3DJanezic%26aufirst%3DM.%26aulast%3DPogorelcnik%26aufirst%3DB.%26aulast%3DBrvar%26aufirst%3DM.%26aulast%3DSolmajer%26aufirst%3DT.%26aulast%3DPerdih%26aufirst%3DA.%26atitle%3D3-substituted-1H-indazoles%2520as%2520catalytic%2520inhibitors%2520of%2520the%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DChemistrySelect.%26date%3D2017%26volume%3D2%26issue%3D1%26spage%3D480%26epage%3D488%26doi%3D10.1002%2Fslct.201601554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahisuddin</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, cytotoxicity, huTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2016.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bioorg.2016.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=27744115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=77-90&author=R.+Alamauthor=D.+Wahiauthor=R.+Singhauthor=D.+Sinhaauthor=V.+Tandonauthor=A.+Groverauthor=+Rahisuddin&title=Design%2C+synthesis%2C+cytotoxicity%2C+huTopoII%CE%B1+inhibitory+activity+and+molecular+docking+studies+of+pyrazole+derivatives+as+potential+anticancer+agents&doi=10.1016%2Fj.bioorg.2016.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents</span></div><div class="casAuthors">Alam, Raquib; Wahi, Divya; Singh, Raja; Sinha, Devapriya; Tandon, Vibha; Grover, Abhinav; Rahisuddin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-90</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an attempt to find potential anticancer agents, a series of novel Et 4-(3-(aryl)-1-phenyl-1H-pyrazol-4-yl)-2-oxo-6-(pyridin-3-yl)cyclohex-3-enecarboxylates 5a-i and 5-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-3-(pyridin-3-yl)-4,5-dihydropyrazole-1-carbothioamides 6a-i were designed, synthesized and evaluated for their topoisomerase IIα inhibitory activity and in vitro cytotoxicity against a panel of cancerous cell lines (MCF-7, NCI-H460, HeLa) and a normal cell line (HEK-293T).  Mol. docking studies of all the synthesized compds. into the binding site of topoisomerase IIα protein (PDB ID: 1ZXM) were performed to gain a comprehensive understanding into plausible binding modes.  These compds. were also screened for in silico drug-likeliness properties on the basis of the absorption, distribution, metab. and excretion (ADME) prediction.  Among all the synthesized compds., analog 5d showed superior cytotoxicity with an IC50 value of 7.01 ± 0.60 μM for HeLa, 8.55 ± 0.35 μM for NCI-H460 and 14.31 ± 0.90 for MCF-7 cancer cell lines.  Further, compd. 5d showed 70.82% inhibition of topoisomerase IIα at a concn. of 100 μM with max. docking score of -8.24.  Results of ADME prediction revealed that most of these compds. showed in silico drug-likeliness properties within the ideal range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLxtbyj0NKn7Vg90H21EOLACvtfcHk0lheOkif38ghKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs7rP&md5=051350f7a9e61669e2421f8477010e3a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2016.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2016.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DWahi%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSinha%26aufirst%3DD.%26aulast%3DTandon%26aufirst%3DV.%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DRahisuddin%26atitle%3DDesign%252C%2520synthesis%252C%2520cytotoxicity%252C%2520huTopoII%25CE%25B1%2520inhibitory%2520activity%2520and%2520molecular%2520docking%2520studies%2520of%2520pyrazole%2520derivatives%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DBioorg.%2520Chem.%26date%3D2016%26volume%3D69%26spage%3D77%26epage%3D90%26doi%3D10.1016%2Fj.bioorg.2016.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. F.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, M. R.</span></span> <span> </span><span class="NLM_article-title">Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6278</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmcl.2008.09.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18929486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6273-6278&issue=23&author=P.+P.+Kungauthor=L.+Funkauthor=J.+Mengauthor=M.+Collinsauthor=J.+Z.+Zhouauthor=M.+C.+Johnsonauthor=A.+Ekkerauthor=J.+Wangauthor=P.+Mehtaauthor=M.+J.+Yinauthor=C.+Rodgersauthor=J.+F.+Daviesauthor=E.+Baymanauthor=T.+Smealauthor=K.+A.+Maegleyauthor=M.+R.+Gehring&title=Dihydroxylphenyl+amides+as+inhibitors+of+the+Hsp90+molecular+chaperone&doi=10.1016%2Fj.bmcl.2008.09.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone</span></div><div class="casAuthors">Kung, Pei-Pei; Funk, Lee; Meng, Jerry; Collins, Michael; Zhou, Joe Zhongxiang; Catherine Johnson, M.; Ekker, Anne; Wang, Jeff; Mehta, Pramod; Yin, Min-Jean; Rodgers, Caroline; Davies, Jay F., II; Bayman, Eileen; Smeal, Tod; Maegley, Karen A.; Gehring, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6273-6278</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Information from X-ray crystal structures were used to optimize the potency of a HTS hit in a Hsp90 competitive binding assay.  A class of novel and potent small mol. Hsp90 inhibitors were thereby identified.  Enantio-pure compds. I [n = 1, 2] were potent in PGA-based competitive binding assay and inhibited proliferation of various human cancer cell lines in vitro, with IC50 values averaging 20 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraBHD3PPbhDbVg90H21EOLACvtfcHk0ljwvMOlUs_w2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtrzE&md5=36eb69d7ffb65443bc5328f74806fa0b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.081%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%2BZ.%26aulast%3DJohnson%26aufirst%3DM.%2BC.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DM.%2BJ.%26aulast%3DRodgers%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DBayman%26aufirst%3DE.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DGehring%26aufirst%3DM.%2BR.%26atitle%3DDihydroxylphenyl%2520amides%2520as%2520inhibitors%2520of%2520the%2520Hsp90%2520molecular%2520chaperone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D23%26spage%3D6273%26epage%3D6278%26doi%3D10.1016%2Fj.bmcl.2008.09.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obermann, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, F. U.</span></span> <span> </span><span class="NLM_article-title"><i>In-vivo</i> function of Hsp90 is dependent on ATP binding and ATP hydrolysis</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>143</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">910</span>, <span class="refDoi"> DOI: 10.1083/jcb.143.4.901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1083%2Fjcb.143.4.901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9817749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVKhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=1998&pages=901-910&issue=4&author=W.+M.+Obermannauthor=H.+Sondermannauthor=A.+A.+Russoauthor=N.+P.+Pavletichauthor=F.+U.+Hartl&title=In-vivo+function+of+Hsp90+is+dependent+on+ATP+binding+and+ATP+hydrolysis&doi=10.1083%2Fjcb.143.4.901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis</span></div><div class="casAuthors">Obermann, Wolfgang M. J.; Sondermann, Holger; Russo, Alicia A.; Pavletich, Nikola P.; Hartl, F. Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">901-910</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90), an abundant mol. chaperone in the eukaryotic cytosol, is involved in the folding of a set of cell regulatory proteins and in the re-folding of stress-denatured polypeptides.  The basic mechanism of action of Hsp90 is not yet understood.  In particular, it has been debated whether Hsp90 function is ATP dependent.  A recent crystal structure of the NH2-terminal domain of yeast Hsp90 established the presence of a conserved nucleotide binding site that is identical with the binding site of geldanamycin, a specific inhibitor of Hsp90.  The functional significance of nucleotide binding by Hsp90 has remained unclear.  Here, the authors present evidence for a slow but clearly detectable ATPase activity in purified Hsp90.  Based on a new crystal structure of the NH2-terminal domain of human Hsp90 with bound ADP-Mg and on the structural homol. of this domain with the ATPase domain of Escherichia coli DNA gyrase, the residues of Hsp90 crit. in ATP binding (D93) and ATP hydrolysis (E47) were identified.  The corresponding mutations were made in the yeast Hsp90 homolog, Hsp82, and tested for their ability to functionally replace wild-type Hsp82.  The results show that both ATP binding and hydrolysis are required for Hsp82 function in vivo.  The mutant Hsp90 proteins tested are defective in the binding and ATP hydrolysis-dependent cycling of the co-chaperone p23, which is thought to regulate the binding and release of substrate polypeptide from Hsp90.  Remarkably, the complete Hsp90 protein is required for ATPase activity and for the interaction with p23, suggesting an intricate allosteric communication between the domains of the Hsp90 dimer.  These results establish Hsp90 as an ATP-dependent chaperone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotcz1fjTlrN7Vg90H21EOLACvtfcHk0ljwvMOlUs_w2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVKhtbY%253D&md5=6286ed975202b5a2fdc38ff5453f3b68</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1083%2Fjcb.143.4.901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.143.4.901%26sid%3Dliteratum%253Aachs%26aulast%3DObermann%26aufirst%3DW.%2BM.%26aulast%3DSondermann%26aufirst%3DH.%26aulast%3DRusso%26aufirst%3DA.%2BA.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DHartl%26aufirst%3DF.%2BU.%26atitle%3DIn-vivo%2520function%2520of%2520Hsp90%2520is%2520dependent%2520on%2520ATP%2520binding%2520and%2520ATP%2520hydrolysis%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1998%26volume%3D143%26issue%3D4%26spage%3D901%26epage%3D910%26doi%3D10.1083%2Fjcb.143.4.901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3085</span>– <span class="NLM_lpage">3085</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-05406-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fs41467-018-05406-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30082834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ls1aktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3085-3085&author=S.+F.+Chenauthor=N.+L.+Huangauthor=J.+H.+Linauthor=C.+C.+Wuauthor=Y.+R.+Wangauthor=Y.+J.+Yuauthor=M.+K.+Gilsonauthor=N.+L.+Chan&title=Structural+insights+into+the+gating+of+DNA+passage+by+the+topoisomerase+II+DNA-gate&doi=10.1038%2Fs41467-018-05406-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate</span></div><div class="casAuthors">Chen Shin-Fu; Wu Chyuan-Chuan; Wang Ying-Ren; Yu Yu-Jen; Chan Nei-Li; Huang Nan-Lan; Lin Jung-Hsin; Huang Nan-Lan; Gilson Michael K; Wu Chyuan-Chuan; Chan Nei-Li; Chan Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3085</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type IIA topoisomerases (Top2s) manipulate the handedness of DNA crossovers by introducing a transient and protein-linked double-strand break in one DNA duplex, termed the DNA-gate, whose opening allows another DNA segment to be transported through to change the DNA topology.  Despite the central importance of this gate-opening event to Top2 function, the DNA-gate in all reported structures of Top2-DNA complexes is in the closed state.  Here we present the crystal structure of a human Top2 DNA-gate in an open conformation, which not only reveals structural characteristics of its DNA-conducting path, but also uncovers unexpected yet functionally significant conformational changes associated with gate-opening.  This structure further implicates Top2's preference for a left-handed DNA braid and allows the construction of a model representing the initial entry of another DNA duplex into the DNA-gate.  Steered molecular dynamics calculations suggests the Top2-catalyzed DNA passage may be achieved by a rocker-switch-type movement of the DNA-gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM5cMY9cr24-dfST00W0BcfW6udTcc2eYWtBt8kLo9Bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ls1aktg%253D%253D&md5=04dc82195836cb9e26bb2967da6f0630</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05406-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05406-y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DHuang%26aufirst%3DN.%2BL.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DYu%26aufirst%3DY.%2BJ.%26aulast%3DGilson%26aufirst%3DM.%2BK.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DStructural%2520insights%2520into%2520the%2520gating%2520of%2520DNA%2520passage%2520by%2520the%2520topoisomerase%2520II%2520DNA-gate%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D3085%26epage%3D3085%26doi%3D10.1038%2Fs41467-018-05406-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">10861</span>– <span class="NLM_lpage">10871</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1093%2Fnar%2Fgkx742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28977631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Kit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=10861-10871&issue=18&author=Y.+R.+Wangauthor=S.+F.+Chenauthor=C.+C.+Wuauthor=Y.+W.+Liaoauthor=T.+S.+Linauthor=K.+T.+Liuauthor=Y.+S.+Chenauthor=T.+K.+Liauthor=T.+C.+Chienauthor=N.+L.+Chan&title=Producing+irreversible+topoisomerase+II-mediated+DNA+breaks+by+site-specific+Pt%28II%29-methionine+coordination+chemistry&doi=10.1093%2Fnar%2Fgkx742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry</span></div><div class="casAuthors">Wang, Ying-Ren; Chen, Shin-Fu; Wu, Chyuan-Chuan; Liao, Yi-Wen; Lin, Te-Sheng; Liu, Ko-Ting; Chen, Yi-Song; Li, Tsai-Kun; Chien, Tun-Cheng; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10861-10871</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Human type II topoisomerase (Top2) isoforms, hTop2α and hTop2β, are targeted by some of the most successful anticancer drugs.  These drugs induce Top2-mediated DNA cleavage to trigger cell-death pathways.  The potency of these drugs correlates pos. with their efficacy in stabilizing the enzyme-mediated DNA breaks.  Structural anal. of hTop2α and hTop2β revealed the presence of methionine residues in the drug binding pocket, we therefore tested whether a tighter Top2-drug assocn. may be accomplished by introducing a methionine-reactive Pt2+ into a drug to further stabilize the DNA break.  Herein, we synthesized an organoplatinum compd., etoplatin-N2β, by replacing the methioninejuxtaposing group of the drug etoposide with a cis-dichlorodiammineplatinum(II) moiety.  Compared to etoposide, etoplatin-N2β more potently inhibits both human Top2s.  While the DNA breaks arrested by etoposide can be rejoined, those captured by etoplatin-N2 are practically irreversible.  Crystallog. analyses of hTop2β complexed with DNA and etoplatin-N2β demonstrate coordinate bond formation between Pt2+ and a flanking methionine.  Notably, this stable coordinate tether can be loosened by disrupting the structural integrity of drug-binding pocket, suggesting that Pt2+ coordination chem. may allow for the development of potent inhibitors with protein conformation-dependent reversibility.  This approach may be exploited to achieve isoformspecific targeting of human Top2s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ_1lsBFMml7Vg90H21EOLACvtfcHk0lgQ8G_Zk4BCew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Kit7k%253D&md5=ddc7d7d51f099dc62d40a04819287178</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx742%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DY.%2BW.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DLiu%26aufirst%3DK.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DChien%26aufirst%3DT.%2BC.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DProducing%2520irreversible%2520topoisomerase%2520II-mediated%2520DNA%2520breaks%2520by%2520site-specific%2520Pt%2528II%2529-methionine%2520coordination%2520chemistry%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2017%26volume%3D45%26issue%3D18%26spage%3D10861%26epage%3D10871%26doi%3D10.1093%2Fnar%2Fgkx742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Settimo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taliani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simorini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Motta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornaciari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, A. M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">4270</span>– <span class="NLM_lpage">4290</span>, <span class="refDoi"> DOI: 10.2174/092986710793361252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F092986710793361252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=20939813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1artr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=4270-4290&issue=35&author=S.+Salernoauthor=F.+Da+Settimoauthor=S.+Talianiauthor=F.+Simoriniauthor=C.+La+Mottaauthor=G.+Fornaciariauthor=A.+M.+Marini&title=Recent+advances+in+the+development+of+dual+topoisomerase+I+and+II+inhibitors+as+anticancer+drugs&doi=10.2174%2F092986710793361252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs</span></div><div class="casAuthors">Salerno, S.; De Settimo, F.; Taliani, S.; Simorini, F.; La Motta, C.; Fornaciari, G.; Marini, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4270-4290</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases (topos) are essential enzymes that regulate the topol. state of DNA during cellular processes such as replication, transcription, recombination, and chromatin remodeling.  Topoisomerase I (Topo I) is a ubiquitous nuclear enzyme which catalyzes the relaxation of superhelical DNA generating a transient single strand nick in the duplex, through cycles of cleavage and religation.  Topoisomerase II (Topo II) mediates the ATP-dependent induction of coordinated nicks in both strands of the DNA duplex, followed by crossing of another double strand DNA through the transiently broken duplex.  Although the biol. functions of Topoisomerases are important for ensuing genomic integrity, the ability to interfere with enzymes or generate enzyme-mediated damage is an effective strategy for cancer therapy and, in this connection, DNA topos (I and II) proved to be the excellent targets of clin. significant classes of anti-cancer drugs.  Actually, specific Topo I and Topo II inhibitors reversibly trap the enzyme-DNA complexes, thus converting topos into physiol. poisons, able to produce permanent DNA damage, which triggers cell death.  Given that both enzymes are good targets, it would be desirable to jointly inhibit them, but use-limiting toxicity of sequential or simultaneous combinations of Topo I and II poisons include severe to life-threatening neutropenia and anemia.  Furthermore, the emergence of resistance phenomena to Topo I inhibitors is often accompanied by a concomitant rise in the level of Topo II expression and viceversa, leading to the failure of clin. therapies.  In this regard, a single compd. able to inhibit both Topo I and II may present the advantage of improving anti-topoisomerase activity, with reduced toxic side effects, with respect to the combination of two inhibitors.  Due to the high interest in such compds., this review represents an update of previous works dealing with the development of dual Topo I and II inhibitors as novel anti-cancer agents.  The newly collected derivs. have been described focusing attention on their chem. structures and their biol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFTv42gLvD4rVg90H21EOLACvtfcHk0ljJbfFiWkgpCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1artr%252FI&md5=39e95fc132e22d69ff3c983504095b4e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2174%2F092986710793361252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710793361252%26sid%3Dliteratum%253Aachs%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DTaliani%26aufirst%3DS.%26aulast%3DSimorini%26aufirst%3DF.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DFornaciari%26aufirst%3DG.%26aulast%3DMarini%26aufirst%3DA.%2BM.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520dual%2520topoisomerase%2520I%2520and%2520II%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26issue%3D35%26spage%3D4270%26epage%3D4290%26doi%3D10.2174%2F092986710793361252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Gijn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lendfers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bult, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J.</span></span> <span> </span><span class="NLM_article-title">Dual topoisomerase I/II inhibitors</span>. <i>J. Oncol. Pharm. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">92</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1191/107815500701563317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1191%2F107815500701563317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVSgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=92-108&issue=3&author=R.+van%0AGijnauthor=R.+Lendfersauthor=J.+Schellensauthor=A.+Bultauthor=J.+Beijnen&title=Dual+topoisomerase+I%2FII+inhibitors&doi=10.1191%2F107815500701563317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Dual topoisomerase I/II inhibitors</span></div><div class="casAuthors">Van Gijn, R.; Lendfers, R. R. H.; Schellens, J. H. M.; Bult, A.; Beijnen, J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Oncology Pharmacy Practice</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">92-108</span>CODEN:
                <span class="NLM_cas:coden">JOPPFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-1552</span>.
    
            (<span class="NLM_cas:orgname">Arnold, Hodder Headline</span>)
        </div><div class="casAbstract">A review is given.  Topoisomerase (topo) I and II are nuclear enzymes, which play a major role in the topol. rearrangement of DNA during replication and transcription processes.  In the course of years, many different agents were found which can inhibit the topos and thereby exploit cytotoxicity, also against tumor cells.  Selective inhibition of the topo I enzyme can, however, induce a reactive increase in topo II levels, and vice versa.  This mechanism is assocd. with the development of drug resistance.  Dual inhibition of both topo I and II may, theor., overcome this resistance problem.  In this review, the most important and promising dual topo I/II inhibitors designed as anticancer agents will be discussed.  Thus far, only the indolyl quinoline deriv. TAS-103, the 7H-benzo[e]pyrido[4,3-b] indole deriv. intoplicine, and the acridine deriv. PZA were shown to be dual topo inhibitors with high cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx0-IuZ8mYR7Vg90H21EOLACvtfcHk0ljJbfFiWkgpCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVSgsrc%253D&md5=e6f08f13165cdbde050e5ee2033f04bc</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1191%2F107815500701563317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1191%252F107815500701563317%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGijn%26aufirst%3DR.%26aulast%3DLendfers%26aufirst%3DR.%26aulast%3DSchellens%26aufirst%3DJ.%26aulast%3DBult%26aufirst%3DA.%26aulast%3DBeijnen%26aufirst%3DJ.%26atitle%3DDual%2520topoisomerase%2520I%252FII%2520inhibitors%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2000%26volume%3D6%26issue%3D3%26spage%3D92%26epage%3D108%26doi%3D10.1191%2F107815500701563317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Arpa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beardmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6919</span>– <span class="NLM_lpage">6924</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1698546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3MXivFQ%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1990&pages=6919-6924&issue=21&author=P.+D%E2%80%99Arpaauthor=C.+Beardmoreauthor=L.+F.+Liu&title=Involvement+of+nucleic+acid+synthesis+in+cell+killing+mechanisms+of+topoisomerase+poisons"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons</span></div><div class="casAuthors">D'Arpa, Peter; Beardmore, Christopher; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6919-24</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The primary cytotoxic mechanism of camptothecin has been proposed to involve an interaction between the replication machinery and the camptothecin-mediated topoisomerase I-DNA cleavable complex.  The present study show that killing of V79 cells by the topoisomerase II poisons 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide may involve ongoing RNA synthesis in addn. to ongoing DNA synthesis.  V79 cells synchronized by mitotic shake-off were treated with topoisomerase poisons in the presence of inhibitors of nucleic acid synthesis.  S-Phase V79 cells were more sensitive to the topoisomerase I poison camptothecin and the topoisomerase II poison m-AMSA than G1-phase cells.  The greater sensitivity of S-phase cells to killing by m-AMSA and camptothecin was abolished during cotreatment, but not posttreatment, with aphidicolin, suggesting that ongoing DNA synthesis is involved in cell killing by both topoisomerase I and II poisons.  Cotreatment with transcription inhibitors, such as 5,6-dichloro-1-β-D-ribofuranosyl benzimidazole or cordycepin, partially protected cells from the cytotoxic effects of m-AMSA but had no effect on camptothecin-mediated cytotoxicity.  These results suggest that ongoing RNA transcription may be involved in cell killing by topoisomerase II poisons but not topoisomerase I poisons.  Cotreatment with camptothecin reduced m-AMSA-mediated cytotoxicity in G1-phase V79 cells, suggesting a possible antagonism between topoisomerase I and II poisons.  This antagonistic effect between topoisomerase I and II poisons could be explained by the strong inhibitory effect of camptothecin on RNA transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKbW8PDr36bVg90H21EOLACvtfcHk0lgf65GXfol6KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXivFQ%253D&md5=cdf75c946eb70fb695a5e6278178aaeb</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Arpa%26aufirst%3DP.%26aulast%3DBeardmore%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DInvolvement%2520of%2520nucleic%2520acid%2520synthesis%2520in%2520cell%2520killing%2520mechanisms%2520of%2520topoisomerase%2520poisons%26jtitle%3DCancer%2520Res.%26date%3D1990%26volume%3D50%26issue%3D21%26spage%3D6919%26epage%3D6924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1705167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3MXhslOqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=1129-1136&issue=4&author=S.+H.+Kaufmann&title=Antagonism+between+camptothecin+and+topoisomerase+II-directed+chemotherapeutic+agents+in+a+human+leukemia+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line</span></div><div class="casAuthors">Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1129-36</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">To search for possible synergy between topoisomerase (topo) II-directed chemotherapeutic agents and topo I-directed agents, HL-60 human progranulocytic leukemia cells were incubated with etoposide in the absence or presence of camptothecin (CPT).  Treatment of HL-60 cells for 1 h with 15-20 μM etoposide resulted in the death of 99-99.9% of the cells as assessed by colony formation in soft agar.  Unexpectedly, simultaneous incubation with 1 μM CPT increased the survival of etoposide-treated cells as much as 30-fold.  Inhibition of etoposide cytotoxicity was obsd. at CPT concns. as low as 0.01 μM and was one-half maximal at 0.1 μM.  CPT also antagonized the cytotoxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide and daunorubicin, two structurally unrelated topo II-directed agents.  Topotecan, a CPT analog currently undergoing Phase I clin. trials, had a similar effect.  Studies using an alk. unwinding assay (to measure DNA strand breaks) and Western blotting (to assess formation of covalent adducts involving topo II) revealed that CPT did not alter the ability of etoposide to stabilize topo II-DNA adducts.  CPT is a potent inhibitor of both DNA and RNA synthesis.  To further assess the mechanism by which CPT diminished the cytotoxicity of topo II-directed agents, inhibitors of DNA synthesis or RNA synthesis were substituted for CPT.  Aphidicolin, an inhibitor of replicative DNA polymerases, enhanced the survival of etoposide-treated HL-60 cells <3-fold.  In contrast, inhibitors of RNA synthesis (cordycepin or 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) enhanced the survival of etoposide-treated HL-60 cells as much as 20-fold.  The potential biol. and therapeutic implications of these results are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOza2BIZerprVg90H21EOLACvtfcHk0lgf65GXfol6KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhslOqurs%253D&md5=cac810ef53df744939858154d0b45755</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DAntagonism%2520between%2520camptothecin%2520and%2520topoisomerase%2520II-directed%2520chemotherapeutic%2520agents%2520in%2520a%2520human%2520leukemia%2520cell%2520line%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26issue%3D4%26spage%3D1129%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirabayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinushi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span> <span> </span><span class="NLM_article-title">Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1002/ijc.2910500516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fijc.2910500516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1312063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK38XisVOqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1992&pages=760-766&issue=5&author=R.+Kimauthor=N.+Hirabayashiauthor=M.+Nishiyamaauthor=K.+Jinushiauthor=T.+Togeauthor=K.+Okada&title=Experimental+studies+on+biochemical+modulation+targeting+topoisomerase+I+and+II+in+human+tumor+xenografts+in+nude+mice&doi=10.1002%2Fijc.2910500516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice</span></div><div class="casAuthors">Kim, Ryungsa; Hirabayashi, Naoki; Nishiyama, Masahiko; Jinushi, Kazuto; Toge, Tetsuya; Okada, Kosuke</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">760-6</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">Topoisomerase (topo) I and II are nuclear enzymes which are novel targets of cancer chemotherapy.  A new camptothecin (CPT) analog, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl-oxy-CPT (CPT-11), is a topo-I inhibitor with a higher activity and less toxicity than CPT.  To investigate topo-I and -II-targeting chemotherapy in an in vivo model, the authors studied the effect of sequential or co-treatment using CPT-11 and adriamycin (ADR), a topo-II inhibitor, in 6 human tumor xenografts (2 esophageal, 2 gastric and 2 colon tumor lines).  In sequential treatment, adriamycin was administered i.v. 24 h after CPT-11 treatment, and no antagonistic effect of this treatment schedule was obsd.  ADR cytotoxicity was potentiated by CPT-11 pretreatment in the case of 2 esophageal and 2 gastric tumor lines and 1 colon tumor line.  On the other hand, co-treatment abolished the sensitivity to CPT-11 and ADR in all 6 tumor lines.  Moreover, CPT-11 did not enhance the cytotoxicity of other agents tested, including mitomycin C (MMC) and cisplatin (CDDP).  Flow cytometry and dot-blot analyses showed that CPT-11 pretreatment induced an increase in the S-phase cell population with an increase of topo-II mRNA expression after 24 and 48 h, resp., in the esophageal and colon tumor lines.  These results suggest that CPT-11 can modulate topo-II levels to enhance the effect of topo-II inhibitors in some human tumors, and this suggests a new clin. method of topo-I and -II targeting chemotherapy for human solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5cfYtwzBXG7Vg90H21EOLACvtfcHk0lgUnODitMH5GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisVOqu78%253D&md5=2cc34b4b4c2d78729a8aa8d7b40a0ad1</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910500516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910500516%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%26aulast%3DHirabayashi%26aufirst%3DN.%26aulast%3DNishiyama%26aufirst%3DM.%26aulast%3DJinushi%26aufirst%3DK.%26aulast%3DToge%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DK.%26atitle%3DExperimental%2520studies%2520on%2520biochemical%2520modulation%2520targeting%2520topoisomerase%2520I%2520and%2520II%2520in%2520human%2520tumor%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1992%26volume%3D50%26issue%3D5%26spage%3D760%26epage%3D766%26doi%3D10.1002%2Fijc.2910500516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerrigan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>28a</i></span> (<span class="NLM_issue">4–5</span>),  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1016/0959-8049(92)90107-D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0959-8049%2892%2990107-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1326304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK38XmtVClurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28a&publication_year=1992&pages=743-748&issue=4%E2%80%935&author=R.+Bertrandauthor=P.+M.+O%E2%80%99Connorauthor=D.+Kerriganauthor=Y.+Pommier&title=Sequential+administration+of+camptothecin+and+etoposide+circumvents+the+antagonistic+cytotoxicity+of+simultaneous+drug+administration+in+slowly+growing+human+colon+carcinoma+HT-29+cells&doi=10.1016%2F0959-8049%2892%2990107-D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells</span></div><div class="casAuthors">Bertrand, Richard; O'Connor, Patrick M.; Kerrigan, Donna; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title"></span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">28A</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">743-8</span>CODEN:
                <span class="NLM_cas:coden">EJCTEA</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The authors compared the cytotoxicity of simultaneous and sequential combination chemotherapy with camptothecin and etoposide, in slowly growing human colon carcinoma, HT-29 cells.  Simultaneous treatments of HT-29 cells with etoposide and camptothecin produced no marked enhancement of cytotoxicity over single agent administration.  This finding demonstrates antagonism of one drug's cytotoxicity over the other.  When these studies were repeated in sequential treatment protocols, the authors obsd. that antagonism could be circumvented if the period between individual drug administration was sepd. by 6-8 h.  The cytotoxicity that was obsd. with this approach was never more than additive and the order of camptothecin or etoposide administration did not significantly affect the extent of combined cytotoxicity obsd.  The protective effect of simultaneous camptothecin and etoposide exposure was not due to reduced formation or alterations in the rate of cleavable complex reversal, and protection persisted for a considerably longer period of time than DNA strand breaks.  Protection correlated with the kinetics of DNA and RNA synthesis inhibition produced by either drug.  Remarkably, full cytotoxic protection could be afforded by one drug over the other, in the presence of only partial inhibition of DNA or RNA synthesis (50-60%).  These findings suggest that sequential rather than simultaneous administration of topoisomerase I and II inhibitors in future cancer chemotherapy schedules will enhance cytotoxicity over single-agent administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwFeqpb3AHZbVg90H21EOLACvtfcHk0lgUnODitMH5GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmtVClurc%253D&md5=5a407cba17cc7b458cdd91574f11cbba</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0959-8049%2892%2990107-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0959-8049%252892%252990107-D%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%2BM.%26aulast%3DKerrigan%26aufirst%3DD.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DSequential%2520administration%2520of%2520camptothecin%2520and%2520etoposide%2520circumvents%2520the%2520antagonistic%2520cytotoxicity%2520of%2520simultaneous%2520drug%2520administration%2520in%2520slowly%2520growing%2520human%2520colon%2520carcinoma%2520HT-29%2520cells%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1992%26volume%3D28a%26issue%3D4%25E2%2580%25935%26spage%3D743%26epage%3D748%26doi%3D10.1016%2F0959-8049%2892%2990107-D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span> <span> </span><span class="NLM_article-title">Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1007/s002800050825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs002800050825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9744779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXls1WltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=327-335&issue=4&author=J.+P.+Ederauthor=V.+Chanauthor=J.+Wongauthor=Y.+W.+Wongauthor=G.+Araauthor=D.+Northeyauthor=N.+Rizviauthor=B.+A.+Teicher&title=Sequence+effect+of+irinotecan+%28CPT-11%29+and+topoisomerase+II+inhibitors+in+vivo&doi=10.1007%2Fs002800050825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo</span></div><div class="casAuthors">Eder, Joseph Paul; Chan, Victor; Wong, Julia; Wong, Yee W.; Ara, Gulshan; Northey, David; Rizvi, Naiyer; Teicher, Beverly A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">327-335</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">To develop empiric treatment regimens of combinations and sequences of the topoisomerase I inhibitor irinotecan (CPT-11) and the topoisomerase II inhibitors etoposide and doxorubicin, in vivo studies were performed in mice bearing the EMT-6 mammary tumor to assess efficacy, host tolerance, and the resultant biochem. changes in topoisomerase mRNA and protein.  At 24 h after therapy, depletion of the target topoisomerase mRNA and protein with reciprocal increases in the alternate topoisomerase mRNA and, to a lesser extent, protein were noted.  No therapeutic antagonism was found with any combination or sequence of agents, and therapeutic antagonism was noted with concurrent irinotecan/etoposide and sequential doxorubicin/irinotecan.  Depletion of target isomerases by combined therapy beyond a threshold necessary for therapeutic efficacy produced no addnl. benefit.  Antineoplastic therapy with combinations of topoisomerase I and II agents was feasible and was supposed to produce therapeutic synergy.  The appropriate sequence was supposed to depend on the particular agents used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryp1iUYS74ALVg90H21EOLACvtfcHk0lh_GBvKHB1bbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1WltLg%253D&md5=b2b1c904e7f26569bad8810d7aed74f3</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs002800050825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050825%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DY.%2BW.%26aulast%3DAra%26aufirst%3DG.%26aulast%3DNorthey%26aufirst%3DD.%26aulast%3DRizvi%26aufirst%3DN.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26atitle%3DSequence%2520effect%2520of%2520irinotecan%2520%2528CPT-11%2529%2520and%2520topoisomerase%2520II%2520inhibitors%2520in%2520vivo%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1998%26volume%3D42%26issue%3D4%26spage%3D327%26epage%3D335%26doi%3D10.1007%2Fs002800050825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshire, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallman, J. D.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9816097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK28Xht1agsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=107-118&issue=1&author=J.+A.+Houghtonauthor=P.+J.+Cheshireauthor=J.+D.+Hallmanauthor=L.+Lutzauthor=X.+Luoauthor=Y.+Liauthor=P.+J.+Houghton&title=Evaluation+of+irinotecan+in+combination+with+5-fluorouracil+or+etoposide+in+xenograft+models+of+colon+adenocarcinoma+and+rhabdomyosarcoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma</span></div><div class="casAuthors">Houghton, Janet A.; Cheshire, Pamela J.; Hallman, James D. II; Lutz, Lois; Luo, Xialolong; Li, Yulan; Houghton, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-18</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Irinotecan [7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin] administered i.v. in two courses, each course consisting of administration every day for 5 days [(d×5)2] on days 1-5 and 8-12, has demonstrated significant activity against advanced human tumor xenografts derived from colon adenocarcinomas and several childhood cancers.  To build on this therapy, the authors have evaluated the combination of irinotecan given on this schedule with 5-fluorouracil given on days 1, 7, and 14 with or without leucovorin [(d×5)3 i.v.] against colon tumors, or combined with etoposide administered (d×5)2 i.v. either 2 h before or 2 h after irinotecan for treatment of colon tumors and rhabdomyosarcomas.  A combination of 5-fluorouracil at 75% and irinotecan at 50% of their resp. max. tolerated doses when administered as single agents on this schedule gave acceptable toxicity.  Against colon adenocarcinoma xenografts, 5-fluorouracil did not enhance the response rate compared with that obtained with the optimum dose of irinotecan given as a single agent.  Against GC3/TK- xenografts, which lack thymidine kinase and cannot salvage thymidine to circumvent the inhibition of thymidylate synthase, the addn. of leucovorin to the combination increased the complete response rate from 10 to >90%, whereas the response rates for the optimal doses of irinotecan or 5-fluorouracil, as single agents, were 30 and <10%, resp.  Etoposide d×5 i.v. for two or three courses or (d×5)3 p.o. did not cause objective regression of any colon tumors.  In contrast, three of five rhabdomyosarcoma lines demonstrated a high frequency of partial regressions or complete regressions when treated (d×5)1 i.v.  Repetitive courses [e.g., (d×5)2 or (d×5)3] i.v. or p.o. or by 4-h infusion d×3 i.v. were either equally effective or less effective.  Irinotecan and etoposide were combined using the (d×5)2 i.v. schedule for both drugs, in which irinotecan was given 2 h before or 2 h after the administration of etoposide.  Each drug could be combined at only 38% of its resp. max. tolerated dose when administered as a single agent, indicating greater than additive toxicity.  Toxicity was similar irresp. of the sequence of administration and was manifested by loss of wt. (73% of the initial wt., nadir day 7), myelosuppression, and prolonged thrombocytopenia.  The responses of colon carcinomas to the combination given in either sequence were similar to that achieved with irinotecan given alone at the same dose as used in the combination.  Similarly, when etoposide was given before irinotecan, the responses of rhabdomyosarcomas were similar to those for irinotecan.  However, in expts. in which etoposide was administered 2 h after each dose of irinotecan, there was significant antagonism of the antitumor activity of irinotecan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSruAY1CS-jrVg90H21EOLACvtfcHk0lh_GBvKHB1bbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xht1agsL4%253D&md5=5777043c817593ae111d0af25f5a0280</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoughton%26aufirst%3DJ.%2BA.%26aulast%3DCheshire%26aufirst%3DP.%2BJ.%26aulast%3DHallman%26aufirst%3DJ.%2BD.%26aulast%3DLutz%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DEvaluation%2520of%2520irinotecan%2520in%2520combination%2520with%25205-fluorouracil%2520or%2520etoposide%2520in%2520xenograft%2520models%2520of%2520colon%2520adenocarcinoma%2520and%2520rhabdomyosarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1996%26volume%3D2%26issue%3D1%26spage%3D107%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2401308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fsj.leu.2401308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10086724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1MXitFamtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=343-347&issue=3&author=M.+Crumpauthor=J.+Liptonauthor=D.+Hedleyauthor=D.+Suttonauthor=F.+Shepherdauthor=M.+Mindenauthor=K.+Stewartauthor=S.+Beareauthor=E.+Eisenhauer&title=Phase+I+trial+of+sequential+topotecan+followed+by+etoposide+in+adults+with+myeloid+leukemia%3A+a+National+Cancer+Institute+of+Canada+Clinical+Trials+Group+Study&doi=10.1038%2Fsj.leu.2401308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study</span></div><div class="casAuthors">Crump, M.; Lipton, J.; Hedley, D.; Sutton, D.; Shepherd, F.; Minden, M.; Stewart, K.; Beare, S.; Eisenhauer, E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-347</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Prolonged exposure to a topoisomerase I inhibitor may increase expression of topoisomerase II, making cells more susceptible inhibitors of that enzyme.  This study was undertaken to establish the max. tolerated dose (MTD) of a topotecan/topoisomerase II inhibitor sequential combination that may be active in acute leukemia, and to evaluate the effects of in vivo exposure to topotecan on topoisomerase II levels in leukemic blast cells as measured by image cytometry.  Patients who were eligible for this phase I study had relapsed or refractory acute myeloid leukemia (≤2 prior regimens) or CML blast crisis (0 or 1 prior regimen).  Topotecan was given as a 5 day continuous i.v. infusion and was to be escalated through three levels (1.5, 1.75 and 2.0 mg/m2 day), followed by etoposide at two dose levels (100 and 150 mg/m2) i.v. bolus days 6, 7 and 8.  Topoisomerase IIα levels in leukemic blasts from bone marrow were measured by image cytometry prior to starting treatment, on day 5 of topotecan infusion and on day 28; and daily during topotecan in peripheral blood blasts.  Dose-limiting toxicity was seen in two of six patients at the first dose level (topotecan 1.5 mg/m2/day, etoposide 100 mg/m2/day; ≥grade 3 mucositis in both cases).  This cohort was expanded to 10 patients; no further non-hematol. dose-limiting toxicity was obsd., but given the extent of toxicity seen, further dose escalation was judged not to be feasible.  Topo IIα levels increased in peripheral blood blasts during the first 72 h of topotecan infusion and returned to near baseline by day 5, whereas levels appeared to decrease in bone marrow blasts by day 5 compared to pretreatment.  One complete hematol. and cytogenetic remission in a patient with CML blast crisis was obsd. in the 10 patients evaluable for response.  The sequential administration of topotecan 1.5 mg/m2/day continuous infusion for 5 days followed by etoposide 100 mg/m2/day × 3 is the recommended phase II dose for this schedule.  Topotecan increases topo IIα expression in vivo in leukemia cells, but levels of the enzyme are cell cycle dependent.  Pharmacodynamic evaluation of the sequential or combination administration of novel antileukemic agents may help improve treatment strategies in acute leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIIsIJN1Tyn7Vg90H21EOLACvtfcHk0liS04orsgloJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFamtr8%253D&md5=1764faacd74ed39f469e6d9fe6455fc6</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2401308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2401308%26sid%3Dliteratum%253Aachs%26aulast%3DCrump%26aufirst%3DM.%26aulast%3DLipton%26aufirst%3DJ.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DShepherd%26aufirst%3DF.%26aulast%3DMinden%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DBeare%26aufirst%3DS.%26aulast%3DEisenhauer%26aufirst%3DE.%26atitle%3DPhase%2520I%2520trial%2520of%2520sequential%2520topotecan%2520followed%2520by%2520etoposide%2520in%2520adults%2520with%2520myeloid%2520leukemia%253A%2520a%2520National%2520Cancer%2520Institute%2520of%2520Canada%2520Clinical%2520Trials%2520Group%2520Study%26jtitle%3DLeukemia%26date%3D1999%26volume%3D13%26issue%3D3%26spage%3D343%26epage%3D347%26doi%3D10.1038%2Fsj.leu.2401308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estey, E.</span></span> <span> </span><span class="NLM_article-title">Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1023/A:1006271618635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1023%2FA%3A1006271618635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10555127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1MXntFOnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=89-95&issue=1&author=N.+Veyauthor=H.+Kantarjianauthor=M.+Beranauthor=S.+O%E2%80%99Brienauthor=J.+Cortesauthor=C.+Kollerauthor=E.+Estey&title=Combination+of+topotecan+with+cytarabine+or+etoposide+in+patients+with+refractory+or+relapsed+acute+myeloid+leukemia%3A+results+of+a+randomized+phase+I%2FII+study&doi=10.1023%2FA%3A1006271618635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study</span></div><div class="casAuthors">Vey, Norbert; Kantarjian, Hagop; Beran, Miloslav; O'Brien, Susan; Cortes, Jorge; Koller, Charles; Estey, Elihu</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-95</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">This study assessed whether topotecan with cytosine arabinoside (ara-C) or with etoposide (VP-16) should be studied in phase II trials in patients with refractory or relapsed acute myeloid leukemia (AML).  Patients with refractory or relapsed AML were assigned to one of 3 strata defined by expected complete response (CR) rates of 7%, 20% and 40%, and then randomly assigned to receive topotecan (days 1-5) and ara-C (1 g/m2 over 2 h; days 1-5), topotecan (days 1-5) followed by VP-16 (250 mg/m2 twice daily, days 6-7), or VP-16 (250 mg/m2 twice daily days 1-2) followed by topotecan (days 3-d7).  A dose-finding phase was conducted in the poorest stratum of each arm (topotecan starting dose: 1.0 mg/m2/day × 5).  A Bayesian prephase II selection design was used to assess whether the CR rate with a given arm was sufficient to merit investigation in phase II.  Thirty-seven patients, median age 58 yr, were treated.  Their median 1st CR duration was after 28 wk, and 24% were primary refractory.  Grade 3-4 mucositis occurred in the initial patients in the topotecan → VP-16 arm, but not in the topotecan plus ara-C or VP-16 → topotecan arms.  Consequently, in subsequent patients, the topotecan dose was lower in the topotecan → VP-16 arm than in the other 2 arms (1.0 vs. 1.25 mg/m2 daily × 5) and the VP-16 dose was lower in the topotecan → VP-16 arm (200 vs. 250 mg/m2 twice daily × 2).  One CR occurred (topotecan → VP-16 arm), and the treatment arms were terminated after 10, 15, and 12 patients had been treated on the topotecan plus ara-C, topotecan → VP-16, and VP-16 → topotecan arms, resp.  The principal cause of failure was insufficient antileukemia effect rather than death during the study, and toxicity was minimal at the final doses used.  It is concluded that none of the combinations studied here warrants phase II evaluation in very-poor-prognosis AML salvage patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVtzdpzFGtbLVg90H21EOLACvtfcHk0liS04orsgloJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFOnu7c%253D&md5=4e6d6fb695156bba039dc5f2668ba8a5</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006271618635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006271618635%26sid%3Dliteratum%253Aachs%26aulast%3DVey%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DEstey%26aufirst%3DE.%26atitle%3DCombination%2520of%2520topotecan%2520with%2520cytarabine%2520or%2520etoposide%2520in%2520patients%2520with%2520refractory%2520or%2520relapsed%2520acute%2520myeloid%2520leukemia%253A%2520results%2520of%2520a%2520randomized%2520phase%2520I%252FII%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D1999%26volume%3D17%26issue%3D1%26spage%3D89%26epage%3D95%26doi%3D10.1023%2FA%3A1006271618635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taudou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portemer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaxel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duguet, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(93)90068-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0006-2952%2893%2990068-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8382059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXhtl2ns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1993&pages=331-337&issue=2&author=G.+Taudouauthor=C.+Portemerauthor=C.+Jaxelauthor=M.+Duguet&title=Inhibition+of+DNA+synthesis+and+DNA+fragmentation+in+stimulated+splenocytes+by+the+concerted+action+of+topoisomerase+I+and+II+poisons&doi=10.1016%2F0006-2952%2893%2990068-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons</span></div><div class="casAuthors">Taudou, Georges; Portemer, Christiane; Jaxel, Christine; Duguet, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-7</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Stimulated splenocytes were used as a model system to investigate the effects of topoisomerase inhibitors on normal, non-transformed, non-tumoral proliferating cells.  The concerted action of camptothecin (a poison of topoisomerase I) and etoposide (a poison of topoisomerase II) lead to nearly complete inhibition of DNA synthesis in Con A-stimulated splenocytes.  Anal. of replicated cellular DNA after a short treatment with both drugs revealed a DNA cleavage to medium size fragments.  This effect was additive, suggesting that cleavable complexes were formed independently by both topoisomerases on their resp. DNA sites.  In contrast, prolonged contact with both drugs was followed by degrdn. of the bulk cellular DNA to nucleosome size fragments, indicating that apoptosis took place in these cells.  Combination of camptothecin and etoposide enhanced this phenomenon, consistent with the fact that degrdn. was the result of secondary events which may amplify the signal.  Thus, aphidicolin, an inhibitor of eukaryotic replicases which blocks replication, also triggered DNA degrdn. in proliferating splenocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMv748H-7UKbVg90H21EOLACvtfcHk0lgUbbfC6JN2Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtl2ns70%253D&md5=5a66cd3e06cf28363aef9f5cd0b7f677</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2893%2990068-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252893%252990068-8%26sid%3Dliteratum%253Aachs%26aulast%3DTaudou%26aufirst%3DG.%26aulast%3DPortemer%26aufirst%3DC.%26aulast%3DJaxel%26aufirst%3DC.%26aulast%3DDuguet%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520DNA%2520synthesis%2520and%2520DNA%2520fragmentation%2520in%2520stimulated%2520splenocytes%2520by%2520the%2520concerted%2520action%2520of%2520topoisomerase%2520I%2520and%2520II%2520poisons%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1993%26volume%3D45%26issue%3D2%26spage%3D331%26epage%3D337%26doi%3D10.1016%2F0006-2952%2893%2990068-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinero, J.</span></span> <span> </span><span class="NLM_article-title">Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1007/BF00685566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2FBF00685566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8070008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2MXit1WmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1994&pages=411-415&issue=5&author=F.+Cortesauthor=J.+Pinero&title=Synergistic+effect+of+inhibitors+of+topoisomerase+I+and+II+on+chromosome+damage+and+cell+killing+in+cultured+Chinese+hamster+ovary+cells&doi=10.1007%2FBF00685566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells</span></div><div class="casAuthors">Cortes, Felipe; Pinero, Joaquin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-15</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">Simultaneous treatment of cultured Chinese hamster ovary cells with the topoisomerase I inhibitor camptothecin and the topoisomerase II inhibitor 4'-(9-acridinylamino)-methanesulfon-m-anisidide results in a clear synergistic effect on both chromosome damage detected at metaphase and loss of colony-forming ability.  In contrast, the effect of combined treatment with these topoisomerase inhibitors on sister chromatid exchanges was not significantly different from that expected if the effects were additive.  Taken as a whole, these results seem to support the hypothesis that topoisomerase inhibitors can lead to cell death, presumably when DNA replication forks collide with drug-stabilized cleavable complexes.  Nevertheless, no evidence of apoptosis was obtained from DNA fragmentation anal.  The possible clin. implications of our findings are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-GMX8e9A1GbVg90H21EOLACvtfcHk0lgUbbfC6JN2Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1WmsLg%253D&md5=ef7a7bac26aec0cdfb51a491366d1352</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1007%2FBF00685566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00685566%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DF.%26aulast%3DPinero%26aufirst%3DJ.%26atitle%3DSynergistic%2520effect%2520of%2520inhibitors%2520of%2520topoisomerase%2520I%2520and%2520II%2520on%2520chromosome%2520damage%2520and%2520cell%2520killing%2520in%2520cultured%2520Chinese%2520hamster%2520ovary%2520cells%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1994%26volume%3D34%26issue%3D5%26spage%3D411%26epage%3D415%26doi%3D10.1007%2FBF00685566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menegatti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogus, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselmo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitragotri, S.</span></span> <span> </span><span class="NLM_article-title">Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2015.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.jconrel.2015.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25921087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFChurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2015&pages=198-207&author=K.+M.+Camachoauthor=S.+Kumarauthor=S.+Menegattiauthor=D.+R.+Vogusauthor=A.+C.+Anselmoauthor=S.+Mitragotri&title=Synergistic+antitumor+activity+of+camptothecin-doxorubicin+combinations+and+their+conjugates+with+hyaluronic+acid&doi=10.1016%2Fj.jconrel.2015.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid</span></div><div class="casAuthors">Camacho, Kathryn M.; Kumar, Sunny; Menegatti, Stefano; Vogus, Douglas R.; Anselmo, Aaron C.; Mitragotri, Samir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">198-207</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Combinations of topoisomerase inhibitors I and II have been found to synergistically inhibit cancer cell growth in vitro, yet clin. studies of these types of combinations have not progressed beyond phase II trials.  The results of clin. combinations of topoisomerase (top) I and II inhibitors typically fall within one of two categories: little to no improvement in therapeutic efficacy, or augmented toxicity compared to the single drug counterparts.  Hence, despite the promising activity of top I and II inhibitor combinations in vitro, their clin. applicability has not been realized.  Here, we report the use of polymer-drug conjugates as a means to co-deliver synergistic doses of top I and II inhibitors camptothecin (CPT) and doxorubicin (DOX) to tumors in vivo in a 4T1 breast cancer model.  At specific molar ratios, DOX and CPT were found to be among the most synergistic combinations reported to date, with combination indexes between 0.01 and 0.1.  The identified optimal ratios were controllably conjugated to hyaluronic acid, and elicited significant tumor redn. of murine 4T1 breast cancer model when administered i.v.  This study elucidates a method to identify synergistic drug combinations and translate them to in vivo by preserving the synergistic ratio via conjugation to a carrier polymer, thus opening a promising approach to translate drug combinations to clin. viable treatment regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn5-cVyTUSCbVg90H21EOLACvtfcHk0lhXJ8j5kd1mxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFChurY%253D&md5=2c98677df8fb4f99ebd972eb1a15215f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2015.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2015.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%26aufirst%3DK.%2BM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DMenegatti%26aufirst%3DS.%26aulast%3DVogus%26aufirst%3DD.%2BR.%26aulast%3DAnselmo%26aufirst%3DA.%2BC.%26aulast%3DMitragotri%26aufirst%3DS.%26atitle%3DSynergistic%2520antitumor%2520activity%2520of%2520camptothecin-doxorubicin%2520combinations%2520and%2520their%2520conjugates%2520with%2520hyaluronic%2520acid%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2015%26volume%3D210%26spage%3D198%26epage%3D207%26doi%3D10.1016%2Fj.jconrel.2015.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasey, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span> <span> </span><span class="NLM_article-title">Combined inhibition of topoisomerases I and II - is this a worthwhile/ feasible strategy?</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1397</span>, <span class="refDoi"> DOI: 10.1038/bjc.1997.568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fbjc.1997.568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9400932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADyaK1c%252Fmt1Wjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1997&pages=1395-1397&issue=11&author=P.+A.+Vaseyauthor=S.+B.+Kaye&title=Combined+inhibition+of+topoisomerases+I+and+II+-+is+this+a+worthwhile%2F+feasible+strategy%3F&doi=10.1038%2Fbjc.1997.568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?</span></div><div class="casAuthors">Vasey P A; Kaye S B</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1395-7</span>
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7KUv6d8-GJf3jf77P2BG3fW6udTcc2eaDb75gvvJ8S7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252Fmt1Wjtg%253D%253D&md5=7f0bd7dc42bbd7c856b61b778df971ae</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1997.568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1997.568%26sid%3Dliteratum%253Aachs%26aulast%3DVasey%26aufirst%3DP.%2BA.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DCombined%2520inhibition%2520of%2520topoisomerases%2520I%2520and%2520II%2520-%2520is%2520this%2520a%2520worthwhile%252F%2520feasible%2520strategy%253F%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1997%26volume%3D76%26issue%3D11%26spage%3D1395%26epage%3D1397%26doi%3D10.1038%2Fbjc.1997.568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span> <span> </span><span class="NLM_article-title">Dual topoisomerase I/II inhibitors in cancer therapy</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.2174/1568026033452555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1568026033452555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12570767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1CksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=339-353&issue=3&author=W.+A.+Dennyauthor=B.+C.+Baguley&title=Dual+topoisomerase+I%2FII+inhibitors+in+cancer+therapy&doi=10.2174%2F1568026033452555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Dual topoisomerase I/II inhibitors in cancer therapy</span></div><div class="casAuthors">Denny, William A.; Baguley, Bruce C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-353</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  While the majority of topoisomerase (topo) inhibitors show selectivity against either topo I or topo II, a small class of compds. can act against both enzymes.  These can be divided into three classes.  The first and largest class comprise drugs that bind to DNA by intercalation and include the clin.-evaluated acridine DACA, the benzopyridoindole intoplicine, the indenoquinolinone TAS-103, the benzophenazine XR11576, and the pyrazoloacridine NSC 366140.  The second category comprises hybrid mols., prepd. by phys. linking sep. inhibitors of topo I and topo II, or by linking pure topo inhibitors to other DNA-interactive carriers.  While several derivs. (e.g., camptothecin-epipodophyllotoxin and ellipticine-distamycin hybrids) have been prepd., there have been no detailed studies.  The third category are less well defined as a structural class, but apparently recognize structural motifs that are present in both topo I and II enzymes.  These include a series of benzoisoquinolinium quaternary salts such as NK 109, and more interestingly modified versions of classical topo I or topo II inhibitors; e.g., the modified camptothecin BN 80927 and the modified epipodophyllotoxin tafluposide (F-11782).  There is as yet no detailed understanding of the factors that result in selective or dual inhibition, but structure-activity studies in several classes show that structural changes can influence topo I/II selectivity.  DNA intercalation mode also appears to play a part.  The basis for the high antitumor activity of some topo inhibitors is not yet understood but may depend on the complex pattern of activities that include both inhibition and poisoning of the two enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSlke14mUdcLVg90H21EOLACvtfcHk0lhXJ8j5kd1mxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1CksA%253D%253D&md5=110f2d5abc8d8bbaf733a1034387c75b</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.2174%2F1568026033452555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026033452555%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26atitle%3DDual%2520topoisomerase%2520I%252FII%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2003%26volume%3D3%26issue%3D3%26spage%3D339%26epage%3D353%26doi%3D10.2174%2F1568026033452555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miskovic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baus Loncar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glavas-Obrovac, L.</span></span> <span> </span><span class="NLM_article-title">Antineoplastic DNA-binding compounds: intercalating and minor groove binding drugs</span>. <i>Arh. Hig. Rada Toksikol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.2478/10004-1254-64-2013-2371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2478%2F10004-1254-64-2013-2371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24384766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFKkt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=593-602&issue=4&author=K.+Miskovicauthor=M.+Bujakauthor=M.+Baus+Loncarauthor=L.+Glavas-Obrovac&title=Antineoplastic+DNA-binding+compounds%3A+intercalating+and+minor+groove+binding+drugs&doi=10.2478%2F10004-1254-64-2013-2371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Antineoplastic DNA-binding compounds: intercalating and minor groove binding drugs</span></div><div class="casAuthors">Miskovic, Katarina; Bujak, Maro; Baus Loncar, Mirela; Glavas-Obrovac, Ljubica</div><div class="citationInfo"><span class="NLM_cas:title">Arhiv za Higijenu Rada i Toksikologiju</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">593-602</span>CODEN:
                <span class="NLM_cas:coden">AHRTAN</span>;
        ISSN:<span class="NLM_cas:issn">0004-1254</span>.
    
            (<span class="NLM_cas:orgname">Institute for Medical Research and Occupational Health</span>)
        </div><div class="casAbstract">A review.  DNA intercalating and minor groove binding compds. are new weapons in the battle against malignant diseases.  These antineoplastic agents target the DNA mol. and interfere with the cell cycle leading to rapidly proliferating cell death.  They are mainly derivates of a naturally occurring org. compd. derived from a microorganism or plant.  Intercalators usually act as topoisomerase I and/or II poisons, while the mechanisms of DNA minor groove binders are a combination of several steps including topoisomerase poisoning.  This paper gives an overview of some of the developed DNA intercalating and minor groove binding compds., as well as an explanation of their chem. structures, origins, and application in chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK1zyx1Qk7JrVg90H21EOLACvtfcHk0ljZKBwGLbGktQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFKkt70%253D&md5=4aeabbfb2dc587a978167b80efbdfa9f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2478%2F10004-1254-64-2013-2371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2478%252F10004-1254-64-2013-2371%26sid%3Dliteratum%253Aachs%26aulast%3DMiskovic%26aufirst%3DK.%26aulast%3DBujak%26aufirst%3DM.%26aulast%3DBaus%2BLoncar%26aufirst%3DM.%26aulast%3DGlavas-Obrovac%26aufirst%3DL.%26atitle%3DAntineoplastic%2520DNA-binding%2520compounds%253A%2520intercalating%2520and%2520minor%2520groove%2520binding%2520drugs%26jtitle%3DArh.%2520Hig.%2520Rada%2520Toksikol.%26date%3D2013%26volume%3D64%26issue%3D4%26spage%3D593%26epage%3D602%26doi%3D10.2478%2F10004-1254-64-2013-2371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, L. H.</span></span> <span> </span><span class="NLM_article-title">DNA and its associated processes as targets for cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1038/nrc749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11990855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1KktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=188-200&issue=3&author=L.+H.+Hurley&title=DNA+and+its+associated+processes+as+targets+for+cancer+therapy&doi=10.1038%2Fnrc749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">DNA and its associated processes as targets for cancer therapy</span></div><div class="casAuthors">Hurley, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">188-200</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA is the mol. target for many of the drugs that are used in cancer therapeutics, and is viewed as a non-specific target of cytotoxic agents.  Although this is true for traditional chemotherapeutics, other agents that were discovered more recently have shown enhanced efficacy.  Furthermore, a new generation of agents that target DNA-assocd. processes are anticipated to be far more specific and effective.  How have these agents evolved, and what are their mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXfymv1PT0YLVg90H21EOLACvtfcHk0ljZKBwGLbGktQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1KktL0%253D&md5=e9ca715b3e7374aeb919f340c46cc59d</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnrc749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc749%26sid%3Dliteratum%253Aachs%26aulast%3DHurley%26aufirst%3DL.%2BH.%26atitle%3DDNA%2520and%2520its%2520associated%2520processes%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26issue%3D3%26spage%3D188%26epage%3D200%26doi%3D10.1038%2Fnrc749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span> <span> </span><span class="NLM_article-title">From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>32a</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1016/0959-8049(95)00604-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0959-8049%2895%2900604-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8695277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK28XjsFSqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32a&publication_year=1996&pages=708-714&issue=4&author=G.+J.+Finlayauthor=J.+F.+Riouauthor=B.+C.+Baguley&title=From+amsacrine+to+DACA+%28N-%5B2-%28dimethylamino%29ethyl%5Dacridine-4-carboxamide%29%3A+selectivity+for+topoisomerases+I+and+II+among+acridine+derivatives&doi=10.1016%2F0959-8049%2895%2900604-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">From Amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): Selectivity for Topoisomerases I and II among acridine derivatives</span></div><div class="casAuthors">Finlay, G. J.; Riou, J. -F.; Baguley, B. C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer, Part A</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">32A</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">708-714</span>CODEN:
                <span class="NLM_cas:coden">EJCTEA</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A no. of acridine derivs., including the clin. antileukemia agent amsacrine and the exptl. agent DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide), target the enzyme topoisomerase II.  We demonstrate here that DACA induces DNA cleavage in the presence of topoisomerase I as well as of topoisomerase II.  We also investigate a series of acridine derivs. which link amsacrine to DACA in terms of DNA binding, topoisomerase poisoning and biol. activity.  The presence of an acridine 4-linked N-2-(dimethylamino)ethyl group provides both a pronounced G-C preference for DNA binding and activity towards topoisomerase I.  The removal of the anilino side chain of amsacrine, in combination with the presence of the N-2-(dimethylamino)ethyl group, provides in vitro biol. activity against "atypical" multidrug resistant leukemia lines with low topoisomerase II activity.  Among these compds., suppression of the ionization of the acridine nitrogen to produce the compd. DACA is assocd. with exptl. activity against solid tumors.  The addn. of an acridine 2-chloro substituent to DACA suppresses the stimulation of topoisomerase II-dependent DNA cleavage but increases stimulation of topoisomerase I cleavage.  2-Substitution also increases activity against the "atypical" multidrug resistant cell lines.  Overall, the results suggest that augmentation of topoisomerase I-dependent activity in this series by appropriate chem. substitution in this series leads to circumvention of topoisomerase II-mediated multidrug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRcA2mITlodbVg90H21EOLACvtfcHk0lhu078RwT81tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsFSqs7k%253D&md5=34e7389becadf899f0e047427f455b96</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2F0959-8049%2895%2900604-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0959-8049%252895%252900604-4%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DG.%2BJ.%26aulast%3DRiou%26aufirst%3DJ.%2BF.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26atitle%3DFrom%2520amsacrine%2520to%2520DACA%2520%2528N-%255B2-%2528dimethylamino%2529ethyl%255Dacridine-4-carboxamide%2529%253A%2520selectivity%2520for%2520topoisomerases%2520I%2520and%2520II%2520among%2520acridine%2520derivatives%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1996%26volume%3D32a%26issue%3D4%26spage%3D708%26epage%3D714%26doi%3D10.1016%2F0959-8049%2895%2900604-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poddevin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavelle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8232227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2cXitlWlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1993&pages=767-774&issue=4&author=B.+Poddevinauthor=J.+F.+Riouauthor=F.+Lavelleauthor=Y.+Pommier&title=Dual+topoisomerase+I+and+II+inhibition+by+intoplicine+%28RP-60475%29%2C+a+new+antitumor+agent+in+early+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials</span></div><div class="casAuthors">Poddevin, Bruno; Riou, Jean Francois; Lavelle, Francois; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">767-74</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The mechanisms of action of intoplicine (RP-60475), a 7H-benzo[e]pyrido[4,3-b]indole deriv. that is presently in early clin. trials, were studied.  Intoplicine induced both topoisomerase I- and II-mediated DNA strand breaks, using purified topoisomerases.  The topoisomerase cleavage site patterns induced by intoplicine were unique, relative to those of camptothecin, 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA), and other known topoisomerase inhibitors.  Both topoisomerase I- and II-induced DNA breaks decreased at drug concns. > 1 μM, which is consistent with the DNA-intercalating activity of intoplicine.  DNA damage was studied in KB cells in culture by using alk. elution.  Intoplicine induced single-strand breaks (SSB) in a bell-shaped manner with respect to drug concn. (max. frequency at 1 μM ≈ 220 rad-equiv.).  SSB formation was fast, whereas reversal after drug removal was slow.  Similar bell-shaped curves were obtained for DNA double-strand breaks (DSB) and DNA-protein cross-links.  SSB and DNA-protein cross-link frequencies were approx. equal, and no protein-free breaks were detectable, indicating the protein concealment of the breaks, as expected for topoisomerase inhibition.  Comparison of SSB and DSB frequencies indicated that intoplicine produced a amt. of SSB not related to DSB, which is consistent with concomitant inhibition of both DNA topoisomerases I and II in cells.  Data derived from resistant cell lines indicated that multidrug-resistant cells were cross-resistant to intoplicine but that m-AMSA- and camptothecin-resistant cells were sensitive to intoplicine.  Hence, intoplicine might circumvent topoisomerase I-mediated and topoisomerase II-mediated resistance by poisoning both enzymes simultaneously.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVYTHAtG4ODbVg90H21EOLACvtfcHk0lhu078RwT81tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlWlsw%253D%253D&md5=f7a79d21f80e1a98b368370954e715df</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPoddevin%26aufirst%3DB.%26aulast%3DRiou%26aufirst%3DJ.%2BF.%26aulast%3DLavelle%26aufirst%3DF.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DDual%2520topoisomerase%2520I%2520and%2520II%2520inhibition%2520by%2520intoplicine%2520%2528RP-60475%2529%252C%2520a%2520new%2520antitumor%2520agent%2520in%2520early%2520clinical%2520trials%26jtitle%3DMol.%2520Pharmacol.%26date%3D1993%26volume%3D44%26issue%3D4%26spage%3D767%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svingen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebolt-Leopold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ames, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9533538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXit1aqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=683-691&issue=3&author=A.+A.+Adjeiauthor=M.+Charronauthor=E.+K.+Rowinskyauthor=P.+A.+Svingenauthor=J.+Millerauthor=J.+M.+Reidauthor=J.+Sebolt-Leopoldauthor=M.+M.+Amesauthor=S.+H.+Kaufmann&title=Effect+of+pyrazoloacridine+%28NSC+366140%29+on+DNA+topoisomerases+I+and+II"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II</span></div><div class="casAuthors">Adjei, Alex A.; Charron, Martin; Rowinsky, Eric K.; Svingen, Phyllis A.; Miller, Jennifer; Reid, Joel M.; Sebolt-Leopold, Judith; Ames, Matthew M.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">683-691</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pyrazoloacridine (PA), an acridine congener with an unknown mechanism of action, has shown selective activity against solid tumor cells, cytotoxicity in noncycling and hypoxic cells, and promising antitumor activity in Phase I clin. trials.  In the present study, the effect of PA on topoisomerase (topo) activity was evaluated using yeast strains lacking functional topo I or II, mammalian cell nuclear exts., purified samples of mammalian topo I and topo II, and intact mammalian tissue culture cells.  Clonogenic assays revealed that PA cytotoxicity in yeast strains was unaffected by selective loss of topo I or topo II activity.  On the other hand, enzyme assays revealed that 2-4 μM PA abolished the catalytic activity of both topo I and topo II in vitro.  In contrast to topotecan and etoposide, PA did not stabilize covalent topo-DNA complexes.  Instead, PA inhibited topotecan-induced stabilization of covalent topo I-DNA complexes and etoposide-induced stabilization of topo II-DNA complexes in vitro and in intact cells.  Consistent with these results, colony-forming assays indicated that short-term PA exposure inhibited the cytotoxicity of topotecan and etoposide, whereas prolonged PA exposure was itself toxic to these cells.  Accumulation studies revealed that PA was concd. as much as 250-fold in drug-treated cells, resulting in intranuclear concns. that far exceeded those required to inhibit topo I and topo II.  Collectively, these results not only suggest that PA can target both topo I and topo II at clin. achievable concns. but also indicate that its mechanism is distinct from topo I and topo II poisons presently licensed for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlQoZ13UrTJ7Vg90H21EOLACvtfcHk0liuXDA4GcqnEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXit1aqu78%253D&md5=2324fba34e332e8ee8fd7d19cea12354</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DCharron%26aufirst%3DM.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DSvingen%26aufirst%3DP.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DEffect%2520of%2520pyrazoloacridine%2520%2528NSC%2520366140%2529%2520on%2520DNA%2520topoisomerases%2520I%2520and%2520II%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1998%26volume%3D4%26issue%3D3%26spage%3D683%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Utsugi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierzba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II</span>. <i>Jpn. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">992</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.1997.tb00320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1111%2Fj.1349-7006.1997.tb00320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9414662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Gjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1997&pages=992-1002&issue=10&author=T.+Utsugiauthor=K.+Aoyagiauthor=T.+Asaoauthor=S.+Okazakiauthor=Y.+Aoyagiauthor=M.+Sanoauthor=K.+Wierzbaauthor=Y.+Yamada&title=Antitumor+activity+of+a+novel+quinoline+derivative%2C+TAS-103%2C+with+inhibitory+effects+on+topoisomerases+I+and+II&doi=10.1111%2Fj.1349-7006.1997.tb00320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II</span></div><div class="casAuthors">Utsugi, Teruhiro; Aoyagi, Kumio; Asao, Tetsuji; Okazaki, Shinji; Aoyagi, Yoshimi; Sano, Masaki; Wierzba, Konstanty; Yamada, Yuji</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">992-1002</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">A novel quinoline deriv., TAS-103 (6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride), was developed as an anticancer agent targeting topoisomerases (topo) I and II, with marked efficacy in solid tumors.  TAS-103 inhibited topo I and II (IC50: 2 μM, 6.5 μM) at a concn. similar to or lower than those of previous agents, and had a strong cytotoxic effect on P388 and KB cells (IC50: 0.0011 μM, 0.0096 μM).  TAS-103 stabilized top I and II-DNA complex to that induced by etoposide (VP-16) but a smaller amt. of topo I-DNA complex than that produced by camptothecin (CPT).  In the in vivo study, intermittent i.v. administration was markedly effective against s.c.-implanted murine tumors.  Furthermore, TAS-103 had marked efficacy against various lung metastatic tumors, and a broad antitumor spectrum in human tumor xenografts (derived from lung, colon, stomach, breast, and pancreatic cancer).  The efficacy of TAS-103 was generally greater than that of irinotecan (CP-11), VP-16, or cis-diamminedichloroplatinum (CDDP).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVovc2P_1CG7Vg90H21EOLACvtfcHk0liuXDA4GcqnEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Gjt7k%253D&md5=078432e189697cb13b8779176e89339d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.1997.tb00320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.1997.tb00320.x%26sid%3Dliteratum%253Aachs%26aulast%3DUtsugi%26aufirst%3DT.%26aulast%3DAoyagi%26aufirst%3DK.%26aulast%3DAsao%26aufirst%3DT.%26aulast%3DOkazaki%26aufirst%3DS.%26aulast%3DAoyagi%26aufirst%3DY.%26aulast%3DSano%26aufirst%3DM.%26aulast%3DWierzba%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26atitle%3DAntitumor%2520activity%2520of%2520a%2520novel%2520quinoline%2520derivative%252C%2520TAS-103%252C%2520with%2520inhibitory%2520effects%2520on%2520topoisomerases%2520I%2520and%2520II%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D1997%26volume%3D88%26issue%3D10%26spage%3D992%26epage%3D1002%26doi%3D10.1111%2Fj.1349-7006.1997.tb00320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[<i>a</i>]phenazin derivatives as dual topoisomerase I/II inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2015.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25599951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFeqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=540-553&author=B.+L.+Yaoauthor=Y.+W.+Maiauthor=S.+B.+Chenauthor=H.+T.+Xieauthor=P.+F.+Yaoauthor=T.+M.+Ouauthor=J.+H.+Tanauthor=H.+G.+Wangauthor=D.+Liauthor=S.+L.+Huangauthor=L.+Q.+Guauthor=Z.+S.+Huang&title=Design%2C+synthesis+and+biological+evaluation+of+novel+7-alkylamino+substituted+benzo%5Ba%5Dphenazin+derivatives+as+dual+topoisomerase+I%2FII+inhibitors&doi=10.1016%2Fj.ejmech.2015.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors</span></div><div class="casAuthors">Yao, Bing-Lei; Mai, Yan-Wen; Chen, Shuo-Bin; Xie, Hua-Ting; Yao, Pei-Fen; Ou, Tian-Miao; Tan, Jia-Heng; Wang, Hong-Gen; Li, Ding; Huang, Shi-Liang; Gu, Lian-Quan; Huang, Zhi-Shu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">540-553</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of benzo[a]phenazine derivs. (e.g. I) bearing alkylamino side chains were designed, synthesized and evaluated for their topoisomerase inhibitory activity as well as cytotoxicity against four human cancer cell lines (HL-60, K-562, HeLa, and A549).  These compds. were found to be dual inhibitors of topoisomerase (Topo) I and Topo II, and exhibited excellent antiproliferative activity, in particular against HL-60 cells with submicromolar IC50 values.  Further mechanistic studies showed that this class of compds. acted as Topo I poisons by stabilizing the Topo I-DNA cleavage complexes and Topo II catalytic inhibitors by inhibiting the ATPase activity of hTopo II.  Mol. docking studies revealed the binding modes of these compds. for Topo I and Topo II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxjnEG72_zALVg90H21EOLACvtfcHk0liuXDA4GcqnEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFeqsQ%253D%253D&md5=01e94691b81dc1185eb5109930b0d41d</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%2BL.%26aulast%3DMai%26aufirst%3DY.%2BW.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DXie%26aufirst%3DH.%2BT.%26aulast%3DYao%26aufirst%3DP.%2BF.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%25207-alkylamino%2520substituted%2520benzo%255Ba%255Dphenazin%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%252FII%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D540%26epage%3D553%26doi%3D10.1016%2Fj.ejmech.2015.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janockova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plsikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jendzelovsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparkova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamulakova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorocko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozurkova, M.</span></span> <span> </span><span class="NLM_article-title">Tacrine derivatives as dual topoisomerase I and II catalytic inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2015.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bioorg.2015.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25827869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFWmtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=168-176&author=J.+Janockovaauthor=J.+Plsikovaauthor=J.+Kovalauthor=R.+Jendzelovskyauthor=J.+Mikesauthor=J.+Kasparkovaauthor=V.+Brabecauthor=S.+Hamulakovaauthor=P.+Fedorockoauthor=M.+Kozurkova&title=Tacrine+derivatives+as+dual+topoisomerase+I+and+II+catalytic+inhibitors&doi=10.1016%2Fj.bioorg.2015.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine derivatives as dual topoisomerase I and II catalytic inhibitors</span></div><div class="casAuthors">Janockova, Jana; Plsikova, Jana; Koval, Jan; Jendzelovsky, Rastislav; Mikes, Jaromir; Kasparkova, Jana; Brabec, Viktor; Hamulakova, Slavka; Fedorocko, Peter; Kozurkova, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">168-176</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study examines the binding properties of a series of newly synthesized tacrine derivs. 1-4 and their anticancer effects.  Spectroscopic techniques (UV-Vis, fluorescence spectroscopy, thermal denaturation, and linear spectropolarimetry) and viscometry were used to study DNA binding properties and to det. the types of DNA interaction with the studied derivs.  The binding consts. for the complexes with DNA were obtained using UV-Vis spectroscopic titrns. (K = 1.6 × 104-4.0 × 105 M-1) and electrophoretic methods were used to det. the effect of the derivs. on topoisomerase I and II activity.  Monotacrine deriv. 1 showed evidence of topoisomerase I relaxation activity at a concn. of 30 × 10-6 M, while bistacrine derivs. 2-4 produced a complete inhibition of topoisomerase I at a concn. of 5 × 10-6 M.  The biol. activities of the derivs. were studied using MTT-assay and flow cytometric methods (detection of mitochondrial membrane potential and measurement of cell viability) following incubation of 24 and 48 h with human leukemic cancer cell line HL60.  The ability of the derivs. to impair cell proliferation was also tested through the anal. of cell cycle distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUjQmb4QejbVg90H21EOLACvtfcHk0ljTnDLDEsWopg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFWmtb4%253D&md5=7bfc53c704e4a38a019345be87e3c471</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2015.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2015.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DJanockova%26aufirst%3DJ.%26aulast%3DPlsikova%26aufirst%3DJ.%26aulast%3DKoval%26aufirst%3DJ.%26aulast%3DJendzelovsky%26aufirst%3DR.%26aulast%3DMikes%26aufirst%3DJ.%26aulast%3DKasparkova%26aufirst%3DJ.%26aulast%3DBrabec%26aufirst%3DV.%26aulast%3DHamulakova%26aufirst%3DS.%26aulast%3DFedorocko%26aufirst%3DP.%26aulast%3DKozurkova%26aufirst%3DM.%26atitle%3DTacrine%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%2520and%2520II%2520catalytic%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2015%26volume%3D59%26spage%3D168%26epage%3D176%26doi%3D10.1016%2Fj.bioorg.2015.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalla
Via, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrarese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gia, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilin, A.</span></span> <span> </span><span class="NLM_article-title">Pyrroloquinolinone-based dual topoisomerase I/II inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.02.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2014.02.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24631729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=103-109&author=L.+Dalla%0AViaauthor=G.+Marzaroauthor=A.+Ferrareseauthor=O.+Giaauthor=A.+Chilin&title=Pyrroloquinolinone-based+dual+topoisomerase+I%2FII+inhibitor&doi=10.1016%2Fj.ejmech.2014.02.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrroloquinolinone-based dual topoisomerase I/II inhibitor</span></div><div class="casAuthors">Dalla Via, Lisa; Marzaro, Giovanni; Ferrarese, Alessandro; Gia, Ornella; Chilin, Adriana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-109</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new series of pyrroloquinolinones I [X = (CH2)2; (CH2)3; (CH2)4; R = Me2N, Me2NCH2CH2] bearing different alkylamino side chains were synthesized and evaluated as cytotoxic compds. against three different human tumor cell lines (HeLa, HL-60 and A431).  Some compds. showed interesting antiproliferative activity, in particular against A431 cells.  The compds. were tested for their ability to counteract topoisomerase II relaxation activity and the most interesting one I [X = (CH2)4; R = Me2NCH2CH2] was tested also against topoisomerase I, resulting a dual inhibitor.  The mol. interactions between this compd. and the intracellular targets were finally investigated through mol. modeling simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0hZVMaV2pFLVg90H21EOLACvtfcHk0lg177bB84mN_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSht7g%253D&md5=d687922a8b6503655fc1363cf85676ab</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.02.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.02.064%26sid%3Dliteratum%253Aachs%26aulast%3DDalla%2BVia%26aufirst%3DL.%26aulast%3DMarzaro%26aufirst%3DG.%26aulast%3DFerrarese%26aufirst%3DA.%26aulast%3DGia%26aufirst%3DO.%26aulast%3DChilin%26aufirst%3DA.%26atitle%3DPyrroloquinolinone-based%2520dual%2520topoisomerase%2520I%252FII%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D77%26spage%3D103%26epage%3D109%26doi%3D10.1016%2Fj.ejmech.2014.02.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbeck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone γ-H2AX as a biomarker of DNA damage</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9971</span>– <span class="NLM_lpage">9979</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-0804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F0008-5472.CAN-07-0804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17942930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9971-9979&issue=20&author=V.+A.+Raoauthor=K.+Agamaauthor=S.+Holbeckauthor=Y.+Pommier&title=Batracylin+%28NSC+320846%29%2C+a+dual+inhibitor+of+DNA+topoisomerases+I+and+II+induces+histone+%CE%B3-H2AX+as+a+biomarker+of+DNA+damage&doi=10.1158%2F0008-5472.CAN-07-0804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Batracylin (NSC 320846), a Dual Inhibitor of DNA Topoisomerases I and II Induces Histone γ-H2AX as a Biomarker of DNA Damage</span></div><div class="casAuthors">Rao, V. Ashutosh; Agama, Keli; Holbeck, Susan; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9971-9979</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Batracylin (8-aminoisoindolo [1,2-b]quinazolin-10(12H)-one; NSC320846) is an investigational clin. anticancer agent.  Previous animal studies showed activity against solid tumors and Adriamycin-resistant leukemia.  We initially sought to test the proposed Top2-mediated DNA cleavage activity of batracylin and identify potential biomarkers for activity.  COMPARE anal. in the NCI-60 cell lines showed batracylin activity to be most closely related to the class of Top2 inhibitors.  The 50% growth inhibition (GI50) value for batracylin in HT29 colon carcinoma cells was 10 μmol/L.  DNA-protein cross-links, consistent with Top2 targeting, were measured by alk. elution.  DNA single-strand breaks were also detected and found to be protein assocd.  However, only a weak induction of DNA double-strand breaks was obsd.  Because batracylin induced almost exclusively DNA single-strand breaks, we tested batracylin as a Top1 inhibitor.  Batracylin exhibited both Top1- and Top2α/β-mediated DNA cleavage in vitro and in cells.  The phosphorylation of histone (γ-H2AX) was tested to measure the extent of DNA damage.  Kinetics of γ-H2AX "foci" showed early activation with low μmol/L concns., thus presenting a useful early biomarker of DNA damage.  The half-life of γ-H2AX signal reversal after drug removal was consistent with reversal of DNA-protein cross-links.  The persistence of the DNA-protein complexes induced by batracylin was markedly longer than by etoposide or camptothecin.  The phosphorylated DNA damage-responsive kinase, ataxia telangiectasia mutated, was also found activated at sites of γ-H2AX.  The cell cycle checkpoint kinase, Chk2, was only weakly phosphorylated.  Thus, batracylin is a dual Top1 and Top2 inhibitor and γ-H2AX could be considered a biomarker in the ongoing clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIPYuZCTcod7Vg90H21EOLACvtfcHk0lg8f-8uySnrAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbbP&md5=0bce626fda4536088a5245f164faa5bf</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-0804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-0804%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DV.%2BA.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DHolbeck%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DBatracylin%2520%2528NSC%2520320846%2529%252C%2520a%2520dual%2520inhibitor%2520of%2520DNA%2520topoisomerases%2520I%2520and%2520II%2520induces%2520histone%2520%25CE%25B3-H2AX%2520as%2520a%2520biomarker%2520of%2520DNA%2520damage%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D20%26spage%3D9971%26epage%3D9979%26doi%3D10.1158%2F0008-5472.CAN-07-0804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westergaard, O.</span></span> <span> </span><span class="NLM_article-title">Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>228</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1016/0022-2836(92)90863-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0022-2836%2892%2990863-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1335085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXlt1Shuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=1992&pages=778-786&issue=3&author=B.+S.+Sorensenauthor=J.+Sindingauthor=A.+H.+Andersenauthor=J.+Alsnerauthor=P.+B.+Jensenauthor=O.+Westergaard&title=Mode+of+action+of+topoisomerase+II-targeting+agents+at+a+specific+DNA+sequence.+Uncoupling+the+DNA+binding%2C+cleavage+and+religation+events&doi=10.1016%2F0022-2836%2892%2990863-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Mode of action of topoisomerase II-targeting agents at a specific DNA sequence.  Uncoupling the DNA binding, cleavage and religation events</span></div><div class="casAuthors">Sorensen, Boe S.; Sinding, Jens; Andersen, Anni H.; Alsner, Jan; Jensen, Peter B.; Westergaard, Ole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">778-86</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">Methods for uncoupling the DNA binding, cleavage and religation reactions of topoisomerase II were employed to investigate the influence of topoisomerase II-directed drugs on the individual steps in the enzyme's catalytic cycle.  A special DNA substrate contg. a major topoisomerase II interaction site, which can be cleaved by the enzyme in the absence of any concomitant religation, was used to examine the effect of topoisomerase II-directed agents upon the DNA cleavage reaction.  The expt. demonstrated that the topoisomerase II targeting agent Ro 15-0216 stimulates the DNA cleavage reaction extensively, whereas the traditional topoisomerase II inhibitor, mAMSA, has only a minor effect on this reaction.  Topoisomerase II trapped in the cleavage complexes can religate to the 3' hydroxyl end of another DNA strand.  Using this religation assay, it was demonstrated that the major effect of mAMSA is an inhibition of the enzyme's religation reaction, whereas Ro 15-0216 has no effect on this reaction.  Recently, considerable attention has been given to drugs preventing topoisomerase II from introducing DNA cleavages.  In the present paper the initial non-covalent DNA binding reaction of topoisomerase II was investigated under conditions excluding enzyme-mediated DNA cleavage.  This demonstrated that the anthracycline, aclarubicin, prevents topoisomerase II from performing its initial non-covalent DNA binding reaction and thereby abolishes the DNA cleavage reaction of the enzyme.  The results presented here demonstrate that profound differences exist in the mode of action of different agents targeting topoisomerase II, and that the enzyme can be affected by such agents at both its DNA binding, cleavage and religation subreactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_qa0T1FlNF7Vg90H21EOLACvtfcHk0lg8f-8uySnrAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlt1Shuw%253D%253D&md5=ee63232df869c9e2b5886e9a0af928d1</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2F0022-2836%2892%2990863-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-2836%252892%252990863-F%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DB.%2BS.%26aulast%3DSinding%26aufirst%3DJ.%26aulast%3DAndersen%26aufirst%3DA.%2BH.%26aulast%3DAlsner%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DP.%2BB.%26aulast%3DWestergaard%26aufirst%3DO.%26atitle%3DMode%2520of%2520action%2520of%2520topoisomerase%2520II-targeting%2520agents%2520at%2520a%2520specific%2520DNA%2520sequence.%2520Uncoupling%2520the%2520DNA%2520binding%252C%2520cleavage%2520and%2520religation%2520events%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1992%26volume%3D228%26issue%3D3%26spage%3D778%26epage%3D786%26doi%3D10.1016%2F0022-2836%2892%2990863-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourquier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binaschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Animati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capranico, G.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase poisoning activity of novel disaccharide anthracyclines</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1124/mol.56.1.77</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1124%2Fmol.56.1.77" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10385686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1MXksFOmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=77-84&issue=1&author=F.+Guanoauthor=P.+Pourquierauthor=S.+Tinelliauthor=M.+Binaschiauthor=M.+Bigioniauthor=F.+Animatiauthor=S.+Manziniauthor=F.+Zuninoauthor=G.+Kohlhagenauthor=Y.+Pommierauthor=G.+Capranico&title=Topoisomerase+poisoning+activity+of+novel+disaccharide+anthracyclines&doi=10.1124%2Fmol.56.1.77"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase poisoning activity of novel disaccharide anthracyclines</span></div><div class="casAuthors">Guano, Fulvio; Pourquier, Philippe; Tinelli, Stella; Binaschi, Monica; Bigioni, Mario; Animati, Fabio; Manzini, Stefano; Zunino, Franco; Kohlhagen, Glenda; Pommier, Yves; Capranico, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-84</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Doxorubicin and idarubicin are very effective anticancer drugs in the treatment of human hematol. malignancies and solid tumors.  These agents are well known topoisomerase II poisons; however, some anthracycline analogs recently have been shown to poison topoisomerase I.  In the present work, we assayed novel disaccharide analogs and the parent drug, idarubicin, for their poisoning effects of human topoisomerase I and topoisomerases IIα and IIβ.  Drugs were evaluated with a DNA cleavage assay in vitro and with a yeast system to test whether the agents were able to poison the enzymes in vivo.  We have found that the test agents are potent poisons of both topoisomerases IIα and IIβ.  The axial orientation of the second sugar relative to the first one of the novel disaccharide analogs was shown to be required for poisoning activity and cytotoxicity.  Interestingly, idarubicin and the new analogs stimulated topoisomerase I-mediated DNA cleavage at low levels in vitro.  As expected, the cytotoxic level of the drug was highly affected by the content of topoisomerase II; nevertheless, the test agents had a yeast cell-killing activity that also was weakly dependent on cellular topoisomerase I content.  The results are relevant for the full understanding of the mol. mechanism of topoisomerase poisoning by anticancer drugs, and they define structural determinants of anthracyclines that may help in the rational design of new compds. directed against topoisomerase I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYw-4euo7PZ7Vg90H21EOLACvtfcHk0liUKS1kkGPWoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksFOmtrc%253D&md5=3cecaa5ccb46a4ced61d0656c8145b3a</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1124%2Fmol.56.1.77&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.56.1.77%26sid%3Dliteratum%253Aachs%26aulast%3DGuano%26aufirst%3DF.%26aulast%3DPourquier%26aufirst%3DP.%26aulast%3DTinelli%26aufirst%3DS.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DBigioni%26aufirst%3DM.%26aulast%3DAnimati%26aufirst%3DF.%26aulast%3DManzini%26aufirst%3DS.%26aulast%3DZunino%26aufirst%3DF.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCapranico%26aufirst%3DG.%26atitle%3DTopoisomerase%2520poisoning%2520activity%2520of%2520novel%2520disaccharide%2520anthracyclines%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26issue%3D1%26spage%3D77%26epage%3D84%26doi%3D10.1124%2Fmol.56.1.77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissery, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saucier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisagni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavelle, F.</span></span> <span> </span><span class="NLM_article-title">Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5987</span>– <span class="NLM_lpage">5993</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8261412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2cXht1Cisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=5987-5993&issue=24&author=J.+F.+Riouauthor=P.+Fosseauthor=C.+H.+Nguyenauthor=A.+K.+Larsenauthor=M.+C.+Bisseryauthor=L.+Grondardauthor=J.+M.+Saucierauthor=E.+Bisagniauthor=F.+Lavelle&title=Intoplicine+%28RP+60475%29+and+its+derivatives%2C+a+new+class+of+antitumor+agents+inhibiting+both+topoisomerase+I+and+II+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities</span></div><div class="casAuthors">Riou, Jean Francois; Fosse, Philippe; Chi Hung Nguyen; Larsen, Annette Kragh; Bissery, Marie Christine; Grondard, Lucile; Saucier, Jean Marie; Bisagni, Emile; Lavelle, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5987-93</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Intoplicine (RP 60475, NSC 645008) (I) is an antitumor compd. of the 7H-benzo[e]pyrido[4,3-b]indole series which is now being tested in clin. trials.  Intoplicine and 22 analogs were evaluated for their effects on topoisomerase I- and II-mediated DNA cleavage reactions by using enzyme purified from calf thymus.  Site-specific DNA cleavage mediated by topoisomerase occurred with 7H-benzo[e]pyrido[4,3-b]indole derivs. but not with 11H-benzo[g]pyrido[4,3-b]indole derivs.  Site-specific DNA cleavage mediated by topoisomerase II occurred with derivs. having OH groups at the 3-position on the 7H-benzo[e]pyrido[4,3-b]indole ring or at the 4-position on the 11H-benzo[g]pyrido[4,3-b]indole ring.  Study of the relationships between the in vivo antitumor activity on P388 leukemia and the topoisomerase I- and/or II-mediated DNA cleavage activity revealed that the most highly active antitumor compds. possessed both topoisomerase I- and II-inhibitory properties.  Compds. selectively inhibiting either topoisomerase I or II were less active.  These results suggest that dual topoisomerase I and II inhibition is crit. for the antitumor activity of this new series of antitumor compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNYqdvrEdRfLVg90H21EOLACvtfcHk0liUKS1kkGPWoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXht1Cisbw%253D&md5=2cbf243e21dbd1b76e971a848da8d1f4</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiou%26aufirst%3DJ.%2BF.%26aulast%3DFosse%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DC.%2BH.%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DBissery%26aufirst%3DM.%2BC.%26aulast%3DGrondard%26aufirst%3DL.%26aulast%3DSaucier%26aufirst%3DJ.%2BM.%26aulast%3DBisagni%26aufirst%3DE.%26aulast%3DLavelle%26aufirst%3DF.%26atitle%3DIntoplicine%2520%2528RP%252060475%2529%2520and%2520its%2520derivatives%252C%2520a%2520new%2520class%2520of%2520antitumor%2520agents%2520inhibiting%2520both%2520topoisomerase%2520I%2520and%2520II%2520activities%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26issue%3D24%26spage%3D5987%26epage%3D5993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelcnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span> <span> </span><span class="NLM_article-title">Recent developments of DNA poisons - human DNA topoisomerase IIα inhibitors - as anticancer agents</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2474</span>– <span class="NLM_lpage">2488</span>, <span class="refDoi"> DOI: 10.2174/1381612811319130016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1381612811319130016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23363399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2474-2488&issue=13&author=B.+Pogorelcnikauthor=A.+Perdihauthor=T.+Solmajer&title=Recent+developments+of+DNA+poisons+-+human+DNA+topoisomerase+II%CE%B1+inhibitors+-+as+anticancer+agents&doi=10.2174%2F1381612811319130016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments of DNA poisons - human DNA topoisomerase IIα inhibitors - as anticancer agents</span></div><div class="casAuthors">Pogorelcnik, Barbara; Perdih, Andrej; Solmajer, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2474-2488</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are an important family of enzymes that catalyze the induction of topol. changes in the DNA mol.  Their ability to modulate the topol. of the DNA makes DNA topoisomerases a key player in several vital cell processes such as replication, transcription, chromosome sepn. and segregation.  Consequently, they already represent an important collection of macromol. targets for some of the established anticancer drugs on the market as well as serve as templates in the development of novel anticancer drugs esp. supported by recent structural advances in the field.  The aim of this review is to provide an overview of the recent developments in the field of DNA poisons - a major class of human topoisomerase IIα inhibitors - of which several are already in clin. use.  Due to frequently experienced occurrence of serious side effects of these mols. during therapy, esp. cardiotoxicity issues, further drug design efforts were initiated already yielding novel promising compds. that have overcome this issue and already entered into clin. studies.  Some of the presented and discussed chem. classes include intercalators, non-intercalators and redox-dependent poisons of human topoisomerase IIα.  In particular, this review focuses on the currently available structure-based standpoint of mol. design and on the medicinal chemist's perspective of this field of anticancer drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC9ShTXwqB17Vg90H21EOLACvtfcHk0ljCL3Qj2SOX9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrw%253D&md5=77e1705a6cf13bda0216d3c73f8ddac9</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.2174%2F1381612811319130016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319130016%26sid%3Dliteratum%253Aachs%26aulast%3DPogorelcnik%26aufirst%3DB.%26aulast%3DPerdih%26aufirst%3DA.%26aulast%3DSolmajer%26aufirst%3DT.%26atitle%3DRecent%2520developments%2520of%2520DNA%2520poisons%2520-%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520inhibitors%2520-%2520as%2520anticancer%2520agents%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26issue%3D13%26spage%3D2474%26epage%3D2488%26doi%3D10.2174%2F1381612811319130016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span>WHO
drug information. Volume  <span class="NLM_volume">1</span>, Number 4, <span class="NLM_year">1987</span>, Recommended INN list 27. <a href="http://apps.who.int/medicinedocs/index/assoc/h5775e/h5775e.pdf" class="extLink">http://apps.who.int/medicinedocs/index/assoc/h5775e/h5775e.pdf</a> (accessed April 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=WHO%0Adrug+information.+Volume+1%2C+Number+4%2C+1987%2C+Recommended+INN+list+27.+http%3A%2F%2Fapps.who.int%2Fmedicinedocs%2Findex%2Fassoc%2Fh5775e%2Fh5775e.pdf+%28accessed+April+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26volume%3D1%26date%3D1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span class="NLM_publisher-name">U.S. National Library of Medicine</span>. Search result
for aclarubicin. <a href="https://clinicaltrials.gov/ct2/results?term=aclarubicin&amp;rank=1#rowId0" class="extLink">https://clinicaltrials.gov/ct2/results?term=aclarubicin&rank=1#rowId0</a> (accessed April 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+U.S.+National+Library+of+Medicine.+Search+result%0Afor+aclarubicin.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3Daclarubicin%26rank%3D1%23rowId0+%28accessed+April+20%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26pub%3DU.S.%2520National%2520Library%2520of%2520Medicine" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis, GC selective DNA binding and topoisomerase II inhibition activities of ruthenium(II) polypyridyl complex containing 11-aminopteridino[6,7-f][1,10]phenanthrolin-13(12<i>H</i>)-one</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1059</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2007.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.jinorgbio.2007.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=18295337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVyjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=1050-1059&issue=5%E2%80%936&author=F.+Gaoauthor=H.+Chaoauthor=F.+Zhouauthor=X.+Chenauthor=Y.+F.+Weiauthor=L.+N.+Ji&title=Synthesis%2C+GC+selective+DNA+binding+and+topoisomerase+II+inhibition+activities+of+ruthenium%28II%29+polypyridyl+complex+containing+11-aminopteridino%5B6%2C7-f%5D%5B1%2C10%5Dphenanthrolin-13%2812H%29-one&doi=10.1016%2Fj.jinorgbio.2007.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, GC selective DNA binding and topoisomerase II inhibition activities of ruthenium(II) polypyridyl complex containing 11-aminopteridino[6,7-f][1,10]phenanthrolin-13(12H)-one</span></div><div class="casAuthors">Gao, Feng; Chao, Hui; Zhou, Feng; Chen, Xin; Wei, Yuan-Fang; Ji, Liang-Nian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">1050-1059</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A DNA-intercalating Ru(II) polypyridyl complex [Ru(bpy)2(appo)]2+ (bpy = 2,2'-bipyridine; appo = 11-aminopteridino[6,7-f][1,10]phenanthrolin-13(12H)-one) has been synthesized and characterized by elemental anal., electrospray mass spectra, 1H NMR, UV/Vis spectrum, fluorescent spectrum and electrochem.  The DNA-binding, photocleavage, and topoisomerase inhibition of the complex was studied.  Interestingly, the complex binds to DNA via an intercalative mode with preference for GC sequences and cleaves the pBR322 DNA upon irradn.  In addn., the complex shows high inhibition activity against topoisomerase II by interfere the DNA religation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdmzHnUcpiJrVg90H21EOLACvtfcHk0ljCL3Qj2SOX9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVyjs7c%253D&md5=ca8943da37c82a045904daa8a79e2eb3</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2007.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2007.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DF.%26aulast%3DChao%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DY.%2BF.%26aulast%3DJi%26aufirst%3DL.%2BN.%26atitle%3DSynthesis%252C%2520GC%2520selective%2520DNA%2520binding%2520and%2520topoisomerase%2520II%2520inhibition%2520activities%2520of%2520ruthenium%2528II%2529%2520polypyridyl%2520complex%2520containing%252011-aminopteridino%255B6%252C7-f%255D%255B1%252C10%255Dphenanthrolin-13%252812H%2529-one%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2008%26volume%3D102%26issue%3D5%25E2%2580%25936%26spage%3D1050%26epage%3D1059%26doi%3D10.1016%2Fj.jinorgbio.2007.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span> <span> </span><span class="NLM_article-title">DNA-binding, topoisomerases I and II inhibition and <i>in-vitro</i> cytotoxicity of ruthenium(II) polypyridyl complexes: [Ru(dppz)2L](2+) (L = dppz-11-CO2Me and dppz)</span>. <i>Spectrochim. Acta, Part A</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.saa.2014.06.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.saa.2014.06.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25062055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KlsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=101-109&author=X.+Heauthor=L.+Jinauthor=L.+Tan&title=DNA-binding%2C+topoisomerases+I+and+II+inhibition+and+in-vitro+cytotoxicity+of+ruthenium%28II%29+polypyridyl+complexes%3A+%5BRu%28dppz%292L%5D%282%2B%29+%28L+%3D+dppz-11-CO2Me+and+dppz%29&doi=10.1016%2Fj.saa.2014.06.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-binding, topoisomerases I and II inhibition and in vitro cytotoxicity of ruthenium(II) polypyridyl complexes: [Ru(dppz)2L]2+ (L = dppz-11-CO2Me and dppz)</span></div><div class="casAuthors">He, Xiaojun; Jin, Lianhe; Tan, Lifeng</div><div class="citationInfo"><span class="NLM_cas:title">Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101-109</span>CODEN:
                <span class="NLM_cas:coden">SAMCAS</span>;
        ISSN:<span class="NLM_cas:issn">1386-1425</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two ruthenium(II) polypyridyl complexes, [Ru(dppz)2dppz-11-CO2Me](ClO4)2 (Ru1) and [Ru(dppz)3](ClO4)2 (Ru2), have been synthesized and characterized (dppz = dipyrido[3,2-a:2',3'-c]phenazine; dppz-11-CO2Me = Me dipyrido[3,2-a:2',3'-c]phenazine-11-carboxylate).  The spectral characteristics of Ru1 and Ru2 were investigated by fluorescence spectroscopy and revealed that both complexes were sensitive to solvent polarity.  The binding properties of the two complexes towards calf-thymus DNA (CT-DNA) have been investigated by different spectrophotometric methods and viscosity measurements, indicating that both complexes bind to CT-DNA by intercalation, but with different binding affinities.  Topoisomerase inhibition and DNA strand passage assay demonstrates that the two complexes are dual inhibitors of topoisomerases I and IIa.  However, the cytotoxicity of both complexes has been evaluated by MTT assays and Giemsa staining expts.  The main results reveal that the ester functional group has a significant effect on the DNA-binding affinities and topoisomerases inhibition effects of Ru1 and Ru2, and further advance the authors' knowledge on the DNA-binding and topoisomerase inhibition by Ru(II) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppit6q12DgL7Vg90H21EOLACvtfcHk0liwHugCBqLlFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KlsrbL&md5=8e0cc6e987cdf93432132daa43790600</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.saa.2014.06.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.saa.2014.06.147%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DL.%26atitle%3DDNA-binding%252C%2520topoisomerases%2520I%2520and%2520II%2520inhibition%2520and%2520in-vitro%2520cytotoxicity%2520of%2520ruthenium%2528II%2529%2520polypyridyl%2520complexes%253A%2520%255BRu%2528dppz%25292L%255D%25282%252B%2529%2520%2528L%2520%253D%2520dppz-11-CO2Me%2520and%2520dppz%2529%26jtitle%3DSpectrochim.%2520Acta%252C%2520Part%2520A%26date%3D2015%26volume%3D135%26spage%3D101%26epage%3D109%26doi%3D10.1016%2Fj.saa.2014.06.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span> <span> </span><span class="NLM_article-title">Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f][1,10]phenanthroline derivatives</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2013.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.jinorgbio.2013.09.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24145066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWju7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2014&pages=15-27&author=Y.+C.+Wangauthor=C.+Qianauthor=Z.+L.+Pengauthor=X.+J.+Houauthor=L.+L.+Wangauthor=H.+Chaoauthor=L.+N.+Ji&title=Dual+topoisomerase+I+and+II+poisoning+by+chiral+Ru%28II%29+complexes+containing+2-thiophenylimidazo%5B4%2C5-f%5D%5B1%2C10%5Dphenanthroline+derivatives&doi=10.1016%2Fj.jinorgbio.2013.09.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f|[1,10|phenanthroline derivatives</span></div><div class="casAuthors">Wang, Yu-Chuan; Qian, Chen; Peng, Zai-Li; Hou, Xiao-Juan; Wang, Li-Li; Chao, Hui; Ji, Liang-Nian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of chiral RuII complexes bearing thiophene ligands were synthesized and characterized.  Both RuII complexes Δ/Λ-Rubpy2pscl|2+ Δ/Λ-1 and Δ/Λ-Rubpy2psbr|2+ Δ/Λ-2 bpy = 2,2'-bipyridine, pscl = 2-5-chlorothiophen-2-ylimidazo4,5-f|1,10|phenanthroline, psbr = 2-5-bromothiophen-2-ylimidazo4,5-f|1,10|phenanthroline showed antitumor activities against A549, HepG2 and BEL-7402 tumor cell lines, esp. HeLa tumor cell line.  Moreover, Δ enantiomers were more active than Λ enantiomers, accounting for the different cellular uptake.  In addn., with the extension of time, these enantiomers could finally accumulate in the nucleus, suggesting that nucleic acids were the cellular target of these enantiomers.  The DNA-binding behaviors of complexes were studied using spectroscopic and viscosity measurements.  Results suggested that four complexes could bind to DNA in an intercalative mode but no obvious DNA-binding selectivity between the enantiomers was obsd.  Topoisomerase inhibition and DNA religation assay confirmed that four complexes acted as efficient dual topoisomerase I and II poisons, DNA strand breaks had also been obsd. from alk. single cell gel electrophoresis comet assay. Δ-1 and Δ-2 inhibited the growth of HeLa cells through the induction of apoptotic cell death, as evidenced by the Alexa Fluor 488 annexin V staining assays and flow cytometry anal.  The results demonstrated that Δ/Λ-1 and Δ/Λ-2 acted as dual topoisomerase I and II poisons and caused DNA damage that could lead to cell cycle arrest by apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5JeacrSJiWrVg90H21EOLACvtfcHk0liwHugCBqLlFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWju7vN&md5=6401d758e09548ffdb3ed7aebb6889e8</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2013.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2013.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DZ.%2BL.%26aulast%3DHou%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DChao%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DL.%2BN.%26atitle%3DDual%2520topoisomerase%2520I%2520and%2520II%2520poisoning%2520by%2520chiral%2520Ru%2528II%2529%2520complexes%2520containing%25202-thiophenylimidazo%255B4%252C5-f%255D%255B1%252C10%255Dphenanthroline%2520derivatives%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2014%26volume%3D130%26spage%3D15%26epage%3D27%26doi%3D10.1016%2Fj.jinorgbio.2013.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A perspective on multi-target drug discovery and design for complex diseases</span>. <i>Clinical and Translational Medicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29340951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=3&issue=1&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+perspective+on+multi-target+drug+discovery+and+design+for+complex+diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on multi-target drug discovery and design for complex diseases</span></div><div class="casAuthors">Ramsay Rona R; Popovic-Nikolic Marija R; Nikolic Katarina; Uliassi Elisa; Bolognesi Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract">Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors.  Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds.  Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done.  These approaches depend on the prior identification of clinically and biologically validated targets.  This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJhSGsWpifCZcXNb62YGmbfW6udTcc2eakAHP-i5koP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D&md5=5b05a73a3bbc955c77b9b2df93deb946</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520perspective%2520on%2520multi-target%2520drug%2520discovery%2520and%2520design%2520for%2520complex%2520diseases%26jtitle%3DClinical%2520and%2520Translational%2520Medicine%26date%3D2018%26volume%3D7%26issue%3D1%26spage%3D3%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korcsmaros, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szalay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csermely, P.</span></span> <span> </span><span class="NLM_article-title">How to design multi-target drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1517/17460441.2.6.799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1517%2F17460441.2.6.799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23488998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptFGru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=799-808&issue=6&author=T.+Korcsmarosauthor=M.+S.+Szalayauthor=C.+Bodeauthor=I.+A.+Kovacsauthor=P.+Csermely&title=How+to+design+multi-target+drugs&doi=10.1517%2F17460441.2.6.799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">How to design multi-target drugs: target search options in cellular networks</span></div><div class="casAuthors">Korcsmaros, Tamas; Szalay, Mate S.; Bode, Csaba; Kovacs, Istvan A.; Csermely, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">799-808</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Despite improved rational drug design and a remarkable progress in genomic, proteomic and high-throughput screening methods, the no. of novel, single-target drugs has fallen far behind expectations during the past decade.  Multi-target drugs multiply the no. of pharmacol. relevant target mols. by introducing a set of indirect, network-dependent effects.  Parallel with this, the low-affinity binding of multi-target drugs eases the constraints of druggability and significantly increases the size of the druggable proteome.  These effects tremendously expand the no. of potential drug targets and introduce novel classes of multi-target drugs with smaller side effects and toxicity.  Here, the authors review the recent progress in this field, compare possible network attack strategies and propose several methods to find target-sets for multi-target drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGAOF7QblLM7Vg90H21EOLACvtfcHk0lhV5nMZNO-AhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptFGru7s%253D&md5=7d132e26ec4f481ee64392f457a2dd6c</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.6.799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.6.799%26sid%3Dliteratum%253Aachs%26aulast%3DKorcsmaros%26aufirst%3DT.%26aulast%3DSzalay%26aufirst%3DM.%2BS.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DKovacs%26aufirst%3DI.%2BA.%26aulast%3DCsermely%26aufirst%3DP.%26atitle%3DHow%2520to%2520design%2520multi-target%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D799%26epage%3D808%26doi%3D10.1517%2F17460441.2.6.799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span> <span> </span><span class="NLM_article-title">Antitumor agents - CLXXIII. Synthesis and evaluation of camptothecin-4 beta-amino-4′-<i>O</i>-demethyl epipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases and as cytotoxic agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1488</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(97)00102-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0968-0896%2897%2900102-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9313854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVGku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1997&pages=1481-1488&issue=8&author=K.+F.+Bastowauthor=H.+K.+Wangauthor=Y.+C.+Chengauthor=K.+H.+Lee&title=Antitumor+agents+-+CLXXIII.+Synthesis+and+evaluation+of+camptothecin-4+beta-amino-4%E2%80%B2-O-demethyl+epipodophyllotoxin+conjugates+as+inhibitors+of+mammalian+DNA+topoisomerases+and+as+cytotoxic+agents&doi=10.1016%2FS0968-0896%2897%2900102-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor agents-CLXXIII. Synthesis and evaluation of camptothecin-4β-amino-4'-O-demethyl epipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases I and as cytotoxic agents</span></div><div class="casAuthors">Bastow, Kenneth F.; Wang, Hui-Kang; Cheng, Yung-Chi; Lee, Kuo-Hsiung</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1481-1488</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Two conjugates composed of a camptothecin and a 4'-O-demethyl epipodophyllotoxin deriv. joined by an imine linkage were prepd. and evaluated as inhibitors of mammalian DNA topoisomerases I and II.  Target compds. stimulated cleavable complex formation with both types of enzyme in vitro although activities were reduced at least 2-fold relative to the activity of unconjugated constituents.  The behavior of the most active conjugate as an inhibitor of cell growth closely resembled both topoisomerase I- and II- inhibitory components in that the compd. displayed a combined spectrum of activity against various drug-resistant KB sublines.  Cytotoxic activity and selectivity were largely retained through conjugation, the exception being a lower than expected activity against a pleiotrophic multidrug-resistant subline.  The induced levels and the properties of cellular protein-assocd. DNA complexes were consistent with topoisomerase involvement and with the in vitro cleavage assay results.  Based on the present findings, conjugation afforded cleavable complex-forming topoisomerase inhibitors which display dual target specificity and a broad spectrum of cytotoxic activity against drug-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdGOBboPvKS7Vg90H21EOLACvtfcHk0lhV5nMZNO-AhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVGku7s%253D&md5=6715e0cf9ffe34007edce360407afbce</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2897%2900102-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252897%252900102-8%26sid%3Dliteratum%253Aachs%26aulast%3DBastow%26aufirst%3DK.%2BF.%26aulast%3DWang%26aufirst%3DH.%2BK.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26aulast%3DLee%26aufirst%3DK.%2BH.%26atitle%3DAntitumor%2520agents%2520-%2520CLXXIII.%2520Synthesis%2520and%2520evaluation%2520of%2520camptothecin-4%2520beta-amino-4%25E2%2580%25B2-O-demethyl%2520epipodophyllotoxin%2520conjugates%2520as%2520inhibitors%2520of%2520mammalian%2520DNA%2520topoisomerases%2520and%2520as%2520cytotoxic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1997%26volume%3D5%26issue%3D8%26spage%3D1481%26epage%3D1488%26doi%3D10.1016%2FS0968-0896%2897%2900102-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Troconiz, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendros, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prunonosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Mayoral, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peraire, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Principe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delavault, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvitkovic, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesimple, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetic/ pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a phase I dose finding study in patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1007/s00280-012-1906-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs00280-012-1906-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=22699813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2012&pages=239-250&issue=2&author=I.+F.+Troconizauthor=J.+M.+Cendrosauthor=E.+Sotoauthor=J.+Prunonosaauthor=A.+Perez-Mayoralauthor=C.+Peraireauthor=P.+Principeauthor=P.+Delavaultauthor=F.+Cvitkovicauthor=T.+Lesimpleauthor=R.+Obach&title=Population+pharmacokinetic%2F+pharmacodynamic+modeling+of+drug-induced+adverse+effects+of+a+novel+homocamptothecin+analog%2C+elomotecan+%28BN80927%29%2C+in+a+phase+I+dose+finding+study+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-012-1906-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors</span></div><div class="casAuthors">Troconiz, Inaki F.; Cendros, Josep-Maria; Soto, Elena; Prunonosa, Joan; Perez-Mayoral, Ana; Peraire, Concepcion; Principe, Paola; Delavault, Patrick; Cvitkovic, Frederique; Lesimple, Thierry; Obach, Rosendo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-250</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">To characterize the pharmacokinetic profile of elomotecan, a novel homocamptothecin analog, evaluate the dose-limiting toxicities, and establish the relationship between exposure and toxicity in the first Phase I study in patients with advanced malignant solid tumors.  Preliminary antitumor efficacy results are also provided.  Elomotecan was administered as a 30-min i.v. infusion at doses ranging from 1.5 to 75 mg once every 3 wk to 56 patients with advanced solid tumors.  Plasma concn. data and adverse effects were modeled using the population approach.  Elomotecan showed linear pharmacokinetics, and clearance was decreased with age.  The model predicts a 47 and 61 % redn. in CL for patients aged 60 and 80 years, resp., when compared with younger patients (30 years).  Neutropenia represented the dose-limiting toxicity.  The max. tolerated dose and the recommended dose (RD) were 75 and 60 mg, resp.  Elomotecan elicited a 20, 5, 2, and 2 % severe (grade 4) neutropenia, asthenia, nausea, and vomiting at the RD, resp.  Of the subjects in the RD cohort, 41.7 % had a stable disease mean duration of 123.6 ± 43.4 days.  The pharmacokinetic parameters and the toxicity pattern of elomotecan suggest that this novel homocamptothecin analog should be further explored in the clin. setting using a dose of 60 mg administered as a 30-min i.v. infusion, once every 3 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLbTogIgYLaLVg90H21EOLACvtfcHk0lhHTE4cTEG2Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhsb3M&md5=f21ecb02aedc90e42f2fdc93ff14f680</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1906-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1906-y%26sid%3Dliteratum%253Aachs%26aulast%3DTroconiz%26aufirst%3DI.%2BF.%26aulast%3DCendros%26aufirst%3DJ.%2BM.%26aulast%3DSoto%26aufirst%3DE.%26aulast%3DPrunonosa%26aufirst%3DJ.%26aulast%3DPerez-Mayoral%26aufirst%3DA.%26aulast%3DPeraire%26aufirst%3DC.%26aulast%3DPrincipe%26aufirst%3DP.%26aulast%3DDelavault%26aufirst%3DP.%26aulast%3DCvitkovic%26aufirst%3DF.%26aulast%3DLesimple%26aufirst%3DT.%26aulast%3DObach%26aufirst%3DR.%26atitle%3DPopulation%2520pharmacokinetic%252F%2520pharmacodynamic%2520modeling%2520of%2520drug-induced%2520adverse%2520effects%2520of%2520a%2520novel%2520homocamptothecin%2520analog%252C%2520elomotecan%2520%2528BN80927%2529%252C%2520in%2520a%2520phase%2520I%2520dose%2520finding%2520study%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D70%26issue%3D2%26spage%3D239%26epage%3D250%26doi%3D10.1007%2Fs00280-012-1906-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennouna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefresne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douillard, J. Y.</span></span> <span> </span><span class="NLM_article-title">First-in-man study of tafluposide, a novel inhibitor of topoisomerase I and II</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">A138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17237274" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=A138&issue=11&author=J.+P.+Delordauthor=J.+Bennounaauthor=V.+Di%C3%A9rasauthor=M.+Camponeauthor=F.+Lefresneauthor=V.+Aslanisauthor=J.+Y.+Douillard&title=First-in-man+study+of+tafluposide%2C+a+novel+inhibitor+of+topoisomerase+I+and+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelord%26aufirst%3DJ.%2BP.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DLefresne%26aufirst%3DF.%26aulast%3DAslanis%26aufirst%3DV.%26aulast%3DDouillard%26aufirst%3DJ.%2BY.%26atitle%3DFirst-in-man%2520study%2520of%2520tafluposide%252C%2520a%2520novel%2520inhibitor%2520of%2520topoisomerase%2520I%2520and%2520II%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D11%26spage%3DA138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span>AdisInsight. <span class="NLM_publisher-name">Springer Science</span>. <a href="https://adisinsight.springer.com/drugs/800012192" class="extLink">https://adisinsight.springer.com/drugs/800012192</a> (accessed April 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AdisInsight.+Springer+Science.+https%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800012192+%28accessed+April+20%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26pub%3DSpringer%2520Science" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span class="NLM_publisher-name">U.S. National Library of Medicine</span>. Search result
for elomotecan. <a href="https://clinicaltrials.gov/ct2/show/record/NCT01435096?term=Elomotecan&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/record/NCT01435096?term=Elomotecan&rank=1</a> (accessed April 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+U.S.+National+Library+of+Medicine.+Search+result%0Afor+elomotecan.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT01435096%3Fterm%3DElomotecan%26rank%3D1+%28accessed+April+20%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26pub%3DU.S.%2520National%2520Library%2520of%2520Medicine" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: synthesis, biological evaluation and 3D-QSAR study</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2016.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26945111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1egu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=228-245&author=R.+Karkiauthor=K.+Y.+Junauthor=T.+M.+Kadayatauthor=S.+Shinauthor=T.+B.+Thapa+Magarauthor=G.+Bistauthor=A.+Shresthaauthor=Y.+Naauthor=Y.+Kwonauthor=E.+S.+Lee&title=A+new+series+of+2-phenol-4-aryl-6-chlorophenyl+pyridine+derivatives+as+dual+topoisomerase+I%2FII+inhibitors%3A+synthesis%2C+biological+evaluation+and+3D-QSAR+study&doi=10.1016%2Fj.ejmech.2016.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study</span></div><div class="casAuthors">Karki, Radha; Jun, Kyu-Yeon; Kadayat, Tara Man; Shin, Somin; Thapa Magar, Til Bahadur; Bist, Ganesh; Shrestha, Aarajana; Na, Younghwa; Kwon, Youngjoo; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-245</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As a continuous effort to develop novel antitumor agents, a new series of forty-five 2-phenol-4-aryl-6-chlorophenyl pyridine compds. I (R1 = 2-HOC6H4, 3-HOC6H4, 4-HOC6H4; R2 = Ph, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl; R3 = 2-ClC6H4, 3-ClC6H4, 4-ClC6H4) were synthesized and evaluated for cytotoxicity against four different human cancer cell lines (DU145, HCT15, T47D, and HeLa), and topoisomerase I and II inhibitory activity.  Several compds. I (R1 = 3-HOC6H4, 4-HOC6H4; R2 = Ph, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl; R3 = 2-ClC6H4, 3-ClC6H4, 4-ClC6H4) displayed strong to moderate dual topoisomerase I and II inhibitory activity at 100 μM.  It was obsd. that hydroxyl and chlorine moiety at meta or para position of Ph ring is favorable for dual topoisomerase inhibitory activity and cytotoxicity.  Most of the compds. I displayed stronger cytotoxicities than those of all pos. controls against the HCT15 and T47D cell lines.  For investigation of the structure-activity relationships, a 3D-QSAR anal. using the method of comparative mol. field anal. (CoMFA) was performed.  The generated 3D contour maps can be used for further rational design of novel terpyridine derivs. I as highly selective and potent cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeg-6-GpSiTrVg90H21EOLACvtfcHk0lhHTE4cTEG2Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1egu70%253D&md5=1d85da38e23e3c8d9e35188d189c64d8</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DA%2520new%2520series%2520of%25202-phenol-4-aryl-6-chlorophenyl%2520pyridine%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%252FII%2520inhibitors%253A%2520synthesis%252C%2520biological%2520evaluation%2520and%25203D-QSAR%2520study%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D113%26spage%3D228%26epage%3D245%26doi%3D10.1016%2Fj.ejmech.2016.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, topoisomerase I inhibition and structure-activity relationship study of 2,4,6-trisubstituted pyridine derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.11.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmcl.2003.11.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=14980693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFelsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1333-1337&issue=5&author=L.+X.+Zhaoauthor=Y.+S.+Moonauthor=A.+Basnetauthor=E.+K.+Kimauthor=Y.+Jahngauthor=J.+G.+Parkauthor=T.+C.+Jeongauthor=W.+J.+Choauthor=S.+U.+Choiauthor=C.+O.+Leeauthor=S.+Y.+Leeauthor=C.+S.+Leeauthor=E.+S.+Lee&title=Synthesis%2C+topoisomerase+I+inhibition+and+structure-activity+relationship+study+of+2%2C4%2C6-trisubstituted+pyridine+derivatives&doi=10.1016%2Fj.bmcl.2003.11.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, topoisomerase I inhibition and structure-activity relationship study of 2,4,6-trisubstituted pyridine derivatives</span></div><div class="casAuthors">Zhao, Long-Xuan; Moon, Yoon-Soo; Basnet, Arjun; Kim, Eun-kyung; Jahng, Yurngdong; Park, Jae Gyu; Jeong, Tae Cheon; Cho, Won-Jea; Choi, Sang-Un; Lee, Chong Ock; Lee, Sun-Young; Lee, Chong-Soon; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">For the development of new anticancer agents, 2,4,6-trisubstituted pyridines carrying Ph, 2-pyridyl, 2-furyl, 2-thienyl, 2-furylvinyl and 2-thienylvinyl substituents were prepd. and evaluated for their topoisomerase I inhibitory activity.  Among the thirteen prepd. compds., four compds. exhibited strong topoisomerase I inhibitory activity.  A structure-activity relationship study indicated that the 2-thienyl-4-furylpyridine skeleton was important for topoisomerase I inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_JMnIZ_8ES7Vg90H21EOLACvtfcHk0ljtsQ1IAIjDRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFelsrc%253D&md5=c32796b3ef09a22f7d697fe903599af1</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.11.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.11.084%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%2BX.%26aulast%3DMoon%26aufirst%3DY.%2BS.%26aulast%3DBasnet%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DE.%2BK.%26aulast%3DJahng%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DJ.%2BG.%26aulast%3DJeong%26aufirst%3DT.%2BC.%26aulast%3DCho%26aufirst%3DW.%2BJ.%26aulast%3DChoi%26aufirst%3DS.%2BU.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DSynthesis%252C%2520topoisomerase%2520I%2520inhibition%2520and%2520structure-activity%2520relationship%2520study%2520of%25202%252C4%252C6-trisubstituted%2520pyridine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D5%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2003.11.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.10.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmc.2009.10.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19939682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFykurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=377-386&issue=1&author=P.+Thapaauthor=R.+Karkiauthor=U.+Thapaauthor=Y.+Jahngauthor=M.+J.+Jungauthor=J.+M.+Namauthor=Y.+Naauthor=Y.+Kwonauthor=E.+S.+Lee&title=2-Thienyl-4-furyl-6-aryl+pyridine+derivatives%3A+synthesis%2C+topoisomerase+I+and+II+inhibitory+activity%2C+cytotoxicity%2C+and+structure-activity+relationship+study&doi=10.1016%2Fj.bmc.2009.10.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">2-Thienyl-4-furyl-6-aryl pyridine derivatives: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study</span></div><div class="casAuthors">Thapa, Pritam; Karki, Radha; Thapa, Uttam; Jahng, Yurngdong; Jung, Mi-Ja; Nam, Jung Min; Na, Younghwa; Kwon, Youngjoo; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">377-386</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Designed and synthesized 60 2-thienyl-4-furyl-6-aryl pyridine derivs. were evaluated for their topoisomerase I and II inhibitory activities at 20 μM and 100 μM and cytotoxicity against several human cancer cell lines.  Compds. 8 (I), 9, 11-29 showed significant topoisomerase II inhibitory activity and compds. 10 and 11 showed significant topoisomerase I inhibitory activity.  Most of the compds. (7-21) possessing 2-(5-chlorothiophen-2-yl)-4-(furan-3-yl) moiety showed higher or similar cytotoxicity against HCT15 cell line as compared to stds.  Most of the selected compds. displayed moderate cytotoxicity against MCF-7, HeLa, DU145, and K562 cell lines.  Structure-activity relationship study revealed that 2-(5-chlorothiophen-2-yl)-4-(furan-3-yl) moiety has an important role in displaying biol. activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps7zeBj2eZmbVg90H21EOLACvtfcHk0ljtsQ1IAIjDRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFykurjL&md5=076ed7207901c120269a5bc2095b45d9</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.10.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.10.049%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DThapa%26aufirst%3DU.%26aulast%3DJahng%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DM.%2BJ.%26aulast%3DNam%26aufirst%3DJ.%2BM.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3D2-Thienyl-4-furyl-6-aryl%2520pyridine%2520derivatives%253A%2520synthesis%252C%2520topoisomerase%2520I%2520and%2520II%2520inhibitory%2520activity%252C%2520cytotoxicity%252C%2520and%2520structure-activity%2520relationship%2520study%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26issue%3D1%26spage%3D377%26epage%3D386%26doi%3D10.1016%2Fj.bmc.2009.10.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.03.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2017.03.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28384547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslejtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2017&pages=69-84&author=G.+Bistauthor=S.+Parkauthor=C.+Songauthor=T.+B.+Thapa+Magarauthor=A.+Shresthaauthor=Y.+Kwonauthor=E.+S.+Lee&title=Dihydroxylated+2%2C6-diphenyl-4-chlorophenylpyridines%3A+topoisomerase+I+and+II%CE%B1+dual+inhibitors+with+DNA+non-intercalative+catalytic+activity&doi=10.1016%2Fj.ejmech.2017.03.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity</span></div><div class="casAuthors">Bist, Ganesh; Park, Seojeong; Song, Chanju; Thapa Magar, Til Bahadur; Shrestha, Aarajana; Kwon, Youngjoo; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-84</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new series of eighteen dihydroxylated 2,6-diphenyl-phenylpyridines I were systematically designed, prepd., and investigated for their topoisomerase (topo) I and IIα inhibitory properties and antiproliferative effect in three different human cancer cell lines (HCT15, T47D, and HeLa).  Compds. I [R1 = R3 = 3-OH, 4-OH; R2 = 2-Cl, 3-Cl, 4-Cl] which possess a meta- or para-phenol on 2-, or 6-position of central pyridine ring showed significant dual topo I and topo IIα inhibitory activities with strong antiproliferative activities against all the tested human cancer cell lines.  However, compds. I [R1 = 2-OH; R3 = 2-OH, 3-OH, 4-OH; R2 = 2-Cl, 3-Cl, 4-Cl] which possess an ortho-phenol on 2-, or 6-position of central pyridine ring did not show significant topo I and topo IIα inhibitory activities but displayed moderate antiproliferative activities against all the tested human cancer cell lines.  Compd. I [R1 = R3 = 3-OH; R2 = 3-Cl] exhibited the highest antiproliferative potency as much as 348.5 and 105 times compared to etoposide and camptothecin, resp., in T47D cancer cell line.  The structure-activity relationship study revealed that the para position of a hydroxyl group at 2-and 6-Ph ring and chlorine atom at the para position of 4-Ph ring of the central pyridine exhibited the most significant topo I and topo IIα inhibition, which might indicate introduction of the chlorine atom at the Ph ring of 4-pyridine had an important role as dual inhibitors of topo I and topo IIα.  Compd. I [R1 = R3 = 4-OH, R2 = 4-Cl] which showed the most potent dual topo I and topo IIα inhibition with strong antiproliferative activity in T47D cell line was selected to perform further study on the mechanism of action, which revealed that compd. I [R1 = R3 = 4-OH, R2 = 4-Cl] functions as a potent DNA non-intercalative catalytic topo I and IIα dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZBmm2O2IZrrVg90H21EOLACvtfcHk0ljtsQ1IAIjDRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslejtL8%253D&md5=81d5d8cee74161de7ddf670bdb26c648</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DBist%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DDihydroxylated%25202%252C6-diphenyl-4-chlorophenylpyridines%253A%2520topoisomerase%2520I%2520and%2520II%25CE%25B1%2520dual%2520inhibitors%2520with%2520DNA%2520non-intercalative%2520catalytic%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D133%26spage%3D69%26epage%3D84%26doi%3D10.1016%2Fj.ejmech.2017.03.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Rational design, synthesis, and evaluation of novel 2,4-chloro- and hydroxy-substituted diphenyl benzofuro[3,2-b]pyridines: non-intercalative catalytic topoisomerase I and II dual inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2017.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28068603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=318-333&author=S.+Parkauthor=T.+B.+Thapa+Magarauthor=T.+M.+Kadayatauthor=H.+J.+Leeauthor=G.+Bistauthor=A.+Shresthaauthor=E.+S.+Leeauthor=Y.+Kwon&title=Rational+design%2C+synthesis%2C+and+evaluation+of+novel+2%2C4-chloro-+and+hydroxy-substituted+diphenyl+benzofuro%5B3%2C2-b%5Dpyridines%3A+non-intercalative+catalytic+topoisomerase+I+and+II+dual+inhibitor&doi=10.1016%2Fj.ejmech.2017.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor</span></div><div class="casAuthors">Park, Seojeong; Thapa Magar, Til Bahadur; Kadayat, Tara Man; Lee, Hwa Jong; Bist, Ganesh; Shrestha, Aarajana; Lee, Eung-Seok; Kwon, Youngjoo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">318-333</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel series of conformationally constrained 2,4-chloro- and hydroxy-substituted di-Ph benzofuro[3,2-b]pyridines were rationally designed and synthesized.  Their biol. activities were evaluated for topoisomerase I and II inhibitory activity, and antiproliferative activity against several human cancer cell lines for the development of novel anticancer agents.  Most of the compds. with phenol moiety at 4-position of central pyridine exhibited significant dual topoisomerase I and II inhibitory activities, and strong antiproliferative activity in low micromolar range.  Structure activity relationship study suggested that phenol moiety at 4-position of the central pyridine regardless of chlorophenyl moiety at 2-position of the central pyridine has an important role in dual topoisomerase inhibitory activity as well as antiproliferative activity.  For investigation of mode of action for compd. I which displayed the most strong dual topoisomerase I and II inhibitory activity and antiproliferative activity against HCT15 cell, cleavable complex assay, band depletion assay, comet assay, and competitive EtBr displacement assays were performed.  This compd. functioned as non-intercalative catalytic topo I and II dual inhibitor.  In addn., compd. I induced apoptosis in HCT15 cells through increase of Bax, decrease of Bcl-2 and increase of PARP cleavage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-jJXfkEZ-RLVg90H21EOLACvtfcHk0lgVuytbawkEjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlChtw%253D%253D&md5=1967ec3a3aa95b573bb8f48886586ce6</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DRational%2520design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520novel%25202%252C4-chloro-%2520and%2520hydroxy-substituted%2520diphenyl%2520benzofuro%255B3%252C2-b%255Dpyridines%253A%2520non-intercalative%2520catalytic%2520topoisomerase%2520I%2520and%2520II%2520dual%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D318%26epage%3D333%26doi%3D10.1016%2Fj.ejmech.2017.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris-Natschke, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span> <span> </span><span class="NLM_article-title">Biologically active quinoline and quinazoline alkaloids, part I</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1002/med.21466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fmed.21466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28902434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=775-828&issue=3&author=X.+F.+Shangauthor=S.+L.+Morris-Natschkeauthor=Y.+Q.+Liuauthor=X.+Guoauthor=X.+S.+Xuauthor=M.+Gotoauthor=J.+C.+Liauthor=G.+Z.+Yangauthor=K.+H.+Lee&title=Biologically+active+quinoline+and+quinazoline+alkaloids%2C+part+I&doi=10.1002%2Fmed.21466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Biologically active quinoline and quinazoline alkaloids part I</span></div><div class="casAuthors">Shang, Xiao-Fei; Morris-Natschke, Susan L.; Liu, Ying-Qian; Guo, Xiao; Xu, Xiao-Shan; Goto, Masuo; Li, Jun-Cai; Yang, Guan-Zhou; Lee, Kuo-Hsiung</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">775-828</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Quinoline and quinazoline alkaloids, two important classes of N-based heterocyclic compds., have attracted tremendous attention from researchers worldwide since the 19th century.  Over the past 200 years, many compds. from these two classes were isolated from natural sources, and most of them and their modified analogs possess significant bioactivities.  Quinine and camptothecin are two of the most famous and important quinoline alkaloids, and their discoveries opened new areas in antimalarial and anticancer drug development, resp.  In this review, we survey the literature on bioactive alkaloids from these two classes and highlight research achievements prior to the year 2008 (Part I).  Over 200 mols. with a broad range of bioactivities, including antitumor, antimalarial, antibacterial and antifungal, antiparasitic and insecticidal, antiviral, antiplatelet, anti-inflammatory, herbicidal, antioxidant and other activities, were reviewed.  This survey should provide new clues or possibilities for the discovery of new and better drugs from the original naturally occurring quinoline and quinazoline alkaloids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS24I0edWKTbVg90H21EOLACvtfcHk0lgVuytbawkEjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGmtL0%253D&md5=2abf4a48e13222579026e74a217ba6c4</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1002%2Fmed.21466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21466%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DX.%2BF.%26aulast%3DMorris-Natschke%26aufirst%3DS.%2BL.%26aulast%3DLiu%26aufirst%3DY.%2BQ.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%2BS.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DG.%2BZ.%26aulast%3DLee%26aufirst%3DK.%2BH.%26atitle%3DBiologically%2520active%2520quinoline%2520and%2520quinazoline%2520alkaloids%252C%2520part%2520I%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26issue%3D3%26spage%3D775%26epage%3D828%26doi%3D10.1002%2Fmed.21466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bligh, S. W.</span></span> <span> </span><span class="NLM_article-title">Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells</span>. <i>Phytomedicine</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1016/j.phymed.2012.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.phymed.2012.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=22402246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=618-624&issue=7&author=X.+Panauthor=J.+M.+Hartleyauthor=J.+A.+Hartleyauthor=K.+N.+Whiteauthor=Z.+Wangauthor=S.+W.+Bligh&title=Evodiamine%2C+a+dual+catalytic+inhibitor+of+type+I+and+II+topoisomerases%2C+exhibits+enhanced+inhibition+against+camptothecin+resistant+cells&doi=10.1016%2Fj.phymed.2012.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells</span></div><div class="casAuthors">Pan, Xiaobei; Hartley, Janet M.; Hartley, John A.; White, Kenneth N.; Wang, Zhengtao; Bligh, S. W. Annie</div><div class="citationInfo"><span class="NLM_cas:title">Phytomedicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">618-624</span>CODEN:
                <span class="NLM_cas:coden">PYTOEY</span>;
        ISSN:<span class="NLM_cas:issn">0944-7113</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">DNA topoisomerases are nuclear enzymes that are the targets for several anticancer drugs.  In this study we investigated the antiproliferative activity against human leukemia cell lines and the effects on topoisomerase I and II of evodiamine, which is a quinazolinocarboline alkaloid isolated from the fruit of a traditional Chinese medicinal plant, Evodia rutaecarpa.  We report here the anti-proliferative activity against human leukemia cells K562, THP-1, CCRF-CEM and CCRF-CEM/C1 and the inhibitory mechanism on human topoisomerases I and II, important anti-cancer drugs targets, of evodiamine.  Evodiamine failed to trap [Topo-DNA] complexes and induce any detectable DNA damage in cells, was unable to bind or intercalate DNA, and arrested cells in the G2/M phase.  The results suggest evodiamine is a dual catalytic inhibitor of topoisomerases I and II, with IC50 of 60.74 and 78.81 μM, resp.  The improved toxicity towards camptothecin resistant cells further supports its inhibitory mechanism which is different from camptothecin, and its therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4xTfr9qM8KbVg90H21EOLACvtfcHk0lgVuytbawkEjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ans7w%253D&md5=1c20f3244e3434eeef44222e9f0bac40</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.phymed.2012.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phymed.2012.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DX.%26aulast%3DHartley%26aufirst%3DJ.%2BM.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BN.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBligh%26aufirst%3DS.%2BW.%26atitle%3DEvodiamine%252C%2520a%2520dual%2520catalytic%2520inhibitor%2520of%2520type%2520I%2520and%2520II%2520topoisomerases%252C%2520exhibits%2520enhanced%2520inhibition%2520against%2520camptothecin%2520resistant%2520cells%26jtitle%3DPhytomedicine%26date%3D2012%26volume%3D19%26issue%3D7%26spage%3D618%26epage%3D624%26doi%3D10.1016%2Fj.phymed.2012.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7593</span>– <span class="NLM_lpage">7613</span>, <span class="refDoi"> DOI: 10.1021/jm300605m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300605m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7593-7613&issue=17&author=G.+Dongauthor=S.+Wangauthor=Z.+Miaoauthor=J.+Yaoauthor=Y.+Zhangauthor=Z.+Guoauthor=W.+Zhangauthor=C.+Sheng&title=New+tricks+for+an+old+natural+product%3A+discovery+of+highly+potent+evodiamine+derivatives+as+novel+antitumor+agents+by+systemic+structure-activity+relationship+analysis+and+biological+evaluations&doi=10.1021%2Fjm300605m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives as Novel Antitumor Agents by Systemic Structure-Activity Relationship Analysis and Biological Evaluations</span></div><div class="casAuthors">Dong, Guoqiang; Wang, Shengzheng; Miao, Zhenyuan; Yao, Jianzhong; Zhang, Yongqiang; Guo, Zizhao; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7593-7613</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Evodiamine is a quinazolinocarboline alkaloid isolated from the fruits of traditional Chinese herb Evodiae fructus.  Herein, a library of novel evodiamine derivs. bearing various substitutions or modified scaffold were synthesized.  Among them, a no. of evodiamine derivs. showed substantial increase of the antitumor activity, with GI50 values lower than 3 nM.  Moreover, these highly potent compds. can effectively induce the apoptosis of A549 cells.  Interestingly, further computational target prediction calcns. in combination with biol. assays confirmed that the evodiamine derivs. acted by dual inhibition of topoisomerases I and II.  Moreover, several hydroxyl derivs., such as 10-hydroxyevodiamine and 3-amino-10-hydroxyevodiamine, also showed good in vivo antitumor efficacy and low toxicity at the dose of 1 mg/kg or 2 mg/kg.  They represent promising candidates for the development of novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocJjv8REdBnrVg90H21EOLACvtfcHk0lhFlcdvwLulfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurfP&md5=6e7d03671ac1be56b8bd68dc0fc03062</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fjm300605m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300605m%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DNew%2520tricks%2520for%2520an%2520old%2520natural%2520product%253A%2520discovery%2520of%2520highly%2520potent%2520evodiamine%2520derivatives%2520as%2520novel%2520antitumor%2520agents%2520by%2520systemic%2520structure-activity%2520relationship%2520analysis%2520and%2520biological%2520evaluations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7593%26epage%3D7613%26doi%3D10.1021%2Fjm300605m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span> <span> </span><span class="NLM_article-title">Epigenetics in cancer</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgp220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1093%2Fcarcin%2Fbgp220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19752007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlCntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=27-36&issue=1&author=S.+Sharmaauthor=T.+K.+Kellyauthor=P.+A.+Jones&title=Epigenetics+in+cancer&doi=10.1093%2Fcarcin%2Fbgp220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics in cancer</span></div><div class="casAuthors">Sharma, Shikhar; Kelly, Theresa K.; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Epigenetic mechanisms are essential for normal development and maintenance of tissue-specific gene expression patterns in mammals.  Disruption of epigenetic processes can lead to altered gene function and malignant cellular transformation.  Global changes in the epigenetic landscape are a hallmark of cancer.  The initiation and progression of cancer, traditionally seen as a genetic disease, is now realized to involve epigenetic abnormalities along with genetic alterations.  Recent advancements in the rapidly evolving field of cancer epigenetics have shown extensive reprogramming of every component of the epigenetic machinery in cancer including DNA methylation, histone modifications, nucleosome positioning and non-coding RNAs, specifically microRNA expression.  The reversible nature of epigenetic aberrations has led to the emergence of the promising field of epigenetic therapy, which is already making progress with the recent FDA approval of three epigenetic drugs for cancer treatment.  In this review, we discuss the current understanding of alterations in the epigenetic landscape that occur in cancer compared with normal cells, the roles of these changes in cancer initiation and progression, including the cancer stem cell model, and the potential use of this knowledge in designing more effective treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqicaNrvhDly7Vg90H21EOLACvtfcHk0lhFlcdvwLulfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlCntw%253D%253D&md5=e44f5fb2c52d06a941eaa03e2a27766d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgp220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgp220%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKelly%26aufirst%3DT.%2BK.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DEpigenetics%2520in%2520cancer%26jtitle%3DCarcinogenesis%26date%3D2010%26volume%3D31%26issue%3D1%26spage%3D27%26epage%3D36%26doi%3D10.1093%2Fcarcin%2Fbgp220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span> <span> </span><span class="NLM_article-title">Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1038/s41591-019-0376-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fs41591-019-0376-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30842676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsV2itLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=403-418&issue=3&author=H.+P.+Mohammadauthor=O.+Barbashauthor=C.+L.+Creasy&title=Targeting+epigenetic+modifications+in+cancer+therapy%3A+erasing+the+roadmap+to+cancer&doi=10.1038%2Fs41591-019-0376-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer</span></div><div class="casAuthors">Mohammad, Helai P.; Barbash, Olena; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-418</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Epigenetic dysregulation is a common feature of most cancers, often occurring directly through alteration of epigenetic machinery.  Over the last several years, a new generation of drugs directed at epigenetic modulators have entered clin. development, and results from these trials are now being disclosed.  Unlike first-generation epigenetic therapies, these new agents are selective, and many are targeted to proteins which are mutated or translocated in cancer.  This review will provide a summary of the epigenetic modulatory agents currently in clin. development and discuss the opportunities and challenges in their development.  As these drugs advance in the clinic, drug discovery has continued with a focus on both novel and existing epigenetic targets.  This article provides an overview of these efforts and the strategies being employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSkOyprsvHNrVg90H21EOLACvtfcHk0lhFlcdvwLulfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsV2itLs%253D&md5=0b306f94147fd7cb89f5eca82496bba7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fs41591-019-0376-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-019-0376-8%26sid%3Dliteratum%253Aachs%26aulast%3DMohammad%26aufirst%3DH.%2BP.%26aulast%3DBarbash%26aufirst%3DO.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DTargeting%2520epigenetic%2520modifications%2520in%2520cancer%2520therapy%253A%2520erasing%2520the%2520roadmap%2520to%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2019%26volume%3D25%26issue%3D3%26spage%3D403%26epage%3D418%26doi%3D10.1038%2Fs41591-019-0376-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piekarz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1586/era.10.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1586%2Fera.10.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=20645688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=997-1008&issue=7&author=C.+Grantauthor=F.+Rahmanauthor=R.+Piekarzauthor=C.+Peerauthor=R.+Fryeauthor=R.+W.+Robeyauthor=E.+R.+Gardnerauthor=W.+D.+Figgauthor=S.+E.+Bates&title=Romidepsin%3A+a+new+therapy+for+cutaneous+T-cell+lymphoma+and+a+potential+therapy+for+solid+tumors&doi=10.1586%2Fera.10.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span></div><div class="casAuthors">Grant, Cliona; Rahman, Fahd; Piekarz, Richard; Peer, Cody; Frye, Robin; Robey, Robert W.; Gardner, Erin R.; Figg, William D.; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">997-1008</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL).  Although various mechanisms have been proposed for the activity of HDIs, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and direct induction of apoptosis, the mechanism underlying activity of romidepsin and other HDIs in CTCL is not known.  Romidepsin induces long-lasting responses.  The side-effect profile is similar to that of other HDIs, causing fatigue, nausea and thrombocytopenia.  Management of the CTCL population requires vigilence to prevent infection with skin contaminants, and monitoring of potassium and magnesium, electrolytes found to be low in a large proportion of patients.  Electrocardiog. (ECG) changes are common but are not assocd. with myocardial damage.  When mol. end points were evaluated in 61 patients enrolled on a Phase II trial with romidepsin, response was assocd. with persistence of acetylated histone H3, suggesting that drug exposure is important in effective therapy with romidepsin.  Future studies will endeavor to identify combination strategies to increase the efficacy both in resistant CTCL and in solid tumors and to identify biomarkers of response that will allow selection of patients most likely to benefit from the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGXcIbdqpk7Vg90H21EOLACvtfcHk0lgknBaHLT3ThA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D&md5=b28fd17c77991e4662f7c0e08d6d7297</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1586%2Fera.10.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.10.88%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DC.%26aulast%3DRahman%26aufirst%3DF.%26aulast%3DPiekarz%26aufirst%3DR.%26aulast%3DPeer%26aufirst%3DC.%26aulast%3DFrye%26aufirst%3DR.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DRomidepsin%253A%2520a%2520new%2520therapy%2520for%2520cutaneous%2520T-cell%2520lymphoma%2520and%2520a%2520potential%2520therapy%2520for%2520solid%2520tumors%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2010%26volume%3D10%26issue%3D7%26spage%3D997%26epage%3D1008%26doi%3D10.1586%2Fera.10.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&issue=10&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0lgknBaHLT3ThA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26issue%3D10%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnock-Jones, K. P.</span></span> <span> </span><span class="NLM_article-title">Panobinostat: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0388-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs40265-015-0388-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25837990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntlCks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=695-704&issue=6&author=K.+P.+Garnock-Jones&title=Panobinostat%3A+first+global+approval&doi=10.1007%2Fs40265-015-0388-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat: First Global Approval</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-704</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Novartis has developed oral and i.v. formulations of panobinostat (Farydak), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer.  HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumor suppressor genes, and thus represent valid targets in the search for cancer therapeutics.  Oral panobinostat is approved in the US, as combination therapy with bortezomib and dexamethasone in patients with recurrent multiple myeloma who have received at least two prior treatment regimens, including bortezomib and an immunomodulatory agent.  Regulatory submissions have been made for the use of combination therapy with panobinostat in patients with recurrent multiple myeloma in the EU and Japan.  Panobinostat is in various stages of clin. development worldwide for a range of haematol. and solid tumors.  This article summarizes the milestones in the development of panobinostat leading to this first approval for multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7ozQIb-0DLVg90H21EOLACvtfcHk0ljb1ImDoeDW9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntlCks7c%253D&md5=87426a90e7cab1334d2a79055af962f1</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0388-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0388-8%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DPanobinostat%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26issue%3D6%26spage%3D695%26epage%3D704%26doi%3D10.1007%2Fs40265-015-0388-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwitkowski, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Valle, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomquist, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrotra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2666</span>– <span class="NLM_lpage">2670</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1078-0432.CCR-14-3119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25802282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2666-2670&issue=12&author=H.+Z.+Leeauthor=V.+E.+Kwitkowskiauthor=P.+L.+Del+Valleauthor=M.+S.+Ricciauthor=H.+Saberauthor=B.+A.+Habtemariamauthor=J.+Bullockauthor=E.+Bloomquistauthor=Y.+Li+Shenauthor=X.+H.+Chenauthor=J.+Brownauthor=N.+Mehrotraauthor=S.+Dorffauthor=R.+Charlabauthor=R.+C.+Kaneauthor=E.+Kaminskasauthor=R.+Justiceauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+approval%3A+belinostat+for+the+treatment+of+patients+with+relapsed+or+refractory+peripheral+T-cell+lymphoma&doi=10.1158%2F1078-0432.CCR-14-3119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma</span></div><div class="casAuthors">Lee, Hyon-Zu; Kwitkowski, Virginia E.; Del Valle, Pedro L.; Ricci, M. Stacey; Saber, Haleh; Habtemariam, Bahru A.; Bullock, Julie; Bloomquist, Erik; Shen, Yuan Li; Chen, Xiao-Hong; Brown, Janice; Mehrotra, Nitin; Dorff, Sarah; Charlab, Rosane; Kane, Robert C.; Kaminskas, Edvardas; Justice, Robert; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2666-2670</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On July 3, 2014, the FDA granted accelerated approval for belinostat (Beleodaq; Spectrum Pharmaceuticals, Inc.), a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).  A single-arm, open-label, multicenter, international trial in the indicated patient population was submitted in support of the application.  Belinostat was administered i.v. at a dose of 1000 mg/m2 over 30 min once daily on days 1 to 5 of a 21-day cycle.  The primary efficacy endpoint was overall response rate (ORR) based on central radiol. readings by an independent review committee.  The ORR was 25.8% [95% confidence interval (CI), 18.3-34.6] in 120 patients that had confirmed diagnoses of PTCL by the Central Pathol. Review Group.  The complete and partial response rates were 10.8% (95% CI, 5.9-17.8) and 15.0% (95% CI, 9.1-22.7), resp.  The median duration of response, the key secondary efficacy endpoint, was 8.4 mo (95% CI, 4.5-29.4).  The most common adverse reactions (>25%) were nausea, fatigue, pyrexia, anemia, and vomiting.  Grade 3/4 toxicities (≥5.0%) included anemia, thrombocytopenia, dyspnea, neutropenia, fatigue, and pneumonia.  Belinostat is the third drug to receive accelerated approval for the treatment of relapsed or refractory PTCL.  Clin Cancer Res; 21(12); 2666-70. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1RbkvuHSk6rVg90H21EOLACvtfcHk0ljb1ImDoeDW9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfM&md5=c1e64c9d01d18272d25ad03001e7041a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3119%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BZ.%26aulast%3DKwitkowski%26aufirst%3DV.%2BE.%26aulast%3DDel%2BValle%26aufirst%3DP.%2BL.%26aulast%3DRicci%26aufirst%3DM.%2BS.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DHabtemariam%26aufirst%3DB.%2BA.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBloomquist%26aufirst%3DE.%26aulast%3DLi%2BShen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DMehrotra%26aufirst%3DN.%26aulast%3DDorff%26aufirst%3DS.%26aulast%3DCharlab%26aufirst%3DR.%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%253A%2520belinostat%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsed%2520or%2520refractory%2520peripheral%2520T-cell%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D12%26spage%3D2666%26epage%3D2670%26doi%3D10.1158%2F1078-0432.CCR-14-3119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">The role of histone deacetylases (HDACs) in human cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.molonc.2007.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19383284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=19-25&issue=1&author=S.+Roperoauthor=M.+Esteller&title=The+role+of+histone+deacetylases+%28HDACs%29+in+human+cancer&doi=10.1016%2Fj.molonc.2007.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histone deacetylases (HDACs) in human cancer</span></div><div class="casAuthors">Ropero, Santiago; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The balance of histone acetylation and deacetylation is an epigenetic layer with a crit. role in the regulation of gene expression.  Histone acetylation induced by histone acetyl transferases (HATs) is assocd. with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is assocd. with gene silencing.  Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis.  Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbJD8bqroSLVg90H21EOLACvtfcHk0lhae4_fDsAPmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI&md5=d925bcde258dce7d53cbb98563e1f2ae</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520histone%2520deacetylases%2520%2528HDACs%2529%2520in%2520human%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26issue%3D1%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.molonc.2007.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1373</span>– <span class="NLM_lpage">1428</span>, <span class="refDoi"> DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&issue=6&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+search+for+potent%2C+small-molecule+HDACIs+in+cancer+treatment%3A+a+decade+after+vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2eb1jDM1FTcYvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520search%2520for%2520potent%252C%2520small-molecule%2520HDACIs%2520in%2520cancer%2520treatment%253A%2520a%2520decade%2520after%2520vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26issue%3D6%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canzoneri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1477</span>, <span class="refDoi"> DOI: 10.1021/jm200799p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200799p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1465-1477&issue=4&author=W.+Guerrantauthor=V.+Patilauthor=J.+C.+Canzoneriauthor=A.+K.+Oyelere&title=Dual+targeting+of+histone+deacetylase+and+topoisomerase+II+with+novel+bifunctional+inhibitors&doi=10.1021%2Fjm200799p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors</span></div><div class="casAuthors">Guerrant, William; Patil, Vishal; Canzoneri, Joshua C.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1465-1477</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Strategies to ameliorate the flaws of current chemotherapeutic agents, while maintaining potent anticancer activity, are of particular interest.  Agents which can modulate multiple targets may have superior utility and fewer side effects than current single-target drugs.  To explore the prospect in cancer therapy of a bivalent agent that combines two complementary chemo-active groups within a single mol. architecture, we have synthesized dual-acting histone deacetylase and topoisomerase II inhibitors.  These dual-acting agents are derived from suberoylanilide hydroxamic acid (SAHA) and anthracycline daunorubicin, prototypical histone deacetylase (HDAC) and topoisomerase II (Topo II) inhibitors, resp.  For example, 4-aminobenzyl alc. reacted with suberic anhydride to give 4-HOCH2C6H4NHCO(CH2)6CO2H, which was oxidized to the corresponding benzaldehyde.  This benzaldehyde reacted with H2NOCPh3 to give the terminal O-tritylated amide, which, after addn. to daunorubicin HCl and removal of the trityl group, produced conjugate I.  We report herein that these agents present the signatures of inhibition of HDAC and Topo II in both cell-free and whole-cell assays.  Moreover, these agents potently inhibit the proliferation of representative cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Yf6AQQjHxLVg90H21EOLACvtfcHk0ljQyfsO4Oj7hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVyhuw%253D%253D&md5=f0d6a8b98bb524de8e9fbbf1680610a1</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm200799p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200799p%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DCanzoneri%26aufirst%3DJ.%2BC.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DDual%2520targeting%2520of%2520histone%2520deacetylase%2520and%2520topoisomerase%2520II%2520with%2520novel%2520bifunctional%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D4%26spage%3D1465%26epage%3D1477%26doi%3D10.1021%2Fjm200799p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&issue=10&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0ljQyfsO4Oj7hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26issue%3D10%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the understanding and treatment of acute myeloid leukemia</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1196</span>, <span class="refDoi"> DOI: 10.12688/f1000research.14116.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.12688%2Ff1000research.14116.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWqsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=1196&author=J.+Wattsauthor=S.+Nimer&title=Recent+advances+in+the+understanding+and+treatment+of+acute+myeloid+leukemia&doi=10.12688%2Ff1000research.14116.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the understanding and treatment of acute myeloid leukemia [version 1; referees: 3 approved]</span></div><div class="casAuthors">Watts, Justin; Nimer, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1196/1-1196/14</span>CODEN:
                <span class="NLM_cas:coden">FRESJL</span>;
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    
            (<span class="NLM_cas:orgname">F1000 Research Ltd.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a clin. and genetically heterogeneous</div> disease that has a poor prognosis.  Recent advances in genomics and</div> mol. biol. have led to a greatly improved understanding of the disease.</div> Until 2017, there had been no new drugs approved for AML in decades.  Here,</div> we review novel drug targets in AML with a focus on epigenetic-targeted</div> therapies in pre-clin. and clin. development as well as the recent new</div> drug approvals.</div>.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_5ZTwW9jqjLVg90H21EOLACvtfcHk0lg-0l2A5IbYBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWqsb7O&md5=262aea9a1152835b47144f52f804b84f</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.14116.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.14116.1%26sid%3Dliteratum%253Aachs%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DNimer%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520the%2520understanding%2520and%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DF1000Research%26date%3D2018%26volume%3D7%26spage%3D1196%26doi%3D10.12688%2Ff1000research.14116.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perissinotti, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benitez, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scappaticci, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, B. L.</span></span> <span> </span><span class="NLM_article-title">The leukemia strikes back: a review of pathogenesis and treatment of secondary AML</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1007/s00277-019-03606-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1007%2Fs00277-019-03606-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=30666431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BB3cjjslenug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2019&pages=541-559&issue=3&author=E.+Cheungauthor=A.+J.+Perissinottiauthor=D.+L.+Bixbyauthor=P.+W.+Burkeauthor=K.+M.+Pettitauthor=L.+L.+Benitezauthor=J.+Brownauthor=G.+B.+Scappaticciauthor=B.+L.+Marini&title=The+leukemia+strikes+back%3A+a+review+of+pathogenesis+and+treatment+of+secondary+AML&doi=10.1007%2Fs00277-019-03606-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The leukemia strikes back: a review of pathogenesis and treatment of secondary AML</span></div><div class="casAuthors">Cheung Edna; Perissinotti Anthony J; Benitez Lydia L; Brown Julia; Scappaticci Gianni B; Marini Bernard L; Bixby Dale L; Burke Patrick W; Pettit Kristen M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of hematology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">541-559</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Secondary AML is associated with a disproportionately poor prognosis, consistently shown to exhibit inferior response rates, event-free survival, and overall survival in comparison with de novo AML.  Secondary AML may arise from the evolution of an antecedent hematologic disorder, or it may arise as a complication of prior cytotoxic chemotherapy or radiation therapy in the case of therapy-related AML.  Because of the high frequency of poor-risk cytogenetics and high-risk molecular features, such as alterations in TP53, leukemic clones are often inherently chemoresistant.  Standard of care induction had long remained conventional 7 + 3 until its reformulation as CPX-351, recently FDA approved specifically for secondary AML.  However, recent data also suggests relatively favorable outcomes with regimens based on high-dose cytarabine or hypomethylating agents.  With several investigational agents being studied, the therapeutic landscape becomes even more complex, and the treatment approach involves patient-specific, disease-specific, and therapy-specific considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKCQUOKEG4Qub6AVA-44PTfW6udTcc2eYQYXTfIUntjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjjslenug%253D%253D&md5=799c29baebc802faae7e06fb409ea9af</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1007%2Fs00277-019-03606-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-019-03606-0%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DE.%26aulast%3DPerissinotti%26aufirst%3DA.%2BJ.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DBurke%26aufirst%3DP.%2BW.%26aulast%3DPettit%26aufirst%3DK.%2BM.%26aulast%3DBenitez%26aufirst%3DL.%2BL.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DScappaticci%26aufirst%3DG.%2BB.%26aulast%3DMarini%26aufirst%3DB.%2BL.%26atitle%3DThe%2520leukemia%2520strikes%2520back%253A%2520a%2520review%2520of%2520pathogenesis%2520and%2520treatment%2520of%2520secondary%2520AML%26jtitle%3DAnn.%2520Hematol.%26date%3D2019%26volume%3D98%26issue%3D3%26spage%3D541%26epage%3D559%26doi%3D10.1007%2Fs00277-019-03606-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">8467</span>– <span class="NLM_lpage">8475</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1078-0432.CCR-05-1073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=16322310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KjsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=8467-8475&issue=23&author=D.+C.+Marchionauthor=E.+Bicakuauthor=J.+G.+Turnerauthor=A.+I.+Daudauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=Synergistic+interaction+between+histone+deacetylase+and+topoisomerase+II+inhibitors+is+mediated+through+topoisomerase+II%CE%B2&doi=10.1158%2F1078-0432.CCR-05-1073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Turner, Joel G.; Daud, Adil I.; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8467-8475</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BACKGROUND: DNA topoisomerase II inhibitors and poisons are among the most efficacious drugs for the treatment of cancer.  Sensitivity of cancer cells to the cytotoxic effects of topoisomerase II targeting agents is thought to depend on the expression of the topoisomerase IIα isoform, and drug resistance is often assocd. with loss or mutation of topoisomerase IIα.  Histone deacetylase inhibitors (HDACi) are a novel class of compds. that potentiate the antitumor effects of topoisomerase II-targeting agents.  METHODS: The interaction between HDACi and topoisomerase II-targeting agents in cancer cells was evaluated as a function of topoisomerase IIα and topoisomerase IIβ expression.  Topoisomerase II isoforms were selectively depleted using small interfering RNA and antisense.  Drug-induced formation of cleavable complexes involving topoisomerase IIα and topoisomerase IIβ was evaluated by trapped-in-agarose DNA immunostaining and band depletion assays in the presence and absence of HDACi.  RESULTS: Preexposure to HDACi increased the cytotoxicity of topoisomerase II poisons.  This was assocd. with a down-regulation of topoisomerase IIα expression but had no effects on topoisomerase IIβ.  In the setting of HDACi-induced chromatin decondensation and topoisomerase IIα depletion, topoisomerase II poison cytotoxicity was mediated through topoisomerase IIβ cleavable complex formation.  The HDACi-induced sensitization was also obsd. in cells with target-specific resistance to topoisomerase II poisons.  CONCLUSIONS: The recruitment of topoisomerase IIβ as a target may overcome primary or emergent drug resistance to topoisomerase II-targeting agents and hence may broaden the applicability of this important class of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozxAiIAX42b7Vg90H21EOLACvtfcHk0lg-0l2A5IbYBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KjsrbF&md5=453b23ac674f68548ed46246b43fabbf</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1073%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DTurner%26aufirst%3DJ.%2BG.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DSynergistic%2520interaction%2520between%2520histone%2520deacetylase%2520and%2520topoisomerase%2520II%2520inhibitors%2520is%2520mediated%2520through%2520topoisomerase%2520II%25CE%25B2%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26issue%3D23%26spage%3D8467%26epage%3D8475%26doi%3D10.1158%2F1078-0432.CCR-05-1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1002/jcb.20045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fjcb.20045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15108350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVaqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2004&pages=223-237&issue=2&author=D.+C.+Marchionauthor=E.+Bicakuauthor=A.+I.+Daudauthor=V.+Richonauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=Sequence-specific+potentiation+of+topoisomerase+II+inhibitors+by+the+histone+deacetylase+inhibitor+suberoylanilide+hydroxamic+acid&doi=10.1002%2Fjcb.20045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Daud, Adil I.; Richon, Victoria; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-237</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Acetylation of histones leads to conformational changes of DNA.  We have previously shown that the histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA), induced cell cycle arrest, differentiation, and apoptosis.  In addn. to their antitumor effects as single agents, HDAC inhibitors may cause conformational changes in the chromatin, rendering the DNA more vulnerable to DNA damaging agents.  We examd. the effects of SAHA on cell death induced by topo II inhibitors in breast cancer cell lines.  Topo II inhibitors stabilize the topo II-DNA complex, resulting in DNA damage.  Treatment of cells with SAHA promoted chromatin decondensation assocd. with increased nuclear concn. and DNA binding of the topo II inhibitor and subsequent potentiation of DNA damage.  While SAHA-induced histone hyperacetylation occurred as early as 4 h, chromatin decondensation was most profound at 48 h.  SAHA-induced potentiation of topo II inhibitors was sequence-specific.  Pre-exposure of cells to SAHA for 48 h was synergistic, whereas shorter pre-exposure periods abrogated synergy and exposure of cells to SAHA after the topo II inhibitor resulted in antagonistic effects.  Synergy was not obsd. in cells with depleted topo II levels.  These effects were not limited to specific types of topo II inhibitors.  We propose that SAHA significantly potentiates the DNA damage induced by topo II inhibitors; however, synergy is dependent on the sequence of drug administration and the expression of the target.  These findings may impact the clin. development of combining HDAC inhibitors with DNA damaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd_EzmdHJvU7Vg90H21EOLACvtfcHk0lgxdu_vgdNDdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVaqs7c%253D&md5=71f10a1a96c0e666a5f410c9b32a3893</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fjcb.20045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.20045%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DSequence-specific%2520potentiation%2520of%2520topoisomerase%2520II%2520inhibitors%2520by%2520the%2520histone%2520deacetylase%2520inhibitor%2520suberoylanilide%2520hydroxamic%2520acid%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2004%26volume%3D92%26issue%3D2%26spage%3D223%26epage%3D237%26doi%3D10.1002%2Fjcb.20045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">7291</span>– <span class="NLM_lpage">7300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=14612526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGlt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7291-7300&issue=21&author=M.+S.+Kimauthor=M.+Blakeauthor=J.+H.+Baekauthor=G.+Kohlhagenauthor=Y.+Pommierauthor=F.+Carrier&title=Inhibition+of+histone+deacetylase+increases+cytotoxicity+to+anticancer+drugs+targeting+DNA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA</span></div><div class="casAuthors">Kim, Myoung Sook; Blake, Mellissa; Baek, Jin Hyen; Kohlhagen, Glenda; Pommier, Yves; Carrier, France</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7291-7300</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Several anticancer drugs target DNA or enzymes acting on the DNA.  Because chromatin DNA is tightly compacted, accessibility to the drug target may reduce the efficiency of these anticancer drugs.  We thus treated four human cancer cell lines and two normal epithelial cell lines with either trichostatin A (TSA) or SAHA, two histone deacetylase inhibitors, before exposing the cells to VP-16, ellipticine, camptothecin, doxorubicin, cisplatin, 5-fluorouracil, or cyclophosphamide.  Pretreatment with TSA or SAHA increased the killing efficiency of VP-16, ellipticine, doxorubicin, and cisplatin.  The magnitude of sensitization is cell type specific and is >10-fold for VP-16 in D54, a brain tumor cell line intrinsically resistant to topoisomerase II inhibitors.  Topoisomerase II levels and activity were not affected by this treatment, but p53, p21, and Gadd45 protein levels were markedly induced.  Moreover, pretreatment with TSA also increased VP-16-induced apoptosis in a p53-dependent and -independent manner.  Treating the cells in the reverse order (anticancer drug first, followed by TSA or SAHA) had no more cytotoxic effect than the drug alone.  These data suggest that loosening-up the chromatin structure by histone acetylation can increase the efficiency of several anticancer drugs targeting DNA.  This may be advantageous for treating tumors intrinsically resistant to these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq24HjggpPirLVg90H21EOLACvtfcHk0lgxdu_vgdNDdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGlt70%253D&md5=6fe3bc8b32550917fc8f80ac648e680b</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DBlake%26aufirst%3DM.%26aulast%3DBaek%26aufirst%3DJ.%2BH.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCarrier%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520histone%2520deacetylase%2520increases%2520cytotoxicity%2520to%2520anticancer%2520drugs%2520targeting%2520DNA%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26issue%3D21%26spage%3D7291%26epage%3D7300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchion, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Valproic acid alters chromatin structure by regulation of chromatin modulation proteins</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3815</span>– <span class="NLM_lpage">3822</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-2478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F0008-5472.CAN-04-2478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15867379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3815-3822&issue=9&author=D.+C.+Marchionauthor=E.+Bicakuauthor=A.+I.+Daudauthor=D.+M.+Sullivanauthor=P.+N.+Munster&title=Valproic+acid+alters+chromatin+structure+by+regulation+of+chromatin+modulation+proteins&doi=10.1158%2F0008-5472.CAN-04-2478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Valproic acid alters chromatin structure by regulation of chromatin modulation proteins</span></div><div class="casAuthors">Marchion, Douglas C.; Bicaku, Elona; Daud, Adil I.; Sullivan, Daniel M.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3815-3822</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are crucial in the regulation of gene expression.  Dynamic changes in gene expression may affect chromatin structure and, consequently, the interaction of chromatin with regulatory factors.  In this study, the effects of the antiseizure drug valproic acid (VPA) on the expression of genes that regulate the structure of chromatin and the access of macromols. to the DNA were investigated.  Exposure of breast cancer cells to VPA resulted in rapid dose-dependent hyperacetylation of the histones H3 and H4.  VPA further induced a depletion of several members of the structural maintenance of chromatin (SMC) proteins, SMC-assocd. proteins, DNA methyltransferase, and heterochromatin proteins.  Down-regulation of these proteins was assocd. with chromatin decondensation.  The obsd. alterations of chromatin structure correlated with enhanced sensitivity of DNA to nucleases and increased interaction of DNA with intercalating agents.  VPA-induced chromatin decondensation led to a sequence-specific potentiation of DNA-damaging agents in cell culture and xenograft models.  Modulation of heterochromatin maintenance proteins was not a direct, but a downstream, effect of histone acetylation.  The effects on the chromatin structure were reversible upon drug withdrawal, but obligatory for the potentiation of DNA-damaging agents.  In addn. to their antitumor activity as single agents, the chromatin decondensation induced by histone deacetylase inhibitors may enhance the efficacy of cytotoxic agents that act by targeting DNA.  The proposed mechanism of action suggests an effect of drug sequencing on the antitumor activity of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoahFbSWhN10bVg90H21EOLACvtfcHk0lioy4ryNZ95ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGks78%253D&md5=50f433688151bbc4795dcd1a3fe33108</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-2478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-2478%26sid%3Dliteratum%253Aachs%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DValproic%2520acid%2520alters%2520chromatin%2520structure%2520by%2520regulation%2520of%2520chromatin%2520modulation%2520proteins%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D9%26spage%3D3815%26epage%3D3822%26doi%3D10.1158%2F0008-5472.CAN-04-2478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niitsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasukabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe-Kado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto-Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, Y.</span></span> <span> </span><span class="NLM_article-title">Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1124/mol.58.1.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1124%2Fmol.58.1.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10860924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Krurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2000&pages=27-36&issue=1&author=N.+Niitsuauthor=T.+Kasukabeauthor=A.+Yokoyamaauthor=J.+Okabe-Kadoauthor=Y.+Yamamoto-Yamaguchiauthor=M.+Umedaauthor=Y.+Honma&title=Anticancer+derivative+of+butyric+acid+%28pivalyloxymethyl+butyrate%29+specifically+potentiates+the+cytotoxicity+of+doxorubicin+and+daunorubicin+through+the+suppression+of+microsomal+glycosidic+activity&doi=10.1124%2Fmol.58.1.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity</span></div><div class="casAuthors">Niitsu, Nozomi; Kasukabe, Takashi; Yokoyama, Akihiro; Okabe-Kado, Junko; Yamamoto-Yamaguchi, Yuri; Umeda, Masanori; Honma, Yoshio</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pivalyloxymethyl butyrate (AN9) is an anticancer deriv. of butyric acid.  In this study, doxorubicin (DXR) and AN9 synergistically inhibited the growth of lymphoma and lung carcinoma cells, whereas there was no synergy between AN9 and antimetabolites.  AN9 did not affect the intracellular uptake of DXR.  Among anthracyclines and their derivs., the synergistic effect was prominent in compds. with a daunosamine moiety, suggesting that AN9 may affect the catabolism of these compds.  The degrdn. of DXR in the ext. from AN9-treated cells was much less than that in ext. from untreated cells.  AN9 did not directly inhibit the enzyme activity but rather suppressed expression of the enzyme.  With respect to the expression of drug resistance-related genes, there was no significant difference between untreated and AN9-treated cells.  However, AN9 significantly down-regulated the levels NADPH-cytochrome P 450 reductase and DT-diaphorase mRNA in the presence of DXR but not the level of xanthine oxidase mRNA.  The enhancement of the sensitivity to anthracyclines was closely assocd. with the suppression of the mRNA expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIATqdykNpG7Vg90H21EOLACvtfcHk0lioy4ryNZ95ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Krurs%253D&md5=3b7fc125787b69583a4857205952159c</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1124%2Fmol.58.1.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.58.1.27%26sid%3Dliteratum%253Aachs%26aulast%3DNiitsu%26aufirst%3DN.%26aulast%3DKasukabe%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DA.%26aulast%3DOkabe-Kado%26aufirst%3DJ.%26aulast%3DYamamoto-Yamaguchi%26aufirst%3DY.%26aulast%3DUmeda%26aufirst%3DM.%26aulast%3DHonma%26aufirst%3DY.%26atitle%3DAnticancer%2520derivative%2520of%2520butyric%2520acid%2520%2528pivalyloxymethyl%2520butyrate%2529%2520specifically%2520potentiates%2520the%2520cytotoxicity%2520of%2520doxorubicin%2520and%2520daunorubicin%2520through%2520the%2520suppression%2520of%2520microsomal%2520glycosidic%2520activity%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D58%26issue%3D1%26spage%3D27%26epage%3D36%26doi%3D10.1124%2Fmol.58.1.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, E. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leader, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampey, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalowich, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, D. J.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase IIα expression and confers hypersensitivity to etoposide in human leukemic cell lines</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12467229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=121-131&issue=2&author=E.+U.+Kurzauthor=S.+E.+Wilsonauthor=K.+B.+Leaderauthor=B.+P.+Sampeyauthor=W.+P.+Allanauthor=J.+C.+Yalowichauthor=D.+J.+Kroll&title=The+histone+deacetylase+inhibitor+sodium+butyrate+induces+DNA+topoisomerase+II%CE%B1+expression+and+confers+hypersensitivity+to+etoposide+in+human+leukemic+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase IIα expression and confers hypersensitivity to etoposide in human leukemic cell lines</span></div><div class="casAuthors">Kurz, Ebba U.; Wilson, Sara E.; Leader, Kelly B.; Sampey, Brante P.; Allan, William P.; Yalowich, Jack C.; Kroll, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-131</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The differentiating agent and histone deacetylase inhibitor, sodium butyrate (NaB), was shown previously to cause a transient, 3-17-fold induction of human DNA topoisomerase IIα (topo IIα) gene promoter activity and a 2-fold increase in topo IIα protein early in monocytic differentiation of HL-60 cells.  This observation has now been extended to other short chain fatty acids and arom. butyrate analogs, and evidence is presented that human topo IIα promoter induction correlates closely with histone H4 acetylation status.  Because increased topo IIα expression is assocd. with enhanced efficacy of topo II-poisoning antitumor drugs such as etoposide, the hypothesis tested in this report was whether NaB pretreatment could sensitize HL-60 myeloid leukemia and K562 erythroleukemia cells to etoposide-triggered DNA damage and cell death.  A 24-72 h NaB treatment (0.4-0.5 mM) induced topo IIα 2-2.5-fold in both HL-60 and K562 cells and caused a dose-dependent enhancement of etoposide-stimulated, protein-linked DNA complexes in both cell lines.  At concns. with minimal effects on cell cycle kinetics (0.4 mM in HL-60; 0.5 mM in K562), NaB pretreatment also modestly enhanced etoposide-triggered apoptosis in HL-60 cells, as detd. morphol. after acridine orange/ethidium bromide staining, and substantially increased K562 growth inhibition and poly(ADP-ribose)polymerase cleavage after etoposide exposure.  Therefore, a temporal window may exist whereby a differentiating agent may sensitize exptl. leukemias to a cytotoxic antitumor agent.  These results indicate that histone deacetylase inhibitors should be investigated for etoposide sensitization of other butyrate-responsive hematopoietic and nonhematopoietic tumor lines in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6QUXll4sIpLVg90H21EOLACvtfcHk0lg5XW9YF6Ct5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbY%253D&md5=62d25117a11f3e994bd81167c7bdac58</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKurz%26aufirst%3DE.%2BU.%26aulast%3DWilson%26aufirst%3DS.%2BE.%26aulast%3DLeader%26aufirst%3DK.%2BB.%26aulast%3DSampey%26aufirst%3DB.%2BP.%26aulast%3DAllan%26aufirst%3DW.%2BP.%26aulast%3DYalowich%26aufirst%3DJ.%2BC.%26aulast%3DKroll%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520sodium%2520butyrate%2520induces%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520expression%2520and%2520confers%2520hypersensitivity%2520to%2520etoposide%2520in%2520human%2520leukemic%2520cell%2520lines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2001%26volume%3D1%26issue%3D2%26spage%3D121%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padget, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span> <span> </span><span class="NLM_article-title">Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4542</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000824200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.C000824200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11136718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlOqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=4539-4542&issue=7&author=C.+A.+Johnsonauthor=K.+Padgetauthor=C.+A.+Austinauthor=B.+M.+Turner&title=Deacetylase+activity+associates+with+topoisomerase+II+and+is+necessary+for+etoposide-induced+apoptosis&doi=10.1074%2Fjbc.C000824200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis</span></div><div class="casAuthors">Johnson, Colin A.; Padget, Kay; Austin, Caroline A.; Turner, Bryan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4539-4542</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">DNA topoisomerase II (topo II) is a ubiquitous nuclear enzyme that is involved in DNA replication, transcription, chromosome segregation, and apoptosis.  Here we show by immunopptn., pull down with glutathione S-transferase fusion proteins, and yeast two-hybrid anal. that both topo IIα and -β phys. interact with the histone deacetylase HDAC1.  The in vitro DNA decatenation activity of recombinant topo IIα and -β is inhibited by assocn. with catalytically inactive, recombinant HDAC1.  We provide evidence for the in vivo significance of the topo II-HDAC1 assocn., showing that inhibition of HDAC activity with trichostatin A suppresses apoptosis induced by the topo II poison etoposide, but not by the topoisomerase I inhibitor camptothecin.  We suggest that chromatin remodeling by an HDAC-contg. complex facilitates both topo II-catalyzed DNA rearrangement and etoposide-induced DNA damage in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG-EArV25rfLVg90H21EOLACvtfcHk0lg5XW9YF6Ct5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlOqsLg%253D&md5=8cfacaa935b0351d3cf55aad2405b138</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000824200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000824200%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BA.%26aulast%3DPadget%26aufirst%3DK.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26atitle%3DDeacetylase%2520activity%2520associates%2520with%2520topoisomerase%2520II%2520and%2520is%2520necessary%2520for%2520etoposide-induced%2520apoptosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26issue%3D7%26spage%3D4539%26epage%3D4542%26doi%3D10.1074%2Fjbc.C000824200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6981</span>– <span class="NLM_lpage">6995</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmc.2013.09.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24095018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOlurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=6981-6995&issue=22&author=X.+Zhangauthor=B.+Baoauthor=X.+Yuauthor=L.+Tongauthor=Y.+Luoauthor=Q.+Huangauthor=M.+Suauthor=L.+Shengauthor=J.+Liauthor=H.+Zhuauthor=B.+Yangauthor=X.+Zhangauthor=Y.+Chenauthor=W.+Lu&title=The+discovery+and+optimization+of+novel+dual+inhibitors+of+topoisomerase+II+and+histone+deacetylase&doi=10.1016%2Fj.bmc.2013.09.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase</span></div><div class="casAuthors">Zhang, Xuan; Bao, Bin; Yu, Xiuhua; Tong, Linjiang; Luo, Yu; Huang, Qingqing; Su, Mingbo; Sheng, Li; Li, Jia; Zhu, Hong; Yang, Bo; Zhang, Xiongwen; Chen, Yi; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6981-6995</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of podophyllotoxin derivs. have been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors.  Their inhibitory activities towards histone deacetylases and Topo II and their cytotoxicities in cancer cell lines were evaluated.  The arom. capping group connection, linker length and zinc-binding group were systematically varied and preliminary conclusions regarding structure-activity relationships are discussed.  Among all of the synthesized hybrid compds., compd. I showed the most potent HDAC inhibitory activity at a low nanomolar level and exhibited powerful antiproliferative activity towards HCT116 colon carcinoma cells at a low micromolar level.  Further exploration of this series led to the discovery of potent dual inhibitor II, which exhibited the strongest in vitro cytotoxic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2q6l9WK2gW7Vg90H21EOLACvtfcHk0lgIxMbv5Epi5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOlurnE&md5=e983212ec3320d5606018e94063f98ad</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520novel%2520dual%2520inhibitors%2520of%2520topoisomerase%2520II%2520and%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26issue%3D22%26spage%3D6981%26epage%3D6995%26doi%3D10.1016%2Fj.bmc.2013.09.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-targeted inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1920</span>– <span class="NLM_lpage">1928</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmc.2018.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29519604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVGhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1920-1928&issue=8&author=M.+Yamashitaauthor=T.+Taharaauthor=S.+Hayakawaauthor=H.+Matsumotoauthor=S.+I.+Wadaauthor=K.+Tomiokaauthor=A.+Iida&title=Synthesis+and+biological+evaluation+of+histone+deacetylase+and+DNA+topoisomerase+II-targeted+inhibitors&doi=10.1016%2Fj.bmc.2018.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors</span></div><div class="casAuthors">Yamashita, Mitsuaki; Tahara, Teruyuki; Hayakawa, Shinya; Matsumoto, Hironobu; Wada, Shun-ichi; Tomioka, Kiyoshi; Iida, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1920-1928</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HDAC inhibitors enable histones to maintain a high degree of acetylation.  The resulting looser state of chromatin DNA may increase the accessibility of DNA drug targets and consequently improve the efficiency of anticancer drugs targeting DNA, such as Topo II inhibitors.  A novel class of nucleoside-SAHA derivs. has been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors.  Their inhibitory activities toward histone deacetylases and Topo II, and their cytotoxicities in cancer cell lines, were evaluated.  Among the synthesized hybrid compds., compd. 16b showed the potent HDAC inhibitory activity at a low nanomolar level and exhibited antiproliferative activity toward cancer cell lines including MCF-7 (breast), HCT-116 (colon), and DU-145 (prostate) cancer cells at a low micromolar level.  Moreover, compd. 16a showed HDAC6-selectivity 20-fold over HDAC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-RP6VIX6qLVg90H21EOLACvtfcHk0lgIxMbv5Epi5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVGhsro%253D&md5=99154f34a66242dc1a2501474a0bf091</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DWada%26aufirst%3DS.%2BI.%26aulast%3DTomioka%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520histone%2520deacetylase%2520and%2520DNA%2520topoisomerase%2520II-targeted%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1920%26epage%3D1928%26doi%3D10.1016%2Fj.bmc.2018.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3958</span>– <span class="NLM_lpage">3966</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmc.2018.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29954683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3958-3966&issue=14&author=J.+Chenauthor=D.+Liauthor=W.+Liauthor=J.+Yinauthor=Y.+Zhangauthor=Z.+Yuanauthor=C.+Gaoauthor=F.+Liuauthor=Y.+Jiang&title=Design%2C+synthesis+and+anticancer+evaluation+of+acridine+hydroxamic+acid+derivatives+as+dual+Topo+and+HDAC+inhibitors&doi=10.1016%2Fj.bmc.2018.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors</span></div><div class="casAuthors">Chen, Jiwei; Li, Dan; Li, Wenlu; Yin, Jingxian; Zhang, Yueying; Yuan, Zigao; Gao, Chunmei; Liu, Feng; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3958-3966</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multitarget inhibitors design has generated great interest in cancer treatment.  Based on the synergistic effects of topoisomerase and histone deacetylase inhibitors, we designed and synthesized a new series of acridine hydroxamic acid derivs. as potential novel dual Topo and HDAC inhibitors.  MTT assays indicated that all the hybrid compds. displayed good antiproliferative activities with IC50 values in low micromolar range, among which compd. 8c displayed potent activity against U937 (IC50=0.90μM).  In addn., compd. 8c also displayed the best HDAC inhibitory activity, which was several times more potent than HDAC inhibitor SAHA.  Subsequent studies indicated that all the compds. displayed Topo II inhibition activity at 50μM.  Moreover, compd. 8c could interact with DNA and induce U937 apoptosis.  This study provides a suite of compds. for further exploration of dual Topo and HDAC inhibitors, and compd. 8c can be a new dual Topo and HDAC inhibitory anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCVb9uGhgIqrVg90H21EOLACvtfcHk0lheumfdxqowxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SjsLrM&md5=bb2ad2ab72c4a871c1ecabda608d31b9</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520anticancer%2520evaluation%2520of%2520acridine%2520hydroxamic%2520acid%2520derivatives%2520as%2520dual%2520Topo%2520and%2520HDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D14%26spage%3D3958%26epage%3D3966%26doi%3D10.1016%2Fj.bmc.2018.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1021/ml500327q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500327q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=239-243&issue=3&author=S.+Heauthor=G.+Dongauthor=Z.+Wangauthor=W.+Chenauthor=Y.+Huangauthor=Z.+Liauthor=Y.+Jiangauthor=N.+Liuauthor=J.+Yaoauthor=Z.+Miaoauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+novel+multiacting+topoisomerase+I%2FII+and+histone+deacetylase+inhibitors&doi=10.1021%2Fml500327q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wang, Zhibin; Chen, Wei; Huang, Yahui; Li, Zhengang; Jiang, Yan; Liu, Na; Yao, Jianzhong; Miao, Zhenyuan; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs remains a significant challenge in current antitumor drug discovery.  Because of the synergistic effect between topoisomerase and HDAC inhibitors, the present study reported the first-in-class triple inhibitors of topoisomerase I/II and HDAC.  On the basis of 3-amino-10-hydroxylevodiamine and SAHA, a series of hybrid mols. was successfully designed and synthesized.  In particular, compd. 8c was proven to be a potent inhibitor of topoisomerase I/II and HDAC with good antiproliferative and apoptotic activities.  This proof-of-concept study also validated the effectiveness of discovering triple topoisomerase I/II and HDAC inhibitors as novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFr6sR4u6kbVg90H21EOLACvtfcHk0lheumfdxqowxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D&md5=9630a82acaa4df7023a07aa7ed395e86</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fml500327q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500327q%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520multiacting%2520topoisomerase%2520I%252FII%2520and%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D3%26spage%3D239%26epage%3D243%26doi%3D10.1021%2Fml500327q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seo, Y. H.</span></span> <span> </span><span class="NLM_article-title">Dual inhibitors against topoisomerases and histone deacetylases</span>. <i>J. Cancer Prev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.15430/JCP.2015.20.2.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.15430%2FJCP.2015.20.2.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26151040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FgvVOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=85-91&issue=2&author=Y.+H.+Seo&title=Dual+inhibitors+against+topoisomerases+and+histone+deacetylases&doi=10.15430%2FJCP.2015.20.2.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitors Against Topoisomerases and Histone Deacetylases</span></div><div class="casAuthors">Seo Young Ho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cancer prevention</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-91</span>
        ISSN:<span class="NLM_cas:issn">2288-3649</span>.
    </div><div class="casAbstract">Topoisomerases and histone deacetylases (HDACs) are considered as important therapeutic targets for a wide range of cancers, due to their association with the initiation, proliferation and survival of cancer cells.  Topoisomerases are involved in the cleavage and religation processes of DNA, while HDACs regulate a dynamic epigenetic modification of the lysine amino acid on various proteins.  Extensive studies have been undertaken to discover small molecule inhibitor of each protein and thereby, several drugs have been transpired from this effort and successfully approved for clinical use.  However, the inherent heterogeneity and multiple genetic abnormalities of cancers challenge the clinical application of these single targeted drugs.  In order to overcome the limitations of a single target approach, a novel approach, simultaneously targeting topoisomerases and HDACs with a single molecule has been recently employed and attracted much attention of medicinal chemists in drug discovery.  This review highlights the current studies on the discovery of dual inhibitors against topoisomerases and HDACs, provides their pharmacological aspects and advantages, and discusses the challenges and promise of the dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM8k2AwC3rWlvAgqb2vdc5fW6udTcc2ebSlCU3Emm5b7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FgvVOgtg%253D%253D&md5=3d3e5d2640e5860e04620d67cca16107</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.15430%2FJCP.2015.20.2.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15430%252FJCP.2015.20.2.85%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DY.%2BH.%26atitle%3DDual%2520inhibitors%2520against%2520topoisomerases%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Cancer%2520Prev.%26date%3D2015%26volume%3D20%26issue%3D2%26spage%3D85%26epage%3D91%26doi%3D10.15430%2FJCP.2015.20.2.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maede, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogame, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, J.</span></span> <span> </span><span class="NLM_article-title">Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-13-0551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24130054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFSmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=214-220&issue=1&author=Y.+Maedeauthor=H.+Shimizuauthor=T.+Fukushimaauthor=T.+Kogameauthor=T.+Nakamuraauthor=T.+Mikiauthor=S.+Takedaauthor=Y.+Pommierauthor=J.+Murai&title=Differential+and+common+DNA+repair+pathways+for+topoisomerase+I-+and+II-targeted+drugs+in+a+genetic+DT40+repair+cell+screen+panel&doi=10.1158%2F1535-7163.MCT-13-0551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel</span></div><div class="casAuthors">Maede, Yuko; Shimizu, Hiroyasu; Fukushima, Toru; Kogame, Toshiaki; Nakamura, Terukazu; Miki, Tsuneharu; Takeda, Shunichi; Pommier, Yves; Murai, Junko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. topoisomerase I (Top1) and II (Top2) inhibitors trap topoisomerases on DNA, thereby inducing protein-linked DNA breaks.  Cancer cells resist the drugs by removing topoisomerase-DNA complexes, and repairing the drug-induced DNA double-strand breaks (DSB) by homologous recombination and nonhomologous end joining (NHEJ).  Because numerous enzymes and cofactors are involved in the removal of the topoisomerase-DNA complexes and DSB repair, it has been challenging to comprehensively analyze the relative contribution of multiple genetic pathways in vertebrate cells.  Comprehending the relative contribution of individual repair factors would give insights into the lesions induced by the inhibitors and genetic determinants of response.  Ultimately, this information would be useful to target specific pathways to augment the therapeutic activity of topoisomerase inhibitors.  To this end, we put together 48 isogenic DT40 mutant cells deficient in DNA repair and generated one cell line deficient in autophagy (ATG5).  Sensitivity profiles were established for three clin. relevant Top1 inhibitors (camptothecin and the indenoisoquinolines LMP400 and LMP776) and three Top2 inhibitors (etoposide, doxorubicin, and ICRF-193).  Highly significant correlations were found among Top1 inhibitors as well as Top2 inhibitors, whereas the profiles of Top1 inhibitors were different from those of Top2 inhibitors.  Most distinct repair pathways between Top1 and Top2 inhibitors include NHEJ, TDP1, TDP2, PARP1, and Fanconi Anemia genes, whereas homologous recombination seems relevant esp. for Top1 and, to a lesser extent, for Top2 inhibitors.  We also found and discuss differential pathways among Top1 inhibitors and Top2 inhibitors.  Mol Cancer Ther; 13(1); 214-20. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrLkuEffSz27Vg90H21EOLACvtfcHk0lhYEhI92QxhEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFSmsg%253D%253D&md5=346456ce64a6e142fb9df968cdc9f05e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0551%26sid%3Dliteratum%253Aachs%26aulast%3DMaede%26aufirst%3DY.%26aulast%3DShimizu%26aufirst%3DH.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DKogame%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DT.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DMurai%26aufirst%3DJ.%26atitle%3DDifferential%2520and%2520common%2520DNA%2520repair%2520pathways%2520for%2520topoisomerase%2520I-%2520and%2520II-targeted%2520drugs%2520in%2520a%2520genetic%2520DT40%2520repair%2520cell%2520screen%2520panel%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D1%26spage%3D214%26epage%3D220%26doi%3D10.1158%2F1535-7163.MCT-13-0551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">DNA repair functions that control sensitivity to topoisomerase-targeting drugs</span>. <i>Eukaryotic Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1128/EC.3.1.82-90.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1128%2FEC.3.1.82-90.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=14871939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1WhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=82-90&issue=1&author=M.+Malikauthor=J.+L.+Nitiss&title=DNA+repair+functions+that+control+sensitivity+to+topoisomerase-targeting+drugs&doi=10.1128%2FEC.3.1.82-90.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair functions that control sensitivity to topoisomerase-targeting drugs</span></div><div class="casAuthors">Malik, Mobeen; Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Eukaryotic Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-90</span>CODEN:
                <span class="NLM_cas:coden">ECUEA2</span>;
        ISSN:<span class="NLM_cas:issn">1535-9778</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">DNA topoisomerases play crit. roles in a wide range of cellular processes by altering DNA topol. to facilitate replication, transcription, and chromosome segregation.  Topoisomerases alter DNA topol. by introducing transient DNA strand breaks that involve a covalent protein DNA intermediate.  Many agents have been found to prevent the religation of DNA strand breaks induced by the enzymes, thereby converting the enzymes into DNA-damaging agents.  Repair of the DNA damage induced by topoisomerases is significant in understanding drug resistance arising following treatment with topoisomerase-targeting drugs.  We have used the fission yeast Schizosaccharomyces pombe to identify DNA repair pathways that are important for cell survival following drug treatment.  S. pombe strains carrying mutations in genes required for homologous recombination such as rad22A or rad32 (homologs of RAD52 and MRE11) are hypersensitive to drugs targeting either topoisomerase I or topoisomerase II.  In contrast to results obsd. with Saccharomyces cerevisiae, S. pombe strains defective in nucleotide excision repair are also hypersensitive to topoisomerase-targeting agents.  The loss of DNA replication or DNA damage checkpoints also sensitizes cells to both topoisomerase I and topoisomerase II inhibitors.  Finally, repair genes (such as the S. pombe rad8+ gene) with no obvious homologs in other systems also play important roles in causing sensitivity to topoisomerase drugs.  Since the pattern of sensitivity is distinct from that seen with other systems (such as the S. cerevisiae system), our results highlight the usefulness of S. pombe in understanding how cells deal with the unique DNA damage induced by topoisomerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD6wsBkilopLVg90H21EOLACvtfcHk0liU3AMjk6Rzig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1WhsLw%253D&md5=ebdda5e1f9faa6a6a904b7ff392e4e2a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1128%2FEC.3.1.82-90.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FEC.3.1.82-90.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DM.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DDNA%2520repair%2520functions%2520that%2520control%2520sensitivity%2520to%2520topoisomerase-targeting%2520drugs%26jtitle%3DEukaryotic%2520Cell%26date%3D2004%26volume%3D3%26issue%3D1%26spage%3D82%26epage%3D90%26doi%3D10.1128%2FEC.3.1.82-90.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kersey, J.</span></span> <span> </span><span class="NLM_article-title">Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-1750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1078-0432.CCR-06-1750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17332306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1591-1600&issue=5&author=Q.+Yaoauthor=B.+Weigelauthor=J.+Kersey&title=Synergism+between+etoposide+and+17-AAG+in+leukemia+cells%3A+critical+roles+for+Hsp90%2C+FLT3%2C+topoisomerase+II%2C+Chk1%2C+and+Rad51&doi=10.1158%2F1078-0432.CCR-06-1750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51</span></div><div class="casAuthors">Yao, Qing; Weigel, Brenda; Kersey, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1591-1600</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">DNA-damaging agents, such as etoposide, while clin. useful in leukemia therapy, are limited by DNA repair pathways that are not well understood.  17-(Allylamino)-17-demethoxygeldanamycin (17-AAG), an inhibitor of the mol. chaperone heat shock protein 90 (Hsp90), inhibits growth and induces apoptosis in FLT3+ leukemia cells.  In this study, we evaluated the effects of etoposide and 17-AAG in leukemia cells and the roles of Hsp90, FMS-like tyrosine kinase 3 (FLT3), checkpoint kinase 1 (Chk1), Rad51, and topoisomerase II in this inhibition.  The single and combined effects of 17-AAG and etoposide and the mechanism of these effects were evaluated.  FLT3 and the DNA repair-related proteins, Chk1 and Rad51, were studied in small interfering RNA (siRNA)-induced cell growth inhibition expts. in human leukemia cells with wild-type or mutated FLT3.  We found that etoposide and the Hsp90/FLT3 inhibitor 17-AAG, had synergistic inhibitory effects on FLT3+ MLL-fusion gene leukemia cells.  Cells with an internal tandem duplication (ITD) FLT3 (Molm13 and MV4;11) were more sensitive to etoposide/17-AAG than leukemias with wild-type FLT3 (HPB-Null and RS4;11).  A crit. role for FLT3 was shown in expts. with FLT3 ligand and siRNA targeted to FLT3.  An important role for topoisomerase II and the DNA repair-related proteins, Chk1 and Rad51, in the synergistic effects was suggested from the results.  The repair of potentially lethal DNA damage by etoposide in leukemia cells is dependent on intact and functioning FLT3 esp. leukemias with ITD-FLT3.  These data suggest a rational therapeutic strategy for FLT3+ leukemias that combines etoposide or other DNA-damaging agents with Hsp90/FLT3 inhibitors such as 17-AAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYkcf05rkfnbVg90H21EOLACvtfcHk0liU3AMjk6Rzig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLY%253D&md5=1baa24d5f1f46ce7eb7ee2eda7075da1</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1750%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DWeigel%26aufirst%3DB.%26aulast%3DKersey%26aufirst%3DJ.%26atitle%3DSynergism%2520between%2520etoposide%2520and%252017-AAG%2520in%2520leukemia%2520cells%253A%2520critical%2520roles%2520for%2520Hsp90%252C%2520FLT3%252C%2520topoisomerase%2520II%252C%2520Chk1%252C%2520and%2520Rad51%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D5%26spage%3D1591%26epage%3D1600%26doi%3D10.1158%2F1078-0432.CCR-06-1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitagawa, I.</span></span> <span> </span><span class="NLM_article-title">Marine natural products. XXXII. Absolute configurations of C-4 of the manoalide family, biologically active sesterterpenes from the marine sponge <i>Hyrtios erecta</i></span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1248/cpb.42.265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1248%2Fcpb.42.265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8149454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK2cXltlShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1994&pages=265-270&issue=2&author=M.+Kobayashiauthor=T.+Okamotoauthor=K.+Hayashiauthor=N.+Yokoyamaauthor=T.+Sasakiauthor=I.+Kitagawa&title=Marine+natural+products.+XXXII.+Absolute+configurations+of+C-4+of+the+manoalide+family%2C+biologically+active+sesterterpenes+from+the+marine+sponge+Hyrtios+erecta&doi=10.1248%2Fcpb.42.265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Marine natural products. XXXII. Absolute configurations of C-4 of the manoalide family, biologically active sesterterpenes from the marine sponge Hyrtios erecta</span></div><div class="casAuthors">Kobayashi, Motomasa; Okamoto, Takumi; Hayashi, Kozo; Yokoyama, Norio; Sasaki, Takuma; Kitagawa, Isao</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-70</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">Cytotoxic sesterterpenes, manoalide 25-acetals (I), seco-manoalide (II), (E)-neomanoalide (III), (Z)-neomanoalide (IV), and heteronemin (V), were isolated from the marine sponge Hyrtios erecta (collected at Amami Island, Kagoshima Prefecture, Japan) by bioassay-guided sepn. and the abs. configurations of these manoalide family members have been detd.  Manoalide 25-acetals (I) were shown to exhibit in vivo antitumor activity and to inhibit the DNA-relaxing activity of mouse DNA topoisomerase I and the DNA-unknotting activity of calf thymus DNA topoisomerase II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr39_b7pYTT5rVg90H21EOLACvtfcHk0lgm5kLyhfmwrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXltlShtbs%253D&md5=1c6f8704a87f032da5d9ff162c2ec7f9</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1248%2Fcpb.42.265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.42.265%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DYokoyama%26aufirst%3DN.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKitagawa%26aufirst%3DI.%26atitle%3DMarine%2520natural%2520products.%2520XXXII.%2520Absolute%2520configurations%2520of%2520C-4%2520of%2520the%2520manoalide%2520family%252C%2520biologically%2520active%2520sesterterpenes%2520from%2520the%2520marine%2520sponge%2520Hyrtios%2520erecta%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1994%26volume%3D42%26issue%3D2%26spage%3D265%26epage%3D270%26doi%3D10.1248%2Fcpb.42.265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Shazly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. C.</span></span> <span> </span><span class="NLM_article-title">Heteronemin, a marine sesterterpenoid-type metabolite, induces apoptosis in prostate LNcap cells via oxidative and ER stress combined with the inhibition of topoisomerase II and Hsp90</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">204</span>, <span class="refDoi"> DOI: 10.3390/md16060204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3390%2Fmd16060204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVersb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=204&issue=6&author=M.+G.+Leeauthor=Y.+C.+Liuauthor=Y.+L.+Leeauthor=M.+El-Shazlyauthor=K.+H.+Laiauthor=S.+P.+Shihauthor=S.+C.+Keauthor=M.+C.+Hongauthor=Y.+C.+Duauthor=J.+C.+Yangauthor=P.+J.+Sungauthor=Z.+H.+Wenauthor=M.+C.+Lu&title=Heteronemin%2C+a+marine+sesterterpenoid-type+metabolite%2C+induces+apoptosis+in+prostate+LNcap+cells+via+oxidative+and+ER+stress+combined+with+the+inhibition+of+topoisomerase+II+and+Hsp90&doi=10.3390%2Fmd16060204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Heteronemin, a marine sesterterpenoid-type metabolite, induces apoptosis in prostate LNcap cells via oxidative and ER stress combined with the inhibition of topoisomerase II and Hsp90</span></div><div class="casAuthors">Lee, Man-Gang; Liu, Yi-Chang; Lee, Yi-Lun; El-Shazly, Mohamed; Lai, Kuei-Hung; Shih, Shou-Ping; Ke, Seng-Chung; Hong, Ming-Chang; Du, Ying-Chi; Yang, Juan-Cheng; Sung, Ping-Jyun; Wen, Zhi-Hong; Lu, Mei-Chin</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">204/1-204/24</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Heteronemin, a marine sesterterpenoid-type natural product, possesses diverse bioactivities, esp. antitumor effect.  Accumulating evidence shows that heteronemin may act as a potent anticancer agent in clin. therapy.  To fully understand the antitumor mechanism of heteronemin, we further explored the precise mol. targets in prostate cancer cells.  Initially, heteronemin exhibited potent cytotoxic effect against LNcap and PC3 prostate cancer cells with IC50 1.4 and 2.7 μM after 24 h, resp.  In the xenograft animal model, the tumor size was significantly suppressed to about 51.9% in the heteronemin-treated group in comparison with the control group with no significant difference in the mice body wts.  In addn., the results of a cell-free system assay indicated that heteronemin could act as topoisomerase II (topo II) catalytic inhibitor through the elimination of essential enzymic activity of topoisomerase IIα expression.  We found that the use of heteronemin-triggered apoptosis by 20.1-68.3%, caused disruption of mitochondrial membrane potential (MMP) by 66.9-99.1% and promoted calcium release by 1.8-, 2.0-, and 2.1-fold compared with the control group in a dose-dependent manner, as demonstrated by annexin-V/PI, rhodamine 123 and Fluo-3 staining assays, resp.  Moreover, our findings indicated that the pretreatment of LNcap cells with an inhibitor of protein tyrosine phosphatase (PTPi) diminished growth inhibition, oxidative and Endoplasmic Reticulum (ER) stress, as well as activation of Chop/Hsp70 induced by heteronemin, suggesting PTP activation plays a crucial rule in the cytotoxic activity of heteronemin.  Using mol. docking anal., heteronemin exhibited more binding affinity to the N-terminal ATP-binding pocket of Hsp90 protein than 17-AAG, a std. Hsp90 inhibitor.  Finally, heteronemin promoted autophagy and apoptosis through the inhibition of Hsp 90 and topo II as well as PTP activation in prostate cancer cells.  Taken together, these multiple targets present heteronemin as an interesting candidate for its future development as an antiprostatic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsfEBw43CTXrVg90H21EOLACvtfcHk0lgm5kLyhfmwrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVersb3M&md5=bfea332fc6c2244f39dcd83eb61e9247</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.3390%2Fmd16060204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd16060204%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BG.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DLee%26aufirst%3DY.%2BL.%26aulast%3DEl-Shazly%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DK.%2BH.%26aulast%3DShih%26aufirst%3DS.%2BP.%26aulast%3DKe%26aufirst%3DS.%2BC.%26aulast%3DHong%26aufirst%3DM.%2BC.%26aulast%3DDu%26aufirst%3DY.%2BC.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DSung%26aufirst%3DP.%2BJ.%26aulast%3DWen%26aufirst%3DZ.%2BH.%26aulast%3DLu%26aufirst%3DM.%2BC.%26atitle%3DHeteronemin%252C%2520a%2520marine%2520sesterterpenoid-type%2520metabolite%252C%2520induces%2520apoptosis%2520in%2520prostate%2520LNcap%2520cells%2520via%2520oxidative%2520and%2520ER%2520stress%2520combined%2520with%2520the%2520inhibition%2520of%2520topoisomerase%2520II%2520and%2520Hsp90%26jtitle%3DMar.%2520Drugs%26date%3D2018%26volume%3D16%26issue%3D6%26spage%3D204%26doi%3D10.3390%2Fmd16060204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Bauman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5926</span>– <span class="NLM_lpage">5932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11479235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVCgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=5926-5932&issue=15&author=S.+D.+Desaiauthor=T.+K.+Liauthor=A.+Rodriguez-Baumanauthor=E.+H.+Rubinauthor=L.+F.+Liu&title=Ubiquitin%2F26S+proteasome-mediated+degradation+of+topoisomerase+I+as+a+resistance+mechanism+to+camptothecin+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells</span></div><div class="casAuthors">Desai, Shyamal D.; Li, Tsai-Kun; Rodriguez-Bauman, Alexandra; Rubin, Eric H.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5926-5932</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Camptothecin (CPT) induces down-regulation of topoisomerase I (TOP1) via an ubiquitin/26S proteasome pathway.  Studies using a panel of breast and colorectal cancer cell lines as well as primary nontransformed and oncogene-transformed cells have demonstrated that CPT-induced down-regulation exhibits a high degree of heterogeneity.  In general, non-transformed cells are much more proficient in CPT-induced TOP1 down-regulation than their transformed counterparts.  Among the breast and colorectal cancer cell lines, there was a general correlation between the extent of CPT-induced TOP1 down-regulation and CPT resistance.  The breast cancer cell line ZR-75-1, the most sensitive to CPT, was completely defective in CPT-induced TOP1 down-regulation, whereas the breast cancer cell line BT474, the least sensitive to CPT, exhibited effective CPT-induced TOP1 down-regulation.  The 26S proteasome inhibitor MG132 was shown to inhibit CPT-induced down-regulation of TOP1 in BT474 cells and selectively sensitized BT474 but not ZR-75-1 cells to CPT-induced cytotoxicity and apoptosis.  In the aggregate, these results suggest that CPT-induced down-regulation of TOP1 could be an important parameter for detg. CPT sensitivity/resistance in tumor cells.  Anal. of the levels of TOP1 cleavable complexes, SUMO-1-TOP1 conjugates, and ubiquitin-TOP1 conjugates in ZR-75-1 and BT474 cells has suggested that the heterogeneity of CPT-induced down-regulation of TOP1 in tumor cells is at least in part attributable to altered regulation of a process(es) downstream from the TOP1 cleavable complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQv9Lv4_pMRrVg90H21EOLACvtfcHk0lgarO1_N-SSpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVCgu7s%253D&md5=f2cc6a3b43b2cf892aa0109c487743f1</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DS.%2BD.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DRodriguez-Bauman%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DUbiquitin%252F26S%2520proteasome-mediated%2520degradation%2520of%2520topoisomerase%2520I%2520as%2520a%2520resistance%2520mechanism%2520to%2520camptothecin%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26issue%3D15%26spage%3D5926%26epage%3D5932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellenberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2.DNA and Top2.RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">17960</span>– <span class="NLM_lpage">17969</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.565374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.M114.565374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24808172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=17960-17969&issue=26&author=R.+Gaoauthor=M.+J.+Schellenbergauthor=S.+Y.+Huangauthor=M.+Abdelmalakauthor=C.+Marchandauthor=K.+C.+Nitissauthor=J.+L.+Nitissauthor=R.+S.+Williamsauthor=Y.+Pommier&title=Proteolytic+degradation+of+topoisomerase+II+%28Top2%29+enables+the+processing+of+Top2.DNA+and+Top2.RNA+covalent+complexes+by+tyrosyl-DNA-phosphodiesterase+2+%28TDP2%29&doi=10.1074%2Fjbc.M114.565374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2·DNA and Top2·RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)</span></div><div class="casAuthors">Gao, Rui; Schellenberg, Matthew J.; Huang, Shar-yin N.; Abdelmalak, Monica; Marchand, Christophe; Nitiss, Karin C.; Nitiss, John L.; Williams, R. Scott; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">17960-17969</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Eukaryotic type II topoisomerases (Top2α and Top2β) are homodimeric enzymes; they are essential for altering DNA topol. by the formation of normally transient double strand DNA cleavage.  Anticancer drugs (etoposide, doxorubicin, and mitoxantrone) and also Top2 oxidn. and DNA helical alterations cause potentially irreversible Top2·DNA cleavage complexes (Top2cc), leading to Top2-linked DNA breaks.  Top2cc are the therapeutic mechanism for killing cancer cells.  Yet Top2cc can also generate recombination, translocations, and apoptosis in normal cells.  The Top2 protein-DNA covalent complexes are excised (in part) by tyrosyl-DNA-phosphodiesterase 2 (TDP2/TTRAP/EAP2/VPg unlinkase).  In this study, we show that irreversible Top2cc induced in suicidal substrates are not processed by TDP2 unless they first undergo proteolytic processing or denaturation.  We also demonstrate that TDP2 is most efficient when the DNA attached to the tyrosyl is in a single-stranded configuration and that TDP2 can efficiently remove a tyrosine linked to a single misincorporated ribonucleotide or to polyribonucleotides, which expands the TDP2 catalytic profile with RNA substrates.  The 1.6-Å resoln. crystal structure of TDP2 bound to a substrate bearing a 5'-ribonucleotide defines a mechanism through which RNA can be accommodated in the TDP2 active site, albeit in a strained conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlhM_DAQWZurVg90H21EOLACvtfcHk0lgarO1_N-SSpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FN&md5=653acb97787ce2f52c0ed47101cfa0d5</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.565374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.565374%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DR.%26aulast%3DSchellenberg%26aufirst%3DM.%2BJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DAbdelmalak%26aufirst%3DM.%26aulast%3DMarchand%26aufirst%3DC.%26aulast%3DNitiss%26aufirst%3DK.%2BC.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26aulast%3DWilliams%26aufirst%3DR.%2BS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DProteolytic%2520degradation%2520of%2520topoisomerase%2520II%2520%2528Top2%2529%2520enables%2520the%2520processing%2520of%2520Top2.DNA%2520and%2520Top2.RNA%2520covalent%2520complexes%2520by%2520tyrosyl-DNA-phosphodiesterase%25202%2520%2528TDP2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D26%26spage%3D17960%26epage%3D17969%26doi%3D10.1074%2Fjbc.M114.565374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prajapati, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span> <span> </span><span class="NLM_article-title">Proteasome-mediated proteostasis: novel medicinal and pharmacological strategies for diseases</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1916</span>– <span class="NLM_lpage">1973</span>, <span class="refDoi"> DOI: 10.1002/med.21502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fmed.21502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29719055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1MjptVGlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=1916-1973&issue=6&author=R.+Mishraauthor=A.+Upadhyayauthor=V.+K.+Prajapatiauthor=A.+Mishra&title=Proteasome-mediated+proteostasis%3A+novel+medicinal+and+pharmacological+strategies+for+diseases&doi=10.1002%2Fmed.21502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome-mediated proteostasis: Novel medicinal and pharmacological strategies for diseases</span></div><div class="casAuthors">Mishra Ribhav; Upadhyay Arun; Mishra Amit; Prajapati Vijay Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1916-1973</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Proteins actively participate in a wide range of cellular physiological functions.  But aggregation of proteins results in cytotoxicity, and unwanted aggregation of misfolded proteins often causes many diseases.  During abnormal protein aggregation events, cells try to cope against such deleterious consequences because of the remarkable functional attempts of two distinct proteolytic mechanisms.  These tightly regulative and signaling mechanisms are autophagy pathway and ubiquitin proteasome system.  Proteasome complex system holds the elimination capacity of intracellular aberrant protein aggregation.  Despite the considerable progress that has been achieved, which elucidates wide function and diverse roles of proteasome system, still several crucial problems remain unanswered.  For example, how the complex proteasomes assembly and their interactive pathways determine the precise sense of several proteotoxic insults, which can severely affect the cell survival and homeostasis? The specific degradation of various aberrant proteins that can disturb cellular homeostasis is achieved by proper proteasome functionality, which is yet another unclear and critical challenge.  Therefore, a better understanding of the various cellular signaling mechanisms composing the proteasome machinery carries broad therapeutic implications linked with proteopathies.  This article signifies the urgent need, which is now crucial for us to improve our understanding of the proteasome architecture, structure, and functions that span multiple level strategies from the molecular level to the cellular level.  This systematic in-depth information of proteasome may be helpful in the near future to design a new molecular framework based on intrinsic and extrinsic cellular mechanisms that drive the assembly of proteasome to induce cellular survival against proteostasis imbalance and disease conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReA_VqWYLezCnGiHuhFGv8fW6udTcc2eanGN7Tem8YKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjptVGlsA%253D%253D&md5=1768ffef72eb04f44d273d8509fd5875</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fmed.21502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21502%26sid%3Dliteratum%253Aachs%26aulast%3DMishra%26aufirst%3DR.%26aulast%3DUpadhyay%26aufirst%3DA.%26aulast%3DPrajapati%26aufirst%3DV.%2BK.%26aulast%3DMishra%26aufirst%3DA.%26atitle%3DProteasome-mediated%2520proteostasis%253A%2520novel%2520medicinal%2520and%2520pharmacological%2520strategies%2520for%2520diseases%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26issue%3D6%26spage%3D1916%26epage%3D1973%26doi%3D10.1002%2Fmed.21502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogiso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruo, T.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2429</span>– <span class="NLM_lpage">2434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10811120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtV2qt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=2429-2434&issue=9&author=Y.+Ogisoauthor=A.+Tomidaauthor=S.+Leiauthor=S.+Omuraauthor=T.+Tsuruo&title=Proteasome+inhibition+circumvents+solid+tumor+resistance+to+topoisomerase+II-directed+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs</span></div><div class="casAuthors">Ogiso, Yasunari; Tomida, Akihiro; Lei, Shuhong; Omura, Satoshi; Tsuruo, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2429-2434</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Physiol. cell conditions, such as glucose deprivation and hypoxia, play a role in developing drug resistance in solid tumors.  These tumor-specific conditions cause decreased expression of DNA topoisomerase IIα (topo IIα), rendering cells resistant to topo II-targeted drugs, such as etoposide and doxorubicin.  We show here that inhibition of proteasome attenuated drug resistance by inhibiting topo IIα depletion induced by glucose starvation and hypoxia.  Topo IIα restoration was seen only at the protein levels, indicating that the topo IIα protein depletion occurred through a proteasome-mediated degrdn. mechanism.  The stress-induced etoposide resistance was effectively prevented in vitro by the proteasome inhibitor lactacystin in both intrinsically resistant and sensitive tumor cells (colon cancer HT-29 and ovarian cancer A2780 cells, resp.).  Furthermore, lactacystin effectively enhanced the antitumor activity of etoposide in the refractory HT-29 xenograft.  These results indicate that lactacystin could serve as a new therapeutic agent to circumvent resistance to topo II-targeted chemotherapy in solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIqgiEa74irVg90H21EOLACvtfcHk0limjukzEiGPpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtV2qt70%253D&md5=c5bec676e519125c1e25150cd3141dff</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOgiso%26aufirst%3DY.%26aulast%3DTomida%26aufirst%3DA.%26aulast%3DLei%26aufirst%3DS.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DTsuruo%26aufirst%3DT.%26atitle%3DProteasome%2520inhibition%2520circumvents%2520solid%2520tumor%2520resistance%2520to%2520topoisomerase%2520II-directed%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26issue%3D9%26spage%3D2429%26epage%3D2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">A protease pathway for the repair of topoisomerase II-DNA covalent complexes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">35997</span>– <span class="NLM_lpage">36003</span>, <span class="refDoi"> DOI: 10.1074/jbc.M604149200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1074%2Fjbc.M604149200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=16973621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ajtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=35997-36003&issue=47&author=A.+Zhangauthor=Y.+L.+Lyuauthor=C.+P.+Linauthor=N.+Zhouauthor=A.+M.+Azarovaauthor=L.+M.+Woodauthor=L.+F.+Liu&title=A+protease+pathway+for+the+repair+of+topoisomerase+II-DNA+covalent+complexes&doi=10.1074%2Fjbc.M604149200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A Protease Pathway for the Repair of Topoisomerase II-DNA Covalent Complexes</span></div><div class="casAuthors">Zhang, Ailing; Lyu, Yi Lisa; Lin, Chao-Po; Zhou, Nai; Azarova, Anna M.; Wood, Laurence M.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">35997-36003</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Despite rapid advances in the field of DNA repair, little is known about the repair of protein-DNA adducts.  Previous studies have demonstrated that topoisomerase II (TopII)-DNA adducts (TopII-DNA covalent complexes) are rapidly degraded by the proteasome.  It has been hypothesized that proteasomal degrdn. of TopII-DNA covalent adducts exposes TopII-concealed DNA double-strand breaks (DSBs) for repair.  To test this hypothesis, the anticancer drug, VP-16 (etoposide), was employed to induce TopII-DNA covalent complexes in mammalian cells, and the involvement of proteasome in processing TopII-DNA covalent complexes into DSBs was investigated.  Consistent with the hypothesis, VP-16-induced DSBs as monitored by neutral comet assay, as well as DNA damage signals (e.g. γ-H2AX) were significantly reduced in the presence of the proteasome inhibitor, MG132.  Using both top2β knock-out mouse embryonic fibroblasts and Top2β small interfering RNA knockdown PC12 cells, as well as postmitotic neurons in which TopIIα was absent, we showed that VP-16-induced DNA damage signals were attenuated upon proteasome inhibition, suggesting the involvement of proteasome in the repair/processing of both TopIIα-DNA and TopIIβ-DNA adducts.  By contrast, hydrogen peroxide-induced γ-H2AX was unaffected upon proteasome inhibition, suggesting a specific requirement of the proteasome pathway in the processing of TopII-DNA covalent complexes into DNA damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj7nwjxWfE47Vg90H21EOLACvtfcHk0li-GiwP2YDlXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ajtrbJ&md5=74210337471ef6053780a3ee8a8e24c4</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M604149200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M604149200%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DLyu%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BP.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DWood%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DA%2520protease%2520pathway%2520for%2520the%2520repair%2520of%2520topoisomerase%2520II-DNA%2520covalent%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26issue%3D47%26spage%3D35997%26epage%3D36003%26doi%3D10.1074%2Fjbc.M604149200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramley, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span> <span> </span><span class="NLM_article-title">Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bcp.2015.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26794000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=29-39&author=K.+C.+Leeauthor=R.+L.+Bramleyauthor=I.+G.+Cowellauthor=G.+H.+Jacksonauthor=C.+A.+Austin&title=Proteasomal+inhibition+potentiates+drugs+targeting+DNA+topoisomerase+II&doi=10.1016%2Fj.bcp.2015.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II</span></div><div class="casAuthors">Lee, Ka C.; Bramley, Rebecca L.; Cowell, Ian G.; Jackson, Graham H.; Austin, Caroline A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The reaction mechanism of DNA topoisomerase II (TOP2) involves a covalent double-strand break intermediate in which the enzyme is coupled to DNA via a 5'-phosphotyrosyl bond.  This normally transient enzyme-bridged break is stabilized by drugs such as mitoxantrone, mAMSA, etoposide, doxorubicin, epirubicin and idarubicin, which are referred to as TOP2 poisons.  Removal of topoisomerase II by the proteasome is involved in the repair of these lesions.  In K562 cells, inhibiting the proteasome with MG132 significantly potentiated the growth inhibition by these six drugs that target topoisomerase II, and the highest level of potentiation was obsd. with mitoxantrone.  Mitoxantrone also showed the greatest potentiation by MG132 in three Nalm 6 cell lines with differing levels of TOP2A or TOP2B.  Mitoxantrone was also potentiated by the clin. used proteasome inhibitor PS341 (Velcade).  We have also shown that proteasome inhibition with MG132 in K562 cells reduces the rate of removal of mitoxantrone or etoposide stabilized topoisomerase complexes from DNA, suggesting a possible mechanism for the potentiation of topoisomerase II drugs by proteasomal inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLiamWQ6CSF7Vg90H21EOLACvtfcHk0li-GiwP2YDlXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVyhtg%253D%253D&md5=ac412751243ac54d9fca38227a13042e</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DBramley%26aufirst%3DR.%2BL.%26aulast%3DCowell%26aufirst%3DI.%2BG.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26atitle%3DProteasomal%2520inhibition%2520potentiates%2520drugs%2520targeting%2520DNA%2520topoisomerase%2520II%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D103%26spage%3D29%26epage%3D39%26doi%3D10.1016%2Fj.bcp.2015.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von Metzler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heider, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamottke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sezer, O.</span></span> <span> </span><span class="NLM_article-title">Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>315</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2471</span>– <span class="NLM_lpage">2478</span>, <span class="refDoi"> DOI: 10.1016/j.yexcr.2009.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.yexcr.2009.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19410573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnslyktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2009&pages=2471-2478&issue=14&author=I.+von+Metzlerauthor=U.+Heiderauthor=M.+Miethauthor=B.+Lamottkeauthor=M.+Kaiserauthor=C.+Jakobauthor=O.+Sezer&title=Synergistic+interaction+of+proteasome+and+topoisomerase+II+inhibition+in+multiple+myeloma&doi=10.1016%2Fj.yexcr.2009.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma</span></div><div class="casAuthors">von Metzler, Ivana; Heider, Ulrike; Mieth, Maren; Lamottke, Britta; Kaiser, Martin; Jakob, Christian; Sezer, Orhan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2471-2478</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multiple myeloma is a malignancy of terminally differentiated plasma cells and is incurable in the majority of the patients.  Thus, novel effective treatment regimens are urgently needed.  In this study, we examd. the effects of co-treatment with proteasome-inhibitor bortezomib and topoisomerase II inhibitor etoposide in multiple myeloma cells lines OPM-2, RPMI-S and NCI-H929.  Using the median effect method of Chou and Talalay, we evaluated the combination indexes (CI) for simultaneous and sequential treatment schedules.  In the sequential treatment schedule, we found strong synergistic effects in all three cell lines, even at low single-agent cytotoxicity levels.  When cells were treated simultaneously with both drugs, the synergy was present but less pronounced than in the sequential treatment schedule.  The synergistic effects obsd. in the co-treatment schedules were accompanied by an inhibition of anti-apoptotic effects that were induced by etoposide alone.  Namely, bortezomib abrogated both etoposide-induced NF-κB activation and etoposide-induced bcl-2 up-regulation.  Our data suggest that combining etoposide with bortezomib might be useful for cancer treatment, as bortezomib potentially inhibits counter-regulatory mechanisms of tumor cells, which are induced by topoisomerase II inhibition and which may contribute to acquired chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIc0Z3J4DBOrVg90H21EOLACvtfcHk0li-GiwP2YDlXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnslyktLw%253D&md5=be75ddc33833dfed0508fec17d7f5481</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2009.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2009.04.019%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMetzler%26aufirst%3DI.%26aulast%3DHeider%26aufirst%3DU.%26aulast%3DMieth%26aufirst%3DM.%26aulast%3DLamottke%26aufirst%3DB.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DJakob%26aufirst%3DC.%26aulast%3DSezer%26aufirst%3DO.%26atitle%3DSynergistic%2520interaction%2520of%2520proteasome%2520and%2520topoisomerase%2520II%2520inhibition%2520in%2520multiple%2520myeloma%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2009%26volume%3D315%26issue%3D14%26spage%3D2471%26epage%3D2478%26doi%3D10.1016%2Fj.yexcr.2009.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q. P.</span></span> <span> </span><span class="NLM_article-title">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.2174/156800911794519752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F156800911794519752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21247388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=239-253&issue=3&author=D.+Chenauthor=M.+Frezzaauthor=S.+Schmittauthor=J.+Kanwarauthor=Q.+P.+Dou&title=Bortezomib+as+the+first+proteasome+inhibitor+anticancer+drug%3A+current+status+and+future+perspectives&doi=10.2174%2F156800911794519752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span></div><div class="casAuthors">Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-253</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer.  Based on pos. preclin. and clin. studies, bortezomib was subsequently approved for the clin. use as a front-line treatment for newly diagnosed multiple myeloma patients and for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this drug has become the staple of treatment.  The approval of bortezomib by the US Food and Drug Administration (FDA) represented a significant milestone as the first proteasome inhibitor to be implemented in the treatment of malignant disease.  Bortezomib has shown a pos. clin. benefit either alone or as a part of combination therapy to induce chemo-/radio-sensitization or overcome drug resistance.  One of the major mechanisms of bortezomib assocd. with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-XL and Bcl-2, and result in apoptotic cell death in malignant cells.  Another important mechanism of bortezomib is through suppression of the NF-κB signaling pathway resulting in the down-regulation of its anti-apoptotic target genes.  Although the majority of success achieved with bortezomib has been in hematol. malignancies, its effect toward solid tumors has been less than encouraging.  Addnl., the widespread clin. use of bortezomib continues to be hampered by the appearance of dose-limiting toxicities, drug-resistance and interference by some natural compds.  These findings could help guide physicians in refining the clin. use of bortezomib, and encourage basic scientists to generate next generation proteasome inhibitors that broaden the spectrum of efficacy and produce a more durable clin. response in cancer patients.  Other desirable applications for the use of proteasome inhibitors include the development of inhibitors against specific E3 ligases, which act at an early step in the ubiquitin-proteasome pathway, and the discovery of less toxic and novel proteasome inhibitors from natural products and traditional medicines, which may provide more viable drug candidates for cancer chemoprevention and the treatment of cancer patients in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4QCk3nP8BLVg90H21EOLACvtfcHk0ljhPHDYyhvF2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D&md5=15becbceb98ec3e244fc066315815dd2</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.2174%2F156800911794519752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911794519752%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFrezza%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DS.%26aulast%3DKanwar%26aufirst%3DJ.%26aulast%3DDou%26aufirst%3DQ.%2BP.%26atitle%3DBortezomib%2520as%2520the%2520first%2520proteasome%2520inhibitor%2520anticancer%2520drug%253A%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26issue%3D3%26spage%3D239%26epage%3D253%26doi%3D10.2174%2F156800911794519752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Hay, M.</span></span> <span> </span><span class="NLM_article-title">Acute lymphoblastic leukemia: a comprehensive review and 2017 update</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e577</span>, <span class="refDoi"> DOI: 10.1038/bcj.2017.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fbcj.2017.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28665419" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e577&issue=6&author=T.+Terwilligerauthor=M.+Abdul-Hay&title=Acute+lymphoblastic+leukemia%3A+a+comprehensive+review+and+2017+update&doi=10.1038%2Fbcj.2017.53"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2017.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2017.53%26sid%3Dliteratum%253Aachs%26aulast%3DTerwilliger%26aufirst%3DT.%26aulast%3DAbdul-Hay%26aufirst%3DM.%26atitle%3DAcute%2520lymphoblastic%2520leukemia%253A%2520a%2520comprehensive%2520review%2520and%25202017%2520update%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2017%26volume%3D7%26issue%3D6%26spage%3De577%26doi%3D10.1038%2Fbcj.2017.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vispe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annereau, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creancier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruczynski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barret, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailly, C.</span></span> <span> </span><span class="NLM_article-title">Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1863</span>– <span class="NLM_lpage">1872</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2007.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bcp.2007.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=17391647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFOjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1863-1872&issue=12&author=S.+Vispeauthor=I.+Vandenbergheauthor=M.+Robinauthor=J.+P.+Annereauauthor=L.+Creancierauthor=V.+Piqueauthor=J.+P.+Galyauthor=A.+Kruczynskiauthor=J.+M.+Barretauthor=C.+Bailly&title=Novel+tetra-acridine+derivatives+as+dual+inhibitors+of+topoisomerase+II+and+the+human+proteasome&doi=10.1016%2Fj.bcp.2007.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome</span></div><div class="casAuthors">Vispe, S.; Vandenberghe, I.; Robin, M.; Annereau, J. P.; Creancier, L.; Pique, V.; Galy, J. P.; Kruczynski, A.; Barret, J. M.; Bailly, C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1863-1872</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acridine derivs., such as amsacrine, represent a well known class of multi-targeted anti-cancer agents that generally interfere with DNA synthesis and inhibit topoisomerase II.  But in addn., these tricyclic mols. often display secondary effects on other biochem. pathways including protein metab.  To identify novel anti-cancer drugs, we evaluated the mechanism of action of a novel series of bis- and tetra-acridines.  As expected, these mols. were found to interact with DNA and inhibit the topoisomerase II-mediated DNA decatenation.  Interestingly when tested on human tumor cells either sensitive (HL-60) or resistant (HL-60/MX2) to topoisomerase II inhibitors, these mols. proved equicytotoxic against the two cell lines, suggesting that they do not only rely on topoisomerase II inhibition to exert their cytotoxic effects.  To identify alternative targets, we tested the capacity of acridines 1-9 to inhibit the proteasome machinery.  Four tetra-acridines inhibited the proteasome in vitro, with IC50 values up to 40 times lower than that of the ref. proteasome inhibitor lactacystin.  Moreover, unlike peptide aldehydes used as ref. inhibitors for the proteasome, these new acridine compds. demonstrated a good selectivity towards the proteasome, when tested against four unrelated proteases.  A cellular assay based on the degrdn. of a proteasome protein substrate indicated that at least two of the tetra-acridines maintained this proteasome inhibition activity in a cellular context.  This is the first report of tetra-acridines that demonstrate dual topoisomerase II and proteasome inhibition properties.  This new dual activity could represent a novel anti-cancer approach to circumvent certain forms of tumor resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXYfECvL9ru7Vg90H21EOLACvtfcHk0ljPKBhPeO49NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFOjtbo%253D&md5=91068f0219e5114ff5a7c2b19010e57f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2007.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2007.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DVispe%26aufirst%3DS.%26aulast%3DVandenberghe%26aufirst%3DI.%26aulast%3DRobin%26aufirst%3DM.%26aulast%3DAnnereau%26aufirst%3DJ.%2BP.%26aulast%3DCreancier%26aufirst%3DL.%26aulast%3DPique%26aufirst%3DV.%26aulast%3DGaly%26aufirst%3DJ.%2BP.%26aulast%3DKruczynski%26aufirst%3DA.%26aulast%3DBarret%26aufirst%3DJ.%2BM.%26aulast%3DBailly%26aufirst%3DC.%26atitle%3DNovel%2520tetra-acridine%2520derivatives%2520as%2520dual%2520inhibitors%2520of%2520topoisomerase%2520II%2520and%2520the%2520human%2520proteasome%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26issue%3D12%26spage%3D1863%26epage%3D1872%26doi%3D10.1016%2Fj.bcp.2007.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Protein kinases - the major drug targets of the twenty-first century?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nrd773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrd773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=12120282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&issue=4&author=P.+Cohen&title=Protein+kinases+-+the+major+drug+targets+of+the+twenty-first+century%3F&doi=10.1038%2Fnrd773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Protein kinases - the major drug targets of the twenty-first century?</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease.  A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clin. use.  Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors.  Here, I give a personal view of some of the most important advances that have shaped this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRd_GqiGAWaLVg90H21EOLACvtfcHk0ljPKBhPeO49NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D&md5=67d2fbc11a55b5980ee0692f7bc13cc9</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fnrd773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd773%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520kinases%2520-%2520the%2520major%2520drug%2520targets%2520of%2520the%2520twenty-first%2520century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D4%26spage%3D309%26epage%3D315%26doi%3D10.1038%2Fnrd773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhullar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagarón, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupasinghe, H. P. V.</span></span> <span> </span><span class="NLM_article-title">Kinase-targeted cancer therapies: progress, challenges and future directions</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">48</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0804-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1186%2Fs12943-018-0804-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29455673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=48&issue=1&author=K.+S.+Bhullarauthor=N.+O.+Lagar%C3%B3nauthor=E.+M.+McGowanauthor=I.+Parmarauthor=A.+Jhaauthor=B.+P.+Hubbardauthor=H.+P.+V.+Rupasinghe&title=Kinase-targeted+cancer+therapies%3A+progress%2C+challenges+and+future+directions&doi=10.1186%2Fs12943-018-0804-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-targeted cancer therapies: progress, challenges and future directions</span></div><div class="casAuthors">Bhullar, Khushwant S.; Lagaron, Naiara Orrego; McGowan, Eileen M.; Parmar, Indu; Jha, Amitabh; Hubbard, Basil P.; Rupasinghe, H. P. Vasantha</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48/1-48/20</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues.  Many of these kinases are assocd. with human cancer initiation and progression.  The recent development of small-mol. kinase inhibitors for the treatment of diverse types of cancer has proven successful in clin. therapy.  Significantly, protein kinases are the second most targeted group of drug targets, after the G-proteincoupled receptors.  Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer.  Furthermore, about 150 kinase-targeted drugs are in clin. phase trials, and many kinase-specific inhibitors are in the preclin. stage of drug development.  Nevertheless, many factors confound the clin. efficacy of these mols.  Specific tumor genetics, tumor microenvironment, drug resistance, and pharmacogenomics det. how useful a compd. will be in the treatment of a given cancer.  This review provides an overview of kinase-targeted drug discovery and development in relation to oncol. and highlights the challenges and future potential for kinase-targeted cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb-edOGHyJPbVg90H21EOLACvtfcHk0ljPKBhPeO49NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7fP&md5=30811747f13749327d998c5dadd2161d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0804-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0804-2%26sid%3Dliteratum%253Aachs%26aulast%3DBhullar%26aufirst%3DK.%2BS.%26aulast%3DLagar%25C3%25B3n%26aufirst%3DN.%2BO.%26aulast%3DMcGowan%26aufirst%3DE.%2BM.%26aulast%3DParmar%26aufirst%3DI.%26aulast%3DJha%26aufirst%3DA.%26aulast%3DHubbard%26aufirst%3DB.%2BP.%26aulast%3DRupasinghe%26aufirst%3DH.%2BP.%2BV.%26atitle%3DKinase-targeted%2520cancer%2520therapies%253A%2520progress%252C%2520challenges%2520and%2520future%2520directions%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D48%26doi%3D10.1186%2Fs12943-018-0804-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardenas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, S. M.</span></span> <span> </span><span class="NLM_article-title">Regulation of topoisomerase II by phosphorylation: a role for casein kinase II</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8389373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXktVeiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1993&pages=219-225&author=M.+E.+Cardenasauthor=S.+M.+Gasser&title=Regulation+of+topoisomerase+II+by+phosphorylation%3A+a+role+for+casein+kinase+II"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of topoisomerase II by phosphorylation: a role for casein kinase II</span></div><div class="casAuthors">Cardenas, Maria E.; Gasser, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-25</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    </div><div class="casAbstract">A review with 74 refs.  Casein kinase II is the major kinase responsible for the phosphorylation of eukaryotic topoisomerase II in vivo.  The phosphorylation is regulated by the cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofq3RL78K34LVg90H21EOLACvtfcHk0ljrSOzvMBVahQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVeiu74%253D&md5=990ff716d1a33072554da8e8699a2e32</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCardenas%26aufirst%3DM.%2BE.%26aulast%3DGasser%26aufirst%3DS.%2BM.%26atitle%3DRegulation%2520of%2520topoisomerase%2520II%2520by%2520phosphorylation%253A%2520a%2520role%2520for%2520casein%2520kinase%2520II%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D1993%26volume%3D104%26spage%3D219%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boichuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunaev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galembikova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeeva, E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1097%2FCAD.0000000000000637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29697413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFOiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=549-559&issue=6&author=S.+Boichukauthor=P.+Dunaevauthor=A.+Galembikovaauthor=I.+Mustafinauthor=E.+Valeeva&title=Inhibition+of+fibroblast+growth+factor+receptor-signaling+sensitizes+imatinib-resistant+gastrointestinal+stromal+tumors+to+low+doses+of+topoisomerase+II+inhibitors&doi=10.1097%2FCAD.0000000000000637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors</span></div><div class="casAuthors">Boichuk, Sergei; Dunaev, Pavel; Galembikova, Aigul; Mustafin, Ilshat; Valeeva, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">549-559</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The acquired resistance of gastrointestinal stromal tumors (GISTs) to the targeted-based therapy remains the driving force to identify the novel approaches that are capable of increasing the sensitivity of GISTs to the current therapeutic regimens.  Our present data show that BGJ398, a selective fibroblast growth factor receptor (FGFR) inhibitor, sensitizes imatinib (IM)-resistant GIST cells with receptor tyrosine kinase (RTK) switch (loss of c-KIT/gain of pFGFR2a) to the low doses of topoisomerase II inhibitors - doxorubicin (Dox) and etoposide (Eto).  Mechanistically, pretreatment of IM-resistant GIST cells with BGJ398 for 12 h markedly enhanced proapoptotic and growth-suppressive effects of Dox (or Eto).  Indeed, a significant cleavage of PARP and caspase-3 was obsd. in GIST cells treated with a combination of FGFR and topoisomerase II inhibitor.  In contrast, no signs of apoptosis were detected in IM-resistant GIST cells treated with BGJ398, whereas the low doses of Dox (Eto) exerted the minor proapoptotic effects on GISTs.  The mechanism of BGJ398-induced sensitization of GIST to topoisomerase II inhibitors might be because of attenuation of DNA damage signaling and repair.  Indeed, we obsd. a marked decrease in Rad51 expression in GIST cells treated with BGJ398 together with Dox.  Similar results were obtained when an overexpressed pFGFR2a was knocked down by corresponding siRNA before Dox (Eto) exposure.  Moreover, FGFR inhibition/depletion caused a loss of Rad51 foci in Dox-treated GIST cells, suggesting that FGFR-signaling plays an important regulatory role in homol.-mediated DNA repair.  Our data show that combined therapy (RTKs inhibitors supplemented with low doses of topoisomerase II inhibitors) might be effective for unresectable and metastatic forms of GISTs.  In case of resistance to IM because of RTKs switch indicated above, FGFR inhibitors (e.g. BGJ398) might be potentially useful because of their ability to sensitize tumor cells to topoisomerase II inhibitors and induce tumor cell apoptosis by targeting DNA double-strand breaks repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8TTqQx7Pm8LVg90H21EOLACvtfcHk0ljrSOzvMBVahQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFOiurY%253D&md5=b3b470cf3c38766aecc4c67ee9fc3b04</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000637%26sid%3Dliteratum%253Aachs%26aulast%3DBoichuk%26aufirst%3DS.%26aulast%3DDunaev%26aufirst%3DP.%26aulast%3DGalembikova%26aufirst%3DA.%26aulast%3DMustafin%26aufirst%3DI.%26aulast%3DValeeva%26aufirst%3DE.%26atitle%3DInhibition%2520of%2520fibroblast%2520growth%2520factor%2520receptor-signaling%2520sensitizes%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%2520to%2520low%2520doses%2520of%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2018%26volume%3D29%26issue%3D6%26spage%3D549%26epage%3D559%26doi%3D10.1097%2FCAD.0000000000000637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVore, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methane-sulfon-m-anisidide</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2156</span>– <span class="NLM_lpage">2161</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1313738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXit1Gjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1992&pages=2156-2161&issue=8&author=R.+F.+DeVoreauthor=A.+H.+Corbettauthor=N.+Osheroff&title=Phosphorylation+of+topoisomerase+II+by+casein+kinase+II+and+protein+kinase+C%3A+effects+on+enzyme-mediated+DNA+cleavage%2Freligation+and+sensitivity+to+the+antineoplastic+drugs+etoposide+and+4%E2%80%B2-%289-acridinylamino%29methane-sulfon-m-anisidide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of topoisomerase II by casein kinase II and protein kinase C:  effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide</span></div><div class="casAuthors">DeVore, Russell F.; Corbett, Anita H.; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2156-61</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The effects of serine phosphorylation on the DNA cleavage/religation equil. of topoisomerase II and the sensitivity of the enzyme to antineoplastic drugs were characterized.  Both casein kinase II and protein kinase C were used for these studies.  Each kinase incorporated a max. of ∼1.4 phosphate mols. per homodimer of topoisomerase II.  When the enzyme was incubated with both kinases simultaneously, phosphate incorporation increased to ∼2.6 mols./homodimer.  In the absence of antineoplastic drugs, phosphorylation had only a slight effect on the DNA cleavage/religation equil. of topoisomerase II.  However, in the presence of etoposide or 4'-(9-acridinylamino)methanesulfon-m-anisidide, phosphorylation attenuated the ability of drugs to stabilize enzyme-DNA cleavage complexes.  Levels of drug-induced DNA cleavage products decreased ∼33% following phosphorylation of topoisomerase II by casein kinase II, ∼17% following modification by protein kinase C, and ∼50% following simultaneous phosphorylation of the enzyme by both kinases.  This latter 50% redn. in DNA cleavage products correlated with an ∼2-fold increase in the apparent first order rate const. for DNA religation mediated by simultaneously modified topoisomerase II.  These results strongly suggest that the sensitivity of topoisomerase II toward antineoplastic drugs can be modulated by altering the phosphorylation state of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMG0WJJv8tI7Vg90H21EOLACvtfcHk0lgXADV3RODaYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit1Gjsbg%253D&md5=bf8b1c47180ae2d60a8bc10b673a1348</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeVore%26aufirst%3DR.%2BF.%26aulast%3DCorbett%26aufirst%3DA.%2BH.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DPhosphorylation%2520of%2520topoisomerase%2520II%2520by%2520casein%2520kinase%2520II%2520and%2520protein%2520kinase%2520C%253A%2520effects%2520on%2520enzyme-mediated%2520DNA%2520cleavage%252Freligation%2520and%2520sensitivity%2520to%2520the%2520antineoplastic%2520drugs%2520etoposide%2520and%25204%25E2%2580%25B2-%25289-acridinylamino%2529methane-sulfon-m-anisidide%26jtitle%3DCancer%2520Res.%26date%3D1992%26volume%3D52%26issue%3D8%26spage%3D2156%26epage%3D2161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guilhot, F.</span></span> <span> </span><span class="NLM_article-title">Indications for imatinib mesylate therapy and clinical management</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.9-3-271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1634%2Ftheoncologist.9-3-271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15169982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFKqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=271-281&issue=3&author=F.+Guilhot&title=Indications+for+imatinib+mesylate+therapy+and+clinical+management&doi=10.1634%2Ftheoncologist.9-3-271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Indications for imatinib mesylate therapy and clinical management</span></div><div class="casAuthors">Guilhot, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-281</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Imatinib mesylate (Gleevec, Glivec, formerly STI571; Novartis Pharma AG; Basel, Switzerland) is a rationally-designed, molecularly-specific oral anticancer agent that selectively inhibits several protein tyrosine kinases central to the pathogenesis of human cancer.  It has demonstrated remarkable clin. efficacy in patients with chronic myeloid leukemia and malignant gastrointestinal stromal tumors.  Treatment with imatinib is generally well tolerated, and the risk for severe adverse effects is low.  Adverse effects most commonly include mild-to-moderate edema, nausea and vomiting, diarrhea, muscle cramps, and cutaneous reactions.  Hepatic transaminase level elevations and myelosuppression occur less frequently and resolve with interruption of imatinib therapy.  In general, the incidence and severity of adverse effects tend to correlate with imatinib dose and, in chronic myeloid leukemia patients, the phase of disease; but, patient age and other factors are also assocd. with some types of reactions.  With prompt and appropriate intervention, adverse effects in imatinib-treated patients have proven to be manageable across the spectrum of severity, and they seldom require permanent cessation of therapy.  Dose redn. is not usually necessary, and redn. to subtherapeutic levels is not recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0LSN0zReO-bVg90H21EOLACvtfcHk0lgXADV3RODaYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFKqurc%253D&md5=32f0f9eec5155fff00b1088ff4d8efdb</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.9-3-271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.9-3-271%26sid%3Dliteratum%253Aachs%26aulast%3DGuilhot%26aufirst%3DF.%26atitle%3DIndications%2520for%2520imatinib%2520mesylate%2520therapy%2520and%2520clinical%2520management%26jtitle%3DOncologist%26date%3D2004%26volume%3D9%26issue%3D3%26spage%3D271%26epage%3D281%26doi%3D10.1634%2Ftheoncologist.9-3-271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. Y.</span></span> <span> </span><span class="NLM_article-title">Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate <i>in vitro</i></span>. <i>Cell Biol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1002/cbin.10686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1002%2Fcbin.10686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=27677634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2ksL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2017&pages=16-23&issue=1&author=M.+Y.+Liuauthor=W.+Z.+Wangauthor=F.+F.+Liaoauthor=Q.+Q.+Wuauthor=X.+H.+Linauthor=Y.+H.+Chenauthor=L.+Chengauthor=X.+B.+Jinauthor=J.+Y.+Zhu&title=Selective+and+effective+targeting+of+chronic+myeloid+leukemia+stem+cells+by+topoisomerase+II+inhibitor+etoposide+in+combination+with+imatinib+mesylate+in+vitro&doi=10.1002%2Fcbin.10686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro</span></div><div class="casAuthors">Liu, Man-Yu; Wang, Wei-Zhang; Liao, Fen-Fang; Wu, Qing-Qing; Lin, Xiang-Hua; Chen, Yong-Hen; Cheng, Lin; Jin, Xiao-Bao; Zhu, Jia-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology International</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">CBIIEV</span>;
        ISSN:<span class="NLM_cas:issn">1095-8355</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (TKIs) have improved chronic myeloid leukemia (CML) patient survival markedly but fail to eradicate quiescent CML leukemia stem cells (LSCs).  Thus, strategies targeting LSCs are required to induce long-term remission and achieve cure.  Here, we investigated the ability of topoisomerase II (Top II) inhibitor etoposide (Eto) to target CML LSCs.  Treatment with Eto combined with IM markedly induced apoptosis in primitive CML CD34+CD38- stem cells resistant to eradication by IM alone, but not in normal hematopoietic stem cells, CML and normal mature CD34- cells, and other leukemia and lymphoma cell lines.  The interaction of IM and Eto significantly inhibited phosphorylation of PDK1, AKT, GSK3, S6, and ERK proteins; increased the expression of pro-apoptotic gene Bax; and decreased the expression of anti-apoptotic gene c-Myc in CML CD34+ cells.  Top II inhibitors treatment represents an attractive approach for targeting LSCs in CML patients undergoing TKIs monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSdID5GFe-KbVg90H21EOLACvtfcHk0lgXADV3RODaYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2ksL3L&md5=3a07ec363ffacd97c59ba459dba7a3ff</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fcbin.10686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbin.10686%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%2BY.%26aulast%3DWang%26aufirst%3DW.%2BZ.%26aulast%3DLiao%26aufirst%3DF.%2BF.%26aulast%3DWu%26aufirst%3DQ.%2BQ.%26aulast%3DLin%26aufirst%3DX.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DX.%2BB.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26atitle%3DSelective%2520and%2520effective%2520targeting%2520of%2520chronic%2520myeloid%2520leukemia%2520stem%2520cells%2520by%2520topoisomerase%2520II%2520inhibitor%2520etoposide%2520in%2520combination%2520with%2520imatinib%2520mesylate%2520in%2520vitro%26jtitle%3DCell%2520Biol.%2520Int.%26date%3D2017%26volume%3D41%26issue%3D1%26spage%3D16%26epage%3D23%26doi%3D10.1002%2Fcbin.10686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span> <span> </span><span class="NLM_article-title">Ciprofloxacin: mammalian DNA topoisomerase type II poison <i>in vivo</i></span>. <i>Mutat. Res. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>301</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/0165-7992(93)90029-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2F0165-7992%2893%2990029-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=7678175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3sXhtFKhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=1993&pages=87-92&issue=2&author=A.+Mukherjeeauthor=S.+Senauthor=K.+Agarwal&title=Ciprofloxacin%3A+mammalian+DNA+topoisomerase+type+II+poison+in+vivo&doi=10.1016%2F0165-7992%2893%2990029-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Ciprofloxacin:  mammalian DNA topoisomerase type II poison in vivo</span></div><div class="casAuthors">Mukherjee, A.; Sen, S.; Agarwal, K.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research Letters</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">MRLEDH</span>;
        ISSN:<span class="NLM_cas:issn">0165-7992</span>.
    </div><div class="casAbstract">Ciprofloxacin (CF), a fluoroquinolone widely used as a potent antimicrobial drug, was evaluated in vivo in mouse bone marrow cells for its ability to induce clastogenicity and DNA damage in terms of increased sister-chromatid exchange (SCE) frequencies.  Doses of 0.6, 6 and 20 mg/kg body wt. of CF given i.p. induced a pos. dose-dependent significant clastogenicity (trend test α ≤ 0.05), though the effects were not specific for specific phases of the cell cycle.  The DNA-damaging effect obsd. as increased SCE frequencies using doses of 0.15, 0.30, 0.60, 1.2 and 6 mg/kg body wt. showed a significant dose-dependent increase (trend test α ≤ 0.05; lowest effective concn. 1.2 mg/kg of body wt.).  Compared to a potent eukaryotic DNA topoisomerase type II poison, etoposide (VP-16, 0.5, 1 and 5 mg/kg body wt., given i.p.), ciprofloxacin produced comparable dose-dependent SCE frequency increases.  Ciprofloxacin was postulated to be specific for the target DNA gyrase, the prokaryotic homolog of DNA topoisomerase type II enzyme.  The present paper along with the existing earlier data strongly suggest that topoisomerase type II and DNA gyrase are physiol. targets for the drug action.  In view of the present significant in vivo mammalian DNA topoisomerase type II-mediated genotoxicity and clastogenicity data, ciprofloxacin should be administered with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRP3mRFCSfabVg90H21EOLACvtfcHk0lj4SAodaIg_DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtFKhtLY%253D&md5=2d3141f04b4f8a62f20bc251394db836</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2F0165-7992%2893%2990029-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-7992%252893%252990029-U%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DAgarwal%26aufirst%3DK.%26atitle%3DCiprofloxacin%253A%2520mammalian%2520DNA%2520topoisomerase%2520type%2520II%2520poison%2520in%2520vivo%26jtitle%3DMutat.%2520Res.%2520Lett.%26date%3D1993%26volume%3D301%26issue%3D2%26spage%3D87%26epage%3D92%26doi%3D10.1016%2F0165-7992%2893%2990029-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bredberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaszyk, M.</span></span> <span> </span><span class="NLM_article-title">Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1128/AAC.35.3.448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1128%2FAAC.35.3.448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1645508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFKlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1991&pages=448-450&issue=3&author=A.+Bredbergauthor=M.+Brantauthor=M.+Jaszyk&title=Ciprofloxacin-induced+inhibition+of+topoisomerase+II+in+human+lymphoblastoid+cells&doi=10.1128%2FAAC.35.3.448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells</span></div><div class="casAuthors">Bredberg, Anders; Brant, Marta; Jaszyk, Malgorzata</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">448-50</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The antibacterial activities of the fluorinated 4-quinolones (e.g., ciprofloxacin) have been ascribed to a marked inhibition of bacterial DNA gyrase.  In contrast, the influence on purified mammalian DNA enzymes, including topoisomerases, has been reported to be several orders of magnitude weaker, occurring at concns. higher than 100 μg of ciprofloxacin per mL.  In this study, using a nondenaturing filter elution method, a marked induction of double-strand DNA breaks in human lymphoblastoid cells exposed to 80 μg of ciprofloxacin per mL was seen.  The proportion of single-strand vs. double-strand DNA breaks was similar to that seen with the topoisomerase II inhibitory antitumor agent VP-16.  The cellular recovery was more rapid after treatment with ciprofloxacin than after treatment with VP-16, displaying a normal elution profile within 15 min at 37° (60 min for VP-16).  These data indicate that ciprofloxacin has an effect on intracellularly located topoisomerase II in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo57QXAcJQTKLVg90H21EOLACvtfcHk0lj4SAodaIg_DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFKlt7Y%253D&md5=fc226cd357f2d97eec40f764a68648f9</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1128%2FAAC.35.3.448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.35.3.448%26sid%3Dliteratum%253Aachs%26aulast%3DBredberg%26aufirst%3DA.%26aulast%3DBrant%26aufirst%3DM.%26aulast%3DJaszyk%26aufirst%3DM.%26atitle%3DCiprofloxacin-induced%2520inhibition%2520of%2520topoisomerase%2520II%2520in%2520human%2520lymphoblastoid%2520cells%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1991%26volume%3D35%26issue%3D3%26spage%3D448%26epage%3D450%26doi%3D10.1128%2FAAC.35.3.448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beberok, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrzesniok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzepka, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Respondek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buszman, E.</span></span> <span> </span><span class="NLM_article-title">Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.3892/ijo.2018.4310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3892%2Fijo.2018.4310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29532860" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Beberokauthor=D.+Wrzesniokauthor=J.+Rokauthor=Z.+Rzepkaauthor=M.+Respondekauthor=E.+Buszman&title=Ciprofloxacin+triggers+the+apoptosis+of+human+triple-negative+breast+cancer+MDA-MB-231+cells+via+the+p53%2FBax%2FBcl-2+signaling+pathway&doi=10.3892%2Fijo.2018.4310"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.3892%2Fijo.2018.4310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2018.4310%26sid%3Dliteratum%253Aachs%26aulast%3DBeberok%26aufirst%3DA.%26aulast%3DWrzesniok%26aufirst%3DD.%26aulast%3DRok%26aufirst%3DJ.%26aulast%3DRzepka%26aufirst%3DZ.%26aulast%3DRespondek%26aufirst%3DM.%26aulast%3DBuszman%26aufirst%3DE.%26atitle%3DCiprofloxacin%2520triggers%2520the%2520apoptosis%2520of%2520human%2520triple-negative%2520breast%2520cancer%2520MDA-MB-231%2520cells%2520via%2520the%2520p53%252FBax%252FBcl-2%2520signaling%2520pathway%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2018%26doi%3D10.3892%2Fijo.2018.4310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Idowu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span> <span> </span><span class="NLM_article-title">Ubiquitous Nature of Fluoroquinolones: The oscillation between antibacterial and anticancer activities</span>. <i>Antibiotics (Basel, Switz.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.3390/antibiotics6040026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3390%2Fantibiotics6040026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVKmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=26&issue=4&author=T.+Idowuauthor=F.+Schweizer&title=Ubiquitous+Nature+of+Fluoroquinolones%3A+The+oscillation+between+antibacterial+and+anticancer+activities&doi=10.3390%2Fantibiotics6040026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitous nature of fluoroquinolones: the oscillation between antibacterial and anticancer activities</span></div><div class="casAuthors">Idowu, Temilolu; Schweizer, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Antibiotics (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">26/1-26/24</span>CODEN:
                <span class="NLM_cas:coden">ABSNC4</span>;
        ISSN:<span class="NLM_cas:issn">2079-6382</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Fluoroquinolones are synthetic antibacterial agents that stabilize the ternary complex of prokaryotic topoisomerase II enzymes (gyrase and Topo IV), leading to extensive DNA fragmentation and bacteria death.  Despite the similar structural folds within the crit. regions of prokaryotic and eukaryotic topoisomerases, clin. relevant fluoroquinolones display a remarkable selectivity for prokaryotic topoisomerase II, with excellent safety records in humans.  Typical agents that target human topoisomerases (such as etoposide, doxorubicin and mitoxantrone) are assocd. with significant toxicities and secondary malignancies, whereas clin. relevant fluoroquinolones are not known to exhibit such propensities.  Although many fluoroquinolones have been shown to display topoisomerase-independent antiproliferative effects against various human cancer cells, those that are significantly active against eukaryotic topoisomerase show the same DNA damaging properties as other topoisomerase poisons.  Empirical models also show that fluoroquinolones mediate some unique immunomodulatory activities of suppressing pro-inflammatory cytokines and super-inducing interleukin-2.  This article reviews the extended roles of fluoroquinolones and their prospects as lead for the unmet needs of "small and safe" multimodal-targeting drug scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBCOvxD53kLrVg90H21EOLACvtfcHk0lj4SAodaIg_DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVKmu7w%253D&md5=a0c215221a571c09eb87ae11d11279df</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.3390%2Fantibiotics6040026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantibiotics6040026%26sid%3Dliteratum%253Aachs%26aulast%3DIdowu%26aufirst%3DT.%26aulast%3DSchweizer%26aufirst%3DF.%26atitle%3DUbiquitous%2520Nature%2520of%2520Fluoroquinolones%253A%2520The%2520oscillation%2520between%2520antibacterial%2520and%2520anticancer%2520activities%26jtitle%3DAntibiotics%2520%2528Basel%252C%2520Switz.%2529%26date%3D2017%26volume%3D6%26issue%3D4%26spage%3D26%26doi%3D10.3390%2Fantibiotics6040026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. J.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of topoisomerase II and tyrosine kinases by the novel bis-fluoroquinolone chalcone-like derivative HMNE3 in human pancreatic cancer cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">e0162821</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0162821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1371%2Fjournal.pone.0162821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=27760157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1ynsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0162821&issue=10&author=Y.+C.+Maauthor=Z.+X.+Wangauthor=S.+J.+Jinauthor=Y.+X.+Zhangauthor=G.+Q.+Huauthor=D.+T.+Cuiauthor=J.+S.+Wangauthor=M.+Wangauthor=F.+Q.+Wangauthor=Z.+J.+Zhao&title=Dual+inhibition+of+topoisomerase+II+and+tyrosine+kinases+by+the+novel+bis-fluoroquinolone+chalcone-like+derivative+HMNE3+in+human+pancreatic+cancer+cells&doi=10.1371%2Fjournal.pone.0162821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of topoisomerase II and tyrosine kinases by the novel bis-fluoroquinolone chalcone-like derivative HMNE3 in human pancreatic cancer cells</span></div><div class="casAuthors">Ma, Yong-Chao; Wang, Zhi-Xin; Jin, Shao-Ju; Zhang, Yan-Xin; Hu, Guo-Qiang; Cui, Dong-Tao; Wang, Jiang-Shuan; Wang, Min; Wang, Fu-Qing; Zhao, Zhi-Jun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0162821/1-e0162821/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Both tyrosine kinase and topoisomerase II (TopII) are important anticancer targets, and their resp. inhibitors are widely used in cancer therapy.  However, some combinations of anticancer drugs could exhibit mutually antagonistic actions and drug resistance, which further limit their therapeutic efficacy.  Here, we report that HMNE3, a novel bis-fluoroquinolone chalcone-like deriv. that targets both tyrosine kinase and TopII, induces tumor cell proliferation and growth inhibition.  The viabilities of 6 different cancer cell lines treated with a range of HMNE3 doses were detected using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  Cellular apoptosis was detd. using Hoechst 33258 fluorescence staining and the terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay.  The expression of activated Caspase-3 was examd. by immunocytochem.  The tyrosine kinase activity was measured with a human receptor tyrosine kinase (RTK) detection kit using a horseradish peroxidase (HRP)-conjugated phosphotyrosine (pY20) antibody as the substrate.  The topoisomerase II activity was measured using agarose gel electrophoresis with the DNA plasmid pBR322 as the substrate.  The expression levels of the P53, Bax, Bcl-2, Caspase-3, -8, -9, p-cSrc, c-Src and topoisomerase II proteins were detected by western blot anal.  The proliferation of five of the six cancer cell lines was significantly inhibited by HMNE3 at 0.312 to 10 μmol/L in a time- and dose-dependent manner.  Treatment of the Capan-1 and Panc-1 cells with 1.6 to 3.2 μM HMNE3 for 48 h significantly increased the percentage of apoptotic cells (P<0.05), and this effect was accompanied by a decrease in tyrosine kinase activity.  HMNE3 potentially inhibited tyrosine kinase activity in vitro with an IC50 value of 0.64 ± 0.34 μmol/L in Capan-1 cells and 3.1 ± 0.86 μmol/L in Panc-1 cells.  The activity of c-Src was significantly inhibited by HMNE3 in a dose- and time-dependent manner in different cellular contexts.  Compared with the control group, HMNE3 induced increased expression of cellular apoptosis-related proteins.  Consistent with cellular apoptosis data, a significant decrease in topoisomerase IIβ activity was noted following treatment with HMNE3 for 24 h.  Our data suggest that HMNE3 induced apoptosis in Capan-1 and Panc-1 cells by inhibiting the activity of both tyrosine kinases and topoisomerase II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroUVWjN_qq-bVg90H21EOLACvtfcHk0likMg1Hihmt0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1ynsbk%253D&md5=57d35af75c7761850331854ec402f964</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0162821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0162821%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%2BC.%26aulast%3DWang%26aufirst%3DZ.%2BX.%26aulast%3DJin%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DHu%26aufirst%3DG.%2BQ.%26aulast%3DCui%26aufirst%3DD.%2BT.%26aulast%3DWang%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%2BQ.%26aulast%3DZhao%26aufirst%3DZ.%2BJ.%26atitle%3DDual%2520inhibition%2520of%2520topoisomerase%2520II%2520and%2520tyrosine%2520kinases%2520by%2520the%2520novel%2520bis-fluoroquinolone%2520chalcone-like%2520derivative%2520HMNE3%2520in%2520human%2520pancreatic%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3De0162821%26doi%3D10.1371%2Fjournal.pone.0162821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) and its cross-talks with topoisomerases: challenges and opportunities for multi-target anticancer drugs</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3226</span>– <span class="NLM_lpage">3236</span>, <span class="refDoi"> DOI: 10.2174/1381612822666160224142200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1381612822666160224142200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=26907945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVags74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=3226-3236&issue=21&author=M.+Chauhanauthor=G.+Sharmaauthor=G.+Joshiauthor=R.+Kumar&title=Epidermal+growth+factor+receptor+%28EGFR%29+and+its+cross-talks+with+topoisomerases%3A+challenges+and+opportunities+for+multi-target+anticancer+drugs&doi=10.2174%2F1381612822666160224142200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor (EGFR) and its Cross-Talks with Topoisomerases: Challenges and Opportunities for Multi-Target Anticancer Drugs</span></div><div class="casAuthors">Chauhan, Monika; Sharma, Gourav; Joshi, Gaurav; Kumar, Raj</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3226-3236</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The interactions of Epidermal Growth Factor Receptor (EGFR) and topoisomerases have been seen in various cancer including brain, breast, ovarian, colorectal, gastric, etc.  Methods: The studies in adenocarcinoma patients, chromogenic in situ hybridization, western blotting, receptor binding assay and electromobility shift assays, etc. threw light on the biophys. and biochem. features of EGFR and Topoisomerase cross-talks.  Results: It has been revealed that both the isomers of topoisomerase (Topo I and Topo II) interact via different mechanisms with EGFR.  Topo II and HER2 share the same location i.e. 17q12-21 regions which could be a possible cause of predominant interactions seen between them.  Topo I and EGFR interactions are mech. related to the nucleolar translocation of heparenase by EGF and c-Jun.  Conclusion: We compiled literature findings including the mechanistic interventions, signaling pathways, patents, in vitro and in vivo data of tested inhibitors and combinations in clin. trials, which provide convincing confirmations for the interactions of EGFR and topoisomerases.  These interactions may be used for deriving a consistent route of mechanism, design and development of std. drug combinations and dual or multi inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPuO9YphOWNLVg90H21EOLACvtfcHk0likMg1Hihmt0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVags74%253D&md5=b169a47d30513c5274cf1146545867b6</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.2174%2F1381612822666160224142200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612822666160224142200%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DJoshi%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520its%2520cross-talks%2520with%2520topoisomerases%253A%2520challenges%2520and%2520opportunities%2520for%2520multi-target%2520anticancer%2520drugs%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2016%26volume%3D22%26issue%3D21%26spage%3D3226%26epage%3D3236%26doi%3D10.2174%2F1381612822666160224142200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angevin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schran, H.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1177/0091270011433330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1177%2F0091270011433330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23400739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ylsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=14-20&issue=1&author=X.+Wangauthor=A.+Kayauthor=O.+Anakauthor=E.+Angevinauthor=B.+Escudierauthor=W.+Zhouauthor=Y.+Fengauthor=M.+Duganauthor=H.+Schran&title=Population+pharmacokinetic%2Fpharmacodynamic+modeling+to+assist+dosing+schedule+selection+for+dovitinib&doi=10.1177%2F0091270011433330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib</span></div><div class="casAuthors">Wang, Xiaofeng; Kay, Andrea; Anak, Oezlem; Angevin, Eric; Escudier, Bernard; Zhou, Wei; Feng, Yilin; Dugan, Margaret; Schran, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-20</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Dovitinib is an oral multitargeted kinase inhibitor with potent activity against receptors for vascular endothelial growth factor, platelet-derived growth factor, and basic fibroblast growth factor.  Initial phase 1 to 2 studies of dovitinib using a continuous daily dosing schedule has shown that dovitinib exhibits a prolonged and overproportional increase in dose and exposure relationship above 400 mg/d.  To address this, intermittent dosing schedules were explored using a model-based approach.  A semi-mechanistic population pharmcokinetic/pharmacodynamic (PD) model was developed from 4 dovitinib phase 1 studies with daily dosing schedules.  Autoinduction of cytochrome P 450 1A (CYP1A) responsible for dovitinib metab. was described using an indirect response model.  Simulation of dovitinib plasma concn. profiles following 4 intermittent dosing schedules suggested that intermittent dosing could prevent prolonged drug accumulation.  Based on the simulated plasma profiles, PD response, and patient compliance, a 5-days-on/2-days-off intermittent dosing schedule was selected for a phase 1 to 2 clin. study.  The obsd. dovitinib plasma concns. in this study confirmed the model predictions.  Furthermore, dovitinib was well tolerated, and antitumor activity was obsd. as well in this new study.  The 5-days-on/2-days-off dosing schedule is currently used in a dovitinib registration trial and other clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrulg5AQZUyZ7Vg90H21EOLACvtfcHk0likMg1Hihmt0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ylsLjN&md5=6f3967fd1d64d33cde4849ad9448e91e</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1177%2F0091270011433330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270011433330%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DAnak%26aufirst%3DO.%26aulast%3DAngevin%26aufirst%3DE.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DSchran%26aufirst%3DH.%26atitle%3DPopulation%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%2520to%2520assist%2520dosing%2520schedule%2520selection%2520for%2520dovitinib%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26issue%3D1%26spage%3D14%26epage%3D20%26doi%3D10.1177%2F0091270011433330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasinoff, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanagasabai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalowich, J. C.</span></span> <span> </span><span class="NLM_article-title">The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>84</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1617</span>– <span class="NLM_lpage">1626</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2012.09.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bcp.2012.09.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23041231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKgu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=1617-1626&issue=12&author=B.+B.+Hasinoffauthor=X.+Wuauthor=J.+L.+Nitissauthor=R.+Kanagasabaiauthor=J.+C.+Yalowich&title=The+anticancer+multi-kinase+inhibitor+dovitinib+also+targets+topoisomerase+I+and+topoisomerase+II&doi=10.1016%2Fj.bcp.2012.09.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II</span></div><div class="casAuthors">Hasinoff, Brian B.; Wu, Xing; Nitiss, John L.; Kanagasabai, Ragu; Yalowich, Jack C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1617-1626</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dovitinib (TKI258/CHIR258) is a multi-kinase inhibitor in phase III development for the treatment of several cancers.  Dovitinib is a benzimidazole-quinolinone compd. that structurally resembles the bisbenzimidazole minor groove binding dye Hoechst 33258.  Dovitinib bound to DNA as shown by its ability to increase the DNA melting temp. and by increases in its fluorescence spectrum that occurred upon the addn. of DNA.  Mol. modeling studies of the docking of dovitinib into an X-ray structure of a Hoechst 33258-DNA complex showed that dovitinib could reasonably be accommodated in the DNA minor groove.  Because DNA binders are often topoisomerase I (EC 5.99.1.2) and topoisomerase II (EC 5.99.1.3) inhibitors, the ability of dovitinib to inhibit these DNA processing enzymes was also investigated.  Dovitinib inhibited the catalytic decatenation activity of topoisomerase IIα.  It also inhibited the DNA-independent ATPase activity of yeast topoisomerase II which suggested that it interacted with the ATP binding site.  Using isolated human topoisomerase IIα, dovitinib stabilized the enzyme-cleavage complex and acted as a topoisomerase IIα poison.  Dovitinib was also found to be a cellular topoisomerase II poison in human leukemia K562 cells and induced double-strand DNA breaks in K562 cells as evidenced by increased phosphorylation of H2AX.  Finally, dovitinib inhibited the topoisomerase I-catalyzed relaxation of plasmid DNA and acted as a cellular topoisomerase I poison.  In conclusion, the cell growth inhibitory activity and the anticancer activity of dovitinib may result not only from its ability to inhibit multiple kinases, but also, in part, from its ability to target topoisomerase I and topoisomerase II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7o2T_-J6Gz7Vg90H21EOLACvtfcHk0liQ_FPgN4MeqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKgu7zP&md5=4522d9895299c2e897d2e00c12a5a0bf</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.09.023%26sid%3Dliteratum%253Aachs%26aulast%3DHasinoff%26aufirst%3DB.%2BB.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26aulast%3DKanagasabai%26aufirst%3DR.%26aulast%3DYalowich%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520anticancer%2520multi-kinase%2520inhibitor%2520dovitinib%2520also%2520targets%2520topoisomerase%2520I%2520and%2520topoisomerase%2520II%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26issue%3D12%26spage%3D1617%26epage%3D1626%26doi%3D10.1016%2Fj.bcp.2012.09.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hisatomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueoka-Aragane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomimasu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueoka, E.</span></span> <span> </span><span class="NLM_article-title">NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIα and DNA-dependent protein kinase</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3575</span>– <span class="NLM_lpage">3584</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-02-270439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1182%2Fblood-2010-02-270439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21245486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslagtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3575-3584&issue=13&author=T.+Hisatomiauthor=N.+Sueoka-Araganeauthor=A.+Satoauthor=R.+Tomimasuauthor=M.+Ideauthor=A.+Kurimasaauthor=K.+Okamotoauthor=S.+Kimuraauthor=E.+Sueoka&title=NK314+potentiates+antitumor+activity+with+adult+T-cell+leukemia-lymphoma+cells+by+inhibition+of+dual+targets+on+topoisomerase+II%CE%B1+and+DNA-dependent+protein+kinase&doi=10.1182%2Fblood-2010-02-270439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIα and DNA-dependent protein kinase</span></div><div class="casAuthors">Hisatomi, Takashi; Sueoka-Aragane, Naoko; Sato, Akemi; Tomimasu, Rika; Ide, Masaru; Kurimasa, Akihiro; Okamoto, Kazuya; Kimura, Shinya; Sueoka, Eisaburo</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3575-3584</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Adult T-cell leukemia-lymphoma (ATL) is an aggressive disease, incurable by std. chemotherapy.  NK314, a new anticancer agent possessing inhibitory activity specific for topoisomerase IIα (Top2α), inhibited the growth of various ATL cell lines (50% inhibitory concn.: 23-70nM) with more potent activity than that of etoposide.  In addn. to the induction of DNA double-strand breaks by inhibition of Top2α, NK314 induced degrdn. of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), resulting in impaired DNA double-strand break repair.  The contribution of DNA-PK to inhibition of cell growth was affirmed by the following results: NK314 inhibited cell growth of M059J (a DNA-PKcs-deficient cell line) and M059K (a cell line with DNA-PKcs present) with the same potency, whereas etoposide exhibited weak inhibition of cell growth with M059K cells.  A DNA-PK specific inhibitor, NU7026, enhanced inhibitory activity of etoposide on M059K as well as on ATL cells.  These results suggest that NK314 is a dual inhibitor of Top2α and DNA-PK.  Because ATL cells express a high amt. of DNA-PKcs, NK314 as a dual mol. targeting anticancer agent is a potential therapeutic tool for treatment of ATL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2J07vNnlfR7Vg90H21EOLACvtfcHk0liQ_FPgN4MeqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslagtbo%253D&md5=a1a0d0ae5e0d958cfeeead0c12393ba6</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-02-270439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-02-270439%26sid%3Dliteratum%253Aachs%26aulast%3DHisatomi%26aufirst%3DT.%26aulast%3DSueoka-Aragane%26aufirst%3DN.%26aulast%3DSato%26aufirst%3DA.%26aulast%3DTomimasu%26aufirst%3DR.%26aulast%3DIde%26aufirst%3DM.%26aulast%3DKurimasa%26aufirst%3DA.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DSueoka%26aufirst%3DE.%26atitle%3DNK314%2520potentiates%2520antitumor%2520activity%2520with%2520adult%2520T-cell%2520leukemia-lymphoma%2520cells%2520by%2520inhibition%2520of%2520dual%2520targets%2520on%2520topoisomerase%2520II%25CE%25B1%2520and%2520DNA-dependent%2520protein%2520kinase%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26issue%3D13%26spage%3D3575%26epage%3D3584%26doi%3D10.1182%2Fblood-2010-02-270439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span> <span> </span><span class="NLM_article-title">DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1124/mol.109.057125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1124%2Fmol.109.057125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21546556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1yqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=321-327&issue=2&author=L.+Guoauthor=X.+Liuauthor=Y.+Jiangauthor=K.+Nishikawaauthor=W.+Plunkett&title=DNA-dependent+protein+kinase+and+ataxia+telangiectasia+mutated+%28ATM%29+promote+cell+survival+in+response+to+NK314%2C+a+topoisomerase+II%CE%B1+inhibitor&doi=10.1124%2Fmol.109.057125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor</span></div><div class="casAuthors">Guo, Lei; Liu, Xiaojun; Jiang, Yingjun; Nishikawa, Kiyohiro; Plunkett, William</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">321-327</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">4-Hydroxy-5-methoxy-2,3-dihydro-1H-[1,3]benzodioxolo[5,6-c]pyrrolo[1,2-f]-phenanthridium chloride (NK314) is a benzo[c] phenanthridine alkaloid that inhibits topoisomerase IIα, leading to the generation of DNA double-strand breaks (DSBs) and activating the G2 checkpoint pathway.  The purpose of the present studies was to investigate the DNA intercalating properties of NK314, to evaluate the DNA repair mechanisms activated in cells that may lead to resistance to NK314, and to develop mechanism-based combination strategies to maximize the antitumor effect of the compd.  A DNA unwinding assay indicated that NK314 intercalates in DNA, a property that likely cooperates with its ability to trap topoisomerase IIα in its cleavage complex form.  The consequence of this is the formation of DNA DSBs, as demonstrated by pulsed-field gel electrophoresis and H2AX phosphorylation.  Clonogenic assays demonstrated a significant sensitization in NK314-treated cells deficient in DNA-dependent protein kinase (DNA-PK) catalytic subunit, Ku80, ataxia telangiectasia mutated (ATM), BRCA2, or XRCC3 compared with wild-type cells, indicating that both nonhomologous end-joining and homologous recombination DNA repair pathways contribute to cell survival.  Furthermore, both the DNA-PK inhibitor 8-(4-dibenzothienyl)-2-(4-morpholinyl)-4H-1-benzopyran-4-one (NU7441) and the ATM inhibitor 2-(4-morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one (KU55933) significantly sensitized cells to NK314.  We conclude that DNA-PK and ATM contribute to cell survival in response to NK314 and could be potential targets for abrogating resistance and maximizing the antitumor effect of NK314.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgVrCSKedkI7Vg90H21EOLACvtfcHk0liQ_FPgN4MeqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1yqsLc%253D&md5=3c0ef03f47e51b3faa638c44e7f63549</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.057125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.057125%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DNishikawa%26aufirst%3DK.%26aulast%3DPlunkett%26aufirst%3DW.%26atitle%3DDNA-dependent%2520protein%2520kinase%2520and%2520ataxia%2520telangiectasia%2520mutated%2520%2528ATM%2529%2520promote%2520cell%2520survival%2520in%2520response%2520to%2520NK314%252C%2520a%2520topoisomerase%2520II%25CE%25B1%2520inhibitor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26issue%3D2%26spage%3D321%26epage%3D327%26doi%3D10.1124%2Fmol.109.057125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, D. J.</span></span> <span> </span><span class="NLM_article-title">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3670</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-08-0715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19074844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3670-3684&issue=12&author=J.+Maauthor=D.+J.+Waxman&title=Combination+of+antiangiogenesis+with+chemotherapy+for+more+effective+cancer+treatment&doi=10.1158%2F1535-7163.MCT-08-0715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span></div><div class="casAuthors">Ma, Jie; Waxman, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3670-3684</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a hallmark of tumor development and metastasis and is now a validated target for cancer treatment.  However, the survival benefits of antiangiogenic drugs have thus far been rather modest, stimulating interest in developing more effective ways to combine antiangiogenic drugs with established chemotherapies.  This review discusses recent progress and emerging challenges in this field; interactions between antiangiogenic drugs and conventional chemotherapeutic agents are examd., and strategies for the optimization of combination therapies are discussed.  Antiangiogenic drugs such as the anti-vascular endothelial growth factor antibody bevacizumab can induce a functional normalization of the tumor vasculature that is transient and can potentiate the activity of coadministered chemoradiotherapies.  However, chronic angiogenesis inhibition typically reduces tumor uptake of coadministered chemotherapeutics, indicating a need to explore new approaches, including intermittent treatment schedules and provascular strategies to increase chemotherapeutic drug exposure.  In cases where antiangiogenesis-induced tumor cell starvation augments the intrinsic cytotoxic effects of a conventional chemotherapeutic drug, combination therapy may increase antitumor activity despite a decrease in cytotoxic drug exposure.  As new angiogenesis inhibitors enter the clinic, reliable surrogate markers are needed to monitor the progress of antiangiogenic therapies and to identify responsive patients.  New targets for antiangiogenesis continue to be discovered, increasing the opportunities to interdict tumor angiogenesis and circumvent resistance mechanisms that may emerge with chronic use of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFuKsU4WlEmLVg90H21EOLACvtfcHk0lgbyFVcf0WGsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN&md5=187b65f71cce4580756ae01973ca758f</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0715%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520of%2520antiangiogenesis%2520with%2520chemotherapy%2520for%2520more%2520effective%2520cancer%2520treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26issue%3D12%26spage%3D3670%26epage%3D3684%26doi%3D10.1158%2F1535-7163.MCT-08-0715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejmech.2013.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23770449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=477-486&author=X.+Wangauthor=Z.+Chenauthor=L.+Tongauthor=S.+Tanauthor=W.+Zhouauthor=T.+Pengauthor=K.+Hanauthor=J.+Dingauthor=H.+Xieauthor=Y.+Xu&title=Naphthalimides+exhibit+in+vitro+antiproliferative+and+antiangiogenic+activities+by+inhibiting+both+topoisomerase+II+%28topo+II%29+and+receptor+tyrosine+kinases+%28RTKs%29&doi=10.1016%2Fj.ejmech.2013.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs)</span></div><div class="casAuthors">Wang, Xin; Chen, Zhuo; Tong, Linjiang; Tan, Shaoying; Zhou, Wei; Peng, Ting; Han, Kun; Ding, Jian; Xie, Hua; Xu, Yufang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">477-486</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel naphthalimide derivs. I [R = Me, Et, n-Bu, etc.] were designed and synthesized to modulate both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).  Most target compds. exhibited effective and selective antiproliferative activities against three cancer cell lines by inhibiting topo II.  The IC50 values ranged from 1.5 to 19.1 μM.  Moreover, compds. 8 d and 12 d moderately inhibited various angiogenesis-related RTKs, including FGFR1, VEGFR2 and PDGFRα.  The representative compd. 8 d was then proved to possess antiangiogenic activity, which was evidenced by the inhibition of migration and tube formation activities of HMEC-1 cells.  To the knowledge, it is the first time naphthalimides were identified as tyrosine kinases inhibitors (TKIs) besides their conventional cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruL6A4uMIwIbVg90H21EOLACvtfcHk0lgbyFVcf0WGsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrrF&md5=703b14b696d6354cfaf8c530d459c735</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DK.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DNaphthalimides%2520exhibit%2520in%2520vitro%2520antiproliferative%2520and%2520antiangiogenic%2520activities%2520by%2520inhibiting%2520both%2520topoisomerase%2520II%2520%2528topo%2520II%2529%2520and%2520receptor%2520tyrosine%2520kinases%2520%2528RTKs%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D477%26epage%3D486%26doi%3D10.1016%2Fj.ejmech.2013.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Counter, C. M.</span></span> <span> </span><span class="NLM_article-title">The roles of telomeres and telomerase in cell life span</span>. <i>Mutat. Res., Rev. Genet. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/S0165-1110(96)90006-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2FS0165-1110%2896%2990006-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=8921986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK28XntVKhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=1996&pages=45-63&issue=1&author=C.+M.+Counter&title=The+roles+of+telomeres+and+telomerase+in+cell+life+span&doi=10.1016%2FS0165-1110%2896%2990006-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of telomeres and telomerase in cell life span</span></div><div class="casAuthors">Counter, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Reviews in Genetic Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-63</span>CODEN:
                <span class="NLM_cas:coden">MRRTEP</span>;
        ISSN:<span class="NLM_cas:issn">0165-1110</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 179 refs.  Telomers cap and protect the ends of chromosomes from degrdn. and illegitimate recombination.  The termini of a linear template cannot, however, be completely replicated by conventional DNA-dependent DNA polymerases, and thus in the absence of a mechanisms of counter this effect, telomers of eukaryotic cells shorten every round of DNA replication.  In humans and possibly other higher eukaryotes, telomere shortening may have been adopted to limit the life span of somatic cells.  Human somatic cells have a finite proliferative capacity and enter a viable growth arrested state called senescence.  Life span appears to be governed by cell division, not time.  The regular loss of telomeric DNA could therefore serve as a mitotic clock in the senescence program, counting cell divisions.  In most eukaryotic organisms, however, telomere shortening can be counted by the de novo addn. of telomeric repeats by the enzyme telomerase.  Cells which are 'immortal' such as the human germ line or tumor cell lines, established mouse cells, yeast and ciliates, all maintain a stable telomere length through the action of telomerase.  Abolition of telomerase activity in such cells nevertheless results in telomere shortening, a process that eventually destabilizes the ends of chromosomes, leading to genomic instability and cell growth arrest or death.  Therefore, loss of terminal DNA sequences may limit cell life span by two mechanisms: by acting a mitotic clock and by denuding chromosomes of protective telomeric DNA necessary for cell viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwuVktuW9lI7Vg90H21EOLACvtfcHk0lgbyFVcf0WGsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntVKhtrc%253D&md5=8774f7b0f01fdcc7acaf7011753e393e</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2FS0165-1110%2896%2990006-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-1110%252896%252990006-8%26sid%3Dliteratum%253Aachs%26aulast%3DCounter%26aufirst%3DC.%2BM.%26atitle%3DThe%2520roles%2520of%2520telomeres%2520and%2520telomerase%2520in%2520cell%2520life%2520span%26jtitle%3DMutat.%2520Res.%252C%2520Rev.%2520Genet.%2520Toxicol.%26date%3D1996%26volume%3D366%26issue%3D1%26spage%3D45%26epage%3D63%26doi%3D10.1016%2FS0165-1110%2896%2990006-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zvereva, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shcherbakova, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontsova, O. A.</span></span> <span> </span><span class="NLM_article-title">Telomerase: structure, functions, and activity regulation</span>. <i>Biochemistry (Moscow)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1563</span>– <span class="NLM_lpage">1583</span>, <span class="refDoi"> DOI: 10.1134/S0006297910130055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1134%2FS0006297910130055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=21417995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFOrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=1563-1583&issue=13&author=M.+I.+Zverevaauthor=D.+M.+Shcherbakovaauthor=O.+A.+Dontsova&title=Telomerase%3A+structure%2C+functions%2C+and+activity+regulation&doi=10.1134%2FS0006297910130055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Telomerase: Structure, functions, and activity regulation</span></div><div class="casAuthors">Zvereva, M. I.; Shcherbakova, D. M.; Dontsova, O. A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1563-1583</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">MAIK Nauka/Interperiodica</span>)
        </div><div class="casAbstract">A review.  Telomerase is the enzyme responsible for maintenance of the length of telomeres by the addn. of guanine-rich repetitive sequences.  Telomerase activity is exhibited in gametes and stem and tumor cells.  In human somatic cells, proliferation potential is strictly limited and senescence follows ∼50-70 cell divisions.  In most tumor cells, on the contrary, replication potential is unlimited.  The key role in this process of the system of telomere length maintenance with involvement of telomerase is still poorly studied.  No doubt, DNA polymerase is not capable to completely copy DNA at the very ends of chromosomes; therefore, ∼50 nucleotides are lost during each cell cycle, which results in gradual telomere length shortening.  Critically short telomeres cause senescence, following crisis, and cell death.  However, in tumor cells the system of telomere length maintenance is activated.  In addn. to catalytic telomere elongation, independent telomerase functions can be also involved in cell cycle regulation.  Inhibition of telomerase catalytic function and the resulting cessation of telomere length maintenance will help in restriction of tumor cell replication potential.  On the other hand, the formation of temporarily active enzyme via its intracellular activation or due to stimulation of expression of telomerase components will result in telomerase activation and telomere elongation that can be used for correction of degenerative changes.  Data on telomerase structure and function are summarized by the authors, and they are compared for evolutionarily remote organisms.  Problems of telomerase activity measurement and modulation by enzyme inhibitors or activators are considered as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVZVLy00ezkbVg90H21EOLACvtfcHk0lg3qrCWOeOPug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFOrtg%253D%253D&md5=468169f6df072ca67437461c6fcaf5cd</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1134%2FS0006297910130055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS0006297910130055%26sid%3Dliteratum%253Aachs%26aulast%3DZvereva%26aufirst%3DM.%2BI.%26aulast%3DShcherbakova%26aufirst%3DD.%2BM.%26aulast%3DDontsova%26aufirst%3DO.%2BA.%26atitle%3DTelomerase%253A%2520structure%252C%2520functions%252C%2520and%2520activity%2520regulation%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26date%3D2010%26volume%3D75%26issue%3D13%26spage%3D1563%26epage%3D1583%26doi%3D10.1134%2FS0006297910130055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span> <span> </span><span class="NLM_article-title">Ruthenium(II) polypyridyl complexes as dual inhibitors of telomerase and topoisomerase</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">15145</span>– <span class="NLM_lpage">15156</span>, <span class="refDoi"> DOI: 10.1039/C4DT03585B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1039%2FC4DT03585B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25604798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=15145-15156&issue=34&author=G.+Liaoauthor=X.+Chenauthor=J.+Wuauthor=C.+Qianauthor=Y.+Wangauthor=L.+Jiauthor=H.+Chao&title=Ruthenium%28II%29+polypyridyl+complexes+as+dual+inhibitors+of+telomerase+and+topoisomerase&doi=10.1039%2FC4DT03585B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium(II) polypyridyl complexes as dual inhibitors of telomerase and topoisomerase</span></div><div class="casAuthors">Liao, Guoliang; Chen, Xiang; Wu, Jingheng; Qian, Chen; Wang, Yi; Ji, Liangnian; Chao, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">15145-15156</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">One novel ruthenium polypyridyl complex, [Ru(bpy)2(icip)]2+ (1), and two previously reported ruthenium polypyridyl complexes, [Ru(bpy)2(pdppz)]2+ (2) and [Ru(bpy)2(tactp)]2+ (3) (bpy = 2,2'-bipyridine, icip = 2-(indeno[2,1-b]chromen-6-yl)-1H-imidazo[4,5-f][1,10]phenanthroline, pdppz = phenanthro[4,5-abc]dipyrido[3,2-h:2',3'-j]phenazine, tactp = 4,5,9,18-tetraazachryseno[9,10-b]-triphenylene), have been synthesized.  As expected, these complexes show inhibition towards telomerase by inducing and stabilizing the G-quadruplex structure, and behave as topoisomerase I/II poisons at the same time.  Addnl., the acute and chronic cytotoxicities of the complexes are considered.  Furthermore, cell apoptosis expts. are used to briefly study the mechanism.  Because studies involving multi-target inhibition towards topoisomerase and telomerase of Ru(II) complexes have not been reported previously, the present research may help to develop innovative chem. strategies and therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQVeScR7gzCrVg90H21EOLACvtfcHk0lg3qrCWOeOPug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFCjtw%253D%253D&md5=5811c8fb4ea224370196e8c79d691e4b</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1039%2FC4DT03585B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4DT03585B%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DH.%26atitle%3DRuthenium%2528II%2529%2520polypyridyl%2520complexes%2520as%2520dual%2520inhibitors%2520of%2520telomerase%2520and%2520topoisomerase%26jtitle%3DDalton%2520Trans.%26date%3D2015%26volume%3D44%26issue%3D34%26spage%3D15145%26epage%3D15156%26doi%3D10.1039%2FC4DT03585B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhami, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, H.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&issue=2&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-13-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0lg3qrCWOeOPug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D2%26spage%3D275%26epage%3D284%26doi%3D10.1158%2F1535-7163.MCT-13-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, T. J.</span></span> <span> </span><span class="NLM_article-title">Microtubule polymerization dynamics</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.13.1.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1146%2Fannurev.cellbio.13.1.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9442869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1997&pages=83-117&author=A.+Desaiauthor=T.+J.+Mitchison&title=Microtubule+polymerization+dynamics&doi=10.1146%2Fannurev.cellbio.13.1.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule polymerization dynamics</span></div><div class="casAuthors">Desai, Arshad; Mitchison, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Cell and Developmental Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-117</span>CODEN:
                <span class="NLM_cas:coden">ARDBF8</span>;
        ISSN:<span class="NLM_cas:issn">1081-0706</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 187 refs.  The polymn. dynamics of microtubules are central to their biol. functions.  Polymn. dynamics allow microtubules to adopt spatial arrangements that can change rapidly in response to cellular needs and, in some cases, to perform mech. work.  Microtubules utilize the energy of GTP hydrolysis to fuel a unique polymn. mechanism termed dynamic instability.  In this review, the authors 1st describe progress toward understanding the mechanism of dynamic instability of pure tubulin and then discuss the function and regulation of microtubule dynamic instability in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2VFXflA9be7Vg90H21EOLACvtfcHk0lg3qrCWOeOPug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSksg%253D%253D&md5=92189bc321980f4162ce2defcddbb48e</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.13.1.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.13.1.83%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DA.%26aulast%3DMitchison%26aufirst%3DT.%2BJ.%26atitle%3DMicrotubule%2520polymerization%2520dynamics%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D1997%26volume%3D13%26spage%3D83%26epage%3D117%26doi%3D10.1146%2Fannurev.cellbio.13.1.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&issue=4&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0liyUVjj5KTfsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26issue%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanbhag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambinder, R. F.</span></span> <span> </span><span class="NLM_article-title">Hodgkin lymphoma: A review and update on recent progress</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.3322/caac.21438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3322%2Fcaac.21438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=29194581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC1M3mvVyksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=116-132&issue=2&author=S.+Shanbhagauthor=R.+F.+Ambinder&title=Hodgkin+lymphoma%3A+A+review+and+update+on+recent+progress&doi=10.3322%2Fcaac.21438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Hodgkin lymphoma: A review and update on recent progress</span></div><div class="casAuthors">Shanbhag Satish; Ambinder Richard F</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-132</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed-Sternberg cells in an inflammatory background.  Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms.  Even in advanced-stage disease, HL is highly curable with combination chemotherapy, radiation, or combined-modality treatment.  Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk-adapted approaches have helped de-escalate therapy in low-risk patients while intensifying treatment for higher risk patients.  Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody-drug conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem cell transplantation.  The programmed death-1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL.  Alternate donor sources and reduced-intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients.  Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long-term treatment toxicities.  CA Cancer J Clin 2018;68:116-132. © 2017 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO_JmRpWRqUpWtyewyzkyLfW6udTcc2eb9PIW7nNHwm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3mvVyksg%253D%253D&md5=9ddf948ca58315d966b68e26b3c7f9e8</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21438%26sid%3Dliteratum%253Aachs%26aulast%3DShanbhag%26aufirst%3DS.%26aulast%3DAmbinder%26aufirst%3DR.%2BF.%26atitle%3DHodgkin%2520lymphoma%253A%2520A%2520review%2520and%2520update%2520on%2520recent%2520progress%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2018%26volume%3D68%26issue%3D2%26spage%3D116%26epage%3D132%26doi%3D10.3322%2Fcaac.21438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nabholtz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, A.</span></span> <span> </span><span class="NLM_article-title">Taxane/anthracycline combinations: setting a new standard in breast cancer?</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">Suppl. 3</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.6-suppl_3-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1634%2Ftheoncologist.6-suppl_3-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11346678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktValur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=5-12&issue=Suppl.+3&author=J.+M.+Nabholtzauthor=A.+Riva&title=Taxane%2Fanthracycline+combinations%3A+setting+a+new+standard+in+breast+cancer%3F&doi=10.1634%2Ftheoncologist.6-suppl_3-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Taxane/anthracycline combinations: Setting a new standard in breast cancer?</span></div><div class="casAuthors">Nabholtz, Jean-Marc; Riva, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">5-12</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review with 26 ref.  Among the novel chemotherapeutic drugs introduced in the 1990s, the taxanes have emerged as the most powerful compds. in breast cancer.  Both compds., paclitaxel and docetaxel, have been evaluated in metastatic settings before adjuvant trials proceeded.  Docetaxel was shown in several phase III trials to be superior, particularly in terms of survival, for salvaging poly-chemotherapies after failure of prior chemotherapy, including that with anthracyclines.  A benefit of docetaxel was also reported when compared with doxorubicin after failure of alkylating agents.  In phase III trials paclitaxel was reported to be as efficacious over 24 h as doxorubicin 60 mg/m2, while paclitaxel was significantly inferior to doxorubicin 75 mg/m2 over 3 h and was close to CMF in another trial.  The role of taxanes in combination with anthracyclines in first-line therapy of advanced breast cancer is emerging.  Following several phase II studies, a phase III trial showed the significant superiority of docetaxel/doxorubicin (AT) vs. doxorubicin/cyclophosphamide (AC) in terms of response and time to progression.  In several phase II studies with paclitaxel (3 h), anthracyclines in the metastatic setting showed high efficacy but produced cardiac toxicity related to a pharmacokinetic interaction between the two agents.  This finding led to the implementation of metastatic strategies (phase III trials) aimed at avoiding the pharmacokinetic interaction, while the adjuvant strategies with paclitaxel focused primarily on the sequential approach (AC followed by paclitaxel).  In contrast, adjuvant strategies with docetaxel/anthracycline-based programs were implemented following both sequential and combination approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfscJLTLeTD7Vg90H21EOLACvtfcHk0liyUVjj5KTfsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktValur4%253D&md5=c038013a18664df7b4420344e5f4e4d5</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.6-suppl_3-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.6-suppl_3-5%26sid%3Dliteratum%253Aachs%26aulast%3DNabholtz%26aufirst%3DJ.%2BM.%26aulast%3DRiva%26aufirst%3DA.%26atitle%3DTaxane%252Fanthracycline%2520combinations%253A%2520setting%2520a%2520new%2520standard%2520in%2520breast%2520cancer%253F%26jtitle%3DOncologist%26date%3D2001%26volume%3D6%26issue%3DSuppl.%25203%26spage%3D5%26epage%3D12%26doi%3D10.1634%2Ftheoncologist.6-suppl_3-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervinka, M.</span></span> <span> </span><span class="NLM_article-title">Topoisomerases and tubulin inhibitors: a promising combination for cancer treatment</span>. <i>Curr. Med. Chem.: Anti-Cancer Agents</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.2174/1568011033482242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.2174%2F1568011033482242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=14529450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFOns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=421-429&issue=6&author=E.+Rudolfauthor=M.+Cervinka&title=Topoisomerases+and+tubulin+inhibitors%3A+a+promising+combination+for+cancer+treatment&doi=10.2174%2F1568011033482242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerases and tubulin inhibitors: A promising combination for cancer treatment</span></div><div class="casAuthors">Rudolf, E.; Cervinka, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">421-429</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Modern approaches to treatment of cancer seek to activate the internal suicide program in the malignant cells, and thereby effectively eliminate them without engaging most of other bodily systems.  Many currently used cytostatics are known to induce apoptosis and efforts are being paid to develop new ones with better and more effective proapoptotic potential.  Nevertheless, despite recent developments in this field, there are still numerous malignancies showing a varying degree of resistance to cell death due to the corrupted signaling pathways and genetic alterations, often in conjunction with expansive proliferation rate.  It has been shown that topoisomerase inhibiting agents such as etoposide, camptothecin and others represent a powerful and dynamic group of cytostatic chems. used in exptl. and clin. conditions.  So, it is a group of microtubule targeting poisons comprising classical colchicines on the one hand and new taxanes on the other hand.  Since several members of both groups have been evidenced as apoptosis inducers operating via distinct mechanism, their combination should theor. enhance the final therapeutic outcome.  This minireview focuses on the possibilities of such a combinational approach with respect to possible benefits and hazards of this strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJiCqrOtqGHLVg90H21EOLACvtfcHk0liyUVjj5KTfsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFOns7s%253D&md5=2ecc33565f5b54921de17a2fac21e916</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.2174%2F1568011033482242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011033482242%26sid%3Dliteratum%253Aachs%26aulast%3DRudolf%26aufirst%3DE.%26aulast%3DCervinka%26aufirst%3DM.%26atitle%3DTopoisomerases%2520and%2520tubulin%2520inhibitors%253A%2520a%2520promising%2520combination%2520for%2520cancer%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2003%26volume%3D3%26issue%3D6%26spage%3D421%26epage%3D429%26doi%3D10.2174%2F1568011033482242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorr, R. T.</span></span> <span> </span><span class="NLM_article-title">Drug interactions with the taxanes: clinical implications</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1053/ctrv.2001.0228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1053%2Fctrv.2001.0228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=11545542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt1SktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2001&pages=221-233&issue=4&author=A.+F.+Bakerauthor=R.+T.+Dorr&title=Drug+interactions+with+the+taxanes%3A+clinical+implications&doi=10.1053%2Fctrv.2001.0228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Drug interactions with the taxanes: Clinical implications</span></div><div class="casAuthors">Baker, A. F.; Dorr, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders</span>)
        </div><div class="casAbstract">A review.  The taxanes paclitaxel and docetaxel are among the most active antitumor agents.  Clin. important pharmacodynamic interactions have been reported to occur with these agents that are sequence or schedule dependent.  Because the taxanes undergo hepatic oxidn. via the cytochrome P 450 system, pharmacokinetic interactions due to enzyme induction or inhibition can also occur.  A comprehensive literature search was conducted using Medline to identify clin. important drug-interactions with the taxanes.  Clin. significant taxane interactions were identified for carboplatin, cisplatin, doxorubicin, docetaxel, epirubicin and anticonvulsants.  Doxorubicin and epirubicin should be administered 24h before paclitaxel, and the cumulative anthracycline dose limited to 360 mg/m2.  This will prevent the enhanced toxicities due to sequence and schedule dependent interactions between anthracyclines and paclitaxel.  Conversely, paclitaxel should be administered at least 24h before cisplatin to avoid a decrease in clearance and increase in myelosuppression.  With concurrent anticonvulsant therapy, cytochrome P 450 enzyme induction results in decreased paclitaxel plasma steady state concns., possibly requiring an increased dose of paclitaxel.  A no. of other drug interactions have been reported in preliminary studies for which clin. significance has yet to be established.  Clin. significant drug interactions have been reported to occur when paclitaxel is administered with doxorubicin, cisplatin, or anticonvulsants (phenytoin, carbamazepine, and phenobarbital).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFYUmRGtPwPbVg90H21EOLACvtfcHk0ljxqBEp6_yOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt1SktLo%253D&md5=b374723b96807c5c10862a7a20cb0eb7</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1053%2Fctrv.2001.0228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fctrv.2001.0228%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DA.%2BF.%26aulast%3DDorr%26aufirst%3DR.%2BT.%26atitle%3DDrug%2520interactions%2520with%2520the%2520taxanes%253A%2520clinical%2520implications%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2001%26volume%3D27%26issue%3D4%26spage%3D221%26epage%3D233%26doi%3D10.1053%2Fctrv.2001.0228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span> <span> </span><span class="NLM_article-title">Review of docetaxel/doxorubicin combination in metastatic breast cancer</span>. <i>Oncology (Williston Park)</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=9364539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADyaK1c%252FjtFWhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=31-33&issue=8&author=V.+Di%C3%A9ras&title=Review+of+docetaxel%2Fdoxorubicin+combination+in+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Review of docetaxel/doxorubicin combination in metastatic breast cancer</span></div><div class="casAuthors">Dieras V</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8 Suppl 8</span>),
    <span class="NLM_cas:pages">31-3</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Docetaxel (Taxotere) and doxorubicin (Adriamycin) have each demonstrated significant activity in metastatic breast cancer.  Thus, the combination of docetaxel and doxorubicin has been evaluated in phase I trials to establish the dose-limiting toxicity, maximum tolerated dose, recommended dose for future phase II and III studies, and toxicity profile of the two agents used in combination.  Results from phase I trials in patients with metastatic breast cancer indicate that the docetaxel/doxorubicin combination is well tolerated.  The recommended dose for the combination regimen is either 50 mg/m2 of doxorubicin followed by 75 mg/m2 of docetaxel or 60 mg/m2 of both drugs, without granulocyte colony-stimulating factor (G-CSF) support.  Febrile neutropenia complicated by grade 3 infection was the dose-limiting effect at the maximum tolerated dose.  The response rate at this dose level was 90%.  Based on the preliminary results of phase I studies, further phase II and III studies of a docetaxel/doxorubicin combination regimen are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRugEZYQeiChWGmni0r9GoKfW6udTcc2eZx_2fMB44p8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252FjtFWhsA%253D%253D&md5=d352b42637b90485d1e996c70fc833e6</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26atitle%3DReview%2520of%2520docetaxel%252Fdoxorubicin%2520combination%2520in%2520metastatic%2520breast%2520cancer%26jtitle%3DOncology%2520%2528Williston%2520Park%2529%26date%3D1997%26volume%3D11%26issue%3D8%26spage%3D31%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cervinka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, E.</span></span> <span> </span><span class="NLM_article-title">Apoptosis in Hep2 cells treated with etoposide and colchicine</span>. <i>Cancer Detect. Prev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1016/j.cdp.2004.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.cdp.2004.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=15225902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVyqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=214-226&issue=3&author=M.+Cervinkaauthor=J.+Cermanauthor=E.+Rudolf&title=Apoptosis+in+Hep2+cells+treated+with+etoposide+and+colchicine&doi=10.1016%2Fj.cdp.2004.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis in Hep2 cells treated with etoposide and colchicine</span></div><div class="casAuthors">Cervinka, Miroslav; Cerman, Jaroslav; Rudolf, Emil</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Detection and Prevention</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-226</span>CODEN:
                <span class="NLM_cas:coden">CDPRD4</span>;
        ISSN:<span class="NLM_cas:issn">0361-090X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">When malignant cells undergo apoptosis, they exhibit many distinct patterns of behavior, with blebbing being one of the most spectacular and mysterious features.  Despite huge advancements in our understanding of cell death, the mechanisms of apoptosis assocd. blebbing have not been elucidated.  In order to verify the putative involvement of actin and tubulin in this process.  Hep2 cells were treated with a combination of etoposide (10 μg/mL) and colchicine (0.2 μg/mL) for 24 h.  Blebbing was analyzed using immunofluorescence staining of actin and tubulin, and the course of apoptosis was followed by time-lapse videomicroscopy, immunofluorescence detection of caspase-3 and cytokeratin fragment 18.  The results indicate that microfilaments (actin) and not microtubules (tubulin) are involved in blebbing of Hep2 cells.  Furthermore, despite the different mechanisms by which both chems. act, their combined effects are not additive, but rather eliminate each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofo3s2OXdvA7Vg90H21EOLACvtfcHk0ljxqBEp6_yOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVyqurs%253D&md5=70531e2f71a164900d5039292344d03a</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.cdp.2004.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cdp.2004.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DCervinka%26aufirst%3DM.%26aulast%3DCerman%26aufirst%3DJ.%26aulast%3DRudolf%26aufirst%3DE.%26atitle%3DApoptosis%2520in%2520Hep2%2520cells%2520treated%2520with%2520etoposide%2520and%2520colchicine%26jtitle%3DCancer%2520Detect.%2520Prev.%26date%3D2004%26volume%3D28%26issue%3D3%26spage%3D214%26epage%3D226%26doi%3D10.1016%2Fj.cdp.2004.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathi, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathi, M. K.</span></span> <span> </span><span class="NLM_article-title">Mechanisms regulating resistance to inhibitors of topoisomerase II</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.3389/fphar.2013.00089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.3389%2Ffphar.2013.00089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23914174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC3sfmslWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=89&author=R.+N.+Ganapathiauthor=M.+K.+Ganapathi&title=Mechanisms+regulating+resistance+to+inhibitors+of+topoisomerase+II&doi=10.3389%2Ffphar.2013.00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms regulating resistance to inhibitors of topoisomerase II</span></div><div class="casAuthors">Ganapathi Ram N; Ganapathi Mahrukh K</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Inhibitors of topoisomerase II (topo II) are clinically effective in the management of hematological malignancies and solid tumors.  The efficacy of anti-tumor drugs targeting topo II is often limited by resistance and studies with in vitro cell culture models have provided several insights on potential mechanisms.  Multidrug transporters that are involved in the efflux and consequently reduced cytotoxicity of diverse anti-tumor agents suggest that they play an important role in resistance to clinically active drugs.  However, in clinical trials, modulating the multidrug-resistant phenotype with agents that inhibit the efflux pump has not had an impact.  Since reduced drug accumulation per se is insufficient to explain tumor cell resistance to topo II inhibitors several studies have focused on characterizing mechanisms that impact on DNA damage mediated by drugs that target the enzyme.  Mammalian topo IIα and topo IIβ isozymes exhibit similar catalytic, but different biologic, activities.  Whereas topo IIα is associated with cell division, topo IIβ is involved in differentiation.  In addition to site specific mutations that can affect drug-induced topo II-mediated DNA damage, post-translation modification of topo II primarily by phosphorylation can potentially affect enzyme-mediated DNA damage and the downstream cytotoxic response of drugs targeting topo II.  Signaling pathways that can affect phosphorylation and changes in intracellular calcium levels/calcium dependent signaling that can regulate site-specific phosphorylation of topoisomerase have an impact on downstream cytotoxic effects of topo II inhibitors.  Overall, tumor cell resistance to inhibitors of topo II is a complex process that is orchestrated not only by cellular pharmacokinetics but more importantly by enzymatic alterations that govern the intrinsic drug sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-P0PWb68VA8ScOqQTSkOffW6udTcc2eZx_2fMB44p8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfmslWqtQ%253D%253D&md5=7828c568fa64b072dd47e8dee2ce767c</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2013.00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2013.00089%26sid%3Dliteratum%253Aachs%26aulast%3DGanapathi%26aufirst%3DR.%2BN.%26aulast%3DGanapathi%26aufirst%3DM.%2BK.%26atitle%3DMechanisms%2520regulating%2520resistance%2520to%2520inhibitors%2520of%2520topoisomerase%2520II%26jtitle%3DFront.%2520Pharmacol.%26date%3D2013%26volume%3D4%26spage%3D89%26doi%3D10.3389%2Ffphar.2013.00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, E. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2095</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1158%2F1535-7163.MCT-09-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=19671735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2086-2095&issue=8&author=E.+A.+Perez&title=Microtubule+inhibitors%3A+Differentiating+tubulin-inhibiting+agents+based+on+mechanisms+of+action%2C+clinical+activity%2C+and+resistance&doi=10.1158%2F1535-7163.MCT-09-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span></div><div class="casAuthors">Perez, Edith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2095</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis.  Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis.  In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clin. efficacy.  Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs.  This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents. [Mol Cancer Ther 2009;8(8):2086-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1HM8JP4QG8LVg90H21EOLACvtfcHk0ljSZwlrIEAPXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D&md5=1d8dec9ed6c0f061032cec57c96c833e</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0366%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26atitle%3DMicrotubule%2520inhibitors%253A%2520Differentiating%2520tubulin-inhibiting%2520agents%2520based%2520on%2520mechanisms%2520of%2520action%252C%2520clinical%2520activity%252C%2520and%2520resistance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D8%26spage%3D2086%26epage%3D2095%26doi%3D10.1158%2F1535-7163.MCT-09-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z. H.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of microtubule and topoisomerase II by alpha-carboline derivative YCH337 for tumor proliferation and growth inhibition</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">8960</span>– <span class="NLM_lpage">8973</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.18632%2Foncotarget.3264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=25840421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjgs1Oltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8960-8973&issue=11&author=J.+M.+Yiauthor=X.+F.+Zhangauthor=X.+J.+Huanauthor=S.+S.+Songauthor=W.+Wangauthor=Q.+T.+Tianauthor=Y.+M.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Q.+Wangauthor=C.+H.+Yangauthor=Z.+H.+Miao&title=Dual+targeting+of+microtubule+and+topoisomerase+II+by+alpha-carboline+derivative+YCH337+for+tumor+proliferation+and+growth+inhibition&doi=10.18632%2Foncotarget.3264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition</span></div><div class="casAuthors">Yi Jun-Mei; Huan Xia-Juan; Song Shan-Shan; Wang Wei; Tian Qian-Ting; Sun Yi-Ming; Chen Yi; Ding Jian; Wang Ying-Qing; Miao Ze-Hong; Zhang Xiao-Fei; Yang Chun-Hao</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8960-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Both microtubule and topoisomerase II (Top2) are important anticancer targets and their respective inhibitors are widely used in combination for cancer therapy.  However, some combinations could be mutually antagonistic and drug resistance further limits their therapeutic efficacy.  Here we report YCH337, a novel α-carboline derivative that targets both microtubule and Top2, eliciting tumor proliferation and growth inhibition and overcoming drug resistance.  YCH337 inhibited microtubule polymerization by binding to the colchicine site and subsequently led to mitotic arrest.  It also suppressed Top2 and caused DNA double-strand breaks.  It disrupted microtubule more potently than Top2.  YCH337 induced reversible mitotic arrest at low concentrations but persistent DNA damage.  YCH337 caused intrinsic and extrinsic apoptosis and decreased MCL-1, cIAP1 and XIAP proteins.  In this aspect, YCH337 behaved differently from the combination of vincristine and etoposide.  YCH337 inhibited proliferation of tumor cells with an averaged IC50 of 0.3 μM.  It significantly suppressed the growth of HT-29 xenografts in nude mice too.  Importantly, YCH337 nearly equally killed different-mechanism-mediated resistant tumor cells and corresponding parent cells.  Together with the novelty of its chemical structure, YCH337 could serve as a promising lead for drug development and a prototype for a dual microtubule/Top2 targeting strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG7_gaQunNwoJKJbLTgsvCfW6udTcc2ebGBzqbQHdXZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjgs1Oltw%253D%253D&md5=bd05960113eda9a65fa6626a8277ca20</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3264%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DX.%2BF.%26aulast%3DHuan%26aufirst%3DX.%2BJ.%26aulast%3DSong%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DQ.%2BT.%26aulast%3DSun%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26atitle%3DDual%2520targeting%2520of%2520microtubule%2520and%2520topoisomerase%2520II%2520by%2520alpha-carboline%2520derivative%2520YCH337%2520for%2520tumor%2520proliferation%2520and%2520growth%2520inhibition%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D11%26spage%3D8960%26epage%3D8973%26doi%3D10.18632%2Foncotarget.3264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silveira-Dorta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios-Luci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, J. M.</span></span> <span> </span><span class="NLM_article-title">Molecular docking studies of the interaction between propargylic enol ethers and human DNA topoisomerase IIα</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5382</span>– <span class="NLM_lpage">5384</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.07.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmcl.2013.07.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=23953196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5382-5384&issue=19&author=G.+Silveira-Dortaauthor=I.+J.+Sousaauthor=C.+Rios-Luciauthor=V.+S.+Martinauthor=M.+X.+Fernandesauthor=J.+M.+Padron&title=Molecular+docking+studies+of+the+interaction+between+propargylic+enol+ethers+and+human+DNA+topoisomerase+II%CE%B1&doi=10.1016%2Fj.bmcl.2013.07.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular docking studies of the interaction between propargylic enol ethers and human DNA topoisomerase IIα</span></div><div class="casAuthors">Silveira-Dorta, Gaston; Sousa, Ines J.; Rios-Luci, Carla; Martin, Victor S.; Fernandes, Miguel X.; Padron, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5382-5384</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Having identified a novel human DNA topoisomerase IIα (TOP2) catalytic inhibitor from a small and structure-focused library of propargylic enol ethers, we decided to analyze if the chirality of these compds. plays a determinant role in their antiproliferative activity.  In this study, we describe for the first time the synthesis of the corresponding enantiomers and the biol. evaluation against a panel of representative human solid tumor cell lines.  Exptl. results show that chirality does not influence the reported antiproliferative activity of these compds.  Docking studies of corresponding enantiomers against TOP2 reinforce the finding that the biol. effect is not chiral-dependent and that these family of compds. seem to act as TOP2 catalytic inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVjr69oup13rVg90H21EOLACvtfcHk0lh3WpOujSmO6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrjK&md5=7598d2e52816ebb4291940cb7c78061c</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.07.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.07.055%26sid%3Dliteratum%253Aachs%26aulast%3DSilveira-Dorta%26aufirst%3DG.%26aulast%3DSousa%26aufirst%3DI.%2BJ.%26aulast%3DRios-Luci%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DV.%2BS.%26aulast%3DFernandes%26aufirst%3DM.%2BX.%26aulast%3DPadron%26aufirst%3DJ.%2BM.%26atitle%3DMolecular%2520docking%2520studies%2520of%2520the%2520interaction%2520between%2520propargylic%2520enol%2520ethers%2520and%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D19%26spage%3D5382%26epage%3D5384%26doi%3D10.1016%2Fj.bmcl.2013.07.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podolski-Renic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios-Luci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacevic-Grujicic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesic, M.</span></span> <span> </span><span class="NLM_article-title">DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.ejps.2017.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=28502672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2017&pages=159-168&author=A.+Podolski-Renicauthor=J.+Bankovicauthor=J.+Dinicauthor=C.+Rios-Luciauthor=M.+X.+Fernandesauthor=N.+Ortegaauthor=N.+Kovacevic-Grujicicauthor=V.+S.+Martinauthor=J.+M.+Padronauthor=M.+Pesic&title=DTA0100%2C+dual+topoisomerase+II+and+microtubule+inhibitor%2C+evades+paclitaxel+resistance+in+P-glycoprotein+overexpressing+cancer+cells&doi=10.1016%2Fj.ejps.2017.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells</span></div><div class="casAuthors">Podolski-Renic, Ana; Bankovic, Jasna; Dinic, Jelena; Rios-Luci, Carla; Fernandes, Miguel X.; Ortega, Nuria; Kovacevic-Grujicic, Natasa; Martin, Victor S.; Padron, Jose M.; Pesic, Milica</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-168</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The efficacy of microtubule targeting agents in cancer treatment has been compromised by the development of drug resistance that may involve both, P-glycoprotein overexpression and the changes in β-tubulin isoforms' expression.  The anti-Topoisomerase II activity of Me 4-((E)-2-(methoxycarbonyl)vinyloxy)oct-2-ynoate (DTA0100) was recently reported.  Herein, we further evaluated this propargylic enol ether deriv. and found that it exerts inhibitory effect on tubulin polymn. by binding to colchicine binding site.  DTA0100 mitotic arrest properties were investigated in two multi-drug resistant cancer cell lines with P-glycoprotein overexpression (colorectal carcinoma and glioblastoma).  The sensitivity of multi-drug resistant cancer cell lines to DTA0100 was not significantly changed in contrast to microtubule targeting agents such as paclitaxel, vinblastine and colchicine.  DTA0100 clearly induced microtubule depolymn., leading to disturbance of cell cycle kinetics and subsequent apoptosis.  The fine-tuning in β-tubulin isoforms expression obsd. in multi-drug resistant cancer cells may influence the efficacy of DTA0100.  Importantly, DTA0100 blocked the P-glycoprotein function in both multi-drug resistant cancer cell lines without inducing the increase in P-glycoprotein expression.  Therefore, DTA0100 acting as dual inhibitor of Topoisomerase II and microtubule formation could be considered as multi-potent anticancer agent.  Besides, it is able to overcome the problem of drug resistance that emerges in the therapeutic approaches with either Topoisomerase II or microtubule targeting agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Yr0A5xxeibVg90H21EOLACvtfcHk0lh3WpOujSmO6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVCmtr4%253D&md5=415d67d933dd9d2933cb3b4f5dd37b45</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DPodolski-Renic%26aufirst%3DA.%26aulast%3DBankovic%26aufirst%3DJ.%26aulast%3DDinic%26aufirst%3DJ.%26aulast%3DRios-Luci%26aufirst%3DC.%26aulast%3DFernandes%26aufirst%3DM.%2BX.%26aulast%3DOrtega%26aufirst%3DN.%26aulast%3DKovacevic-Grujicic%26aufirst%3DN.%26aulast%3DMartin%26aufirst%3DV.%2BS.%26aulast%3DPadron%26aufirst%3DJ.%2BM.%26aulast%3DPesic%26aufirst%3DM.%26atitle%3DDTA0100%252C%2520dual%2520topoisomerase%2520II%2520and%2520microtubule%2520inhibitor%252C%2520evades%2520paclitaxel%2520resistance%2520in%2520P-glycoprotein%2520overexpressing%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D105%26spage%3D159%26epage%3D168%26doi%3D10.1016%2Fj.ejps.2017.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, L.</span></span> <span> </span><span class="NLM_article-title">Novel conjugates of podophyllotoxin and coumarin: Synthesis, cytotoxicities, cell cycle arrest, binding CT DNA and inhibition of Topo IIβ</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2135</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.06.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=10.1016%2Fj.bmcl.2019.06.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=31278032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlejs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2129-2135&issue=16&author=S.+Y.+Haoauthor=S.+L.+Fengauthor=X.+R.+Wangauthor=Z.+Wangauthor=S.+W.+Chenauthor=L.+Hui&title=Novel+conjugates+of+podophyllotoxin+and+coumarin%3A+Synthesis%2C+cytotoxicities%2C+cell+cycle+arrest%2C+binding+CT+DNA+and+inhibition+of+Topo+II%CE%B2&doi=10.1016%2Fj.bmcl.2019.06.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Novel conjugates of podophyllotoxin and coumarin: Synthesis, cytotoxicities, cell cycle arrest, binding CT DNA and inhibition of Topo IIβ</span></div><div class="casAuthors">Hao, Shu-Yi; Feng, Shi-Liang; Wang, Xing-Rong; Wang, Zhichao; Chen, Shi-Wu; Hui, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2129-2135</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of conjugates of podophyllotoxin and coumarin, I (X = O, NH, R1 = H, Me, Br, OMe, R2 = H, Br, OMe), were prepd. using the click reaction, and their cytotoxicities against A549, HepG2, HeLa, and LoVo cells were evaluated.  Among them, compd. I (X = NH, R1 = OMe, R2 = H) (II) exhibited the strongest cytotoxicities against these cancer cells with IC50 values of 4.9-17.5 μM.  Furthermore, II disrupted microtubules and induced cell cycle arrest at G1 phase by regulating P21 and Cyclin D1 in LoVo cells.  In addn., II bound CT DNA and selectively inhibited Topo IIβ over Topo IIα.  Mol. docking model showed that II appeared to form stable hydrogen bonds with several DNA bases and residue Gln778.  Taken together, these conjugates have the potential to be developed as anti-tumor drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-st5yLtlaqrVg90H21EOLACvtfcHk0lh3WpOujSmO6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlejs77N&md5=5e9deabb0c6d9ad91c5ec1e9eedde56c</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.06.063%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DS.%2BY.%26aulast%3DFeng%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BR.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%2BW.%26aulast%3DHui%26aufirst%3DL.%26atitle%3DNovel%2520conjugates%2520of%2520podophyllotoxin%2520and%2520coumarin%253A%2520Synthesis%252C%2520cytotoxicities%252C%2520cell%2520cycle%2520arrest%252C%2520binding%2520CT%2520DNA%2520and%2520inhibition%2520of%2520Topo%2520II%25CE%25B2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2129%26epage%3D2135%26doi%3D10.1016%2Fj.bmcl.2019.06.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM','PDB','1ZXM'); return false;">PDB: 1ZXM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKR','PDB','3EKR'); return false;">PDB: 3EKR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BYQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BYQ','PDB','1BYQ'); return false;">PDB: 1BYQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3','PDB','3QX3'); return false;">PDB: 3QX3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZRF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZRF','PDB','5ZRF'); return false;">PDB: 5ZRF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FM9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FM9','PDB','4FM9'); return false;">PDB: 4FM9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GWK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GWK','PDB','5GWK'); return false;">PDB: 5GWK</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00726&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-3%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00726%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00726" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a7fc49e4f24eb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
